anastrozole has been researched along with Breast Neoplasms in 1082 studies
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tamoxifen has been the gold standard adjuvant therapeutic agent for postmenopausal women with hormone-sensitive breast cancer for > 25 years." | 10.20 | Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial. ( Buzdar, A, 2003) |
| "Our findings suggest that dalpiciclib plus letrozole or anastrozole could be a novel standard first-line treatment for patients with hormone receptor-positive, HER2-negative advanced breast cancer, and is an alternative option to the current treatment landscape." | 9.69 | Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-con ( Bayaxi, N; Cheng, Y; Geng, C; Hu, C; Hu, X; Li, W; Ouyang, Q; Pan, Y; Shi, Y; Sun, T; Teng, Y; Tong, Z; Wang, X; Wang, Y; Wei, W; Wu, X; Xie, W; Xu, B; Xu, J; Yan, M; Yan, X; Zeng, X; Zhang, H; Zhang, P; Zhang, Q; Zhong, J; Zhu, X, 2023) |
| " We report the primary and final analyses of the coopERA Breast Cancer study, designed to test whether giredestrant, a highly potent, non-steroidal, oral SERD, would show a stronger anti-proliferative effect than anastrozole after 2 weeks for oestrogen receptor-positive, HER2-negative, untreated early breast cancer." | 9.69 | Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study. ( Adamchuk, H; Alonso-Romero, JL; Badovinac Crnjevic, T; Bardia, A; Berzoy, O; Blancas, I; Chan, D; Fasching, PA; Fernando, TM; Ferreira, E; Hurvitz, SA; López-Valverde, V; Moore, HM; Park, YH; Pérez-Moreno, PD; Quiroga, V; Salgado, M; Spera, G; Steinseifer, J; Vasiliev, A; Xue, C; Yardley, DA; Zamora-Auñón, P, 2023) |
| "Patients with histologically confirmed, untreated ER+/HER2- breast cancer, primary tumour ≥2 cm, ECOG performance status ≤1, and eligible for post-treatment surgery received nivolumab 480 mg intravenously every 4 weeks, palbociclib 125 mg or 100 mg orally once daily for 3 weeks per cycle, and anastrozole 1 mg orally once daily for five 4-week cycles, or until disease progression." | 9.69 | Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8. ( Ades, F; Filian, J; Huang, N; Jerusalem, G; Mazzei-Abba, A; Nikolinakos, P; Prat, A; Reinisch, M; Ruiz-Borrego, M; Salgado, R; Saura, C; Tolaney, SM, 2023) |
| "This was a Japanese subpopulation analysis of MONARCH 3, a randomized, double-blind, placebo-controlled phase 3 study of abemaciclib plus nonsteroidal aromatase inhibitors (NSAIs) for initial therapy for advanced breast cancer (ABC)." | 9.51 | Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. ( Goetz, MP; Kawaguchi, T; Mori, J; Takahashi, M; Tanizawa, Y; Toi, M; Tokunaga, E; van der Walt, JS, 2022) |
| "Although power of the study was limited, the findings were unable to support the routine use of everolimus combination endocrine therapy in the first-line treatment of advanced hormone-sensitive breast cancer." | 9.51 | A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222. ( Balcueva, E; Barlow, WE; Conlin, AK; Dy, PA; Gralow, JR; Hayes, DF; Hicks, JB; Hortobagyi, GN; Kuhn, P; Lew, DL; Moore, HCF; Pusztai, L; Schott, AF; Somlo, G; Tripathy, D; Welter, L; Yeon, CH, 2022) |
| "This post hoc analysis of MONARCH 2 and MONARCH 3 assesses the efficacy, safety, and pharmacokinetics (PK) of abemaciclib in combination with endocrine therapy (ET) in East Asian patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer." | 9.41 | Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials. ( André, VAM; Chen, SC; Enatsu, S; Goetz, MP; Hae Park, I; Hardebeck, MC; Im, SA; Inoue, K; Iwata, H; Masuda, N; Sakaguchi, S; Sledge, GW; Sohn, J; Toi, M; Turner, PK, 2021) |
| " Postmenopausal women at increased risk of developing breast cancer were recruited and were randomly assigned (1:1) to either anastrozole (1 mg per day, oral) or matching placebo daily for 5 years." | 9.34 | Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. ( Bonanni, B; Cawthorn, S; Cuzick, J; Dowsett, M; Evans, DG; Forbes, JF; Howell, A; Loibl, S; Mansel, RE; Sestak, I, 2020) |
| "The DATA study (NCT00301457) compared 6 and 3 years of anastrozole in postmenopausal women with hormone receptor-positive early breast cancer after 2-3 years of tamoxifen." | 9.30 | Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure. ( de Boer, M; de Graaf, H; de Roos, WK; Erdkamp, FLG; Honkoop, AH; Imholz, ALT; Kroep, JR; Linn, SC; Peer, PGM; Seynaeve, CM; Smorenburg, CH; Swinkels, ACP; Tjan-Heijnen, VCG; van den Berkmortel, FWPJ; van der Sangen, MJC; van Hellemond, IEG; Vriens, IJH, 2019) |
| "We previously reported prolonged progression-free survival and marginally prolonged overall survival among postmenopausal patients with hormone receptor-positive metastatic breast cancer who had been randomly assigned to receive the aromatase inhibitor anastrozole plus the selective estrogen-receptor down-regulator fulvestrant, as compared with anastrozole alone, as first-line therapy." | 9.30 | Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. ( Albain, KS; Barlow, WE; Dakhil, SR; Gralow, JR; Hayes, DF; Hortobagyi, GN; Lew, DL; Linden, HH; Livingston, RB; Mehta, RS; Tirumali, NR; Vandenberg, TA, 2019) |
| "Anastrozole has been shown to prevent breast cancer in postmenopausal women at high risk of the disease, but has been associated with substantial accelerated loss of bone mineral density (BMD) and increased fractures." | 9.30 | Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. ( Blake, GM; Coleman, RE; Cuzick, J; Eastell, R; Patel, R; Sestak, I, 2019) |
| "GEICAM/2006-10 compared anastrozole (A) versus fulvestrant plus anastrozole (A + F) to test the hypothesis of whether a complete oestrogen blockade is superior to aromatase inhibitors alone in breast cancer patients receiving hormone adjuvant therapy." | 9.30 | Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study. ( Alba, E; Álvarez, I; Antolín, S; Antón, A; Baena-Cañada, JM; Bermejo, B; Carrasco, E; Chacón, JI; Cirauqui, B; Cruz, J; Del Barco, S; Escudero, MJ; Guerrero-Zotano, A; Martín, M; Martínez-Jáñez, N; Muñoz, M; Ramos, M; Rodríguez-Lescure, Á; Ruiz, V; Ruíz-Borrego, M; Sevillano, E, 2019) |
| "Anastrozole reduces breast cancer risk in women at high risk, but implementing preventive therapy in clinical practice is difficult." | 9.27 | Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II. ( Cuzick, J; Forbes, JF; Howell, A; Sestak, I; Smith, SG, 2018) |
| "27 compared 5 years of adjuvant anastrozole or exemestane in postmenopausal patients with hormone receptor positive early breast cancer." | 9.27 | Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27. ( Chen, BE; Goss, PE; Liedke, PER; O'Shaughnessy, J; Parulekar, WR; Ramjeesingh, R; Shepherd, LE; Strasser-Weippl, K; Sudan, G, 2018) |
| "The international, phase III FALCON study (NCT01602380) in postmenopausal patients with hormone receptor-positive, locally advanced/metastatic breast cancer (LA/MBC) who had not received prior endocrine therapy, demonstrated statistically significant improvement in progression-free survival (PFS) for patients who received fulvestrant 500 mg vs anastrozole 1 mg." | 9.27 | Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON). ( Ellis, MJ; Fazal, M; Noguchi, S; Robertson, JFR; Shao, Z; Thirlwell, J, 2018) |
| "This phase II study evaluated the efficacy and safety of anastrozole concurrent with tegafur/uracil (UFT) as neoadjuvant therapy for ER-positive postmenopausal breast cancer." | 9.27 | Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC). ( Aono, T; Ito, T; Kagimura, T; Masuda, N; Matsunami, N; Miyoshi, Y; Nakayama, T; Noguchi, S; Sagara, Y; Taguchi, T; Takashima, T, 2018) |
| "Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly compared the three aromatase inhibitors anastrozole, exemestane, and letrozole." | 9.27 | Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. ( Amoroso, D; Arpino, G; Bernardo, A; Bisagni, G; Carlini, P; Cognetti, F; Cogoni, AA; De Laurentiis, M; De Placido, S; Del Mastro, L; Foglietta, J; Frassoldati, A; Gallo, C; Gori, S; Gravina, A; Lai, A; Laudadio, L; Lauria, R; Lorusso, V; Mocerino, C; Montemurro, F; Moretti, G; Moscetti, L; Nuzzo, F; Perrone, F; Riccardi, F; Rizzo, S; Russo, A; Sarobba, MG; Verusio, C, 2018) |
| "The phase III randomised FALCON trial (NCT01602380) demonstrated improved progression-free survival with fulvestrant 500 mg versus anastrozole 1 mg in endocrine therapy-naïve postmenopausal women with hormone receptor-positive (HR+) locally advanced or metastatic breast cancer (LA/MBC)." | 9.27 | Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer. ( Cheung, KL; Degboe, A; Ellis, MJ; Fazal, M; Lichfield, J; Noguchi, S; Robertson, JFR; Shao, Z; Thirlwell, J, 2018) |
| "We investigated the efficacy and safety of fulvestrant plus goserelin (F + G) versus anastrozole plus goserelin (A + G) in comparison with goserelin (G) alone in premenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), tamoxifen-pretreated metastatic breast cancer (MBC)." | 9.27 | Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, ( Ahn, JH; Ahn, JS; Im, SA; Im, YH; Jung, KH; Kim, GM; Kim, JH; Kim, JY; Kim, S; Kim, SB; Kim, SH; Kim, TY; Lee, KH; Lee, KS; Park, IH; Park, YH; Ro, J; Sohn, J, 2018) |
| "Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy and in combination with fulvestrant in women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer previously treated with endocrine therapy." | 9.24 | MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. ( Barriga, S; Bourayou, N; Campone, M; Chen, SC; Di Leo, A; Forrester, T; Freedman, OC; Frenzel, M; Garnica Jaliffe, G; Goetz, MP; Huober, J; Manso, L; Paluch-Shimon, S; Park, IH; Smith, IC; Sohn, J; Toi, M; Trédan, O, 2017) |
| "Purpose The Letrozole (Femara) Versus Anastrozole Clinical Evaluation (FACE) study compared the efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor (HR) -positive and node-positive early breast cancer (eBC)." | 9.24 | Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation ( Amadori, D; Burris, H; Comarella, L; De Boer, R; Dowsett, M; Ejlertsen, B; Gnant, M; Hart, L; Jonat, W; McIntyre, K; O'Shaughnessy, J; Poggio, S; Pritchard, KI; Salomon, H; Smith, I; Wamil, B; Yardley, D, 2017) |
| "To assess the joint symptoms and the impact on patients' health-related quality of life (HRQOL) due to 5 years of anastrozole from the baseline data in the N-SAS BC 05 trial, a randomized clinical trial was designed to assess the efficacy of 5 additional years of anastrozole among women with breast cancer." | 9.22 | Joint symptoms and health-related quality of life in postmenopausal women with breast cancer who completed 5 years of anastrozole. ( Iwase, T; Komoike, Y; Nakamura, T; Ohashi, Y; Ohtsu, H; Saji, S; Shimozuma, K; Takei, H; Yagata, H, 2016) |
| "This was an exploratory analysis of the International Breast Cancer Intervention Study II, a double-blind randomized clinical trial in which women at increased risk of breast cancer were randomly assigned to receive anastrozole or placebo." | 9.22 | Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial. ( Cuzick, J; Forbes, JF; Howell, A; Sestak, I; Spagnolo, F, 2016) |
| "Third-generation aromatase inhibitors are more effective than tamoxifen for preventing recurrence in postmenopausal women with hormone-receptor-positive invasive breast cancer." | 9.22 | Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. ( Bonanni, B; Bundred, N; Coleman, RE; Cuzick, J; Eiermann, W; Ellis, I; Forbes, JF; Holcombe, C; Howell, A; Jones, L; Levy, C; Neven, P; Sestak, I; Stierer, M; von Minckwitz, G, 2016) |
| " gefitinib) can delay endocrine resistance in breast cancer." | 9.22 | A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378) ( Basaran, G; Bogaerts, J; Cameron, D; Cufer, T; Debled, M; Dirix, L; Piccart, M; Thery, JC; Tjan-Heijnen, VC; Tryfonidis, K; Van den Weyngaert, D, 2016) |
| "In the SWOG S0226 trial the combination of anastrozole plus fulvestrant (n = 349) was superior to anastrozole alone (n = 345) in hormone receptor (HR)-positive metastatic breast cancer." | 9.22 | Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226. ( Albain, KS; Barlow, WE; Dakhil, SR; Gralow, J; Hayes, DF; Hertz, DL; Hortobagyi, GN; Kidwell, KM; Livingston, RB; Mehta, RS; Rae, JM; Tirumali, NR; Vandenberg, TA, 2016) |
| "Adding pictilisib to anastrozole significantly increases suppression of tumor cell proliferation in luminal B primary breast cancer." | 9.22 | Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer. ( Bundred, N; Butler, H; Derynck, M; Earl, G; Gazinska, P; Gendreau, S; Hadad, S; Hu, J; Korbie, D; Lackner, MR; Lim, L; Macaskill, J; Mainwaring, P; Parker, P; Pinder, SE; Price, R; Purushotham, A; Sarker, SJ; Schmid, P; Shia, A; Thompson, A; Trau, M; Wheatley, D; Wilson, TR; Woodman, N; Zammit, C, 2016) |
| "Fulvestrant has superior efficacy and is a preferred treatment option for patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not received previous endocrine therapy compared with a third-generation aromatase inhibitor, a standard of care for first-line treatment of these patients." | 9.22 | Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. ( Bondarenko, IM; Cardona-Huerta, S; Cheung, KL; Dvorkin, M; Ellis, MJ; Fazal, M; Grinsted, LM; Manikhas, A; Noguchi, S; Panasci, L; Philco-Salas, MJ; Robertson, JFR; Rowbottom, J; Ruiz-Borrego, M; Shao, Z; Shparyk, Y; Stuart, M; Trishkina, E, 2016) |
| "Postmenopausal women who were to receive adjuvant anastrozole for resected early breast cancer were studied." | 9.20 | Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. ( Barman, P; Buzdar, AU; Desta, Z; Dudenkov, TT; Flockhart, DA; Goetz, MP; Ingle, JN; Kalari, KR; Northfelt, DW; Perez, EA; Robson, ME; Wang, L; Weinshilboum, RM; Williard, CV, 2015) |
| "Patients were premenopausal women who had undergone primary surgery for stage I/II estrogen-receptor-positive and/or progesterone-receptor-positive breast cancer with <10 positive lymph nodes, and were scheduled for standard goserelin therapy." | 9.20 | Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. ( Balic, M; Bartsch, R; Bjelic-Radisic, V; Dubsky, P; Eidtmann, H; Eiermann, W; Fesl, C; Fitzal, F; Gnant, M; Greil, R; Hochreiner, G; Jakesz, R; Knauer, M; Kwasny, W; Luschin-Ebengreuth, G; Mlineritsch, B; Moik, M; Ploner, F; Seifert, M; Selim, U; Sevelda, P; Steger, G; Stoeger, H; Taucher, S; Wette, V, 2015) |
| "The aim of this study was to assess the efficacy of neoadjuvant anastrozole and fulvestrant treatment of large operable or locally advanced hormone-receptor-positive breast cancer not eligible for initial breast-conserving surgery, and to identify genomic changes occurring after treatment." | 9.20 | Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer. ( Bachelot, T; Bonnefoi, H; Breton-Callu, C; Dalenc, F; Daly, C; de Lara, CT; Debled, M; Fournier, M; Gros, A; Iggo, R; Lortal, B; MacGrogan, G; Madranges, N; Mauriac, L; Nikolski, M; Pulido, M; Quenel-Tueux, N; Rabbitts, P; Rudewicz, J; Soueidan, H; Wood, H, 2015) |
| "To compare overall survival (OS) for fulvestrant 500 mg versus anastrozole as first-line endocrine therapy for advanced breast cancer." | 9.20 | Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study. ( Dewar, JA; Ellis, MJ; Feltl, D; Hewson, N; Jasiówka, M; Llombart-Cussac, A; Robertson, JF; Rukazenkov, Y, 2015) |
| "Anastrozole effectively reduces incidence of breast cancer in high-risk postmenopausal women." | 9.19 | Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. ( Bonanni, B; Cawthorn, S; Cuzick, J; Dowsett, M; Forbes, JF; Howell, A; Knox, J; Mansel, RE; Palva, T; Roche, N; Saunders, C; Sestak, I; von Minckwitz, G, 2014) |
| "This prospective study evaluated the relationship between arthralgia and compliance during the first year of adjuvant anastrozole therapy in postmenopausal women with hormone receptor-positive early breast cancer." | 9.19 | COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy. ( Blettner, M; Bolten, W; Hadji, P; Harbeck, N; Hindenburg, HJ; Jackisch, C; Klein, P; König, K; Kreienberg, R; Rief, W; Wallwiener, D; Zaun, S, 2014) |
| "27, postmenopausal women with early stage hormone (oestrogen) receptor-positive invasive breast cancer were randomly assigned to exemestane 25 mg versus anastrozole 1 mg, daily." | 9.19 | Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. ( Badovinac-Crnjevic, T; Chalchal, H; Chapman, JA; Cheung, AM; Elliott, CR; Goss, PE; Hershman, DL; Ingle, JN; Khosla, S; Linden, HM; Muss, HB; Pritchard, KI; Rowland, K; Scher, J; Shepherd, LE; St Louis, J; Stearns, V, 2014) |
| "Tamoxifen and anastrozole are widely used as adjuvant treatment for early stage breast cancer, but their hepatotoxicity is not fully defined." | 9.19 | A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer. ( Chen, D; Deng, Y; Feng, G; He, P; Hu, R; Huang, T; Li, E; Li, L; Li, Y; Liang, Z; Lin, Y; Liu, J; Lu, Y; Ma, R; Su, F; Sun, S; Tong, Z; Wang, S; Wang, X; Wu, Y; Xu, Z; Zhang, H; Zhang, X; Zhang, Y; Zhao, Y, 2014) |
| "This study aimed to investigate calcitonin as an effective therapy for osteoporosis in patients with bone pain during the anastrozole treatment of breast cancer." | 9.19 | Effect of calcitonin on anastrozole-induced bone pain during aromatase inhibitor therapy for breast cancer. ( Liu, M; Liu, P; Xie, F; Yang, DQ; Zhou, B, 2014) |
| "Aromatase inhibitors are superior to tamoxifen as adjuvant therapy in postmenopausal patients with hormone-responsive breast cancer." | 9.19 | Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial. ( Aihara, T; Andoh, M; Aogi, K; Fukuuchi, A; Hozumi, Y; Iwata, H; Kim, R; Makino, H; Mukai, H; Ohashi, Y; Ohno, S; Takatsuka, Y; Tamura, M; Tsugawa, K; Watanabe, T; Yamaguchi, T; Yokota, I, 2014) |
| "The aim of this study was to assess the efficacy and safety of neoadjuvant anastrozole and radiation in postmenopausal breast cancer patients with hormone-receptor-positive tumors." | 9.19 | Phase II study of neoadjuvant anastrozole and concurrent radiotherapy for postmenopausal breast cancer patients. ( Inaji, H; Ishitobi, M; Komoike, Y; Nakahara, S; Ohsumi, S; Suzuki, O; Tomita, Y; Yagi, T; Yoshinami, T, 2014) |
| "In this bone substudy, bone mineral density (BMD) was assessed by dual energy X-ray absorptiometry at baseline and after 12- and 24-month treatment in 63 patients receiving Anastrozole as adjuvant treatment for hormone receptor-positive early breast cancer." | 9.17 | Influence of compliance on bone mineral density changes in postmenopausal women with early breast cancer on Anastrozole. ( Hadji, P; Hars, O; Kalder, M; Knöll, D; Kyvernitakis, I; Ziller, V, 2013) |
| " Premenopausal women with estrogen receptor (ER)-positive and/or progesterone-receptor positive, advanced or recurrent breast cancer refractory to an LH-RH analogue plus TAM received goserelin (GOS) in conjunction with anastrozole (ANA)." | 9.17 | Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial. ( Anan, K; Higaki, K; Mase, T; Nishimura, R; Ohno, S; Sagara, Y; Shibuta, K; Tanaka, M; Teramukai, S; Tsuyuki, S; Yamamoto, Y, 2013) |
| "The aromatase inhibitors exemestane and anastrozole are approved in Japan for first-line treatment of postmenopausal patients with advanced, hormone-receptor-positive breast cancer." | 9.17 | A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer. ( Hashigaki, S; Hiraoka, M; Iwata, H; Masuda, N; Morimoto, T; Nishizawa, Y; Noguchi, S; Ohno, S; Ohsumi, S; Rai, Y; Saeki, T; Sasano, H; Sato, Y, 2013) |
| "After loss of response to NSAIs in postmenopausal women with hormone-receptor-positive advanced breast cancer, maximum double endocrine treatment with 250 mg fulvestrant combined with oestrogen deprivation is no better than either fulvestrant alone or exemestane." | 9.17 | Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr ( Bliss, JM; Braybrooke, JP; Brunt, AM; Cameron, D; Cheung, KL; Coombes, G; Dodwell, D; Dowsett, M; Ellis, P; Folkerd, E; Hayward, L; Howell, A; Im, YH; Johnston, SR; Jyothirmayi, R; Kilburn, LS; Robinson, A; Sergenson, N; Sin, HJ; Wardley, AM; Wheatley, D, 2013) |
| "In a phase 3, double-blind, randomized trial (National Clinical Trials identifier NCT00605267), premenopausal women with ER-positive, early stage breast cancer received either anastrozole plus goserelin or tamoxifen plus goserelin for 24 weeks before surgery." | 9.17 | Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer. ( Hayashi, N; Iwase, H; Iwata, H; Kamigaki, S; Kinoshita, T; Masuda, N; Nakamura, S; Nishimura, R; Noguchi, S; Sagara, Y; Takei, H; Tsuda, H; Yanagita, Y, 2013) |
| "In patients with hormone-dependent postmenopausal breast cancer, standard adjuvant therapy involves 5 years of the nonsteroidal aromatase inhibitors anastrozole and letrozole." | 9.17 | Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. ( Ansari, RH; Budd, GT; Chalchal, H; Chapman, JA; D'Souza, DP; Elliott, C; Ellis, MJ; Gelmon, KA; Goss, PE; Ingle, JN; Johnson, DB; Lang, I; Liedke, PE; Perez, EA; Pritchard, KI; Rabaglio, M; Shepherd, LE; Sledge, GW; Spadafora, S; Stearns, V; Tozer, R, 2013) |
| " In the current study, the authors formally evaluated the activity of anastrozole and exemestane in postmenopausal women with hormone-responsive, advanced breast cancer." | 9.16 | Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial. ( Alés-Martínez, JE; Alvarez, I; Andrés, R; Antolín, S; Antón, A; Barnadas, A; Cámara, C; Carrasco, E; Casas, I; García Saenz, JA; Lao, J; Llombart-Cussac, A; Martín, M; Ruiz, A, 2012) |
| "The present study examined long-term efficacy outcomes in a subgroup of postmenopausal, estrogen receptor-positive Japanese breast cancer patients from the Pre-Operative "Arimidex" Compared with Tamoxifen trial, following pre-operative (3 months) and post-operative (5 years) adjuvant treatment with either anastrozole or tamoxifen." | 9.16 | Outcomes of Japanese breast cancer patients treated with pre-operative and post-operative anastrozole or tamoxifen. ( Akiyama, F; Fujiwara, Y; Ikeda, T; Imoto, S; Inaji, H; Iwata, H; Mitsuyama, S; Miyoshi, K; Noguchi, S; Takatsuka, Y; Tamura, M, 2012) |
| "Health-related quality of life (HRQOL), symptoms of depression, and adverse events (AEs) were compared between Japanese postmenopausal patients with hormone-sensitive breast cancer (BC) who received adjuvant tamoxifen, exemestane, or anastrozole in an open-labeled, randomized, multicenter trial designated as the National Surgical Adjuvant Study of Breast Cancer (N-SAS BC) 04 substudy of the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial." | 9.16 | Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N- ( Hozumi, Y; Ohashi, Y; Ohsumi, S; Shimozuma, K; Suemasu, K; Takehara, M; Takei, H, 2012) |
| "Given its favourable risk-benefit profile, the combination of anastrozole plus goserelin could represent an alternative neoadjuvant treatment option for premenopausal women with early-stage breast cancer." | 9.16 | Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. ( Iwase, H; Iwata, H; Kamigaki, S; Kinoshita, T; Masuda, N; Nakamura, S; Nishimura, R; Noguchi, S; Sagara, Y; Takei, H; Yanagita, Y, 2012) |
| "Anastrozole (ANA) alone delivers significant disease-free survival benefits over tamoxifen (TAM) monotherapy in postmenopausal women with early estrogen receptor-positive breast cancer." | 9.16 | Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. ( Bartsch, R; Dubsky, PC; Filipcic, L; Fitzal, F; Gnant, M; Greil, R; Haider, K; Jakesz, R; Kwasny, W; Luschin-Ebengreuth, G; Mlineritsch, B; Pöstlberger, S; Rudas, M; Samonigg, H; Sevelda, P; Singer, CF; Steger, GG; Stierer, M; Stöger, H; Taucher, S; Tausch, C, 2012) |
| "To compare the effect of therapy with anastrozole versus a combination of fulvestrant and anastrozole in women in first relapse of endocrine-responsive breast cancer." | 9.16 | FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. ( Bergh, J; Brattström, D; Eiermann, W; Henriksson, R; Jönsson, PE; Lidbrink, EK; Lindemann, JP; Trudeau, M; Wiklund, F, 2012) |
| "To clarify these challenging and partly contrasting treatment predictive and prognostic links for cyclin D1 we analysed a large cohort of postmenopausal breast cancer patients randomised to receive either adjuvant anastrozole or tamoxifen, as part of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial." | 9.16 | Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. ( Brown, M; Cuzick, J; Dowsett, M; Howell, A; Landberg, G; Lundgren, K; Pineda, S; Salter, J; Zabaglo, L, 2012) |
| "The combination of anastrozole and fulvestrant was superior to anastrozole alone or sequential anastrozole and fulvestrant for the treatment of HR-positive metastatic breast cancer, despite the use of a dose of fulvestrant that was below the current standard." | 9.16 | Combination anastrozole and fulvestrant in metastatic breast cancer. ( Albain, KS; Barlow, WE; Dakhil, SR; Gralow, JR; Hayes, DF; Hortobagyi, GN; Lew, DL; Livingston, RB; Mehta, RS; Tirumali, NR; Vandenberg, TA, 2012) |
| "Fulvestrant fIRst-line Study comparing endocrine Treatments is a phase II, randomized, open-label study comparing fulvestrant 500 mg with anastrozole 1 mg as first-line endocrine therapy for postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer." | 9.16 | Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study. ( Dean, A; Dewar, J; Ellis, MJ; Emerson, L; Feltl, D; Lindemann, JP; Llombart-Cussac, A; Robertson, JF; Rolski, J, 2012) |
| "We recruited consecutive postmenopausal women, age ≥ 18 years, with hormone-sensitive nonmetastatic breast cancer who were prescribed anastrozole at least 3 months before enrollment." | 9.16 | Use of a urine anastrozole assay to determine treatment discontinuation among women with hormone-sensitive breast cancer: a pilot study. ( Clarke Hillyer, G; Crew, KD; Danaceau, J; Hershman, DL; Kalinsky, K; Maurer, MA; Neugut, AI; Rotsides, DZ, 2012) |
| "The objective of this study was to compare Ki-67, Bcl-2, Bax, Bak, ER, and PgR expression in postmenopausal women with ER-positive invasive breast cancer (IBC) before and after short-term hormone therapy (HT) with either tamoxifen or anastrozole in order to identify a possible biomarker profile associated with hormone resistance." | 9.15 | Short-term anastrozole therapy reduces Ki-67 and progesterone receptor expression in invasive breast cancer: a prospective, placebo-controlled, double-blind trial. ( Facina, G; Gebrim, LH; Logullo, AF; Mattar, A; Nonogaki, S; Soares, FA, 2011) |
| "These data demonstrate that fulvestrant 250 mg and anastrozole were similarly effective and well tolerated in the treatment of postmenopausal Chinese women with advanced breast cancer whose disease had progressed or recurred on prior endocrine treatment." | 9.15 | Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial. ( Chen, Z; Feng, J; Gu, K; Jiang, Z; Shao, Z; Song, S; Wang, C; Wang, J; Xu, B; Yang, J; Yu, S; Zhang, F; Zhang, Y, 2011) |
| "We evaluated the use of sorafenib to overcome resistance to aromatase inhibitors (AIs) in patients with metastatic breast cancer who had disease recurrence or progression while on AIs." | 9.15 | Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer. ( Chung, GG; Cohen, P; Creswell, K; Eng-Wong, J; Herbolsheimer, P; Isaacs, C; Liu, MC; Novielli, A; Ottaviano, Y; Slack, R; Smith, KL; Warren, R; Wilkinson, M, 2011) |
| "In this Tamoxifen Exemestane Adjuvant Multinational Japan sub-study, we evaluated the time course of changes in serum lipids in postmenopausal women with hormone-sensitive early breast cancer treated with exemestane, anastrozole, or tamoxifen for postoperative adjuvant therapy." | 9.15 | The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study. ( Aihara, T; Hozumi, Y; Masuda, N; Ohashi, Y; Ohsumi, S; Saito, T; Suemasu, K; Takehara, M; Takei, H, 2011) |
| "To investigate whether the health-related quality of life (HRQOL) of patients switching from tamoxifen to anastrozole in a randomized trial is identical to that of those who continued tamoxifen after 1-4 years of adjuvant tamoxifen in Japanese postmenopausal breast cancer patients." | 9.15 | Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1-4 years: N-SAS BC 03. ( Aihara, T; Hozumi, Y; Mukai, H; Ohashi, Y; Ohsumi, S; Shimozuma, K; Shinji, M; Takatsuka, Y, 2011) |
| "Three hundred seventy-seven postmenopausal women with clinical stage II to III ER-positive (Allred score 6-8) breast cancer were randomly assigned to receive neoadjuvant exemestane, letrozole, or anastrozole." | 9.15 | Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int ( Allred, DC; Babiera, GV; DeSchryver, K; Ellis, MJ; Esserman, LJ; Guenther, JM; Hoog, J; Hunt, K; Leitch, M; Lin, L; Luo, J; Marcom, PK; Margenthaler, J; Olson, JA; Parker, JS; Prat, A; Snider, J; Suman, VJ; Unzeitig, GW; Watson, MA, 2011) |
| "Incidence of joint symptoms and bone fractures as well as changes in bone mineral density (BMD) in Japanese postmenopausal breast cancer patients treated with adjuvant anastrozole were investigated to determine whether there is an ethnic difference from Caucasian patients in the incidence of these adverse events of anastrozole." | 9.14 | Incidence of joint symptoms and bone fractures in Japanese postmenopausal breast cancer patients treated with adjuvant anastrozole. ( Kim, SJ; Noguchi, S; Okishiro, M; Shimazu, K; Taguchi, T; Tamaki, Y; Tanji, Y, 2009) |
| "We examined the effect of adding zoledronic acid to a combination of either goserelin and tamoxifen or goserelin and anastrozole in premenopausal women with endocrine-responsive early breast cancer." | 9.14 | Endocrine therapy plus zoledronic acid in premenopausal breast cancer. ( Bjelic-Radisic, V; Dubsky, P; Eidtmann, H; Fitzal, F; Fridrik, M; Gnant, M; Greil, R; Hubalek, M; Jakesz, R; Kwasny, W; Luschin-Ebengreuth, G; Marth, C; Menzel, C; Mlineritsch, B; Pöstlberger, S; Rücklinger, E; Samonigg, H; Schippinger, W; Seifert, M; Steger, G; Stierer, M; Tausch, C, 2009) |
| "Postmenopausal women with advanced breast cancer and > or = 1 visceral (liver or lung) lesion were randomized to anastrozole (1 mg/day orally) or exemestane (25 mg/day orally) for > or = 8 weeks." | 9.14 | A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. ( Abreu, P; Cameron, DA; Campos, SM; Guastalla, JP; Subar, M; Winer, EP, 2009) |
| "To compare the clinical activity of the pure antiestrogen fulvestrant at 500 mg/mo (double the approved dose) with the aromatase inhibitor anastrozole as first-line endocrine therapy for advanced hormone receptor-positive breast cancer in postmenopausal women." | 9.14 | Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. ( Dewar, J; Ellis, MJ; Feltl, D; Lindemann, J; Llombart-Cussac, A; Macpherson, E; Robertson, JF; Rolski, J, 2009) |
| " Letrozole, an Investigation of Quality Of Life and Tolerability) was a prospective, open-label, randomized pharmacodynamic study designed to assess the effects of aromatase inhibitors (AIs) on bone turnover in healthy postmenopausal women with estrogen receptor-positive breast cancer." | 9.14 | A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer. ( Dixon, JM; Hannon, R; Macaskill, EJ; McCaig, FM; McHugh, M; Murray, J; Renshaw, L; Williams, L; Young, O, 2010) |
| "This phase II randomized trial evaluated the efficacy and tolerability of anastrozole combined with gefitinib or anastrozole with placebo in women with hormone receptor-positive metastatic breast cancer (MBC)." | 9.14 | Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. ( Anderson, E; Arena, FP; Bacus, S; Cora, EM; Cristofanilli, M; Curcio, E; Kroener, JF; Magill, PJ; Mangalik, A; Rabinowitz, I; Royce, M; Valero, V; Watkins, C, 2010) |
| "In the 'Arimidex', Tamoxifen Alone or in Combination (ATAC) trial, the aromatase inhibitor (AI) anastrozole had a significantly better efficacy and safety profile than tamoxifen as initial adjuvant therapy for hormone receptor-positive (HR+) early breast cancer (EBC) in postmenopausal patients." | 9.14 | Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system. ( Beckmann, MW; Benedict, A; Buchholz, S; Distler, W; Hadji, P; Harbeck, N; Jonat, W; Kaufmann, M; Kreienberg, R; Kreif, N; Lux, MP; Possinger, K; Raab, G; Schneeweiss, A; Tesch, H; Weyers, G; Wöckel, A, 2010) |
| "Clinical trials conducted in Western countries have shown that aromatase inhibitors are associated with better disease-free survival (DFS) than tamoxifen in postmenopausal early breast cancer." | 9.14 | Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study. ( Abe, H; Aihara, T; Aogi, K; Hisamatsu, K; Hozumi, Y; Imoto, S; Ito, T; Iwata, H; Masuda, N; Mitsuyama, S; Mukai, H; Nakagami, K; Ogino, N; Ohashi, Y; Ohsumi, S; Shimizu, C; Takatsuka, Y; Tamura, M; Tanaka, S; Watanabe, T; Yamaguchi, T, 2010) |
| "The aim of this multicenter, phase III, prospective open label clinical trial was to investigate the effect of risedronate (R) on bone mineral density (BMD) in postmenopausal, early breast cancer (BC) patients scheduled to receive anastrozole (A)." | 9.14 | Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. ( Antonopoulou, Z; Dafni, U; Gogas, H; Kalogerakos, K; Koukouras, D; Lazarou, S; Markopoulos, C; Misitzis, J; Papadiamantis, J; Polychronis, A; Sarantopoulou, A; Siasos, N; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2010) |
| "The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was designed to compare the efficacy and safety of anastrozole (1 mg) with tamoxifen (20 mg), both given orally every day for 5 years, as adjuvant treatment for postmenopausal women with early-stage breast cancer." | 9.14 | Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. ( Baum, M; Buzdar, A; Cuzick, J; Dowsett, M; Forbes, JF; Howell, A; Sestak, I, 2010) |
| "Evaluation of endometrial thickness by transvaginal ultrasonography (TVUS) in postmenopausal estrogen receptor positive breast cancer patients treated with anastrozole after tamoxifen therapy." | 9.13 | Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole. ( Bogliolo, S; Costantini, S; Dugnani, MC; Ferrero, S; Moioli, M; Papadia, A; Valenzano Menada, M, 2008) |
| "6 mg subcutaneously every 28 days), both with or without zoledronic acid (4 mg intravenously every 6 months) for 3 years in premenopausal women with endocrine-responsive breast cancer." | 9.13 | Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. ( Bjelic-Radisic, V; Dubsky, P; Fitzal, F; Gnant, M; Greil, R; Jakesz, R; Kainberger, F; Kässmann, H; Kubista, E; Luschin-Ebengreuth, G; Marth, C; Menzel, C; Mittlböck, M; Mlineritsch, B; Piswanger-Sölkner, JC; Ploner, F; Samonigg, H; Seifert, M; Steger, G; Wohlmuth, P, 2008) |
| "To evaluate the influence of the third-generation aromatase inhibitor letrozole (Femara) on breast cancer tissue levels of estrone (E(1)), estradiol (E(2)), and estrone sulfate (E(1)S) in postmenopausal women undergoing primary treatment for locally advanced estrogen receptor/progesterone receptor-positive breast cancers." | 9.13 | Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. ( Aas, T; Duong, NK; Ekse, D; Evans, DB; Geisler, J; Helle, H; Lønning, PE; Nordbø, Y, 2008) |
| "The aromatase inhibitor anastrozole is a highly effective well-tolerated treatment for postmenopausal endocrine-responsive breast cancer." | 9.13 | Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. ( Brown, JE; Coleman, RE; Dodwell, D; Ellis, SP; Gutcher, SA; Hannon, RA; Horsman, JM; Lester, JE; Purohit, OP; Thorpe, R, 2008) |
| "The PReOperative 'Arimidex' Compared with Tamoxifen (PROACT) trial compared neoadjuvant anastrozole and tamoxifen in postmenopausal women with large, operable or potentially operable, locally advanced hormone receptor-positive breast cancer." | 9.13 | Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial. ( Akiyama, F; Ikeda, T; Imoto, S; Inaji, H; Kurosumi, M; Noguchi, S; Sakamoto, G; Takatsuka, Y; Tsuda, H; Watanabe, T, 2008) |
| "These data show long-term safety findings and establish clearly the long-term efficacy of anastrozole compared with tamoxifen as initial adjuvant treatment for postmenopausal women with hormone-sensitive, early breast cancer, and provide statistically significant evidence of a larger carryover effect after 5 years of adjuvant treatment with anastrozole compared with tamoxifen." | 9.13 | Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. ( Baum, M; Buzdar, A; Cuzick, J; Forbes, JF; Howell, A; Tobias, JS, 2008) |
| "Fifty-four postmenopausal women with estrogen receptor-positive breast cancer receiving aromatase inhibitors (AIs) as part of their adjuvant therapy were randomly assigned to receive either 3 months of anastrozole (1 mg) followed by 3 months of letrozole (2." | 9.13 | Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. ( A'Hern, RP; Cameron, DA; Dixon, JM; Dowsett, M; Folkerd, E; Macaskill, EJ; McHugh, M; Murray, J; Renshaw, L; Young, O, 2008) |
| "The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) trial compared the preoperative use of anastrozole with tamoxifen in postmenopausal women with estrogen receptor-positive primary operable breast cancer over 12 weeks." | 9.13 | The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer. ( A'hern, R; Banerjee, S; Dowsett, M; Ghazoui, Z; Martin, LA; Pancholi, S; Smith, IE, 2008) |
| "The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial compared the efficacy and safety of anastrozole versus tamoxifen versus the combination as initial adjuvant treatment for early breast cancer in over 9,000 postmenopausal women." | 9.12 | Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data. ( Buzdar, AU; Cuzick, J, 2006) |
| "To investigate the effect of switching from adjuvant tamoxifen to anastrozole (Arimidex) treatment in postmenopausal women with endocrine-responsive breast cancer and histologically proven tamoxifen-induced benign endometrial pathology." | 9.12 | Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology. ( Gerber, B; Janni, W; Krause, A; Kundt, G; Makovitzky, J; Mylonas, I; Reimer, T, 2006) |
| "The Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) study was a randomized, multicenter study comparing anastrozole with tamoxifen as a preoperative treatment of postmenopausal women with large, operable (T2/3, N0-2, M0), or potentially operable (T4b, N0-2, M0) breast cancer." | 9.12 | Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. ( Bines, J; Buzdar, AU; Cataliotti, L; de Oliveira, CT; Dube, P; Noguchi, S; Petrakova, K; Takatsuka, Y, 2006) |
| "Switching to anastrozole after the first 2-3 years of treatment was confirmed to improve event-free and relapse-free survival of postmenopausal, node-positive, ER-positive early breast cancer patients already receiving adjuvant tamoxifen." | 9.12 | Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. ( Amadori, D; Benedetto, C; Boccardo, F; Buzzi, F; Distante, V; Fini, A; Franchi, R; Guglielmini, P; Massidda, B; Mesiti, M; Paladini, G; Porpiglia, M; Restuccia, N; Rinaldini, M; Rubagotti, A; Scali, S; Sismondi, P, 2006) |
| "The Arimidex (anastrozole), Tamoxifen, Alone or in Combination (ATAC) trial was designed to compare the efficacy and safety of anastrozole with tamoxifen as adjuvant treatment for postmenopausal women with early-stage breast cancer." | 9.12 | Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. ( Buzdar, A; Cuzick, J; Distler, W; Hoctin-Boes, G; Houghton, J; Howell, A; Locker, GY; Nabholtz, JM; Wale, C, 2006) |
| "6 mg every 28 days subcutaneously) +/- zoledronic acid (4 mg intravenously every 6 months) versus anastrozole (1 mg/d orally) and goserelin +/- zoledronic acid for 3 years in premenopausal women with hormone-responsive breast cancer." | 9.12 | Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. ( Galid, A; Gnant, MF; Grampp, S; Hausmaninger, H; Jakesz, R; Kaessmann, H; Luschin-Ebengreuth, G; Menzel, C; Mittlboeck, M; Mlineritsch, B; Piswanger-Soelkner, JC; Schmid, M, 2007) |
| "The aim of the study was to determine the potency of anastrozole to suppress serum E(2) levels in breast cancer patients undergoing COH." | 9.12 | Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization. ( Azim, AA; Costantini-Ferrando, M; Lostritto, K; Oktay, K, 2007) |
| "In women with favorable early breast cancer treated by lumpectomy plus tamoxifen or anastrazole, it remains unclear whether whole breast radiotherapy is beneficial." | 9.12 | Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. ( Draxler, W; Gnant, M; Haider, K; Hammer, J; Handl-Zeller, L; Hofbauer, F; Jakesz, R; Kapp, K; Kwasny, W; Luschin-Ebengreuth, G; Pakisch, B; Pöstlberger, S; Pötter, R; Reiner, G; Rottenfusser, A; Schmid, M; Sedlmayer, F; Stierer, M; Taucher, S; Tausch, C, 2007) |
| "Postmenopausal women who have taken tamoxifen for 2 years as adjuvant therapy are less likely to experience a recurrence of breast cancer and have improved overall survival if they switch to anastrozole compared with continuing to receive tamoxifen." | 9.12 | Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. ( Eidtmann, H; Gademann, G; Hilfrich, J; Jonat, W; Kaufmann, M; von Minckwitz, G; Zuna, I, 2007) |
| "Results from the completed treatment analysis of the ATAC (Arimidex, Tamoxifen alone or in combination) trial indicated that anastrozole was significantly superior to tamoxifen in terms of efficacy and safety in the adjuvant treatment of postmenopausal women with hormone receptor-positive (HR+) early breast cancer." | 9.12 | Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial. ( Benedict, A; Fallowfield, L; Jones, D; Locker, G; Mansel, R, 2007) |
| "Postmenopausal women with stage I to IIIB hormone receptor-positive early breast cancer received anastrozole 1 mg daily for 16 weeks and were randomly assigned at a ratio of 2:5:5 to receive, in addition, gefitinib 250 mg/d orally for 16 weeks: placebo 1 tablet/d orally for 2 weeks and then gefitinib for 14 weeks or placebo for 16 weeks." | 9.12 | A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. ( Clark, E; Detre, S; Dowsett, M; Llombart, A; Magill, P; Mayordomo, JI; Salter, J; Skene, A; Smith, IE; Walsh, G, 2007) |
| "3 months, women who received anastrozole (n = 387) had a statistically significantly reduced risk of recurrence (locoregional recurrence, contralateral breast cancer, or distant metastasis) compared with women who received no further treatment (n = 469; hazard ratio = 0." | 9.12 | Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. ( Dadak, C; Gnant, M; Greil, R; Hofbauer, F; Jakesz, R; Kubista, E; Kwasny, W; Mlineritsch, B; Renner, K; Rücklinger, E; Samonigg, H; Schmid, M; Stierer, M; Tausch, C, 2007) |
| "A total of 16 premenopausal women with metastatic breast cancer (N=13) or locally advanced primary breast cancer (N=3) were treated with a combination of a gonadotropin-releasing hormone agonist goserelin, and a selective aromatase inhibitor anastrozole." | 9.11 | Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. ( Cheung, KL; Forward, DP; Jackson, L; Robertson, JF, 2004) |
| "The 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial is a randomized, double-blind trial comparing anastrozole ('Arimidex'), alone or in combination with tamoxifen, relative to tamoxifen alone as 5 year adjuvant treatment for post-menopausal women with early breast cancer." | 9.11 | The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy. ( Bianco, AR; Clack, G; Coibion, M; Duffy, S; Jackson, TL; Lansdown, M; Philips, K; Pollard, S; Wells, M, 2005) |
| "This study was undertaken to assess baseline endometrial molecular events in the ATAC (Arimidex, tamoxifen, alone, or in combination) trial of breast cancer adjuvant therapy." | 9.11 | Molecular markers in the endometrium at baseline of postmenopausal patients with early breast cancer in the ATAC (Arimidex, tamoxifen, alone, or in combination) trial. ( Duffy, SR; Taylor, L, 2004) |
| "The IMPACT trial compared the preoperative use of tamoxifen with anastrozole alone or in combination in postmenopausal women (n = 330) with primary breast cancer." | 9.11 | Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists. ( Ashley, S; Boeddinghaus, I; Detre, S; Dixon, JM; Dowsett, M; Ebbs, SR; Francis, S; Griffith, C; Hills, M; Salter, J; Skene, A; Smith, IE; Walsh, G, 2005) |
| " This study evaluated the effect on lipid metabolism of one such agent, the new generation aromatase inhibitor anastrozole, compared with tamoxifen, when used as adjuvant treatment in postmenopausal Japanese women with early breast cancer." | 9.11 | Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer. ( Ayaori, M; Hiraide, H; Kusuhara, M; Mochizuki, H; Ohsuzu, F; Sato, K; Sawada, S; Tamaki, K; Yonemura, A, 2005) |
| "In a double-blind, placebo-controlled randomised trial of 56 postmenopausal patients with ER-positive and EGFR-positive primary breast cancer, 27 women were randomly assigned to the tyrosine-kinase inhibitor of EGFR gefitinib (250 mg given orally once a day) and the aromatase inhibitor anastrozole (1 mg given orally once a day), and 29 women to gefitinib (250 mg given orally once a day) and placebo of identical appearance to anastrozole given orally once a day, all given for 4-6 weeks before surgery." | 9.11 | Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. ( Ali, S; Barrett, N; Beresford, E; Coombes, RC; Hadjiminas, D; Jiang, J; Mansi, JL; Morrison, K; Peston, D; Polychronis, A; Shivapatham, D; Shousha, S; Singhal, H; Sinnett, HD; Slade, MJ; Vigushin, D, 2005) |
| "The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) trial was designed to test the hypothesis that the clinical and/or biologic effects of neoadjuvant tamoxifen compared with anastrozole and with the combination of tamoxifen and anastrozole before surgery in postmenopausal women with estrogen receptor (ER) -positive, invasive, nonmetastatic breast cancer might predict for outcome in the Arimidex, Tamoxifen Alone or in Combination (ATAC) adjuvant therapy trial." | 9.11 | Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. ( Ashley, SE; Blohmer, JU; Boeddinghaus, I; Dixon, JM; Dowsett, M; Ebbs, SR; Francis, S; Skene, A; Smith, IE; Walsh, G, 2005) |
| "Switching to anastrozole after the first 2 to 3 years of treatment is well tolerated and significantly improves event-free and recurrence-free survival in postmenopausal patients with early breast cancer." | 9.11 | Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. ( Amadori, D; Amoroso, D; Benedetto, C; Boccardo, F; Buzzi, F; Distante, V; Fini, A; Franchi, R; Guglielmini, P; Massidda, B; Mesiti, M; Paladini, G; Porpiglia, M; Puntoni, M; Restuccia, N; Rinaldini, M; Romeo, D; Rubagotti, A; Scali, S; Sismondi, P, 2005) |
| "To compare the efficacy and tolerability of fulvestrant (formerly ICI 182,780) with anastrozole in the treatment of advanced breast cancer in patients whose disease progresses on prior endocrine treatment." | 9.10 | Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. ( Burton, G; Buzdar, A; Come, S; Dimery, I; Elledge, R; Ellis, M; Gertler, SZ; Jones, SE; May, JT; Morris, C; Osborne, CK; Parker, LM; Pippen, J; Webster, A, 2002) |
| "To compare the efficacy and tolerability of fulvestrant (formerly ICI 182,780) and anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment." | 9.10 | Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. ( Aschermannova, A; Erikstein, B; Howell, A; Kleeberg, UR; Mauriac, L; Morris, C; Quaresma Albano, J; Robertson, JF; Vergote, I; Webster, A, 2002) |
| "Anastrozole is an orally active, non-steroidal aromatase inhibitor which appears effective as neoadjuvant treatment of breast cancer." | 9.10 | Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer. ( Anderson, TJ; Dixon, JM; Miller, WR; Sahmoud, T; Stuart, M, 2002) |
| "The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial is a randomised, double-blind, double-dummy trial, evaluating anastrozole alone or in combination with tamoxifen compared with tamoxifen alone, as a 5-year adjuvant treatment for postmenopausal patients with early breast cancer." | 9.10 | The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal patients: factors influencing the success of patient recruitment. ( Baum, M, 2002) |
| "The efficacy of fulvestrant (Faslodex), a novel oestrogen receptor (ER) antagonist that downregulates the ER and has no known agonist effects, was compared with the aromatase inhibitor anastrozole (Arimidex) for the second-line treatment of advanced breast cancer in postmenopausal women with visceral and non-visceral metastases." | 9.10 | Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. ( Gertler, SZ; Mauriac, L; Osborne, CK; Pippen, JE; Quaresma Albano, J, 2003) |
| "A prospective phase III trial comparing anastrozole with tamoxifen as first-line therapy in postmenopausal, hormone-dependent, advanced breast cancer (ABC)." | 9.10 | Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study. ( Casanovas, J; Milla, L; Milla-Santos, A; Pons, M; Portella, J; Puig-Gali, M; Rallo, L; Rodes, E, 2003) |
| "We present an initial survival analysis and an update of the safety data of the North American and Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability (TARGET) double-blind, randomised, multicentre studies which compared anastrozole with tamoxifen as first-line treatment in postmenopausal patients with oestrogen receptor and/or progesterone receptor-positive (ER+/PR+) or receptor-unknown advanced breast cancer (ABC)." | 9.10 | Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. ( Bonneterre, J; Buzdar, A; Nabholtz, JM; Robertson, JF; Thürlimann, B, 2003) |
| "To explore the different sequence interactions between reversible non-steroidal (anastrozole, ANZ and letrozole, LTZ) and non-reversible steroidal aromatase inhibitors (formestane, FOR and exemestane, EXE), we evaluated the clinical benefit (CB) in postmenopausal breast cancer patients, who had previously received anastrozole and subsequently formestane." | 9.10 | Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women? ( Carlini, P; Cognetti, F; Colella, E; Di Cosimo, S; Fabi, A; Ferretti, G; Frassoldati, A; Papaldo, P; Romiti, A; Ruggeri, EM; Tomao, S; Tonachella, R, 2003) |
| "It was previously shown that letrozole (Femara) was significantly more potent than anastrozole (Arimidex) in inhibiting aromatase activity in vitro and in inhibiting total body aromatisation in patients with breast cancer." | 9.10 | An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. ( Ben Ayed, F; Burdette-Radoux, S; Caicedo, JJ; Chaudri-Ross, HA; Davidson, N; Gershanovich, M; Gervasio, H; Johnson, S; Lang, R; Manikhas, G; Pluzanska, A; Rose, C; Thomas, R; Vtoraya, O, 2003) |
| "The first analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial (median follow-up, 33 months) demonstrated that in adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer, anastrozole was superior to tamoxifen in terms of disease-free survival (DFS), time to recurrence (TTR), and incidence of contralateral breast cancer (CLBC)." | 9.10 | Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update ana ( Baum, M; Buzdar, A; Cuzick, J; Forbes, J; Houghton, J; Howell, A; Sahmoud, T, 2003) |
| "Results from two studies, the North American trial and the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability (TARGET) trial carried out in Europe/rest of the world comparing 'Arimidex' (anastrozole) 1 mg with tamoxifen 20 mg for treatment of advanced breast cancer in postmenopausal women, have previously been reported individually and as a prospectively combined analysis." | 9.10 | Advanced breast cancer updates on anastrozole versus tamoxifen. ( Nabholtz, JM, 2003) |
| "ATAC, a randomized, double-blind trial, compared tamoxifen (20 mg) with anastrozole ('Arimidex') (1 mg) alone, and the combination of anastrozole plus tamoxifen (combination), as adjuvant endocrine treatment for postmenopausal patients with early breast cancer." | 9.10 | 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview. ( Buzdar, AU, 2003) |
| "Twelve postmenopausal women with estrogen receptor-positive, metastatic breast cancer were treated with anastrozole 1 mg orally (PO) and letrozole 2." | 9.10 | Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. ( Anker, G; Dowsett, M; Geisler, J; Haynes, B; Lønning, PE, 2002) |
| "Anastrozole is an effective and well tolerated endocrine option for the treatment of postmenopausal patients with hormone-sensitive early breast cancer." | 9.10 | Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. ( Baum, M; Budzar, AU; Cuzick, J; Forbes, J; Houghton, JH; Klijn, JG; Sahmoud, T, 2002) |
| "Thirty-four post-menopausal women with early breast cancer who had received 20 mg tamoxifen once daily as adjuvant therapy for at least 10 weeks participated in a randomized, double-blind, parallel-group, multicentre trial." | 9.09 | The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer. ( Baum, M; Blackman, GM; Dowsett, M; Howell, A; King, N; Ponzone, R; Tobias, JS; von Euler, M; Welch, H, 1999) |
| "Sixty postmenopausal women with advanced breast cancer were randomized to receive either anastrozole 1 mg once daily orally (n = 29), or formestane 250 mg once every two weeks by intramuscular injection (n = 31)." | 9.09 | A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex) with intramuscular formestane in postmenopausal women with advanced breast cancer. ( Calvo, L; Clack, G; Dodwell, DJ; Dowsett, M; Kleeberg, UR; Perez-Carrion, R; Robertson, JF; Vorobiof, DA, 1999) |
| "This paper reports on the clinical relevance of durable static disease (SD) (> or = 24 weeks) in breast cancer patients treated with the aromatase inhibitor anastrozole." | 9.09 | Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer. ( Buzdar, A; Howell, A; Lee, D; Robertson, JF; von Euler, M, 1999) |
| "Anastrozole, an orally active, nonsteroidal aromatase inhibitor, was evaluated in a randomized, double-blind, single-center study to determine its efficacy as neoadjuvant therapy in postmenopausal women with newly diagnosed, estrogen receptor-rich, locally advanced or large (>3 cm), operable breast cancers." | 9.09 | The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. ( Bellamy, C; Dixon, JM; Hoctin-Boes, G; Miller, WR; Renshaw, L; Stuart, M, 2000) |
| "To compare the efficacy and tolerability of anastrozole (Arimidex; AstraZeneca, Wilmington, DE, and Macclesfield, United Kingdom) with that of tamoxifen as first-line therapy for advanced breast cancer (ABC) in postmenopausal women." | 9.09 | Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. ( Bonneterre, J; Koralewski, P; Krzakowski, M; Mauriac, L; Robertson, JF; Steinberg, M; Thürlimann, B; Vergote, I; von Euler, M; Webster, A, 2000) |
| "The efficacy and tolerability of anastrozole (Arimidex; AstraZeneca, Wilmington, DE, and Macclesfield, United Kingdom) and tamoxifen were compared as first-line therapy for advanced breast cancer in 353 postmenopausal women." | 9.09 | Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. ( Burton, G; Buzdar, A; Harwin, W; Mangalik, A; Nabholtz, JM; Pollak, M; Steinberg, M; von Euler, M; Webster, A, 2000) |
| "Anastrozole (Arimidex) is a novel, selective, and potent aromatase inhibitor used for the treatment of postmenopausal breast cancer." | 9.09 | Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. ( Berntsen, H; Detre, S; Dowsett, M; Einstein Lønning, P; Geisler, J; Lindtjørn, B; Ottestad, L, 2001) |
| "The ATAC trial evaluates in a randomized, double-blind design, Arimidextrade mark (anastrozole) alone or in combination with tamoxifen, relative to tamoxifen alone as 5-year adjuvant treatment in postmenopausal women with early breast cancer." | 9.09 | Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial. ( Cuzick, J; Dowsett, M; Howell, A; Jackson, I, 2001) |
| "Anastrozole, 1 and 10 mg once daily, is well tolerated and as effective as megestrol acetate in the treatment of postmenopausal women with advanced breast cancer who progressed following tamoxifen treatment." | 9.08 | Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. ( Azab, M; Blomqvist, C; Buzdar, A; Eiermann, W; Howell, A; Jonat, W; Jones, SE; Plourde, PV; Vogel, CL; Webster, A; Wolter, JM, 1996) |
| "The aim of this study was to compare the efficacy and tolerability of the new aromatase inhibitor 'ARIMIDEX' (anastrozole) with megestrol acetate in the treatment of advanced breast cancer in postmenopausal women." | 9.08 | A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. ( Azab, M; Blomqvist, C; Eiermann, W; Hellmund, R; Howell, A; Jonat, W; Lundgren, S; Mauriac, L; Roche, H; Tyrrell, C; Winblad, G, 1996) |
| "The effect of anastrozole ('Arimidex', ZD1033), a new, selective, non-steroidal aromatase inhibitor on in vivo aromatisation and plasma oestrogen levels was evaluated in post-menopausal women with breast cancer." | 9.08 | Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. ( Dowsett, M; Geisler, J; King, N; Kormeset, PO; Lundgren, S; Lønning, PE; Ottestad, L; Walton, P, 1996) |
| "Anastrozole, given in doses of 1 and 10 mg once daily, represents a well tolerated and effective therapeutic option for the treatment of postmenopausal women with advanced breast carcinoma who progress after tamoxifen treatment." | 9.08 | A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. ( Buzdar, AU; Jones, SE; Plourde, P; Vogel, CL; Webster, A; Wolter, J, 1997) |
| "The relative efficacy and tolerability of the aromatase inhibitors anastrozole (Arimidex) and formestane are assessed in a direct comparative trial in postmenopausal women with advanced breast cancer." | 9.08 | A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer. ( Aparicio, LA; Carrion, RP; Dodwell, DJ; Dowsett, M; Kleeberg, UR; Robertson, JF; Vorobiof, DA, 1997) |
| "For patients with hormone receptor (HR)-positive advanced breast cancer, whether the combination of anastrozole and fulvestrant is more effective than anastrozole alone is controversial." | 9.05 | Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials. ( Duan, S; He, Y; Li, M; Liao, C; Wei, Y; Xiong, Y; Yi, F; Zhang, W, 2020) |
| " Herein, we reported a case of hallucination related to anastrozole in a patient with metastatic breast cancer." | 9.01 | In case of anastrozole-related hallucinations, can switching to letrozole be a treatment option? A case report and literature review. ( Bozkaya, Y; Demirci, NS; Erdem, GU, 2019) |
| "Fulvestrant, a selective estrogen receptor degrader, is approved for first- and second-line treatment of postmenopausal women with hormone receptor-positive advanced breast cancer (ABC)." | 9.01 | A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer. ( Bradbury, I; Campbell, C; Di Leo, A; Ellis, M; Jiang, Z; Ohno, S; Pritchard, KI; Robertson, JFR, 2019) |
| "Whether anastrozole has superior effects to tamoxifen for breast cancer remains controversial." | 8.95 | A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancer. ( Pan, W; Sun, X; Tang, X; Wu, S; Yang, Y, 2017) |
| "Fulvestrant is a selective oestrogen receptor down-regulator (SERD), which by blocking proliferation of breast cancer cells, is an effective endocrine treatment for women with hormone-sensitive advanced breast cancer." | 8.95 | Fulvestrant for hormone-sensitive metastatic breast cancer. ( Goodwin, A; Lee, CI; Wilcken, N, 2017) |
| "We conducted a review of randomized trials to compare the overall survival (OS) with fulvestrant 500 mg versus alternative treatment for estrogen receptor-positive advanced breast cancer following endocrine therapy failure." | 8.93 | Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy. ( Batson, S; Jones, N; Livings, C; Telford, C, 2016) |
| " We report an unusual case of urticarial vasculitis following the aromatase inhibitor anastrozole that localised to the unilateral trunk and mastectomy scar, and review the literature on the cutaneous adverse effects of hormonal therapy for breast cancer." | 8.90 | Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: a case of localised urticarial vasculitis following anastrozole therapy and a review of the literature. ( Bock, VL; Friedlander, M; Kossard, S; Waring, D; Wood, GK, 2014) |
| " Only RCTs that compared fulvestrant 250 mg to anastrozole 1mg in postmenopausal women with advanced breast cancer were selected." | 8.90 | Fulvestrant 250 mg versus anastrozole 1 mg in the treatment of advanced breast cancer: a meta-analysis of randomized controlled trials. ( Fan, Y; Gong, DD; Man, CF; Xu, J, 2014) |
| "Fulvestrant is a highly active systemic therapy in patients with metastatic hormone receptor positive breast cancer." | 8.89 | A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer. ( Haaland, B; Lopes, G; Montero, AJ; Tan, PS, 2013) |
| "Anastrozole (Arimidex) is an aromatase inhibitor approved in the EU, the US and in other countries worldwide for use as an adjuvant treatment in postmenopausal women with early-stage, hormone receptor-positive breast cancer." | 8.84 | Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer. ( Plosker, GL; Sanford, M, 2008) |
| "A 5-year regimen of tamoxifen hormone therapy has historically been the recommendation for hormone receptor-positive, postmenopausal women with early-stage breast cancer." | 8.84 | Review of the ATAC study: tamoxifen versus anastrozole in early-stage breast cancer. ( Needleman, SJ; Tobias, JS, 2008) |
| " The PCT responded partially to the cessation of oral contraceptives and to phlebotomy therapy to maintain low iron stores, but only remitted after she received anastrozole therapy for management of adenocarcinoma of the breast at age 59 years." | 8.84 | Remission of porphyria cutanea tarda after anastrozole treatment of breast cancer. ( Barton, JC; Bertoli, LF, 2007) |
| " PubMed and MEDLINE were searched for descriptions of clinical trials published from 1990 to 2007 using the terms breast cancer, extended adjuvant, aromatase inhibitor, anastrozole, exemestane, and letrozole." | 8.84 | Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women. ( Jahanzeb, M, 2007) |
| "Third-generation aromatase inhibitors are accepted widely as alternatives to tamoxifen for the treatment of advanced breast cancer in postmenopausal women and, currently, are increasingly replacing tamoxifen in the adjuvant setting." | 8.83 | Anastrozole for breast cancer: recent advances and ongoing challenges. ( Buzdar, AU, 2006) |
| "We did a meta-analysis of three clinical trials--the Austrian Breast and Colorectal Cancer Study Group (ABCSG 8), Arimidex-Nolvadex (ARNO 95), and the Italian Tamoxifen Anastrozole (ITA) studies--in which postmenopausal women with histologically confirmed, hormone-sensitive early-stage breast cancer were randomised to 1 mg/day anastrozole (n=2009) after 2-3 years of tamoxifen treatment or to continued 20 or 30 mg/day tamoxifen (n=1997)." | 8.83 | Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. ( Boccardo, F; Gnant, M; Greenwood, M; Jakesz, R; Jonat, W; Kaufmann, M; Rubagotti, A; Zuna, I, 2006) |
| "Current prevention trials have shown that tamoxifen can reduce the incidence of breast cancer by about 30%-40% in high-risk women, but that the risk of thromboembolic disease and endometrial cancer are increased about twofold." | 8.82 | Aromatase inhibitors in prevention--data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). ( Cuzick, J, 2003) |
| "Anastrozole ('Arimidex') is indicated for the treatment of advanced breast cancer in postmenopausal women." | 8.82 | Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. ( Bonneterre, J; Buzdar, A; Nabholtz, JM; Robertson, JF; Thürlimann, B, 2003) |
| "This commentary article provides an overview of recent clinical research trials involving anastrozole and its evolving role in the management of breast cancer." | 8.82 | Focus on anastrozole and breast cancer. ( Mokbel, K, 2003) |
| " Here we review available efficacy data to address whether or not anastrozole, a non-steroidal aromatase inhibitor (AI), is effective in postmenopausal patients with advanced breast cancer (ABC) and visceral metastases." | 8.82 | A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases. ( Howell, A; Robertson, JF; Vergote, I, 2003) |
| "Tamoxifen is currently a standard of care for postmenopausal patients with breast cancer with hormone receptor-positive tumors who are candidates for adjuvant endocrine therapy." | 8.82 | Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer. ( Boccardo, F, 2004) |
| "For many years, tamoxifen has been the 'gold standard' amongst anti-oestrogen therapies for breast cancer." | 8.82 | Endocrine treatment options for advanced breast cancer--the role of fulvestrant. ( Beex, L; Come, SE; Jones, SE; Kaufmann, M; Makris, A; Nortier, JW; Possinger, K; Robertson, JF; Rutqvist, LE, 2005) |
| "Fulvestrant, an estrogen receptor antagonist that downregulates the estrogen receptor but has no known agonist effects, has been evaluated in 2 randomized trials involving postmenopausal women with hormone receptor-positive, progressive advanced-stage breast cancer after disease progression with antiestrogen therapy." | 8.82 | Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer. ( Jones, SE; Pippen, J, 2005) |
| "Fulvestrant, a new type of oestrogen receptor antagonist with no agonist effects, is now licensed in the EU and USA for the treatment of postmenopausal women with hormone-sensitive advanced breast cancer following progression on prior antioestrogen therapy." | 8.82 | A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer. ( Dodwell, D; Vergote, I, 2005) |
| "Letrozole, a third-generation aromatase inhibitor, has been the only aromatase inhibitor to date to show unequivocal superiority to tamoxifen as first-line treatment of metastatic postmenopausal breast cancer." | 8.81 | Letrozole for the management of breast cancer. ( Goss, PE; Smith, RE, 2002) |
| "Anastrozole, a nonsteroidal selective aromatase inhibitor, has recently been approved in the US and several other countries for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer." | 8.81 | Anastrozole: in early breast cancer. ( Faulds, DM; Wellington, K, 2002) |
| "The role of anastrozole, a new selective aromatase inhibitor, in treating hormone-responsive metastatic breast cancer is discussed." | 8.80 | Anastrozole: a selective aromatase inhibitor for the treatment of breast cancer. ( alKhouri, N; Higa, GM, 1998) |
| "Anastrozole is a new oral nonsteroidal aromatase inhibitor indicated for the second-line endocrine treatment of postmenopausal women with advanced breast cancer." | 8.80 | Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer. ( Adkins, JC; Wiseman, LR, 1998) |
| "In patients with metastatic breast cancer, second-line therapy with aromatase inhibitors can improve survival in comparison with megestrol." | 8.80 | Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol. ( Cattel, F; Messori, A; Trippoli, S; Vaiani, M, 2000) |
| " There have been few reports in the literature on visual disturbance in patients on long-term treatment with Anastrozole for breast cancer prevention; but none had symptoms worse than blurry vision and/or xerostomia." | 8.31 | Optic Neuritis as a Consequence of Long-Term Medical Treatment Using Anastrozole: A Case Report. ( Velez Oquendo, G, 2023) |
| " Anastrozole, a nonselective aromatase inhibitor used in breast cancer management has been associated with different cutaneous side effects, of which EM is rarely seen and usually in a minor or major form with typical target lesions." | 8.31 | Segmental Erythema Multiforme: An Unusual Drug Reaction to Anastrozole. ( Buljan, M; Filipović, N; Poduje, S; Vučić, M; Vujević, L, 2023) |
| "Our previous matched case-control study of postmenopausal women with resected early-stage breast cancer revealed that only anastrozole, but not exemestane or letrozole, showed a significant association between the 6-month estrogen concentrations and risk of breast cancer." | 8.12 | Anastrozole Regulates Fatty Acid Synthase in Breast Cancer. ( Bari, MG; Cairns, J; Gao, H; Goetz, MP; Ingle, JN; Kalari, KR; Li, H; Wang, L; Weinshilboum, RM, 2022) |
| "This study aimed to reveal the treatment patterns and clinical outcomes of diverse palbociclib-based regimens in Han patients with estrogen receptor-positive (ER+) metastatic breast cancer in routine clinical practice." | 8.12 | Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population. ( Cai, R; Li, Q; Luo, Y; Ma, F; Mo, H; Wang, J; Xu, B; Yuan, P; Zhang, P, 2022) |
| "A 73- year-old woman was diagnosed by chance with late recurrence of HR+ breast cancer 21 years after undergoing radical resection followed by adjuvant anastrozole for 5 years for stage Ⅲb right breast cancer." | 8.02 | [A Case of Advanced Late Recurrence of Hormone Receptor Positive Breast Cancer Successfully Treated with Abemaciclib and Anastrozole]. ( Araki, K; Hamada, M; Ikeda, T; Minamoto, K, 2021) |
| "This case highlights the dual benefit of tamoxifen therapy in the treatment of hormone-receptor-positive breast cancer and acromegaly." | 8.02 | Dual treatment of acromegaly and hormone-receptor-positive breast cancer with tamoxifen: a case report. ( Abramowitz, J; Chan, AVC; Ganji, N; Mirfakhraee, S, 2021) |
| " This study investigated the effects of anastrozole and antiplatelet therapy (aspirin/clopidogrel cocktail or atopaxar) treatment on the tumour responses of luminal phenotype breast cancer cells and induced hypercoagulation." | 8.02 | Antiplatelet Therapy Combined with Anastrozole Induces Features of Partial EMT in Breast Cancer Cells and Fails to Mitigate Breast-Cancer Induced Hypercoagulation. ( Augustine, TN; Xulu, KR, 2021) |
| "In a recent randomized, open-label trial (S0226), the addition of fulvestrant to anastrozole therapy decreased the risk of progression and death in patients with hormone-receptor-positive metastatic breast cancer." | 7.96 | First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis. ( Bai, L; Huang, J; Li, Q; Liao, W; Wen, F; Wu, Q; Zhang, N; Zhou, K, 2020) |
| "A 61-year-old woman was found to have multiple pulmonary nodules on chest computed tomography (CT) after being treated for 5 months with anastrozole as an adjuvant breast cancer therapy." | 7.96 | Anastrozole-induced pulmonary cryptococcosis in a patient with early breast cancer: A case report. ( Liu, K; Wei, M; Wen, P; Xu, YR, 2020) |
| "To determine if the degree of estrogen suppression with aromatase inhibitors (AI: anastrozole, exemestane, letrozole) is associated with efficacy in early-stage breast cancer, and to examine for differences in the mechanism of action between the three AIs." | 7.96 | Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α. ( Barman, P; Cairns, J; Carlson, EE; Chen, BE; Correia, C; Cuellar, ME; Desta, Z; Ellis, MJ; Fasching, PA; Goetz, MP; Goodnature, B; Goss, PE; Haddad, T; Hoskin, TL; Ingle, JN; Kalari, KR; Kaufmann, SH; Shepherd, LE; Singh, RJ; Suman, VJ; Volz, B; Walters, MA; Wang, L; Weinshilboum, RM, 2020) |
| "Our results suggested that BMI and AI drug (letrozole versus anastrozole) were clinical predictors of arthralgia, while genetic variants rs4775936, rs9322336, rs2234693, and rs9340799 were genetic predictors of AI-induced arthralgia." | 7.96 | Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients. ( Borrie, AE; Choi, YH; Hahn, K; Kim, RB; Lenehan, J; Lock, M; Logan, D; Perera, FE; Potvin, K; Read, N; Rose, FA; Sexton, T; Teft, WA; Vandenberg, TA; Welch, S; Yaremko, B; Younus, J; Yu, E, 2020) |
| "The S0226 trial demonstrated that the combination of half-dose fulvestrant (FUL) and anastrozole (ANA) (F&A) caused a significant improvement in overall survival (OS) versus ANA monotherapy for first-line treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer (PMW-MBC (HR+))." | 7.96 | Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis. ( Huang, P; Huang, X; Lin, S; Liu, Y; Luo, S; Ming, WK; Wang, H; Weng, X, 2020) |
| "Platelet-tumour cell interaction is implicated in the initiation of breast cancer-associated thrombosis, with hormone-therapy (Tamoxifen/Anastrozole), increasing this risk." | 7.91 | Breast cancer cell-induced platelet activation is compounded by tamoxifen and anastrozole in vitro. ( Augustine, TN; Chetty, N; Dix-Peek, T; Duarte, R; Pather, K, 2019) |
| "Anastrozole (ANS) is an aromatase inhibitor that is widely used as a treatment for breast cancer in postmenopausal women." | 7.88 | Preparation of anastrozole loaded PEG-PLA nanoparticles: evaluation of apoptotic response of breast cancer cell lines. ( Alaamery, M; Alghamdi, B; Almutairi, MS; Alomran, N; Alyafee, YA; Bawazeer, S; Daghestani, M; Massadeh, S; Sheereen, A, 2018) |
| "Fulvestrant is a steroidal selective estrogen receptor degrader that was approved by the US FDA in 2002 for treatment of ER-positive metastatic breast cancer (ER + MBC) post-progression on aromatase inhibitors." | 7.88 | Fulvestrant in management of hormone receptor-positive metastatic breast cancer. ( Ellis, MJ; Shafaee, MN, 2018) |
| "We determined gonadotropin-, estradiol- and anastrozole- serum concentrations from postmenopausal, early stage breast cancer patients receiving upfront anastrozole within routine after care." | 7.85 | Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole? ( Beer, B; Czech, T; Daniaux, M; Holzner, B; Hubalek, M; Kemmler, G; Meraner, V; Oberacher, H; Oberguggenberger, A; Sperner-Unterweger, B; Sztankay, M; Weigel, G; Wildt, L, 2017) |
| "Among 1203 subjects who were taking adjuvant TMX or AI (anastrozole or letrozole) without fatty liver at baseline, those taking TMX or AI were 1:1 matched on the propensity score." | 7.85 | Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study. ( Hong, N; Kim, SI; Park, S; Rhee, Y; Seo, DH; Sohn, JH; Yoon, HG, 2017) |
| "Although recent studies demonstrated that fulvestrant is superior to anastrozole as first-line treatment for hormone receptor (HR)-positive advanced breast cancer, the cost-effectiveness of fulvestrant versus anastrozole remained uncertain." | 7.85 | Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer. ( Ding, H; Fang, L; Huang, P; Tong, Y; Xin, W; Zhou, Q, 2017) |
| "We report the case of a patient in which S-1 plus anastrozole was administered as first-line chemotherapy for Stage IV breast cancer with skin invasion, multiple lymph node metastasis, and lymphangitis carcinomatosis." | 7.85 | [A Case of Stage IV Breast Cancer with Extensive Metastasis Successfully Treated with S-1 plus Anastrozole Therapy]. ( Akami, T; Hatakeyama, T; Matsumura, A; Mugitani, T; Ogino, S; Okano, S; Sakai, T, 2017) |
| "Anastrozole, an aromatase inhibitor widely used in breast cancer, has recently been indicated to be a P-glycoprotein (ABCB1) substrate." | 7.85 | Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients. ( Carrillo, JA; Gervasini, G; Jara, C; Martínez, R; Olier, C; Romero, N, 2017) |
| "Treatment with the CDK4/6 inhibitor abemaciclib, alone or in combination with endocrine therapy, significantly lowered expression of the protein Ki67-a key marker of cell proliferation-in women with hormone receptor-positive, HER2-negative breast cancer." | 7.85 | Abemaciclib Shows Promise for Early Breast Cancer. ( , 2017) |
| "The aim of present study was to develop conventional and PEGylated (long circulating), liposomes containing anastrozole (ANS) for effective treatment of breast cancer." | 7.83 | PEGylated liposomes of anastrozole for long-term treatment of breast cancer: in vitro and in vivo evaluation. ( Behl, G; Dave, V; Deshpande, PB; Kumar, AR; Kushwaha, K; Nayak, UY; Raghavendra, R; Shavi, GV; Sreenivasa Reddy, M; Udupa, N, 2016) |
| "A total of 391 postmenopausal Japanese women with estrogen receptor-positive breast cancer and treated with adjuvant anastrozole were enrolled from 28 centers for assessment of patient-reported outcomes (PROs) in this prospective cohort study (SAVS-JP, UMIN000002455)." | 7.83 | Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes. ( Baba, M; Egawa, C; Hashimoto, T; Hidaka, T; Hirokaga, K; Ichii, S; Kikawa, Y; Kitatsuji, K; Kokufu, I; Konishi, M; Konishi, Y; Kono, S; Matsumoto, T; Minohata, J; Mitsunobu, M; Miya, A; Miyashita, M; Miyauchi, K; Miyoshi, Y; Nishikawa, H; Nishino, M; Oh, K; Okuno, T; Sakita, I; Sakoda, Y; Suwa, H; Takao, S; Wakita, K; Yamagami, K, 2016) |
| "A limited number of studies have been conducted on the effects of hormonal therapy with tamoxifen (TMX) or aromatase inhibitors (AIs) on plasma levels of leptin and adiponectin, as well as body composition in breast cancer (BC) patients." | 7.83 | The Effects of Adjuvant Endocrine Treatment on Serum Leptin, Serum Adiponectin and Body Composition in Patients with Breast Cancer: The Izmir Oncology Group (IZOG) Study. ( Akyol, M; Alacacioglu, A; Bayoglu, V; Demir, L; Dirican, A; Ellidokuz, H; Gumus, Z; Kucukzeybek, B; Kucukzeybek, Y; Salman, T; Sutcu, R; Tarhan, MO; Varol, U; Yildiz, I; Yildiz, Y, 2016) |
| "This was an exploratory secondary analysis in 49 postmenopausal women receiving anastrozole therapy for early-stage breast cancer." | 7.83 | The association between pre-treatment occupational skill level and mood and symptom burden in early-stage, postmenopausal breast cancer survivors during the first year of anastrozole therapy. ( Bender, CM; McCue, M; Merriman, JD; Nugent, BD; Rosenzweig, M; Sereika, SM, 2016) |
| "The aim of this study was to investigate the influence of anastrozole on serum hormone levels in postmenopausal women with hormone receptor-positive breast cancer." | 7.81 | Effect of anastrozole on hormone levels in postmenopausal women with early breast cancer. ( Albert, US; Hadji, P; Hars, O; Kalder, M; Kyvernitakis, I; Winarno, AS, 2015) |
| "The aim of this study was to determine the budget impact of everolimus (in combination with letrozole/anastrozole) as a second-line treatment for ER+ HER2- negative advanced and metastatic breast cancer in post-menopausal women." | 7.81 | Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in Kazakhstan. ( Kaldygul Kabakovna, S; Kuanysh Shadybayevich, N; Lewis, L; Ramil Zufarovich, A; Suriya Ertugyrovna, Y; Taylor, M, 2015) |
| "The present study aimed to assess the effects of aromatase inhibitor anastrozole and testosterone undecanoate, separately and in combination, on proliferation and apoptosis in MCF-7 human breast cancer cells cultured in vitro." | 7.81 | Antiproliferative effects of anastrozole on MCF-7 human breast cancer cells in vitro are significantly enhanced by combined treatment with testosterone undecanoate. ( Chen, R; Cui, J; Hu, H; Li, P; Liu, X; Wang, Q; Wei, W, 2015) |
| "Patients with hormone receptor-positive metastatic breast cancer treated between 1st January 2005 and 31st December 2010 with a combination of capecitabine and AI were evaluated and outcomes were compared with those of women treated with capecitabine in conventional dose or AI as a monotherapy." | 7.81 | Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis. ( Jeyaraj, PA; Julka, PK; Kamal, VK; Mahajan, MK; Malik, A; Patil, J; Rath, GK; Roy, S; Shankar, A, 2015) |
| "Estradiol concentrations in postmenopausal women with early, ER-positive breast cancer on anastrozole were significantly different in normal weight versus overweight or obese patients at baseline, but not at 12 and 24 months." | 7.80 | Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole. ( Bauer, T; Hadji, P; Hars, O; Knöll, D; Kyvernitakis, I; Struck, M, 2014) |
| "In this paper, computational studies were carried out on anastrozole and letrozole, chemotherapy drugs used against breast cancer." | 7.80 | Computational studies on the anastrozole and letrozole, effective chemotherapy drugs against breast cancer. ( Akçay, HT; Bayrak, R, 2014) |
| "We identified the first dispensing of tamoxifen, anastrozole or letrozole for women diagnosed with invasive breast cancer in the 45 and Up Study from 2004-2009 (N = 1266)." | 7.80 | Women commencing anastrozole, letrozole or tamoxifen for early breast cancer: the impact of comorbidity and demographics on initial choice. ( Boyle, F; Bulsara, M; Holman, CD; Kemp, A; Malacova, E; Preen, DB; Roughead, EE; Saunders, C, 2014) |
| "A total of 216 postmenopausal patients with early-stage breast cancer who were receiving AI treatment with anastrozole constituted the final sample included in the analysis." | 7.80 | Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels. ( Beer, B; Giesinger, J; Holzner, B; Hubalek, M; Kemmler, G; Meraner, V; Oberacher, H; Oberguggenberger, A; Schubert, B; Seeber, B; Sperner-Unterweger, B; Sztankay, M; Wildt, L, 2014) |
| "In the IBIS II Prevention Study, postmenopausal women at high risk of breast cancer given the aromatase inhibitor anastrozole were 53% less likely to develop the disease after 10 years than women who took placebo." | 7.80 | Anastrozole may aid breast cancer prevention. ( , 2014) |
| "A 65-year-old woman on anastrozole treatment because of a recurrent breast cancer developed hypercalcaemia and increased parathyroid hormone (PTH) levels 2½ years after start of the treatment." | 7.80 | Anastrozole can cause severe hypercalcaemia mimicking primary hyperparathyroidism. ( Järhult, J, 2014) |
| "Because of its superior efficacy to tamoxifen, anastrozole has been widely used in Japan as an adjuvant treatment for postmenopausal, hormone-responsive breast cancer patients." | 7.80 | A multicenter prospective study to evaluate bone fracture related to adjuvant anastrozole in Japanese postmenopausal women with breast cancer: two-year interim analysis of Saitama Breast Cancer Clinical Study Group (SBCCSG-06). ( Futsuhara, K; Kai, T; Kojima, M; Tabei, T; Takei, H; Takeuchi, H; Yoshida, T, 2014) |
| "A 69-year-old postmenopausal woman who was prescribed anastrozole for 10 months after surgical removal of her breast cancer, was referred to our hospital for acute renal failure." | 7.79 | [A case of crescentic glomerulonephritis developed under oral anastrozole treatment]. ( Fujiki, K; Fujimoto, T; Inoue, F; Ishikawa, H; Maruyama, N; Nakano, T; Nakatani, K; Oka, H; Ueshima, K; Yoshimoto, S, 2013) |
| "This is a 5-year interim analysis of a 10-year, prospective, observational, IRB approved study investigating the incidence of breast cancer in women presenting with symptoms of hormone deficiency treated with subcutaneous testosterone (T) implants or, T combined with the aromatase inhibitor anastrozole (A), i." | 7.79 | Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study. ( Dimitrakakis, C; Glaser, RL, 2013) |
| "To estimate the budget impact of everolimus as the first and second treatment option after letrozole or anastrozole (L/A) failure for post-menopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (ABC)." | 7.79 | Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. ( De, G; Diener, M; Namjoshi, M; Wu, EQ; Xie, J; Yang, H, 2013) |
| "The aim of this study was to assess the effect of adjuvant anastrozole, alone or associated with risedronate, on BMD and bone fracture risk in women more than 70 years old with hormone receptor-positive early breast cancer (EBC)." | 7.78 | Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer. ( Basso, U; Berton, L; Brunello, A; Coin, A; Falci, C; Manzato, E; Monfardini, S; Perissinotto, E; Pintore, G; Sergi, G; Veronese, N, 2012) |
| "Tumor specimens from a subset of postmenopausal patients with hormone receptor-positive early-stage (stages I, II, and IIIA) breast cancer, who were enrolled in the randomized double-blind Arimidex, Tamoxifen, Alone or in Combination (ATAC) clinical trial, were genotyped for variants in CYP2D6 (N = 1203 patients: anastrozole [trade name: Arimidex] group, n = 615 patients; tamoxifen group, n = 588 patients) and UDP-glucuronosyltransferase-2B7 (UGT2B7), whose gene product inactivates endoxifen (N = 1209 patients; anastrozole group, n = 606 patients; tamoxifen group, n = 603 patients)." | 7.78 | CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. ( Cuzick, J; Dowsett, M; Drury, S; Hayes, DF; Haynes, BP; Rae, JM; Salter, J; Sestak, I; Stearns, V; Thibert, JN, 2012) |
| "We report a case of recurrent hormone receptor-positive breast cancer with brain metastases that showed good response to vinorelbine(VNR)and anastrozole(ANA)." | 7.78 | [A case of recurrent breast cancer with brain metastases successfully treated with vinorelbine and anastrozole after multiple chemo-endocrine therapies]. ( Hikino, H; Koike, M; Mukai, T; Murata, Y, 2012) |
| "Weight gain is commonly reported by breast cancer patients on tamoxifen or aromatase inhibitors." | 7.78 | Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. ( Cuzick, J; Dowsett, M; Forbes, JF; Harvie, M; Howell, A; Sestak, I, 2012) |
| "To investigate whether suppression of plasma estradiol and estrone sulfate levels by the aromatase inhibitors (AIs) anastrozole and letrozole is related to body mass index (BMI) in postmenopausal women with early estrogen receptor (ER) -positive breast cancer." | 7.78 | Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. ( A'Hern, RP; Dixon, JM; Dowsett, M; Folkerd, EJ; Renshaw, L, 2012) |
| "Bilateral salpingo-oophrectomy rendered the patient postmenopausal and enabled the commencement of the aromatase inhibitor anastrozole as an alternative adjuvant therapy for breast cancer." | 7.77 | Ovarian hyperstimulation syndrome in a patient treated with tamoxifen for breast cancer. ( Baigent, A; Lashen, H, 2011) |
| "Study 1: Blood was collected from ten postmenopausal women with breast cancer before and after two-week treatment with anastrozole and serum concentrations of androstenediol and other androgens and estrogens were assessed." | 7.77 | Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer. ( Coombes, RC; Dowsett, M; Folkerd, EJ; Palmieri, C; Purohit, A; Reed, MJ; Stanczyk, FZ; Stanway, SJ; Ward, R, 2011) |
| "To assess the predictive value of Ki67 expression in postmenopausal hormone receptor-positive early-breast cancer patients, who were either treated with adjuvant tamoxifen (TAM) alone or with TAM followed by anastrozole (ANA)." | 7.77 | Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer. ( Bago-Horvath, Z; Böhm, G; Dubsky, P; Filipits, M; Gnant, M; Greil, R; Gruber, C; Haid, A; Jakesz, R; Jasarevic, Z; Jelen, A; Kemmerling, R; Pöstlberger, S; Rudas, M; Singer, CF, 2011) |
| "The aim of this study was to evaluate the effect of anastrozole, a new generation aromatase inhibitor, on the lipid metabolism in postmenopausal Chinese women with early breast cancer, and observe the adverse reactions as well." | 7.77 | [Effects of anastrozole on lipid metabolism in Chinese postmenopausal women with breast cancer]. ( Cai, RG; Li, Q; Lu, HH; Wang, JY; Xu, BH; Yuan, P; Zhang, P, 2011) |
| "To investigate differences of platelet indices in breast cancer patients after tamoxifen (tmx) and anastrazole adjuvant treatment." | 7.76 | Mean platelet volume increase after tamoxifen, but not after anastrazole in adjuvant therapy of breast cancer. ( Alacacioğlu, A; Bilgi, O; Erikçi, AA; Kandemir, EG; Karagöz, B; Ozgün, A; Sayan, O, 2010) |
| "Although anastrozole (ANA), an aromatase inhibitor (AI), has been widely used for breast cancer patients; adverse events during ANA therapy in Japanese patients have not been reported." | 7.76 | Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients. ( Ando, M; Baba, S; Dokiya, F; Douchi, T; Kosha, S; Matsuyama, Y; Ohi, Y; Rai, Y; Sagara, Y; Tamada, S, 2010) |
| " We investigated antitumoral effects of the specific ETAR antagonist ZD4054 in breast cancer cells and xenografts, and assessed antitumoral efficacy of the combinations of ZD4054 with aromatase inhibitors and fulvestrant." | 7.76 | ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole. ( Brodie, A; Chen, S; Fischgräbe, J; Götte, M; Kiesel, L; Macedo, LF; Radke, I; Smollich, M; Wülfing, P, 2010) |
| "To investigate the efficacy and safety of goserelin plus anastrozole in advanced premenopausal breast cancer patients." | 7.76 | [Goserelin plus anastrozole in the treatment of premenopausal patients with metastatic breast cancer]. ( Cai, RG; Li, Q; Ma, F; Wang, JY; Xu, BH; Yao, SY; Yuan, P; Zhang, P, 2010) |
| "Aromatase inhibition (AI) is the most effective endocrine treatment for breast cancer in post-menopausal patients, but a percentage of hormone receptor-positive cancers do not benefit from such therapy: for example, about 20% of patients treated with anastrozole do not respond and it is still impossible to accurately predict sensitivity." | 7.76 | Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer. ( Baiardi, P; Chiorino, G; Costa, A; Da Prada, GA; Fregoni, V; Ghimenti, C; Grosso, E; Marsoni, S; Mello-Grand, M; Miller, WR; Regolo, L; Scatolini, M; Singh, V; Villani, L; Zambelli, A, 2010) |
| "The Breast International Group (BIG) 1-98 and Arimidex, Tamoxifen Alone or in Combination (ATAC) trials demonstrated that, in postmenopausal women with hormone receptor positive (HR+) early-stage breast cancer, 5 years of initial adjuvant endocrine therapy with letrozole or anastrozole is superior to tamoxifen." | 7.76 | Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer. ( Delea, TE; Guo, A; Lipsitz, M, 2010) |
| "We report a 69-year-old woman with breast cancer who was effectively treated with letrozole as a second-line therapy after becoming resistant to anastrozole." | 7.76 | [Advanced breast cancer in a patient achieving long-term SD after letrozole administration for liver metastasis developing during anastrozole therapy]. ( Fujimoto, A; Goto, K; Ichinose, Y; Kobayashi, T; Sasaoki, T; Uchida, S, 2010) |
| "Anastrozole, an aromatase inhibitor, is commonly used in the adjuvant treatment of breast cancer." | 7.75 | Hemicentral retinal artery occlusion in a breast cancer patient using anastrozole. ( Ayata, A; Bilgi, O; Kandemir, EG; Karagöz, B; Ozgün, A; Türken, O; Unal, M; Uzun, G, 2009) |
| "Anastrozole is a selective aromatase inhibitor and is used for the hormonal treatment of postmenopausal breast cancer." | 7.74 | Anastrozole-associated sclerosing glomerulonephritis in a patient with breast cancer. ( Akgul, B; Camci, C; Kalender, ME; Karakok, M; Sevinc, A; Turk, HM, 2007) |
| "The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial showed that 5 years of adjuvant therapy with anastrozole reduced recurrence of breast cancer to a greater extent than did tamoxifen." | 7.74 | Is long-term adjuvant treatment of breast cancer with anastrozole indicated? ( Doggrell, SA, 2008) |
| "This study evaluated the cost-effectiveness of anastrozole versus generic tamoxifen for primary adjuvant treatment of postmenopausal women with hormone receptor-positive (HR+) early breast cancer (EBC), from a US healthcare perspective." | 7.74 | Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone ( Cella, D; Dobrez, D; Gandhi, SK; Locker, GY; Mansel, R; Sorensen, S, 2007) |
| "Optic nerve head (ONH) topography was measured using a commercially available, confocal scanning laser ophthalmoscope for three populations of amenorrheic women ages 40-69 years: subjects using (1) tamoxifen (20 mg/day) or (2) anastrozole (1 mg/day) for < or = 2 years as adjuvant therapy after successful primary treatment for breast cancer, and (3) control subjects with no breast cancer histories and not using any hormonal medication." | 7.74 | Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors. ( Eisner, A; Falardeau, J; Samples, JR; Toomey, MD; Vetto, JT, 2007) |
| "Five years with the aromatase inhibitors letrozole or anastrozole is clinically superior to 5 years tamoxifen in postmenopausal women with early breast cancer." | 7.74 | Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. ( Barghout, V; Delea, T; Karnon, J, 2008) |
| "Adjuvant therapy with anastrozole may be beneficial in resolving endometrial hyperplasia in patients with breast cancer." | 7.74 | Resolution of endometrial hyperplasia with adjuvant anastrozole treatment in postmenopausal breast cancer: a case report. ( Cooper, BC; Stilwill, SE, 2007) |
| "We used longitudinal claims data from three large commercial health programs to estimate adherence with anastrozole therapy among women with early-stage breast cancer." | 7.74 | Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. ( Asnis-Alibozek, A; LaFountain, A; Mayer, E; Partridge, AH; Taylor, BS; Winer, E, 2008) |
| "To examine retrospectively the difference in efficacy by the AI sequence when anastrozole ( ANA) and exemestane (EXE) are clinically administered sequentially for patients with metastatic breast cancer." | 7.74 | [Efficacy of sequential treatment with anastrozole following exemestane compared with exemestane following anastrozole in patients with metastatic breast cancer]. ( Ikeda, M; Kurebayashi, J; Miyake, A; Nakashima, K; Nomura, T; Shiiki, S; Sonoo, H; Tanaka, K; Yamamoto, Y, 2008) |
| "We report three cases with advanced breast cancer were treated with a weekly dose of paclitaxel (TXL)." | 7.73 | [Three cases of advanced breast cancer successfully treated with a weekly dose of paclitaxel]. ( Katsumine, Y; Noda, N; Osawa, I; Uehara, S; Yuasa, H, 2005) |
| "Two third-generation aromatase inhibitors, letrozole and anastrozole, and the antiestrogen tamoxifen, were compared for growth-inhibiting activity in two estrogen receptor (ER)-positive aromatase-overexpressing human breast cancer cell lines, MCF-7aro and T-47Daro." | 7.73 | Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen. ( Chen, S; Itoh, T; Kijima, I, 2005) |
| "The introduction of third generation aromatase inhibitors [anastrozole, letrozole, and exemestane] has certainly improved outcomes inpatients with early breast cancer." | 7.73 | Changing the gold standard in adjuvant therapy for breast cancer:from tamoxifen to aromatase inhibition. ( Gltick, S, 2005) |
| "To conduct an economic analysis comparing tamoxifen and anastrozole (Arimidex) in the adjuvant treatment of hormone receptor-positive (HR+), post-menopausal early breast cancer patients." | 7.73 | Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis. ( Rocchi, A; Verma, S, 2006) |
| "To compare the efficiency of adjuvant therapy with aromatase inhibitors or with tamoxifen in postmenopausal women with operable breast cancer and positive estrogen receptors." | 7.73 | Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer. ( Canorea, F; Del Castillo, A; Gil, JM; González, P; Rubio-Terrés, C, 2006) |
| "The 5-year completed treatment analysis of the Anastrozole and Tamoxifen-Alone or in Combination (ATAC) trial showed the superiority of anastrozole over tamoxifen for reduction of disease progression in patients with hormone receptor-positive (HR+) early breast cancer (EBC)." | 7.73 | Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial. ( Annemans, L; Moeremans, K, 2006) |
| "Recent randomized clinical trials (RCT) comparing anastrozole (Arimidex) and letrozole (Femara) to tamoxifen in the first-line treatment of postmenopausal women with advanced hormone-sensitive breast cancer have demonstrated that both agents were at least as effective as tamoxifen." | 7.72 | Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen. ( Dranitsaris, G; Trudeau, M; Verma, S, 2003) |
| "In a recent trial of first-line therapy in 353 postmenopausal women with predominantly hormone receptor-positive advanced breast cancer (the North American trial), anastrozole 1 mg QD produced a significantly longer time to disease progression (TTP) than tamoxifen 20 mg QD (11." | 7.72 | Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer. ( Buzdar, A; Jones, D; Simons, WR, 2003) |
| "A computer simulation model assessed the outcomes of 64-year-old women with ER-positive breast cancer who subsequently received either anastrozole or tamoxifen for 5 years." | 7.72 | Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. ( Hillner, BE, 2004) |
| "We reviewed therapeutic effects and harmful side effects in 33 patients with advanced or recurrent breast cancer who underwent treatment with Anastrozole 1 mg/day in our department." | 7.72 | [Therapeutic effects of Anastrozole in patients with advanced and recurrent breast cancer]. ( Hirono, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, T; Okubo, S; Sonoo, H; Tanaka, K; Udagawa, K, 2004) |
| "To determine the quality of life (QoL) of women participating in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial during the first 2 years of treatment." | 7.72 | Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. ( Cella, D; Cuzick, J; Fallowfield, L; Francis, S; Howell, A; Locker, G, 2004) |
| "Thirty-four consecutive patients with advanced breast cancer received anastrozole 1 mg/day." | 7.71 | Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism. ( Bajetta, E; Bombardieri, E; Ferrari, L; La Torre, I; Longarini, R; Martinetti, A; Pozzi, P; Salvucci, G; Seregni, E; Zilembo, N, 2002) |
| "To evaluate the response rate and survival duration of patients treated with anastrozole for metastatic breast cancer, who had previously received at least one line of hormonal therapy." | 7.71 | Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer. ( Cohen, Y; Geffen, DB; Lavrenkov, K; Man, S, 2002) |
| "Randomized trials comparing the aromatase inhibitors, anastrozole and letrozole, to megestrol acetate (MA) in postmenopausal women with advanced breast cancer demonstrated that both agents are better tolerated than MA with comparable efficacy." | 7.70 | Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate. ( Dranitsaris, G; Leung, P; Mather, J; Oza, A, 2000) |
| "To study the effect and adverse reactions of anastrozole in the treatment of postmenopausal women with advanced breast cancer." | 7.70 | [Clinical study of anastrozole in the treatment of postmenopausal women with advanced breast cancer]. ( Feng, F; Jiang, Z; Xu, B, 1999) |
| "Aromatase inhibitors (AIs) reduce breast cancer recurrence and prolong survival, but up to 30% of patients exhibit recurrence." | 6.94 | Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action. ( Bari, MG; Buzdar, AU; Cairns, J; Carlson, EE; Dudenkov, TM; Ellis, MJ; Goetz, MP; Goodnature, B; Goss, PE; Ingle, JN; Kalari, KR; Li, H; Na, J; Robson, ME; Shepherd, LE; Wang, L; Weinshilboum, RM, 2020) |
| "Patients were randomized 1:1:1 to receive daily anastrozole (1 mg) in combination with AZD8931 20 mg twice daily (bid), AZD8931 40 mg bid, or placebo." | 6.82 | Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer. ( Basik, M; Clemons, M; Cristofanilli, M; Dreosti, L; Grzeda, L; Hegg, R; Johnston, S; Lausoontornsiri, W; Mann, H; Stuart, M, 2016) |
| "Endocrine therapy in patients with breast cancer can be limited by the problem of resistance." | 6.76 | A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. ( Beyer, A; Cai, WY; Elledge, R; Fuqua, S; Hilsenbeck, S; Huang, J; Massarweh, S; Rimawi, M; Sexton, K; Tham, YL; Tsimelzon, A; Weiss, H, 2011) |
| " Our results confirmed that longterm postoperative therapy with UFT alone was feasible, provided that early adverse events are carefully monitored." | 6.74 | [Safety and compliance with UFT (tegafur and uracil) alone and in combination with hormone therapy in patients with breast cancer]. ( Noguchi, S; Taguchi, T, 2009) |
| "Anastrozole induced an increase in bone remodelling: osteocalcin (+36." | 6.73 | Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. ( Brun, J; Confavreux, CB; Delmas, PD; Fontana, A; Guastalla, JP; Munoz, F, 2007) |
| "Tamoxifen treatment results in a doubling of the risk of endometrial cancer after 1-2 years of treatment and a quadrupling after 5 years." | 6.72 | The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. ( Bianco, AR; Clack, G; Coibion, M; Duffy, S; Jackson, TL; Lansdown, M; Philips, K; Pollard, S; Wells, M, 2006) |
| "Treatment with tamoxifen may still be useful upon subsequent progression." | 6.71 | Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and ( Aebi, S; Ballabeni, P; Goldhirsch, A; Hess, D; Köberle, D; Pagani, O; Perey, L; Rochlitz, C; Senn, I; Thürlimann, B, 2004) |
| "Endocrine treatments of breast cancer patients antagonize estrogen and may lead to consequences of estrogen deprivation including menopausal symptoms." | 6.71 | Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. ( Ameye, L; Carbonez, A; Christiaens, MR; Morales, L; Neven, P; Paridaens, R; Timmerman, D; Van Huffel, S; Van Limbergen, E; Vergote, I, 2004) |
| "Neoadjuvant (preoperative) therapy for breast cancer may allow for the development of intermediate markers of treatment benefit, thereby circumventing the need for efficacy trials of adjuvant therapy, which require much larger patient numbers and longer follow-up." | 6.71 | Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. ( Ashley, S; Boeddinghaus, I; Detre, S; Dixon, JM; Dowsett, M; Ebbs, SR; Francis, S; Griffith, C; Hills, M; Salter, J; Skene, A; Smith, IE; Walsh, G, 2005) |
| "In Mexico the breast cancer occupies the second place as cause of death by oncological illness and the etiology is considered multifactorial." | 6.71 | [Survival of breast cancer patients treated with inhibitors of the aromatase vs tamoxifen]. ( Angeles Victoria, L; Basavilvazo Rodríguez, MA; Castelazo Rico, G; Hernández Valencia, M; Molotla Xolalpa, D; Zárate, A, 2004) |
| "Anastrozole was given in a dose of 1 mg once daily and compared with tamoxifen 20 mg daily in postmenopausal patients with tumours that were hormone-receptor positive or of unknown receptor status." | 6.69 | Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. ( Bonneterre, J; Koralewski, L; Krzakowski, M; Mauriac, L; Robertson, J; Steinberg, M; Thürlimann, B; Vergote, I; von Euler, M; Webster, A, 2000) |
| "Anastrozole is a nonsteroidal compound and a potent selective inhibitor of the aromatase enzyme." | 6.55 | Use of anastrozole in the chemoprevention and treatment of breast cancer: A literature review. ( Andrade, DB; Barros-Oliveira, MDC; Borges, RS; Borges, US; Costa-Silva, DR; Silva, BBD; Silva, JM; Tavares, CB, 2017) |
| " Nevertheless, this approach is still associated with many challenges, ranging from the recurrence of breast cancer to considerable interindividual variability in the tolerability of anastrozole, which may cause adverse effects, such as musculoskeletal symptoms, and lead to the withdrawal of many patients from treatment." | 6.50 | The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients. ( Abubakar, MB; Gan, SH; Wei, K, 2014) |
| "To review the clinical effectiveness and cost-effectiveness evidence base for lapatinib (LAP) in combination with an aromatase inhibitor (AI) and trastuzumab (TRA) in combination with an AI for the first-line treatment of patients who have hormone receptor-positive (HR+)/human epidermal growth factor 2-positive (HER2+) mBC." | 6.47 | Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis. ( Armstrong, A; Bagust, A; Blundell, M; Boland, A; Davis, H; Dickson, R; Dundar, Y; Fleeman, N; Moonan, M; Oyee, J; Thorp, N, 2011) |
| "Treatment with fulvestrant has also demonstrated clinical efficacy among patients who progressed following treatment with tamoxifen followed by nonsteroidal aromatase inhibitors." | 6.43 | Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer. ( Bundred, N, 2005) |
| "Fulvestrant is a new type of oestrogen receptor antagonist with no agonist effects." | 6.43 | Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents. ( Abram, P; Vergote, I, 2006) |
| "Tamoxifen has been the principal adjuvant hormonal therapy in pre- and postmenopausal women with hormone receptor-positive breast cancer for nearly 20 years." | 6.42 | Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. ( Carlson, RW; Henderson, IC, 2003) |
| "Patients with hormone-sensitive breast cancer who have responded to tamoxifen (TAM) may receive additional benefit from a second endocrine agent after progression or relapse after TAM therapy." | 6.42 | Fulvestrant in postmenopausal women with advanced breast cancer. ( Baird, A; Bross, PF; Chen, G; Jee, JM; Lostritto, RT; Morse, DE; Pazdur, R; Rahman, A; Rosario, LA; Williams, G; Williams, GM; Yang, P, 2003) |
| "Fulvestrant (Faslodex) is a novel estrogen receptor (ER) antagonist that competitively binds to the ER with a much greater affinity than that of tamoxifen." | 6.42 | Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. ( Curran, MP; McKeage, K; Plosker, GL, 2004) |
| "Anastrozole (Arimidex) was the first of these agents to become available and is currently widely indicated for both first- and second-line treatment for postmenopausal women with breast cancer." | 6.41 | Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer. ( Köberle, D; Thürlimann, B, 2001) |
| "Anastrozole was as well-tolerated as megestrol acetate, while weight gain was significantly increased in the megestrol acetate group compared with the anastrozole group." | 6.41 | Anastrozole in the management of breast cancer. ( Nabholtz, JM; Reese, D, 2002) |
| "Anastrozole is a new, highly selective, nonsteroidal aromatase inhibitor capable of maximal estrogen depletion with fewer side effects than other hormonal therapies." | 6.40 | Anastrozole: a new addition to the armamentarium against advanced breast cancer. ( Buzdar, AU, 1998) |
| "Tamoxifen has been the gold standard adjuvant therapeutic agent for postmenopausal women with hormone-sensitive breast cancer for > 25 years." | 6.20 | Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial. ( Buzdar, A, 2003) |
| "Thus, for BQ-overexpressing breast cancer, targeting AR can combat anastrozole resistance." | 5.91 | Overexpression of BQ323636.1 contributes to anastrozole resistance in AR+ve/ER+ve breast cancer. ( Chan, SY; Chan, WL; Cheng, CN; Khoo, US; Leung, MH; Lok, J; Man, EP; Tsoi, H; You, CP, 2023) |
| "Our findings suggest that dalpiciclib plus letrozole or anastrozole could be a novel standard first-line treatment for patients with hormone receptor-positive, HER2-negative advanced breast cancer, and is an alternative option to the current treatment landscape." | 5.69 | Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-con ( Bayaxi, N; Cheng, Y; Geng, C; Hu, C; Hu, X; Li, W; Ouyang, Q; Pan, Y; Shi, Y; Sun, T; Teng, Y; Tong, Z; Wang, X; Wang, Y; Wei, W; Wu, X; Xie, W; Xu, B; Xu, J; Yan, M; Yan, X; Zeng, X; Zhang, H; Zhang, P; Zhang, Q; Zhong, J; Zhu, X, 2023) |
| " We report the primary and final analyses of the coopERA Breast Cancer study, designed to test whether giredestrant, a highly potent, non-steroidal, oral SERD, would show a stronger anti-proliferative effect than anastrozole after 2 weeks for oestrogen receptor-positive, HER2-negative, untreated early breast cancer." | 5.69 | Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study. ( Adamchuk, H; Alonso-Romero, JL; Badovinac Crnjevic, T; Bardia, A; Berzoy, O; Blancas, I; Chan, D; Fasching, PA; Fernando, TM; Ferreira, E; Hurvitz, SA; López-Valverde, V; Moore, HM; Park, YH; Pérez-Moreno, PD; Quiroga, V; Salgado, M; Spera, G; Steinseifer, J; Vasiliev, A; Xue, C; Yardley, DA; Zamora-Auñón, P, 2023) |
| "Patients with histologically confirmed, untreated ER+/HER2- breast cancer, primary tumour ≥2 cm, ECOG performance status ≤1, and eligible for post-treatment surgery received nivolumab 480 mg intravenously every 4 weeks, palbociclib 125 mg or 100 mg orally once daily for 3 weeks per cycle, and anastrozole 1 mg orally once daily for five 4-week cycles, or until disease progression." | 5.69 | Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8. ( Ades, F; Filian, J; Huang, N; Jerusalem, G; Mazzei-Abba, A; Nikolinakos, P; Prat, A; Reinisch, M; Ruiz-Borrego, M; Salgado, R; Saura, C; Tolaney, SM, 2023) |
| "Obesity represents a risk factor for breast cancer development and therapy resistance, but the molecular players underling these links are unclear." | 5.56 | Leptin Signaling Contributes to Aromatase Inhibitor Resistant Breast Cancer Cell Growth and Activation of Macrophages. ( Andò, S; Barone, I; Bonofiglio, D; Camera, G; Campana, A; Catalano, S; Fuqua, S; Gelsomino, L; Giordano, C; Grande, F; Leggio, A; Marsico, S; Rinaldi, A; Sisci, D; Tarallo, R, 2020) |
| "Fulvestrant has been studied as second line or first line treatment for post-menopausal hormone receptor positive breast cancers as a single agent or in combination with AIs." | 5.56 | Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity. ( Goloubeva, O; Kazi, A; Sabnis, GJ; Schech, A; Yu, S, 2020) |
| "This was a Japanese subpopulation analysis of MONARCH 3, a randomized, double-blind, placebo-controlled phase 3 study of abemaciclib plus nonsteroidal aromatase inhibitors (NSAIs) for initial therapy for advanced breast cancer (ABC)." | 5.51 | Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. ( Goetz, MP; Kawaguchi, T; Mori, J; Takahashi, M; Tanizawa, Y; Toi, M; Tokunaga, E; van der Walt, JS, 2022) |
| "Although power of the study was limited, the findings were unable to support the routine use of everolimus combination endocrine therapy in the first-line treatment of advanced hormone-sensitive breast cancer." | 5.51 | A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222. ( Balcueva, E; Barlow, WE; Conlin, AK; Dy, PA; Gralow, JR; Hayes, DF; Hicks, JB; Hortobagyi, GN; Kuhn, P; Lew, DL; Moore, HCF; Pusztai, L; Schott, AF; Somlo, G; Tripathy, D; Welter, L; Yeon, CH, 2022) |
| " RS, alone or in combination with clinicopathological variables expressed by the Clinical Treatment Score (CTS), for the prognostication of DR in a retrospective cohort of 776 postmenopausal patients with ER+/HER2-breast cancer enrolled in the translational arm of the randomised Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial." | 5.51 | Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy. ( Buus, R; Chu, K; Colleoni, M; Cuzick, J; Di Fiore, PP; Disalvatore, D; Dowsett, M; Freddi, S; Maisonneuve, P; Montani, F; Pece, S; Sestak, I; Tillhon, M; Veronesi, P; Viale, G, 2022) |
| "The risk of OFR during AI treatment in breast cancer patients with chemotherapy-induced ovarian function failure is relevant, even beyond 45 years." | 5.46 | Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure. ( de Boer, M; de Graaf, H; de Roos, WK; Erdkamp, FLG; Honkoop, AH; Imholz, ALT; Kitzen, JJEM; Kroep, JR; Linn, SC; Peer, PGM; Seynaeve, CM; Smorenburg, CH; Swinkels, ACP; Tjan-Heijnen, VCG; van den Berkmortel, FWPJ; van der Sangen, MJC; van Hellemond, IEG; Vriens, IJH, 2017) |
| "The Austrian Breast and Colorectal Cancer Study Group (ABCSG) 8 RCT compared 5 years of tamoxifen with tamoxifen for 2 years followed by anastrozole for 3 years in postmenopausal women with endocrine receptor-positive breast cancer." | 5.41 | PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial. ( Balic, M; Bartsch, R; Dubsky, P; Ferree, S; Fesl, C; Filipits, M; Fitzal, F; Gnant, M; Greil, R; Herz, W; Moinfar, F; Rudas, M; Schaper, C, 2021) |
| "This post hoc analysis of MONARCH 2 and MONARCH 3 assesses the efficacy, safety, and pharmacokinetics (PK) of abemaciclib in combination with endocrine therapy (ET) in East Asian patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer." | 5.41 | Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials. ( André, VAM; Chen, SC; Enatsu, S; Goetz, MP; Hae Park, I; Hardebeck, MC; Im, SA; Inoue, K; Iwata, H; Masuda, N; Sakaguchi, S; Sledge, GW; Sohn, J; Toi, M; Turner, PK, 2021) |
| "In this prospective, phase 3 trial, we randomly assigned postmenopausal women with hormone-receptor-positive breast cancer who had received 5 years of adjuvant endocrine therapy to receive the aromatase inhibitor anastrozole for an additional 2 years (2-year group, receiving a total of 7 years) or an additional 5 years (5-year group, receiving a total of 10 years)." | 5.41 | Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. ( Balic, M; Bartsch, R; Bjelic-Radisic, V; Brunner, C; Deutschmann, C; Egle, D; Fesl, C; Fitzal, F; Gampenrieder, SP; Gnant, M; Greil, R; Greil-Ressler, S; Haslbauer, F; Heck, D; Jakesz, R; Kacerovsky-Strobl, S; Manfreda, D; Melbinger-Zeinitzer, E; Rinnerthaler, G; Sevelda, P; Singer, CF; Soelkner, L; Steger, GG; Suppan, C; Thaler, J; Trapl, H; Wette, V; Wieder, U; Wimmer, K, 2021) |
| "Median time to first report of joint pain was 7 weeks (range, 1-38)." | 5.39 | Anastrozole-associated joint pain and other symptoms in patients with breast cancer. ( Cleeland, CS; Giordano, SH; Lu, H; Malveaux, D; Saleeba, AK; Shi, Q, 2013) |
| "Patient acceptance of SERMs for breast cancer prevention is low due to toxicities." | 5.38 | Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer. ( Akar, U; Arun, B; Brewster, A; Buzdar, AU; Esteva, FJ; Green, M; Gutierrez-Barrera, A; Hortobagyi, GN; Liu, D; Rivera, E; Sneige, N; Valero, V, 2012) |
| "In patients with mild or severe osteopenia or osteoporosis, treated with A + R, no age effect was observed for LS or HP (p = 0." | 5.38 | Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. ( Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2012) |
| "Due to the recognition and diagnosis of breast cancer in increasingly early stages, quality of life becomes an important part of treatment beyond the efficacy indicators." | 5.38 | [Quality of life analysis of postmenopausal, early breast cancer patients treated with anastrozole (RADAR-II)]. ( Horváth, Z, 2012) |
| "The primary end point is breast cancer incidence, but major efforts are also being directed at minimizing any fracture risk." | 5.35 | IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. ( Cuzick, J, 2008) |
| "Anastrozole therapy is a useful treatment for postmenopausal woman with ER-positive recurrent breast cancer." | 5.35 | [A case of recurrent breast cancer with multiple lung metastases responding to anastrozole monotherapy]. ( Hashida, S; Hirano, Y; Iga, K; Inukai, M; Ito, M; Kanaya, Y; Maruyama, S; Shimo, T; Yokoyama, N, 2008) |
| "We diagnosed it as inflammatory breast cancer with positive hormone receptor (ER+, PgR+) and unexpression of HER2 (HercepTest 1 +)." | 5.35 | [A case of inflammatory breast cancer responding to anastrozole]. ( Kubota, K; Kuwayama, T; Nakagawa, T; Sato, T; Sugihara, K; Suzuki, S, 2009) |
| "Letrozole was chosen for the next therapy." | 5.35 | [A case of elderly breast cancer achieving partial response by letrozole with stable disease to anastrozole as neoadjuvant endocrine therapy]. ( Kihara, M; Miyauchi, A, 2008) |
| " Postmenopausal women at increased risk of developing breast cancer were recruited and were randomly assigned (1:1) to either anastrozole (1 mg per day, oral) or matching placebo daily for 5 years." | 5.34 | Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. ( Bonanni, B; Cawthorn, S; Cuzick, J; Dowsett, M; Evans, DG; Forbes, JF; Howell, A; Loibl, S; Mansel, RE; Sestak, I, 2020) |
| "It is well-known that breast cancer easily metastasizes to the bone, liver, pleura and lymph node, but rarely to the ovarium or peritoneum when chemotherapy is conducted." | 5.33 | [Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report]. ( Deguchi, Y; Kamimura, K; Kaneko, I; Kii, E; Murata, T; Nonogaki, H; Tanaka, T; Tsubono, M; Yasumizu, R, 2005) |
| "Endocrine therapy for hormone-sensitive breast cancer is a well-established treatment option, both in adjuvant and palliative settings." | 5.33 | Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis. ( Langenegger, T; Schiesser, D; Thürlimann, B; Wahl, P, 2006) |
| "We describe a woman with metastatic breast cancer treated with multiple rounds of prior cytotoxic and endocrine therapies, who presented with ipsilateral diaphragmatic paralysis." | 5.32 | Anastrozole-induced remission of diaphragmatic paralysis from metastatic breast cancer treated with multiple prior therapies. ( Okamura, Y; Sakurai, T; Shimizu, Y; Suzuma, T; Umemura, T; Yang, QF; Yoshimura, G, 2003) |
| "For metastatic breast cancer patients who have hormone receptor-positive tumors, hormonal therapy aiming at optimal palliation and prolongation of life is the initial treatment of choice." | 5.32 | [Combination therapy with Anastrozole and 5'-DFUR as a treatment for metastatic breast cancer]. ( Fuchimoto, S; Inagaki, M; Miyoshi, K; Nakagawa, T; Ohsaki, T; Ohtsuka, S; Yumura, M, 2004) |
| "Osteoprotegerin (OPG) is a potent antiresorptive molecule that binds NF-kappaB ligand, the final effector for osteoclastogenesis." | 5.32 | Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. ( Bajetta, E; Bombardieri, E; Del Vecchio, M; Ferrari, L; La Torre, I; Longarini, R; Martinetti, A; Paleari, D; Seregni, E; Toffolatti, L; Zilembo, N, 2004) |
| "Anastrozole therapy is a useful treatment for postmenopausal women with ER positive advanced breast cancer." | 5.31 | [Advanced breast cancer with lung and pleural metastases responsive to anastrozole--a case report]. ( Enomoto, K; Kinoshita, T; Nishimura, M; Okamura, Y; Oura, S; Sakurai, T; Yokochi, H, 2002) |
| "Estrone and E(1)S were converted into E(2), and all three estrogen fractions were finally measured by the same highly sensitive and specific radioimmunoassay using estradiol-6-(O-carboxymethyl)-oximino-2-(2--iodo-histamine) as a ligand." | 5.31 | A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue. ( Berntsen, H; Geisler, J; Lonning, PE, 2000) |
| "The DATA study (NCT00301457) compared 6 and 3 years of anastrozole in postmenopausal women with hormone receptor-positive early breast cancer after 2-3 years of tamoxifen." | 5.30 | Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure. ( de Boer, M; de Graaf, H; de Roos, WK; Erdkamp, FLG; Honkoop, AH; Imholz, ALT; Kroep, JR; Linn, SC; Peer, PGM; Seynaeve, CM; Smorenburg, CH; Swinkels, ACP; Tjan-Heijnen, VCG; van den Berkmortel, FWPJ; van der Sangen, MJC; van Hellemond, IEG; Vriens, IJH, 2019) |
| " 3 year) in postmenopausal women with breast cancer previously treated with 2-3 years of tamoxifen." | 5.30 | Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study. ( de Boer, M; de Graaf, H; de Roos, WK; Erdkamp, FLG; Honkoop, AH; Imholz, ALT; Kroep, JR; Linn, SC; Peer, PGM; Seynaeve, CM; Smorenburg, CH; Swinkels, ACP; Tjan-Heijnen, VCG; van den Berkmortel, FWPJ; van der Sangen, MJC; van Hellemond, IEG, 2019) |
| "We previously reported prolonged progression-free survival and marginally prolonged overall survival among postmenopausal patients with hormone receptor-positive metastatic breast cancer who had been randomly assigned to receive the aromatase inhibitor anastrozole plus the selective estrogen-receptor down-regulator fulvestrant, as compared with anastrozole alone, as first-line therapy." | 5.30 | Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. ( Albain, KS; Barlow, WE; Dakhil, SR; Gralow, JR; Hayes, DF; Hortobagyi, GN; Lew, DL; Linden, HH; Livingston, RB; Mehta, RS; Tirumali, NR; Vandenberg, TA, 2019) |
| "Anastrozole has been shown to prevent breast cancer in postmenopausal women at high risk of the disease, but has been associated with substantial accelerated loss of bone mineral density (BMD) and increased fractures." | 5.30 | Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. ( Blake, GM; Coleman, RE; Cuzick, J; Eastell, R; Patel, R; Sestak, I, 2019) |
| "GEICAM/2006-10 compared anastrozole (A) versus fulvestrant plus anastrozole (A + F) to test the hypothesis of whether a complete oestrogen blockade is superior to aromatase inhibitors alone in breast cancer patients receiving hormone adjuvant therapy." | 5.30 | Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study. ( Alba, E; Álvarez, I; Antolín, S; Antón, A; Baena-Cañada, JM; Bermejo, B; Carrasco, E; Chacón, JI; Cirauqui, B; Cruz, J; Del Barco, S; Escudero, MJ; Guerrero-Zotano, A; Martín, M; Martínez-Jáñez, N; Muñoz, M; Ramos, M; Rodríguez-Lescure, Á; Ruiz, V; Ruíz-Borrego, M; Sevillano, E, 2019) |
| "Anastrozole reduces breast cancer risk in women at high risk, but implementing preventive therapy in clinical practice is difficult." | 5.27 | Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II. ( Cuzick, J; Forbes, JF; Howell, A; Sestak, I; Smith, SG, 2018) |
| "27 compared 5 years of adjuvant anastrozole or exemestane in postmenopausal patients with hormone receptor positive early breast cancer." | 5.27 | Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27. ( Chen, BE; Goss, PE; Liedke, PER; O'Shaughnessy, J; Parulekar, WR; Ramjeesingh, R; Shepherd, LE; Strasser-Weippl, K; Sudan, G, 2018) |
| "The international, phase III FALCON study (NCT01602380) in postmenopausal patients with hormone receptor-positive, locally advanced/metastatic breast cancer (LA/MBC) who had not received prior endocrine therapy, demonstrated statistically significant improvement in progression-free survival (PFS) for patients who received fulvestrant 500 mg vs anastrozole 1 mg." | 5.27 | Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON). ( Ellis, MJ; Fazal, M; Noguchi, S; Robertson, JFR; Shao, Z; Thirlwell, J, 2018) |
| "This phase II study evaluated the efficacy and safety of anastrozole concurrent with tegafur/uracil (UFT) as neoadjuvant therapy for ER-positive postmenopausal breast cancer." | 5.27 | Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC). ( Aono, T; Ito, T; Kagimura, T; Masuda, N; Matsunami, N; Miyoshi, Y; Nakayama, T; Noguchi, S; Sagara, Y; Taguchi, T; Takashima, T, 2018) |
| "Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly compared the three aromatase inhibitors anastrozole, exemestane, and letrozole." | 5.27 | Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. ( Amoroso, D; Arpino, G; Bernardo, A; Bisagni, G; Carlini, P; Cognetti, F; Cogoni, AA; De Laurentiis, M; De Placido, S; Del Mastro, L; Foglietta, J; Frassoldati, A; Gallo, C; Gori, S; Gravina, A; Lai, A; Laudadio, L; Lauria, R; Lorusso, V; Mocerino, C; Montemurro, F; Moretti, G; Moscetti, L; Nuzzo, F; Perrone, F; Riccardi, F; Rizzo, S; Russo, A; Sarobba, MG; Verusio, C, 2018) |
| "The phase III randomised FALCON trial (NCT01602380) demonstrated improved progression-free survival with fulvestrant 500 mg versus anastrozole 1 mg in endocrine therapy-naïve postmenopausal women with hormone receptor-positive (HR+) locally advanced or metastatic breast cancer (LA/MBC)." | 5.27 | Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer. ( Cheung, KL; Degboe, A; Ellis, MJ; Fazal, M; Lichfield, J; Noguchi, S; Robertson, JFR; Shao, Z; Thirlwell, J, 2018) |
| "We investigated the efficacy and safety of fulvestrant plus goserelin (F + G) versus anastrozole plus goserelin (A + G) in comparison with goserelin (G) alone in premenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), tamoxifen-pretreated metastatic breast cancer (MBC)." | 5.27 | Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, ( Ahn, JH; Ahn, JS; Im, SA; Im, YH; Jung, KH; Kim, GM; Kim, JH; Kim, JY; Kim, S; Kim, SB; Kim, SH; Kim, TY; Lee, KH; Lee, KS; Park, IH; Park, YH; Ro, J; Sohn, J, 2018) |
| "The PARP inhibitor olaparib is efficacious as monotherapy and has potential application in combination with endocrine therapy for the treatment of breast cancer." | 5.27 | Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours. ( Bailey, C; Birkett, J; De Grève, J; De Vos, FYFL; Dean, E; Dirix, L; Goessl, C; Grundtvig-Sørensen, P; Italiano, A; Jerusalem, G; Learoyd, M; Leunen, K; Molife, LR; Plummer, R; Rolfo, C; Rottey, S; Spencer, S; Spicer, J; Verheul, HM, 2018) |
| "Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy and in combination with fulvestrant in women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer previously treated with endocrine therapy." | 5.24 | MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. ( Barriga, S; Bourayou, N; Campone, M; Chen, SC; Di Leo, A; Forrester, T; Freedman, OC; Frenzel, M; Garnica Jaliffe, G; Goetz, MP; Huober, J; Manso, L; Paluch-Shimon, S; Park, IH; Smith, IC; Sohn, J; Toi, M; Trédan, O, 2017) |
| " We randomly assigned postmenopausal women with hormone receptor-positive early breast cancer with no signs of disease recurrence after 2-3 years of adjuvant tamoxifen to either 3 or 6 years of anastrozole treatment (1 mg orally once a day) in a 1:1 ratio." | 5.24 | Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. ( de Boer, M; De Graaf, H; de Roos, WK; Erdkamp, FLG; Honkoop, AH; Imholz, ALT; Kroep, JR; Linn, SC; Peer, PGM; Seynaeve, CM; Smorenburg, CH; Swinkels, ACP; Tjan-Heijnen, VCG; van den Berkmortel, FWPJ; van der Sangen, MJC; van Hellemond, IEG, 2017) |
| "Purpose The Letrozole (Femara) Versus Anastrozole Clinical Evaluation (FACE) study compared the efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor (HR) -positive and node-positive early breast cancer (eBC)." | 5.24 | Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation ( Amadori, D; Burris, H; Comarella, L; De Boer, R; Dowsett, M; Ejlertsen, B; Gnant, M; Hart, L; Jonat, W; McIntyre, K; O'Shaughnessy, J; Poggio, S; Pritchard, KI; Salomon, H; Smith, I; Wamil, B; Yardley, D, 2017) |
| "To assess the joint symptoms and the impact on patients' health-related quality of life (HRQOL) due to 5 years of anastrozole from the baseline data in the N-SAS BC 05 trial, a randomized clinical trial was designed to assess the efficacy of 5 additional years of anastrozole among women with breast cancer." | 5.22 | Joint symptoms and health-related quality of life in postmenopausal women with breast cancer who completed 5 years of anastrozole. ( Iwase, T; Komoike, Y; Nakamura, T; Ohashi, Y; Ohtsu, H; Saji, S; Shimozuma, K; Takei, H; Yagata, H, 2016) |
| "This was an exploratory analysis of the International Breast Cancer Intervention Study II, a double-blind randomized clinical trial in which women at increased risk of breast cancer were randomly assigned to receive anastrozole or placebo." | 5.22 | Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial. ( Cuzick, J; Forbes, JF; Howell, A; Sestak, I; Spagnolo, F, 2016) |
| "Third-generation aromatase inhibitors are more effective than tamoxifen for preventing recurrence in postmenopausal women with hormone-receptor-positive invasive breast cancer." | 5.22 | Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. ( Bonanni, B; Bundred, N; Coleman, RE; Cuzick, J; Eiermann, W; Ellis, I; Forbes, JF; Holcombe, C; Howell, A; Jones, L; Levy, C; Neven, P; Sestak, I; Stierer, M; von Minckwitz, G, 2016) |
| "Compared with tamoxifen, anastrozole treatment provided a significant improvement in breast cancer-free interval, mainly in women younger than 60 years of age." | 5.22 | Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. ( Albain, KS; Brufsky, AM; Cecchini, RS; Cianfrocca, ME; Costantino, JP; Fehrenbacher, L; Ganz, PA; Gross, HM; Hopkins, JO; Julian, TB; Mamounas, EP; Margolese, RG; Seay, TE; Soori, GS; Sturtz, K; Vallow, LA; Whitworth, PW; Wolmark, N; Wozniak, TF, 2016) |
| "The NSABP B-35 trial compared 5 years of treatment with anastrozole versus tamoxifen for reducing subsequent occurrence of breast cancer in postmenopausal patients with ductal carcinoma in situ." | 5.22 | Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. ( Albain, KS; Brufsky, AM; Cecchini, RS; Cianfrocca, ME; Costantino, JP; Fehrenbacher, L; Ganz, PA; Gross, HM; Hopkins, JO; Julian, TB; Mamounas, EP; Margolese, RG; Seay, TE; Soori, GS; Sturtz, K; Vallow, LA; Whitworth, PW; Wolmark, N; Wozniak, TF, 2016) |
| " gefitinib) can delay endocrine resistance in breast cancer." | 5.22 | A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378) ( Basaran, G; Bogaerts, J; Cameron, D; Cufer, T; Debled, M; Dirix, L; Piccart, M; Thery, JC; Tjan-Heijnen, VC; Tryfonidis, K; Van den Weyngaert, D, 2016) |
| " MK-2206 in combination with anastrozole is being further evaluated in a phase II neoadjuvant trial for newly diagnosed ER(+)HER2(-) breast cancer." | 5.22 | A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer. ( Creekmore, A; Crowder, R; Doyle, A; Ellis, MJ; Erlichman, C; Gao, F; Guo, Z; Hoog, J; Lockhart, AC; Ma, CX; Naughton, M; Pluard, T; Sanchez, C, 2016) |
| "In the SWOG S0226 trial the combination of anastrozole plus fulvestrant (n = 349) was superior to anastrozole alone (n = 345) in hormone receptor (HR)-positive metastatic breast cancer." | 5.22 | Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226. ( Albain, KS; Barlow, WE; Dakhil, SR; Gralow, J; Hayes, DF; Hertz, DL; Hortobagyi, GN; Kidwell, KM; Livingston, RB; Mehta, RS; Rae, JM; Tirumali, NR; Vandenberg, TA, 2016) |
| "Adding pictilisib to anastrozole significantly increases suppression of tumor cell proliferation in luminal B primary breast cancer." | 5.22 | Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer. ( Bundred, N; Butler, H; Derynck, M; Earl, G; Gazinska, P; Gendreau, S; Hadad, S; Hu, J; Korbie, D; Lackner, MR; Lim, L; Macaskill, J; Mainwaring, P; Parker, P; Pinder, SE; Price, R; Purushotham, A; Sarker, SJ; Schmid, P; Shia, A; Thompson, A; Trau, M; Wheatley, D; Wilson, TR; Woodman, N; Zammit, C, 2016) |
| "In a prospective-retrospective analysis, we assessed ESR1 mutations in available archived baseline plasma from the SoFEA (Study of Faslodex Versus Exemestane With or Without Arimidex) trial, which compared exemestane with fulvestrant-containing regimens in patients with prior sensitivity to nonsteroidal AI and in baseline plasma from the PALOMA3 (Palbociclib Combined With Fulvestrant in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer After Endocrine Failure) trial, which compared fulvestrant plus placebo with fulvestrant plus palbociclib in patients with progression after receiving prior endocrine therapy." | 5.22 | Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. ( Andre, F; Bartlett, CH; Beaney, M; Bliss, JM; Cristofanilli, M; Dowsett, M; Fribbens, C; Garcia-Murillas, I; Hrebien, S; Jiang, J; Johnston, SR; Kilburn, L; Koehler, M; Loi, S; Loibl, S; O'Leary, B; Turner, NC, 2016) |
| "Fulvestrant has superior efficacy and is a preferred treatment option for patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not received previous endocrine therapy compared with a third-generation aromatase inhibitor, a standard of care for first-line treatment of these patients." | 5.22 | Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. ( Bondarenko, IM; Cardona-Huerta, S; Cheung, KL; Dvorkin, M; Ellis, MJ; Fazal, M; Grinsted, LM; Manikhas, A; Noguchi, S; Panasci, L; Philco-Salas, MJ; Robertson, JFR; Rowbottom, J; Ruiz-Borrego, M; Shao, Z; Shparyk, Y; Stuart, M; Trishkina, E, 2016) |
| "Postmenopausal women who were to receive adjuvant anastrozole for resected early breast cancer were studied." | 5.20 | Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. ( Barman, P; Buzdar, AU; Desta, Z; Dudenkov, TT; Flockhart, DA; Goetz, MP; Ingle, JN; Kalari, KR; Northfelt, DW; Perez, EA; Robson, ME; Wang, L; Weinshilboum, RM; Williard, CV, 2015) |
| "Patients were premenopausal women who had undergone primary surgery for stage I/II estrogen-receptor-positive and/or progesterone-receptor-positive breast cancer with <10 positive lymph nodes, and were scheduled for standard goserelin therapy." | 5.20 | Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. ( Balic, M; Bartsch, R; Bjelic-Radisic, V; Dubsky, P; Eidtmann, H; Eiermann, W; Fesl, C; Fitzal, F; Gnant, M; Greil, R; Hochreiner, G; Jakesz, R; Knauer, M; Kwasny, W; Luschin-Ebengreuth, G; Mlineritsch, B; Moik, M; Ploner, F; Seifert, M; Selim, U; Sevelda, P; Steger, G; Stoeger, H; Taucher, S; Wette, V, 2015) |
| "27 randomly assigned 7,576 postmenopausal women with breast cancer to 5 years of anastrozole or exemestane." | 5.20 | Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial. ( Budd, GT; Chapman, JA; Ellis, MJ; Goss, PE; Ingle, JN; Kundapur, J; Le Maitre, A; Liedke, PE; Ma, CX; Pritchard, KI; Rabaglio, M; Shepherd, LE; Sledge, GW; Stearns, V, 2015) |
| "Eligible newly diagnosed postmenopausal, estrogen receptor positive breast cancer patients awaiting primary surgery received anastrozole daily until surgery." | 5.20 | Evaluating the feasibility of performing window of opportunity trials in breast cancer. ( Addison, CL; Arnaout, A; Clemons, M; Kuchuk, I; Namazi, M; Pond, GR; Robertson, S; Simos, D, 2015) |
| " This phase III open-label study compared the impact of tamoxifen and AI on verbal episodic memory (Rey auditory verbal learning test-RAVLT) and other cognitive functions (visual memory, psychomotor speed, and executive functions) after 6 and 12 months of treatment in breast cancer patients undergoing adjuvant hormonotherapy." | 5.20 | A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy. ( Bonneterre, J; Delbeuck, X; Kramar, A; Le Rhun, E; Lefeuvre-Plesse, C; Pasquier, F; Skrobala, E, 2015) |
| "The aim of this study was to assess the efficacy of neoadjuvant anastrozole and fulvestrant treatment of large operable or locally advanced hormone-receptor-positive breast cancer not eligible for initial breast-conserving surgery, and to identify genomic changes occurring after treatment." | 5.20 | Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer. ( Bachelot, T; Bonnefoi, H; Breton-Callu, C; Dalenc, F; Daly, C; de Lara, CT; Debled, M; Fournier, M; Gros, A; Iggo, R; Lortal, B; MacGrogan, G; Madranges, N; Mauriac, L; Nikolski, M; Pulido, M; Quenel-Tueux, N; Rabbitts, P; Rudewicz, J; Soueidan, H; Wood, H, 2015) |
| "To compare overall survival (OS) for fulvestrant 500 mg versus anastrozole as first-line endocrine therapy for advanced breast cancer." | 5.20 | Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study. ( Dewar, JA; Ellis, MJ; Feltl, D; Hewson, N; Jasiówka, M; Llombart-Cussac, A; Robertson, JF; Rukazenkov, Y, 2015) |
| "Anastrozole effectively reduces incidence of breast cancer in high-risk postmenopausal women." | 5.19 | Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. ( Bonanni, B; Cawthorn, S; Cuzick, J; Dowsett, M; Forbes, JF; Howell, A; Knox, J; Mansel, RE; Palva, T; Roche, N; Saunders, C; Sestak, I; von Minckwitz, G, 2014) |
| "This prospective study evaluated the relationship between arthralgia and compliance during the first year of adjuvant anastrozole therapy in postmenopausal women with hormone receptor-positive early breast cancer." | 5.19 | COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy. ( Blettner, M; Bolten, W; Hadji, P; Harbeck, N; Hindenburg, HJ; Jackisch, C; Klein, P; König, K; Kreienberg, R; Rief, W; Wallwiener, D; Zaun, S, 2014) |
| "27, postmenopausal women with early stage hormone (oestrogen) receptor-positive invasive breast cancer were randomly assigned to exemestane 25 mg versus anastrozole 1 mg, daily." | 5.19 | Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. ( Badovinac-Crnjevic, T; Chalchal, H; Chapman, JA; Cheung, AM; Elliott, CR; Goss, PE; Hershman, DL; Ingle, JN; Khosla, S; Linden, HM; Muss, HB; Pritchard, KI; Rowland, K; Scher, J; Shepherd, LE; St Louis, J; Stearns, V, 2014) |
| "Tamoxifen and anastrozole are widely used as adjuvant treatment for early stage breast cancer, but their hepatotoxicity is not fully defined." | 5.19 | A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer. ( Chen, D; Deng, Y; Feng, G; He, P; Hu, R; Huang, T; Li, E; Li, L; Li, Y; Liang, Z; Lin, Y; Liu, J; Lu, Y; Ma, R; Su, F; Sun, S; Tong, Z; Wang, S; Wang, X; Wu, Y; Xu, Z; Zhang, H; Zhang, X; Zhang, Y; Zhao, Y, 2014) |
| "This study aimed to investigate calcitonin as an effective therapy for osteoporosis in patients with bone pain during the anastrozole treatment of breast cancer." | 5.19 | Effect of calcitonin on anastrozole-induced bone pain during aromatase inhibitor therapy for breast cancer. ( Liu, M; Liu, P; Xie, F; Yang, DQ; Zhou, B, 2014) |
| "Aromatase inhibitors are superior to tamoxifen as adjuvant therapy in postmenopausal patients with hormone-responsive breast cancer." | 5.19 | Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial. ( Aihara, T; Andoh, M; Aogi, K; Fukuuchi, A; Hozumi, Y; Iwata, H; Kim, R; Makino, H; Mukai, H; Ohashi, Y; Ohno, S; Takatsuka, Y; Tamura, M; Tsugawa, K; Watanabe, T; Yamaguchi, T; Yokota, I, 2014) |
| "The aim of this study was to assess the efficacy and safety of neoadjuvant anastrozole and radiation in postmenopausal breast cancer patients with hormone-receptor-positive tumors." | 5.19 | Phase II study of neoadjuvant anastrozole and concurrent radiotherapy for postmenopausal breast cancer patients. ( Inaji, H; Ishitobi, M; Komoike, Y; Nakahara, S; Ohsumi, S; Suzuki, O; Tomita, Y; Yagi, T; Yoshinami, T, 2014) |
| "In this bone substudy, bone mineral density (BMD) was assessed by dual energy X-ray absorptiometry at baseline and after 12- and 24-month treatment in 63 patients receiving Anastrozole as adjuvant treatment for hormone receptor-positive early breast cancer." | 5.17 | Influence of compliance on bone mineral density changes in postmenopausal women with early breast cancer on Anastrozole. ( Hadji, P; Hars, O; Kalder, M; Knöll, D; Kyvernitakis, I; Ziller, V, 2013) |
| " Premenopausal women with estrogen receptor (ER)-positive and/or progesterone-receptor positive, advanced or recurrent breast cancer refractory to an LH-RH analogue plus TAM received goserelin (GOS) in conjunction with anastrozole (ANA)." | 5.17 | Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial. ( Anan, K; Higaki, K; Mase, T; Nishimura, R; Ohno, S; Sagara, Y; Shibuta, K; Tanaka, M; Teramukai, S; Tsuyuki, S; Yamamoto, Y, 2013) |
| "Women with hormone receptor (HR)-positive breast cancer who remained amenorrheic and had hormonal levels consistent with ovarian failure after adjuvant chemotherapy were enrolled in a multi-institutional clinical trial of anastrozole." | 5.17 | Predictors of recovery of ovarian function during aromatase inhibitor therapy. ( Banerjee, M; Gersch, C; Giacherio, D; Hayes, DF; Henry, NL; McConnell, D; Partridge, AH; Pearlman, M; Schott, AF; Stearns, V; Xia, R, 2013) |
| "The aromatase inhibitors exemestane and anastrozole are approved in Japan for first-line treatment of postmenopausal patients with advanced, hormone-receptor-positive breast cancer." | 5.17 | A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer. ( Hashigaki, S; Hiraoka, M; Iwata, H; Masuda, N; Morimoto, T; Nishizawa, Y; Noguchi, S; Ohno, S; Ohsumi, S; Rai, Y; Saeki, T; Sasano, H; Sato, Y, 2013) |
| "After loss of response to NSAIs in postmenopausal women with hormone-receptor-positive advanced breast cancer, maximum double endocrine treatment with 250 mg fulvestrant combined with oestrogen deprivation is no better than either fulvestrant alone or exemestane." | 5.17 | Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr ( Bliss, JM; Braybrooke, JP; Brunt, AM; Cameron, D; Cheung, KL; Coombes, G; Dodwell, D; Dowsett, M; Ellis, P; Folkerd, E; Hayward, L; Howell, A; Im, YH; Johnston, SR; Jyothirmayi, R; Kilburn, LS; Robinson, A; Sergenson, N; Sin, HJ; Wardley, AM; Wheatley, D, 2013) |
| "In a phase 3, double-blind, randomized trial (National Clinical Trials identifier NCT00605267), premenopausal women with ER-positive, early stage breast cancer received either anastrozole plus goserelin or tamoxifen plus goserelin for 24 weeks before surgery." | 5.17 | Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer. ( Hayashi, N; Iwase, H; Iwata, H; Kamigaki, S; Kinoshita, T; Masuda, N; Nakamura, S; Nishimura, R; Noguchi, S; Sagara, Y; Takei, H; Tsuda, H; Yanagita, Y, 2013) |
| "In patients with hormone-dependent postmenopausal breast cancer, standard adjuvant therapy involves 5 years of the nonsteroidal aromatase inhibitors anastrozole and letrozole." | 5.17 | Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. ( Ansari, RH; Budd, GT; Chalchal, H; Chapman, JA; D'Souza, DP; Elliott, C; Ellis, MJ; Gelmon, KA; Goss, PE; Ingle, JN; Johnson, DB; Lang, I; Liedke, PE; Perez, EA; Pritchard, KI; Rabaglio, M; Shepherd, LE; Sledge, GW; Spadafora, S; Stearns, V; Tozer, R, 2013) |
| " In the current study, the authors formally evaluated the activity of anastrozole and exemestane in postmenopausal women with hormone-responsive, advanced breast cancer." | 5.16 | Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial. ( Alés-Martínez, JE; Alvarez, I; Andrés, R; Antolín, S; Antón, A; Barnadas, A; Cámara, C; Carrasco, E; Casas, I; García Saenz, JA; Lao, J; Llombart-Cussac, A; Martín, M; Ruiz, A, 2012) |
| " We report results of a pilot trial designed to determine if treatment-mediated changes in gene expression can be detected in formalin-fixed paraffin-embedded (FFPE) samples after 10-d exposure to anastrozole in estrogen receptor (ER)-positive breast cancer compared with untreated controls." | 5.16 | Differentially expressed genes in window trials are influenced by the wound-healing process: lessons learned from a pilot study with anastrozole. ( Andrade, VP; Arroyo, CD; Brogi, E; King, TA; Mo, Q; Morrogh, M; Morrow, M; Patil, AJ; Qin, LX; Sakr, R, 2012) |
| "The present study examined long-term efficacy outcomes in a subgroup of postmenopausal, estrogen receptor-positive Japanese breast cancer patients from the Pre-Operative "Arimidex" Compared with Tamoxifen trial, following pre-operative (3 months) and post-operative (5 years) adjuvant treatment with either anastrozole or tamoxifen." | 5.16 | Outcomes of Japanese breast cancer patients treated with pre-operative and post-operative anastrozole or tamoxifen. ( Akiyama, F; Fujiwara, Y; Ikeda, T; Imoto, S; Inaji, H; Iwata, H; Mitsuyama, S; Miyoshi, K; Noguchi, S; Takatsuka, Y; Tamura, M, 2012) |
| "Health-related quality of life (HRQOL), symptoms of depression, and adverse events (AEs) were compared between Japanese postmenopausal patients with hormone-sensitive breast cancer (BC) who received adjuvant tamoxifen, exemestane, or anastrozole in an open-labeled, randomized, multicenter trial designated as the National Surgical Adjuvant Study of Breast Cancer (N-SAS BC) 04 substudy of the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial." | 5.16 | Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N- ( Hozumi, Y; Ohashi, Y; Ohsumi, S; Shimozuma, K; Suemasu, K; Takehara, M; Takei, H, 2012) |
| "Given its favourable risk-benefit profile, the combination of anastrozole plus goserelin could represent an alternative neoadjuvant treatment option for premenopausal women with early-stage breast cancer." | 5.16 | Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. ( Iwase, H; Iwata, H; Kamigaki, S; Kinoshita, T; Masuda, N; Nakamura, S; Nishimura, R; Noguchi, S; Sagara, Y; Takei, H; Yanagita, Y, 2012) |
| "Anastrozole (ANA) alone delivers significant disease-free survival benefits over tamoxifen (TAM) monotherapy in postmenopausal women with early estrogen receptor-positive breast cancer." | 5.16 | Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. ( Bartsch, R; Dubsky, PC; Filipcic, L; Fitzal, F; Gnant, M; Greil, R; Haider, K; Jakesz, R; Kwasny, W; Luschin-Ebengreuth, G; Mlineritsch, B; Pöstlberger, S; Rudas, M; Samonigg, H; Sevelda, P; Singer, CF; Steger, GG; Stierer, M; Stöger, H; Taucher, S; Tausch, C, 2012) |
| "To compare the effect of therapy with anastrozole versus a combination of fulvestrant and anastrozole in women in first relapse of endocrine-responsive breast cancer." | 5.16 | FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. ( Bergh, J; Brattström, D; Eiermann, W; Henriksson, R; Jönsson, PE; Lidbrink, EK; Lindemann, JP; Trudeau, M; Wiklund, F, 2012) |
| "To clarify these challenging and partly contrasting treatment predictive and prognostic links for cyclin D1 we analysed a large cohort of postmenopausal breast cancer patients randomised to receive either adjuvant anastrozole or tamoxifen, as part of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial." | 5.16 | Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. ( Brown, M; Cuzick, J; Dowsett, M; Howell, A; Landberg, G; Lundgren, K; Pineda, S; Salter, J; Zabaglo, L, 2012) |
| "Lipid profiles in women with early breast cancer receiving anastrozole with or without risedronate were examined within an international Phase III/IV study to assess for possible treatment related changes." | 5.16 | Lipid profiles within the SABRE trial of anastrozole with and without risedronate. ( Barlow, DH; Clack, G; Eastell, R; Makris, A; Van Poznak, C, 2012) |
| "The combination of anastrozole and fulvestrant was superior to anastrozole alone or sequential anastrozole and fulvestrant for the treatment of HR-positive metastatic breast cancer, despite the use of a dose of fulvestrant that was below the current standard." | 5.16 | Combination anastrozole and fulvestrant in metastatic breast cancer. ( Albain, KS; Barlow, WE; Dakhil, SR; Gralow, JR; Hayes, DF; Hortobagyi, GN; Lew, DL; Livingston, RB; Mehta, RS; Tirumali, NR; Vandenberg, TA, 2012) |
| "Fulvestrant fIRst-line Study comparing endocrine Treatments is a phase II, randomized, open-label study comparing fulvestrant 500 mg with anastrozole 1 mg as first-line endocrine therapy for postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer." | 5.16 | Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study. ( Dean, A; Dewar, J; Ellis, MJ; Emerson, L; Feltl, D; Lindemann, JP; Llombart-Cussac, A; Robertson, JF; Rolski, J, 2012) |
| "We recruited consecutive postmenopausal women, age ≥ 18 years, with hormone-sensitive nonmetastatic breast cancer who were prescribed anastrozole at least 3 months before enrollment." | 5.16 | Use of a urine anastrozole assay to determine treatment discontinuation among women with hormone-sensitive breast cancer: a pilot study. ( Clarke Hillyer, G; Crew, KD; Danaceau, J; Hershman, DL; Kalinsky, K; Maurer, MA; Neugut, AI; Rotsides, DZ, 2012) |
| "Asymptomatic postmenopausal women who took adjuvant tamoxifen for 2 to 3 years for operable breast cancer with a double endometrial thickness greater than 7 mm were randomized to 20 mg tamoxifen or 1 mg anastrozole for the remaining duration, totaling 5 years." | 5.15 | Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole. ( Amant, F; Berteloot, P; Blomme, C; De Jonge, E; Depypere, H; Neven, P; Timmerman, D; Van Calster, B; Van de Putte, G; Van den Broecke, R; Van Ginderachter, J; Van Huffel, S; Vergote, I; Vlaemynck, G; Vlasselaer, J, 2011) |
| "The objective of this study was to compare Ki-67, Bcl-2, Bax, Bak, ER, and PgR expression in postmenopausal women with ER-positive invasive breast cancer (IBC) before and after short-term hormone therapy (HT) with either tamoxifen or anastrozole in order to identify a possible biomarker profile associated with hormone resistance." | 5.15 | Short-term anastrozole therapy reduces Ki-67 and progesterone receptor expression in invasive breast cancer: a prospective, placebo-controlled, double-blind trial. ( Facina, G; Gebrim, LH; Logullo, AF; Mattar, A; Nonogaki, S; Soares, FA, 2011) |
| "These data demonstrate that fulvestrant 250 mg and anastrozole were similarly effective and well tolerated in the treatment of postmenopausal Chinese women with advanced breast cancer whose disease had progressed or recurred on prior endocrine treatment." | 5.15 | Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial. ( Chen, Z; Feng, J; Gu, K; Jiang, Z; Shao, Z; Song, S; Wang, C; Wang, J; Xu, B; Yang, J; Yu, S; Zhang, F; Zhang, Y, 2011) |
| "We evaluated the use of sorafenib to overcome resistance to aromatase inhibitors (AIs) in patients with metastatic breast cancer who had disease recurrence or progression while on AIs." | 5.15 | Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer. ( Chung, GG; Cohen, P; Creswell, K; Eng-Wong, J; Herbolsheimer, P; Isaacs, C; Liu, MC; Novielli, A; Ottaviano, Y; Slack, R; Smith, KL; Warren, R; Wilkinson, M, 2011) |
| "In this Tamoxifen Exemestane Adjuvant Multinational Japan sub-study, we evaluated the time course of changes in serum lipids in postmenopausal women with hormone-sensitive early breast cancer treated with exemestane, anastrozole, or tamoxifen for postoperative adjuvant therapy." | 5.15 | The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study. ( Aihara, T; Hozumi, Y; Masuda, N; Ohashi, Y; Ohsumi, S; Saito, T; Suemasu, K; Takehara, M; Takei, H, 2011) |
| "To investigate whether the health-related quality of life (HRQOL) of patients switching from tamoxifen to anastrozole in a randomized trial is identical to that of those who continued tamoxifen after 1-4 years of adjuvant tamoxifen in Japanese postmenopausal breast cancer patients." | 5.15 | Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1-4 years: N-SAS BC 03. ( Aihara, T; Hozumi, Y; Mukai, H; Ohashi, Y; Ohsumi, S; Shimozuma, K; Shinji, M; Takatsuka, Y, 2011) |
| "6 mg subcutaneously every 28 days) in combination with anastrozole or tamoxifen with or without zoledronic acid (4 mg intravenously every 6 months) in premenopausal women with endocrine-responsive breast cancer." | 5.15 | Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. ( Bjelic-Radisic, V; Dubsky, P; Fesl, C; Gnant, M; Greil, R; Königsberg, R; Marth, C; Mlineritsch, B; Pfeiler, G; Pöstlberger, S; Samonigg, H; Seifert, M; Singer, CF; Steger, GG; Stoeger, H; Taucher, S, 2011) |
| "Three hundred seventy-seven postmenopausal women with clinical stage II to III ER-positive (Allred score 6-8) breast cancer were randomly assigned to receive neoadjuvant exemestane, letrozole, or anastrozole." | 5.15 | Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int ( Allred, DC; Babiera, GV; DeSchryver, K; Ellis, MJ; Esserman, LJ; Guenther, JM; Hoog, J; Hunt, K; Leitch, M; Lin, L; Luo, J; Marcom, PK; Margenthaler, J; Olson, JA; Parker, JS; Prat, A; Snider, J; Suman, VJ; Unzeitig, GW; Watson, MA, 2011) |
| "Bevacizumab combined with either anastrozole or fulvestrant was feasible and active in the first-line treatment of patients who have hormone receptor-positive metastatic breast cancer." | 5.15 | Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium. ( Arrowsmith, E; Barton, J; Burris, HA; Clark, BL; Hainsworth, JD; Rubin, M; Shipley, D; Yardley, DA, 2011) |
| "The Arimidex, Tamoxifen Alone or in Combination (ATAC) study was a double-blind randomized trial in which postmenopausal women with early-stage breast cancer were assigned to receive anastrozole, tamoxifen, or the combination." | 5.15 | Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial. ( Baum, M; Buzdar, A; Cuzick, J; Dowsett, M; Forbes, JF; Howell, A; Ring, A; Sestak, I, 2011) |
| "Incidence of joint symptoms and bone fractures as well as changes in bone mineral density (BMD) in Japanese postmenopausal breast cancer patients treated with adjuvant anastrozole were investigated to determine whether there is an ethnic difference from Caucasian patients in the incidence of these adverse events of anastrozole." | 5.14 | Incidence of joint symptoms and bone fractures in Japanese postmenopausal breast cancer patients treated with adjuvant anastrozole. ( Kim, SJ; Noguchi, S; Okishiro, M; Shimazu, K; Taguchi, T; Tamaki, Y; Tanji, Y, 2009) |
| "We examined the effect of adding zoledronic acid to a combination of either goserelin and tamoxifen or goserelin and anastrozole in premenopausal women with endocrine-responsive early breast cancer." | 5.14 | Endocrine therapy plus zoledronic acid in premenopausal breast cancer. ( Bjelic-Radisic, V; Dubsky, P; Eidtmann, H; Fitzal, F; Fridrik, M; Gnant, M; Greil, R; Hubalek, M; Jakesz, R; Kwasny, W; Luschin-Ebengreuth, G; Marth, C; Menzel, C; Mlineritsch, B; Pöstlberger, S; Rücklinger, E; Samonigg, H; Schippinger, W; Seifert, M; Steger, G; Stierer, M; Tausch, C, 2009) |
| "Postmenopausal women with advanced breast cancer and > or = 1 visceral (liver or lung) lesion were randomized to anastrozole (1 mg/day orally) or exemestane (25 mg/day orally) for > or = 8 weeks." | 5.14 | A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. ( Abreu, P; Cameron, DA; Campos, SM; Guastalla, JP; Subar, M; Winer, EP, 2009) |
| "This study examined postmenopausal estrogen receptor-positive breast cancer patients who received prospective neoadjuvant endocrine therapy (NAET) with tamoxifen or anastrozole to determine if the 21-gene recurrence score (RS) predicts NAET responses." | 5.14 | 21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients. ( Akashi-Tanaka, S; Ando, M; Fujiwara, Y; Hojo, T; Katsumata, N; Kinoshita, T; Kouno, T; Shibata, T; Shien, T; Shimizu, C; Terada, K; Yoshida, M; Yoshimura, K, 2009) |
| "To compare the clinical activity of the pure antiestrogen fulvestrant at 500 mg/mo (double the approved dose) with the aromatase inhibitor anastrozole as first-line endocrine therapy for advanced hormone receptor-positive breast cancer in postmenopausal women." | 5.14 | Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. ( Dewar, J; Ellis, MJ; Feltl, D; Lindemann, J; Llombart-Cussac, A; Macpherson, E; Robertson, JF; Rolski, J, 2009) |
| " Letrozole, an Investigation of Quality Of Life and Tolerability) was a prospective, open-label, randomized pharmacodynamic study designed to assess the effects of aromatase inhibitors (AIs) on bone turnover in healthy postmenopausal women with estrogen receptor-positive breast cancer." | 5.14 | A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer. ( Dixon, JM; Hannon, R; Macaskill, EJ; McCaig, FM; McHugh, M; Murray, J; Renshaw, L; Williams, L; Young, O, 2010) |
| "PURPOSE To investigate the management of bone health in women with early breast cancer (EBC) who were scheduled to receive anastrozole." | 5.14 | Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. ( Apffelstaedt, JP; Barlow, D; Campone, M; Clack, G; Eastell, R; Hannon, RA; Mackey, JR; Makris, A; Van Poznak, C, 2010) |
| "This phase II randomized trial evaluated the efficacy and tolerability of anastrozole combined with gefitinib or anastrozole with placebo in women with hormone receptor-positive metastatic breast cancer (MBC)." | 5.14 | Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. ( Anderson, E; Arena, FP; Bacus, S; Cora, EM; Cristofanilli, M; Curcio, E; Kroener, JF; Magill, PJ; Mangalik, A; Rabinowitz, I; Royce, M; Valero, V; Watkins, C, 2010) |
| "In the 'Arimidex', Tamoxifen Alone or in Combination (ATAC) trial, the aromatase inhibitor (AI) anastrozole had a significantly better efficacy and safety profile than tamoxifen as initial adjuvant therapy for hormone receptor-positive (HR+) early breast cancer (EBC) in postmenopausal patients." | 5.14 | Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system. ( Beckmann, MW; Benedict, A; Buchholz, S; Distler, W; Hadji, P; Harbeck, N; Jonat, W; Kaufmann, M; Kreienberg, R; Kreif, N; Lux, MP; Possinger, K; Raab, G; Schneeweiss, A; Tesch, H; Weyers, G; Wöckel, A, 2010) |
| "Clinical trials conducted in Western countries have shown that aromatase inhibitors are associated with better disease-free survival (DFS) than tamoxifen in postmenopausal early breast cancer." | 5.14 | Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study. ( Abe, H; Aihara, T; Aogi, K; Hisamatsu, K; Hozumi, Y; Imoto, S; Ito, T; Iwata, H; Masuda, N; Mitsuyama, S; Mukai, H; Nakagami, K; Ogino, N; Ohashi, Y; Ohsumi, S; Shimizu, C; Takatsuka, Y; Tamura, M; Tanaka, S; Watanabe, T; Yamaguchi, T, 2010) |
| "The aim of this multicenter, phase III, prospective open label clinical trial was to investigate the effect of risedronate (R) on bone mineral density (BMD) in postmenopausal, early breast cancer (BC) patients scheduled to receive anastrozole (A)." | 5.14 | Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. ( Antonopoulou, Z; Dafni, U; Gogas, H; Kalogerakos, K; Koukouras, D; Lazarou, S; Markopoulos, C; Misitzis, J; Papadiamantis, J; Polychronis, A; Sarantopoulou, A; Siasos, N; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2010) |
| "The Arimidex, Tamoxifen Alone or in Combination (ATAC) study was a double-blind randomized clinical trial in which postmenopausal women with early-stage breast cancer were randomly assigned to receive oral daily anastrozole (1 mg) alone, tamoxifen (20 mg) alone, or the combination in a double-blind fashion." | 5.14 | Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. ( Cuzick, J; Distler, W; Dowsett, M; Forbes, JF; Howell, A; Sestak, I, 2010) |
| "To explore the antitumor activity of the aromatase inhibitor, anastrozole, in the treatment of premenopausal women with hormone receptor-positive, metastatic breast cancer who have been rendered functionally postmenopausal with the use of the luteinizing hormone-releasing hormone agonist, goserelin." | 5.14 | Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. ( Arun, B; Carlson, RW; Chiv, VY; Chung, CT; Dice, K; Green, M; Phan, SC; Rivera, E; Schurman, CM; Theriault, R; Valero, V, 2010) |
| "Postmenopausal women with localised, early breast cancer (n = 285) were enrolled in a prospective subprotocol of the 'arimidex, tamoxifen, alone or in combination' (ATAC) trial to assess gynaecological abnormalities arising during treatment with anastrozole (1 mg/day) or tamoxifen (20 mg/day)." | 5.14 | The ATAC adjuvant breast-cancer trial: six-year results of the endometrial subprotocol. ( Bianco, AR; Clack, G; Duffy, S; Jackson, TL; Lansdown, M; Philips, K; Wells, M, 2010) |
| "The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was designed to compare the efficacy and safety of anastrozole (1 mg) with tamoxifen (20 mg), both given orally every day for 5 years, as adjuvant treatment for postmenopausal women with early-stage breast cancer." | 5.14 | Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. ( Baum, M; Buzdar, A; Cuzick, J; Dowsett, M; Forbes, JF; Howell, A; Sestak, I, 2010) |
| "Evaluation of endometrial thickness by transvaginal ultrasonography (TVUS) in postmenopausal estrogen receptor positive breast cancer patients treated with anastrozole after tamoxifen therapy." | 5.13 | Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole. ( Bogliolo, S; Costantini, S; Dugnani, MC; Ferrero, S; Moioli, M; Papadia, A; Valenzano Menada, M, 2008) |
| "6 mg subcutaneously every 28 days), both with or without zoledronic acid (4 mg intravenously every 6 months) for 3 years in premenopausal women with endocrine-responsive breast cancer." | 5.13 | Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. ( Bjelic-Radisic, V; Dubsky, P; Fitzal, F; Gnant, M; Greil, R; Jakesz, R; Kainberger, F; Kässmann, H; Kubista, E; Luschin-Ebengreuth, G; Marth, C; Menzel, C; Mittlböck, M; Mlineritsch, B; Piswanger-Sölkner, JC; Ploner, F; Samonigg, H; Seifert, M; Steger, G; Wohlmuth, P, 2008) |
| "These findings show little or no impairment of cognitive performance with the use of anastrozole compared with placebo in postmenopausal women at high risk of developing breast cancer who were able to tolerate endocrine-related side-effects." | 5.13 | Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). ( Ambroisine, LM; Atkins, L; Cuzick, J; Fallowfield, LJ; Howell, A; Jenkins, VA, 2008) |
| "This study piloted a DA booklet for a high priority breast cancer prevention trial, IBIS-II DCIS, which compares the efficacy of an aromatase inhibitor (anastrozole) with tamoxifen in women who have had surgery for ductal carcinoma in situ (DCIS)." | 5.13 | Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS). ( Boyle, F; Butow, P; Coates, A; Forbes, JF; Juraskova, I; Lopez, A; McCarthy, N; Reaby, L; Seccombe, M, 2008) |
| "To evaluate the influence of the third-generation aromatase inhibitor letrozole (Femara) on breast cancer tissue levels of estrone (E(1)), estradiol (E(2)), and estrone sulfate (E(1)S) in postmenopausal women undergoing primary treatment for locally advanced estrogen receptor/progesterone receptor-positive breast cancers." | 5.13 | Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. ( Aas, T; Duong, NK; Ekse, D; Evans, DB; Geisler, J; Helle, H; Lønning, PE; Nordbø, Y, 2008) |
| "The aromatase inhibitor anastrozole is a highly effective well-tolerated treatment for postmenopausal endocrine-responsive breast cancer." | 5.13 | Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. ( Brown, JE; Coleman, RE; Dodwell, D; Ellis, SP; Gutcher, SA; Hannon, RA; Horsman, JM; Lester, JE; Purohit, OP; Thorpe, R, 2008) |
| "The PReOperative 'Arimidex' Compared with Tamoxifen (PROACT) trial compared neoadjuvant anastrozole and tamoxifen in postmenopausal women with large, operable or potentially operable, locally advanced hormone receptor-positive breast cancer." | 5.13 | Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial. ( Akiyama, F; Ikeda, T; Imoto, S; Inaji, H; Kurosumi, M; Noguchi, S; Sakamoto, G; Takatsuka, Y; Tsuda, H; Watanabe, T, 2008) |
| "These data show long-term safety findings and establish clearly the long-term efficacy of anastrozole compared with tamoxifen as initial adjuvant treatment for postmenopausal women with hormone-sensitive, early breast cancer, and provide statistically significant evidence of a larger carryover effect after 5 years of adjuvant treatment with anastrozole compared with tamoxifen." | 5.13 | Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. ( Baum, M; Buzdar, A; Cuzick, J; Forbes, JF; Howell, A; Tobias, JS, 2008) |
| "To determine the relationship between quantitative estrogen-receptor (ER) and progesterone-receptor (PgR) expression and human epidermal growth factor 2 (HER-2) status with time to recurrence (TTR) in postmenopausal women with hormone receptor-positive primary breast cancer treated with anastrozole or tamoxifen as adjuvant therapy." | 5.13 | Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. ( Allred, C; Bishop, H; Buzdar, A; Carder, P; Cussac, AL; Cuzick, J; Dowsett, M; Ellis, I; Forbes, J; Houghton, J; Knox, F; Knox, J; Larsimont, D; Mallon, E; Quinn, E; Salter, J; Sasano, H; Speirs, V; Wale, C; Williams, N, 2008) |
| "This prospective substudy of the ATAC trial assessed BMD changes in postmenopausal women with invasive primary breast cancer receiving anastrozole (1 mg/d) or tamoxifen (20 mg/d) as adjuvant therapy for 5 years." | 5.13 | Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. ( Adams, JE; Beckmann, MW; Clack, G; Coleman, RE; Cuzick, J; Eastell, R; Hannon, RA; Howell, A; Mackey, JR, 2008) |
| "Fifty-four postmenopausal women with estrogen receptor-positive breast cancer receiving aromatase inhibitors (AIs) as part of their adjuvant therapy were randomly assigned to receive either 3 months of anastrozole (1 mg) followed by 3 months of letrozole (2." | 5.13 | Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. ( A'Hern, RP; Cameron, DA; Dixon, JM; Dowsett, M; Folkerd, E; Macaskill, EJ; McHugh, M; Murray, J; Renshaw, L; Young, O, 2008) |
| "The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) trial compared the preoperative use of anastrozole with tamoxifen in postmenopausal women with estrogen receptor-positive primary operable breast cancer over 12 weeks." | 5.13 | The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer. ( A'hern, R; Banerjee, S; Dowsett, M; Ghazoui, Z; Martin, LA; Pancholi, S; Smith, IE, 2008) |
| "The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial compared the efficacy and safety of anastrozole versus tamoxifen versus the combination as initial adjuvant treatment for early breast cancer in over 9,000 postmenopausal women." | 5.12 | Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data. ( Buzdar, AU; Cuzick, J, 2006) |
| "To investigate the effect of switching from adjuvant tamoxifen to anastrozole (Arimidex) treatment in postmenopausal women with endocrine-responsive breast cancer and histologically proven tamoxifen-induced benign endometrial pathology." | 5.12 | Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology. ( Gerber, B; Janni, W; Krause, A; Kundt, G; Makovitzky, J; Mylonas, I; Reimer, T, 2006) |
| "The Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) study was a randomized, multicenter study comparing anastrozole with tamoxifen as a preoperative treatment of postmenopausal women with large, operable (T2/3, N0-2, M0), or potentially operable (T4b, N0-2, M0) breast cancer." | 5.12 | Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. ( Bines, J; Buzdar, AU; Cataliotti, L; de Oliveira, CT; Dube, P; Noguchi, S; Petrakova, K; Takatsuka, Y, 2006) |
| "Switching to anastrozole after the first 2-3 years of treatment was confirmed to improve event-free and relapse-free survival of postmenopausal, node-positive, ER-positive early breast cancer patients already receiving adjuvant tamoxifen." | 5.12 | Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. ( Amadori, D; Benedetto, C; Boccardo, F; Buzzi, F; Distante, V; Fini, A; Franchi, R; Guglielmini, P; Massidda, B; Mesiti, M; Paladini, G; Porpiglia, M; Restuccia, N; Rinaldini, M; Rubagotti, A; Scali, S; Sismondi, P, 2006) |
| "This prospectively designed subprotocol (n = 308) of ATAC assessed changes in BMD and bone turnover markers in postmenopausal women with invasive primary breast cancer receiving anastrozole 1 mg/day, tamoxifen 20 mg/day, or combination treatment with both agents for 5 years." | 5.12 | Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). ( Adams, JE; Clack, G; Cuzick, J; Dowsett, M; Eastell, R; Hannon, RA, 2006) |
| "The Arimidex (anastrozole), Tamoxifen, Alone or in Combination (ATAC) trial was designed to compare the efficacy and safety of anastrozole with tamoxifen as adjuvant treatment for postmenopausal women with early-stage breast cancer." | 5.12 | Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. ( Buzdar, A; Cuzick, J; Distler, W; Hoctin-Boes, G; Houghton, J; Howell, A; Locker, GY; Nabholtz, JM; Wale, C, 2006) |
| "6 mg every 28 days subcutaneously) +/- zoledronic acid (4 mg intravenously every 6 months) versus anastrozole (1 mg/d orally) and goserelin +/- zoledronic acid for 3 years in premenopausal women with hormone-responsive breast cancer." | 5.12 | Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. ( Galid, A; Gnant, MF; Grampp, S; Hausmaninger, H; Jakesz, R; Kaessmann, H; Luschin-Ebengreuth, G; Menzel, C; Mittlboeck, M; Mlineritsch, B; Piswanger-Soelkner, JC; Schmid, M, 2007) |
| "The aim of the study was to determine the potency of anastrozole to suppress serum E(2) levels in breast cancer patients undergoing COH." | 5.12 | Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization. ( Azim, AA; Costantini-Ferrando, M; Lostritto, K; Oktay, K, 2007) |
| "In women with favorable early breast cancer treated by lumpectomy plus tamoxifen or anastrazole, it remains unclear whether whole breast radiotherapy is beneficial." | 5.12 | Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. ( Draxler, W; Gnant, M; Haider, K; Hammer, J; Handl-Zeller, L; Hofbauer, F; Jakesz, R; Kapp, K; Kwasny, W; Luschin-Ebengreuth, G; Pakisch, B; Pöstlberger, S; Pötter, R; Reiner, G; Rottenfusser, A; Schmid, M; Sedlmayer, F; Stierer, M; Taucher, S; Tausch, C, 2007) |
| "Aromatase inhibitors such as anastrozole and letrozole are highly effective suppressants of estrogen synthesis in postmenopausal women and are the most effective endocrine treatments for hormone receptor positive breast cancer in such women." | 5.12 | Molecular response to aromatase inhibitor treatment in primary breast cancer. ( Ashworth, A; Dexter, T; Dixon, JM; Dowsett, M; Drury, S; Evans, DB; Fenwick, K; Larionov, A; Mackay, A; Miller, WR; Urruticoechea, A; White, S; Young, O, 2007) |
| "Postmenopausal women who have taken tamoxifen for 2 years as adjuvant therapy are less likely to experience a recurrence of breast cancer and have improved overall survival if they switch to anastrozole compared with continuing to receive tamoxifen." | 5.12 | Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. ( Eidtmann, H; Gademann, G; Hilfrich, J; Jonat, W; Kaufmann, M; von Minckwitz, G; Zuna, I, 2007) |
| "Results from the completed treatment analysis of the ATAC (Arimidex, Tamoxifen alone or in combination) trial indicated that anastrozole was significantly superior to tamoxifen in terms of efficacy and safety in the adjuvant treatment of postmenopausal women with hormone receptor-positive (HR+) early breast cancer." | 5.12 | Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial. ( Benedict, A; Fallowfield, L; Jones, D; Locker, G; Mansel, R, 2007) |
| "Postmenopausal women with stage I to IIIB hormone receptor-positive early breast cancer received anastrozole 1 mg daily for 16 weeks and were randomly assigned at a ratio of 2:5:5 to receive, in addition, gefitinib 250 mg/d orally for 16 weeks: placebo 1 tablet/d orally for 2 weeks and then gefitinib for 14 weeks or placebo for 16 weeks." | 5.12 | A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. ( Clark, E; Detre, S; Dowsett, M; Llombart, A; Magill, P; Mayordomo, JI; Salter, J; Skene, A; Smith, IE; Walsh, G, 2007) |
| "Third-generation nonsteroidal aromatase inhibitors (AIs), letrozole and anastrozole, are superior to tamoxifen as initial therapy for early breast cancer but have not been directly compared in a head-to-head adjuvant trial." | 5.12 | A decade of letrozole: FACE. ( O'Shaughnessy, J, 2007) |
| "The Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial was the first trial to explore the use of aromatase inhibitors in post-menopausal women with early breast cancer and is the largest published cancer treatment trial in breast cancer." | 5.12 | The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer. ( Cuzick, J, 2007) |
| "3 months, women who received anastrozole (n = 387) had a statistically significantly reduced risk of recurrence (locoregional recurrence, contralateral breast cancer, or distant metastasis) compared with women who received no further treatment (n = 469; hazard ratio = 0." | 5.12 | Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. ( Dadak, C; Gnant, M; Greil, R; Hofbauer, F; Jakesz, R; Kubista, E; Kwasny, W; Mlineritsch, B; Renner, K; Rücklinger, E; Samonigg, H; Schmid, M; Stierer, M; Tausch, C, 2007) |
| "A total of 16 premenopausal women with metastatic breast cancer (N=13) or locally advanced primary breast cancer (N=3) were treated with a combination of a gonadotropin-releasing hormone agonist goserelin, and a selective aromatase inhibitor anastrozole." | 5.11 | Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. ( Cheung, KL; Forward, DP; Jackson, L; Robertson, JF, 2004) |
| "The 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial is a randomized, double-blind trial comparing anastrozole ('Arimidex'), alone or in combination with tamoxifen, relative to tamoxifen alone as 5 year adjuvant treatment for post-menopausal women with early breast cancer." | 5.11 | The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy. ( Bianco, AR; Clack, G; Coibion, M; Duffy, S; Jackson, TL; Lansdown, M; Philips, K; Pollard, S; Wells, M, 2005) |
| "This study was undertaken to assess baseline endometrial molecular events in the ATAC (Arimidex, tamoxifen, alone, or in combination) trial of breast cancer adjuvant therapy." | 5.11 | Molecular markers in the endometrium at baseline of postmenopausal patients with early breast cancer in the ATAC (Arimidex, tamoxifen, alone, or in combination) trial. ( Duffy, SR; Taylor, L, 2004) |
| " In this study, adjuvant tamoxifen and anastrozole ('Arimidex') were compared alone and in combination in more than 9000 women with breast cancer." | 5.11 | Biomarker investigations from the ATAC trial: the role of TA01. ( Dowsett, M, 2004) |
| "The IMPACT trial compared the preoperative use of tamoxifen with anastrozole alone or in combination in postmenopausal women (n = 330) with primary breast cancer." | 5.11 | Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists. ( Ashley, S; Boeddinghaus, I; Detre, S; Dixon, JM; Dowsett, M; Ebbs, SR; Francis, S; Griffith, C; Hills, M; Salter, J; Skene, A; Smith, IE; Walsh, G, 2005) |
| " This study evaluated the effect on lipid metabolism of one such agent, the new generation aromatase inhibitor anastrozole, compared with tamoxifen, when used as adjuvant treatment in postmenopausal Japanese women with early breast cancer." | 5.11 | Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer. ( Ayaori, M; Hiraide, H; Kusuhara, M; Mochizuki, H; Ohsuzu, F; Sato, K; Sawada, S; Tamaki, K; Yonemura, A, 2005) |
| "In a double-blind, placebo-controlled randomised trial of 56 postmenopausal patients with ER-positive and EGFR-positive primary breast cancer, 27 women were randomly assigned to the tyrosine-kinase inhibitor of EGFR gefitinib (250 mg given orally once a day) and the aromatase inhibitor anastrozole (1 mg given orally once a day), and 29 women to gefitinib (250 mg given orally once a day) and placebo of identical appearance to anastrozole given orally once a day, all given for 4-6 weeks before surgery." | 5.11 | Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. ( Ali, S; Barrett, N; Beresford, E; Coombes, RC; Hadjiminas, D; Jiang, J; Mansi, JL; Morrison, K; Peston, D; Polychronis, A; Shivapatham, D; Shousha, S; Singhal, H; Sinnett, HD; Slade, MJ; Vigushin, D, 2005) |
| "The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) trial was designed to test the hypothesis that the clinical and/or biologic effects of neoadjuvant tamoxifen compared with anastrozole and with the combination of tamoxifen and anastrozole before surgery in postmenopausal women with estrogen receptor (ER) -positive, invasive, nonmetastatic breast cancer might predict for outcome in the Arimidex, Tamoxifen Alone or in Combination (ATAC) adjuvant therapy trial." | 5.11 | Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. ( Ashley, SE; Blohmer, JU; Boeddinghaus, I; Dixon, JM; Dowsett, M; Ebbs, SR; Francis, S; Skene, A; Smith, IE; Walsh, G, 2005) |
| "Switching to anastrozole after the first 2 to 3 years of treatment is well tolerated and significantly improves event-free and recurrence-free survival in postmenopausal patients with early breast cancer." | 5.11 | Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. ( Amadori, D; Amoroso, D; Benedetto, C; Boccardo, F; Buzzi, F; Distante, V; Fini, A; Franchi, R; Guglielmini, P; Massidda, B; Mesiti, M; Paladini, G; Porpiglia, M; Puntoni, M; Restuccia, N; Rinaldini, M; Romeo, D; Rubagotti, A; Scali, S; Sismondi, P, 2005) |
| "Arimidex, tamoxifen alone, or in combination (ATAC) trial of anastrozole (Arimidex) versus tamoxifen or a combination of the two in 9,366 postmenopausal patients with primary breast cancer found a significant improvement in disease-free survival and time to recurrence (TTR) for anastrozole compared with tamoxifen, that was restricted to patients with hormone receptor-positive (ie, estrogen receptor-positive [ER+] and/or progesterone receptor-positive [PgR+]) disease, the target population for these therapies." | 5.11 | Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. ( Baum, M; Cuzick, J; Dowsett, M; Houghton, J; Howell, T; Wale, C, 2005) |
| "To compare the efficacy and tolerability of fulvestrant (formerly ICI 182,780) with anastrozole in the treatment of advanced breast cancer in patients whose disease progresses on prior endocrine treatment." | 5.10 | Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. ( Burton, G; Buzdar, A; Come, S; Dimery, I; Elledge, R; Ellis, M; Gertler, SZ; Jones, SE; May, JT; Morris, C; Osborne, CK; Parker, LM; Pippen, J; Webster, A, 2002) |
| "To compare the efficacy and tolerability of fulvestrant (formerly ICI 182,780) and anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment." | 5.10 | Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. ( Aschermannova, A; Erikstein, B; Howell, A; Kleeberg, UR; Mauriac, L; Morris, C; Quaresma Albano, J; Robertson, JF; Vergote, I; Webster, A, 2002) |
| "Anastrozole is an orally active, non-steroidal aromatase inhibitor which appears effective as neoadjuvant treatment of breast cancer." | 5.10 | Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer. ( Anderson, TJ; Dixon, JM; Miller, WR; Sahmoud, T; Stuart, M, 2002) |
| "The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial is a randomised, double-blind, double-dummy trial, evaluating anastrozole alone or in combination with tamoxifen compared with tamoxifen alone, as a 5-year adjuvant treatment for postmenopausal patients with early breast cancer." | 5.10 | The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal patients: factors influencing the success of patient recruitment. ( Baum, M, 2002) |
| "The efficacy of fulvestrant (Faslodex), a novel oestrogen receptor (ER) antagonist that downregulates the ER and has no known agonist effects, was compared with the aromatase inhibitor anastrozole (Arimidex) for the second-line treatment of advanced breast cancer in postmenopausal women with visceral and non-visceral metastases." | 5.10 | Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. ( Gertler, SZ; Mauriac, L; Osborne, CK; Pippen, JE; Quaresma Albano, J, 2003) |
| "A prospective phase III trial comparing anastrozole with tamoxifen as first-line therapy in postmenopausal, hormone-dependent, advanced breast cancer (ABC)." | 5.10 | Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study. ( Casanovas, J; Milla, L; Milla-Santos, A; Pons, M; Portella, J; Puig-Gali, M; Rallo, L; Rodes, E, 2003) |
| "This retrospective evaluation of data from two randomized, multicenter trials examined whether tumor responses to further endocrine therapy were seen in postmenopausal women with advanced breast cancer who had progressed on both initial endocrine therapy, usually tamoxifen, and on the estrogen receptor (ER) antagonist fulvestrant ('Faslodex')." | 5.10 | Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. ( Burton, G; Kleeberg, U; Mauriac, L; Osborne, CK; Robertson, JF; Vergote, I, 2003) |
| "We present an initial survival analysis and an update of the safety data of the North American and Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability (TARGET) double-blind, randomised, multicentre studies which compared anastrozole with tamoxifen as first-line treatment in postmenopausal patients with oestrogen receptor and/or progesterone receptor-positive (ER+/PR+) or receptor-unknown advanced breast cancer (ABC)." | 5.10 | Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. ( Bonneterre, J; Buzdar, A; Nabholtz, JM; Robertson, JF; Thürlimann, B, 2003) |
| "To explore the different sequence interactions between reversible non-steroidal (anastrozole, ANZ and letrozole, LTZ) and non-reversible steroidal aromatase inhibitors (formestane, FOR and exemestane, EXE), we evaluated the clinical benefit (CB) in postmenopausal breast cancer patients, who had previously received anastrozole and subsequently formestane." | 5.10 | Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women? ( Carlini, P; Cognetti, F; Colella, E; Di Cosimo, S; Fabi, A; Ferretti, G; Frassoldati, A; Papaldo, P; Romiti, A; Ruggeri, EM; Tomao, S; Tonachella, R, 2003) |
| "It was previously shown that letrozole (Femara) was significantly more potent than anastrozole (Arimidex) in inhibiting aromatase activity in vitro and in inhibiting total body aromatisation in patients with breast cancer." | 5.10 | An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. ( Ben Ayed, F; Burdette-Radoux, S; Caicedo, JJ; Chaudri-Ross, HA; Davidson, N; Gershanovich, M; Gervasio, H; Johnson, S; Lang, R; Manikhas, G; Pluzanska, A; Rose, C; Thomas, R; Vtoraya, O, 2003) |
| "The first analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial (median follow-up, 33 months) demonstrated that in adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer, anastrozole was superior to tamoxifen in terms of disease-free survival (DFS), time to recurrence (TTR), and incidence of contralateral breast cancer (CLBC)." | 5.10 | Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update ana ( Baum, M; Buzdar, A; Cuzick, J; Forbes, J; Houghton, J; Howell, A; Sahmoud, T, 2003) |
| "Results from two studies, the North American trial and the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability (TARGET) trial carried out in Europe/rest of the world comparing 'Arimidex' (anastrozole) 1 mg with tamoxifen 20 mg for treatment of advanced breast cancer in postmenopausal women, have previously been reported individually and as a prospectively combined analysis." | 5.10 | Advanced breast cancer updates on anastrozole versus tamoxifen. ( Nabholtz, JM, 2003) |
| "ATAC, a randomized, double-blind trial, compared tamoxifen (20 mg) with anastrozole ('Arimidex') (1 mg) alone, and the combination of anastrozole plus tamoxifen (combination), as adjuvant endocrine treatment for postmenopausal patients with early breast cancer." | 5.10 | 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview. ( Buzdar, AU, 2003) |
| "The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial is a randomised, double-blind trial comparing 'Arimidex' (anastrozole), alone or in combination with tamoxifen, relative to tamoxifen alone as a five year adjuvant treatment for postmenopausal women with early breast cancer." | 5.10 | The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data. ( Bianco, AR; Clack, G; Coibion, M; Cuzick, J; Duffy, S; Jackson, TL; Lansdown, M; Philips, K; Pollard, S; Wells, M, 2003) |
| "Twelve postmenopausal women with estrogen receptor-positive, metastatic breast cancer were treated with anastrozole 1 mg orally (PO) and letrozole 2." | 5.10 | Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. ( Anker, G; Dowsett, M; Geisler, J; Haynes, B; Lønning, PE, 2002) |
| "Anastrozole is an effective and well tolerated endocrine option for the treatment of postmenopausal patients with hormone-sensitive early breast cancer." | 5.10 | Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. ( Baum, M; Budzar, AU; Cuzick, J; Forbes, J; Houghton, JH; Klijn, JG; Sahmoud, T, 2002) |
| "Thirty-four post-menopausal women with early breast cancer who had received 20 mg tamoxifen once daily as adjuvant therapy for at least 10 weeks participated in a randomized, double-blind, parallel-group, multicentre trial." | 5.09 | The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer. ( Baum, M; Blackman, GM; Dowsett, M; Howell, A; King, N; Ponzone, R; Tobias, JS; von Euler, M; Welch, H, 1999) |
| "Formestane (Lentaron) and anastrozole (Arimidex) are in clinical use as second-line treatments for advanced breast cancer." | 5.09 | Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy. ( Coombes, RC; Harper-Wynne, C, 1999) |
| "Sixty postmenopausal women with advanced breast cancer were randomized to receive either anastrozole 1 mg once daily orally (n = 29), or formestane 250 mg once every two weeks by intramuscular injection (n = 31)." | 5.09 | A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex) with intramuscular formestane in postmenopausal women with advanced breast cancer. ( Calvo, L; Clack, G; Dodwell, DJ; Dowsett, M; Kleeberg, UR; Perez-Carrion, R; Robertson, JF; Vorobiof, DA, 1999) |
| "This paper reports on the clinical relevance of durable static disease (SD) (> or = 24 weeks) in breast cancer patients treated with the aromatase inhibitor anastrozole." | 5.09 | Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer. ( Buzdar, A; Howell, A; Lee, D; Robertson, JF; von Euler, M, 1999) |
| "Anastrozole, an orally active, nonsteroidal aromatase inhibitor, was evaluated in a randomized, double-blind, single-center study to determine its efficacy as neoadjuvant therapy in postmenopausal women with newly diagnosed, estrogen receptor-rich, locally advanced or large (>3 cm), operable breast cancers." | 5.09 | The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. ( Bellamy, C; Dixon, JM; Hoctin-Boes, G; Miller, WR; Renshaw, L; Stuart, M, 2000) |
| "To compare the efficacy and tolerability of anastrozole (Arimidex; AstraZeneca, Wilmington, DE, and Macclesfield, United Kingdom) with that of tamoxifen as first-line therapy for advanced breast cancer (ABC) in postmenopausal women." | 5.09 | Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. ( Bonneterre, J; Koralewski, P; Krzakowski, M; Mauriac, L; Robertson, JF; Steinberg, M; Thürlimann, B; Vergote, I; von Euler, M; Webster, A, 2000) |
| "The efficacy and tolerability of anastrozole (Arimidex; AstraZeneca, Wilmington, DE, and Macclesfield, United Kingdom) and tamoxifen were compared as first-line therapy for advanced breast cancer in 353 postmenopausal women." | 5.09 | Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. ( Burton, G; Buzdar, A; Harwin, W; Mangalik, A; Nabholtz, JM; Pollak, M; Steinberg, M; von Euler, M; Webster, A, 2000) |
| "Anastrozole (Arimidex) is a novel, selective, and potent aromatase inhibitor used for the treatment of postmenopausal breast cancer." | 5.09 | Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. ( Berntsen, H; Detre, S; Dowsett, M; Einstein Lønning, P; Geisler, J; Lindtjørn, B; Ottestad, L, 2001) |
| "The ATAC trial evaluates in a randomized, double-blind design, Arimidextrade mark (anastrozole) alone or in combination with tamoxifen, relative to tamoxifen alone as 5-year adjuvant treatment in postmenopausal women with early breast cancer." | 5.09 | Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial. ( Cuzick, J; Dowsett, M; Howell, A; Jackson, I, 2001) |
| "Anastrozole, 1 and 10 mg once daily, is well tolerated and as effective as megestrol acetate in the treatment of postmenopausal women with advanced breast cancer who progressed following tamoxifen treatment." | 5.08 | Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. ( Azab, M; Blomqvist, C; Buzdar, A; Eiermann, W; Howell, A; Jonat, W; Jones, SE; Plourde, PV; Vogel, CL; Webster, A; Wolter, JM, 1996) |
| "The aim of this study was to compare the efficacy and tolerability of the new aromatase inhibitor 'ARIMIDEX' (anastrozole) with megestrol acetate in the treatment of advanced breast cancer in postmenopausal women." | 5.08 | A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. ( Azab, M; Blomqvist, C; Eiermann, W; Hellmund, R; Howell, A; Jonat, W; Lundgren, S; Mauriac, L; Roche, H; Tyrrell, C; Winblad, G, 1996) |
| "The effect of anastrozole ('Arimidex', ZD1033), a new, selective, non-steroidal aromatase inhibitor on in vivo aromatisation and plasma oestrogen levels was evaluated in post-menopausal women with breast cancer." | 5.08 | Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. ( Dowsett, M; Geisler, J; King, N; Kormeset, PO; Lundgren, S; Lønning, PE; Ottestad, L; Walton, P, 1996) |
| "Anastrozole, given in doses of 1 and 10 mg once daily, represents a well tolerated and effective therapeutic option for the treatment of postmenopausal women with advanced breast carcinoma who progress after tamoxifen treatment." | 5.08 | A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. ( Buzdar, AU; Jones, SE; Plourde, P; Vogel, CL; Webster, A; Wolter, J, 1997) |
| "The relative efficacy and tolerability of the aromatase inhibitors anastrozole (Arimidex) and formestane are assessed in a direct comparative trial in postmenopausal women with advanced breast cancer." | 5.08 | A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer. ( Aparicio, LA; Carrion, RP; Dodwell, DJ; Dowsett, M; Kleeberg, UR; Robertson, JF; Vorobiof, DA, 1997) |
| "For patients with hormone receptor (HR)-positive advanced breast cancer, whether the combination of anastrozole and fulvestrant is more effective than anastrozole alone is controversial." | 5.05 | Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials. ( Duan, S; He, Y; Li, M; Liao, C; Wei, Y; Xiong, Y; Yi, F; Zhang, W, 2020) |
| "For young patients with hormone receptor-positive early breast cancer, tamoxifen for at least 5 years is the standard endocrine treatment." | 5.01 | [Endocrine adjuvant treatment specific features for young breast cancer women]. ( Petit, T, 2019) |
| " Herein, we reported a case of hallucination related to anastrozole in a patient with metastatic breast cancer." | 5.01 | In case of anastrozole-related hallucinations, can switching to letrozole be a treatment option? A case report and literature review. ( Bozkaya, Y; Demirci, NS; Erdem, GU, 2019) |
| "Fulvestrant, a selective estrogen receptor degrader, is approved for first- and second-line treatment of postmenopausal women with hormone receptor-positive advanced breast cancer (ABC)." | 5.01 | A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer. ( Bradbury, I; Campbell, C; Di Leo, A; Ellis, M; Jiang, Z; Ohno, S; Pritchard, KI; Robertson, JFR, 2019) |
| "Whether anastrozole has superior effects to tamoxifen for breast cancer remains controversial." | 4.95 | A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancer. ( Pan, W; Sun, X; Tang, X; Wu, S; Yang, Y, 2017) |
| "We performed a network meta-analysis for a comprehensive analysis of 6 first-line endocrine monotherapies (letrozole, anastrozole, exemestane, tamoxifen, fulvestrant 250 mg and 500 mg) for HR+ HER2- metastatic or locally advanced breast cancer in postmenopausal patients." | 4.95 | Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis. ( He, Y; Huang, Y; Wang, C; Wu, K; Zhang, J; Zheng, S, 2017) |
| "Fulvestrant is a selective oestrogen receptor down-regulator (SERD), which by blocking proliferation of breast cancer cells, is an effective endocrine treatment for women with hormone-sensitive advanced breast cancer." | 4.95 | Fulvestrant for hormone-sensitive metastatic breast cancer. ( Goodwin, A; Lee, CI; Wilcken, N, 2017) |
| "We conducted a review of randomized trials to compare the overall survival (OS) with fulvestrant 500 mg versus alternative treatment for estrogen receptor-positive advanced breast cancer following endocrine therapy failure." | 4.93 | Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy. ( Batson, S; Jones, N; Livings, C; Telford, C, 2016) |
| "RCTs investigating 3 different anticancer strategies in metastatic breast cancer were identified: (1) new hormonal therapy, (2) new targeted therapies in hormone receptor positive tumours (everolimus or palbociclib), and (3) new anti-HER2 therapies." | 4.93 | Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy. ( Niraula, S; Ocana, A, 2016) |
| " We report an unusual case of urticarial vasculitis following the aromatase inhibitor anastrozole that localised to the unilateral trunk and mastectomy scar, and review the literature on the cutaneous adverse effects of hormonal therapy for breast cancer." | 4.90 | Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: a case of localised urticarial vasculitis following anastrozole therapy and a review of the literature. ( Bock, VL; Friedlander, M; Kossard, S; Waring, D; Wood, GK, 2014) |
| " Only RCTs that compared fulvestrant 250 mg to anastrozole 1mg in postmenopausal women with advanced breast cancer were selected." | 4.90 | Fulvestrant 250 mg versus anastrozole 1 mg in the treatment of advanced breast cancer: a meta-analysis of randomized controlled trials. ( Fan, Y; Gong, DD; Man, CF; Xu, J, 2014) |
| "A PubMed search (1966-July 2014) was conducted using the key terms breast cancer risk reduction, with anastrozole, exemestane, or letrozole, or aromatase inhibitors." | 4.90 | Aromatase inhibitors in breast cancer prevention. ( Olin, JL; St Pierre, M, 2014) |
| "Fulvestrant is a highly active systemic therapy in patients with metastatic hormone receptor positive breast cancer." | 4.89 | A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer. ( Haaland, B; Lopes, G; Montero, AJ; Tan, PS, 2013) |
| "Clinical trials conducted over the last two decades have demonstrated that 5 years of treatment with tamoxifen (TAM) after local treatment in postmenopausal patients with positive hormone receptor early breast cancer improves disease-free survival and overall survival." | 4.87 | Update on adjuvant hormonal treatment of early breast cancer. ( Ciruelos Gil, EM; Fernández Martínez, R; Fernández Pérez, I; Garcerá Juan, S; Illarramendi Mañas, JJ; Iranzo González Cruz, V; Lao Romera, J; Peláez Fernández, I; Puertolas Hernández, TJ; Sampedro Gimeno, T, 2011) |
| "Aromatase inhibitors (AIs) have largely replaced tamoxifen as adjuvant hormonal therapy for postmenopausal women with early breast cancer." | 4.86 | Adjuvant endocrine therapy for early breast cancer: the story so far. ( Gradishar, WJ, 2010) |
| "To undertake a systematic review of three first-line treatments (letrozole, anastrozole and exemestane) for hormone sensitive advanced or metastatic breast cancer (MBC) in post-menopausal women." | 4.86 | Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer. ( Amonkar, MM; Forbes, CA; Kessels, A; Kleijnen, J; Lykopoulos, K; Rea, DW; Riemsma, R, 2010) |
| "Anastrozole is a third-generation aromatase inhibitor used in the adjuvant setting for the treatment of hormone receptor-positive breast cancer." | 4.86 | Anastrozole. ( Buzdar, AU; Kelly, CM, 2010) |
| "Anastrozole (Arimidex) is an aromatase inhibitor approved in the EU, the US and in other countries worldwide for use as an adjuvant treatment in postmenopausal women with early-stage, hormone receptor-positive breast cancer." | 4.84 | Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer. ( Plosker, GL; Sanford, M, 2008) |
| "A 5-year regimen of tamoxifen hormone therapy has historically been the recommendation for hormone receptor-positive, postmenopausal women with early-stage breast cancer." | 4.84 | Review of the ATAC study: tamoxifen versus anastrozole in early-stage breast cancer. ( Needleman, SJ; Tobias, JS, 2008) |
| "To establish the clinical and cost-effectiveness of aromatase inhibitors (AIs) anastrozole, letrozole and exemestane compared with tamoxifen in the adjuvant treatment of early oestrogen receptor-positive breast cancer in postmenopausal women." | 4.84 | Hormonal therapies for early breast cancer: systematic review and economic evaluation. ( Carroll, C; De Nigris, E; Hind, D; Simpson, E; Ward, S; Wyld, L, 2007) |
| "The third-generation aromatase inhibitors (AIs) anastrozole, exemestane and letrozole have largely replaced tamoxifen as the preferred treatment for hormone receptor - positive breast cancer in postmenopausal women." | 4.84 | The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. ( Fabian, CJ, 2007) |
| "The third-generation aromatase inhibitors (AIs) letrozole, anastrozole, and exemestane are replacing tamoxifen as adjuvant therapy in most postmenopausal women with early breast cancer." | 4.84 | Safety of aromatase inhibitors in the adjuvant setting. ( Perez, EA, 2007) |
| " The PCT responded partially to the cessation of oral contraceptives and to phlebotomy therapy to maintain low iron stores, but only remitted after she received anastrozole therapy for management of adenocarcinoma of the breast at age 59 years." | 4.84 | Remission of porphyria cutanea tarda after anastrozole treatment of breast cancer. ( Barton, JC; Bertoli, LF, 2007) |
| " PubMed and MEDLINE were searched for descriptions of clinical trials published from 1990 to 2007 using the terms breast cancer, extended adjuvant, aromatase inhibitor, anastrozole, exemestane, and letrozole." | 4.84 | Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women. ( Jahanzeb, M, 2007) |
| "Anastrozole is a third-generation aromatase inhibitor with an extensive evidence base to preferentially support its use in multiple scenarios in endocrine-responsive breast cancer." | 4.84 | Anastrozole for malignant and benign conditions: present applications and future therapeutic integrations. ( Graham, PH, 2007) |
| "A systematic review was undertaken to review the evidence for the use of third-generation aromatase inhibitors (anastrozole, letrozole and exemestane) as adjuvant therapy for post-menopausal women with early-stage, hormone receptor-positive breast cancer and to develop and support recommendations for their use, with regard to three areas: aromatase inhibitors compared to tamoxifen, aromatase inhibitors in sequence with tamoxifen for a total of five years, and aromatase inhibitors given after five years of tamoxifen therapy." | 4.84 | Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. ( Eisen, A; Messersmith, H; Pritchard, KI; Shelley, W; Trudeau, M, 2008) |
| "This paper describes the clinical evidence for using the aromatase inhibitors (AIs), anastrozole, letrozole and exemestane, as adjuvant therapy for postmenopausal women with early breast cancer." | 4.84 | Aromatase inhibitors in early breast-cancer treatment: The story so far. ( Cuzick, J, 2008) |
| "Tamoxifen is the established adjuvant treatment for postmenopausal women with hormone-sensitive early breast cancer." | 4.83 | Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data. ( Grana, G, 2006) |
| "Third-generation aromatase inhibitors are accepted widely as alternatives to tamoxifen for the treatment of advanced breast cancer in postmenopausal women and, currently, are increasingly replacing tamoxifen in the adjuvant setting." | 4.83 | Anastrozole for breast cancer: recent advances and ongoing challenges. ( Buzdar, AU, 2006) |
| "Anastrozole is a nonsteroidal, third-generation aromatase inhibitor, which is heralded as an effective alternative endocrine therapy to tamoxifen in postmenopausal women with hormone-responsive breast cancer." | 4.83 | The adjuvant endocrine treatment revolution: focus on anastrozole. ( Jakesz, R, 2006) |
| "An analysis of TTR was performed on data from 2 phase III trials comparing fulvestrant and anastrozole as second-line treatments for postmenopausal women with advanced-stage, tamoxifen-resistant breast cancer." | 4.83 | Time to response: comparison of fulvestrant and oral endocrine agents. ( Dodwell, D; Pippen, J, 2006) |
| "It is clear that letrozole and anastrozole provide significant benefits for patients with breast cancer." | 4.83 | Refining the postmenopausal breast cancer treatment paradigm: the FACE trial. ( Monnier, A, 2006) |
| "We did a meta-analysis of three clinical trials--the Austrian Breast and Colorectal Cancer Study Group (ABCSG 8), Arimidex-Nolvadex (ARNO 95), and the Italian Tamoxifen Anastrozole (ITA) studies--in which postmenopausal women with histologically confirmed, hormone-sensitive early-stage breast cancer were randomised to 1 mg/day anastrozole (n=2009) after 2-3 years of tamoxifen treatment or to continued 20 or 30 mg/day tamoxifen (n=1997)." | 4.83 | Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. ( Boccardo, F; Gnant, M; Greenwood, M; Jakesz, R; Jonat, W; Kaufmann, M; Rubagotti, A; Zuna, I, 2006) |
| "A search of the Medline database from 1976 through 2006 was performed for the following terms: breast cancer, adjuvant, aromatase inhibitors, anastrozole, letrozole, exemestane, tamoxifen, sequential, switching." | 4.83 | Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data. ( Ellis, MJ; Rigden, CE, 2006) |
| "Adjuvant hormonal therapy for patients with endocrine sensitive breast cancer has been dominated for several decades by the gold standard tamoxifen." | 4.83 | The emerging role of aromatase inhibitors in the adjuvant management of breast cancer. ( Gligorov, J; Nabholtz, JM, 2006) |
| "Adjuvant endocrine therapy with tamoxifen has a clearly established benefit in postmenopausal women with resected early breast cancer that expresses the estrogen receptor and/or progesterone receptor." | 4.82 | Adjuvant endocrine therapy in postmenopausal breast cancer. ( Ingle, JN, 2003) |
| " For more than 20 years, standard first-line treatment for postmenopausal women with metastatic breast cancer has been the antiestrogen tamoxifen, a selective estrogen receptor modulator (SERM) with differential effects on breast, endometrial, bone, and vascular tissues." | 4.82 | Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy. ( Brodie, AH; Mouridsen, HT, 2003) |
| "Randomized clinical trials have established the role of third-generation aromatase inhibitors (AIs) (letrozole, anastrozole, and exemestane) as standard treatment for patients with hormone-sensitive metastatic breast cancer who have experienced disease progression with antiestrogen therapy." | 4.82 | A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer. ( Rose, C, 2003) |
| "Current prevention trials have shown that tamoxifen can reduce the incidence of breast cancer by about 30%-40% in high-risk women, but that the risk of thromboembolic disease and endometrial cancer are increased about twofold." | 4.82 | Aromatase inhibitors in prevention--data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). ( Cuzick, J, 2003) |
| "Six years ago, we reviewed the selective aromatase inhibitors, anastrozole and letrozole, for the treatment of women with breast cancer." | 4.82 | Should aromatase inhibitors replace tamoxifen? ( , 2003) |
| "The latest generation of nonsteroidal aromatase inhibitors (anastrozole and letrozole) has been approved by the US Food and Drug Administration for use in the first- and second-line treatment of postmenopausal women with hormone receptor-positive (or unknown) breast cancer." | 4.82 | Pharmacokinetics of third-generation aromatase inhibitors. ( Lønning, P; Martoni, A; Pfister, C; Zamagni, C, 2003) |
| "Tamoxifen is currently the adjuvant treatment of choice for postmenopausal women with hormone-sensitive breast cancer." | 4.82 | Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate. ( Aapro, MS; Forbes, JF, 2003) |
| "Anastrozole ('Arimidex') is indicated for the treatment of advanced breast cancer in postmenopausal women." | 4.82 | Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. ( Bonneterre, J; Buzdar, A; Nabholtz, JM; Robertson, JF; Thürlimann, B, 2003) |
| "For the past 25 years tamoxifen has been the mainstay for adjuvant treatment of postmenopausal patients with hormone-sensitive breast cancer." | 4.82 | Role of anastrozole in adjuvant therapy for postmenopausal patients. ( Buzdar, AU, 2003) |
| "For over a decade, the selective estrogen receptor modulator, tamoxifen, has been the primary agent for adjuvant endocrine therapy for steroid receptor-positive breast cancer." | 4.82 | New findings about endocrine therapy for breast cancer. ( Davidson, NE; Emens, L; Visvanathan, K, 2003) |
| " Adjuvant ovarian ablation with or without tamoxifen produces effects which are equivalent to those of CMF (cyclophosphamide, methotrexate and 5-fluorouracil) chemotherapy in premenopausal women with oestrogen receptor (ER) and/or progesterone receptor (PgR) positive breast cancer." | 4.82 | The best use of adjuvant endocrine treatments. ( Pritchard, KI, 2003) |
| "Recent advances have been made in the hormonal treatment of breast cancer with the advent of third-generation aromatase inhibitors (anastrozole, letrozole, and exemestane)." | 4.82 | Aromatase inhibitors in breast cancer therapy. ( Buzdar, AU, 2003) |
| "This commentary article provides an overview of recent clinical research trials involving anastrozole and its evolving role in the management of breast cancer." | 4.82 | Focus on anastrozole and breast cancer. ( Mokbel, K, 2003) |
| " Here we review available efficacy data to address whether or not anastrozole, a non-steroidal aromatase inhibitor (AI), is effective in postmenopausal patients with advanced breast cancer (ABC) and visceral metastases." | 4.82 | A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases. ( Howell, A; Robertson, JF; Vergote, I, 2003) |
| " These agents are active against breast cancer in hormone-naïve postmenopausal women and in women who have experienced failure of tamoxifen or failure of tamoxifen plus other hormonal therapy." | 4.82 | Aromatase inhibitors for breast cancer in postmenopausal women. ( Campos, SM, 2004) |
| " Until recently, tamoxifen was the drug of choice for the treatment of hormone-responsive early and advanced breast cancer." | 4.82 | Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy? ( Sainsbury, R, 2004) |
| "Tamoxifen is currently a standard of care for postmenopausal patients with breast cancer with hormone receptor-positive tumors who are candidates for adjuvant endocrine therapy." | 4.82 | Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer. ( Boccardo, F, 2004) |
| "Until recently, tamoxifen was the only adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early-stage breast cancer." | 4.82 | The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial: an update. ( Buzdar, AU, 2004) |
| "Anastrozole, letrozole, and exemestane are the 3 commercially available aromatase inhibitors approved by the US Food and Drug Administration for the treatment of hormone receptor-positive breast cancer in postmenopausal women." | 4.82 | Role of aromatase inhibitors in the treatment of breast cancer. ( Abou-Jawde, RM; Alemany, CA; Budd, GT; Choueiri, TK, 2004) |
| " However, results from the ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial have shown anastrozole to be more effective than tamoxifen as adjuvant therapy for postmenopausal women with hormone-responsive early breast cancer." | 4.82 | Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention. ( Tobias, JS, 2004) |
| " These agents have been shown to be more effective than tamoxifen in first-line treatment of oestrogen receptor-positive advanced and metastatic breast cancer." | 4.82 | Aromatase inhibitors and breast cancer: time for a change? ( Fentiman, IS, 2004) |
| "For many years, tamoxifen has been the 'gold standard' amongst anti-oestrogen therapies for breast cancer." | 4.82 | Endocrine treatment options for advanced breast cancer--the role of fulvestrant. ( Beex, L; Come, SE; Jones, SE; Kaufmann, M; Makris, A; Nortier, JW; Possinger, K; Robertson, JF; Rutqvist, LE, 2005) |
| " Clinical trials using aromatase inhibitors in the adjuvant treatment of postmenopausal women with breast cancer are few but significant because of their comparative design with tamoxifen given for five years, long regarded as the gold standard for breast cancer treatment." | 4.82 | Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer. ( Michaud, LB, 2005) |
| " In women with hormone-sensitive breast cancer, three of these agents, letrozole, anastrozole, and exemestane, provide an important alternative endocrine therapy to the antiestrogen tamoxifen, which blocks estrogen activation of the estrogen receptor." | 4.82 | Aromatase inhibitors in advanced breast cancer. ( Mouridsen, HT, 2004) |
| "The third generation aromatase inhibitors anastrozole, exemestane, and letrozole have been compared with tamoxifen and other endocrine therapies in several studies in early and advanced breast cancer." | 4.82 | Aromatase inhibitors in the treatment of early and advanced breast cancer. ( Ejlertsen, B; Joensuu, H; Lønning, PE; Rutqvist, LE, 2005) |
| "Fulvestrant, an estrogen receptor antagonist that downregulates the estrogen receptor but has no known agonist effects, has been evaluated in 2 randomized trials involving postmenopausal women with hormone receptor-positive, progressive advanced-stage breast cancer after disease progression with antiestrogen therapy." | 4.82 | Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer. ( Jones, SE; Pippen, J, 2005) |
| "Fulvestrant, a new type of oestrogen receptor antagonist with no agonist effects, is now licensed in the EU and USA for the treatment of postmenopausal women with hormone-sensitive advanced breast cancer following progression on prior antioestrogen therapy." | 4.82 | A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer. ( Dodwell, D; Vergote, I, 2005) |
| "In postmenopausal women with advanced breast cancer, numerous phase III trials have been performed comparing the third-generation non-steroidal aromatase inhibitors (NS-AIs) anastrozole and letrozole and the steroidal AI (S-AI) exemestane in the "first-line" setting against tamoxifen and in the "second-line" setting against megestrol acetate." | 4.82 | Aromatase inhibitors for therapy of advanced breast cancer. ( Ingle, JN; Suman, VJ, 2005) |
| "Recent trials have indicated that the aromatase inhibitors (anastrozole, letrozole, exemestane) are more effective than tamoxifen, the standard adjuvant treatment for estrogen receptor-positive breast cancer, both in adjuvant and first-line advanced settings." | 4.82 | Anastrozole. ( Cuzick, J, 2005) |
| "Tamoxifen has been the standard of care for adjuvant endocrine therapy of early breast cancer." | 4.82 | Adjuvant endocrine therapy in postmenopausal women with early breast cancer: where are we now? ( Baum, M, 2005) |
| "Because of its proven efficacy profile based on long-term data, tamoxifen has been the standard adjuvant endocrine therapy for hormone-sensitive early breast cancer for the past 30 years." | 4.82 | Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women. ( Gradishar, WJ, 2005) |
| "New aromatase inhibitors (AI) (second-generation: formestane and fadrozole; third-generation: letrozole, anastrozole, vorozole, and exemestane) have been tested in several controlled clinical trials after tamoxifen failure in metastatic breast carcinoma (MBC)." | 4.82 | New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials. ( Bria, E; Carlini, P; Cognetti, F; Di Cosimo, S; Fabi, A; Felici, A; Ferretti, G; Giannarelli, D; Milella, M; Mottolese, M; Nisticò, C; Papaldo, P; Ruggeri, EM; Terzoli, E, 2005) |
| "Tamoxifen has been the endocrine agent of choice for adjuvant hormonal therapy for early breast cancer since approval in 1986." | 4.82 | Adjuvant endocrine therapy in postmenopausal breast cancer patients. ( Köberle, D; Thürlimann, B, 2005) |
| "In recent years, new agents have challenged tamoxifen as the standard endocrine therapy for postmenopausal breast cancer." | 4.82 | New developments in the treatment of postmenopausal breast cancer. ( Howell, A, 2005) |
| "The widespread use of tamoxifen has led to significant improvements in survival for postmenopausal women with early-stage hormone receptor-positive breast cancer; however, approximately 30% of patients die despite receiving tamoxifen as adjuvant treatment." | 4.82 | Defining the roles of aromatase inhibitors in the adjuvant treatment of early-stage breast cancer. ( Howell, A; Locker, GY, 2005) |
| "The third-generation aromatase inhibitors, letrozole, anastrozole, and exemestane, have been shown to be effective both as alternatives to tamoxifen in first-line treatment of hormone-sensitive advanced breast cancer in postmenopausal women and following failure of first-line tamoxifen for endocrine therapy." | 4.82 | Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer. ( Mouridsen, HT; Robert, NJ, 2005) |
| "Letrozole, a third-generation aromatase inhibitor, has been the only aromatase inhibitor to date to show unequivocal superiority to tamoxifen as first-line treatment of metastatic postmenopausal breast cancer." | 4.81 | Letrozole for the management of breast cancer. ( Goss, PE; Smith, RE, 2002) |
| "Although tamoxifen has been the gold standard of HT for breast cancer, results of ongoing trials assessing the newer HTs as initial, neoadjuvant, adjuvant, and chemopreventive therapies may substantially change our current clinical practice patterns." | 4.81 | Evolving uses of hormonal agents for breast cancer therapy. ( Cummings, FJ, 2002) |
| "Third-generation aromatase inhibitors (anastrozole, letrozole, and exemestane) have emerged as an alternative first-line endocrine treatment for postmenopausal breast cancer patients with hormone-responsive disease." | 4.81 | Recent advances in aromatase inhibitor therapy for breast cancer. ( Assikis, VJ; Buzdar, A, 2002) |
| "To conduct an evidence-based technology assessment to determine whether the routine use of anastrozole or any of the aromatase inhibitors in the adjuvant breast cancer setting is appropriate for broad-based conventional use in clinical practice." | 4.81 | American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. ( Braun, S; Browman, GP; Burstein, HJ; Chlebowski, RT; Cobleigh, MA; Edge, SB; Goldstein, LJ; Gralow, J; Hudis, C; Ingle, JN; Langer, AS; Mamounas, EP; Perotti, J; Powles, TJ; Pritchard, KI; Whelan, TJ; Winer, EP, 2002) |
| "Anastrozole, a nonsteroidal selective aromatase inhibitor, has recently been approved in the US and several other countries for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer." | 4.81 | Anastrozole: in early breast cancer. ( Faulds, DM; Wellington, K, 2002) |
| "This article reviews the recent findings of the IBIS-1 and ATAC trials regarding the role of tamoxifen and anastrozole in the chemoprevention of breast cancer." | 4.81 | Breast cancer chemoprevention--an update. ( Mokbel, K; Singh-Ranger, G, 2002) |
| "For the past 25 years, the estrogen antagonist tamoxifen has been considered the 'gold standard' for the treatment of breast cancer, despite certain tolerability issues and the risk of developing resistance." | 4.81 | Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen. ( Buzdar, AU, 2002) |
| "Anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin) are members of the third generation of aromatase inhibitors that has now replaced aminoglutethimide (Cytadren), the progestins, and tamoxifen (Nolvadex) as the hormonal therapy of choice in estrogen-receptor-positive, postmenopausal, metastatic breast cancer." | 4.81 | Nonsteroidal and steroidal aromatase inhibitors in breast cancer. ( Hamilton, A; Volm, M, 2001) |
| "Tamoxifen is the standard first-line therapy for advanced breast cancer." | 4.81 | Role of anti-aromatase agents in postmenopausal advanced breast cancer. ( Murray, R, 2001) |
| "The new generation of selective aromatase inhibitors (anastrozole, letrozole and exemestane) offer a significant efficacy and safety advantage over both older agents in this class (aminoglutethimide) and the progestins (megestrol acetate (MA)), as second-line treatment for postmenopausal women with advanced hormone-dependent breast cancer who have failed on tamoxifen therapy." | 4.81 | A summary of second-line randomized studies of aromatase inhibitors. ( Buzdar, AU, 2001) |
| "Anastrozole (Arimidex) is a third-generation aromatase inhibitor which has been shown to possess superior efficacy and tolerability over established endocrine agents in advanced breast cancer." | 4.81 | Anastrozole (Arimidex)--an aromatase inhibitor for the adjuvant setting? ( Buzdar, AU, 2001) |
| "With recent results showing letrozole and anastrozole to be superior to tamoxifen as initial therapy for advanced disease, the aromatase inhibitors are poised to establish their place in the adjuvant therapy of postmenopausal receptor-positive breast cancer." | 4.81 | Preliminary data from ongoing adjuvant aromatase inhibitor trials. ( Goss, PE, 2001) |
| "During recent years the development of hormone therapy for the treatment breast neoplasms has seen, in addition to classic aspecific antiestrogens (AE) like tamoxifen (TAM) and to a lesser extent toremifen, a major development of new molecules divided into two groups: the first is the so-called selective estrogen receptor modulators (SERMs), the most important of which is Raloxifen, which mediate estrogen-agonist effects in some tissues and estrogen-antagonist effects in others; the second group includes the aromatase inhibitors (AI), important enzymes for peripheral estrogen conversion." | 4.81 | [Antiestrogen therapy in the treatment of breast neoplasms]. ( Alba, E; Colla, F; Farina, C; Mazzoleni, A; Ragonesi, G, 2002) |
| "The role of anastrozole, a new selective aromatase inhibitor, in treating hormone-responsive metastatic breast cancer is discussed." | 4.80 | Anastrozole: a selective aromatase inhibitor for the treatment of breast cancer. ( alKhouri, N; Higa, GM, 1998) |
| "Anastrozole is a new oral nonsteroidal aromatase inhibitor indicated for the second-line endocrine treatment of postmenopausal women with advanced breast cancer." | 4.80 | Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer. ( Adkins, JC; Wiseman, LR, 1998) |
| "Three new aromatase inhibitors have recently completed phase III evaluation as treatment of metastatic breast cancer in post-menopausal women whose disease has progressed despite tamoxifen therapy: anastrozole (ARIMIDEX, Zeneca), letrozole (FEMARA, Novartis) and vorozole (RIVIZOR, Janssen)." | 4.80 | The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. ( Hamilton, A; Piccart, M, 1999) |
| "Aromatase inhibitors used in breast cancer, are drugs that inhibit the transformation of androstenedione and testosterone, respectively in estradiol and estrone." | 4.80 | [Aromatase inhibitors]. ( Bonneterre, J; Feutrie, ML, 1999) |
| "In patients with metastatic breast cancer, second-line therapy with aromatase inhibitors can improve survival in comparison with megestrol." | 4.80 | Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol. ( Cattel, F; Messori, A; Trippoli, S; Vaiani, M, 2000) |
| "To increase the therapeutic index of second line hormonal treatment of breast cancer, new aromatase inhibitors have been synthetized; they belong to two groups: type I (formestane and exemestane) are steroidal irreversible and specific inhibitors, type II (anastrozole, letrozole and vorozole) are non steroidal reversible inhibitors, interfering with the aromatase heme." | 4.80 | [Aromatase inhibitors: a review of clinical trials]. ( Kerbrat, P; Lefeuvre, C, 2000) |
| "The efficacy and tolerability of the new selective aromatase inhibitor, anastrozole (Arimidex), was compared with megestrol acetate in the treatment of advanced breast cancer in postmenopausal women." | 4.79 | Clinical overview of anastrozole--a new selective oral aromatase inhibitor. ( Jonat, W, 1997) |
| " We included women aged ≥ 65 years with newly diagnosed hormone receptor-positive breast cancer and who had initiated AET (anastrozole, letrozole, exemestane, or tamoxifen)." | 4.31 | Adherence to Adjuvant Endocrine Therapy and Survival Among Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer. ( Han, S; Heo, JH; Mehta, S; Park, C; Spencer, JC, 2023) |
| " There have been few reports in the literature on visual disturbance in patients on long-term treatment with Anastrozole for breast cancer prevention; but none had symptoms worse than blurry vision and/or xerostomia." | 4.31 | Optic Neuritis as a Consequence of Long-Term Medical Treatment Using Anastrozole: A Case Report. ( Velez Oquendo, G, 2023) |
| " Anastrozole, a nonselective aromatase inhibitor used in breast cancer management has been associated with different cutaneous side effects, of which EM is rarely seen and usually in a minor or major form with typical target lesions." | 4.31 | Segmental Erythema Multiforme: An Unusual Drug Reaction to Anastrozole. ( Buljan, M; Filipović, N; Poduje, S; Vučić, M; Vujević, L, 2023) |
| "Our previous matched case-control study of postmenopausal women with resected early-stage breast cancer revealed that only anastrozole, but not exemestane or letrozole, showed a significant association between the 6-month estrogen concentrations and risk of breast cancer." | 4.12 | Anastrozole Regulates Fatty Acid Synthase in Breast Cancer. ( Bari, MG; Cairns, J; Gao, H; Goetz, MP; Ingle, JN; Kalari, KR; Li, H; Wang, L; Weinshilboum, RM, 2022) |
| "Currently there are no assays that can simultaneously quantify serum levels of the third-generation aromatase inhibitors (AIs): letrozole, anastrozole, and exemestane, and the ultra-low levels of estrogens in postmenopausal breast cancer patients on AI treatment." | 4.12 | Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients. ( Almås, B; Bertelsen, BE; Geisler, J; Hagland, M; Helland, T; Lende, TH; Lønning, PE; Mellgren, G; Sagen, JV; Søiland, H; Viste, K, 2022) |
| "Out of 3537 older women with breast cancer, anastrozole was the most commonly prescribed (n = 1945, 55." | 4.12 | Health-related quality of life among elderly breast cancer patients treated with adjuvant endocrine therapy: a U.S Medicare population-based study. ( Ng, BP; Park, C; Park, SK; Woo, A, 2022) |
| "The study population included patients diagnosed of ER+/HER2- metastatic breast cancer who started first-line treatment with anastrozole or letrozole between November 18, 2014, and November 18, 2015." | 4.12 | Approaches for Enhanced Extrapolation of Long-Term Survival Outcomes Using Electronic Health Records of Patients With Cancer. ( Adamson, BJ; Bargo, D; Baxi, S; Briggs, A; Ghosh, S; Ramsey, S; Tan, K; Wang, X, 2022) |
| "Anastrozole (ATZ) is a selective non-steroidal inhibitor widely used for the treatment of breast cancer in post-menopausal women." | 4.12 | Simultaneous Method Development and Validation of Anastrozole Along with Piperine: Degradation Studies and Degradants Characterization Using LC-QTOF-ESI-MS Along with In-silico ADMET Predictions. ( Alexander, A; Gajbhiye, R; Kumar, P; Mehta, P; Murty, US; Pawar, SD; Ravichandiran, V; Sarmah, B; Susanna, KJ, 2022) |
| "Anastrozole (ANA), is an inhibitor of non-steroidal aromatase, widely employed for the treatment of breast cancer." | 4.12 | Anastrozole and related glucuronic acid conjugate are electrophilic species. ( Chen, Y; Ding, S; Liu, S; Peng, Y; Zheng, J, 2022) |
| "This study aimed to reveal the treatment patterns and clinical outcomes of diverse palbociclib-based regimens in Han patients with estrogen receptor-positive (ER+) metastatic breast cancer in routine clinical practice." | 4.12 | Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population. ( Cai, R; Li, Q; Luo, Y; Ma, F; Mo, H; Wang, J; Xu, B; Yuan, P; Zhang, P, 2022) |
| "A 73- year-old woman was diagnosed by chance with late recurrence of HR+ breast cancer 21 years after undergoing radical resection followed by adjuvant anastrozole for 5 years for stage Ⅲb right breast cancer." | 4.02 | [A Case of Advanced Late Recurrence of Hormone Receptor Positive Breast Cancer Successfully Treated with Abemaciclib and Anastrozole]. ( Araki, K; Hamada, M; Ikeda, T; Minamoto, K, 2021) |
| "These are the first results reporting BMD changes after stopping anastrozole in a breast cancer prevention setting." | 4.02 | Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial. ( Blake, G; Coleman, R; Cuzick, J; Eastell, R; Howell, A; Patel, R; Sestak, I, 2021) |
| "This case highlights the dual benefit of tamoxifen therapy in the treatment of hormone-receptor-positive breast cancer and acromegaly." | 4.02 | Dual treatment of acromegaly and hormone-receptor-positive breast cancer with tamoxifen: a case report. ( Abramowitz, J; Chan, AVC; Ganji, N; Mirfakhraee, S, 2021) |
| " This study investigated the effects of anastrozole and antiplatelet therapy (aspirin/clopidogrel cocktail or atopaxar) treatment on the tumour responses of luminal phenotype breast cancer cells and induced hypercoagulation." | 4.02 | Antiplatelet Therapy Combined with Anastrozole Induces Features of Partial EMT in Breast Cancer Cells and Fails to Mitigate Breast-Cancer Induced Hypercoagulation. ( Augustine, TN; Xulu, KR, 2021) |
| "In a recent randomized, open-label trial (S0226), the addition of fulvestrant to anastrozole therapy decreased the risk of progression and death in patients with hormone-receptor-positive metastatic breast cancer." | 3.96 | First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis. ( Bai, L; Huang, J; Li, Q; Liao, W; Wen, F; Wu, Q; Zhang, N; Zhou, K, 2020) |
| "A 61-year-old woman was found to have multiple pulmonary nodules on chest computed tomography (CT) after being treated for 5 months with anastrozole as an adjuvant breast cancer therapy." | 3.96 | Anastrozole-induced pulmonary cryptococcosis in a patient with early breast cancer: A case report. ( Liu, K; Wei, M; Wen, P; Xu, YR, 2020) |
| "To determine if the degree of estrogen suppression with aromatase inhibitors (AI: anastrozole, exemestane, letrozole) is associated with efficacy in early-stage breast cancer, and to examine for differences in the mechanism of action between the three AIs." | 3.96 | Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α. ( Barman, P; Cairns, J; Carlson, EE; Chen, BE; Correia, C; Cuellar, ME; Desta, Z; Ellis, MJ; Fasching, PA; Goetz, MP; Goodnature, B; Goss, PE; Haddad, T; Hoskin, TL; Ingle, JN; Kalari, KR; Kaufmann, SH; Shepherd, LE; Singh, RJ; Suman, VJ; Volz, B; Walters, MA; Wang, L; Weinshilboum, RM, 2020) |
| "Aromatase inhibitors (anastrozole, letrozole) and selective estrogen receptor modulators (tamoxifen) are widely used as adjuvant hormonal therapy in women with hormone receptor-positive breast cancer." | 3.96 | The effects of adjuvant hormonotherapy on tear functions in patients with breast cancer. ( Avarisli, NA; Bicer, BK; Bicer, T; Dogan, AS; Gurdal, C; Imamoglu, GI; Kabatas, N, 2020) |
| " Breast cancer was diagnosed in 2013 and she has been receiving anastrozole treatment for 6 years after local mass excision surgery and radiotherapy." | 3.96 | The Effect of Theracurmin on Cognitive Function in an Older Patient with Chemobrain. ( Dost Gunay, FS; Erken, N; Isik, AT; Soysal, P, 2020) |
| "Our results suggested that BMI and AI drug (letrozole versus anastrozole) were clinical predictors of arthralgia, while genetic variants rs4775936, rs9322336, rs2234693, and rs9340799 were genetic predictors of AI-induced arthralgia." | 3.96 | Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients. ( Borrie, AE; Choi, YH; Hahn, K; Kim, RB; Lenehan, J; Lock, M; Logan, D; Perera, FE; Potvin, K; Read, N; Rose, FA; Sexton, T; Teft, WA; Vandenberg, TA; Welch, S; Yaremko, B; Younus, J; Yu, E, 2020) |
| "The S0226 trial demonstrated that the combination of half-dose fulvestrant (FUL) and anastrozole (ANA) (F&A) caused a significant improvement in overall survival (OS) versus ANA monotherapy for first-line treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer (PMW-MBC (HR+))." | 3.96 | Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis. ( Huang, P; Huang, X; Lin, S; Liu, Y; Luo, S; Ming, WK; Wang, H; Weng, X, 2020) |
| " We aimed to compare AIs and tamoxifen with regard to cardiovascular events among older breast cancer patients outside of clinical trials." | 3.91 | Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study. ( Kamaraju, S; Laud, P; Nattinger, AB; Neuner, J; Shi, Y; Smith, E, 2019) |
| "Anastrozole is a widely prescribed aromatase inhibitor for the therapy of estrogen receptor positive (ER+) breast cancer." | 3.91 | Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2. ( Barman, P; Batzler, A; Buzdar, AU; Cairns, J; Carlson, EE; Desta, Z; Devarajan, S; Dudenkov, TM; Goetz, MP; Ingle, JN; Jenkins, GD; Kalari, KR; Kubo, M; Liu, D; Moreno-Aspitia, A; Northfelt, DW; Reid, JM; Robson, ME; Wang, L; Weinshilboum, RM; Zhuang, Y, 2019) |
| "Platelet-tumour cell interaction is implicated in the initiation of breast cancer-associated thrombosis, with hormone-therapy (Tamoxifen/Anastrozole), increasing this risk." | 3.91 | Breast cancer cell-induced platelet activation is compounded by tamoxifen and anastrozole in vitro. ( Augustine, TN; Chetty, N; Dix-Peek, T; Duarte, R; Pather, K, 2019) |
| "Quantitative immune scores of cell abundance and spatial heterogeneity were computed using a fully automated hematoxylin and eosin-stained image analysis algorithm and spatial statistics for 1178 postmenopausal patients with ER+ breast cancer treated with five years' tamoxifen or anastrozole." | 3.88 | Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer. ( Cuzick, J; Dowsett, M; Heindl, A; Naidoo, K; Sestak, I; Yuan, Y, 2018) |
| " We aimed to investigate the effects of different aromatase inhibitors, including letrozole, anastrozole, and exemestane, on the lipid profile of eastern Chinese breast cancer patients." | 3.88 | Comparison of Changes in the Lipid Profiles of Eastern Chinese Postmenopausal Women With Early-Stage Breast Cancer Treated With Different Aromatase Inhibitors: A Retrospective Study. ( Deng, Y; Tian, W; Wu, M, 2018) |
| "Anastrozole (ANS) is an aromatase inhibitor that is widely used as a treatment for breast cancer in postmenopausal women." | 3.88 | Preparation of anastrozole loaded PEG-PLA nanoparticles: evaluation of apoptotic response of breast cancer cell lines. ( Alaamery, M; Alghamdi, B; Almutairi, MS; Alomran, N; Alyafee, YA; Bawazeer, S; Daghestani, M; Massadeh, S; Sheereen, A, 2018) |
| "Hormonal therapy is a useful adjunct for chemoprevention in breast cancer; however, use of letrozole in patients undergoing reconstruction with pedicled TRAM can lead to increase in certain complication rates." | 3.88 | The Impact of Perioperative Hormonal Therapy for Breast Cancer on Transverse Rectus Abdominis Myocutaneous Flap Abdominal Complications. ( Clayman, E; Huber, KM; Kumar, A; Smith, P, 2018) |
| "Fulvestrant is a steroidal selective estrogen receptor degrader that was approved by the US FDA in 2002 for treatment of ER-positive metastatic breast cancer (ER + MBC) post-progression on aromatase inhibitors." | 3.88 | Fulvestrant in management of hormone receptor-positive metastatic breast cancer. ( Ellis, MJ; Shafaee, MN, 2018) |
| "We determined gonadotropin-, estradiol- and anastrozole- serum concentrations from postmenopausal, early stage breast cancer patients receiving upfront anastrozole within routine after care." | 3.85 | Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole? ( Beer, B; Czech, T; Daniaux, M; Holzner, B; Hubalek, M; Kemmler, G; Meraner, V; Oberacher, H; Oberguggenberger, A; Sperner-Unterweger, B; Sztankay, M; Weigel, G; Wildt, L, 2017) |
| "Among 1203 subjects who were taking adjuvant TMX or AI (anastrozole or letrozole) without fatty liver at baseline, those taking TMX or AI were 1:1 matched on the propensity score." | 3.85 | Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study. ( Hong, N; Kim, SI; Park, S; Rhee, Y; Seo, DH; Sohn, JH; Yoon, HG, 2017) |
| "Although recent studies demonstrated that fulvestrant is superior to anastrozole as first-line treatment for hormone receptor (HR)-positive advanced breast cancer, the cost-effectiveness of fulvestrant versus anastrozole remained uncertain." | 3.85 | Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer. ( Ding, H; Fang, L; Huang, P; Tong, Y; Xin, W; Zhou, Q, 2017) |
| "We report the case of a patient in which S-1 plus anastrozole was administered as first-line chemotherapy for Stage IV breast cancer with skin invasion, multiple lymph node metastasis, and lymphangitis carcinomatosis." | 3.85 | [A Case of Stage IV Breast Cancer with Extensive Metastasis Successfully Treated with S-1 plus Anastrozole Therapy]. ( Akami, T; Hatakeyama, T; Matsumura, A; Mugitani, T; Ogino, S; Okano, S; Sakai, T, 2017) |
| "Although anastrozole (Anas) plays a key role in the management of endocrine sensitive post-menopausal (PM) breast cancer (BC), there is much variability in its efficacy and tolerability." | 3.85 | Correlation of Serum Estradiol and Duration of Anastrazole Therapy with Treatment Related Adverse Effects Among Postmenopausal Breast Cancer Women: A Cross-sectional Study. ( Abubakar, MB; Gan, SH, 2017) |
| "Anastrozole, an aromatase inhibitor widely used in breast cancer, has recently been indicated to be a P-glycoprotein (ABCB1) substrate." | 3.85 | Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients. ( Carrillo, JA; Gervasini, G; Jara, C; Martínez, R; Olier, C; Romero, N, 2017) |
| "Combined therapy with BJD and alendronate can act synergistically against osteoporosis, which was possibly related to a reduced bone conversion rate through inhibiting bone resorption." | 3.85 | Mechanism of Bushen Jianpi decoction in preventing and treating osteoporosis caused by aromatase inhibitors in breast cancer treatment. ( Guo, W; Huang, XH; Liang, RH; Su, L; Wang, CJ, 2017) |
| "Treatment with the CDK4/6 inhibitor abemaciclib, alone or in combination with endocrine therapy, significantly lowered expression of the protein Ki67-a key marker of cell proliferation-in women with hormone receptor-positive, HER2-negative breast cancer." | 3.85 | Abemaciclib Shows Promise for Early Breast Cancer. ( , 2017) |
| "The aim of present study was to develop conventional and PEGylated (long circulating), liposomes containing anastrozole (ANS) for effective treatment of breast cancer." | 3.83 | PEGylated liposomes of anastrozole for long-term treatment of breast cancer: in vitro and in vivo evaluation. ( Behl, G; Dave, V; Deshpande, PB; Kumar, AR; Kushwaha, K; Nayak, UY; Raghavendra, R; Shavi, GV; Sreenivasa Reddy, M; Udupa, N, 2016) |
| "A total of 391 postmenopausal Japanese women with estrogen receptor-positive breast cancer and treated with adjuvant anastrozole were enrolled from 28 centers for assessment of patient-reported outcomes (PROs) in this prospective cohort study (SAVS-JP, UMIN000002455)." | 3.83 | Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes. ( Baba, M; Egawa, C; Hashimoto, T; Hidaka, T; Hirokaga, K; Ichii, S; Kikawa, Y; Kitatsuji, K; Kokufu, I; Konishi, M; Konishi, Y; Kono, S; Matsumoto, T; Minohata, J; Mitsunobu, M; Miya, A; Miyashita, M; Miyauchi, K; Miyoshi, Y; Nishikawa, H; Nishino, M; Oh, K; Okuno, T; Sakita, I; Sakoda, Y; Suwa, H; Takao, S; Wakita, K; Yamagami, K, 2016) |
| "A limited number of studies have been conducted on the effects of hormonal therapy with tamoxifen (TMX) or aromatase inhibitors (AIs) on plasma levels of leptin and adiponectin, as well as body composition in breast cancer (BC) patients." | 3.83 | The Effects of Adjuvant Endocrine Treatment on Serum Leptin, Serum Adiponectin and Body Composition in Patients with Breast Cancer: The Izmir Oncology Group (IZOG) Study. ( Akyol, M; Alacacioglu, A; Bayoglu, V; Demir, L; Dirican, A; Ellidokuz, H; Gumus, Z; Kucukzeybek, B; Kucukzeybek, Y; Salman, T; Sutcu, R; Tarhan, MO; Varol, U; Yildiz, I; Yildiz, Y, 2016) |
| "This was an exploratory secondary analysis in 49 postmenopausal women receiving anastrozole therapy for early-stage breast cancer." | 3.83 | The association between pre-treatment occupational skill level and mood and symptom burden in early-stage, postmenopausal breast cancer survivors during the first year of anastrozole therapy. ( Bender, CM; McCue, M; Merriman, JD; Nugent, BD; Rosenzweig, M; Sereika, SM, 2016) |
| "The aim of this study was to investigate the influence of anastrozole on serum hormone levels in postmenopausal women with hormone receptor-positive breast cancer." | 3.81 | Effect of anastrozole on hormone levels in postmenopausal women with early breast cancer. ( Albert, US; Hadji, P; Hars, O; Kalder, M; Kyvernitakis, I; Winarno, AS, 2015) |
| "The aim of this study was to determine the budget impact of everolimus (in combination with letrozole/anastrozole) as a second-line treatment for ER+ HER2- negative advanced and metastatic breast cancer in post-menopausal women." | 3.81 | Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in Kazakhstan. ( Kaldygul Kabakovna, S; Kuanysh Shadybayevich, N; Lewis, L; Ramil Zufarovich, A; Suriya Ertugyrovna, Y; Taylor, M, 2015) |
| "The present study aimed to assess the effects of aromatase inhibitor anastrozole and testosterone undecanoate, separately and in combination, on proliferation and apoptosis in MCF-7 human breast cancer cells cultured in vitro." | 3.81 | Antiproliferative effects of anastrozole on MCF-7 human breast cancer cells in vitro are significantly enhanced by combined treatment with testosterone undecanoate. ( Chen, R; Cui, J; Hu, H; Li, P; Liu, X; Wang, Q; Wei, W, 2015) |
| "The purpose of this study was to examine and compare the effects of the first 18 months of anastrozole therapy on cognitive function in women with breast cancer." | 3.81 | Patterns of change in cognitive function with anastrozole therapy. ( Ahrendt, GM; Bender, CM; Berga, SL; Brufsky, AM; Casillo, FE; Dailey, MM; Erickson, KI; Gentry, AL; Kratofil, FM; McAuliffe, PF; Merriman, JD; Rosenzweig, MQ; Ryan, CM; Sereika, SM, 2015) |
| "Developing depressive disorders are at higher risk in breast cancer survivors aged 40-59 who received adjuvant treatments including chemotherapy, radiotherapy, tamoxifen, AIs or trastuzumab." | 3.81 | Adjuvant treatments of breast cancer increase the risk of depressive disorders: A population-based study. ( Chang, CH; Chen, SJ; Liu, CY, 2015) |
| "We performed in-depth molecular analysis of patients with estrogen receptor-positive, HER2-negative, hormone therapy-refractory breast cancer, who achieved partial or complete responses when treated with anastrozole and everolimus." | 3.81 | Multiple gene aberrations and breast cancer: lessons from super-responders. ( Atkins, JT; Janku, F; Kurzrock, R; Moulder, SL; Stephens, PJ; Wheler, JJ; Yelensky, R, 2015) |
| "Patients with hormone receptor-positive metastatic breast cancer treated between 1st January 2005 and 31st December 2010 with a combination of capecitabine and AI were evaluated and outcomes were compared with those of women treated with capecitabine in conventional dose or AI as a monotherapy." | 3.81 | Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis. ( Jeyaraj, PA; Julka, PK; Kamal, VK; Mahajan, MK; Malik, A; Patil, J; Rath, GK; Roy, S; Shankar, A, 2015) |
| "A total of 148 postmenopausal women (including bilateral ovariectomy) with hormone dependent metastatic breast cancer receiving aromatase inhibitors (letrozole, anastrozole or exemestane) were analyzed retrospectively." | 3.81 | [Efficacies of aromatase inhibitors in the treatment of hormone dependent metastatic breast cancer in postmenopausal women: a report of 148 cases]. ( Cui, S; Lü, H; Niu, L; Yan, M; Zeng, H; Zhang, M, 2015) |
| " The objectives of this analysis were (1) to identify differences in model structure and parameterization for cost-effectiveness analyses (CEAs) comparing tamoxifen and anastrazole for adjuvant breast cancer (ABC) treatment; and (2) to quantify the impact of these differences on analysis outcome metrics." | 3.80 | The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance. ( Frederix, GW; Hövels, AM; Huitema, AD; Raaijmakers, JA; Schellens, JH; Severens, JL; van Hasselt, JG, 2014) |
| "Estradiol concentrations in postmenopausal women with early, ER-positive breast cancer on anastrozole were significantly different in normal weight versus overweight or obese patients at baseline, but not at 12 and 24 months." | 3.80 | Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole. ( Bauer, T; Hadji, P; Hars, O; Knöll, D; Kyvernitakis, I; Struck, M, 2014) |
| "In this paper, computational studies were carried out on anastrozole and letrozole, chemotherapy drugs used against breast cancer." | 3.80 | Computational studies on the anastrozole and letrozole, effective chemotherapy drugs against breast cancer. ( Akçay, HT; Bayrak, R, 2014) |
| "One thousand four hundred seventy-eight postmenopausal women with estrogen receptor (ER)+ early breast cancer (EBC) treated with tamoxifen or tamoxifen followed by anastrozole from the prospective randomized ABCSG-8 trial were entered into this study." | 3.80 | Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. ( Bago-Horvath, Z; Balic, M; Bartsch, R; Cowens, JW; Dubsky, P; Ferree, S; Fesl, C; Filipits, M; Fitzal, F; Gnant, M; Greil, R; Jakesz, R; Knauer, M; Kwasny, W; Liu, S; Mlineritsch, B; Nielsen, TO; Ressler, S; Rudas, M; Schaper, C; Singer, C; Steger, G; Stoeger, H; Storhoff, J, 2014) |
| "We identified the first dispensing of tamoxifen, anastrozole or letrozole for women diagnosed with invasive breast cancer in the 45 and Up Study from 2004-2009 (N = 1266)." | 3.80 | Women commencing anastrozole, letrozole or tamoxifen for early breast cancer: the impact of comorbidity and demographics on initial choice. ( Boyle, F; Bulsara, M; Holman, CD; Kemp, A; Malacova, E; Preen, DB; Roughead, EE; Saunders, C, 2014) |
| "A total of 216 postmenopausal patients with early-stage breast cancer who were receiving AI treatment with anastrozole constituted the final sample included in the analysis." | 3.80 | Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels. ( Beer, B; Giesinger, J; Holzner, B; Hubalek, M; Kemmler, G; Meraner, V; Oberacher, H; Oberguggenberger, A; Schubert, B; Seeber, B; Sperner-Unterweger, B; Sztankay, M; Wildt, L, 2014) |
| "In the IBIS II Prevention Study, postmenopausal women at high risk of breast cancer given the aromatase inhibitor anastrozole were 53% less likely to develop the disease after 10 years than women who took placebo." | 3.80 | Anastrozole may aid breast cancer prevention. ( , 2014) |
| "Aromatase inhibitors (AIs) are more effective than tamoxifen as neoadjuvant endocrine therapy (NET) for hormone receptor (HR)-positive breast cancer." | 3.80 | Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer. ( Angelucci, D; Ausili Cefaro, G; Cianchetti, E; Cioffi, P; De Tursi, M; Di Nicola, M; Grassadonia, A; Grossi, S; Iacobelli, S; Iezzi, L; Marinelli, C; Natoli, C; Noccioli, P; Politi, R; Tavoletta, S; Tinari, N; Zilli, M, 2014) |
| " Anastrozole, an FDA approved active ingredient for the treatment of breast cancer, was used as a model drug to investigate viability of the silk reservoir rod technology for sustained drug delivery." | 3.80 | Silk fibroin rods for sustained delivery of breast cancer therapeutics. ( Coonahan, E; Giangregorio, R; Kaplan, DL; Lovett, ML; Yucel, T, 2014) |
| "Postmenopausal women with an early breast cancer scheduled to start adjuvant endocrine therapy with an AI or tamoxifen were recruited." | 3.80 | Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens. ( Billen, J; Christiaens, MR; Jans, I; Laenen, A; Lintermans, A; Neven, P; Paridaens, R; Pauwels, S; Van Asten, K; Van Herck, E; Vanderschueren, D; Verhaeghe, J; Vermeersch, P; Wildiers, H, 2014) |
| "A 65-year-old woman on anastrozole treatment because of a recurrent breast cancer developed hypercalcaemia and increased parathyroid hormone (PTH) levels 2½ years after start of the treatment." | 3.80 | Anastrozole can cause severe hypercalcaemia mimicking primary hyperparathyroidism. ( Järhult, J, 2014) |
| "Because of its superior efficacy to tamoxifen, anastrozole has been widely used in Japan as an adjuvant treatment for postmenopausal, hormone-responsive breast cancer patients." | 3.80 | A multicenter prospective study to evaluate bone fracture related to adjuvant anastrozole in Japanese postmenopausal women with breast cancer: two-year interim analysis of Saitama Breast Cancer Clinical Study Group (SBCCSG-06). ( Futsuhara, K; Kai, T; Kojima, M; Tabei, T; Takei, H; Takeuchi, H; Yoshida, T, 2014) |
| "A 69-year-old postmenopausal woman who was prescribed anastrozole for 10 months after surgical removal of her breast cancer, was referred to our hospital for acute renal failure." | 3.79 | [A case of crescentic glomerulonephritis developed under oral anastrozole treatment]. ( Fujiki, K; Fujimoto, T; Inoue, F; Ishikawa, H; Maruyama, N; Nakano, T; Nakatani, K; Oka, H; Ueshima, K; Yoshimoto, S, 2013) |
| "Baseline and 2-week posttreatment biopsies were obtained from 112 postmenopausal women with ER+ breast cancer receiving neoadjuvant anastrozole." | 3.79 | Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance. ( A'hern, R; Anderson, H; Dowsett, M; Dunbier, AK; Ghazoui, Z; Miller, WR; Nerurkar, A; Osin, P; Salter, J; Smith, IE, 2013) |
| " Here, we report an advanced case of breast cancer with vertebra-Th7 metastasis that showed complete response to combined treatments with formalin-fixed autologous tumor vaccine (AFTV), palliative radiation therapy with 36 Gy, and adjuvant chemotherapy with standardized CEF (cyclophosphamide, epirubicin, and 5FU), zoledronic acid, and aromatase inhibitors following mastectomy for the breast tumor." | 3.79 | Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report. ( Kuranishi, F; Ohno, T, 2013) |
| "mRNA from 1,017 patients with ER-positive primary breast cancer treated with anastrozole or tamoxifen in the ATAC trial was assessed for ROR using the NanoString nCounter." | 3.79 | Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. ( Cowens, JW; Cuzick, J; Dowsett, M; Dunbier, AK; Ferree, S; Lopez-Knowles, E; Schaper, C; Sestak, I; Sidhu, K; Storhoff, J, 2013) |
| " Analysis of BAG1 was performed on archival tumour blocks from patients from the anastrozole and tamoxifen arms of the ATAC trial of 5 years endocrine therapy in postmenopausal women with oestrogen receptor (ER)-positive primary breast cancer." | 3.79 | Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study. ( Afentakis, M; Buzdar, A; Cuzick, J; Dowsett, M; Forbes, J; Howell, T; Salter, J; Sestak, I, 2013) |
| "This is a 5-year interim analysis of a 10-year, prospective, observational, IRB approved study investigating the incidence of breast cancer in women presenting with symptoms of hormone deficiency treated with subcutaneous testosterone (T) implants or, T combined with the aromatase inhibitor anastrozole (A), i." | 3.79 | Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study. ( Dimitrakakis, C; Glaser, RL, 2013) |
| "To estimate the budget impact of everolimus as the first and second treatment option after letrozole or anastrozole (L/A) failure for post-menopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (ABC)." | 3.79 | Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. ( De, G; Diener, M; Namjoshi, M; Wu, EQ; Xie, J; Yang, H, 2013) |
| "The subjects were 10 patients with breast cancer who were undergoing antiestrogen therapy with tamoxifen or anastrozole and who were suffering from hot flashes." | 3.79 | Acupuncture for the treatment of hot flashes in patients with breast cancer receiving antiestrogen therapy: a pilot study in Korean women. ( Bong, JG; Jeong, YJ; Kwon, HJ; Park, SH; Park, YS; Shin, IH, 2013) |
| "We have prospectively tested the effects of simvastatin on the pharmacokinetics of anastrozole and on estrogen concentrations in postmenopausal women with hormone receptor-positive breast cancer who were receiving adjuvant anastrozole." | 3.78 | Effect of simvastatin on the pharmacokinetics of anastrozole. ( Bao, T; Blackford, AL; Stearns, V, 2012) |
| "The aim of this study was to assess the effect of adjuvant anastrozole, alone or associated with risedronate, on BMD and bone fracture risk in women more than 70 years old with hormone receptor-positive early breast cancer (EBC)." | 3.78 | Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer. ( Basso, U; Berton, L; Brunello, A; Coin, A; Falci, C; Manzato, E; Monfardini, S; Perissinotto, E; Pintore, G; Sergi, G; Veronese, N, 2012) |
| "Tumor specimens from a subset of postmenopausal patients with hormone receptor-positive early-stage (stages I, II, and IIIA) breast cancer, who were enrolled in the randomized double-blind Arimidex, Tamoxifen, Alone or in Combination (ATAC) clinical trial, were genotyped for variants in CYP2D6 (N = 1203 patients: anastrozole [trade name: Arimidex] group, n = 615 patients; tamoxifen group, n = 588 patients) and UDP-glucuronosyltransferase-2B7 (UGT2B7), whose gene product inactivates endoxifen (N = 1209 patients; anastrozole group, n = 606 patients; tamoxifen group, n = 603 patients)." | 3.78 | CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. ( Cuzick, J; Dowsett, M; Drury, S; Hayes, DF; Haynes, BP; Rae, JM; Salter, J; Sestak, I; Stearns, V; Thibert, JN, 2012) |
| "We report a case of recurrent hormone receptor-positive breast cancer with brain metastases that showed good response to vinorelbine(VNR)and anastrozole(ANA)." | 3.78 | [A case of recurrent breast cancer with brain metastases successfully treated with vinorelbine and anastrozole after multiple chemo-endocrine therapies]. ( Hikino, H; Koike, M; Mukai, T; Murata, Y, 2012) |
| "Weight gain is commonly reported by breast cancer patients on tamoxifen or aromatase inhibitors." | 3.78 | Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. ( Cuzick, J; Dowsett, M; Forbes, JF; Harvie, M; Howell, A; Sestak, I, 2012) |
| " Postmenopausal women with breast cancer and MR imaging findings of the contralateral unaffected breast, before and during 6-12 months of AI treatment (anastrozole, letrozole, or exemestane), between August 1999 and June 2010 were retrospectively identified (n = 149)." | 3.78 | Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging. ( Brooks, JD; Dickler, MN; Goldfarb, SB; Jozefara, JE; King, V; Morris, EA; Nulsen, BF; Pike, MC; Sung, JS, 2012) |
| "To investigate whether suppression of plasma estradiol and estrone sulfate levels by the aromatase inhibitors (AIs) anastrozole and letrozole is related to body mass index (BMI) in postmenopausal women with early estrogen receptor (ER) -positive breast cancer." | 3.78 | Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. ( A'Hern, RP; Dixon, JM; Dowsett, M; Folkerd, EJ; Renshaw, L, 2012) |
| "Outpatients with early breast cancer treated with anastrozole completed the multi-method assessment of adherence." | 3.78 | Adherence evaluation of endocrine treatment in breast cancer: methodological aspects. ( Beer, B; Gamper, E; Giesinger, J; Holzner, B; Hubalek, M; Kemmler, G; Marth, C; Meraner, V; Oberacher, H; Oberguggenberger, AS; Schubert, B; Sperner-Unterweger, B; Sztankay, M, 2012) |
| "Long term treatment of breast cancer patients with 10 mg/day has continued in 17 patients without an escape of estradiol suppression." | 3.78 | ARIMIDEX: a new oral, once-a-day aromatase inhibitor. ( Demers, L; Dowsett, M; Dyroff, M; Plourde, PV; Webster, A; Yates, R, 1995) |
| "The present preclinical study was designed to evaluate a new combination therapy comprised of the aromatase inhibitor anastrozole (ANA) and the oral fluoropyrimidines, UFT and S-1 against the estrogen receptor (ER)-positive human breast cancer cell line MCF-7/Arom 14, which was stably transfected with the cDNA of human aromatase." | 3.77 | Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts. ( Abe, M; Kiniwa, M; Matsuo, K; Nakagawa, F; Noguchi, S; Nukatsuka, M; Saito, H; Shibata, J; Uchida, J, 2011) |
| "The aim of this study was to determine whether the bone-resorption response to anastrozole differed according to initial patient age in postmenopausal women with breast cancer in a cross-sectional study." | 3.77 | Does anastrozole affect bone resorption similarly in early and late postmenopausal women? ( Cochrane, RA; Davie, MW; Powell, DE, 2011) |
| "We conducted a prospective study including postmenopausal early breast cancer patients receiving either an aromatase inhibitor (AI) or tamoxifen." | 3.77 | Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. ( Christiaens, MR; De Smet, L; Dieudonné, AS; Henry, NL; Leunen, K; Lintermans, A; Morales, L; Neven, P; Pans, S; Paridaens, R; Timmerman, D; Van Calster, B; Van Hoydonck, M; Vergote, I; Verhaeghe, J; Verschueren, K; Westhovens, R; Wildiers, H, 2011) |
| "A gene expression signature derived from ER(+) breast cancer cells with acquired hormone independence predicted tumor response to aromatase inhibitors and associated with clinical markers of resistance to tamoxifen." | 3.77 | A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. ( Anderson, H; Arteaga, CL; Balko, JM; Dowsett, M; Dunbier, A; Ghazoui, Z; González-Angulo, AM; Miller, TW; Miller, WR; Mills, GB; Shyr, Y; Wu, H, 2011) |
| "The purpose of this study was to develop sustained release formulation of anastrozole-loaded chitosan microspheres for treatment of breast cancer." | 3.77 | Sustained release optimized formulation of anastrozole-loaded chitosan microspheres: in vitro and in vivo evaluation. ( Deshpande, PB; Karthik, A; Kumar, AR; Nayak, UY; Reddy, MS; Shavi, GV; Udupa, N, 2011) |
| "Bilateral salpingo-oophrectomy rendered the patient postmenopausal and enabled the commencement of the aromatase inhibitor anastrozole as an alternative adjuvant therapy for breast cancer." | 3.77 | Ovarian hyperstimulation syndrome in a patient treated with tamoxifen for breast cancer. ( Baigent, A; Lashen, H, 2011) |
| "Study 1: Blood was collected from ten postmenopausal women with breast cancer before and after two-week treatment with anastrozole and serum concentrations of androstenediol and other androgens and estrogens were assessed." | 3.77 | Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer. ( Coombes, RC; Dowsett, M; Folkerd, EJ; Palmieri, C; Purohit, A; Reed, MJ; Stanczyk, FZ; Stanway, SJ; Ward, R, 2011) |
| "To assess the predictive value of Ki67 expression in postmenopausal hormone receptor-positive early-breast cancer patients, who were either treated with adjuvant tamoxifen (TAM) alone or with TAM followed by anastrozole (ANA)." | 3.77 | Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer. ( Bago-Horvath, Z; Böhm, G; Dubsky, P; Filipits, M; Gnant, M; Greil, R; Gruber, C; Haid, A; Jakesz, R; Jasarevic, Z; Jelen, A; Kemmerling, R; Pöstlberger, S; Rudas, M; Singer, CF, 2011) |
| " Because her arthralgia showed no improvement, powdered processed aconitine root was added." | 3.77 | A case of aromatase inhibitor (anastrozole)-induced side-effects successfully treated with Kampo medicines. ( Chino, A; Hirasaki, Y; Namiki, T; Ogawa, K; Okamoto, H; Ueda, K, 2011) |
| "The aim of this study was to evaluate the effect of anastrozole, a new generation aromatase inhibitor, on the lipid metabolism in postmenopausal Chinese women with early breast cancer, and observe the adverse reactions as well." | 3.77 | [Effects of anastrozole on lipid metabolism in Chinese postmenopausal women with breast cancer]. ( Cai, RG; Li, Q; Lu, HH; Wang, JY; Xu, BH; Yuan, P; Zhang, P, 2011) |
| "We present the case of a 79-year-old woman with a history of breast cancer who developed Grover disease (transient acantholytic dermatosis) following initiation of an aromatase inhibitor, anastrozole, as adjunctive treatment of her breast cancer." | 3.77 | Grover disease (transient acantholytic dermatosis) induced by anastrozole. ( Burkemper, NM; Crockett, JS, 2011) |
| "To investigate differences of platelet indices in breast cancer patients after tamoxifen (tmx) and anastrazole adjuvant treatment." | 3.76 | Mean platelet volume increase after tamoxifen, but not after anastrazole in adjuvant therapy of breast cancer. ( Alacacioğlu, A; Bilgi, O; Erikçi, AA; Kandemir, EG; Karagöz, B; Ozgün, A; Sayan, O, 2010) |
| "Although anastrozole (ANA), an aromatase inhibitor (AI), has been widely used for breast cancer patients; adverse events during ANA therapy in Japanese patients have not been reported." | 3.76 | Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients. ( Ando, M; Baba, S; Dokiya, F; Douchi, T; Kosha, S; Matsuyama, Y; Ohi, Y; Rai, Y; Sagara, Y; Tamada, S, 2010) |
| "We have been treating hormone receptor-positive, postmenopausal women with breast cancer with a regimen of neoadjuvant chemotherapy (NAC), FEC (fluorouracil, epirubicin, and cyclophosphamide), followed by weekly doses of paclitaxel combined with the concurrent administration of anastrozole." | 3.76 | Concurrent administration of chemo-endocrine therapy for postmenopausal breast cancer patients. ( Kaide, A; Kodama, K; Matsuoka, J; Ootawa, Y; Ootsuka, N; Watanabe, N, 2010) |
| "Tamoxifen (TAM) is a selective estrogen-receptor modulator that is widely used in the prevention and treatment of estrogen-receptor-positive breast cancer." | 3.76 | Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors. ( Lazarus, P; Sun, D, 2010) |
| " We investigated antitumoral effects of the specific ETAR antagonist ZD4054 in breast cancer cells and xenografts, and assessed antitumoral efficacy of the combinations of ZD4054 with aromatase inhibitors and fulvestrant." | 3.76 | ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole. ( Brodie, A; Chen, S; Fischgräbe, J; Götte, M; Kiesel, L; Macedo, LF; Radke, I; Smollich, M; Wülfing, P, 2010) |
| ", tamoxifen and anastrozole) on cognitive functioning by comparing 28 postmenopausal women with breast cancer to 37 healthy age-equivalent controls." | 3.76 | Endocrine therapy is associated with low performance on some estrogen-sensitive cognitive tasks in postmenopausal women with breast cancer. ( Crossley, M; Lejbak, L; Vrbancic, M, 2010) |
| "To investigate the efficacy and safety of goserelin plus anastrozole in advanced premenopausal breast cancer patients." | 3.76 | [Goserelin plus anastrozole in the treatment of premenopausal patients with metastatic breast cancer]. ( Cai, RG; Li, Q; Ma, F; Wang, JY; Xu, BH; Yao, SY; Yuan, P; Zhang, P, 2010) |
| "Aromatase inhibition (AI) is the most effective endocrine treatment for breast cancer in post-menopausal patients, but a percentage of hormone receptor-positive cancers do not benefit from such therapy: for example, about 20% of patients treated with anastrozole do not respond and it is still impossible to accurately predict sensitivity." | 3.76 | Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer. ( Baiardi, P; Chiorino, G; Costa, A; Da Prada, GA; Fregoni, V; Ghimenti, C; Grosso, E; Marsoni, S; Mello-Grand, M; Miller, WR; Regolo, L; Scatolini, M; Singh, V; Villani, L; Zambelli, A, 2010) |
| "The ABCSG-12 trial investigated the efficacy of gonadotropin-releasing hormone (GnRH)analogs in combination with tamoxifen or anastrozole + or - zoledronic acid (4 mg, q6m for 3 years) in 1,803 premenopausal women with hormone receptor-positive (HR+) breast cancer." | 3.76 | Results of the Zometa cost-utility model for the german healthcare system based on the results of the ABCSG-12 study. ( Beckmann, MW; Gnant, M; Jonat, W; Kreienberg, R; Lux, MP; Reichelt, C; Thiel, FC; Wallwiener, D, 2010) |
| "The Breast International Group (BIG) 1-98 and Arimidex, Tamoxifen Alone or in Combination (ATAC) trials demonstrated that, in postmenopausal women with hormone receptor positive (HR+) early-stage breast cancer, 5 years of initial adjuvant endocrine therapy with letrozole or anastrozole is superior to tamoxifen." | 3.76 | Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer. ( Delea, TE; Guo, A; Lipsitz, M, 2010) |
| "Trials have shown superiority of aromatase inhibitors (AIs) over tamoxifen for post-menopausal oestrogen receptor-positive advanced breast cancer (ER+ABC)." | 3.76 | Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women. ( Agrawal, A; Cheung, KL; Dowsett, M; Folkerd, E; Robertson, JF; Winterbottom, L, 2010) |
| "We report a 69-year-old woman with breast cancer who was effectively treated with letrozole as a second-line therapy after becoming resistant to anastrozole." | 3.76 | [Advanced breast cancer in a patient achieving long-term SD after letrozole administration for liver metastasis developing during anastrozole therapy]. ( Fujimoto, A; Goto, K; Ichinose, Y; Kobayashi, T; Sasaoki, T; Uchida, S, 2010) |
| "Retinal thickness was measured for 3 groups of amenorrheic women: (1) anastrozole users and (2) tamoxifen users undergoing adjuvant therapy for early-stage breast cancer, and (3) control subjects not using hormonal medication." | 3.75 | Vitreo-retinal traction and anastrozole use. ( Eisner, A; Falardeau, J; Thielman, EJ; Vetto, JT, 2009) |
| "The lower incidence of gynecologic adverse events and interventions with anastrozole and the early occurrence of these events provide further support for using anastrozole as the initial adjuvant treatment for early hormone receptor-positive breast cancer." | 3.75 | A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial. ( Baum, M; Cuzick, J; Distler, W; Duffy, SR; Howell, A, 2009) |
| "Post-menopausal breast cancer patients scheduled to receive tamoxifen (n=31) or anastrozole (n=14) completed neuropsychological testing around the time of commencement of treatment (T1), and again 5-6 months later (T2)." | 3.75 | Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study. ( Bielajew, C; Collins, B; Mackenzie, J; Stewart, A; Verma, S, 2009) |
| " The aim of this study was to evaluate the rate of adherent patients in a randomly selected sample of postmenopausal women with primary breast cancer, who had been assigned to an adjuvant endocrine treatment with TAM or anastrozole (ANA)." | 3.75 | Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. ( Albert, US; Hadji, P; Holzhauer, W; Kalder, M; Wagner, U; Ziller, M; Ziller, V, 2009) |
| "These data support clinical investigation of anastrozole-AZD0530 therapy for postmenopausal ER-positive breast cancer." | 3.75 | Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors. ( Chen, Y; Gonzalez-Angulo, A; Guggisberg, N; Hennessy, B; Jorda, M; Mills, GB; Slingerland, JM; Tan, CK, 2009) |
| "Taken together, data indicate that SERMs/antiestrogens and aromatase inhibitors exhibit opposed effects on the ER expression of breast cancer cells: tamoxifen and fulvestrant up-regulate ERalpha expression, while aromatase inhibitors increase ERbeta expression, which may contribute to the aromatase inhibitors' therapeutic superiority over antiestrogens." | 3.75 | Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells. ( Fischgräbe, J; Götte, M; Kiesel, L; Radke, I; Smollich, M; Wülfing, P, 2009) |
| "Anastrozole, an aromatase inhibitor, is commonly used in the adjuvant treatment of breast cancer." | 3.75 | Hemicentral retinal artery occlusion in a breast cancer patient using anastrozole. ( Ayata, A; Bilgi, O; Kandemir, EG; Karagöz, B; Ozgün, A; Türken, O; Unal, M; Uzun, G, 2009) |
| "Anastrozole, a selective nonsteroidal aromatase inhibitor is widely used as an adjuvant therapy for postmenopausal women with early hormone-sensitive breast cancer." | 3.75 | Drug-induced pruritic micropapular eruption: anastrozole, a commonly used aromatase inhibitor. ( Bremec, T; Demsar, J; Luzar, B; Pavlović, MD, 2009) |
| "Anastrozole is a selective aromatase inhibitor and is used for the hormonal treatment of postmenopausal breast cancer." | 3.74 | Anastrozole-associated sclerosing glomerulonephritis in a patient with breast cancer. ( Akgul, B; Camci, C; Kalender, ME; Karakok, M; Sevinc, A; Turk, HM, 2007) |
| "The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial showed that 5 years of adjuvant therapy with anastrozole reduced recurrence of breast cancer to a greater extent than did tamoxifen." | 3.74 | Is long-term adjuvant treatment of breast cancer with anastrozole indicated? ( Doggrell, SA, 2008) |
| " The aim of this study was to assess the relative importance of different risk factors for treatment-emergent joint symptoms in patients assigned to anastrozole or tamoxifen as adjuvant treatment for postmenopausal breast cancer." | 3.74 | Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. ( Bianco, AR; Buzdar, AU; Cuzick, J; Eastell, R; Forbes, JF; Sapunar, F; Sestak, I, 2008) |
| "Tumors from 228 postmenopausal women with confirmed ER+ stage 2 and 3 breast cancers in the P024 neoadjuvant endocrine therapy trial, which compared letrozole and tamoxifen for 4 months before surgery, were analyzed for posttreatment ER status, Ki67 proliferation index, histological grade, pathological tumor size, node status, and treatment response." | 3.74 | Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. ( A'Hern, R; Bhatnagar, AS; Chaudri Ross, HA; Dowsett, M; Eiermann, W; Ellis, MJ; Evans, DB; Luo, J; Miller, WR; Smith, I; Tao, Y; von Kameke, A, 2008) |
| "Women with hormone-receptor-positive tumours who reported vasomotor or joint symptoms at the first follow-up visit (3 months) in the ATAC trial, (which assessed tamoxifen or anastrozole for adjuvant treatment of postmenopausal breast cancer), were compared with women without these symptoms to see if there was a relation between these symptoms and subsequent recurrence." | 3.74 | Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. ( Cella, D; Cuzick, J; Fallowfield, L; Sestak, I, 2008) |
| "To determine cost-effective (CE) strategies comparing adjuvant upfront aromatase inhibitor (AI) with sequential tamoxifen (TAM) AI in postmenopausal (PM) women with breast cancer (BC)." | 3.74 | Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer. ( Dewar, R; Rayson, D; Skedgel, C; Younis, T, 2007) |
| "This study evaluated the cost-effectiveness of anastrozole versus generic tamoxifen for primary adjuvant treatment of postmenopausal women with hormone receptor-positive (HR+) early breast cancer (EBC), from a US healthcare perspective." | 3.74 | Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone ( Cella, D; Dobrez, D; Gandhi, SK; Locker, GY; Mansel, R; Sorensen, S, 2007) |
| "Optic nerve head (ONH) topography was measured using a commercially available, confocal scanning laser ophthalmoscope for three populations of amenorrheic women ages 40-69 years: subjects using (1) tamoxifen (20 mg/day) or (2) anastrozole (1 mg/day) for < or = 2 years as adjuvant therapy after successful primary treatment for breast cancer, and (3) control subjects with no breast cancer histories and not using any hormonal medication." | 3.74 | Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors. ( Eisner, A; Falardeau, J; Samples, JR; Toomey, MD; Vetto, JT, 2007) |
| "The aromatase inhibitors Anastrozole, Letrozole (type 2 nonsteroidal aromatase inhibitors: n-SAI) and Exemestane (type 1 steroidal aromatase inactivator) are used respectively as first- and second-line hormonal therapy in postmenopausal metastatic breast cancer women." | 3.74 | Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients. ( Alimonti, A; Bria, E; Carlini, P; Cognetti, F; Cresti, N; Di Cosimo, S; Fabi, A; Ferretti, G; Giannarelli, D; Michelotti, A; Milella, M; Papaldo, P; Pellegrini, M; Ricci, S; Ruggeri, EM; Salesi, N, 2007) |
| ", versus a control group of healthy postmenopausal women): (a) healthy postmenopausal women receiving tamoxifen; (b) postmenopausal women who had received treatment for early breast cancer; (c) postmenopausal breast cancer patients on adjuvant tamoxifen therapy; (d) postmenopausal breast cancer patients on adjuvant anastrozole therapy." | 3.74 | Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer. ( Bell, R; Lewis, J, 2007) |
| "Five years with the aromatase inhibitors letrozole or anastrozole is clinically superior to 5 years tamoxifen in postmenopausal women with early breast cancer." | 3.74 | Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. ( Barghout, V; Delea, T; Karnon, J, 2008) |
| " We have determined the effects of combining lonafarnib with the antiestrogen 4-hydroxy tamoxifen on hormone-dependent breast cancer cell lines in vitro." | 3.74 | Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336). ( Basso, AD; Black, S; Kirschmeier, P; Liu, G; Liu, M; Long, BJ; Marrinan, CH; Robert Bishop, W; Taylor, SA, 2007) |
| "Adjuvant therapy with anastrozole may be beneficial in resolving endometrial hyperplasia in patients with breast cancer." | 3.74 | Resolution of endometrial hyperplasia with adjuvant anastrozole treatment in postmenopausal breast cancer: a case report. ( Cooper, BC; Stilwill, SE, 2007) |
| "We used longitudinal claims data from three large commercial health programs to estimate adherence with anastrozole therapy among women with early-stage breast cancer." | 3.74 | Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. ( Asnis-Alibozek, A; LaFountain, A; Mayer, E; Partridge, AH; Taylor, BS; Winer, E, 2008) |
| "To examine retrospectively the difference in efficacy by the AI sequence when anastrozole ( ANA) and exemestane (EXE) are clinically administered sequentially for patients with metastatic breast cancer." | 3.74 | [Efficacy of sequential treatment with anastrozole following exemestane compared with exemestane following anastrozole in patients with metastatic breast cancer]. ( Ikeda, M; Kurebayashi, J; Miyake, A; Nakashima, K; Nomura, T; Shiiki, S; Sonoo, H; Tanaka, K; Yamamoto, Y, 2008) |
| "Although the aromatase inhibitor anastrozole has been shown to be very effective in the treatment of hormone-dependent postmenopausal breast cancer, some patients with advanced disease will develop resistance to treatment." | 3.74 | Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model. ( Brodie, A; Goloubeva, OG; Macedo, LF; Sabnis, GJ, 2008) |
| "Fundus photographs were obtained for a study comparing effects on vision and the eye of anastrozole (1 mg/d) and tamoxifen (20 mg/d) for women receiving adjuvant endocrine therapy for early-stage breast cancer." | 3.74 | Retinal hemorrhages in anastrozole users. ( Eisner, A; Falardeau, J; Toomey, MD; Vetto, JT, 2008) |
| " Here we discuss the influence of clinical trial results from the Arimidex, Tamoxifen Alone or in Combination trial on the usage of tamoxifen and anastrozole in the treatment of postmenopausal women with hormone receptor-positive early breast cancer." | 3.73 | How rapidly do oncologists respond to clinical trial data? ( Buzdar, A; Macahilig, C, 2005) |
| "We report three cases with advanced breast cancer were treated with a weekly dose of paclitaxel (TXL)." | 3.73 | [Three cases of advanced breast cancer successfully treated with a weekly dose of paclitaxel]. ( Katsumine, Y; Noda, N; Osawa, I; Uehara, S; Yuasa, H, 2005) |
| "Fulvestrant, an estrogen receptor antagonist with no known agonist effects, is effective and well tolerated in the treatment of hormone-sensitive breast cancer after antiestrogen failure in postmenopausal women." | 3.73 | Current and future perspectives on fulvestrant. ( Gradishar, WJ; Sahmoud, T, 2005) |
| "Two third-generation aromatase inhibitors, letrozole and anastrozole, and the antiestrogen tamoxifen, were compared for growth-inhibiting activity in two estrogen receptor (ER)-positive aromatase-overexpressing human breast cancer cell lines, MCF-7aro and T-47Daro." | 3.73 | Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen. ( Chen, S; Itoh, T; Kijima, I, 2005) |
| "The steroidal aromatase inactivator exemestane has demonstrated activity after prior failure of non-steroidal aromatase inhibitors (including third-generation inhibitors letrozole and anastrozole) in postmenopausal women with advanced breast cancer." | 3.73 | Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. ( Bertelli, G; Bertolotti, L; Castiglione, F; Del Mastro, L; Fusco, O; Garrone, O; Leonard, RC; Merlano, M; Occelli, M; Pepi, F, 2005) |
| "The introduction of third generation aromatase inhibitors [anastrozole, letrozole, and exemestane] has certainly improved outcomes inpatients with early breast cancer." | 3.73 | Changing the gold standard in adjuvant therapy for breast cancer:from tamoxifen to aromatase inhibition. ( Gltick, S, 2005) |
| "To conduct an economic analysis comparing tamoxifen and anastrozole (Arimidex) in the adjuvant treatment of hormone receptor-positive (HR+), post-menopausal early breast cancer patients." | 3.73 | Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis. ( Rocchi, A; Verma, S, 2006) |
| "To compare the efficiency of adjuvant therapy with aromatase inhibitors or with tamoxifen in postmenopausal women with operable breast cancer and positive estrogen receptors." | 3.73 | Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer. ( Canorea, F; Del Castillo, A; Gil, JM; González, P; Rubio-Terrés, C, 2006) |
| "At our clinic from August 2001 to March 2005, 53 postmenopausal women with estrogen receptor-positive breast cancer were treated with anastrozole." | 3.73 | Joint symptoms: a practical problem of anastrozole. ( Inoue, K; Nagamoto, N; Nakahara, O; Ohsako, T; Sakamoto, N; Yoshida, Y, 2006) |
| "The 5-year completed treatment analysis of the Anastrozole and Tamoxifen-Alone or in Combination (ATAC) trial showed the superiority of anastrozole over tamoxifen for reduction of disease progression in patients with hormone receptor-positive (HR+) early breast cancer (EBC)." | 3.73 | Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial. ( Annemans, L; Moeremans, K, 2006) |
| "We report a breast cancer patient who developed acute myeloid leukemia (AML) one year following her adjuvant chemotherapy consisting of cyclophosphamide, adriamycin and 5-fluorouracil." | 3.73 | t(8;16) AML developed subsequent to breast cancer therapy. ( Akçali, Z; Boğa, S; DemIrhan, B; Karakuş, S; Sahin, FI; Yilmaz, Z, 2006) |
| "Recent randomized clinical trials (RCT) comparing anastrozole (Arimidex) and letrozole (Femara) to tamoxifen in the first-line treatment of postmenopausal women with advanced hormone-sensitive breast cancer have demonstrated that both agents were at least as effective as tamoxifen." | 3.72 | Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen. ( Dranitsaris, G; Trudeau, M; Verma, S, 2003) |
| "An economic evaluation was conducted comparing anastrozole, exemestane, letrozole and megestrol for the second-line treatment of postmenopausal patients with hormone-sensitive metastatic breast cancer who had failed tamoxifen." | 3.72 | Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer. ( Rocchi, A; Verma, S, 2003) |
| "Data from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial have indicated that anastrozole ('Arimidex') may supplant tamoxifen as the preferred adjuvant endocrine therapy for hormone receptor-positive, early breast cancer in postmenopausal women." | 3.72 | Future directions in the endocrine therapy of breast cancer. ( Hortobagyi, GN, 2003) |
| "In a recent trial of first-line therapy in 353 postmenopausal women with predominantly hormone receptor-positive advanced breast cancer (the North American trial), anastrozole 1 mg QD produced a significantly longer time to disease progression (TTP) than tamoxifen 20 mg QD (11." | 3.72 | Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer. ( Buzdar, A; Jones, D; Simons, WR, 2003) |
| "The third-generation aromatase inhibitors (AIs) have improved efficacy and safety versus tamoxifen for treatment of advanced breast cancer." | 3.72 | Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003. ( Buzdar, AU, 2004) |
| "Aromatase (estrogen synthetase) inhibitors are superior to tamoxifen in terms of both efficacy and toxicity in the treatment of advanced breast cancer and also in the neoadjuvant setting." | 3.72 | Prevention strategies with aromatase inhibitors. ( Goss, PE; Strasser-Weippl, K, 2004) |
| "A computer simulation model assessed the outcomes of 64-year-old women with ER-positive breast cancer who subsequently received either anastrozole or tamoxifen for 5 years." | 3.72 | Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. ( Hillner, BE, 2004) |
| "We reviewed therapeutic effects and harmful side effects in 33 patients with advanced or recurrent breast cancer who underwent treatment with Anastrozole 1 mg/day in our department." | 3.72 | [Therapeutic effects of Anastrozole in patients with advanced and recurrent breast cancer]. ( Hirono, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, T; Okubo, S; Sonoo, H; Tanaka, K; Udagawa, K, 2004) |
| "To determine the quality of life (QoL) of women participating in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial during the first 2 years of treatment." | 3.72 | Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. ( Cella, D; Cuzick, J; Fallowfield, L; Francis, S; Howell, A; Locker, G, 2004) |
| "In this cost-effectiveness analysis using previously published clinical data and year-2003 cost data from a community hospital in the Italian National Health Service, anastrozole and letrozole were both cost-effective alternatives to tamoxifen for first-line therapy of postmenopausal women with advanced estrogen receptor-positive breast cancer." | 3.72 | Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service. ( Caruggi, M; Colombo, G; Marchetti, M, 2004) |
| "Thirty-four consecutive patients with advanced breast cancer received anastrozole 1 mg/day." | 3.71 | Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism. ( Bajetta, E; Bombardieri, E; Ferrari, L; La Torre, I; Longarini, R; Martinetti, A; Pozzi, P; Salvucci, G; Seregni, E; Zilembo, N, 2002) |
| "Tamoxifen is probably the most important drug in the history of the management of breast cancer and its development is a tribute to cross talk between laboratory scientists and clinical investigators." | 3.71 | Has tamoxifen had its day? ( Baum, M, 2002) |
| " Five applications supporting new claims will be discussed: Trisenox (arsenic trioxide) for induction of remission and consolidation in patients with acute promyelocytic leukemia who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose disease is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression; Nolvadex (tamoxifen citrate) in women with ductal carcinoma in situ, following breast surgery and radiation, to reduce the risk of invasive breast cancer; Arimidex (anastrazole) for first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer; Taxol (paclitaxel), 175 mg/m(2) by 3 h infusion in combination with cisplatin for first-line treatment of advanced ovarian cancer; and Targretin gel (bexarotene) for the topical treatment of cutaneous lesions in patients with stage IA and IB cutaneous T-cell lymphoma who have not tolerated other therapies or who have refractory or persistent disease." | 3.71 | Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. ( Cohen, MH; Flamm Honig, S; Hirschfeld, S; Ibrahim, A; Johnson, JR; O'Leary, JJ; Pazdur, R; White, RM; Williams, GA, 2001) |
| "In experimental models, human epidermal growth factor receptor-2 (HER-2) amplification leads to estrogen independence and tamoxifen resistance in estrogen receptor (ER)-positive human breast cancer cells." | 3.71 | HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. ( Boeddinghaus, I; Dixon, M; Dowsett, M; Ebbs, S; Gui, G; Harper-Wynne, C; Hills, M; Sacks, N; Salter, J; Smith, I, 2001) |
| " This paper focuses on the relevance of clinical benefit CB (CR + PR + SD > or = 6 months) in postmenopausal metastatic breast cancer (MBC) patients treated with the steroidal aromatase inhibitor (SAI) formestane (FOR)." | 3.71 | Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable? ( Carlini, P; Casali, A; Cognetti, F; De Marco, S; Fabi, A; Frassoldati, A; Nardi, M; Paoloni, F; Papaldo, P; Ruggeri, EM, 2001) |
| "To determine the effects of aromatase inhibitors on oestrogen uptake, in situ aromatase activity and endogenous oestrogens in the breast, postmenopausal women with large primary ER-rich breast cancers have been treated neoadjuvantly for 3 months with either letrozole (2." | 3.71 | Local endocrine effects of aromatase inhibitors within the breast. ( Dixon, JM; Miller, WR, 2001) |
| "Postmenopausal women with large primary oestrogen receptor-rich (>20 fmol/mg protein or 80 histoscore) breast cancers have been treated neoadjuvantly with either letrozole (2." | 3.71 | Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. ( Anderson, TJ; Cameron, DA; Dixon, JM; Miller, WR, 2001) |
| "To evaluate the response rate and survival duration of patients treated with anastrozole for metastatic breast cancer, who had previously received at least one line of hormonal therapy." | 3.71 | Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer. ( Cohen, Y; Geffen, DB; Lavrenkov, K; Man, S, 2002) |
| "High-dose estrogen was generally considered the endocrine therapy of choice for postmenopausal women with breast cancer prior to the introduction of tamoxifen." | 3.71 | Estrogen as therapy for breast cancer. ( Ingle, JN, 2002) |
| "Anastrozole is the first aromatase inhibitor to show a significant survival advantage over megestrol acetate in post-menopausal women with advanced breast cancer." | 3.70 | Aromatase inhibitors and their future role in post-menopausal women with early breast cancer. ( Lønning, PE, 1998) |
| "Randomized trials comparing the aromatase inhibitors, anastrozole and letrozole, to megestrol acetate (MA) in postmenopausal women with advanced breast cancer demonstrated that both agents are better tolerated than MA with comparable efficacy." | 3.70 | Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate. ( Dranitsaris, G; Leung, P; Mather, J; Oza, A, 2000) |
| "To study the effect and adverse reactions of anastrozole in the treatment of postmenopausal women with advanced breast cancer." | 3.70 | [Clinical study of anastrozole in the treatment of postmenopausal women with advanced breast cancer]. ( Feng, F; Jiang, Z; Xu, B, 1999) |
| "Anastrozole offers a new option for many postmenopausal women with metastatic breast cancer who no longer respond to antiestrogen therapy." | 3.69 | Role of new selective aromatase inhibitor in therapy for metastatic breast cancer in postmenopausal women. ( Hannaford, M, 1997) |
| "Obesity has been associated with an adverse prognosis and reduced efficacy of endocrine therapy in patients with hormone receptor-positive (HR+) breast cancer (BC)." | 3.30 | The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer. ( de Graaf, H; de Roos, WK; Erdkamp, FLG; Geurts, SME; Honkoop, AH; Imholz, ALT; Kroep, JR; Lammers, SWM; Linn, SC; Smidt, ML; Smorenburg, CH; Swinkels, ACP; Tjan-Heijnen, VCG; van der Sangen, MJC; van Hellemond, IEG; Vriens, IJH, 2023) |
| "The primary end point was serious adverse events for the safety run-in period and progression-free rate at 8 weeks (8wk-PFR)-assessed with a blinded independent central review in phase 2." | 3.11 | Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial. ( Abdeddaim, C; Arnaud, A; Augereau, P; Bazan, F; Chakiba, C; Chevalier-Place, A; Dalban, C; Diaz, JJ; Fabbro, M; Frenel, JS; Garin, G; Heudel, P; Joly, F; Lancry-Lecomte, L; Marcel, V; Pautier, P; Pérol, D; Ray-Coquard, I; Treilleux, I; You, B, 2022) |
| "Aromatase inhibitors (AIs) reduce breast cancer recurrence and prolong survival, but up to 30% of patients exhibit recurrence." | 2.94 | Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action. ( Bari, MG; Buzdar, AU; Cairns, J; Carlson, EE; Dudenkov, TM; Ellis, MJ; Goetz, MP; Goodnature, B; Goss, PE; Ingle, JN; Kalari, KR; Li, H; Na, J; Robson, ME; Shepherd, LE; Wang, L; Weinshilboum, RM, 2020) |
| "NBRST IHC/FISH HR+/HER2- breast cancer patients (n = 474) were classified into four molecular subgroups by MammaPrint/BluePrint subtyping: Luminal A, Luminal B, HER2, and Basal type." | 2.84 | Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping. ( Baron, P; Beatty, J; Beitsch, P; de Snoo, FA; Dul, CL; Lee, LA; Mislowsky, A; Murray, M; Nash, C; Pellicane, JV; Rotkis, M; Stork-Sloots, L; Whitworth, P, 2017) |
| "MA." | 2.82 | Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27. ( Chapman, JA; Elliott, C; Gelmon, KA; Goss, PE; Ingle, JN; Muss, HB; Pritchard, KI; Shepherd, LE; Whelan, TJ, 2016) |
| "Patients were randomized 1:1:1 to receive daily anastrozole (1 mg) in combination with AZD8931 20 mg twice daily (bid), AZD8931 40 mg bid, or placebo." | 2.82 | Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer. ( Basik, M; Clemons, M; Cristofanilli, M; Dreosti, L; Grzeda, L; Hegg, R; Johnston, S; Lausoontornsiri, W; Mann, H; Stuart, M, 2016) |
| "In HER2-positive breast cancer patients the addition of trastuzumab to neoadjuvant chemotherapy improved the overall and pathological complete response." | 2.80 | [BREAST-CONSERVING SURGERY AFTER NEOADJUVANT THERAPY FOR BREAST CANCER]. ( Bozhok, AA; Dashyan, GA; Komyakhov, AV; Lalak, IA; Manikhas, AG; Paltuev, RM; Petrenko, OL; Semiglazov, VF; Semiglazov, VV; Semiglazova, TY, 2015) |
| "Women with early stage breast cancer exhibited an unexpectedly low TFCA, most likely due to their high calcium intake." | 2.77 | Aromatase inhibitors and calcium absorption in early stage breast cancer. ( Burkard, ME; Crone, E; Davis, LA; Gogineni, J; Hansen, KE; Shafer, MM; Tevaarwerk, A; Wisinski, KB, 2012) |
| "Anastrozole treatment-related bone loss did not continue into the off-treatment follow-up period." | 2.76 | Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. ( Adams, J; Beckmann, MW; Clack, G; Coleman, RE; Cuzick, J; Eastell, R; Howell, A; Mackey, J, 2011) |
| "Additionally, breast cancer patients with new onset or worsening of pain over the study period had a significantly smaller change in mean DHEAS concentration from baseline to 3 months (P = 0." | 2.76 | Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy. ( Gallicchio, L; Helzlsouer, KJ; Macdonald, R; Rushovich, E; Wood, B, 2011) |
| "Patients with early breast cancer and AIMSS were stratified according to their baseline 25-hydroxy vitamin D (25OHD) level." | 2.76 | Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. ( Armamento-Villareal, R; Ellis, MJ; Gao, F; Jamalabadi-Majidi, S; Napoli, N; Rastelli, AL; Taylor, ME, 2011) |
| "Endocrine therapy in patients with breast cancer can be limited by the problem of resistance." | 2.76 | A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. ( Beyer, A; Cai, WY; Elledge, R; Fuqua, S; Hilsenbeck, S; Huang, J; Massarweh, S; Rimawi, M; Sexton, K; Tham, YL; Tsimelzon, A; Weiss, H, 2011) |
| " Our results confirmed that longterm postoperative therapy with UFT alone was feasible, provided that early adverse events are carefully monitored." | 2.74 | [Safety and compliance with UFT (tegafur and uracil) alone and in combination with hormone therapy in patients with breast cancer]. ( Noguchi, S; Taguchi, T, 2009) |
| " We assessed whether the addition of a lower dose of tamoxifen influenced anastrozole bioavailability and favorably modulated biomarkers of bone fracture, breast cancer, cardiovascular disease, and endometrial cancer risk." | 2.74 | Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia. ( Bonanni, B; Cassano, E; Cazzaniga, M; Decensi, A; Gandini, S; Guerrieri-Gonzaga, A; Johansson, H; Lien, EA; Luini, A; Macis, D; Oldani, S; Pelosi, G; Serrano, D, 2009) |
| "Anastrozole induced an increase in bone remodelling: osteocalcin (+36." | 2.73 | Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. ( Brun, J; Confavreux, CB; Delmas, PD; Fontana, A; Guastalla, JP; Munoz, F, 2007) |
| "HER2-positive (HER2+) breast cancer represents a heterogeneous breast cancer subtype, including both oestrogen receptor (ER) positive and negative tumours." | 2.72 | CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer. ( Agostinetto, E; de Azambuja, E; Debien, V; Lambertini, M; Marta, GN; Piccart-Gebhart, M, 2021) |
| "For certain women at high risk for breast cancer, endocrine therapy (ET) can greatly decrease the risk." | 2.72 | Preventing Breast Cancer Through Identification and Pharmacologic Management of High-Risk Patients. ( Gilman, EA; Hofstatter, EW; Mussallem, DM; Pruthi, S, 2021) |
| "Tamoxifen treatment results in a doubling of the risk of endometrial cancer after 1-2 years of treatment and a quadrupling after 5 years." | 2.72 | The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. ( Bianco, AR; Clack, G; Coibion, M; Duffy, S; Jackson, TL; Lansdown, M; Philips, K; Pollard, S; Wells, M, 2006) |
| "In France, 20% of breast cancers occur in women over the age of 70 and 10% in women over the age of 80." | 2.72 | Estrogen receptors evolution in neoadjuvant aromatase inhibitor (AI) therapy for breast cancer in elderly women: stability of hormonal receptor expression during treatment. ( Alran, S; Campana, F; de Cremoux, P; Languille, O; Malka, I; Rosty, C; Salmon, RJ; Sigal-Zafrani, B, 2006) |
| "Fulvestrant (ICI 182,780) is a new type of estrogen receptor (ER) antagonist that down-regulates the ER and has no known agonist effects." | 2.71 | Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. ( Buzdar, A; Come, SE; Ellis, M; Gertler, S; Howell, A; Jones, SE; Kleeberg, UR; Mauriac, L; Morris, C; Osborne, CK; Robertson, JF; Vergote, I; Webster, A, 2003) |
| "Treatment with tamoxifen may still be useful upon subsequent progression." | 2.71 | Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and ( Aebi, S; Ballabeni, P; Goldhirsch, A; Hess, D; Köberle, D; Pagani, O; Perey, L; Rochlitz, C; Senn, I; Thürlimann, B, 2004) |
| "Endocrine treatments of breast cancer patients antagonize estrogen and may lead to consequences of estrogen deprivation including menopausal symptoms." | 2.71 | Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. ( Ameye, L; Carbonez, A; Christiaens, MR; Morales, L; Neven, P; Paridaens, R; Timmerman, D; Van Huffel, S; Van Limbergen, E; Vergote, I, 2004) |
| "Neoadjuvant (preoperative) therapy for breast cancer may allow for the development of intermediate markers of treatment benefit, thereby circumventing the need for efficacy trials of adjuvant therapy, which require much larger patient numbers and longer follow-up." | 2.71 | Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. ( Ashley, S; Boeddinghaus, I; Detre, S; Dixon, JM; Dowsett, M; Ebbs, SR; Francis, S; Griffith, C; Hills, M; Salter, J; Skene, A; Smith, IE; Walsh, G, 2005) |
| "In Mexico the breast cancer occupies the second place as cause of death by oncological illness and the etiology is considered multifactorial." | 2.71 | [Survival of breast cancer patients treated with inhibitors of the aromatase vs tamoxifen]. ( Angeles Victoria, L; Basavilvazo Rodríguez, MA; Castelazo Rico, G; Hernández Valencia, M; Molotla Xolalpa, D; Zárate, A, 2004) |
| "Fulvestrant is an estrogen receptor antagonist with no agonist effects." | 2.71 | Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. ( Come, SE; Elledge, RM; Howell, A; Jones, SE; Mauriac, L; Osborne, CK; Pippen, J; Robertson, JF; Vergote, I, 2005) |
| "Anastrozole was associated with a significant increase in HDL-C (11." | 2.71 | Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial. ( Banerjee, S; Barker, P; Dowsett, M; Folkerd, L; Iqbal, J; Smith, IE, 2005) |
| "Both anastrozole and tamoxifen were well tolerated." | 2.70 | Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. ( Bonneterre, J; Buzdar, A; Nabholtz, JM; Robertson, JF; Sahmoud, T; Steinberg, M; Thürlimann, B; von Euler, M; Webster, A, 2001) |
| "Anastrozole was given in a dose of 1 mg once daily and compared with tamoxifen 20 mg daily in postmenopausal patients with tumours that were hormone-receptor positive or of unknown receptor status." | 2.69 | Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. ( Bonneterre, J; Koralewski, L; Krzakowski, M; Mauriac, L; Robertson, J; Steinberg, M; Thürlimann, B; Vergote, I; von Euler, M; Webster, A, 2000) |
| "The management of ductal carcinoma in situ (DCIS) with endocrine therapy remains controversial." | 2.66 | Endocrine Therapy for Ductal Carcinoma In Situ (DCIS) of the Breast with Breast Conserving Surgery (BCS) and Radiotherapy (RT): a Meta-Analysis. ( Drokow, EK; Li, Z; Liu, J; Ma, X; Ren, J; Shao, S; Shi, X; Tan, L; Xue, C; Yan, Y; Zhang, L; Zhang, X; Zhang, Y, 2020) |
| "Anastrozole is a nonsteroidal compound and a potent selective inhibitor of the aromatase enzyme." | 2.55 | Use of anastrozole in the chemoprevention and treatment of breast cancer: A literature review. ( Andrade, DB; Barros-Oliveira, MDC; Borges, RS; Borges, US; Costa-Silva, DR; Silva, BBD; Silva, JM; Tavares, CB, 2017) |
| "The only alternative to breast cancer screening available in France is surgical prevention by prophylactic mastectomy." | 2.53 | [Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?]. ( Callet, N; Fourme, E; Noguès, C; Reyal, F; Sénéchal, C; Stoppa-Lyonnet, D; This, P, 2016) |
| "However, concern for under- or over-treatment of DCIS has led many surgeons to question historically standardized approaches and instead begin to tailor treatment based on individual prognostic indicators." | 2.52 | Ductal Carcinoma In Situ: Treatment Update and Current Trends. ( Kuerer, H; Mitchell, KB, 2015) |
| "In Western countries, breast cancer is the most common cancer in women but available interventions can reduce risk." | 2.50 | Current concepts in breast cancer chemoprevention. ( Chlebowski, RT, 2014) |
| "Here we report a case of breast cancer that recurred after a 39-year latency period." | 2.50 | [A case of local recurrence developing thirty-nine years after mastectomy for breast cancer]. ( Kawano, K; Tashima, Y, 2014) |
| " Nevertheless, this approach is still associated with many challenges, ranging from the recurrence of breast cancer to considerable interindividual variability in the tolerability of anastrozole, which may cause adverse effects, such as musculoskeletal symptoms, and lead to the withdrawal of many patients from treatment." | 2.50 | The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients. ( Abubakar, MB; Gan, SH; Wei, K, 2014) |
| "The natural history of HR+ breast cancer tends to be different from hormone receptor-negative disease in terms of time to recurrence, site of recurrence and overall aggressiveness of the disease." | 2.50 | Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer. ( Armengol-Alonso, A; Dalmau, E; Muñoz, M; Seguí-Palmer, MÁ, 2014) |
| "Targeting of RTKs in HER2-negative breast cancer presents a major therapeutic opportunity in breast cancer, although robust selection strategies will be required to identify cancers with activation of specific RTKs if this potential is to be realized." | 2.49 | Targeting receptor tyrosine kinases in HER2-negative breast cancer. ( Anandappa, G; Turner, NC, 2013) |
| "We present a case of breast carcinoma in the axillary ectopic mammary gland and summarize the clinical features of 94 cases, including ours, in Japan." | 2.47 | A case of ectopic breast cancer with a literature review. ( Kameda, N; Nihon-Yanagi, Y; Okazumi, S; Ueda, T, 2011) |
| "In March, 2010, a group of breast cancer experts met to develop a consensus statement on breast cancer prevention, with a focus on medical and therapeutic interventions." | 2.47 | Preventive therapy for breast cancer: a consensus statement. ( Arun, B; Brown, PH; Castiglione, M; Cuzick, J; DeCensi, A; Dunn, B; Forbes, JF; Glaus, A; Howell, A; Vogel, V; von Minckwitz, G; Zwierzina, H, 2011) |
| "To review the clinical effectiveness and cost-effectiveness evidence base for lapatinib (LAP) in combination with an aromatase inhibitor (AI) and trastuzumab (TRA) in combination with an AI for the first-line treatment of patients who have hormone receptor-positive (HR+)/human epidermal growth factor 2-positive (HER2+) mBC." | 2.47 | Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis. ( Armstrong, A; Bagust, A; Blundell, M; Boland, A; Davis, H; Dickson, R; Dundar, Y; Fleeman, N; Moonan, M; Oyee, J; Thorp, N, 2011) |
| "HER2-positive breast cancer accounts for 20 to 25% of breast cancers." | 2.46 | [Management of metastatic HER2-positive breast cancer: present and future]. ( Arnould, L; Coudert, B; Favier, L; Fumoleau, P; Guiu, S, 2010) |
| "Postmenopausal women with early breast cancer (EBC) are already at risk for bone loss, osteoporosis and fracture as they age because of declining estrogen levels." | 2.46 | Women and bone health: maximizing the benefits of aromatase inhibitor therapy. ( Tang, SC, 2010) |
| "We have developed a breast cancer intratumoral aromatase model to simulate the postmenopausal breast cancer patient in order to compare the antitumor efficacy of aromatase inhibitors (AIs) and antiestrogens (AEs)." | 2.45 | Aromatase inhibitors and breast cancer. ( Brodie, A; Macedo, LF; Sabnis, G, 2009) |
| "Given the common hormonal dependence of breast cancer and the potential synergistic effect of these two treatment modalities, this strategy has been increasing in the adjuvant setting." | 2.45 | [Adjuvant breast cancer treatment with hormono-radiotherapy]. ( Azria, D; Belkacémi, Y; Gligorov, J; Jacot, W; Ozsahin, M; Romieu, G; Zaman, K, 2009) |
| "Effects on bone, endometrium and breast cancer are of interest." | 2.45 | Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer. ( Baumann, CK; Castiglione-Gertsch, M, 2009) |
| "Medico-economic evaluation of breast cancer is very significant and valuable and is expected to stimulate efficient utilization of healthcare resources." | 2.44 | Economic evaluation of the prevention and treatment of breast cancer--present status and open issues. ( Imai, H; Kuroi, K; Ohsumi, S; Ono, M; Shimozuma, K, 2007) |
| "The majority of invasive breast cancer patients present with hormone receptor-positive disease, and modulation of estrogen receptor (ER) activation is an essential component of systemic adjuvant therapy for these women." | 2.44 | Optimizing endocrine therapy for premenopausal and postmenopausal women with breast cancer. ( Cianfrocca, M; Wolff, AC, 2007) |
| "The endocrine therapy for breast cancer has made progress with the development of new endocrine drugs." | 2.44 | [Advancement in endocrine therapy for breast cancer]. ( Lian, ZQ; Yang, MT, 2007) |
| "Women with early breast cancer are exposed to an ongoing risk of relapse, even after successful surgical resection of the primary tumor and, where given, radiotherapy." | 2.44 | Reducing the risk of late recurrence in hormone-responsive breast cancer. ( Cufer, T, 2007) |
| "Hormonal therapy for breast carcinoma lowers estrogen levels or blocks the growth-promoting effects of estrogens." | 2.44 | Effects of hormonal therapy on cognitive functioning in breast cancer patients: a review of the literature. ( Schagen, SB; Schilder, CM, 2007) |
| "Hormone receptor-positive breast cancer is increasingly considered a chronic disease, as there remains an ongoing risk of local and distant relapse for years after diagnosis." | 2.44 | The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer. ( Pennery, E, 2008) |
| "Treatment with fulvestrant has also demonstrated clinical efficacy among patients who progressed following treatment with tamoxifen followed by nonsteroidal aromatase inhibitors." | 2.43 | Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer. ( Bundred, N, 2005) |
| "The 50% reduction in breast cancer incidence seen with tamoxifen is significant for women at increased risk but is accompanied by notable toxicities such as thrombotic events and endometrial cancer." | 2.43 | Aromatase inhibitors for the treatment and prevention of breast cancer. ( Brown, P; Kalidas, M, 2005) |
| "They are effective as therapies for breast cancer only in postmenopausal women whose tumours express oestrogen or progesterone receptors." | 2.43 | The aromatase inhibitors in early breast cancer: who, when, and why? ( Hamilton, AL; Nordman, IC; Spillane, AJ, 2005) |
| "We report a case of breast carcinoma metastatic to an epidural cervical meningioma, summarize the literature on metastases to central nervous system meningiomas, and suggest a possible mechanism." | 2.43 | Breast adenocarcinoma metastatic to epidural cervical spine meningioma: case report and review of the literature. ( Aghi, M; Brisman, JL; Kiehl, TR, 2005) |
| "Fulvestrant ('Faslodex') is a new ER antagonist with no agonist effects that binds, blocks and degrades the ER." | 2.43 | Life following aromatase inhibitors--where now for endocrine sequencing? ( Dowsett, M; Johnston, SR; Martin, LA, 2005) |
| "Fulvestrant is a new type of oestrogen receptor antagonist with no agonist effects." | 2.43 | Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents. ( Abram, P; Vergote, I, 2006) |
| "Bone loss may be a potential side effect of implementing aromatase inhibitors in the adjuvant setting." | 2.43 | Bone safety of aromatase inhibitors versus tamoxifen. ( Lønning, PE, 2006) |
| "The treatment of node-positive breast cancer has improved dramatically in the last 3 decades." | 2.43 | Adjuvant therapy for patients who have node-positive breast cancer. ( Chu, QD; Li, BD; McDonald, JC, 2006) |
| "Anastrozole treatment has no impact on plasma lipid levels, whereas both letrozole and exemestane have an unfavorable effect." | 2.42 | Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. ( Buzdar, AU, 2003) |
| "Anastrozole (Arimidex) was recently approved by the Food and Drug Administration for the adjuvant treatment of postmenopausal women with hormone-receptor-positive early breast cancer." | 2.42 | Aromatase inhibitors as adjuvant therapy in breast cancer. ( Davidson, NE; Visvanathan, K, 2003) |
| " Although published information about the side effects of AIs is scarce, it is likely that they will have adverse effects on bone and possibly also on lipid metabolism." | 2.42 | Safety issues surrounding the use of aromatase inhibitors in breast cancer. ( Dixon, JM; Jackson, J; Miller, WR, 2003) |
| "Risk factors of breast cancer are listed and evaluated individually." | 2.42 | [Perspectives for the hormonal therapy of breast cancer]. ( Eckhardt, S, 2003) |
| "Tamoxifen has been the principal adjuvant hormonal therapy in pre- and postmenopausal women with hormone receptor-positive breast cancer for nearly 20 years." | 2.42 | Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. ( Carlson, RW; Henderson, IC, 2003) |
| "Patients with hormone-sensitive breast cancer who have responded to tamoxifen (TAM) may receive additional benefit from a second endocrine agent after progression or relapse after TAM therapy." | 2.42 | Fulvestrant in postmenopausal women with advanced breast cancer. ( Baird, A; Bross, PF; Chen, G; Jee, JM; Lostritto, RT; Morse, DE; Pazdur, R; Rahman, A; Rosario, LA; Williams, G; Williams, GM; Yang, P, 2003) |
| "The activity of the enzyme network in breast cancer tissue is modified by a variety of factors like growth factors and cytokines." | 2.42 | Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. ( Geisler, J, 2003) |
| "The goal of endocrine therapy in breast cancer is to block the action of estrogen on the tumor cells either by inhibiting estrogen from binding to the specific estrogen receptor or by inhibiting its synthesis." | 2.42 | Challenges in the endocrine management of breast cancer. ( Brodie, AH; Mouridsen, HT; Rose, C; Smith, IE, 2003) |
| "Fulvestrant (Faslodex) is a novel estrogen receptor (ER) antagonist that competitively binds to the ER with a much greater affinity than that of tamoxifen." | 2.42 | Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. ( Curran, MP; McKeage, K; Plosker, GL, 2004) |
| "The death rate from breast cancer is falling rapidly in most developed countries due, at least in part, to the use of adjuvant endocrine therapy in women with endocrine responsive disease." | 2.42 | Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard? ( Clemons, M; Coleman, RE; Verma, S, 2004) |
| " Clinical trials have begun to define the role of these agents and their unique side-effect profiles." | 2.42 | Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life. ( Harwood, KV, 2004) |
| "Anastrozole (Arimidex) was the first of these agents to become available and is currently widely indicated for both first- and second-line treatment for postmenopausal women with breast cancer." | 2.41 | Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer. ( Köberle, D; Thürlimann, B, 2001) |
| "Anastrozole was as well-tolerated as megestrol acetate, while weight gain was significantly increased in the megestrol acetate group compared with the anastrozole group." | 2.41 | Anastrozole in the management of breast cancer. ( Nabholtz, JM; Reese, D, 2002) |
| "Letrozole 2." | 2.41 | New generation aromatase inhibitors--from the advanced to the adjuvant setting. ( Buzdar, AU, 2002) |
| "Anastrozole treatment had no impact on plasma lipid levels, whereas both letrozole and exemestane had an unfavorable effect on plasma lipid levels." | 2.41 | An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. ( Buzdar, AU; Eiermann, W; Nabholtz, JM; Robertson, JF, 2002) |
| "Formestane has been studied in elderly patients with breast cancer and has been found to induce an overall response rate of 51% (95% CI, 35-67%)." | 2.41 | Steroidal aromatase inhibitors in elderly patients. ( Bajetta, E; Bichisao, E; Pozzi, P; Toffolatti, L; Zilembo, N, 2000) |
| "Anastrozole has shown to be at least as effective as tamoxifen, standard endocrine therapy for breast cancer, with good safety profiles." | 2.41 | [Development of a novel aromatase inhibitor, anastrozole (Arimidex)--its basic and clinical studies]. ( Tsukagoshi, S, 2001) |
| "Letrozole was shown to be a better AI than fadrozole by prospective randomized double blind examination; however, it is not licenced yet." | 2.41 | [Developments of hormonal agents for breast cancer]. ( Tominaga, T, 2001) |
| "Anastrozole has a better therapeutic index (fewer side-effects) and has recently been approved by the FDA and a number of other regulatory agencies around the world for the treatment of advanced breast cancer." | 2.40 | ARIMIDEX: a potent and selective aromatase inhibitor for the treatment of advanced breast cancer. ( Buzdar, AU; Howell, A; Jonat, W; Plourde, PV, 1997) |
| "Thus, management of metastatic breast cancer has largely shifted from surgeons to medical oncologists." | 2.40 | Use of aromatase inhibitors in postmenopausal women with advanced breast cancer. ( Buzdar, AU; Roseman, BJ; Singletary, SE, 1997) |
| "1 mg/kg, and the clearance half-life of 7-16 h indicated that once-daily dosing would be possible in humans." | 2.40 | The relevance of preclinical models to the treatment of postmenopausal breast cancer. ( Dukes, M, 1997) |
| "Anastrozole is a new, highly selective, nonsteroidal aromatase inhibitor capable of maximal estrogen depletion with fewer side effects than other hormonal therapies." | 2.40 | Anastrozole: a new addition to the armamentarium against advanced breast cancer. ( Buzdar, AU, 1998) |
| "Aminoglutethimide was the first widely used aromatase inhibitor but had several clinical drawbacks." | 2.40 | Use of aromatase inhibitors in breast carcinoma. ( Harvey, HA; Santen, RJ, 1999) |
| " This study provides RiBi-based markers relevant for a better selection of patients with advanced endometrial carcinoma by predicting the response of endocrine therapy combined with mTOR inhibitor." | 1.91 | Ribosome biogenesis-based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group. ( Abadie-Lacourtoisie, S; Bazan, F; Chabaud, S; Colombe-Vermorel, A; Coquan, E; Dalban, C; Diaz, JJ; Fabbro, M; Frenel, JS; Garin, G; Heudel, PE; Marcel, V; Martinez, S; Mourksi, NE; Odeyer, L; Pérol, D; Ray-Coquard, I; Simioni, V; Tabone-Eglinger, S; Treilleux, I, 2023) |
| "Thus, for BQ-overexpressing breast cancer, targeting AR can combat anastrozole resistance." | 1.91 | Overexpression of BQ323636.1 contributes to anastrozole resistance in AR+ve/ER+ve breast cancer. ( Chan, SY; Chan, WL; Cheng, CN; Khoo, US; Leung, MH; Lok, J; Man, EP; Tsoi, H; You, CP, 2023) |
| "Globally, breast cancer is among the most frequently diagnosed and common cause of death among women." | 1.91 | Breast Tumor Cells Evade the Cytotoxic Action of Anastrozole, Aspirin, and Clopidogrel Cocktail. ( Arnachellen, D; Augustine, TN; Pillay, K; Xulu, KR, 2023) |
| "For anastrozole-treated patients, predictive factors included baseline body mass index (BMI) and longitudinal patient-reported symptoms such as insomnia, joint pain, hot flashes, headaches, gynecologic symptoms, and vaginal discharge, all collected up to 12 months [Brier score, 0." | 1.91 | Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial. ( Calsavara, VF; Cecchini, RS; Diniz, MA; Ganz, PA; Gresham, G; Hays, RD; Henry, NL; Kim, S; Luu, M; Rogatko, A; Tighiouart, M; Yothers, G, 2023) |
| "Potent breast cancer drugs are Tamoxifen, Paclitaxel, Cyclophosphamide, Trastuzumab, etc." | 1.72 | ( Elancheran, R; Maruthanila, VL; Mirunalini, S, 2022) |
| "The molecular classification of breast cancer (BC) dictates pharmacological treatment." | 1.72 | Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers. ( Acconcia, F, 2022) |
| "After confirming the diagnosis of ovarian cancer with a laparoscopic biopsy, neoadjuvant chemotherapy was scheduled." | 1.72 | [Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report]. ( Fukino, S; Hamasaki, T; Kodama, W; Nishimura, K; Oota, R; Suo, K; Takagi, Y; Tanaka, Y, 2022) |
| "Occult breast cancer (OBC) is characterized by metastatic presentation of undetectable breast tumor on imaging exams." | 1.62 | Cutaneous metastasis of occult breast cancer: a case report. ( Araújo, ALN; da Costa, REAR; de Oliveira, FTR; Dos Reis, CA; Moura, RD; Vieira, SC, 2021) |
| "The question of whether treatment of breast cancer during pregnancy (PrBC) should be similar to non-pregnant young patients with breast cancer is controversial." | 1.62 | Ovarian tissue cryopreservation in a patient with breast cancer during pregnancy: a case report. ( Cheng, J; Du, J; Gu, M; Jin, F; Li, Y; Liu, X; Mueck, AO; Ruan, X; Wang, H, 2021) |
| "From the group with therapy change, 'disease progression' was reason of change in 124 (58." | 1.62 | Switching of Hormone Therapies in Breast Cancer Women. ( Ferracini, AC; Juliato, CRT; Mazzola, PG; Medeiros, LM; Souza, CM; Stahlschmidt, R, 2021) |
| "Obesity represents a risk factor for breast cancer development and therapy resistance, but the molecular players underling these links are unclear." | 1.56 | Leptin Signaling Contributes to Aromatase Inhibitor Resistant Breast Cancer Cell Growth and Activation of Macrophages. ( Andò, S; Barone, I; Bonofiglio, D; Camera, G; Campana, A; Catalano, S; Fuqua, S; Gelsomino, L; Giordano, C; Grande, F; Leggio, A; Marsico, S; Rinaldi, A; Sisci, D; Tarallo, R, 2020) |
| "Steroidal drugs have been suggested for breast cancer treatment as aromatase enzymes inhibitors ." | 1.56 | Structural Recognition and Binding Pattern Analysis of Human Topoisomerase II Alpha with Steroidal Drugs: In Silico Study to Switchover the Cancer Treatment. ( Jamal, QMS, 2020) |
| "Fulvestrant has been studied as second line or first line treatment for post-menopausal hormone receptor positive breast cancers as a single agent or in combination with AIs." | 1.56 | Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity. ( Goloubeva, O; Kazi, A; Sabnis, GJ; Schech, A; Yu, S, 2020) |
| "Fourteen (24." | 1.56 | Urinary Incontinence and Overactive Bladder Symptoms in Women with Breast Cancer Being Treated with Oral Hormone Therapy. ( Ferracini, AC; Juliato, CRT; Mazzola, PG; Medeiros, LM; Souza, CM; Stahlschmidt, R, 2020) |
| "We report a case of local recurrence of breast cancer 8 years after mastectomy." | 1.56 | [Local Recurrence of Breast Cancer Eight Years after Mastectomy-A Case Report]. ( Adachi, K; Hirano, T; Sakurai, K; Suzuki, S, 2020) |
| "Women with breast cancer often experience multiple concurrent symptoms during AI therapy." | 1.51 | Impact of chemotherapy on symptoms and symptom clusters in postmenopausal women with breast cancer prior to aromatase inhibitor therapy. ( Bender, CM; Conley, YP; Li, H; Marsland, AL; Sereika, SM, 2019) |
| "Metastatic breast cancer (MBC) represents a wide spectrum of heterogeneous conditions with different secondary spread sites, time to relapse and biology." | 1.51 | Long-Term Survival and Complete Response to ( Sedloev, T; Spirdonov, J; Spiridonova, T; Usheva, S; Vasileva-Slaveva, M; Vlahova, A, 2019) |
| "Psoriasis is a common chronic inflammatory skin disorder that is characterized by scaly, erythematous, sharply demarcated plaques." | 1.48 | A Case of Psoriasis Complicated by Breast Cancer after Systemic Treatments Including Biologics. ( Iwatsuki, K; Katayama, N; Morizane, S; Motoki, T; Omori, M; Sugimoto, S, 2018) |
| "Radiation-induced morphea (RIM) is a circumscribed localized scleroderma that occurs most often in the breast." | 1.48 | Radiation-induced morphea-a rare but severe late effect of adjuvant breast irradiation : Case report and review of the literature. ( Bjelic-Radisic, V; Kapp, KS; Partl, R; Pötscher, M; Regitnig, P; Tauber, G, 2018) |
| "The risk of OFR during AI treatment in breast cancer patients with chemotherapy-induced ovarian function failure is relevant, even beyond 45 years." | 1.46 | Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure. ( de Boer, M; de Graaf, H; de Roos, WK; Erdkamp, FLG; Honkoop, AH; Imholz, ALT; Kitzen, JJEM; Kroep, JR; Linn, SC; Peer, PGM; Seynaeve, CM; Smorenburg, CH; Swinkels, ACP; Tjan-Heijnen, VCG; van den Berkmortel, FWPJ; van der Sangen, MJC; van Hellemond, IEG; Vriens, IJH, 2017) |
| "This effect was ER dependent as breast cancer cells with undetectable levels of ER failed to exhibit metabolic plasticity." | 1.43 | miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors. ( Bacci, M; Chiarugi, P; Dowsett, M; Fearns, A; Gao, Q; Giannoni, E; Isacke, CM; Martin, LA; Morandi, A; Pintus, G; Ribas, R; Taddei, ML, 2016) |
| "Breast cancer is one of the most common malignancies in women." | 1.43 | Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study. ( Arpino, G; De Placido, G; De Placido, S; De Rosa, P; Locci, M; Nazzaro, G; Pagano, T; Schettini, F; Vallone, R, 2016) |
| "106 patients treated for breast cancer at Southampton University Hospital with PHT without surgery were identified (Mean age 84." | 1.42 | Tumour grade on core biopsy and evidence of axillary involvement on ultrasound predicts response in elderly co-morbid patients treated with primary hormone therapy for oestrogen receptor positive breast carcinoma. ( Cutress, RI; Layfield, DM; Mohamud, M; Odofin, O; Royle, GT; Walsh, C, 2015) |
| "Up to 50% of breast cancer cases occur in patients over the age of 65 years." | 1.42 | Primary Hormonal Therapy for Elderly Breast Cancer Patients: Single Institution Experience. ( Abehsera, D; de Santiago, J; Panal, M; Revello, R; Sánchez-Mendez, JI; Zapardiel, I, 2015) |
| "Although approximately 60 % of breast cancers in premenopausal women are HR positive, the role of neoadjuvant ET in this population is not well defined." | 1.42 | Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience. ( Barbie, TU; Ma, C; Margenthaler, JA, 2015) |
| "Breast cancer is the most frequent primary site of metastasis to the uterine corpus, with invasive lobular carcinoma more likely to spread to gynecologic organs than invasive ductal carcinoma." | 1.42 | Solitary uterine metastasis of invasive lobular carcinoma after adjuvant endocrine therapy: a case report. ( Akagi, K; Hayasaka, A; Igeta, S; Ishigaki, N; Iwahashi, H; Kudo, T; Makino, H; Matsuura, R; Sakurada, J; Shima, T; Suzuki, H; Toyoshima, M; Yoshinaga, K, 2015) |
| "As most node-positive patients with HR+ breast cancer currently receive adjuvant chemotherapy improved methods for characterization of individuals' metastasis risk are needed to reduce overtreatment." | 1.42 | Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence ( Balic, M; Cowens, JW; Cuzick, J; Dowsett, M; Dubsky, P; Ferree, S; Fesl, C; Filipits, M; Gnant, M; Greil, R; Jakesz, R; Lopez-Knowles, E; Nielsen, T; Rudas, M; Schaper, C; Sestak, I; Stoeger, H, 2015) |
| "Anastrozole was then tested in vivo on mice, which received subcutaneous drug injections for 1 week." | 1.42 | Marketed Drugs Can Inhibit Cytochrome P450 27A1, a Potential New Target for Breast Cancer Adjuvant Therapy. ( Lin, JB; Mast, N; Pikuleva, IA, 2015) |
| "Premenopausal patients with breast cancer and more than 10 positive axillary nodes (BC>10) have a poor prognosis: In these patients the best adjuvant therapy (CT) has not yet been established." | 1.42 | Adjuvant Ovarian Suppression, High-dose Chemotherapy and Immunotherapy for Premenopausal Patients with High-risk Breast Cancer. ( Bratta, M; Candeloro, G; D'Orazi, V; Fumagalli, LA; Pasta, V; Rea, S; Recchia, F; Rosselli, M, 2015) |
| "Anastrozole (ANS) was loaded on the GO-IOI and GO-IOF via simple stirring method to form GO-IOA and GO-IOFA respectively." | 1.40 | Graphene oxide based magnetic nanocomposites for efficient treatment of breast cancer. ( Bari, SB; Chaudhari, NS; Deshmukh, PK; Pandey, AP; Patil, PO; Tekade, AR, 2014) |
| "A solitary pulmonary metastasis from breast cancer with a disease-free interval of longer than 15 years has been quite rarely reported." | 1.40 | [Pulmonary metastasis from breast cancer 38 years after mastectomy; report of a case]. ( Andou, A; Higashi, R; Okutani, D; Yamadori, I, 2014) |
| "A 48-year old woman with metastatic breast cancer and extensive bone marrow infiltration was admitted with extreme lethargy, jaundice and deranged liver function tests." | 1.40 | An unusual cause of jaundice in a patient with breast cancer. ( Evans, A; Lacey, R, 2014) |
| "Median time to first report of joint pain was 7 weeks (range, 1-38)." | 1.39 | Anastrozole-associated joint pain and other symptoms in patients with breast cancer. ( Cleeland, CS; Giordano, SH; Lu, H; Malveaux, D; Saleeba, AK; Shi, Q, 2013) |
| "Obesity is associated with an increased body aromatisation and may be a cause of insufficient estradiol depletion." | 1.39 | Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer. ( Dressel-Ban, G; Dubsky, P; Exner, R; Fitzal, F; Gnant, M; Hadji, P; Königsberg, R; Maroske, M; Pfeiler, G; Seifert, M; Singer, C; Zellinger, J, 2013) |
| "ER+/HER2- breast cancers have a proclivity for late recurrence." | 1.39 | The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. ( Bachner, M; Brase, JC; Dietze, O; Dubsky, P; Filipits, M; Fisch, K; Gehrmann, MC; Gnant, M; Greil, R; Jakesz, R; Klug, E; Kronenwett, R; Luisser, I; Mayr, D; Petry, C; Rudas, M; Schmidt, M; Sedivy, R; Singer, CF; Weber, KE, 2013) |
| "Primary breast carcinomas were obtained from 112 women who received AI therapy after failing adjuvant tamoxifen therapy and developing recurrent breast cancer." | 1.39 | Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness. ( Bulun, SE; Khan, SA; Lin, Z; Moy, I; Rademaker, AW; Reierstad, S, 2013) |
| "02) and grade III-IV adverse events." | 1.39 | Efficacy and safety of Trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients. ( Chen, ML; Li, K; Zhang, J; Zhu, ZL, 2013) |
| "Blepharitis was noted in 68 of 82 eyes (73%), decreased or poor tear function in 24 eyes (29%), conjunctival injection in 18 eyes (22%) and superficial punctate keratitis in 12 eyes (29%)." | 1.39 | Dry eye syndrome in aromatase inhibitor users. ( Hammersmith, KM; Nagra, PK; Nottage, JM; Rapuano, CJ; Turaka, K, 2013) |
| "To test this, we examined if accidental trauma or surgery, unrelated to the original cancer, might stimulate the growth of dormant micrometastases and be related to an increase in the recurrence rate in the period after the event." | 1.38 | Does trauma or an intercurrent surgical intervention lead to a short-term increase in breast cancer recurrence rates? ( Allawi, Z; Baum, M; Cuzick, J, 2012) |
| "The percentage of women≥75 years with breast cancer receiving PET in the south of the Netherlands decreased from 23% in the period 1988-1992 to 12% in 1997-2000, and increased to 29% in 2005-2008." | 1.38 | Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer. ( Hutschemaekers, S; Nieuwenhuijzen, GA; Roukema, JA; Tjan-Heijnen, VC; van der Sangen, MJ; Voogd, AC; Wink, CJ; Woensdregt, K, 2012) |
| "Patient acceptance of SERMs for breast cancer prevention is low due to toxicities." | 1.38 | Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer. ( Akar, U; Arun, B; Brewster, A; Buzdar, AU; Esteva, FJ; Green, M; Gutierrez-Barrera, A; Hortobagyi, GN; Liu, D; Rivera, E; Sneige, N; Valero, V, 2012) |
| "Arthralgias have been frequently cited as the primary reason for discontinuation of AI therapy." | 1.38 | Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic. ( Carro, G; Harper, A; Hui, W; Lawton, J; Menas, P; Merkel, D, 2012) |
| "In patients with mild or severe osteopenia or osteoporosis, treated with A + R, no age effect was observed for LS or HP (p = 0." | 1.38 | Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. ( Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2012) |
| "The majority of breast tumors at primary diagnosis are estrogen receptor positive (ER+)." | 1.38 | Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer. ( Dowsett, M; Dunbier, A; Ghazoui, Z; Martin, LA; Pancholi, S; Weigel, MT, 2012) |
| "Several methods available to cure the breast cancer based on stage." | 1.38 | Impact of Aromatase protein variants and drug interactions in breast cancer: a molecular docking approach. ( Kalyan, CS; Naresh, B; Pawar, SC; Priyamvada Devi, A; Setti, A; Venugopal Rao, V, 2012) |
| "When anastrozole was compared with letrozole in the subgroup analysis no difference with regard to DFS and overall survival was detected." | 1.38 | Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index. ( Aksoy, S; Altundag, K; Sendur, MA; Zengin, N, 2012) |
| "Due to the recognition and diagnosis of breast cancer in increasingly early stages, quality of life becomes an important part of treatment beyond the efficacy indicators." | 1.38 | [Quality of life analysis of postmenopausal, early breast cancer patients treated with anastrozole (RADAR-II)]. ( Horváth, Z, 2012) |
| "We diagnosed her with left breast cancer(luminal A type) T2N0M0, stage IIA." | 1.38 | [A successful case of a super-elderly breast cancer patient treated with hormone therapy]. ( Aomatsu, N; Asano, Y; Hirakawa, K; Ishikawa, T; Kashiwagi, S; Kawajiri, H; Morisaki, T; Nakamura, M; Onoda, N; Takashima, T, 2012) |
| "Overall, the breast cancer patients demonstrated significantly lower values for volumetric bone density and content at the radius and tibia compared with healthy postmenopausal women." | 1.37 | Cortical and trabecular bone at the radius and tibia in postmenopausal breast cancer patients: a Peripheral Quantitative Computed Tomography (pQCT) study. ( Adachi, JD; Gordon, C; Papaioannou, A; Szabo, KA; Tozer, R; Webber, CE, 2011) |
| "Two hundred and ninety-two breast cancer patients who had undergone breast-conserving surgery and been treated with Tam or Ana, with or without RT, were retrospectively analyzed." | 1.37 | Risk of Ipsilateral breast tumor recurrence in patients treated with Tamoxifen or Anastrozole following breast-conserving surgery with or without radiotherapy. ( Inaji, H; Ishitobi, M; Komoike, Y; Koyama, H; Motomura, K; Nakahara, S, 2011) |
| "The majority of breast cancer patients who have estrogen receptor positive (ER(+)) tumors whose proliferation is reduced after estrogen deprivation by aromatase inhibitors (AI)." | 1.37 | Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor-treated ER-positive breast cancer. ( Anderson, H; Buffa, FM; Detre, S; Dexter, T; Dowsett, M; Dunbier, AK; Ghazoui, Z; Harris, AL; Salter, J; Smith, IE, 2011) |
| "Estrogen receptor (ER) positive primary breast cancers have a wide range of clinical outcomes." | 1.37 | Predictive algorithms for adjuvant therapy: TransATAC. ( Buzdar, AU; Cuzick, J; Dowsett, M; Forbes, J; Howell, A; Mallon, E; Pineda, S; Salter, J; Zabaglo, L, 2011) |
| "Twelve patients (15%) had disease progression while taking PHT." | 1.37 | Is primary endocrine therapy effective in treating the elderly, unfit patient with breast cancer? ( Champ, C; Gower-Thomas, K; Jones, M; Osborn, G; Vaughan-Williams, E, 2011) |
| "Endocrine therapy in the setting of breast cancer has undoubtedly advanced clinical outcomes in this disease, but treatment with endocrine therapy is accompanied by a wide spectrum of side effects." | 1.36 | Cognitive changes associated with endocrine therapy for breast cancer. ( Agrawal, K; Mortimer, JE; Onami, S; Pal, SK, 2010) |
| "Rectal metastases from breast carcinomas are very rare." | 1.36 | Rectal metastasis from lobular carcinoma of the breast: a case report. ( Balja, MP; Knezević, F; Sitić, S; Stanec, M; Supić, DK; Vrdoljak, DV, 2010) |
| "Plasma samples of 310 breast cancer patients undergoing anti-estrogen therapy were analyzed." | 1.36 | Development and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of tamoxifen, anastrozole, and letrozole in human plasma and its application to a clinical study. ( Beer, B; Hubalek, M; Meraner, V; Oberacher, H; Oberguggenberger, A; Schubert, B, 2010) |
| "We performed a case-control genome-wide association study (GWAS) to identify single nucleotide polymorphisms (SNPs) associated with musculoskeletal adverse events (MS-AEs) in women treated with aromatase inhibitors (AIs) for early breast cancer." | 1.36 | Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. ( Batzler, A; Chapman, JA; Ellis, MJ; Flockhart, DA; Goetz, MP; Goss, PE; Ingle, JN; Jenkins, GD; Kubo, M; Liu, M; Mushiroda, T; Nakamura, Y; Pater, J; Pritchard, KI; Rohrer, DC; Schaid, DJ; Shepherd, L; Stearns, V; Wang, L; Weinshilboum, RM, 2010) |
| "Anastrozole metabolism was characterized using human liver microsomes (HLMs), expressed cytochrome P450s (CYPs) and UDP-glucuronosyltransferases (UGTs)." | 1.36 | In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. ( Desta, Z; Flockhart, DA; Jeter, S; Kadlubar, SA; Kamdem, LK; Liu, Y; Ogburn, E; Ramirez, J; Ratain, MJ; Shahverdi, K; Stearns, V; Ward, BA, 2010) |
| "Anastrozole was superior to tamoxifen with respect to TTP (median values of 10." | 1.36 | [A case of stage IV breast cancer with bone metastases that responded well for long-term to hormonal therapy]. ( Kawachi, H; Kubota, K; Kuwayama, T; Nakagawa, T; Oda, G; Sato, T; Sugihara, K; Yamamoto, K, 2010) |
| "University of Colorado Cancer Center breast cancer patients treated with aromatase inhibitor therapy during July 2005 through July 2006 were studied." | 1.35 | Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors. ( Gibson, K; O'Bryant, CL, 2008) |
| "The primary end point is breast cancer incidence, but major efforts are also being directed at minimizing any fracture risk." | 1.35 | IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. ( Cuzick, J, 2008) |
| "Anastrozole therapy is a useful treatment for postmenopausal woman with ER-positive recurrent breast cancer." | 1.35 | [A case of recurrent breast cancer with multiple lung metastases responding to anastrozole monotherapy]. ( Hashida, S; Hirano, Y; Iga, K; Inukai, M; Ito, M; Kanaya, Y; Maruyama, S; Shimo, T; Yokoyama, N, 2008) |
| "This case is an example of breast cancer presenting with paraneoplastic manifestations." | 1.35 | A paraneoplastic manifestation of metastatic breast cancer responding to endocrine therapy: a case report. ( Cheung, KL; Haynes, AP; Wood, JP, 2008) |
| "In this population, ERalpha+ breast cancer also appears to have a less aggressive biological profile favouring better hormone sensitivity." | 1.35 | Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapy. ( Agrawal, A; Aleskandrany, M; Cheung, KL; Ellis, IO; Green, AR; Hassell, K; Morgan, DA; Okunade, G; Paish, EC; Winterbottom, L; Ying, M, 2009) |
| "Lobular carcinoma is the most common type of breast cancer that metastasizes to the uterus." | 1.35 | Metastasis of lobular breast carcinoma to the uterus in a patient under anastrozole therapy. ( Barisik, NO; Bilici, A; Gumus, M; Salepci, T; Salman, T; Seker, M; Ustaalioglu, BB; Yaylaci, M, 2009) |
| "The results indicate that, in some breast cancer patients with ordinary menopause, E2 rebounds following AI therapy." | 1.35 | Serum estradiol should be monitored not only during the peri-menopausal period but also the post-menopausal period at the time of aromatase inhibitor administration. ( Hirose, T; Honda, J; Kira, M; Nagao, T; Nakamura, Y; Sasa, M; Takahashi, M; Tangoku, A; Zembutsu, H, 2009) |
| "We diagnosed it as inflammatory breast cancer with positive hormone receptor (ER+, PgR+) and unexpression of HER2 (HercepTest 1 +)." | 1.35 | [A case of inflammatory breast cancer responding to anastrozole]. ( Kubota, K; Kuwayama, T; Nakagawa, T; Sato, T; Sugihara, K; Suzuki, S, 2009) |
| "The current status of breast cancer prevention efforts was examined." | 1.35 | Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference. ( Brodie, AM; Buzdar, AU; Come, SE; Coombes, RC; Goss, PE; Ingle, JN; Johnston, SRD; Miller, WR; Pritchard, KI; Winer, EP; Zujewski, JA, 2008) |
| "Letrozole was chosen for the next therapy." | 1.35 | [A case of elderly breast cancer achieving partial response by letrozole with stable disease to anastrozole as neoadjuvant endocrine therapy]. ( Kihara, M; Miyauchi, A, 2008) |
| "Fifty-two advanced and female breast cancer patients with measurable and /or bone valuable tumor lesions were observed from June 2003 to September 2006." | 1.34 | [Clinical study of aromatase inhibitors in advanced breast cancer]. ( Hou, KY; Ji, JF; Jia, TZ; Li, HP; Wang, MP; Wang, YF; Xiao, Y; Zhao, HM, 2007) |
| "Subjects were 17 postmenopausal breast cancer patients (mean age, 63." | 1.34 | Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients. ( Douchi, T; Iwamoto, I; Kosha, S; Rai, Y; Sagara, Y; Yonehara, Y, 2007) |
| "With these treatments, joint pain is frequent (30% to 40%) and quite often disabling (5% to 10%)." | 1.34 | Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome. ( Borg, S; De Lafontan, B; Laroche, M; Lassoued, S; Roché, H, 2007) |
| "Forty-two breast carcinomas in 41 women were treated with HT and concurrent RT to the breast +/- lymph node bearing areas." | 1.34 | Responses to concurrent radiotherapy and hormone-therapy and outcome for large breast cancers in post-menopausal women. ( Antoni, G; Bollet, MA; Campana, F; Cottu, P; Dendale, R; Fourquet, A; Kirova, YM; Laki, F; Pierga, JY; Salmon, R; Sigal-Zafrani, B, 2007) |
| "The biology of metastatic breast cancer may demand palliation by oesophageal intubation or stenting combined with adjuvant chemo, radio or hormonal therapy in such instances." | 1.34 | [Solitary oesophageal metastasis of breast cancer after 17 years latency]. ( Kotsis, L; Kovács, O; Krasznai, G, 2007) |
| "It is well-known that breast cancer easily metastasizes to the bone, liver, pleura and lymph node, but rarely to the ovarium or peritoneum when chemotherapy is conducted." | 1.33 | [Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report]. ( Deguchi, Y; Kamimura, K; Kaneko, I; Kii, E; Murata, T; Nonogaki, H; Tanaka, T; Tsubono, M; Yasumizu, R, 2005) |
| "The San Antonio Breast Cancer Symposium is now considered the most important international breast cancer meeting worldwide." | 1.33 | Selected highlights from the 27th San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2004. ( Ponzone, R; Sismondi, P, 2005) |
| "This is the first report of breast carcinoma metastatic to the endometrium in a patient on adjuvant anastrozole therapy." | 1.33 | Lobular carcinoma of the breast metastatic to the uterus in a patient under adjuvant anastrozole therapy. ( Bolat, F; Erkanli, S; Haberal, A; Kayaselcuk, F; Kuscu, E; Sakalli, H, 2006) |
| "When tamoxifen therapy was discontinued after 4 years of use in the first patient, her DM rash worsened and remained difficult to control with conventional immunosuppressant medication." | 1.33 | Improvement in dermatomyositis rash associated with the use of antiestrogen medication. ( Sereda, D; Werth, VP, 2006) |
| "Metastatic breast cancer (MBC) is incurable in most cases." | 1.33 | Does survival increase in metastatic breast cancer with recently available anticancer drugs? ( Abrial, C; Cabrespine, A; Chollet, P; Cure, H; Durando, X; Ferriere, JP; Kwiatkowski, F; Leheurteur, M; Mouret-Reynier, MA; Penault-Llorca, F, 2006) |
| "Endocrine therapy for hormone-sensitive breast cancer is a well-established treatment option, both in adjuvant and palliative settings." | 1.33 | Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis. ( Langenegger, T; Schiesser, D; Thürlimann, B; Wahl, P, 2006) |
| "The primary use of ERalpha in breast cancer is for predicting likely response to hormone treatment." | 1.33 | Estrogen receptors: role in breast cancer. ( Duffy, MJ, 2006) |
| "MRI study revealed brain metastases with a diameter of 1 cm in her right midbrain in April 2005, so a gamma knife radio-surgery was performed." | 1.33 | [Two patients having recurrent breast cancer with brain metastases well controlled with a gamma knife radio-surgery]. ( Endo, W; Fujie, Y; Fukunaga, H; Hojo, S; Maeura, Y; Okada, Y; Ota, H; Yoshioka, S, 2006) |
| "We describe a woman with metastatic breast cancer treated with multiple rounds of prior cytotoxic and endocrine therapies, who presented with ipsilateral diaphragmatic paralysis." | 1.32 | Anastrozole-induced remission of diaphragmatic paralysis from metastatic breast cancer treated with multiple prior therapies. ( Okamura, Y; Sakurai, T; Shimizu, Y; Suzuma, T; Umemura, T; Yang, QF; Yoshimura, G, 2003) |
| "Modern treatment of cancer of the breast is based on established prognostic factors (patient age, receptor status, tumor size, lymph node involvement, tumor grading), and thus takes the patient's individual risk profile into account." | 1.32 | [Hormone therapy, chemotherapy and immunotherapy in breast carcinoma. The best strategy for your patient]. ( Höffken, K; Sayer, HG, 2003) |
| "Letrozole was superior to anastrozole with respect to both quality of life and toxicity evaluations." | 1.32 | Examining quality of life issues in relation to endocrine therapy for breast cancer. ( Thomas, R, 2003) |
| " As a result, the long-term use of anti-oestrogens may have potential consequences for cognition." | 1.32 | The effects of hormone therapy on cognition in breast cancer. ( Fallowfield, L; Howell, T; Jenkins, V; Shilling, V, 2003) |
| "For metastatic breast cancer patients who have hormone receptor-positive tumors, hormonal therapy aiming at optimal palliation and prolongation of life is the initial treatment of choice." | 1.32 | [Combination therapy with Anastrozole and 5'-DFUR as a treatment for metastatic breast cancer]. ( Fuchimoto, S; Inagaki, M; Miyoshi, K; Nakagawa, T; Ohsaki, T; Ohtsuka, S; Yumura, M, 2004) |
| "Osteoprotegerin (OPG) is a potent antiresorptive molecule that binds NF-kappaB ligand, the final effector for osteoclastogenesis." | 1.32 | Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. ( Bajetta, E; Bombardieri, E; Del Vecchio, M; Ferrari, L; La Torre, I; Longarini, R; Martinetti, A; Paleari, D; Seregni, E; Toffolatti, L; Zilembo, N, 2004) |
| "Anastrozole therapy is a useful treatment for postmenopausal women with ER positive advanced breast cancer." | 1.31 | [Advanced breast cancer with lung and pleural metastases responsive to anastrozole--a case report]. ( Enomoto, K; Kinoshita, T; Nishimura, M; Okamura, Y; Oura, S; Sakurai, T; Yokochi, H, 2002) |
| "Estrone and E(1)S were converted into E(2), and all three estrogen fractions were finally measured by the same highly sensitive and specific radioimmunoassay using estradiol-6-(O-carboxymethyl)-oximino-2-(2--iodo-histamine) as a ligand." | 1.31 | A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue. ( Berntsen, H; Geisler, J; Lonning, PE, 2000) |
| "Anastrozole, 1 mg/day, was given once daily for 16 days." | 1.31 | Effects of the aromatase inhibitor anastrozole on serum oestrogens in Japanese and Caucasian women. ( Donaldson, K; Dowsett, M; Tsuboi, M; Wong, J; Yates, R, 2000) |
| "Estrogen receptor (ER)-positive breast cancers initially respond well to estrogen ablation treatment but finally acquire refractoriness, the phenomenon that is a major clinical problem." | 1.31 | Gonadotropins stimulate growth of MCF-7 human breast cancer cells by promoting intracellular conversion of adrenal androgens to estrogens. ( Fujita, T; Kaiho, S; Kuwabara, K; Ogata, E; Oizumi, I; Okazaki, T; Tanaka, Y, 2000) |
| "Among endocrine therapies used to treat breast cancer, fulvestrant is unique not only in its mechanism of action but also in its mode of administration." | 1.31 | The oncology nurse's role in educating patients on endocrine therapy for metastatic breast cancer--focus on fulvestrant. ( Lynn, J, 2002) |
| "Letrozole was found to be a highly potent inhibitor of tumor proliferation and more effective than tamoxifen." | 1.30 | Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer. ( Brodie, A; Liu, Y; Long, B; Lu, Q; Wang, JP; Yue, W, 1998) |
| "Advanced breast cancer patients' quality of life was high, showing the efficacy of endocrine therapy, but women with primary disease reported better physical, social, and functional well-being and fewer breast cancer concerns." | 1.30 | Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. ( Benson, S; Cella, D; Fallowfield, LJ; Howell, A; Leaity, SK, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 48 (4.44) | 18.2507 |
| 2000's | 504 (46.58) | 29.6817 |
| 2010's | 433 (40.02) | 24.3611 |
| 2020's | 97 (8.96) | 2.80 |
| Authors | Studies |
|---|---|
| Lézé, MP | 1 |
| Palusczak, A | 1 |
| Hartmann, RW | 1 |
| Le Borgne, M | 1 |
| Muftuoglu, Y | 1 |
| Mustata, G | 1 |
| Thomas, MP | 1 |
| Potter, BV | 1 |
| Khan, MZI | 1 |
| Uzair, M | 1 |
| Nazli, A | 1 |
| Chen, JZ | 1 |
| Minamoto, K | 1 |
| Ikeda, T | 6 |
| Araki, K | 1 |
| Hamada, M | 1 |
| Takahashi, M | 2 |
| Tokunaga, E | 1 |
| Mori, J | 1 |
| Tanizawa, Y | 1 |
| van der Walt, JS | 1 |
| Kawaguchi, T | 1 |
| Goetz, MP | 12 |
| Toi, M | 6 |
| Cairns, J | 6 |
| Ingle, JN | 26 |
| Kalari, KR | 8 |
| Weinshilboum, RM | 10 |
| Gao, H | 2 |
| Li, H | 3 |
| Bari, MG | 2 |
| Wang, L | 9 |
| da Costa, REAR | 1 |
| Dos Reis, CA | 1 |
| Moura, RD | 1 |
| Araújo, ALN | 1 |
| de Oliveira, FTR | 1 |
| Vieira, SC | 1 |
| Moore, HCF | 1 |
| Barlow, WE | 5 |
| Somlo, G | 1 |
| Gralow, JR | 5 |
| Schott, AF | 2 |
| Hayes, DF | 7 |
| Kuhn, P | 1 |
| Hicks, JB | 1 |
| Welter, L | 1 |
| Dy, PA | 1 |
| Yeon, CH | 1 |
| Conlin, AK | 1 |
| Balcueva, E | 1 |
| Lew, DL | 3 |
| Tripathy, D | 2 |
| Pusztai, L | 2 |
| Hortobagyi, GN | 10 |
| Cheng, J | 1 |
| Ruan, X | 1 |
| Du, J | 1 |
| Jin, F | 1 |
| Li, Y | 3 |
| Liu, X | 2 |
| Wang, H | 2 |
| Gu, M | 1 |
| Mueck, AO | 1 |
| Bertelsen, BE | 1 |
| Viste, K | 1 |
| Helland, T | 1 |
| Hagland, M | 1 |
| Søiland, H | 1 |
| Geisler, J | 14 |
| Lende, TH | 1 |
| Lønning, PE | 17 |
| Sagen, JV | 1 |
| Mellgren, G | 2 |
| Almås, B | 1 |
| Liang, JJ | 1 |
| Yu, WL | 1 |
| Yang, L | 1 |
| Xie, BH | 1 |
| Qin, KM | 1 |
| Yin, YP | 1 |
| Yan, JJ | 1 |
| Gong, S | 1 |
| Liu, TY | 1 |
| Zhou, HB | 1 |
| Hong, K | 1 |
| Oshima, K | 1 |
| Kikumori, K | 1 |
| Yanagawa, T | 1 |
| Egawa, C | 4 |
| Takatsuka, Y | 9 |
| Shinke, G | 1 |
| Katsuyama, S | 1 |
| Kawai, K | 1 |
| Hiraki, M | 1 |
| Katsura, Y | 2 |
| Ohmura, Y | 1 |
| Masuzawa, T | 1 |
| Hata, T | 1 |
| Takeda, Y | 2 |
| Murata, K | 1 |
| Park, C | 2 |
| Park, SK | 1 |
| Woo, A | 1 |
| Ng, BP | 1 |
| Wang, X | 7 |
| Adamson, BJ | 1 |
| Briggs, A | 1 |
| Tan, K | 1 |
| Bargo, D | 1 |
| Ghosh, S | 1 |
| Baxi, S | 1 |
| Ramsey, S | 1 |
| Susanna, KJ | 1 |
| Gajbhiye, R | 1 |
| Sarmah, B | 1 |
| Pawar, SD | 1 |
| Mehta, P | 1 |
| Murty, US | 1 |
| Ravichandiran, V | 1 |
| Alexander, A | 1 |
| Kumar, P | 1 |
| Pece, S | 1 |
| Sestak, I | 30 |
| Montani, F | 1 |
| Tillhon, M | 1 |
| Maisonneuve, P | 1 |
| Freddi, S | 1 |
| Chu, K | 1 |
| Colleoni, M | 3 |
| Veronesi, P | 1 |
| Disalvatore, D | 1 |
| Viale, G | 3 |
| Buus, R | 6 |
| Cuzick, J | 62 |
| Dowsett, M | 82 |
| Di Fiore, PP | 1 |
| Mizuta, T | 1 |
| Kato, M | 1 |
| Heudel, P | 1 |
| Frenel, JS | 2 |
| Dalban, C | 2 |
| Bazan, F | 2 |
| Joly, F | 1 |
| Arnaud, A | 1 |
| Abdeddaim, C | 1 |
| Chevalier-Place, A | 1 |
| Augereau, P | 1 |
| Pautier, P | 1 |
| Chakiba, C | 1 |
| You, B | 1 |
| Lancry-Lecomte, L | 1 |
| Garin, G | 2 |
| Marcel, V | 2 |
| Diaz, JJ | 2 |
| Treilleux, I | 3 |
| Pérol, D | 2 |
| Fabbro, M | 2 |
| Ray-Coquard, I | 2 |
| Maruthanila, VL | 1 |
| Elancheran, R | 1 |
| Mirunalini, S | 1 |
| Ding, S | 1 |
| Liu, S | 2 |
| Chen, Y | 2 |
| Peng, Y | 1 |
| Zheng, J | 1 |
| Mo, H | 1 |
| Ma, F | 2 |
| Li, Q | 7 |
| Zhang, P | 5 |
| Yuan, P | 3 |
| Wang, J | 2 |
| Luo, Y | 2 |
| Cai, R | 1 |
| Xu, B | 4 |
| McCall, MK | 1 |
| Sereika, SM | 6 |
| Snader, S | 1 |
| Lavanchy, A | 1 |
| Rosenzweig, MQ | 3 |
| Conley, YP | 4 |
| Beumer, JH | 1 |
| Bender, CM | 7 |
| Acconcia, F | 1 |
| Mourksi, NE | 1 |
| Colombe-Vermorel, A | 1 |
| Odeyer, L | 1 |
| Simioni, V | 1 |
| Abadie-Lacourtoisie, S | 1 |
| Coquan, E | 1 |
| Martinez, S | 1 |
| Tabone-Eglinger, S | 1 |
| Chabaud, S | 1 |
| Heudel, PE | 2 |
| Tanaka, Y | 5 |
| Oota, R | 3 |
| Takagi, Y | 3 |
| Kodama, W | 3 |
| Nishimura, K | 3 |
| Hamasaki, T | 3 |
| Fukino, S | 3 |
| Suo, K | 3 |
| Ward, MC | 2 |
| Recht, A | 2 |
| Vicini, F | 2 |
| Al-Hilli, Z | 1 |
| Asha, W | 1 |
| Chadha, M | 2 |
| Abraham, A | 1 |
| Thaker, N | 1 |
| Khan, AJ | 1 |
| Keisch, M | 2 |
| Shah, C | 2 |
| Hunt, KK | 1 |
| Suman, VJ | 6 |
| Wingate, HF | 1 |
| Leitch, AM | 1 |
| Unzeitig, G | 3 |
| Boughey, JC | 1 |
| Meric-Bernstam, F | 1 |
| Ellis, MJ | 25 |
| Olson, J | 2 |
| Li, YC | 1 |
| Deng, ZX | 1 |
| Wang, YJ | 1 |
| Xu, T | 1 |
| Sun, Q | 2 |
| Shen, SJ | 1 |
| Hollins, AW | 1 |
| Hein, RE | 1 |
| Atia, AN | 1 |
| Zhang, GX | 1 |
| Sergesketter, AR | 1 |
| Darner, G | 1 |
| Morris, M | 2 |
| Mithani, SK | 1 |
| Luo, B | 1 |
| Kong, L | 1 |
| Yuan, M | 1 |
| Heo, JH | 1 |
| Mehta, S | 1 |
| Han, S | 1 |
| Spencer, JC | 1 |
| Velez Oquendo, G | 1 |
| Adon, T | 1 |
| Shanmugarajan, D | 1 |
| Ather, H | 1 |
| Ansari, SMA | 1 |
| Hani, U | 1 |
| Madhunapantula, SV | 1 |
| Honnavalli, YK | 1 |
| Corpes, EF | 1 |
| Yanez, RJV | 1 |
| Silva, DMD | 1 |
| Leite, KM | 1 |
| Martins, MCT | 1 |
| Vieira, MM | 1 |
| Santos, CPRSD | 1 |
| Fernandes, AFC | 1 |
| Castro, RCMB | 1 |
| Iwase, T | 2 |
| Saji, S | 4 |
| Iijima, K | 1 |
| Higaki, K | 2 |
| Ohtani, S | 1 |
| Sato, Y | 3 |
| Hozumi, Y | 7 |
| Hasegawa, Y | 1 |
| Yanagita, Y | 5 |
| Takei, H | 8 |
| Tanaka, M | 3 |
| Masuoka, H | 1 |
| Tanabe, M | 1 |
| Komoike, Y | 6 |
| Nakamura, T | 2 |
| Ohtsu, H | 2 |
| Mukai, H | 4 |
| Zhang, Q | 1 |
| Tong, Z | 2 |
| Sun, T | 1 |
| Li, W | 2 |
| Ouyang, Q | 1 |
| Hu, X | 1 |
| Cheng, Y | 1 |
| Yan, M | 2 |
| Pan, Y | 1 |
| Teng, Y | 1 |
| Yan, X | 1 |
| Wang, Y | 2 |
| Xie, W | 1 |
| Zeng, X | 1 |
| Hu, C | 1 |
| Geng, C | 1 |
| Zhang, H | 2 |
| Wu, X | 1 |
| Zhong, J | 1 |
| Xu, J | 2 |
| Shi, Y | 2 |
| Wei, W | 2 |
| Bayaxi, N | 1 |
| Zhu, X | 1 |
| Salmon, RJ | 2 |
| Tsoi, H | 1 |
| Lok, J | 1 |
| Man, EP | 1 |
| Cheng, CN | 1 |
| Leung, MH | 1 |
| You, CP | 1 |
| Chan, SY | 1 |
| Chan, WL | 1 |
| Khoo, US | 1 |
| Rutherford, DV | 1 |
| Medley, S | 1 |
| Henderson, NC | 1 |
| Gersch, CL | 1 |
| Vandenberg, TA | 5 |
| Albain, KS | 6 |
| Dakhil, SR | 4 |
| Tirumali, NR | 4 |
| Mehta, RS | 4 |
| Kidwell, KM | 2 |
| Henry, NL | 4 |
| Rae, JM | 3 |
| Hertz, DL | 2 |
| Hurvitz, SA | 1 |
| Bardia, A | 1 |
| Quiroga, V | 1 |
| Park, YH | 2 |
| Blancas, I | 1 |
| Alonso-Romero, JL | 1 |
| Vasiliev, A | 1 |
| Adamchuk, H | 1 |
| Salgado, M | 1 |
| Yardley, DA | 2 |
| Berzoy, O | 1 |
| Zamora-Auñón, P | 1 |
| Chan, D | 1 |
| Spera, G | 1 |
| Xue, C | 2 |
| Ferreira, E | 1 |
| Badovinac Crnjevic, T | 1 |
| Pérez-Moreno, PD | 1 |
| López-Valverde, V | 1 |
| Steinseifer, J | 1 |
| Fernando, TM | 1 |
| Moore, HM | 1 |
| Fasching, PA | 3 |
| Jerusalem, G | 4 |
| Prat, A | 3 |
| Salgado, R | 1 |
| Reinisch, M | 1 |
| Saura, C | 1 |
| Ruiz-Borrego, M | 3 |
| Nikolinakos, P | 1 |
| Ades, F | 1 |
| Filian, J | 1 |
| Huang, N | 1 |
| Mazzei-Abba, A | 1 |
| Tolaney, SM | 1 |
| Arnachellen, D | 1 |
| Xulu, KR | 2 |
| Pillay, K | 1 |
| Augustine, TN | 3 |
| Calsavara, VF | 1 |
| Hays, RD | 1 |
| Kim, S | 2 |
| Luu, M | 1 |
| Diniz, MA | 1 |
| Gresham, G | 1 |
| Cecchini, RS | 3 |
| Yothers, G | 1 |
| Ganz, PA | 4 |
| Rogatko, A | 1 |
| Tighiouart, M | 1 |
| Kantor, O | 1 |
| King, TA | 2 |
| Jones, A | 2 |
| Glass, C | 1 |
| Leonard, SJ | 1 |
| Ogayo, ER | 1 |
| Mayer, EL | 1 |
| Chavez-MacGregor, M | 1 |
| Newman, LA | 1 |
| Freedman, RA | 1 |
| Mittendorf, EA | 1 |
| Poduje, S | 1 |
| Vujević, L | 1 |
| Filipović, N | 1 |
| Vučić, M | 1 |
| Buljan, M | 1 |
| Mahase, E | 1 |
| Lammers, SWM | 1 |
| Geurts, SME | 1 |
| van Hellemond, IEG | 5 |
| Swinkels, ACP | 5 |
| Smorenburg, CH | 5 |
| van der Sangen, MJC | 5 |
| Kroep, JR | 5 |
| de Graaf, H | 5 |
| Honkoop, AH | 5 |
| Erdkamp, FLG | 5 |
| de Roos, WK | 5 |
| Linn, SC | 5 |
| Imholz, ALT | 5 |
| Smidt, ML | 1 |
| Vriens, IJH | 3 |
| Tjan-Heijnen, VCG | 5 |
| Marsland, AL | 1 |
| Giuliano, M | 1 |
| Schettini, F | 2 |
| Rognoni, C | 1 |
| Milani, M | 1 |
| Bachelot, T | 4 |
| De Laurentiis, M | 2 |
| Thomas, G | 1 |
| De Placido, P | 1 |
| Arpino, G | 3 |
| De Placido, S | 3 |
| Cristofanilli, M | 4 |
| Giordano, A | 1 |
| Puglisi, F | 1 |
| Pistilli, B | 1 |
| Del Mastro, L | 3 |
| Venturini, S | 1 |
| Generali, D | 1 |
| Farkas, A | 1 |
| Vanderberg, R | 1 |
| Merriam, S | 1 |
| DiNardo, D | 1 |
| Barron, S | 2 |
| Loughman, T | 2 |
| Fender, B | 1 |
| Ruiz, CL | 1 |
| Dynoodt, P | 1 |
| Wang, CA | 1 |
| O'Leary, D | 2 |
| Gallagher, WM | 2 |
| Forbes, JF | 15 |
| Cawthorn, S | 2 |
| Mansel, RE | 2 |
| Loibl, S | 2 |
| Bonanni, B | 4 |
| Evans, DG | 2 |
| Howell, A | 49 |
| Chumsri, S | 1 |
| Thompson, EA | 1 |
| Liao, W | 1 |
| Huang, J | 2 |
| Wu, Q | 1 |
| Wen, F | 1 |
| Zhang, N | 1 |
| Zhou, K | 1 |
| Bai, L | 1 |
| Glaser, RL | 3 |
| York, AE | 1 |
| Dimitrakakis, C | 4 |
| He, T | 1 |
| Yang, W | 1 |
| Zhang, X | 4 |
| Li, P | 2 |
| Yang, D | 1 |
| Wu, Y | 2 |
| Fan, Y | 2 |
| Xiang, M | 1 |
| Huang, Q | 1 |
| Chen, J | 3 |
| Zhou, R | 1 |
| Lv, Q | 1 |
| Wei, M | 1 |
| Xu, YR | 1 |
| Liu, K | 1 |
| Wen, P | 1 |
| Boughdad, S | 1 |
| Champion, L | 1 |
| Becette, V | 3 |
| Cherel, P | 2 |
| Fourme, E | 2 |
| Lemonnier, J | 3 |
| Lerebours, F | 3 |
| Alberini, JL | 1 |
| Nicolini, A | 1 |
| Rossi, G | 1 |
| Ferrari, P | 1 |
| Morganti, R | 1 |
| Carpi, A | 1 |
| Li, M | 1 |
| Xiong, Y | 1 |
| Liao, C | 1 |
| He, Y | 2 |
| Duan, S | 1 |
| Yi, F | 1 |
| Wei, Y | 1 |
| Zhang, W | 1 |
| Petit, T | 1 |
| Shepherd, LE | 13 |
| Hoskin, TL | 2 |
| Singh, RJ | 1 |
| Desta, Z | 5 |
| Goss, PE | 23 |
| Chen, BE | 2 |
| Volz, B | 1 |
| Barman, P | 5 |
| Carlson, EE | 5 |
| Haddad, T | 1 |
| Goodnature, B | 3 |
| Cuellar, ME | 1 |
| Walters, MA | 1 |
| Correia, C | 1 |
| Kaufmann, SH | 1 |
| Fan, T | 1 |
| Fakolade, A | 1 |
| Xulu, K | 1 |
| Duarte, R | 2 |
| Augustine, T | 1 |
| Gelsomino, L | 1 |
| Giordano, C | 1 |
| Camera, G | 1 |
| Sisci, D | 1 |
| Marsico, S | 1 |
| Campana, A | 1 |
| Tarallo, R | 1 |
| Rinaldi, A | 1 |
| Fuqua, S | 2 |
| Leggio, A | 1 |
| Grande, F | 1 |
| Bonofiglio, D | 1 |
| Andò, S | 2 |
| Barone, I | 2 |
| Catalano, S | 1 |
| Krug, D | 1 |
| Duma, MN | 1 |
| Streff, A | 1 |
| Chu-Pilli, M | 1 |
| Stopeck, A | 1 |
| Chalasani, P | 1 |
| Bicer, T | 1 |
| Imamoglu, GI | 1 |
| Dogan, AS | 1 |
| Avarisli, NA | 1 |
| Kabatas, N | 1 |
| Bicer, BK | 1 |
| Gurdal, C | 1 |
| Maguire, M | 1 |
| Drumm, C | 1 |
| Woods, G | 1 |
| Mullally, W | 1 |
| Redmond, M | 1 |
| Grogan, L | 1 |
| O'Kane, M | 1 |
| Bojanic, K | 1 |
| Kuna, L | 1 |
| Bilic Curcic, I | 1 |
| Wagner, J | 1 |
| Smolic, R | 1 |
| Kralik, K | 1 |
| Kizivat, T | 1 |
| Ivanac, G | 1 |
| Vcev, A | 1 |
| Wu, GY | 1 |
| Smolic, M | 1 |
| Jamal, QMS | 1 |
| Kazi, A | 2 |
| Goloubeva, O | 1 |
| Schech, A | 1 |
| Yu, S | 2 |
| Sabnis, GJ | 3 |
| Benson, JR | 1 |
| Dumitru, D | 1 |
| Jatoi, I | 1 |
| Sun, J | 1 |
| Wang, Q | 2 |
| Gui, L | 1 |
| Zhang, S | 1 |
| Ma, S | 1 |
| Shepard, DS | 1 |
| Ritter, GA | 1 |
| Martell, RE | 1 |
| Thomas, CP | 1 |
| Erken, N | 1 |
| Dost Gunay, FS | 1 |
| Soysal, P | 1 |
| Isik, AT | 1 |
| Trabitzsch, J | 1 |
| Schenke, H | 1 |
| Borrie, AE | 1 |
| Rose, FA | 1 |
| Choi, YH | 1 |
| Perera, FE | 1 |
| Read, N | 1 |
| Sexton, T | 1 |
| Lock, M | 1 |
| Hahn, K | 1 |
| Younus, J | 1 |
| Logan, D | 1 |
| Potvin, K | 1 |
| Yaremko, B | 1 |
| Yu, E | 1 |
| Lenehan, J | 1 |
| Welch, S | 1 |
| Teft, WA | 1 |
| Kim, RB | 1 |
| Buzdar, AU | 38 |
| Robson, ME | 5 |
| Eyman Casey, A | 1 |
| Goodnature, BA | 1 |
| Haddad, TC | 1 |
| Wang, C | 3 |
| Lin, Y | 2 |
| Zhou, Y | 2 |
| Mao, F | 1 |
| Zhu, H | 1 |
| Guan, J | 1 |
| Shen, S | 1 |
| Huang, X | 2 |
| Chen, C | 1 |
| Yao, R | 1 |
| Zhao, J | 1 |
| Graham, D | 1 |
| DiNome, ML | 1 |
| Dudenkov, TM | 2 |
| Na, J | 1 |
| Weng, X | 1 |
| Lin, S | 1 |
| Liu, Y | 3 |
| Luo, S | 1 |
| Ming, WK | 1 |
| Huang, P | 3 |
| Fritzsche, D | 1 |
| Indorf, A | 1 |
| Miske, A | 1 |
| Banda, K | 1 |
| Kronenwett, R | 5 |
| Ferree, S | 7 |
| Schnabel, CA | 3 |
| Baehner, FL | 3 |
| Mallon, EA | 3 |
| Stahlschmidt, R | 2 |
| Ferracini, AC | 2 |
| Medeiros, LM | 2 |
| Souza, CM | 2 |
| Juliato, CRT | 2 |
| Mazzola, PG | 2 |
| Adachi, K | 1 |
| Suzuki, S | 2 |
| Hirano, T | 1 |
| Sakurai, K | 1 |
| Blake, G | 1 |
| Patel, R | 2 |
| Coleman, R | 2 |
| Eastell, R | 8 |
| Fitzal, F | 11 |
| Filipits, M | 8 |
| Fesl, C | 9 |
| Rudas, M | 8 |
| Greil, R | 16 |
| Balic, M | 7 |
| Moinfar, F | 1 |
| Herz, W | 1 |
| Dubsky, P | 18 |
| Bartsch, R | 5 |
| Schaper, C | 5 |
| Gnant, M | 26 |
| Agostinetto, E | 1 |
| Debien, V | 1 |
| Marta, GN | 1 |
| Lambertini, M | 1 |
| Piccart-Gebhart, M | 1 |
| de Azambuja, E | 1 |
| Inoue, K | 3 |
| Masuda, N | 8 |
| Iwata, H | 7 |
| Sohn, J | 3 |
| Hae Park, I | 1 |
| Im, SA | 2 |
| Chen, SC | 2 |
| Enatsu, S | 1 |
| Turner, PK | 1 |
| André, VAM | 1 |
| Hardebeck, MC | 1 |
| Sakaguchi, S | 1 |
| Sledge, GW | 7 |
| Filip-Psurska, B | 1 |
| Psurski, M | 1 |
| Anisiewicz, A | 1 |
| Libako, P | 1 |
| Zbrojewicz, E | 1 |
| Maciejewska, M | 1 |
| Chodyński, M | 1 |
| Kutner, A | 1 |
| Wietrzyk, J | 1 |
| Gilman, EA | 1 |
| Pruthi, S | 1 |
| Hofstatter, EW | 1 |
| Mussallem, DM | 1 |
| Mirfakhraee, S | 1 |
| Chan, AVC | 1 |
| Ganji, N | 1 |
| Abramowitz, J | 1 |
| Rinnerthaler, G | 1 |
| Steger, GG | 3 |
| Greil-Ressler, S | 1 |
| Heck, D | 2 |
| Jakesz, R | 19 |
| Thaler, J | 1 |
| Egle, D | 2 |
| Manfreda, D | 1 |
| Bjelic-Radisic, V | 6 |
| Wieder, U | 1 |
| Singer, CF | 7 |
| Melbinger-Zeinitzer, E | 1 |
| Haslbauer, F | 1 |
| Sevelda, P | 3 |
| Trapl, H | 1 |
| Wette, V | 2 |
| Wimmer, K | 1 |
| Gampenrieder, SP | 1 |
| Kacerovsky-Strobl, S | 1 |
| Suppan, C | 1 |
| Brunner, C | 1 |
| Deutschmann, C | 1 |
| Soelkner, L | 1 |
| Kainz, V | 1 |
| Bago-Horvath, Z | 3 |
| Regitnig, P | 2 |
| Halper, S | 1 |
| Hulla, W | 1 |
| Hlauschek, D | 1 |
| Augusto, TV | 1 |
| Amaral, C | 2 |
| Almeida, CF | 1 |
| Teixeira, N | 2 |
| Correia-da-Silva, G | 2 |
| Klar, N | 1 |
| Adams, S | 1 |
| Oberguggenberger, A | 3 |
| Meraner, V | 4 |
| Sztankay, M | 3 |
| Beer, B | 4 |
| Weigel, G | 1 |
| Oberacher, H | 4 |
| Kemmler, G | 3 |
| Czech, T | 1 |
| Holzner, B | 3 |
| Wildt, L | 2 |
| Sperner-Unterweger, B | 3 |
| Daniaux, M | 1 |
| Hubalek, M | 6 |
| Shavi, GV | 4 |
| Nayak, UY | 4 |
| Reddy, MS | 2 |
| Ginjupalli, K | 1 |
| Deshpande, PB | 4 |
| Averineni, RK | 1 |
| Udupa, N | 4 |
| Sadhu, SS | 1 |
| Danilenkoff, C | 1 |
| Raghavendra, R | 3 |
| Yang, Y | 1 |
| Pan, W | 1 |
| Tang, X | 1 |
| Wu, S | 2 |
| Sun, X | 1 |
| Lipton, A | 1 |
| Chapman, JW | 3 |
| Leitzel, K | 1 |
| Garg, A | 1 |
| Pritchard, KI | 15 |
| Budd, GT | 6 |
| Rabaglio, M | 3 |
| Han, L | 1 |
| Elliott, CR | 2 |
| Ali, SM | 1 |
| Bartlett, JMS | 1 |
| Ahmed, I | 1 |
| Regan, MM | 2 |
| Dell'Orto, P | 1 |
| Thürlimann, B | 12 |
| Seynaeve, C | 2 |
| Putter, H | 2 |
| Van de Velde, CJH | 1 |
| Brookes, CL | 1 |
| Rea, DW | 2 |
| Yanase, T | 1 |
| Kikuchi, A | 1 |
| Sasagawa, M | 1 |
| Honma, S | 1 |
| Goncalves, R | 2 |
| Reinert, T | 1 |
| Barros-Oliveira, MDC | 1 |
| Costa-Silva, DR | 1 |
| Andrade, DB | 1 |
| Borges, US | 1 |
| Tavares, CB | 1 |
| Borges, RS | 1 |
| Silva, JM | 1 |
| Silva, BBD | 1 |
| Hong, N | 1 |
| Yoon, HG | 1 |
| Seo, DH | 1 |
| Park, S | 1 |
| Kim, SI | 1 |
| Sohn, JH | 1 |
| Rhee, Y | 1 |
| Ding, H | 1 |
| Fang, L | 1 |
| Xin, W | 1 |
| Tong, Y | 1 |
| Zhou, Q | 1 |
| Klapko, O | 1 |
| Ghoulam, E | 1 |
| Jakate, S | 1 |
| Eswaran, S | 1 |
| Usha, L | 1 |
| Zhang, J | 3 |
| Huang, Y | 1 |
| Zheng, S | 1 |
| Wu, K | 2 |
| Heindl, A | 1 |
| Naidoo, K | 1 |
| Yuan, Y | 1 |
| Campone, M | 2 |
| Paluch-Shimon, S | 1 |
| Huober, J | 1 |
| Park, IH | 2 |
| Trédan, O | 1 |
| Manso, L | 1 |
| Freedman, OC | 4 |
| Garnica Jaliffe, G | 1 |
| Forrester, T | 1 |
| Frenzel, M | 1 |
| Barriga, S | 1 |
| Smith, IC | 1 |
| Bourayou, N | 1 |
| Di Leo, A | 4 |
| Correa de Mello, P | 1 |
| Brasil, OFM | 1 |
| Peer, PGM | 4 |
| van den Berkmortel, FWPJ | 4 |
| de Boer, M | 4 |
| Seynaeve, CM | 4 |
| Smith, SG | 1 |
| Niravath, P | 1 |
| Chen, B | 1 |
| Agarwal, SK | 1 |
| Welschhans, RL | 1 |
| Bongartz, T | 1 |
| Bartlett, J | 1 |
| Pritchard, K | 1 |
| Gelmon, K | 1 |
| Hilsenbeck, SG | 1 |
| Rimawi, MF | 2 |
| Osborne, CK | 8 |
| Chung, C | 1 |
| Strasser-Weippl, K | 2 |
| Sudan, G | 1 |
| Ramjeesingh, R | 1 |
| O'Shaughnessy, J | 3 |
| Parulekar, WR | 1 |
| Liedke, PER | 1 |
| Tian, W | 1 |
| Wu, M | 1 |
| Deng, Y | 2 |
| Alyafee, YA | 1 |
| Alaamery, M | 1 |
| Bawazeer, S | 1 |
| Almutairi, MS | 1 |
| Alghamdi, B | 1 |
| Alomran, N | 1 |
| Sheereen, A | 1 |
| Daghestani, M | 1 |
| Massadeh, S | 1 |
| Weiner, A | 1 |
| D'Andrea, GM | 1 |
| Huber, KM | 1 |
| Clayman, E | 1 |
| Kumar, A | 1 |
| Smith, P | 1 |
| Tsujio, G | 2 |
| Kashiwagi, S | 2 |
| Hatano, T | 1 |
| Asano, Y | 2 |
| Goto, W | 1 |
| Takada, K | 1 |
| Noda, S | 1 |
| Takashima, T | 3 |
| Onoda, N | 2 |
| Motomura, H | 1 |
| Hirakawa, K | 2 |
| Ohira, M | 1 |
| Mugitani, T | 1 |
| Hatakeyama, T | 1 |
| Sakai, T | 1 |
| Matsumura, A | 1 |
| Ogino, S | 1 |
| Akami, T | 1 |
| Okano, S | 1 |
| Denkert, C | 2 |
| Sgroi, D | 2 |
| Schnabel, C | 1 |
| Mallon, E | 3 |
| Noguchi, S | 17 |
| Robertson, JFR | 4 |
| Thirlwell, J | 2 |
| Fazal, M | 3 |
| Shao, Z | 4 |
| Wagner, LI | 1 |
| Zhao, F | 1 |
| Whelan, TJ | 3 |
| Mattar, BI | 1 |
| Bufill, JA | 1 |
| Schultz, WC | 1 |
| LaFrancis, IE | 1 |
| Nagargoje, GG | 1 |
| Vemuri, R | 1 |
| Nikcevich, DA | 1 |
| Cella, D | 6 |
| Nakayama, T | 1 |
| Sagara, Y | 10 |
| Matsunami, N | 1 |
| Miyoshi, Y | 3 |
| Taguchi, T | 5 |
| Aono, T | 1 |
| Ito, T | 2 |
| Kagimura, T | 1 |
| Dirix, LY | 1 |
| Gallo, C | 1 |
| Bisagni, G | 1 |
| Sarobba, MG | 1 |
| Riccardi, F | 1 |
| Russo, A | 1 |
| Cogoni, AA | 1 |
| Cognetti, F | 6 |
| Gori, S | 1 |
| Foglietta, J | 1 |
| Frassoldati, A | 3 |
| Amoroso, D | 2 |
| Laudadio, L | 1 |
| Moscetti, L | 1 |
| Montemurro, F | 2 |
| Verusio, C | 1 |
| Bernardo, A | 1 |
| Lorusso, V | 2 |
| Gravina, A | 1 |
| Moretti, G | 1 |
| Lauria, R | 1 |
| Lai, A | 1 |
| Mocerino, C | 1 |
| Rizzo, S | 1 |
| Nuzzo, F | 1 |
| Carlini, P | 6 |
| Perrone, F | 1 |
| Abubakar, MB | 2 |
| Gan, SH | 2 |
| Bozkaya, Y | 1 |
| Erdem, GU | 1 |
| Demirci, NS | 1 |
| Kitzen, JJEM | 1 |
| Cheung, KL | 10 |
| Degboe, A | 1 |
| Lichfield, J | 1 |
| Telford, C | 2 |
| Howell, SJ | 1 |
| Morizane, S | 1 |
| Sugimoto, S | 1 |
| Motoki, T | 1 |
| Katayama, N | 1 |
| Omori, M | 1 |
| Iwatsuki, K | 1 |
| Dodson, A | 1 |
| Merriman, JD | 3 |
| Gentry, AL | 2 |
| Casillo, FE | 2 |
| Koleck, TA | 2 |
| Brufsky, AM | 7 |
| McAuliffe, P | 1 |
| Zhu, Y | 1 |
| Shafaee, MN | 1 |
| Sathiamoorthi, S | 1 |
| Ruddy, KJ | 1 |
| Bakri, SJ | 1 |
| Partl, R | 1 |
| Tauber, G | 1 |
| Pötscher, M | 1 |
| Kapp, KS | 1 |
| Ogasa, Y | 1 |
| Kuwamura, T | 1 |
| Akiyoshi, T | 2 |
| Murakami, S | 1 |
| Tanaka, H | 1 |
| Umeda, S | 2 |
| Suematsu, F | 1 |
| Yeo, B | 2 |
| Brentnall, AR | 1 |
| Klintman, M | 1 |
| Cheang, MCU | 1 |
| Khabra, K | 1 |
| Gao, Q | 3 |
| Kim, JY | 1 |
| Jung, KH | 1 |
| Ro, J | 1 |
| Kim, JH | 1 |
| Kim, TY | 1 |
| Kim, SB | 1 |
| Lee, KS | 1 |
| Kim, GM | 1 |
| Kim, SH | 1 |
| Ahn, JS | 1 |
| Lee, KH | 1 |
| Ahn, JH | 1 |
| Im, YH | 2 |
| Liang, X | 1 |
| Briaux, A | 1 |
| Benoist, C | 1 |
| Boulai, A | 1 |
| Chemlali, W | 1 |
| Schnitzler, A | 1 |
| Baulande, S | 1 |
| Rivera, S | 2 |
| Mouret-Reynier, MA | 4 |
| Bouvet, LV | 1 |
| De La Motte Rouge, T | 1 |
| Callens, C | 1 |
| Li, L | 2 |
| Chang, B | 1 |
| Jiang, X | 1 |
| Fan, X | 1 |
| Li, T | 1 |
| Kariminia, S | 1 |
| Plummer, R | 1 |
| Verheul, HM | 1 |
| De Vos, FYFL | 1 |
| Leunen, K | 2 |
| Molife, LR | 1 |
| Rolfo, C | 1 |
| Grundtvig-Sørensen, P | 1 |
| De Grève, J | 1 |
| Rottey, S | 1 |
| Italiano, A | 1 |
| Spicer, J | 1 |
| Dirix, L | 2 |
| Goessl, C | 1 |
| Birkett, J | 1 |
| Spencer, S | 1 |
| Learoyd, M | 1 |
| Bailey, C | 1 |
| Dean, E | 1 |
| Kamaraju, S | 2 |
| Smith, E | 1 |
| Nattinger, AB | 1 |
| Laud, P | 1 |
| Neuner, J | 1 |
| Yan, Y | 1 |
| Zhang, L | 1 |
| Tan, L | 1 |
| Ma, X | 1 |
| Zhang, Y | 5 |
| Shao, S | 1 |
| Liu, J | 4 |
| Li, Z | 1 |
| Drokow, EK | 1 |
| Shi, X | 1 |
| Ren, J | 1 |
| Campbell, AM | 1 |
| Gallagher, R | 1 |
| Boyd, R | 1 |
| Carson, H | 1 |
| Harkin, DP | 1 |
| Wielogorska, E | 1 |
| Elliott, C | 3 |
| Savage, KI | 1 |
| McIntosh, SA | 1 |
| Anan, K | 3 |
| Mitsuyama, S | 4 |
| Kimura, M | 2 |
| Doihara, H | 2 |
| Komaki, K | 2 |
| Kusama, M | 2 |
| Livi, L | 1 |
| Scotti, V | 1 |
| Desideri, I | 1 |
| Saieva, C | 1 |
| Cecchini, S | 1 |
| Francolini, G | 1 |
| Becherini, C | 1 |
| Delli Paoli, C | 1 |
| Visani, L | 1 |
| Salvestrini, V | 1 |
| De Feo, ML | 1 |
| Nori, J | 1 |
| Bernini, M | 1 |
| Sanchez, L | 1 |
| Orzalesi, L | 2 |
| Bianchi, S | 1 |
| Meattini, I | 1 |
| Liu, D | 2 |
| Devarajan, S | 1 |
| Zhuang, Y | 1 |
| Kubo, M | 4 |
| Batzler, A | 3 |
| Jenkins, GD | 3 |
| Northfelt, DW | 3 |
| Moreno-Aspitia, A | 1 |
| Reid, JM | 1 |
| Wieder, MS | 1 |
| Harooni, M | 1 |
| Rusu, I | 1 |
| Pather, K | 1 |
| Dix-Peek, T | 1 |
| Chetty, N | 1 |
| Tervonen, HE | 1 |
| Daniels, B | 1 |
| Tang, M | 1 |
| Preen, DB | 2 |
| Pearson, SA | 1 |
| Linden, HH | 1 |
| Livingston, RB | 4 |
| Tenti, S | 1 |
| Giordano, N | 1 |
| Cutolo, M | 1 |
| Giannini, F | 1 |
| Fioravanti, A | 1 |
| Burki, TK | 1 |
| Sidaway, P | 1 |
| Morgan, MM | 1 |
| Arendt, LM | 1 |
| Alarid, ET | 1 |
| Beebe, DJ | 1 |
| Johnson, BP | 1 |
| Blake, GM | 1 |
| Coleman, RE | 8 |
| Jiang, Z | 3 |
| Ohno, S | 4 |
| Ellis, M | 3 |
| Bradbury, I | 1 |
| Campbell, C | 1 |
| Guerrero-Zotano, A | 1 |
| Bermejo, B | 1 |
| Ramos, M | 1 |
| Cruz, J | 1 |
| Baena-Cañada, JM | 1 |
| Cirauqui, B | 1 |
| Rodríguez-Lescure, Á | 1 |
| Alba, E | 2 |
| Martínez-Jáñez, N | 1 |
| Muñoz, M | 2 |
| Antolín, S | 2 |
| Álvarez, I | 2 |
| Del Barco, S | 1 |
| Sevillano, E | 1 |
| Chacón, JI | 1 |
| Antón, A | 2 |
| Escudero, MJ | 1 |
| Ruiz, V | 1 |
| Carrasco, E | 2 |
| Martín, M | 3 |
| Pierce, L | 1 |
| Hayman, J | 1 |
| Thaker, NG | 1 |
| Khan, A | 1 |
| Sedloev, T | 1 |
| Vlahova, A | 1 |
| Usheva, S | 1 |
| Vasileva-Slaveva, M | 1 |
| Spiridonova, T | 1 |
| Spirdonov, J | 1 |
| Yoshimoto, S | 1 |
| Nakatani, K | 2 |
| Maruyama, N | 1 |
| Fujiki, K | 1 |
| Nakano, T | 1 |
| Ueshima, K | 1 |
| Fujimoto, T | 1 |
| Oka, H | 1 |
| Ishikawa, H | 1 |
| Inoue, F | 1 |
| Boccardo, F | 6 |
| Guglielmini, P | 3 |
| Bordonaro, R | 1 |
| Fini, A | 3 |
| Massidda, B | 3 |
| Porpiglia, M | 4 |
| Roagna, R | 1 |
| Serra, P | 1 |
| Ucci, G | 2 |
| Rubagotti, A | 4 |
| Kalder, M | 4 |
| Ziller, V | 3 |
| Kyvernitakis, I | 4 |
| Knöll, D | 2 |
| Hars, O | 4 |
| Hadji, P | 11 |
| Nishimura, R | 3 |
| Yamamoto, Y | 3 |
| Shibuta, K | 1 |
| Tsuyuki, S | 1 |
| Mase, T | 1 |
| Teramukai, S | 1 |
| Shi, Q | 1 |
| Giordano, SH | 2 |
| Lu, H | 2 |
| Saleeba, AK | 1 |
| Malveaux, D | 1 |
| Cleeland, CS | 1 |
| Aapro, M | 3 |
| van de Velde, CJ | 2 |
| Markopoulos, C | 6 |
| Bartlett, JM | 1 |
| Dunbier, AK | 5 |
| Ghazoui, Z | 10 |
| Anderson, H | 6 |
| Salter, J | 17 |
| Nerurkar, A | 2 |
| Osin, P | 2 |
| A'hern, R | 8 |
| Miller, WR | 18 |
| Smith, IE | 17 |
| Robertson, JF | 23 |
| Dixon, JM | 23 |
| Sibbering, DM | 1 |
| Jahan, A | 1 |
| Ellis, IO | 3 |
| Channon, E | 1 |
| Hyman-Taylor, P | 1 |
| Nicholson, RI | 2 |
| Gee, JM | 1 |
| Inari, H | 2 |
| Hashimoto, M | 1 |
| Uesugi, K | 1 |
| Goto, N | 2 |
| Hatori, S | 2 |
| Tanabe, H | 2 |
| Iwasaki, H | 1 |
| Golubeva, O | 1 |
| Shah, P | 2 |
| Brodie, A | 6 |
| Tan, PS | 1 |
| Haaland, B | 1 |
| Montero, AJ | 1 |
| Lopes, G | 1 |
| Vilquin, P | 1 |
| Villedieu, M | 1 |
| Grisard, E | 1 |
| Ben Larbi, S | 1 |
| Ghayad, SE | 1 |
| Corbo, L | 1 |
| Vendrell, JA | 1 |
| Cohen, PA | 1 |
| von Minckwitz, G | 6 |
| Shimomura, Y | 1 |
| Masuda, S | 1 |
| Okamoto, Y | 1 |
| Hiura, S | 1 |
| Kato, H | 1 |
| Asayama, T | 1 |
| Ohtani, H | 1 |
| Xia, R | 1 |
| Banerjee, M | 1 |
| Gersch, C | 1 |
| McConnell, D | 1 |
| Giacherio, D | 1 |
| Pearlman, M | 1 |
| Stearns, V | 10 |
| Partridge, AH | 2 |
| Rai, Y | 4 |
| Ohsumi, S | 8 |
| Hashigaki, S | 1 |
| Nishizawa, Y | 1 |
| Hiraoka, M | 1 |
| Morimoto, T | 1 |
| Sasano, H | 2 |
| Saeki, T | 1 |
| Munoz, J | 1 |
| Kumar, VA | 1 |
| Hamilton, J | 1 |
| Pasche, LJ | 1 |
| Langford, LA | 1 |
| Taggart, MW | 1 |
| Kamiya-Matsuoka, C | 1 |
| Tummala, S | 1 |
| Moulder, S | 1 |
| Kurzrock, R | 3 |
| Kuranishi, F | 1 |
| Ohno, T | 1 |
| Bauer, M | 1 |
| Lopez-Knowles, E | 5 |
| Sidhu, K | 2 |
| Cowens, JW | 4 |
| Storhoff, J | 2 |
| Afentakis, M | 2 |
| Howell, T | 4 |
| Buzdar, A | 27 |
| Forbes, J | 8 |
| Pfeiler, G | 3 |
| Stöger, H | 2 |
| Mlineritsch, B | 10 |
| Kwasny, W | 8 |
| Seifert, M | 7 |
| Stierer, M | 6 |
| Steger, G | 7 |
| Samonigg, H | 6 |
| Johnston, SR | 3 |
| Kilburn, LS | 1 |
| Ellis, P | 1 |
| Dodwell, D | 4 |
| Cameron, D | 2 |
| Hayward, L | 1 |
| Braybrooke, JP | 1 |
| Brunt, AM | 1 |
| Jyothirmayi, R | 1 |
| Robinson, A | 1 |
| Wardley, AM | 1 |
| Wheatley, D | 2 |
| Coombes, G | 1 |
| Sergenson, N | 1 |
| Sin, HJ | 1 |
| Folkerd, E | 6 |
| Bliss, JM | 2 |
| Königsberg, R | 2 |
| Maroske, M | 1 |
| Dressel-Ban, G | 1 |
| Zellinger, J | 1 |
| Exner, R | 1 |
| Singer, C | 2 |
| Manjunatha, N | 1 |
| Ganjekar, S | 1 |
| Mahendra, JV | 1 |
| Kilara, N | 1 |
| Srinivasa, R | 1 |
| Sgroi, DC | 2 |
| Schroeder, B | 1 |
| Erlander, MG | 1 |
| Dunbier, A | 6 |
| Madeira, M | 1 |
| Mattar, A | 2 |
| Logullo, AF | 2 |
| Soares, FA | 2 |
| Gebrim, LH | 2 |
| Bell, MJ | 1 |
| Terhorst, L | 2 |
| Liu, L | 1 |
| Bai, YX | 1 |
| Zhou, JH | 1 |
| Sun, XW | 1 |
| Sui, H | 1 |
| Zhang, WJ | 1 |
| Yuan, HH | 1 |
| Xie, R | 1 |
| Wei, XL | 1 |
| Zhang, TT | 1 |
| Li, YJ | 1 |
| Wang, JX | 1 |
| Zhao, S | 1 |
| Zhang, QY | 2 |
| Lu, Y | 2 |
| You, M | 1 |
| Liu, P | 2 |
| Vedell, PT | 1 |
| Wen, W | 1 |
| Bode, AM | 1 |
| Grubbs, CJ | 1 |
| Lubet, RA | 1 |
| Anandappa, G | 1 |
| Turner, NC | 3 |
| Brase, JC | 2 |
| Dietze, O | 2 |
| Luisser, I | 2 |
| Klug, E | 2 |
| Sedivy, R | 2 |
| Bachner, M | 2 |
| Mayr, D | 2 |
| Schmidt, M | 2 |
| Gehrmann, MC | 2 |
| Petry, C | 3 |
| Weber, KE | 2 |
| Fisch, K | 1 |
| Mehta, A | 1 |
| Moy, I | 1 |
| Lin, Z | 1 |
| Rademaker, AW | 1 |
| Reierstad, S | 1 |
| Khan, SA | 1 |
| Bulun, SE | 1 |
| Frederix, GW | 2 |
| van Hasselt, JG | 1 |
| Schellens, JH | 2 |
| Hövels, AM | 2 |
| Raaijmakers, JA | 2 |
| Huitema, AD | 1 |
| Severens, JL | 2 |
| Struck, M | 1 |
| Bauer, T | 1 |
| Akçay, HT | 1 |
| Bayrak, R | 1 |
| Cameron, DA | 8 |
| Knox, J | 2 |
| Saunders, C | 2 |
| Roche, N | 1 |
| Palva, T | 1 |
| Stoeger, H | 5 |
| Knauer, M | 2 |
| Ressler, S | 1 |
| Nielsen, TO | 1 |
| Jackisch, C | 2 |
| Bolten, W | 1 |
| Blettner, M | 2 |
| Hindenburg, HJ | 1 |
| Klein, P | 1 |
| König, K | 1 |
| Kreienberg, R | 6 |
| Rief, W | 1 |
| Wallwiener, D | 2 |
| Zaun, S | 2 |
| Harbeck, N | 4 |
| Kemp, A | 1 |
| Boyle, F | 2 |
| Bulsara, M | 1 |
| Holman, CD | 1 |
| Malacova, E | 1 |
| Roughead, EE | 1 |
| Layfield, DM | 1 |
| Mohamud, M | 1 |
| Odofin, O | 1 |
| Walsh, C | 1 |
| Royle, GT | 1 |
| Cutress, RI | 1 |
| Zhu, ZL | 1 |
| Chen, ML | 1 |
| Li, K | 1 |
| Schubert, B | 3 |
| Seeber, B | 1 |
| Giesinger, J | 2 |
| Hampton, T | 1 |
| Haynes, BP | 2 |
| Grassadonia, A | 1 |
| Di Nicola, M | 1 |
| Grossi, S | 1 |
| Noccioli, P | 1 |
| Tavoletta, S | 1 |
| Politi, R | 1 |
| Angelucci, D | 1 |
| Marinelli, C | 1 |
| Zilli, M | 1 |
| Ausili Cefaro, G | 1 |
| Tinari, N | 1 |
| De Tursi, M | 1 |
| Iezzi, L | 1 |
| Cioffi, P | 1 |
| Iacobelli, S | 1 |
| Natoli, C | 1 |
| Cianchetti, E | 1 |
| Arnedos, M | 1 |
| Drury, S | 3 |
| Hills, M | 7 |
| Reis-Filho, JS | 1 |
| Brown, P | 3 |
| Bock, VL | 1 |
| Friedlander, M | 1 |
| Waring, D | 1 |
| Kossard, S | 1 |
| Wood, GK | 1 |
| Chaudhari, NS | 1 |
| Pandey, AP | 1 |
| Patil, PO | 1 |
| Tekade, AR | 1 |
| Bari, SB | 1 |
| Deshmukh, PK | 1 |
| Chlebowski, RT | 4 |
| Mathew, A | 1 |
| Brufsky, A | 1 |
| Hershman, DL | 2 |
| Cheung, AM | 1 |
| Khosla, S | 1 |
| Chalchal, H | 2 |
| Rowland, K | 1 |
| Muss, HB | 3 |
| Linden, HM | 1 |
| Scher, J | 1 |
| Badovinac-Crnjevic, T | 1 |
| St Louis, J | 1 |
| Chapman, JA | 5 |
| McCann, SE | 1 |
| Edge, SB | 2 |
| Hicks, DG | 1 |
| Thompson, LU | 1 |
| Morrison, CD | 1 |
| Fetterly, G | 1 |
| Andrews, C | 1 |
| Clark, K | 1 |
| Wilton, J | 1 |
| Kulkarni, S | 1 |
| Neven, P | 8 |
| Tanner, M | 2 |
| Marty, M | 2 |
| Atkins, L | 3 |
| Franquet, A | 2 |
| Neciosup, S | 2 |
| Tesarova, P | 2 |
| Barni, S | 2 |
| Deschamp, V | 2 |
| Gong, DD | 1 |
| Man, CF | 1 |
| Tashima, Y | 1 |
| Kawano, K | 1 |
| Inafuku, K | 1 |
| Kawamoto, M | 1 |
| Masuda, M | 1 |
| Temin, S | 1 |
| Kirshner, JJ | 1 |
| Chandarlapaty, S | 1 |
| Crews, JR | 1 |
| Davidson, NE | 6 |
| Esteva, FJ | 3 |
| Gonzalez-Angulo, AM | 2 |
| Krop, I | 1 |
| Levinson, J | 1 |
| Lin, NU | 2 |
| Modi, S | 1 |
| Patt, DA | 1 |
| Perez, EA | 6 |
| Perlmutter, J | 1 |
| Ramakrishna, N | 1 |
| Winer, EP | 8 |
| Mathew, J | 1 |
| Prinsloo, P | 1 |
| Agrawal, A | 3 |
| Gutteridge, E | 1 |
| Marenah, C | 1 |
| Albert, US | 2 |
| Winarno, AS | 1 |
| Wheler, JJ | 2 |
| Moulder, SL | 2 |
| Naing, A | 1 |
| Janku, F | 2 |
| Piha-Paul, SA | 1 |
| Falchook, GS | 1 |
| Zinner, R | 1 |
| Tsimberidou, AM | 1 |
| Fu, S | 1 |
| Hong, DS | 1 |
| Atkins, JT | 2 |
| Yelensky, R | 2 |
| Stephens, PJ | 2 |
| Harrow, A | 1 |
| Dryden, R | 1 |
| McCowan, C | 1 |
| Radley, A | 1 |
| Parsons, M | 1 |
| Thompson, AM | 1 |
| Wells, M | 5 |
| Hu, R | 1 |
| Chen, D | 1 |
| Zhao, Y | 2 |
| Sun, S | 1 |
| Ma, R | 1 |
| He, P | 1 |
| Li, E | 1 |
| Xu, Z | 1 |
| Huang, T | 1 |
| Liang, Z | 1 |
| Wang, S | 3 |
| Su, F | 1 |
| Feng, G | 1 |
| Segal, CV | 1 |
| Garcia-Murillas, I | 2 |
| Smith, I | 5 |
| Martin, LA | 6 |
| Yucel, T | 1 |
| Lovett, ML | 1 |
| Giangregorio, R | 1 |
| Coonahan, E | 1 |
| Kaplan, DL | 1 |
| Mao, JJ | 2 |
| Farrar, JT | 1 |
| Bruner, D | 1 |
| Zee, J | 1 |
| Bowman, M | 1 |
| Seluzicki, C | 1 |
| DeMichele, A | 2 |
| Xie, SX | 1 |
| Yang, DQ | 1 |
| Xie, F | 1 |
| Zhou, B | 1 |
| Liu, M | 3 |
| Okutani, D | 1 |
| Andou, A | 1 |
| Yamadori, I | 1 |
| Higashi, R | 1 |
| Olin, JL | 1 |
| St Pierre, M | 1 |
| Klein, KO | 1 |
| Dudenkov, TT | 1 |
| Flockhart, DA | 4 |
| Williard, CV | 2 |
| Rechoum, Y | 1 |
| Rovito, D | 1 |
| Iacopetta, D | 1 |
| Weigel, NL | 1 |
| O'Malley, BW | 1 |
| Brown, PH | 2 |
| Fuqua, SA | 1 |
| Wei, K | 1 |
| Lintermans, A | 2 |
| Vanderschueren, D | 1 |
| Verhaeghe, J | 2 |
| Van Asten, K | 1 |
| Jans, I | 1 |
| Van Herck, E | 1 |
| Laenen, A | 1 |
| Paridaens, R | 3 |
| Billen, J | 1 |
| Pauwels, S | 1 |
| Vermeersch, P | 1 |
| Wildiers, H | 2 |
| Christiaens, MR | 3 |
| Dalmau, E | 1 |
| Armengol-Alonso, A | 1 |
| Seguí-Palmer, MÁ | 1 |
| Aihara, T | 6 |
| Yokota, I | 1 |
| Aogi, K | 2 |
| Tamura, M | 3 |
| Fukuuchi, A | 1 |
| Makino, H | 2 |
| Kim, R | 1 |
| Andoh, M | 1 |
| Tsugawa, K | 1 |
| Yamaguchi, T | 2 |
| Ohashi, Y | 7 |
| Watanabe, T | 4 |
| Kelly, E | 1 |
| Lu, CY | 1 |
| Albertini, S | 1 |
| Vitry, A | 1 |
| Panal, M | 1 |
| Sánchez-Mendez, JI | 1 |
| Revello, R | 1 |
| Abehsera, D | 1 |
| de Santiago, J | 1 |
| Zapardiel, I | 1 |
| Luschin-Ebengreuth, G | 7 |
| Moik, M | 1 |
| Taucher, S | 4 |
| Eidtmann, H | 4 |
| Eiermann, W | 10 |
| Selim, U | 1 |
| Hochreiner, G | 2 |
| Ploner, F | 2 |
| Lewis, L | 1 |
| Taylor, M | 1 |
| Suriya Ertugyrovna, Y | 1 |
| Kuanysh Shadybayevich, N | 1 |
| Kaldygul Kabakovna, S | 1 |
| Ramil Zufarovich, A | 1 |
| Ma, CX | 3 |
| Le Maitre, A | 1 |
| Kundapur, J | 1 |
| Liedke, PE | 2 |
| Gradishar, WJ | 4 |
| Lacey, R | 1 |
| Evans, A | 2 |
| Moy, B | 1 |
| Specht, MC | 1 |
| Lanuti, M | 1 |
| Rafferty, EA | 1 |
| Lerwill, MF | 1 |
| Barrios, C | 1 |
| Janni, W | 2 |
| de Boer, R | 2 |
| Schiff, R | 1 |
| Moschos, MM | 1 |
| Chatziralli, IP | 1 |
| Sergentanis, T | 1 |
| Zagouri, F | 1 |
| Chrysikos, D | 1 |
| Ladas, I | 1 |
| Zografos, G | 1 |
| Arnaout, A | 1 |
| Robertson, S | 1 |
| Kuchuk, I | 1 |
| Simos, D | 1 |
| Pond, GR | 1 |
| Addison, CL | 1 |
| Namazi, M | 1 |
| Clemons, M | 4 |
| Kusama, H | 1 |
| Okishiro, M | 3 |
| Ishida, T | 1 |
| Morimoto, Y | 1 |
| Matsushita, K | 1 |
| Hashimoto, T | 2 |
| Kimura, K | 1 |
| Nitta, K | 1 |
| Kagawa, Y | 1 |
| Takeno, A | 1 |
| Sakisaka, H | 1 |
| Nakahira, S | 1 |
| Taniguchi, K | 1 |
| Kato, T | 1 |
| Tamura, S | 1 |
| Oku, K | 1 |
| Goto, T | 1 |
| Nagano, T | 1 |
| Nakatsuka, S | 1 |
| Chen, R | 1 |
| Cui, J | 1 |
| Hu, H | 1 |
| Barbie, TU | 1 |
| Ma, C | 1 |
| Margenthaler, JA | 1 |
| Sreenivasa Reddy, M | 1 |
| Kumar, AR | 3 |
| Behl, G | 1 |
| Dave, V | 1 |
| Kushwaha, K | 1 |
| Bevers, TB | 1 |
| Toyoshima, M | 1 |
| Iwahashi, H | 1 |
| Shima, T | 1 |
| Hayasaka, A | 1 |
| Kudo, T | 1 |
| Igeta, S | 1 |
| Matsuura, R | 1 |
| Ishigaki, N | 1 |
| Akagi, K | 1 |
| Sakurada, J | 1 |
| Suzuki, H | 1 |
| Yoshinaga, K | 1 |
| Ahrendt, GM | 1 |
| Berga, SL | 2 |
| Dailey, MM | 1 |
| Erickson, KI | 1 |
| Kratofil, FM | 1 |
| McAuliffe, PF | 2 |
| Ryan, CM | 2 |
| Nielsen, T | 1 |
| Neuner, JM | 1 |
| Charlson, JA | 1 |
| Wozniak, EM | 1 |
| Smith, EC | 1 |
| Biggers, A | 1 |
| Smallwood, AJ | 1 |
| Laud, PW | 1 |
| Pezzin, LE | 1 |
| Chang, CH | 1 |
| Chen, SJ | 1 |
| Liu, CY | 1 |
| Khatri, R | 1 |
| Guha, R | 1 |
| Rassool, FV | 1 |
| Tomkinson, AE | 1 |
| Jaiswal, AK | 1 |
| Mast, N | 1 |
| Lin, JB | 1 |
| Pikuleva, IA | 1 |
| Morgan, JL | 1 |
| Collins, K | 1 |
| Robinson, TG | 1 |
| Audisio, R | 1 |
| Reed, MW | 1 |
| Wyld, L | 2 |
| Yagata, H | 1 |
| Shimozuma, K | 4 |
| Le Rhun, E | 1 |
| Delbeuck, X | 1 |
| Lefeuvre-Plesse, C | 1 |
| Kramar, A | 1 |
| Skrobala, E | 1 |
| Pasquier, F | 1 |
| Bonneterre, J | 7 |
| Glaser, R | 1 |
| Quenel-Tueux, N | 1 |
| Debled, M | 2 |
| Rudewicz, J | 1 |
| MacGrogan, G | 1 |
| Pulido, M | 1 |
| Mauriac, L | 10 |
| Dalenc, F | 1 |
| Lortal, B | 1 |
| Breton-Callu, C | 1 |
| Madranges, N | 1 |
| de Lara, CT | 1 |
| Fournier, M | 1 |
| Bonnefoi, H | 1 |
| Soueidan, H | 1 |
| Nikolski, M | 1 |
| Gros, A | 1 |
| Daly, C | 1 |
| Wood, H | 1 |
| Rabbitts, P | 1 |
| Iggo, R | 1 |
| Semiglazov, VF | 4 |
| Semiglazov, VV | 3 |
| Petrenko, OL | 1 |
| Komyakhov, AV | 1 |
| Dashyan, GA | 2 |
| Paltuev, RM | 3 |
| Semiglazova, TY | 1 |
| Manikhas, AG | 1 |
| Bozhok, AA | 3 |
| Lalak, IA | 1 |
| Munzone, E | 1 |
| Llombart-Cussac, A | 4 |
| Feltl, D | 3 |
| Dewar, JA | 1 |
| Jasiówka, M | 1 |
| Hewson, N | 1 |
| Rukazenkov, Y | 1 |
| Mitchell, KB | 1 |
| Kuerer, H | 1 |
| Hirokaga, K | 1 |
| Takao, S | 1 |
| Yamagami, K | 1 |
| Miyashita, M | 1 |
| Baba, M | 1 |
| Ichii, S | 1 |
| Konishi, M | 1 |
| Kikawa, Y | 1 |
| Minohata, J | 1 |
| Okuno, T | 1 |
| Miyauchi, K | 1 |
| Wakita, K | 1 |
| Suwa, H | 1 |
| Nishino, M | 1 |
| Matsumoto, T | 1 |
| Hidaka, T | 1 |
| Konishi, Y | 1 |
| Sakoda, Y | 1 |
| Miya, A | 1 |
| Mitsunobu, M | 1 |
| Nishikawa, H | 1 |
| Kono, S | 1 |
| Kokufu, I | 1 |
| Sakita, I | 1 |
| Kitatsuji, K | 1 |
| Oh, K | 1 |
| Maliyakkal, N | 1 |
| Reddya, MS | 1 |
| Shrawan, B | 1 |
| Shankar, A | 1 |
| Roy, S | 1 |
| Rath, GK | 1 |
| Julka, PK | 1 |
| Kamal, VK | 1 |
| Malik, A | 1 |
| Patil, J | 1 |
| Jeyaraj, PA | 1 |
| Mahajan, MK | 1 |
| Zulfiqar, AA | 1 |
| Martin-Kleisch, A | 1 |
| Akyol, M | 1 |
| Demir, L | 2 |
| Alacacioglu, A | 2 |
| Ellidokuz, H | 1 |
| Kucukzeybek, Y | 1 |
| Yildiz, Y | 1 |
| Gumus, Z | 1 |
| Bayoglu, V | 1 |
| Yildiz, I | 1 |
| Salman, T | 2 |
| Varol, U | 1 |
| Kucukzeybek, B | 1 |
| Dirican, A | 1 |
| Sutcu, R | 1 |
| Tarhan, MO | 1 |
| Spagnolo, F | 1 |
| Recchia, F | 2 |
| Candeloro, G | 2 |
| Rosselli, M | 1 |
| Bratta, M | 1 |
| Pasta, V | 1 |
| D'Orazi, V | 1 |
| Fumagalli, LA | 1 |
| Rea, S | 2 |
| Bundred, N | 3 |
| Levy, C | 1 |
| Holcombe, C | 1 |
| Jones, L | 1 |
| Ellis, I | 2 |
| Margolese, RG | 2 |
| Julian, TB | 2 |
| Costantino, JP | 3 |
| Vallow, LA | 2 |
| Whitworth, PW | 2 |
| Cianfrocca, ME | 2 |
| Gross, HM | 2 |
| Soori, GS | 2 |
| Hopkins, JO | 2 |
| Fehrenbacher, L | 2 |
| Sturtz, K | 2 |
| Wozniak, TF | 2 |
| Seay, TE | 2 |
| Mamounas, EP | 3 |
| Wolmark, N | 2 |
| Zhang, M | 1 |
| Niu, L | 1 |
| Zeng, H | 1 |
| Cui, S | 1 |
| Park, YJ | 1 |
| Ahn, HY | 1 |
| Kim, HR | 1 |
| Chung, KH | 1 |
| Oh, SM | 1 |
| Tryfonidis, K | 1 |
| Basaran, G | 1 |
| Bogaerts, J | 1 |
| Thery, JC | 1 |
| Tjan-Heijnen, VC | 2 |
| Van den Weyngaert, D | 1 |
| Cufer, T | 3 |
| Piccart, M | 2 |
| Sanchez, C | 1 |
| Gao, F | 2 |
| Crowder, R | 2 |
| Naughton, M | 1 |
| Pluard, T | 2 |
| Creekmore, A | 1 |
| Guo, Z | 1 |
| Hoog, J | 5 |
| Lockhart, AC | 1 |
| Doyle, A | 1 |
| Erlichman, C | 1 |
| Bacci, M | 1 |
| Giannoni, E | 1 |
| Fearns, A | 1 |
| Ribas, R | 1 |
| Taddei, ML | 1 |
| Pintus, G | 1 |
| Isacke, CM | 1 |
| Chiarugi, P | 1 |
| Morandi, A | 1 |
| Aomatsu, N | 2 |
| Tei, S | 1 |
| Haraoka, G | 1 |
| Hosoi, K | 1 |
| Fujii, N | 1 |
| Hiramatsu, S | 1 |
| Wang, E | 1 |
| Iwauchi, T | 1 |
| Morimoto, J | 1 |
| Nishii, T | 1 |
| Kosaka, K | 1 |
| Uchima, Y | 1 |
| Takeuchi, K | 1 |
| Beauchemin, C | 1 |
| Letarte, N | 1 |
| Mathurin, K | 1 |
| Yelle, L | 1 |
| Lachaine, J | 1 |
| Sénéchal, C | 1 |
| Reyal, F | 1 |
| Callet, N | 1 |
| This, P | 1 |
| Noguès, C | 1 |
| Stoppa-Lyonnet, D | 1 |
| Sansone, P | 1 |
| Ceccarelli, C | 1 |
| Berishaj, M | 1 |
| Chang, Q | 1 |
| Rajasekhar, VK | 1 |
| Perna, F | 1 |
| Bowman, RL | 1 |
| Vidone, M | 1 |
| Daly, L | 1 |
| Nnoli, J | 1 |
| Santini, D | 1 |
| Taffurelli, M | 1 |
| Shih, NN | 1 |
| Feldman, M | 1 |
| Colameco, C | 1 |
| Fabbri, N | 1 |
| Healey, JH | 1 |
| Cricca, M | 1 |
| Gasparre, G | 1 |
| Lyden, D | 1 |
| Bonafé, M | 1 |
| Bromberg, J | 1 |
| Gralow, J | 2 |
| Shapiro, AC | 1 |
| Adlis, SA | 1 |
| Robien, K | 1 |
| Kirstein, MN | 1 |
| Liang, S | 1 |
| Richter, SA | 1 |
| Lerner, RE | 1 |
| Saha, P | 1 |
| Amico, AL | 1 |
| Olopade, OI | 1 |
| Jones, N | 1 |
| Livings, C | 1 |
| Batson, S | 1 |
| Schmid, P | 1 |
| Pinder, SE | 2 |
| Macaskill, J | 1 |
| Zammit, C | 1 |
| Hu, J | 1 |
| Price, R | 1 |
| Hadad, S | 1 |
| Shia, A | 1 |
| Sarker, SJ | 1 |
| Lim, L | 1 |
| Gazinska, P | 1 |
| Woodman, N | 1 |
| Korbie, D | 1 |
| Trau, M | 1 |
| Mainwaring, P | 1 |
| Gendreau, S | 1 |
| Lackner, MR | 1 |
| Derynck, M | 1 |
| Wilson, TR | 1 |
| Butler, H | 1 |
| Earl, G | 1 |
| Parker, P | 1 |
| Purushotham, A | 1 |
| Thompson, A | 1 |
| Nugent, BD | 1 |
| Rosenzweig, M | 1 |
| McCue, M | 1 |
| Sobral, AF | 1 |
| Gelmon, KA | 2 |
| Schroeder, BE | 1 |
| Fribbens, C | 1 |
| O'Leary, B | 1 |
| Kilburn, L | 1 |
| Hrebien, S | 1 |
| Beaney, M | 1 |
| Andre, F | 1 |
| Loi, S | 1 |
| Jiang, J | 2 |
| Bartlett, CH | 1 |
| Koehler, M | 1 |
| Alran, S | 2 |
| Venat-Bouvet, L | 1 |
| Kerbrat, P | 2 |
| Salmon, R | 2 |
| Bourgier, C | 1 |
| Boussion, V | 1 |
| Balleyguier, C | 1 |
| Thibault, F | 1 |
| Lavau-Denes, S | 1 |
| Nabholz, JM | 1 |
| Sigal, B | 1 |
| Trassard, M | 1 |
| Mathieu, MC | 1 |
| Martin, AL | 1 |
| Mouret-Fourme, E | 1 |
| Lopez-Tarruella, S | 1 |
| Gilarranz, YJ | 1 |
| Flågeng, MH | 1 |
| Larionov, A | 3 |
| Knappskog, S | 1 |
| Prestvik, WS | 1 |
| Bjørkøy, G | 1 |
| Lilleng, PK | 1 |
| Yu, R | 1 |
| Krappmann, K | 1 |
| Scheer, M | 1 |
| Fisher, J | 1 |
| Patel, M | 1 |
| Miller, M | 1 |
| Burris, K | 1 |
| Pagano, T | 1 |
| De Rosa, P | 1 |
| Vallone, R | 1 |
| Nazzaro, G | 1 |
| Locci, M | 1 |
| De Placido, G | 1 |
| Johnston, S | 3 |
| Basik, M | 1 |
| Hegg, R | 1 |
| Lausoontornsiri, W | 1 |
| Grzeda, L | 1 |
| Dreosti, L | 1 |
| Mann, H | 1 |
| Stuart, M | 5 |
| Niraula, S | 1 |
| Ocana, A | 1 |
| Gervasini, G | 1 |
| Jara, C | 1 |
| Olier, C | 1 |
| Romero, N | 1 |
| Martínez, R | 1 |
| Carrillo, JA | 1 |
| Whitworth, P | 2 |
| Beitsch, P | 1 |
| Mislowsky, A | 1 |
| Pellicane, JV | 1 |
| Nash, C | 1 |
| Murray, M | 1 |
| Lee, LA | 1 |
| Dul, CL | 1 |
| Rotkis, M | 1 |
| Baron, P | 1 |
| Stork-Sloots, L | 1 |
| de Snoo, FA | 1 |
| Beatty, J | 1 |
| Chia, SK | 1 |
| Simmons, C | 1 |
| McLeod, D | 1 |
| Paterson, A | 1 |
| Provencher, L | 1 |
| Rayson, D | 4 |
| Bondarenko, IM | 1 |
| Trishkina, E | 1 |
| Dvorkin, M | 1 |
| Panasci, L | 1 |
| Manikhas, A | 1 |
| Shparyk, Y | 1 |
| Cardona-Huerta, S | 1 |
| Philco-Salas, MJ | 1 |
| Rowbottom, J | 1 |
| Grinsted, LM | 1 |
| Huang, XH | 1 |
| Liang, RH | 1 |
| Su, L | 1 |
| Guo, W | 1 |
| Wang, CJ | 1 |
| Lee, CI | 1 |
| Goodwin, A | 1 |
| Wilcken, N | 1 |
| Sanati, S | 1 |
| Creighton, CJ | 1 |
| DeSchryver, K | 3 |
| Crouch, E | 1 |
| Brink, A | 1 |
| Watson, M | 2 |
| Luo, J | 4 |
| Tao, Y | 3 |
| Barnes, M | 1 |
| Winer, E | 2 |
| Silverman, P | 1 |
| Esserman, L | 2 |
| Carey, L | 1 |
| Babiera, G | 1 |
| Guenther, JM | 3 |
| Dayao, Z | 1 |
| Ota, D | 2 |
| Leitch, M | 3 |
| Olson, JA | 2 |
| Allred, DC | 3 |
| Hunt, K | 3 |
| Sweis, RF | 1 |
| Ratain, MJ | 2 |
| Ghotkar, P | 1 |
| Jankowitz, RC | 1 |
| Clark, BZ | 1 |
| Yardley, D | 1 |
| Burris, H | 1 |
| Amadori, D | 3 |
| McIntyre, K | 1 |
| Ejlertsen, B | 2 |
| Jonat, W | 11 |
| Hart, L | 1 |
| Poggio, S | 1 |
| Comarella, L | 1 |
| Salomon, H | 1 |
| Wamil, B | 1 |
| Brower, V | 1 |
| Coscia, EB | 1 |
| Sabha, M | 1 |
| Gerenutti, M | 1 |
| Groppo, FC | 1 |
| Bergamaschi, CC | 1 |
| Jinih, M | 1 |
| Relihan, N | 1 |
| Corrigan, MA | 1 |
| O'Reilly, S | 1 |
| Redmond, HP | 1 |
| Khachidze, N | 1 |
| Giorgadze, E | 1 |
| Tsagareli, M | 1 |
| Murphy, CC | 1 |
| Tiro, JA | 1 |
| Jean, GW | 1 |
| Balasubramian, BA | 1 |
| Alvarez, CA | 1 |
| Kalender, ME | 1 |
| Sevinc, A | 1 |
| Camci, C | 1 |
| Turk, HM | 1 |
| Karakok, M | 1 |
| Akgul, B | 1 |
| Doggrell, SA | 1 |
| Sanford, M | 1 |
| Plosker, GL | 2 |
| Nemitz, N | 1 |
| Kurmann, PT | 1 |
| Van Linthoudt, D | 1 |
| Valenzano Menada, M | 1 |
| Costantini, S | 1 |
| Moioli, M | 1 |
| Bogliolo, S | 1 |
| Papadia, A | 1 |
| Ferrero, S | 1 |
| Dugnani, MC | 1 |
| Wong, M | 1 |
| Grossman, J | 1 |
| Hahn, BH | 1 |
| La Cava, A | 1 |
| Nagykálnai, T | 2 |
| Kahán, Z | 1 |
| Masri, S | 2 |
| Lui, K | 1 |
| Phung, S | 2 |
| Ye, J | 2 |
| Zhou, D | 1 |
| Chen, S | 5 |
| Sapunar, F | 2 |
| Bianco, AR | 5 |
| Eisner, A | 3 |
| Thielman, EJ | 1 |
| Falardeau, J | 3 |
| Vetto, JT | 3 |
| Kainberger, F | 1 |
| Kässmann, H | 1 |
| Piswanger-Sölkner, JC | 1 |
| Menzel, C | 4 |
| Marth, C | 4 |
| Kubista, E | 2 |
| Wohlmuth, P | 1 |
| Mittlböck, M | 1 |
| Gibson, K | 1 |
| O'Bryant, CL | 1 |
| Jenkins, VA | 1 |
| Ambroisine, LM | 1 |
| Fallowfield, LJ | 3 |
| Col, N | 1 |
| Gurwitz, D | 1 |
| Newman, W | 1 |
| Evans, DB | 4 |
| Bhatnagar, AS | 1 |
| Chaudri Ross, HA | 1 |
| von Kameke, A | 1 |
| Juraskova, I | 1 |
| Butow, P | 1 |
| Lopez, A | 1 |
| Seccombe, M | 1 |
| Coates, A | 2 |
| McCarthy, N | 1 |
| Reaby, L | 1 |
| Helle, H | 1 |
| Ekse, D | 1 |
| Duong, NK | 1 |
| Nordbø, Y | 1 |
| Aas, T | 1 |
| Lester, JE | 1 |
| Purohit, OP | 1 |
| Gutcher, SA | 1 |
| Ellis, SP | 1 |
| Thorpe, R | 1 |
| Horsman, JM | 1 |
| Brown, JE | 1 |
| Hannon, RA | 4 |
| Gottwald, L | 1 |
| Gora, E | 1 |
| Korczynski, J | 1 |
| Piekarski, JH | 1 |
| Morawiec, Z | 1 |
| Jesionek-Kupnicka, D | 1 |
| Sowa, P | 1 |
| Cialkowska-Rysz, A | 1 |
| Bienkiewicz, A | 1 |
| Maruyama, S | 1 |
| Ito, M | 1 |
| Hirano, Y | 1 |
| Shimo, T | 1 |
| Hashida, S | 1 |
| Iga, K | 1 |
| Inukai, M | 1 |
| Kanaya, Y | 1 |
| Yokoyama, N | 1 |
| Fallowfield, L | 6 |
| Duffy, SR | 2 |
| Distler, W | 5 |
| Baum, M | 18 |
| Kim, SJ | 1 |
| Tanji, Y | 2 |
| Shimazu, K | 1 |
| Tamaki, Y | 3 |
| Needleman, SJ | 1 |
| Tobias, JS | 7 |
| Collins, B | 1 |
| Mackenzie, J | 1 |
| Stewart, A | 1 |
| Bielajew, C | 1 |
| Verma, S | 9 |
| Wood, JP | 1 |
| Haynes, AP | 1 |
| Thomas, RJ | 1 |
| Williams, M | 2 |
| Glen, J | 1 |
| Callam, M | 1 |
| Holzhauer, W | 1 |
| Ziller, M | 1 |
| Wagner, U | 1 |
| Schippinger, W | 1 |
| Pöstlberger, S | 5 |
| Tausch, C | 4 |
| Fridrik, M | 1 |
| Rücklinger, E | 2 |
| Macedo, LF | 3 |
| Sabnis, G | 1 |
| Karagöz, B | 2 |
| Bilgi, O | 2 |
| Ozgün, A | 2 |
| Sayan, O | 1 |
| Erikçi, AA | 1 |
| Kandemir, EG | 2 |
| Campos, SM | 3 |
| Guastalla, JP | 4 |
| Subar, M | 2 |
| Abreu, P | 2 |
| Azria, D | 1 |
| Jacot, W | 1 |
| Gligorov, J | 2 |
| Belkacémi, Y | 1 |
| Zaman, K | 1 |
| Romieu, G | 1 |
| Ozsahin, M | 1 |
| Schwartzberg, LS | 1 |
| Cobb, P | 1 |
| Senecal, F | 1 |
| Henry, D | 1 |
| Kulig, K | 1 |
| Walker, MS | 1 |
| Houts, AC | 1 |
| Stepanski, EJ | 1 |
| Murata, T | 2 |
| Yoshino, H | 1 |
| Bandou, H | 1 |
| Morita, K | 1 |
| Kurokawa, M | 1 |
| Inaki, N | 1 |
| Kotake, M | 1 |
| Kadoya, S | 1 |
| Yamamoto, M | 1 |
| Takayanagi, T | 1 |
| Yamada, T | 1 |
| Akashi-Tanaka, S | 2 |
| Shimizu, C | 3 |
| Ando, M | 4 |
| Shibata, T | 1 |
| Katsumata, N | 1 |
| Kouno, T | 1 |
| Terada, K | 2 |
| Shien, T | 2 |
| Yoshida, M | 1 |
| Hojo, T | 1 |
| Kinoshita, T | 6 |
| Fujiwara, Y | 3 |
| Yoshimura, K | 1 |
| Nabholtz, JM | 13 |
| Durando, X | 2 |
| Van Praagh, I | 1 |
| Al-Sukhun, S | 1 |
| Ferriere, JP | 2 |
| Chollet, P | 2 |
| Guggisberg, N | 1 |
| Jorda, M | 1 |
| Gonzalez-Angulo, A | 1 |
| Hennessy, B | 1 |
| Mills, GB | 2 |
| Tan, CK | 1 |
| Slingerland, JM | 1 |
| Sakurai, T | 5 |
| Umemura, T | 2 |
| Jinta, E | 1 |
| Suzuma, T | 2 |
| Yoshimura, G | 2 |
| Shimizu, S | 1 |
| Wenz, F | 1 |
| Gelber, RD | 2 |
| Aebi, S | 3 |
| Katz, A | 1 |
| Calabrich, A | 1 |
| Saad, ED | 1 |
| Reimer, T | 2 |
| Gerber, B | 3 |
| Berruti, A | 1 |
| Buttigliero, C | 1 |
| Dogliotti, L | 1 |
| Li, LN | 1 |
| Dong, PW | 1 |
| Okunade, G | 1 |
| Green, AR | 1 |
| Ying, M | 1 |
| Paish, EC | 1 |
| Aleskandrany, M | 1 |
| Winterbottom, L | 2 |
| Hassell, K | 1 |
| Morgan, DA | 1 |
| Kosha, S | 2 |
| Baba, S | 1 |
| Dokiya, F | 1 |
| Tamada, S | 1 |
| Matsuyama, Y | 2 |
| Ohi, Y | 1 |
| Douchi, T | 2 |
| Smollich, M | 2 |
| Götte, M | 2 |
| Fischgräbe, J | 2 |
| Radke, I | 2 |
| Kiesel, L | 2 |
| Wülfing, P | 2 |
| Ayata, A | 1 |
| Uzun, G | 1 |
| Unal, M | 1 |
| Türken, O | 1 |
| Ustaalioglu, BB | 1 |
| Bilici, A | 1 |
| Seker, M | 1 |
| Gumus, M | 1 |
| Barisik, NO | 1 |
| Salepci, T | 1 |
| Yaylaci, M | 1 |
| Blaha, P | 1 |
| Bachleitner-Hofmann, T | 1 |
| Rolski, J | 2 |
| Dewar, J | 2 |
| Macpherson, E | 1 |
| Lindemann, J | 1 |
| Chlebowski, R | 1 |
| Amakye, D | 1 |
| Bauerfeind, I | 1 |
| Chia, S | 1 |
| Cutuli, B | 1 |
| Linforth, R | 1 |
| Maass, N | 1 |
| Robidoux, A | 1 |
| Watanabe, N | 1 |
| Ootawa, Y | 1 |
| Kodama, K | 1 |
| Kaide, A | 1 |
| Ootsuka, N | 1 |
| Matsuoka, J | 1 |
| Glück, S | 4 |
| Amir, E | 1 |
| Hanna, W | 1 |
| Kahn, H | 1 |
| O'Malley, F | 1 |
| Dranitsaris, G | 3 |
| Cole, DE | 1 |
| Cortes, J | 1 |
| Baselga, J | 1 |
| Kaufman, B | 1 |
| Mackey, JR | 3 |
| Clemens, MR | 1 |
| Bapsy, PP | 1 |
| Vaid, A | 1 |
| Wardley, A | 1 |
| Tjulandin, S | 1 |
| Jahn, M | 1 |
| Lehle, M | 1 |
| Feyereislova, A | 1 |
| Révil, C | 1 |
| Lazarus, P | 1 |
| Sun, D | 1 |
| Nihon-Yanagi, Y | 1 |
| Ueda, T | 1 |
| Kameda, N | 1 |
| Okazumi, S | 1 |
| Serrano, D | 1 |
| Gandini, S | 1 |
| Guerrieri-Gonzaga, A | 1 |
| Johansson, H | 1 |
| Macis, D | 1 |
| Cazzaniga, M | 1 |
| Luini, A | 1 |
| Cassano, E | 1 |
| Oldani, S | 1 |
| Lien, EA | 1 |
| Pelosi, G | 1 |
| Decensi, A | 2 |
| Santiago, F | 1 |
| Saleiro, S | 1 |
| Brites, MM | 1 |
| Frutuoso, C | 1 |
| Figueiredo, A | 1 |
| Bremec, T | 1 |
| Demsar, J | 1 |
| Luzar, B | 1 |
| Pavlović, MD | 1 |
| Nagao, T | 1 |
| Kira, M | 1 |
| Honda, J | 1 |
| Hirose, T | 1 |
| Tangoku, A | 1 |
| Zembutsu, H | 1 |
| Nakamura, Y | 2 |
| Sasa, M | 1 |
| McCaig, FM | 1 |
| Renshaw, L | 9 |
| Williams, L | 3 |
| Young, O | 3 |
| Murray, J | 5 |
| Macaskill, EJ | 3 |
| McHugh, M | 3 |
| Hannon, R | 1 |
| Baumann, CK | 1 |
| Castiglione-Gertsch, M | 2 |
| Auboire, L | 1 |
| Landy, S | 1 |
| Perrot, JY | 1 |
| Maïza, D | 1 |
| Le Hello, C | 1 |
| Ishitobi, M | 4 |
| Motomura, K | 3 |
| Koyama, H | 3 |
| Nishiyama, K | 1 |
| Inaji, H | 6 |
| Briot, K | 1 |
| Tubiana-Hulin, M | 1 |
| Bastit, L | 1 |
| Kloos, I | 1 |
| Roux, C | 1 |
| Sato, T | 2 |
| Nakagawa, T | 3 |
| Kuwayama, T | 2 |
| Kubota, K | 2 |
| Sugihara, K | 2 |
| Hayashi, K | 1 |
| Sengoku, N | 1 |
| Kosaka, Y | 1 |
| Kondou, Y | 1 |
| Sugiyama, N | 1 |
| Enomoto, T | 1 |
| Kuranami, M | 1 |
| Watanabe, M | 1 |
| Van Poznak, C | 2 |
| Apffelstaedt, JP | 1 |
| Clack, G | 10 |
| Barlow, D | 1 |
| Makris, A | 4 |
| Folkerd, EJ | 3 |
| Crowder, RJ | 1 |
| Parker, JS | 3 |
| Perou, CM | 2 |
| Guiu, S | 1 |
| Coudert, B | 1 |
| Favier, L | 1 |
| Arnould, L | 1 |
| Fumoleau, P | 1 |
| O'Connor, SM | 1 |
| Beriwal, S | 1 |
| Dabbs, DJ | 1 |
| Bhargava, R | 1 |
| Wale, C | 4 |
| Quinn, E | 2 |
| Bugarini, R | 1 |
| Shak, S | 1 |
| Valero, V | 3 |
| Mangalik, A | 2 |
| Royce, M | 1 |
| Rabinowitz, I | 1 |
| Arena, FP | 1 |
| Kroener, JF | 1 |
| Curcio, E | 1 |
| Watkins, C | 1 |
| Bacus, S | 1 |
| Cora, EM | 1 |
| Anderson, E | 1 |
| Magill, PJ | 1 |
| Loehberg, CR | 1 |
| Jud, SM | 1 |
| Haeberle, L | 1 |
| Heusinger, K | 1 |
| Dilbat, G | 1 |
| Hein, A | 1 |
| Rauh, C | 1 |
| Dall, P | 1 |
| Rix, N | 1 |
| Heinrich, S | 1 |
| Buchholz, S | 2 |
| Lex, B | 1 |
| Reichler, B | 1 |
| Adamietz, B | 1 |
| Schulz-Wendtland, R | 1 |
| Beckmann, MW | 5 |
| Lejbak, L | 1 |
| Vrbancic, M | 1 |
| Crossley, M | 1 |
| Schaid, DJ | 3 |
| Olson, JE | 1 |
| Weintraub, RA | 1 |
| Yao, SY | 1 |
| Xu, BH | 2 |
| Wang, JY | 2 |
| Cai, RG | 2 |
| Lux, MP | 2 |
| Wöckel, A | 1 |
| Benedict, A | 2 |
| Kreif, N | 1 |
| Kaufmann, M | 5 |
| Raab, G | 1 |
| Tesch, H | 1 |
| Weyers, G | 1 |
| Possinger, K | 3 |
| Schneeweiss, A | 1 |
| Imoto, S | 3 |
| Nakagami, K | 1 |
| Ogino, N | 1 |
| Hisamatsu, K | 1 |
| Abe, H | 1 |
| Tanaka, S | 1 |
| Tzoracoleftherakis, E | 2 |
| Polychronis, A | 2 |
| Venizelos, B | 2 |
| Dafni, U | 1 |
| Xepapadakis, G | 2 |
| Papadiamantis, J | 1 |
| Zobolas, V | 2 |
| Misitzis, J | 2 |
| Kalogerakos, K | 1 |
| Sarantopoulou, A | 1 |
| Siasos, N | 1 |
| Koukouras, D | 2 |
| Antonopoulou, Z | 1 |
| Lazarou, S | 1 |
| Gogas, H | 2 |
| Fox, KR | 1 |
| Mello-Grand, M | 1 |
| Singh, V | 1 |
| Ghimenti, C | 1 |
| Scatolini, M | 1 |
| Regolo, L | 1 |
| Grosso, E | 1 |
| Zambelli, A | 1 |
| Da Prada, GA | 1 |
| Villani, L | 1 |
| Fregoni, V | 1 |
| Baiardi, P | 1 |
| Marsoni, S | 1 |
| Costa, A | 1 |
| Chiorino, G | 1 |
| Sedjo, RL | 1 |
| Devine, S | 1 |
| Riemsma, R | 1 |
| Forbes, CA | 1 |
| Kessels, A | 1 |
| Lykopoulos, K | 1 |
| Amonkar, MM | 1 |
| Kleijnen, J | 1 |
| Goodwin, PJ | 1 |
| Bertolini, E | 1 |
| Letho-Gyselinck, H | 1 |
| Prati, C | 1 |
| Wendling, D | 1 |
| Valakh, V | 1 |
| Trombetta, MG | 1 |
| Werts, ED | 1 |
| Labban, G | 1 |
| Khalid, MK | 1 |
| Kaminsky, A | 1 |
| Parda, D | 1 |
| Reichelt, C | 1 |
| Thiel, FC | 1 |
| Kykalos, S | 1 |
| Mantas, D | 1 |
| Dimitroulis, D | 1 |
| Alexandrou, P | 1 |
| Kostakis, A | 1 |
| Mouridsen, HT | 6 |
| Chen, LR | 1 |
| Blair-Belansky, H | 1 |
| Moore, PJ | 1 |
| Bender, C | 1 |
| Carlson, RW | 3 |
| Theriault, R | 1 |
| Schurman, CM | 1 |
| Rivera, E | 2 |
| Chung, CT | 1 |
| Phan, SC | 1 |
| Arun, B | 3 |
| Dice, K | 1 |
| Chiv, VY | 1 |
| Green, M | 2 |
| Agrawal, K | 1 |
| Onami, S | 1 |
| Mortimer, JE | 1 |
| Pal, SK | 1 |
| Balja, MP | 1 |
| Vrdoljak, DV | 1 |
| Stanec, M | 1 |
| Sitić, S | 1 |
| Supić, DK | 1 |
| Knezević, F | 1 |
| Duffy, S | 4 |
| Jackson, TL | 4 |
| Lansdown, M | 4 |
| Philips, K | 4 |
| Matsui, K | 1 |
| Tazawa, K | 1 |
| Karato, M | 1 |
| Nagata, T | 1 |
| Shimada, Y | 1 |
| Tsukada, K | 1 |
| Lipsitz, M | 1 |
| Delea, TE | 1 |
| Guo, A | 1 |
| Nukatsuka, M | 1 |
| Saito, H | 1 |
| Nakagawa, F | 1 |
| Abe, M | 1 |
| Uchida, J | 1 |
| Shibata, J | 1 |
| Matsuo, K | 1 |
| Kiniwa, M | 1 |
| Langridge, C | 1 |
| Young, OE | 2 |
| McCaig, F | 1 |
| Dixon, OM | 1 |
| Szabo, KA | 1 |
| Webber, CE | 1 |
| Adachi, JD | 1 |
| Tozer, R | 2 |
| Gordon, C | 1 |
| Papaioannou, A | 1 |
| Mushiroda, T | 1 |
| Shepherd, L | 1 |
| Pater, J | 1 |
| Rohrer, DC | 1 |
| Rosman, M | 1 |
| Mylander, WC | 1 |
| Tafra, L | 1 |
| Krell, J | 1 |
| Ewart, EK | 1 |
| Stebbing, J | 3 |
| Van Calster, B | 2 |
| Van Ginderachter, J | 1 |
| Vlasselaer, J | 1 |
| Van de Putte, G | 1 |
| Berteloot, P | 1 |
| Timmerman, D | 3 |
| Depypere, H | 1 |
| Blomme, C | 1 |
| Vlaemynck, G | 1 |
| De Jonge, E | 1 |
| Van den Broecke, R | 1 |
| Vergote, I | 13 |
| Amant, F | 1 |
| Van Huffel, S | 2 |
| Facina, G | 1 |
| Nonogaki, S | 1 |
| Kelly, CM | 2 |
| Adams, J | 1 |
| Mackey, J | 2 |
| Feng, J | 1 |
| Song, S | 1 |
| Chen, Z | 1 |
| Gu, K | 1 |
| Zhang, F | 1 |
| Yang, J | 1 |
| Isaacs, C | 1 |
| Herbolsheimer, P | 1 |
| Liu, MC | 1 |
| Wilkinson, M | 1 |
| Ottaviano, Y | 1 |
| Chung, GG | 1 |
| Warren, R | 1 |
| Eng-Wong, J | 1 |
| Cohen, P | 1 |
| Smith, KL | 1 |
| Creswell, K | 1 |
| Novielli, A | 1 |
| Slack, R | 1 |
| Tang, SC | 1 |
| Nagase, H | 1 |
| Harris, CA | 1 |
| Ward, RL | 1 |
| Dobbins, TA | 1 |
| Drew, AK | 1 |
| Pearson, S | 1 |
| Ichinose, Y | 1 |
| Kobayashi, T | 1 |
| Fujimoto, A | 1 |
| Uchida, S | 1 |
| Sasaoki, T | 1 |
| Goto, K | 1 |
| Powell, DE | 1 |
| Cochrane, RA | 1 |
| Davie, MW | 1 |
| Kamdem, LK | 1 |
| Kadlubar, SA | 1 |
| Ramirez, J | 1 |
| Jeter, S | 1 |
| Shahverdi, K | 1 |
| Ward, BA | 1 |
| Ogburn, E | 1 |
| Oda, G | 1 |
| Yamamoto, K | 1 |
| Kawachi, H | 1 |
| Van Hoydonck, M | 1 |
| Pans, S | 1 |
| Westhovens, R | 1 |
| Dieudonné, AS | 1 |
| Morales, L | 2 |
| Verschueren, K | 1 |
| De Smet, L | 1 |
| Nakahara, S | 2 |
| Suemasu, K | 3 |
| Takehara, M | 3 |
| Saito, T | 2 |
| Järhult, J | 1 |
| Buffa, FM | 1 |
| Dexter, T | 2 |
| Detre, S | 7 |
| Harris, AL | 1 |
| Miller, TW | 1 |
| Balko, JM | 1 |
| Wu, H | 1 |
| Shyr, Y | 1 |
| Arteaga, CL | 1 |
| Shinji, M | 1 |
| Doughty, JC | 1 |
| Tannock, IF | 1 |
| Necozione, S | 1 |
| Desideri, G | 1 |
| Recchia, CO | 1 |
| Piazze, J | 1 |
| Karthik, A | 1 |
| Castiglione, M | 2 |
| Dunn, B | 1 |
| Glaus, A | 1 |
| Vogel, V | 1 |
| Zwierzina, H | 1 |
| Inno, A | 1 |
| Basso, M | 1 |
| Vecchio, FM | 1 |
| Marsico, VA | 1 |
| Cerchiaro, E | 1 |
| D'Argento, E | 1 |
| Bagalà, C | 1 |
| Barone, C | 1 |
| Zabaglo, L | 2 |
| Pineda, S | 2 |
| Weigel, MT | 2 |
| Pancholi, S | 3 |
| Baigent, A | 1 |
| Lashen, H | 1 |
| Stanway, SJ | 1 |
| Palmieri, C | 1 |
| Stanczyk, FZ | 1 |
| Ward, R | 1 |
| Coombes, RC | 4 |
| Reed, MJ | 1 |
| Purohit, A | 1 |
| Lin, L | 2 |
| Snider, J | 2 |
| Esserman, LJ | 1 |
| Unzeitig, GW | 1 |
| Margenthaler, J | 2 |
| Babiera, GV | 2 |
| Marcom, PK | 2 |
| Watson, MA | 1 |
| Zhang, B | 1 |
| Landherr, L | 1 |
| Mészáros, E | 1 |
| Pristauz, G | 1 |
| Bauernhofer, T | 1 |
| Forsthuber, EP | 1 |
| Gallicchio, L | 1 |
| Macdonald, R | 1 |
| Wood, B | 1 |
| Rushovich, E | 1 |
| Helzlsouer, KJ | 1 |
| Burris, HA | 1 |
| Clark, BL | 1 |
| Shipley, D | 1 |
| Rubin, M | 1 |
| Barton, J | 1 |
| Arrowsmith, E | 1 |
| Hainsworth, JD | 1 |
| Rastelli, AL | 1 |
| Taylor, ME | 1 |
| Armamento-Villareal, R | 1 |
| Jamalabadi-Majidi, S | 1 |
| Napoli, N | 1 |
| Ruiz, A | 1 |
| Barnadas, A | 2 |
| Alés-Martínez, JE | 1 |
| Andrés, R | 1 |
| García Saenz, JA | 1 |
| Lao, J | 1 |
| Cámara, C | 1 |
| Casas, I | 1 |
| Allawi, Z | 1 |
| Morrogh, M | 1 |
| Andrade, VP | 1 |
| Patil, AJ | 1 |
| Qin, LX | 1 |
| Mo, Q | 1 |
| Sakr, R | 1 |
| Arroyo, CD | 1 |
| Brogi, E | 1 |
| Morrow, M | 1 |
| Massarweh, S | 1 |
| Tham, YL | 1 |
| Sexton, K | 1 |
| Weiss, H | 1 |
| Tsimelzon, A | 1 |
| Beyer, A | 1 |
| Rimawi, M | 1 |
| Cai, WY | 1 |
| Hilsenbeck, S | 1 |
| Elledge, R | 2 |
| Gorouhi, F | 1 |
| Prowell, TM | 2 |
| Blackford, AL | 2 |
| Byrne, C | 1 |
| Khouri, NF | 1 |
| Tarpinian, KS | 1 |
| Powers, PP | 1 |
| Wright, LA | 1 |
| Donehower, MG | 1 |
| Jeter, SC | 1 |
| Armstrong, DK | 1 |
| Emens, LA | 1 |
| Fetting, JH | 1 |
| Wolff, AC | 2 |
| Garrett-Mayer, E | 1 |
| Skaar, TC | 1 |
| Lao Romera, J | 1 |
| Puertolas Hernández, TJ | 1 |
| Peláez Fernández, I | 2 |
| Sampedro Gimeno, T | 2 |
| Fernández Martínez, R | 2 |
| Fernández Pérez, I | 1 |
| Iranzo González Cruz, V | 1 |
| Illarramendi Mañas, JJ | 1 |
| Garcerá Juan, S | 1 |
| Ciruelos Gil, EM | 1 |
| Cruz Jurado, J | 1 |
| Richart Aznar, P | 1 |
| García Mata, J | 1 |
| Galve Calvo, E | 1 |
| Murillo Jaso, L | 1 |
| Polo Marqués, E | 1 |
| García Palomo, A | 1 |
| Martínez Guisado, A | 1 |
| Sánchez Muñoz, A | 1 |
| de la Cabeza Lomas Garrido, M | 1 |
| Ruíz Borrego, M | 1 |
| Bayo Calero, J | 1 |
| de Toro Salas, R | 1 |
| González Mancha, R | 1 |
| de la Haba Rodríguez, J | 1 |
| Alba Conejo, E | 1 |
| Osborn, G | 1 |
| Jones, M | 1 |
| Champ, C | 1 |
| Gower-Thomas, K | 1 |
| Vaughan-Williams, E | 1 |
| Hurria, A | 1 |
| Ring, A | 1 |
| Kemmerling, R | 1 |
| Jelen, A | 1 |
| Böhm, G | 1 |
| Jasarevic, Z | 1 |
| Haid, A | 1 |
| Gruber, C | 1 |
| Schmidt, C | 1 |
| Wink, CJ | 1 |
| Woensdregt, K | 1 |
| Nieuwenhuijzen, GA | 1 |
| van der Sangen, MJ | 1 |
| Hutschemaekers, S | 1 |
| Roukema, JA | 1 |
| Voogd, AC | 1 |
| Robertson, J | 2 |
| Robison, L | 1 |
| Pinhel, I | 1 |
| Johnson, L | 1 |
| Skene, T | 1 |
| Iskender, A | 1 |
| Wilcox, M | 1 |
| Bliss, J | 1 |
| Chino, A | 1 |
| Okamoto, H | 1 |
| Hirasaki, Y | 1 |
| Ueda, K | 1 |
| Ogawa, K | 1 |
| Namiki, T | 1 |
| Bao, T | 1 |
| Lu, HH | 1 |
| Brewster, A | 1 |
| Gutierrez-Barrera, A | 1 |
| Akar, U | 1 |
| Sneige, N | 1 |
| Crockett, JS | 1 |
| Burkemper, NM | 1 |
| Akiyama, F | 2 |
| Miyoshi, K | 2 |
| Woods, B | 1 |
| Veenstra, D | 1 |
| Hawkins, N | 1 |
| Fleeman, N | 1 |
| Bagust, A | 1 |
| Boland, A | 1 |
| Dickson, R | 1 |
| Dundar, Y | 1 |
| Moonan, M | 1 |
| Oyee, J | 1 |
| Blundell, M | 1 |
| Davis, H | 1 |
| Armstrong, A | 1 |
| Thorp, N | 1 |
| Sergi, G | 1 |
| Pintore, G | 1 |
| Falci, C | 1 |
| Veronese, N | 1 |
| Berton, L | 1 |
| Perissinotto, E | 1 |
| Basso, U | 1 |
| Brunello, A | 1 |
| Monfardini, S | 1 |
| Manzato, E | 1 |
| Coin, A | 1 |
| Sinnwell, JP | 1 |
| McDonnell, SK | 1 |
| Wickerham, DL | 1 |
| Singh, S | 1 |
| Mesher, D | 1 |
| Richmond, B | 1 |
| Nakamura, S | 2 |
| Iwase, H | 2 |
| Kamigaki, S | 2 |
| Burstein, HJ | 3 |
| Griggs, JJ | 1 |
| Dubsky, PC | 1 |
| Haider, K | 2 |
| Filipcic, L | 1 |
| Menas, P | 1 |
| Merkel, D | 1 |
| Hui, W | 1 |
| Lawton, J | 1 |
| Harper, A | 1 |
| Carro, G | 1 |
| Tevaarwerk, A | 1 |
| Burkard, ME | 1 |
| Wisinski, KB | 1 |
| Shafer, MM | 1 |
| Davis, LA | 1 |
| Gogineni, J | 1 |
| Crone, E | 1 |
| Hansen, KE | 1 |
| Bergh, J | 1 |
| Jönsson, PE | 1 |
| Lidbrink, EK | 1 |
| Trudeau, M | 3 |
| Brattström, D | 1 |
| Lindemann, JP | 2 |
| Wiklund, F | 1 |
| Henriksson, R | 1 |
| Thibert, JN | 1 |
| O'Neill, A | 1 |
| Vidaurre, T | 1 |
| Gomez, HL | 1 |
| Badve, SS | 1 |
| Mukai, T | 1 |
| Hikino, H | 1 |
| Koike, M | 1 |
| Murata, Y | 1 |
| Lundgren, K | 1 |
| Brown, M | 1 |
| Landberg, G | 1 |
| Yu, KD | 1 |
| Liu, GY | 1 |
| Li, B | 1 |
| He, PQ | 1 |
| Zhang, HW | 1 |
| Lou, LH | 1 |
| Wang, XJ | 1 |
| Tang, JH | 1 |
| Liu, YH | 1 |
| Jiang, ZF | 2 |
| Ma, LW | 1 |
| Gu, L | 1 |
| Cao, MZ | 1 |
| Wang, SM | 1 |
| Su, FX | 1 |
| Zheng, H | 1 |
| Li, HY | 1 |
| Tang, LL | 1 |
| Sun, SR | 1 |
| Liu, JP | 1 |
| Shao, ZM | 1 |
| Shen, ZZ | 1 |
| Malorni, L | 1 |
| Harvie, M | 1 |
| Onishi, H | 1 |
| Kuroki, S | 1 |
| Okido, M | 1 |
| Shimada, K | 1 |
| Yokohata, K | 1 |
| Ogawa, T | 1 |
| Katano, M | 1 |
| Setti, A | 1 |
| Venugopal Rao, V | 1 |
| Priyamvada Devi, A | 1 |
| Pawar, SC | 1 |
| Naresh, B | 1 |
| Kalyan, CS | 1 |
| Ding, L | 1 |
| Shen, D | 1 |
| Wallis, JW | 1 |
| Van Tine, BA | 1 |
| Goiffon, RJ | 1 |
| Goldstein, TC | 1 |
| Ng, S | 1 |
| Ballman, K | 1 |
| Weber, J | 1 |
| Chen, K | 1 |
| Koboldt, DC | 1 |
| Kandoth, C | 1 |
| Schierding, WS | 1 |
| McMichael, JF | 1 |
| Miller, CA | 1 |
| Lu, C | 1 |
| Harris, CC | 1 |
| McLellan, MD | 1 |
| Wendl, MC | 1 |
| Maher, CA | 1 |
| Fulton, LL | 1 |
| Fulton, RS | 1 |
| Harrison, M | 1 |
| Oberkfell, B | 1 |
| Du, F | 1 |
| Demeter, R | 1 |
| Vickery, TL | 1 |
| Elhammali, A | 1 |
| Piwnica-Worms, H | 1 |
| McDonald, S | 1 |
| Dooling, DJ | 1 |
| Chang, LW | 1 |
| Bose, R | 1 |
| Ley, TJ | 1 |
| Piwnica-Worms, D | 1 |
| Stuart, JM | 1 |
| Wilson, RK | 1 |
| Mardis, ER | 1 |
| Barlow, DH | 1 |
| King, V | 1 |
| Goldfarb, SB | 1 |
| Brooks, JD | 1 |
| Sung, JS | 1 |
| Nulsen, BF | 1 |
| Jozefara, JE | 1 |
| Pike, MC | 1 |
| Dickler, MN | 1 |
| Morris, EA | 1 |
| Williams, S | 1 |
| Michael, B | 1 |
| Mewar, D | 1 |
| Tunn, E | 1 |
| A'Hern, RP | 2 |
| Ligibel, JA | 1 |
| Goldhirsch, A | 3 |
| Potter, JE | 1 |
| Moore, KA | 1 |
| Turaka, K | 1 |
| Nottage, JM | 1 |
| Hammersmith, KM | 1 |
| Nagra, PK | 1 |
| Rapuano, CJ | 1 |
| Tsuda, H | 2 |
| Hayashi, N | 1 |
| Emerson, L | 1 |
| Dean, A | 1 |
| Oberguggenberger, AS | 1 |
| Gamper, E | 1 |
| Magee, PJ | 1 |
| Rowland, I | 1 |
| Sendur, MA | 1 |
| Aksoy, S | 1 |
| Zengin, N | 1 |
| Altundag, K | 4 |
| Suzuki, O | 1 |
| Yagi, T | 1 |
| Yoshinami, T | 1 |
| Tomita, Y | 1 |
| Davis, SR | 1 |
| Bell, RJ | 1 |
| Hanna, F | 1 |
| Davies-Tuck, M | 1 |
| Bell, R | 2 |
| Chirgwin, J | 1 |
| Cicuttini, F | 1 |
| Xie, J | 1 |
| Diener, M | 1 |
| De, G | 1 |
| Yang, H | 1 |
| Wu, EQ | 1 |
| Namjoshi, M | 1 |
| Horváth, Z | 1 |
| Morisaki, T | 1 |
| Nakamura, M | 1 |
| Kawajiri, H | 1 |
| Ishikawa, T | 2 |
| Clarke Hillyer, G | 1 |
| Neugut, AI | 1 |
| Crew, KD | 1 |
| Kalinsky, K | 1 |
| Maurer, MA | 1 |
| Rotsides, DZ | 1 |
| Danaceau, J | 1 |
| Takeuchi, H | 1 |
| Futsuhara, K | 1 |
| Yoshida, T | 1 |
| Kojima, M | 1 |
| Kai, T | 1 |
| Tabei, T | 1 |
| Untch, M | 1 |
| Ansari, RH | 1 |
| Johnson, DB | 1 |
| D'Souza, DP | 1 |
| Spadafora, S | 1 |
| Lang, I | 1 |
| Tung, N | 1 |
| Lück, HJ | 1 |
| Windemuth-Kieselbach, C | 1 |
| Jeong, YJ | 1 |
| Park, YS | 1 |
| Kwon, HJ | 1 |
| Shin, IH | 1 |
| Bong, JG | 1 |
| Park, SH | 1 |
| Köberle, D | 3 |
| Smith, RE | 1 |
| Cummings, FJ | 1 |
| Assikis, VJ | 1 |
| Hudis, C | 1 |
| Goldstein, LJ | 1 |
| Braun, S | 1 |
| Cobleigh, MA | 1 |
| Langer, AS | 1 |
| Perotti, J | 1 |
| Powles, TJ | 1 |
| Browman, GP | 1 |
| Bajetta, E | 5 |
| Martinetti, A | 3 |
| Zilembo, N | 5 |
| Pozzi, P | 3 |
| La Torre, I | 3 |
| Ferrari, L | 3 |
| Seregni, E | 3 |
| Longarini, R | 2 |
| Salvucci, G | 1 |
| Bombardieri, E | 3 |
| Pippen, J | 4 |
| Jones, SE | 9 |
| Parker, LM | 1 |
| Come, S | 1 |
| Gertler, SZ | 2 |
| May, JT | 1 |
| Burton, G | 3 |
| Dimery, I | 1 |
| Webster, A | 11 |
| Morris, C | 3 |
| Quaresma Albano, J | 2 |
| Aschermannova, A | 1 |
| Kleeberg, UR | 4 |
| Erikstein, B | 1 |
| Anderson, TJ | 4 |
| Sahmoud, T | 6 |
| Reese, D | 1 |
| Winquist, E | 1 |
| Bramwell, V | 1 |
| Vandenberg, T | 1 |
| Oura, S | 2 |
| Yokochi, H | 2 |
| Enomoto, K | 1 |
| Nishimura, M | 1 |
| Okamura, Y | 3 |
| Bruntsch, U | 1 |
| Mokbel, K | 5 |
| Beat, T | 1 |
| McClellan, MB | 1 |
| Wellington, K | 1 |
| Faulds, DM | 1 |
| Basu, S | 1 |
| Last, A | 1 |
| Shinkfield, M | 1 |
| Singh-Ranger, G | 2 |
| Jordan, VC | 2 |
| Stasi, R | 1 |
| Terzoli, E | 2 |
| Thornton, H | 4 |
| Mori, K | 1 |
| Chiba, N | 1 |
| Yonekawa, H | 1 |
| Aumiller, J | 3 |
| Visvanathan, K | 2 |
| Zapatero, A | 1 |
| Martín de Vidales, C | 1 |
| Pérez-Torrubia, A | 1 |
| Shimizu, Y | 1 |
| Yang, QF | 1 |
| Pippen, JE | 1 |
| Milla-Santos, A | 1 |
| Milla, L | 1 |
| Portella, J | 1 |
| Rallo, L | 1 |
| Pons, M | 1 |
| Rodes, E | 1 |
| Casanovas, J | 1 |
| Puig-Gali, M | 1 |
| Goodare, H | 1 |
| Dimmer, C | 1 |
| Page, K | 1 |
| Kleeberg, U | 1 |
| Sayer, HG | 1 |
| Höffken, K | 1 |
| Come, SE | 4 |
| Gertler, S | 1 |
| Rocchi, A | 2 |
| Brodie, AH | 2 |
| Rose, C | 4 |
| Thomas, R | 3 |
| Jackson, J | 3 |
| Ferretti, G | 4 |
| Di Cosimo, S | 3 |
| Colella, E | 1 |
| Tonachella, R | 1 |
| Romiti, A | 1 |
| Tomao, S | 1 |
| Papaldo, P | 5 |
| Fabi, A | 5 |
| Ruggeri, EM | 5 |
| Eckhardt, S | 1 |
| O'Neill, C | 1 |
| Repetto, L | 1 |
| Vannozzi, O | 1 |
| Hazini, A | 1 |
| Sestini, A | 1 |
| Pietropaolo, M | 1 |
| Rosso, R | 1 |
| Mouridsen, H | 2 |
| Gershanovich, M | 2 |
| Lønning, P | 1 |
| Pfister, C | 1 |
| Martoni, A | 1 |
| Zamagni, C | 1 |
| Kmietowicz, Z | 1 |
| Henderson, IC | 1 |
| Aapro, MS | 1 |
| Bross, PF | 1 |
| Baird, A | 1 |
| Chen, G | 1 |
| Jee, JM | 1 |
| Lostritto, RT | 1 |
| Morse, DE | 1 |
| Rosario, LA | 1 |
| Williams, GM | 1 |
| Yang, P | 1 |
| Rahman, A | 1 |
| Williams, G | 1 |
| Pazdur, R | 2 |
| Vtoraya, O | 1 |
| Pluzanska, A | 1 |
| Davidson, N | 1 |
| Johnson, S | 1 |
| Caicedo, JJ | 1 |
| Gervasio, H | 1 |
| Manikhas, G | 1 |
| Ben Ayed, F | 1 |
| Burdette-Radoux, S | 1 |
| Chaudri-Ross, HA | 2 |
| Lang, R | 1 |
| Fleming, GF | 1 |
| Houghton, J | 5 |
| Shilling, V | 2 |
| Jenkins, V | 2 |
| Emens, L | 1 |
| Pollard, S | 3 |
| Coibion, M | 3 |
| Simons, WR | 1 |
| Jones, D | 2 |
| Hutton, S | 1 |
| Munakata, S | 1 |
| Morino, H | 1 |
| Forward, DP | 1 |
| Jackson, L | 1 |
| Kammerer, S | 1 |
| Domont, J | 1 |
| Namer, M | 1 |
| Khayat, D | 2 |
| Spano, JP | 2 |
| Wilkinson, K | 1 |
| Kawakami, M | 1 |
| McKeage, K | 1 |
| Curran, MP | 1 |
| Baron, M | 1 |
| Dessogne, P | 1 |
| d'Anjou, J | 1 |
| Arora, A | 1 |
| Potter, JF | 1 |
| Bianco, R | 1 |
| Constenla, M | 1 |
| Williams, N | 2 |
| Locker, G | 4 |
| Sainsbury, R | 2 |
| Tobias, J | 1 |
| Hess, D | 1 |
| Senn, I | 1 |
| Ballabeni, P | 1 |
| Pagani, O | 2 |
| Perey, L | 2 |
| Rochlitz, C | 1 |
| Russo, F | 1 |
| Martincich, L | 1 |
| Cirillo, S | 1 |
| Gatti, M | 1 |
| Aglietta, M | 1 |
| Regge, D | 1 |
| Baumann, ChK | 1 |
| Locker, GY | 4 |
| Sainsbury, JR | 1 |
| Sonntag, M | 1 |
| Reifenberger, J | 1 |
| Megahed, M | 1 |
| Schulte, KW | 1 |
| Hillner, BE | 1 |
| Morandi, P | 1 |
| Rouzier, R | 1 |
| Theriault, RL | 1 |
| Hortobagyi, G | 1 |
| Choueiri, TK | 1 |
| Alemany, CA | 1 |
| Abou-Jawde, RM | 1 |
| Godward, S | 1 |
| Bloomfield, D | 1 |
| Moody, AM | 1 |
| Van Limbergen, E | 1 |
| Carbonez, A | 1 |
| Ameye, L | 1 |
| Okubo, S | 1 |
| Sonoo, H | 4 |
| Hirono, M | 1 |
| Nomura, T | 2 |
| Udagawa, K | 1 |
| Ikeda, M | 2 |
| Nakashima, K | 2 |
| Tanaka, K | 2 |
| Kurebayashi, J | 2 |
| Ohtsuka, S | 1 |
| Inagaki, M | 1 |
| Ohsaki, T | 1 |
| Fuchimoto, S | 1 |
| Yumura, M | 1 |
| Francis, S | 5 |
| Marchetti, M | 1 |
| Caruggi, M | 1 |
| Colombo, G | 1 |
| Hirai, I | 1 |
| Tanino, H | 1 |
| Yoshimas, T | 1 |
| Kokawa, Y | 1 |
| Nishida, M | 1 |
| Sasaki, R | 1 |
| Bessho, T | 1 |
| Nishimura, O | 1 |
| Tse, EY | 1 |
| Loo, WT | 1 |
| Cheung, MN | 1 |
| Chow, LW | 1 |
| Cheng, CW | 1 |
| Mitwally, MF | 1 |
| Casper, RF | 1 |
| Diamond, MP | 1 |
| Taylor, L | 1 |
| Del Vecchio, M | 1 |
| Toffolatti, L | 2 |
| Paleari, D | 1 |
| Macahilig, C | 1 |
| de Cremoux, P | 2 |
| Diéras, V | 1 |
| Poupon, MF | 1 |
| Magdelénat, H | 1 |
| Sigal-Zafrani, B | 3 |
| Fourquet, A | 2 |
| Pierga, JY | 2 |
| Harwood, KV | 1 |
| Fentiman, IS | 1 |
| Travis, K | 1 |
| Beex, L | 1 |
| Nortier, JW | 2 |
| Rutqvist, LE | 2 |
| Ebbs, SR | 5 |
| Skene, A | 6 |
| Griffith, C | 3 |
| Boeddinghaus, I | 5 |
| Ashley, S | 3 |
| Walsh, G | 7 |
| Clemons, MJ | 2 |
| Michaud, LB | 1 |
| Bershtein, LM | 2 |
| Poroshina, TE | 1 |
| Zimarina, TS | 1 |
| Tsyrlina, EV | 1 |
| Zhil'tsova, EK | 2 |
| Kovalevskii, AY | 1 |
| Sawada, S | 1 |
| Sato, K | 1 |
| Kusuhara, M | 1 |
| Ayaori, M | 1 |
| Yonemura, A | 1 |
| Tamaki, K | 1 |
| Hiraide, H | 1 |
| Mochizuki, H | 1 |
| Ohsuzu, F | 1 |
| Castelazo Rico, G | 1 |
| Molotla Xolalpa, D | 1 |
| Basavilvazo Rodríguez, MA | 1 |
| Angeles Victoria, L | 1 |
| Zárate, A | 1 |
| Hernández Valencia, M | 1 |
| Tsubono, M | 1 |
| Kaneko, I | 1 |
| Kii, E | 1 |
| Tanaka, T | 1 |
| Kamimura, K | 1 |
| Deguchi, Y | 1 |
| Nonogaki, H | 1 |
| Yasumizu, R | 1 |
| Itoh, T | 2 |
| Karlsberg, K | 1 |
| Kijima, I | 2 |
| Yuan, YC | 1 |
| Smith, D | 1 |
| Chettle, C | 1 |
| Baker, MA | 1 |
| Joensuu, H | 1 |
| Yuasa, H | 1 |
| Katsumine, Y | 1 |
| Uehara, S | 1 |
| Noda, N | 1 |
| Osawa, I | 1 |
| Iaffaioli, RV | 1 |
| Formato, R | 1 |
| Tortoriello, A | 1 |
| Del Prete, S | 1 |
| Caraglia, M | 1 |
| Pappagallo, G | 1 |
| Pisano, A | 1 |
| Gebbia, V | 1 |
| Fanelli, F | 1 |
| Ianniello, G | 1 |
| Cigolari, S | 1 |
| Pizza, C | 1 |
| Marano, O | 1 |
| Pezzella, G | 1 |
| Pedicini, T | 1 |
| Febbraro, A | 1 |
| Incoronato, P | 1 |
| Manzione, L | 1 |
| Ferrari, E | 1 |
| Marzano, N | 1 |
| Quattrin, S | 1 |
| Pisconti, S | 1 |
| Nasti, G | 1 |
| Giotta, G | 1 |
| Colucci, G | 1 |
| Kalidas, M | 1 |
| Delozier, T | 1 |
| Manquez, ME | 2 |
| Shields, CL | 2 |
| Karatza, EC | 1 |
| Shields, JA | 2 |
| Sinnett, HD | 1 |
| Hadjiminas, D | 1 |
| Singhal, H | 1 |
| Mansi, JL | 1 |
| Shivapatham, D | 1 |
| Shousha, S | 1 |
| Peston, D | 1 |
| Barrett, N | 1 |
| Vigushin, D | 1 |
| Morrison, K | 1 |
| Beresford, E | 1 |
| Ali, S | 1 |
| Slade, MJ | 1 |
| Elledge, RM | 1 |
| Ponzone, R | 2 |
| Sismondi, P | 3 |
| Nordman, IC | 1 |
| Spillane, AJ | 1 |
| Hamilton, AL | 1 |
| Blohmer, JU | 1 |
| Ashley, SE | 1 |
| White, S | 3 |
| Evans, D | 1 |
| Krause, A | 2 |
| Puntoni, M | 1 |
| Paladini, G | 2 |
| Mesiti, M | 2 |
| Romeo, D | 1 |
| Rinaldini, M | 2 |
| Scali, S | 2 |
| Benedetto, C | 3 |
| Restuccia, N | 2 |
| Buzzi, F | 2 |
| Franchi, R | 2 |
| Distante, V | 2 |
| Kristensen, VN | 1 |
| Sørlie, T | 1 |
| Yoshimura, N | 1 |
| Linegjaerde, OC | 1 |
| Glad, I | 1 |
| Frigessi, A | 1 |
| Harada, N | 1 |
| Børresen-Dale, AL | 1 |
| Banerjee, S | 2 |
| Folkerd, L | 1 |
| Iqbal, J | 1 |
| Barker, P | 2 |
| Bria, E | 2 |
| Giannarelli, D | 2 |
| Felici, A | 2 |
| Nisticò, C | 1 |
| Milella, M | 3 |
| Mottolese, M | 1 |
| Ryan, PD | 1 |
| Kopans, DB | 1 |
| Aghi, M | 1 |
| Kiehl, TR | 1 |
| Brisman, JL | 1 |
| Glassman, R | 1 |
| Chowdhury, S | 1 |
| Ellis, PA | 1 |
| Chen, V | 1 |
| Takahama, T | 1 |
| Ooi, Y | 1 |
| Song, ST | 1 |
| Doody, D | 1 |
| Haynes, B | 2 |
| Dickler, M | 1 |
| Abram, P | 1 |
| Denes, AE | 1 |
| Erkanli, S | 1 |
| Kayaselcuk, F | 1 |
| Kuscu, E | 1 |
| Bolat, F | 1 |
| Sakalli, H | 1 |
| Haberal, A | 1 |
| Haberstich, R | 1 |
| Tuech, JJ | 1 |
| Wilt, M | 1 |
| Rodier, JF | 1 |
| Demonty, G | 1 |
| Robert, NJ | 2 |
| Yoneda, K | 1 |
| Bertelli, G | 1 |
| Garrone, O | 1 |
| Merlano, M | 1 |
| Occelli, M | 1 |
| Bertolotti, L | 1 |
| Castiglione, F | 1 |
| Pepi, F | 1 |
| Fusco, O | 1 |
| Leonard, RC | 3 |
| Sereda, D | 1 |
| Werth, VP | 1 |
| Tuma, RS | 1 |
| Rundle, P | 1 |
| Rennie, I | 1 |
| Wang, LP | 1 |
| Shen, KW | 1 |
| Shan, ZZ | 1 |
| Mylonas, I | 1 |
| Makovitzky, J | 1 |
| Kundt, G | 1 |
| Gltick, S | 1 |
| Abrial, C | 1 |
| Leheurteur, M | 1 |
| Cabrespine, A | 1 |
| Kwiatkowski, F | 1 |
| Penault-Llorca, F | 1 |
| Cure, H | 1 |
| Cataliotti, L | 1 |
| Bines, J | 1 |
| Petrakova, K | 1 |
| Dube, P | 1 |
| de Oliveira, CT | 1 |
| Langenegger, T | 1 |
| Wahl, P | 1 |
| Schiesser, D | 1 |
| Grana, G | 1 |
| Mareck, U | 1 |
| Geyer, H | 1 |
| Guddat, S | 1 |
| Haenelt, N | 1 |
| Koch, A | 1 |
| Kohler, M | 1 |
| Opfermann, G | 1 |
| Thevis, M | 1 |
| Schänzer, W | 1 |
| Yap, YS | 1 |
| Santen, RJ | 2 |
| Hayes, D | 1 |
| Lycette, JL | 1 |
| Luoh, SW | 1 |
| Beer, TM | 1 |
| Deloughery, TG | 1 |
| Gil, JM | 1 |
| Rubio-Terrés, C | 1 |
| Del Castillo, A | 1 |
| González, P | 1 |
| Canorea, F | 1 |
| Maciá Escalante, S | 1 |
| Pons Sanz, V | 1 |
| Rodríguez Lescure, A | 1 |
| Ballester Navarro, I | 1 |
| Carrato Mena, A | 1 |
| Duffy, MJ | 1 |
| Brown, MM | 1 |
| Adams, JE | 2 |
| Hoctin-Boes, G | 2 |
| Malka, I | 1 |
| Rosty, C | 1 |
| Languille, O | 1 |
| Campana, F | 2 |
| Skedgel, C | 3 |
| Dewar, R | 3 |
| Younis, T | 3 |
| Piskur, P | 1 |
| Sonc, M | 1 |
| Borstnar, S | 1 |
| Mrhar, A | 1 |
| Ohsako, T | 2 |
| Nagamoto, N | 2 |
| Yoshida, Y | 2 |
| Nakahara, O | 1 |
| Sakamoto, N | 1 |
| El-Saghir, NS | 1 |
| El-Hajj, II | 1 |
| Makarem, JA | 1 |
| Otrock, ZK | 1 |
| Mauri, D | 1 |
| Pavlidis, N | 1 |
| Polyzos, NP | 1 |
| Ioannidis, JP | 1 |
| Moeremans, K | 1 |
| Annemans, L | 1 |
| Brueggemeier, RW | 1 |
| Zapata, E | 1 |
| Zubiaurre, L | 1 |
| Bujanda, L | 1 |
| Piérola, A | 1 |
| Goodwin, GM | 1 |
| Conti-Beltraminelli, M | 1 |
| Ballerini, G | 1 |
| Richetti, A | 1 |
| Graffeo, R | 1 |
| Ruggeri, M | 1 |
| Forni, V | 1 |
| Pianca, S | 1 |
| Schönholzer, C | 1 |
| Mainetti, C | 1 |
| Cavalli, F | 1 |
| Monnier, A | 1 |
| Resnik, KS | 1 |
| DiLeonardo, M | 1 |
| Gibbons, G | 1 |
| Chien, AJ | 1 |
| Zuna, I | 2 |
| Greenwood, M | 1 |
| Ciccarese, M | 1 |
| Nuzzo, C | 1 |
| Gnant, MF | 1 |
| Grampp, S | 1 |
| Kaessmann, H | 1 |
| Schmid, M | 3 |
| Piswanger-Soelkner, JC | 1 |
| Galid, A | 1 |
| Mittlboeck, M | 1 |
| Hausmaninger, H | 1 |
| Chu, QD | 1 |
| McDonald, JC | 1 |
| Li, BD | 1 |
| Hojo, S | 1 |
| Maeura, Y | 1 |
| Yoshioka, S | 1 |
| Fujie, Y | 1 |
| Fukunaga, H | 1 |
| Okada, Y | 1 |
| Ota, H | 1 |
| Endo, W | 1 |
| Tanaka, E | 1 |
| Lewis, S | 1 |
| Imai, H | 1 |
| Kuroi, K | 1 |
| Ono, M | 1 |
| Mansel, R | 2 |
| Dobrez, D | 1 |
| Sorensen, S | 1 |
| Gandhi, SK | 1 |
| Rigden, CE | 1 |
| Toomey, MD | 2 |
| Samples, JR | 1 |
| Cianfrocca, M | 1 |
| van Nes, JG | 1 |
| Sahin, FI | 1 |
| Yilmaz, Z | 1 |
| Karakuş, S | 1 |
| Boğa, S | 1 |
| Akçali, Z | 1 |
| DemIrhan, B | 1 |
| Margolis, R | 1 |
| Singh, AD | 1 |
| Matsumoto, C | 1 |
| Momiyama, N | 1 |
| Chishima, T | 1 |
| Ichikawa, Y | 1 |
| Togo, S | 1 |
| Inui, K | 1 |
| Shimada, H | 1 |
| Azim, AA | 1 |
| Costantini-Ferrando, M | 1 |
| Lostritto, K | 1 |
| Oktay, K | 1 |
| Pötter, R | 1 |
| Handl-Zeller, L | 1 |
| Pakisch, B | 1 |
| Hammer, J | 1 |
| Sedlmayer, F | 1 |
| Reiner, G | 1 |
| Kapp, K | 1 |
| Hofbauer, F | 2 |
| Rottenfusser, A | 1 |
| Draxler, W | 1 |
| Mundhenke, C | 1 |
| Roche, M | 1 |
| Daly, P | 1 |
| Crowley, V | 1 |
| Darby, C | 1 |
| Barnes, L | 1 |
| Omatsu, M | 1 |
| Seki, K | 1 |
| Hasegawa, T | 1 |
| Fukutomi, T | 1 |
| Yang, MT | 1 |
| Lian, ZQ | 1 |
| Li, HP | 1 |
| Ji, JF | 1 |
| Hou, KY | 1 |
| Jia, TZ | 1 |
| Zhao, HM | 1 |
| Xiao, Y | 1 |
| Wang, MP | 1 |
| Wang, YF | 1 |
| Wengström, Y | 2 |
| Leto di Priolo, S | 1 |
| Cannon, H | 1 |
| Georgiou, V | 1 |
| Martino, S | 1 |
| Piccart, MJ | 1 |
| Tu, D | 1 |
| Norton, L | 1 |
| Abrams, JS | 1 |
| Palmer, MJ | 1 |
| Pater, JL | 1 |
| Michelotti, A | 1 |
| Ricci, S | 1 |
| Pellegrini, M | 1 |
| Cresti, N | 1 |
| Alimonti, A | 1 |
| Salesi, N | 1 |
| Perez-Fidalgo, JA | 1 |
| Chirivella, I | 1 |
| Laforga, J | 1 |
| Colio, JM | 1 |
| Blanes, MD | 1 |
| Baydal, R | 1 |
| Roselló, S | 1 |
| De-la-Morena, E | 1 |
| Lluch, A | 1 |
| Lewis, J | 1 |
| Ziltsova, EK | 1 |
| Ivanov, VG | 2 |
| Melnikova, OA | 1 |
| Kletzel, A | 1 |
| Berstein, LM | 1 |
| Mackay, A | 1 |
| Urruticoechea, A | 1 |
| Fenwick, K | 1 |
| Ashworth, A | 1 |
| Hilfrich, J | 1 |
| Gademann, G | 1 |
| Karnon, J | 1 |
| Delea, T | 1 |
| Barghout, V | 1 |
| Hind, D | 1 |
| Ward, S | 1 |
| De Nigris, E | 1 |
| Simpson, E | 1 |
| Carroll, C | 1 |
| Confavreux, CB | 1 |
| Fontana, A | 1 |
| Munoz, F | 1 |
| Brun, J | 1 |
| Delmas, PD | 1 |
| Winters, L | 1 |
| Habin, K | 1 |
| Gallagher, J | 1 |
| Liu, G | 1 |
| Marrinan, CH | 1 |
| Taylor, SA | 1 |
| Black, S | 1 |
| Basso, AD | 1 |
| Kirschmeier, P | 1 |
| Robert Bishop, W | 1 |
| Long, BJ | 2 |
| Llombart, A | 2 |
| Mayordomo, JI | 1 |
| Clark, E | 1 |
| Magill, P | 1 |
| Thomsen, T | 1 |
| Banke-Bochita, J | 1 |
| Yonehara, Y | 1 |
| Iwamoto, I | 1 |
| Lindberg, H | 1 |
| Nielsen, DL | 1 |
| Tuxen, M | 1 |
| Kamby, C | 1 |
| Fabian, CJ | 1 |
| Dede, D | 1 |
| Harputluoglu, H | 2 |
| Gullu, I | 1 |
| Bertoli, LF | 1 |
| Barton, JC | 1 |
| Jahanzeb, M | 1 |
| Schilder, CM | 1 |
| Schagen, SB | 1 |
| Graham, PH | 1 |
| Laroche, M | 1 |
| Borg, S | 1 |
| Lassoued, S | 1 |
| De Lafontan, B | 1 |
| Roché, H | 2 |
| Bollet, MA | 1 |
| Kirova, YM | 1 |
| Antoni, G | 1 |
| Laki, F | 1 |
| Dendale, R | 1 |
| Cottu, P | 1 |
| Dashian, GA | 1 |
| Tonuzov, EE | 1 |
| Mel'nikova, OA | 1 |
| Klettsel', AA | 1 |
| Krivorot'ko, PV | 1 |
| Donskikh, RV | 1 |
| Kochetova, IA | 1 |
| Damenia, AO | 1 |
| Zernov, KIu | 1 |
| Voskresenskiĭ, DA | 1 |
| Stilwill, SE | 1 |
| Cooper, BC | 1 |
| Dizdar, O | 1 |
| Kovács, O | 1 |
| Kotsis, L | 1 |
| Krasznai, G | 1 |
| Johnston, SRD | 1 |
| Brodie, AM | 2 |
| Zujewski, JA | 1 |
| Renner, K | 1 |
| Dadak, C | 1 |
| Kurosumi, M | 1 |
| Sakamoto, G | 1 |
| Eisen, A | 1 |
| Shelley, W | 1 |
| Messersmith, H | 1 |
| LaFountain, A | 1 |
| Mayer, E | 1 |
| Taylor, BS | 1 |
| Asnis-Alibozek, A | 1 |
| Allred, C | 1 |
| Bishop, H | 1 |
| Larsimont, D | 1 |
| Carder, P | 1 |
| Cussac, AL | 1 |
| Knox, F | 1 |
| Speirs, V | 1 |
| Matsumoto, M | 1 |
| Ue, H | 1 |
| Nishioka, A | 1 |
| Kodama, H | 1 |
| Sasaguri, S | 1 |
| Ogawa, Y | 1 |
| Herold, CI | 2 |
| Blackwell, KL | 2 |
| Miyake, A | 1 |
| Shiiki, S | 1 |
| Carpenter, R | 1 |
| Thiery-Vuillemin, A | 1 |
| Chaigneau, L | 1 |
| Meaux-Ruault, N | 1 |
| Villanueva, C | 1 |
| N'guyen, T | 1 |
| Maurina, T | 1 |
| Stein, U | 1 |
| Lorgis, V | 1 |
| Demarchi, M | 1 |
| Pivot, X | 1 |
| Pennery, E | 1 |
| Kihara, M | 1 |
| Miyauchi, A | 1 |
| Thomas, JS | 1 |
| Goloubeva, OG | 1 |
| Gil, M | 1 |
| Sánchez-Rovira, P | 1 |
| Adrover, E | 1 |
| Estevez, LG | 1 |
| de la Haba, J | 1 |
| Calvo, L | 2 |
| Mellington, TE | 1 |
| Fields, MM | 1 |
| Plourde, PV | 5 |
| Dyroff, M | 2 |
| Demers, L | 1 |
| Yates, R | 2 |
| Dukes, M | 2 |
| Blomqvist, C | 2 |
| Vogel, CL | 3 |
| Wolter, JM | 2 |
| Azab, M | 2 |
| Winblad, G | 1 |
| Tyrrell, C | 1 |
| Lundgren, S | 2 |
| Hellmund, R | 1 |
| King, N | 2 |
| Ottestad, L | 2 |
| Walton, P | 1 |
| Kormeset, PO | 1 |
| Wolter, J | 1 |
| Plourde, P | 1 |
| Hannaford, M | 1 |
| Tekmal, RR | 1 |
| Durgam, VR | 1 |
| Roseman, BJ | 1 |
| Singletary, SE | 1 |
| Willsher, PC | 1 |
| Elston, CW | 1 |
| Blamey, RW | 1 |
| Tye, LM | 1 |
| Carrion, RP | 1 |
| Dodwell, DJ | 2 |
| Vorobiof, DA | 2 |
| Aparicio, LA | 1 |
| Higa, GM | 1 |
| alKhouri, N | 1 |
| Harvey, HA | 2 |
| Lu, Q | 1 |
| Long, B | 1 |
| Wang, JP | 1 |
| Yue, W | 2 |
| Blomqvist, CP | 1 |
| Steinberg, M | 5 |
| Lee, D | 2 |
| Wiseman, LR | 1 |
| Adkins, JC | 1 |
| Tilghman, SL | 1 |
| Thiantanawat, A | 1 |
| Grigoryev, DN | 1 |
| Blackman, GM | 1 |
| Welch, H | 1 |
| von Euler, M | 6 |
| Hamilton, A | 2 |
| de Jong, PC | 1 |
| Blijham, GH | 1 |
| Leaity, SK | 1 |
| Benson, S | 1 |
| Harper-Wynne, C | 2 |
| Feutrie, ML | 1 |
| Perez-Carrion, R | 1 |
| Bland, KI | 2 |
| Love, CD | 1 |
| Bellamy, C | 2 |
| Bichisao, E | 2 |
| Berntsen, H | 2 |
| Lonning, PE | 1 |
| Donaldson, K | 1 |
| Tsuboi, M | 1 |
| Wong, J | 1 |
| Masamura, S | 1 |
| Matsui, A | 1 |
| Hohjoh, T | 1 |
| Kawaguchi, M | 1 |
| Takayama, S | 1 |
| Tokura, H | 1 |
| Mitsui, Y | 1 |
| Fujiwara, K | 1 |
| Kitajima, M | 1 |
| Crucitta, E | 1 |
| Attolico, M | 1 |
| Sambiasi, D | 1 |
| Mazzei, A | 1 |
| De Lena, M | 1 |
| Leung, P | 1 |
| Mather, J | 1 |
| Oza, A | 1 |
| Krzakowski, M | 2 |
| Koralewski, L | 1 |
| Koralewski, P | 1 |
| Pollak, M | 1 |
| Harwin, W | 1 |
| Kuwabara, K | 1 |
| Okazaki, T | 1 |
| Fujita, T | 1 |
| Oizumi, I | 1 |
| Kaiho, S | 1 |
| Ogata, E | 1 |
| Messori, A | 1 |
| Cattel, F | 1 |
| Trippoli, S | 1 |
| Vaiani, M | 1 |
| Cohen, MH | 1 |
| Hirschfeld, S | 1 |
| Flamm Honig, S | 1 |
| Ibrahim, A | 1 |
| Johnson, JR | 1 |
| O'Leary, JJ | 1 |
| White, RM | 1 |
| Williams, GA | 1 |
| Lefeuvre, C | 1 |
| Tsukagoshi, S | 1 |
| Panasci, LC | 1 |
| Bagley, CM | 1 |
| Rowbotham, RK | 1 |
| Tonkin, K | 1 |
| Copur, MS | 1 |
| Ledakis, P | 1 |
| Bolton, M | 1 |
| Norvell, M | 1 |
| Muhvic, J | 1 |
| Costa, SD | 1 |
| Lindtjørn, B | 1 |
| Einstein Lønning, P | 1 |
| Donnellan, PP | 1 |
| Douglas, SL | 1 |
| Bergmann, L | 1 |
| Tominaga, T | 1 |
| Jackson, I | 1 |
| Volm, M | 1 |
| Murray, R | 1 |
| Dixon, M | 1 |
| Ebbs, S | 1 |
| Gui, G | 1 |
| Sacks, N | 1 |
| Feng, F | 1 |
| Reese, DM | 1 |
| Bando, H | 1 |
| Anker, G | 1 |
| De Marco, S | 1 |
| Casali, A | 1 |
| Nardi, M | 1 |
| Paoloni, F | 1 |
| Junker, A | 1 |
| Wiedemann, GJ | 1 |
| Lavrenkov, K | 1 |
| Man, S | 1 |
| Geffen, DB | 1 |
| Cohen, Y | 1 |
| Johnson, PE | 1 |
| Nicholls, H | 1 |
| Soudon, J | 1 |
| Buzzoni, R | 1 |
| Gattinoni, L | 1 |
| Catena, L | 1 |
| Vitali, M | 1 |
| Celio, L | 1 |
| Genta, F | 1 |
| Vicelli, R | 1 |
| De Nicola, B | 1 |
| Ferraris, F | 1 |
| Piccinno, R | 1 |
| Ragonesi, G | 1 |
| Colla, F | 1 |
| Mazzoleni, A | 1 |
| Farina, C | 1 |
| Lynn, J | 1 |
| Ravdin, P | 1 |
| Budzar, AU | 1 |
| Houghton, JH | 1 |
| Klijn, JG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregional[NCT02246621] | Phase 3 | 493 participants (Actual) | Interventional | 2014-11-06 | Active, not recruiting | ||
| A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormon[NCT02730923] | Phase 1/Phase 2 | 72 participants (Anticipated) | Interventional | 2016-04-30 | Active, not recruiting | ||
| Testosterone Implants and the Incidence of Breast Cancer RETROSPECTIVE CHART REVIEW[NCT03768258] | 1,268 participants (Actual) | Observational | 2008-03-31 | Completed | |||
| A Single-arm Phase II Trial to Evaluate Serum Estradiol Levels in Patients With Breast Cancer Treated With Vaginal Estrogen, Estring[NCT01923298] | Phase 2 | 14 participants (Actual) | Interventional | 2013-08-09 | Completed | ||
| A Randomized, Open-label Study of First Line Pyrotinib, Trastuzumab With an Aromatase Inhibitors, in the Treatment of HER2 Positive and HR Positive Metastatic or Inoperable Locally Advanced Breast Cancer[NCT03910712] | Phase 2 | 250 participants (Anticipated) | Interventional | 2019-06-01 | Not yet recruiting | ||
| A Prospective, Randomized, Open, Multicentre Phase III-study to Assess the Efficacy of Secondary Adjuvant Endocrine Anastrozole Therapy for 2 Further Yrs vs 5 Further Yrs in Patients With HR +ve Breast Cancer After 5-yr Primary Adjuvant Endocrine Therapy[NCT00295620] | Phase 3 | 3,484 participants (Actual) | Interventional | 2004-03-01 | Completed | ||
| A Phase II Randomized Trial of Lenvatinib Combined With Letrozole Versus Fulvestrant in Metastatic Estrogen Receptor (ER) Positive, HER2 Negative Breast Cancer, Who Have Progressed on First-line Aromatase Inhibitor + a CDK4/6 Inhibitor.[NCT05181033] | Phase 2 | 120 participants (Anticipated) | Interventional | 2021-12-27 | Recruiting | ||
| Phase II, Multicenter, Single Arm Trial to Assess the Feasibility of First Line Ribociclib in Combination With a Non Steroidal Aromatase Inhibitor in Elderly Patients With Hormone Receptor Positive/HER2 Negative Advanced Breast Cancer[NCT03944434] | Phase 2 | 116 participants (Actual) | Interventional | 2018-12-27 | Active, not recruiting | ||
| Trial of Tucidinostat in Combination With Fulvestrant in Patients With Hormone-receptor Positive Advanced Breast Cancer[NCT04999540] | Phase 2 | 73 participants (Anticipated) | Interventional | 2021-11-01 | Not yet recruiting | ||
| LA LEAST- Luminal A, Limited Endocrine Adjuvant Systemic Therapy. A Trial of Abbreviated Hormone Therapy for Low Risk Hormone Receptor Positive, HER2 Negative Early Breast Cancer[NCT03917082] | Phase 2 | 290 participants (Anticipated) | Interventional | 2019-09-23 | Active, not recruiting | ||
| A Prospective Randomised, Open, Multicentre, Phase III Study to Assess Different Durations of Anastrozole Therapy After 2 to 3 Years Tamoxifen as Adjuvant Therapy in Postmenopausal Women With Breast Cancer.[NCT00301457] | Phase 3 | 1,914 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| International Breast Cancer Intervention Study[NCT00078832] | Phase 3 | 3,864 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| International Breast Cancer Intervention Study II (IBIS-II) (DCIS)[NCT00072462] | Phase 3 | 2,980 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| A Randomized Phase III Trial Of Exemestane Versus Anastrozole In Postmenopausal Women With Receptor Positive Primary Breast Cancer[NCT00066573] | Phase 3 | 7,576 participants (Actual) | Interventional | 2003-06-06 | Completed | ||
| A Phase III Study Comparing Anastrozole, Letrozole and Exemestane, Upfront (for 5 Years) or Sequentially (for 3 Years After 2 Years of Tamoxifen), as Adjuvant Treatment of Postmenopausal Patients With Endocrine-responsive Breast Cancer[NCT00541086] | Phase 3 | 3,697 participants (Actual) | Interventional | 2007-03-31 | Active, not recruiting | ||
| A Randomised, Double-blind, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg With Anastrozole (ARIMIDEX) 1 mg as Hormonal Treatment for Postmenopausal Women With Hormone Receptor-Positi[NCT01602380] | Phase 3 | 462 participants (Actual) | Interventional | 2012-10-17 | Active, not recruiting | ||
| A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors[NCT00004205] | Phase 3 | 8,028 participants (Actual) | Interventional | 1998-03-31 | Completed | ||
| Randomized Phase II Study OF Goserelin (G) Plus Fulvestrant (F) vs. G Plus Anastrozole (A)vs. G Alone for HR+, Tamoxifen Pretreated, Premenopausal Woman[NCT01266213] | Phase 2 | 147 participants (Anticipated) | Interventional | 2010-12-31 | Active, not recruiting | ||
| A Randomized Multicenter Phase II Study Identifying Hormone Sensitivity Profiles and Evaluating the Efficacy of Anastrozole and Fulvestrant in the Neo-adjuvant Treatment of Operable Breast Cancer in Postmenopausal Women.[NCT00629616] | Phase 2 | 116 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| An Open-Label, Non-randomised, Parallel Group, Multicentre, Phase I Study to Assess the Safety and Effect of Olaparib at Steady State on the Pharmacokinetics of the Anti-hormonal Agents Anastrozole, Letrozole and Tamoxifen at Steady State, and the Effect [NCT02093351] | Phase 1 | 79 participants (Actual) | Interventional | 2014-09-01 | Completed | ||
| A Single--blind, Randomized, Placebo--controlled Phase II Study to Evaluate the Impact of Oral Bisphosphonate Treatment on Bone Mineral Density in Osteopenic Women Receiving Adjuvant Aromatase Inhibitors - BONADIUV Trial[NCT02616744] | Phase 2 | 171 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women With Metastatic Breast Cancer[NCT00075764] | Phase 3 | 695 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Phase III Trial Comparing Efficacy and Tolerance of Fulvestrant for 3 Years (y) Combined With Anastrozole 5 y Versus Anastrozole 5 y as Adjuvant Hormonotherapy in Postmenopausal With Early Breast Cancer and Positive Hormone Receptors[NCT00543127] | Phase 3 | 870 participants (Actual) | Interventional | 2007-11-30 | Terminated (stopped due to Unjustified decision of company that funded the trial.) | ||
| A Double-blind, Randomized, Multicentre Trial to Compare the Anti-tumour Effects and Tolerability of a 500 mg Dose of Faslodex (Fulvestrant) Plus Arimidex (Anastrozole) With a 500 mg Dose of Faslodex(Fulvestrant) Alone and With Arimidex(Anastrozole) Alone[NCT00259090] | Phase 2 | 120 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure[NCT00555477] | Phase 2 | 69 participants (Actual) | Interventional | 2007-08-31 | Terminated (stopped due to The study was stopped after 69 subjects were enrolled because of poor accrual.) | ||
| Light Emitting Diode for the Treatment of Genitourinary Syndrome of Menopause Associated With Hormonal Therapy for Treating Breast Cancer: Randomized Controlled Clinical Trial[NCT03833726] | 77 participants (Actual) | Interventional | 2019-01-30 | Completed | |||
| A Randomized, Open, Comparative Multicentre Trial of 3 Years Anastrozole Treatment vs. 3 Years no Treatment in Postmenopausal Patients With Breast Cancer Who Have Completed 5 Years Adjuvant Hormone Therapy.[NCT00300508] | Phase 3 | 856 participants | Interventional | 1996-01-31 | Completed | ||
| A Partially-Blind Phase III Randomized Trial of Fulvestrant (Faslodex™) With or Without Concomitant Anastrozole (Arimidex™) Compared With Exemestane in Postmenopausal Women With ER+ve Locally Advanced/Metastatic Breast Cancer Following Progression on Non-[NCT00253422] | Phase 3 | 750 participants (Anticipated) | Interventional | 2004-03-31 | Active, not recruiting | ||
| A Partially-blind Phase III Randomised Trial of Fulvestrant (Faslodex) With or Without Concomitant Anastrozole (Arimidex) Compared With Exemestane in Postmenopausal Women With ER+ve Locally Advanced/Metastatic Breast Cancer Following Progression on Non-st[NCT00944918] | Phase 3 | 25 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Breast Cancer Index (BCI) Registry[NCT04875351] | 3,000 participants (Anticipated) | Observational [Patient Registry] | 2021-04-14 | Recruiting | |||
| Prospective Assessment of Disease Progression in Primary Breast Cancer Patients Undergoing EndoPredict® Gene Expression Testing - a Care Research Study[NCT03503799] | 1,191 participants (Actual) | Observational [Patient Registry] | 2018-07-17 | Active, not recruiting | |||
| Effects of Progressive Relaxation Training on Artralgia, Quality of Life and Emotional Status in Breast Cancer Patients Receiving Aromatatase Inhibitor Therapy[NCT04163692] | 44 participants (Actual) | Interventional | 2019-10-25 | Completed | |||
| Adjuvant Endocrine Therapy in Postmenopausal Patients With HR +ve BC With Good to Moderate Differentiation - ARNO (Arimidex + Nolvadex). Primary Treatment for 2 Years With Tamoxifen Thereafter Randomisation to: Tamoxifen 3 Years or Anastrozole 3 Years.[NCT00291759] | Phase 3 | 3,858 participants (Actual) | Interventional | 1996-01-31 | Completed | ||
| Arimidex: Compliance and Arthralgias in Clinical Therapy (COMPACT): An in Practice Assessment of Arthralgias and Related Costs as Well as Compliance in the First Year of Anastrozole Therapy[NCT00857012] | 2,313 participants (Actual) | Observational | 2009-04-30 | Completed | |||
| The Influence of Five Years of Adjuvant Anastrozole or Exemestane on Bone Mineral Density In Postmenopausal Women With Primary Breast Cancer[NCT00354302] | Phase 3 | 497 participants (Actual) | Interventional | 2006-04-24 | Completed | ||
| Flaxseed vs. Aromatase Inhibitors: Breast Tumor Characteristics and Prognosis[NCT00612560] | 28 participants (Actual) | Interventional | 2007-11-30 | Completed | |||
| A Randomized, Open-label Phase III Trial to Evaluate the Efficacy and Safety of Pertuzumab Retreatment in Previously Pertuzumab, Trastuzuamb and Chemotherapy Treated Her2-Positive Metastatic Advanced Breast Cancer[NCT02514681] | Phase 3 | 370 participants (Anticipated) | Interventional | 2015-08-01 | Active, not recruiting | ||
| Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance[NCT01197170] | Phase 1 | 277 participants (Actual) | Interventional | 2010-09-07 | Completed | ||
| Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid, in Premenopausal, Hormone Receptor-positive Breast Cancer Patients (Stage I, II)[NCT00295646] | Phase 3 | 1,803 participants (Actual) | Interventional | 1999-06-30 | Completed | ||
| Impact of Routine Assessment of Health-Related Quality of Life Coupled With Therapeutic Information on Compliance With Endocrine Therapy in Patients With Non-metastatic Breast Cancer[NCT04176809] | 342 participants (Anticipated) | Interventional | 2021-05-14 | Recruiting | |||
| Response to Neoadjuvant Treatment With Anti-aromatase Anastrozole and Anti-estrogen Fulvestrant: a Randomized Phase II Study in Postmenopausal Patients With Hormone-sensitive Non-metastatic Breast Cancer and an Exploratory Study of Molecular Signatures of[NCT00871858] | Phase 2 | 120 participants (Actual) | Interventional | 2008-03-18 | Completed | ||
| Randomized Phase II Trial of Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer[NCT02955394] | Phase 2 | 61 participants (Actual) | Interventional | 2017-09-21 | Active, not recruiting | ||
| Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study (CONCEPT Trial)[NCT04012918] | Phase 2 | 124 participants (Anticipated) | Interventional | 2018-08-30 | Recruiting | ||
| Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast.[NCT03002766] | Phase 2 | 224 participants (Actual) | Interventional | 2000-03-31 | Completed | ||
| A Clinical Trial Comparing Anastrozole With Tamoxifen in Postmenopausal Patients With Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy With Radiation Therapy[NCT00053898] | Phase 3 | 3,104 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| An EORTC Randomized, Double Blind, Placebo-Controlled, Phase II Multi-Center Trial Of Anastrozole (Arimidex) In Combination With ZD 1839 (Iressa) Or Placebo In Patients With Advanced Breast Cancer[NCT00066378] | Phase 2 | 71 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| Phase 2 Study Vitamin D3 Effects on Musculoskeletal Symptoms With Use of Aromatase Inhibitors[NCT01509079] | Phase 2 | 116 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF FULVESTRANT (FASLODEX (REGISTERED)). WITH OR WITHOUT PD-0332991 (PALBOCICLIB) +/- GOSERELIN IN WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER WHOSE D[NCT01942135] | Phase 3 | 521 participants (Actual) | Interventional | 2013-09-26 | Completed | ||
| Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA[NCT05814224] | 164 participants (Anticipated) | Interventional | 2018-05-22 | Recruiting | |||
| A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of AZD8931 In Combination With Anastrozole, Compared to Anastrozole Alone, in Post Menopausal Women With Hormone Receptor Positive, Endocrine Th[NCT01151215] | Phase 2 | 482 participants (Actual) | Interventional | 2010-06-30 | Terminated (stopped due to Futility) | ||
| Phase II Study of Pyrotinib in Combination With Fulvestrant in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive，Hormone Receptor（HR）-Positive Metastatic Breast Cancer[NCT04034589] | Phase 2 | 46 participants (Anticipated) | Interventional | 2019-07-17 | Recruiting | ||
| A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg Daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer[NCT00265759] | Phase 3 | 622 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study[NCT01953588] | Phase 3 | 1,473 participants (Actual) | Interventional | 2013-12-13 | Active, not recruiting | ||
| Phase Ib Study of Neoadjuvant DPX-Survivac, Aromatase Inhibition, and With/Without Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer[NCT04895761] | Phase 1 | 6 participants (Actual) | Interventional | 2021-09-10 | Active, not recruiting | ||
| A Randomised Effectiveness-implementation Trial for Evaluating Dietary and Manual Treatment With Osteopathic Techniques on Quality of Life and on Modulation of the Inflammatory State of Patients Diagnosed With Breast Cancer Undergoing Antiestrogenic Hormo[NCT06164119] | 600 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | |||
| A Multicenter, Single-arm, Phase II Study to Evaluate the Activity of Pre-operative Zoledronate in Triple Negative Breast Cancer Patients, According to p53 Level[NCT02347163] | Phase 2 | 22 participants (Actual) | Interventional | 2015-02-03 | Terminated (stopped due to The study stopped prematurely due to the low accrual rate) | ||
| A Prospective, Randomized, Multicenter, Open-label Comparison of Pre-surgical Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy Given for Twelve Weeks With a Quality of Life Assessment of Trastuzumab, Pertu[NCT03272477] | Phase 2 | 257 participants (Actual) | Interventional | 2017-10-05 | Active, not recruiting | ||
| Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy. A Prospective Placebo Double Blind Study[NCT01016665] | 71 participants (Actual) | Interventional | 2005-04-30 | Completed | |||
| Presurgical Treatment With Ribociclib and Letrozole in Patients With Locally Advanced Breast Cancer: the NEOLETRIB Study.[NCT05163106] | Phase 2 | 100 participants (Anticipated) | Interventional | 2022-12-01 | Recruiting | ||
| A Prospective, Longitudinal Investigation of the Neuropsychological and Psychosocial Effects of Cancer Therapy[NCT00260975] | 112 participants (Actual) | Observational | 2001-06-30 | Completed | |||
| The Relationship Between Biopsychosocial Functioning and Work-Related Cognitive Limitation Among Employed Breast Cancer Survivors: Case Control Study.[NCT02303145] | 187 participants (Actual) | Observational | 2014-09-30 | Completed | |||
| Chemotherapy-Related Changes in Neurocognitive Function and Symptoms in Colorectal Cancer Patients: A Pilot Study[NCT03683004] | 40 participants (Actual) | Observational | 2018-01-22 | Completed | |||
| Phase II Open-label, Multicentre, Randomized Trial of Neoadjuvant Palbociclib in Combination With Hormonal Therapy and HER2 Blockade Versus Paclitaxel in Combination With HER2 Blockade for Postmenopausal Patients With Hormone Receptor Positive/HER2 Positi[NCT03644186] | Phase 2 | 144 participants (Actual) | Interventional | 2019-04-16 | Completed | ||
| Gonadotropin-releasing Hormone Agonist Combined With Letrozole Compared With Megestrol Acetate or Medroxyprogesterone Acetate Alone as Fertility-sparing Treatment in Early Endometrial Cancer[NCT05247268] | Phase 2 | 104 participants (Anticipated) | Interventional | 2022-03-11 | Recruiting | ||
| Pharmacogenetics of Aromatase Inhibitors[NCT00283608] | 1,000 participants (Anticipated) | Observational | 2005-07-31 | Completed | |||
| A Phase III-IV, Multicenter Open Label Trial of Arimidex Alone Versus Arimidex Plus Bisphosphonates in Postmenopausal Patients With Early, Endocrine Positive Breast Cancer.[NCT00809484] | 220 participants (Actual) | Observational | 2004-05-31 | Completed | |||
| Preoperative Use of Tocotrienol Associated With Personalized Nutritional and Psychoeducational Support in Women With Primary Breast Cancer.[NCT04496492] | Phase 2 | 50 participants (Actual) | Interventional | 2016-02-09 | Completed | ||
| Impact of Body Mass Index on Outcomes of Breast Cancer Management (Retrospective Study)[NCT03429504] | 300 participants (Anticipated) | Observational | 2018-02-12 | Not yet recruiting | |||
| A Phase II Trial of Arimidex Plus Zoladex in the Treatment of Hormone Receptor Positive, Metastatic Carcinoma of the Breast in Premenopausal Women[NCT00186121] | Phase 2 | 35 participants (Actual) | Interventional | 2000-10-31 | Completed | ||
| A Double Blind, Double Dummy, Randomised, Multicentre Study to Compare the Efficacy and Safety of Fulvestrant 250mg With Arimidex 1mg as a Secondary-line Therapy in the Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer[NCT00327769] | Phase 3 | 234 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Long-term Anastrozole Versus Tamoxifen Treatment Effects (LATTE)[NCT01745289] | 2,671 participants (Actual) | Observational | 2010-10-31 | Completed | |||
| Androgen-mediated Pathways in the Regulation of Insulin Sensitivity in Men[NCT01686828] | Phase 1/Phase 2 | 53 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Comparison of Neoadjuvant Aromatase Inhibitors With Ovarian Suppression Versus Chemotherapy in Premenopausal Patients With Hormone Receptor-positive Breast Cancer (COMPETE): a Randomized Phase 3 Trial[NCT02532400] | Phase 3 | 21 participants (Actual) | Interventional | 2016-03-31 | Terminated (stopped due to Hard to enroll expected number of eligible patients.) | ||
| Multicenter, Randomized, Phase II Study of Neoadjuvant Chemotherapy Associated or Not With Zoledronate and Atorvastatin in Triple Negative Breast Cancers - YAPPETIZER Study[NCT03358017] | Phase 2 | 54 participants (Actual) | Interventional | 2018-03-05 | Completed | ||
| A Phase II Trial of Open-Label Bevacizumab Administered With Anastrozole or Fulvestrant as First-Line Therapy in Postmenopausal Hormone Receptor- Positive Metastatic Breast Cancer (With Trastuzumab in HER2-Positive Patients)[NCT00405938] | Phase 2 | 79 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Phase II Randomized, Multicenter, Crossover Clinical Trial for Administration of Exemestane vs. Anastrozole as First Line Treatment for Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer[NCT00128843] | Phase 2 | 103 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| Arimidex/Faslodex/Iressa Study: A Phase II Trial of Primary Systemic Therapy Using a Combination of Arimidex, Faslodex and Iressa (Gefitinib) in Postmenopausal Women With Hormone Receptor Positive Breast Cancer[NCT00206414] | Phase 2 | 15 participants (Actual) | Interventional | 2003-01-31 | Terminated (stopped due to Difficulty accruing subjects the study accrual was closed) | ||
| Surrogate Markers of Response: A Phase II Study of Changes in Breast Density Among Postmenopausal Women Receiving Adjuvant Anastrozole Therapy[NCT00244959] | Phase 2 | 54 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| An Adaptive Randomized Neoadjuvant Two Arm Trial in Triple-negative Breast Cancer Comparing a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy (neoMono)[NCT04770272] | Phase 2 | 416 participants (Actual) | Interventional | 2021-03-01 | Active, not recruiting | ||
| A Randomised, Double-blind, Study Comparing ARIMIDEX™ With NOLVADEX™ as Neo-adjuvant and Adjuvant Treatment in Post-menopausal Women With Large Operable (T2 (≥3cm), T3, N0-2, M0) or Potentially-operable, Locally Advanced (T4b, N0-2, M0), ER+ and/or PR+ Br[NCT00232661] | Phase 3 | 452 participants (Actual) | Interventional | 2000-08-31 | Completed | ||
| Multi-centre, Randomised, Double-blind, Parallel-group Study to Compare Efficacy and Safety Between Anastrozole (ZD1033) and Tamoxifen in Pre- and Post-operative Administration Under Goserelin Acetate Treatment for Premenopausal Breast Cancer Patients[NCT00605267] | Phase 3 | 197 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption?[NCT00766532] | Phase 4 | 12 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Randomized Phase II Trial of Combination Anastrozole (NSC #719344) Plus ZD1839 (Iressa, NSC #715055, IND #61187) and of Combination Fulvestrant (NSC #719276) Plus ZD1839 in the Treatment of Postmenopausal Women With Hormone Receptor-Positive Metastatic [NCT00057941] | Phase 2 | 148 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| A Prospective, Multicentre, Controlled, Observational Study to Evaluate the Performance of Patient Support Programme (PSP) in Improving Patient Adherence With Adjuvant Aromatase Inhibitors (AI) Medication for Postmenopausal, Early Stage Breast Cancer[NCT00769080] | 524 participants (Actual) | Observational | 2008-09-30 | Completed | |||
| A Phase II Study of Palbociclib Plus Fulvestrant for Pretreated Patients With ER+/HER2- Metastatic Breast Cancer[NCT02536742] | Phase 2 | 124 participants (Actual) | Interventional | 2016-08-30 | Active, not recruiting | ||
| Evaluation of Eating Habits and Dysgeusia During Chemotherapy Treatment: a Prospective Cohort Study on Patients Affected by Breast Cancer[NCT03210441] | 204 participants (Anticipated) | Observational | 2014-05-06 | Recruiting | |||
| A Randomised in Practice Evaluation of the Influence of Patient's Understanding of Her Disease and Therapy on Persistence and Compliance to Adjuvant Therapy for Post-menopausal Hormone Sensitive Early Breast Cancer[NCT00555867] | 4,923 participants (Actual) | Observational | 2006-10-31 | Terminated (stopped due to High drop-out rate leads to the conclusion: not enough data will be available to perform proper analyses of data collected after follow-up month 24 visit) | |||
| A Randomized Trial With Factorial Design Comparing Fulvestrant ± Lapatinib ± Aromatase Inhibitor in Metastatic Breast Cancer Progressing After Aromatase Inhibitor Therapy[NCT02394496] | Phase 3 | 396 participants (Anticipated) | Interventional | 2007-11-30 | Recruiting | ||
| A Multicenter, Non-interventional, Prospective Study to Collect Efficacy and Safety Data in Chinese Patients Who Have Received Faslodex 250mg Treatment Under the Condition of Actual Usage in Clinical Practice[NCT01425294] | 231 participants (Actual) | Observational | 2011-08-01 | Terminated (stopped due to The study has been decided to be early terminated for the FAS 500 mg has launched in 2015. The use mothod of 250mg per month in clinical practice is off-label.) | |||
| Treating Verbal Memory Deficits Following Chemotherapy for Breast Cancer[NCT03017560] | 45 participants (Actual) | Interventional | 2015-12-31 | Completed | |||
| Aromatase Inhibitors: Skeletal Effects and the Role of CYP19 Gene Polymorphisms[NCT00603967] | 151 participants (Actual) | Interventional | 2006-03-31 | Completed | |||
| A Phase III Randomized Double Blind Study of Letrozole Versus Placebo in Women With Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen[NCT00003140] | Phase 3 | 5,187 participants (Actual) | Interventional | 1998-08-24 | Completed | ||
| Investigation of Sex Hormone Levels in Chinese Women With Invasive Breast Cancer[NCT02263846] | 1,183 participants (Actual) | Observational | 2011-11-30 | Completed | |||
| Randomized Controlled Evaluating the Role of Exercise in Women Undergoing Treatment for Breast Cancer[NCT05009849] | 850 participants (Actual) | Interventional | 2010-11-23 | Active, not recruiting | |||
| Stereotactic Body Radiotherapy (SBRT) for the Treatment of OligoMetastasis in Breast Cancer Patients (STOMP): A Prospective Feasibility Trial[NCT03295916] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2018-01-01 | Recruiting | ||
| Metabolic and Bone Changes After Adjuvant Cancer Treatments in Early Non-metastatic Breast Cancer - a 5-year Follow-up Study.[NCT03784651] | 120 participants (Anticipated) | Observational | 2018-12-17 | Recruiting | |||
| Vitrification of Oocytes From Female Cancer Patients to Preserve Their Fertility Potential[NCT01268592] | 16 participants (Actual) | Interventional | 2010-10-31 | Terminated (stopped due to Study technique has been declared part of standard care) | |||
| Phase Ib Followed by Phase II Study of Pre-operative Treatment With Lenvatinib Combined With Letrozole in Post-menopausal Women With Newly Diagnosed Hormone Receptor Positive Breast Cancer With Measurable Primary Breast Tumor[NCT02562118] | Phase 1/Phase 2 | 40 participants (Anticipated) | Interventional | 2015-09-30 | Recruiting | ||
| Preoperative Neoadjuvant Hormonal Therapy and Neoadjuvant Chemotherapy for Stage IIIB and IV Breast Cancer Patients in Dharmais National Cancer Center Hospital, Indonesia[NCT02995772] | Phase 3 | 122 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Phase II Randomized Study of Neoadjuvant Metformin Plus Letrozole vs Placebo Plus Letrozole for ER-positive Postmenopausal Breast Cancer[NCT01589367] | Phase 2 | 208 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Safety, Feasibility and Efficacy of Vitamin D Supplementation in Women With Metastatic Breast Cancer (SAFE-D)[NCT02186015] | Phase 2 | 43 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| Personalised Electronic Record Supported Two-Stage Observational Study of Sleep in Patients With Breast Cancer[NCT05093426] | 226 participants (Actual) | Observational | 2022-01-15 | Completed | |||
| Prospective Study of UDP-gluconoryltransferase (UGT) 2B17 Genotype as a Predictive Marker of Exemestane Pharmacokinetics and Pharmacodynamics in Asian Women With Hormone Receptor-positive Advanced Breast Cancer[NCT01655004] | 110 participants (Anticipated) | Interventional | 2012-08-31 | Recruiting | |||
| A Trial of Exemestane in Postmenopausal Women With DCIS or at High Risk for Invasive Breast Cancer[NCT00073073] | Phase 2 | 46 participants (Actual) | Interventional | 2003-11-30 | Completed | ||
| Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)[NCT00712985] | Phase 3 | 18 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The EuroQol-5D (version 5L) is a brief self-administered, validated instrument consisting of 2 parts. The second part consists of the EQ-5D general health status as measured by a visual analog scale (EQ-5D VAS). EQ-5D VAS measures the participant's self-rated health status on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state). Minimally important differences in the EQ-5D VAS score are 7 or greater in cancer patients. Least Square(LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, Visit, Treatment*Visit and Baseline. (NCT02246621)
Timeframe: Baseline, End of Study (Up to 32 Months)
| Intervention | millimeter (mm) (Least Squares Mean) |
|---|---|
| Abemaciclib + NSAI | 0.49 |
| Placebo + NSAI | 1.51 |
The EuroQol-5D (version 5L) is a brief self-administered, validated instrument consisting of 2 parts.The first part consists of 5 descriptors of current health state (mobility, self care, usual activities, pain/discomfort, and anxiety/ depression); a participant is asked to rate each state on a five level scale (no problem, slight problem, moderate problem, severe problem and extreme problem) with higher levels indicating greater severity/ impairment. Published weights are available that allow for the creation of a single summary score called the EQ-5D index that ranges from 0 to 1, with low scores representing a higher level of dysfunction and 1 as perfect health. Minimally important differences in the EQ-5D index score are 0.06 or greater in cancer patients. Least Square(LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, Visit, Treatment*Visit and Baseline. (NCT02246621)
Timeframe: Baseline, End of Study (Up to 32 Months)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Abemaciclib + NSAI | 0.01 |
| Placebo + NSAI | 0.01 |
DOR was the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR were defined using the RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. If a responder was not known to have died or have objective progression as of the data inclusion cutoff date, duration of response was censored at the last adequate tumor assessment date. (NCT02246621)
Timeframe: CR or PR to Disease Progression or Death Due to Any Cause (Up to 32 Months)
| Intervention | Months (Median) |
|---|---|
| Abemaciclib + NSAI | 27.39 |
| Placebo + NSAI | 17.46 |
ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. (NCT02246621)
Timeframe: Randomization to Progressive Disease or Death Due to Any Cause (Up to 32 Months)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Abemaciclib + NSAI | 49.7 |
| Placebo + NSAI | 37 |
DCR was the percentage of participants with a best overall response of CR, PR, or SD as per response using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. (NCT02246621)
Timeframe: Randomization to Progressive Disease or Death Due to Any Cause (Up to 32 Months)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Abemaciclib + NSAI | 88.7 |
| Placebo + NSAI | 86.7 |
CBR defined as percentage of participants with best overall response of CR, PR, or SD with a duration of at least 6 months. CR, PR, or SD were defined using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. Percentage of participants = (participants with CR+PR+SD with a duration of at least 6 months / number of participants enrolled) * 100. (NCT02246621)
Timeframe: Randomization to Progressive Disease or Death Due to Any Cause (Up to 32 Months)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Abemaciclib + NSAI | 78.0 |
| Placebo + NSAI | 71.5 |
PFS defined as the time from the first day of therapy to the first evidence of disease progression as defined by RECIST v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date. (NCT02246621)
Timeframe: Randomization to Progressive Disease or Death Due to Any Cause (Up to 32 Months)
| Intervention | Months (Median) |
|---|---|
| Abemaciclib + NSAI | 28.18 |
| Placebo + NSAI | 14.76 |
"The EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual functioning, sexual enjoyment, future perspective) and four symptom scales (systemic side effects, breast symptoms, arm symptoms, upset by hair loss). QLQ-BR23 questionnaire employs 4-point scales with responses from: 1, Not at all; 2, A little; 3, Quite a bit; to 4, Very much. All scores are converted to a 0 to 100 scale. A higher score representing a higher (better) level of functioning (BR23: body image, sexual functioning, future perspective), or a higher (worse) level of symptoms. Least Square (LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, Visit, Treatment*Visit and Baseline." (NCT02246621)
Timeframe: Baseline, End of Study (Up to 32 Months)
| Intervention | score on a scale (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| Body image | Sexual functioning | Future perspective | Systemic therapy side effects | Breast symptoms | Arm symptoms | |
| Abemaciclib + NSAI | -4.5 | -0.2 | 12.7 | 8.15 | -6.12 | -1.14 |
| Placebo + NSAI | 0.6 | -0.1 | 11.9 | 3.68 | -6.23 | -2.23 |
"EORTC QLQ-C30 v3.0 is a self-administered questionnaire with multidimensional scales that measures 5 functional domains (physical, role, cognitive, emotional, and social), global health status, and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation and diarrhea, and financial difficulties. Symptom scale ranges from: 1, Not at all; 2, A little; 3, Quite a bit; to 4, Very much. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For symptoms scales, higher scores indicated greater symptom burden. Least Square(LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, Visit, Treatment*Visit and Baseline. Small changes are generally defined as at least a 3, 4 or 5 point change from baseline." (NCT02246621)
Timeframe: Baseline, End of Study (Up to 32 Months)
| Intervention | score on a scale (Least Squares Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Fatigue | Nausea and Vomiting | Pain | Dyspnea | Insomnia | Appetite loss | Constipation | Diarrhea | Financial difficulties | |
| Abemaciclib + NSAI | 2.4 | 2.4 | -4.8 | 0.9 | -1.7 | 0.2 | -0.8 | 18.2 | -0.7 |
| Placebo + NSAI | -2.6 | -0.4 | -5.7 | -1.6 | -4.1 | -3.9 | 1.6 | -0.5 | -1.2 |
"EORTC QLQ-C30 v3.0 is a self-administered questionnaire with multidimensional scales that measures 5 functional domains(physical,role,cognitive,emotional, and social),global health status, and symptom scales of fatigue, pain, nausea and vomiting,dyspnea,loss of appetite,insomnia,constipation and diarrhea, and financial difficulties.Functional scale options are defined on a 7-point scale ranging from 1, Very poor to 7, Excellent. A linear transformation is applied to standardize the raw scores to range between 0 and 100 with higher score indicating better functioning. For functional domains and global health status, higher scores represent a better level of functioning. Least Square(LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, Visit, Treatment*Visit and Baseline." (NCT02246621)
Timeframe: Baseline, End of Study (Up to 32 Months)
| Intervention | score on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Physical | Role | Emotional | Cognitive | Social | |
| Abemaciclib + NSAI | -1.0 | -1.4 | 4.7 | -4.0 | -0.1 |
| Placebo + NSAI | 1.7 | 2.9 | 4.0 | -4.0 | 3.3 |
Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve From Time 0 Hour to Infinity [AUC(0-∞)] of Abemaciclib and Its Metabolites M2 and M20 (NCT02246621)
Timeframe: Cycle 1 Day 1; 2 to 4 hours (h) post dose, Cycle 2 Day 1; 3 h post dose; 7 h post dose, Cycle 3 Day 1; pre dose, 3 h post dose
| Intervention | nanogram*hours/milliliter (ng*h/mL) (Geometric Mean) | ||
|---|---|---|---|
| Abemaciclib | M2 | M20 | |
| Abemaciclib + NSAI | 3360 | 1290 | 2300 |
PK: Hepatic Clearance of Abemaciclib, and apparent hepatic clearance of its Metabolites M2 and M20 (NCT02246621)
Timeframe: Cycle 1 Day 1; 2 to 4 hours (h) post dose, Cycle 2 Day 1; 3 h post dose; 7 h post dose, Cycle 3 Day 1; pre dose, 3 h post dose
| Intervention | liters/hour (L/h) (Geometric Mean) | ||
|---|---|---|---|
| Abemaciclib | M2 | M20 | |
| Abemaciclib + NSAI | 23.0 | 21.6 | 26.0 |
To measure changes in serum estradiol level compared to their baseline in patients with breast cancer when treated with vaginal estrogen preparation, Estring (NCT01923298)
Timeframe: Baseline, 16 weeks
| Intervention | pg/mL (Median) |
|---|---|
| Estring Group | 3.9 |
To determine whether 5 years of additional Anastrozole was more effective than 2 years of additional Anastrozole after 5 years of adjuvant endocrine therapy in terms of disease-free survival. (NCT00295620)
Timeframe: DFS was defined as the time from two years after randomization to the earliest occurrence of loco-regional recurrence, distant recurrence, contralateral new breast cancer, second cancer or death from any cause, assessed up to a maximum of 8.5 years
| Intervention | Years (Median) |
|---|---|
| Arm A: Anastrozol | NA |
| Arm B: Anastrozol | NA |
To determine whether 5 years of additional Anastrozole was more effective than 2 years of additional Anastrozole after 5 years of adjuvant endocrine therapy in terms of overall survival. (NCT00295620)
Timeframe: Overall survival was defined as the time from two years after randomization to death due to any cause, assessed up to a maximum of 8.5 years
| Intervention | Years (Median) |
|---|---|
| Arm A: Anastrozol | NA |
| Arm B: Anastrozol | NA |
To determine whether 5 years of additional Anastrozole was more effective than 2 years of additional Anastrozole after 5 years of adjuvant endocrine therapy in terms of lowering the risk of contralateral breast cancer. Subjects without contralateral breast cancer event were censored at the last date when they were known to be contralateral breast cancer free. (NCT00295620)
Timeframe: Risk of contralateral breast cancer was defined as the time from two years after randomization to first occurrence of new contralateral breast cancer, assessed up to a maximum of 8.5 years
| Intervention | Years (Median) |
|---|---|
| Arm A: Anastrozol | NA |
| Arm B: Anastrozol | NA |
To determine the effect of 2 years versus 5 years of additional Anastrozole after 5 years of adjuvant endocrine therapy on the time to first clinical fracture. Patients without clinical fractures where censored at their last therapy visit (approximately 5 years after randomization). (NCT00295620)
Timeframe: Time to first clinical fracture was defined as time to first clinical fracture, in the period from 2 years until 5 years after randomization for each patient.
| Intervention | Years (Median) |
|---|---|
| Arm A: Anastrozol | NA |
| Arm B: Anastrozol | NA |
To determine whether 5 years of additional Anastrozole was more effective than 2 years of additional Anastrozole after 5 years of adjuvant endocrine therapy in terms of lowering the risk of secondary carcinoma. Subjects without secondary cancer event were censored at the last date when they were known to be secondary cancer free. (NCT00295620)
Timeframe: Risk of secondary carcinoma was defined as the time from two years after randomization to first occurrence of new secondary cancer without new breast cancer (local or contralateral), assessed up to a maximum of 8.5 years
| Intervention | Years (Median) |
|---|---|
| Arm A: Anastrozol | NA |
| Arm B: Anastrozol | NA |
Clinical fracture at any time, including hip, spine, wrist fractures and other bone fractures. (NCT00066573)
Timeframe: 8 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Exemestane | 358 |
| Anastrozole | 354 |
Time to distant disease-free survival (DDFS) is defined as the time from randomization to the time of documented distant recurrence. Distant recurrence is the cancer coming back in a part of the body away from the breast, such as the bones or liver. (NCT00066573)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Exemestane | 157 |
| Anastrozole | 164 |
Event free survival, the primary endpoint of this study, is defined as the time from randomization to the time of documented locoregional or distant recurrence, new primary breast cancer, or death from any cause. (NCT00066573)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Exemestane | 88 |
| Anastrozole | 89 |
Overall survival is defined as the time from randomization to the time of death from any cause. (NCT00066573)
Timeframe: 5 years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Exemestane | 92 |
| Anastrozole | 92 |
CBR was defined as the percentage of patients who had a clinical benefit (i.e. best objective response of CR, PR or stable disease), that was maintained for at least 24 weeks, prior to any evidence of progression. Note that a minimum duration of 22 weeks for CBR was applicable in the analysis (rather than 24 weeks) to allow for the protocolled window of +/-2 weeks. (NCT01602380)
Timeframe: Baseline RECIST 1.1 assessments and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months for the primary analysis data cut-off).
| Intervention | Percentage of participants (Number) |
|---|---|
| Fulvestrant 500 mg | 78.3 |
| Anastrozole 1 mg | 74.1 |
OS was defined as the time from randomisation until death by any cause. Two timepoints were planned for OS analysis: an interim OS analysis at the time of the data cut-off for PFS analysis and a final OS analysis when 75% of the deaths have occurred. The current OS data correspond to that of the interim analysis only and the outcome measure is reported as percentage of patients with events. (NCT01602380)
Timeframe: Baseline up to data cut-off for PFS analysis (up to approximately 38 months). Following disease progression, patients were to be contacted at 12 weekly intervals to to determine survival status.
| Intervention | Percentage of participants (Number) |
|---|---|
| Fulvestrant 500 mg | 29.1 |
| Anastrozole 1 mg | 32.3 |
PFS was defined as the time from randomisation until objective disease progression according to Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1), surgery or radiotherapy to manage worsening of disease or death by any cause (in the absence of progression). Outcome measure is reported as median time from randomisation to PFS, calculated using the Kaplan-Meier technique. (NCT01602380)
Timeframe: Baseline RECIST 1.1 assessments and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months for the primary analysis data cut-off).
| Intervention | Months (Median) |
|---|---|
| Fulvestrant 500 mg | 16.6 |
| Anastrozole 1 mg | 13.8 |
DoCB was defined only for patients who had clinical benefit, as the time in days from date of randomisation until the date of disease progression. (NCT01602380)
Timeframe: Baseline RECIST 1.1 assessments and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months for the primary analysis data cut-off).
| Intervention | Months (Median) |
|---|---|
| Fulvestrant 500 mg | 22.1 |
| Anastrozole 1 mg | 19.1 |
DoR was defined only for patients who had an objective response, as the time in days from date of first documentation of response (CR/PR) until date of disease progression. (NCT01602380)
Timeframe: Baseline RECIST 1.1 assessments and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months for the primary analysis data cut-off)..
| Intervention | Months (Median) |
|---|---|
| Fulvestrant 500 mg | 20.0 |
| Anastrozole 1 mg | 13.2 |
EDoCB was estimated using the formula EDoCB = p Efp(x), where x = EDoCB, p = proportion of responders, and Efp(x) = mean duration of response for responders. The estimation was completed by using the maximum likelihood estimates of p and Efp(x), as described by Ellis (Ellis S et al. Analysis of duration of response in oncology trials, Contemp Clin Trials 2008; 29:456-65). (NCT01602380)
Timeframe: Baseline RECIST 1.1 assessments and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months for the primary analysis data cut-off).
| Intervention | Days (Number) |
|---|---|
| Fulvestrant 500 mg | 667.94 |
| Anastrozole 1 mg | 532.04 |
EDoR was estimated using the formula EDoR = p Efp(x), where x = DoR, p = proportion of responders, and Efp(x) = mean duration of response for responders. The estimation was completed by using the maximum likelihood estimates of p and Efp(x), as described by Ellis (Ellis S et al. Analysis of duration of response in oncology trials, Contemp Clin Trials 2008; 29:456-65). (NCT01602380)
Timeframe: Baseline RECIST 1.1 assessments and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months for the primary analysis data cut-off).
| Intervention | Days (Number) |
|---|---|
| Fulvestrant 500 mg | 346.84 |
| Anastrozole 1 mg | 227.58 |
ORR was defined as the percentage patients with an objective response (i.e. those recording a partial response [PR] or complete response [CR]) at some point during the study, prior to disease progression. ORR was assessed in patients with measurable disease at baseline only. The determination of measurable disease at baseline was done using baseline RECIST data. (NCT01602380)
Timeframe: Baseline RECIST 1.1 assessments and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months for the primary analysis data cut-off).
| Intervention | Percentage of participants (Number) |
|---|---|
| Fulvestrant 500 mg | 46.1 |
| Anastrozole 1 mg | 44.9 |
The Functional Assessment of Cancer Therapy - Breast (FACT-B) questionnaire was the instrument selected to assess HRQoL and comprises the following subscales: physical well-being (PWB), functional well-being (FWB), social well-being, emotional well-being, and breast cancer subscale (BCS). The main outcome measure from the FACT-B questionnaire was the Trial Outcome Index (TOI), which was a summary of the following subscales: PWB, FWB, and BCS. Outcome measure is reported as median time to deterioration, defined as the interval from the date of randomisation to the first assessment of worsened without an improvement in the next 12 weeks in FACT-B TOI, or the date of death (by any cause in the absence of symptom deterioration). Time to deterioration as measured by FACT-B total score was derived similarly and is also reported. (NCT01602380)
Timeframe: Quality of life questionnaires completed at baseline and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months for the primary analysis data cut-off).
| Intervention | months (Median) | |
|---|---|---|
| Time to TOI deterioration | Time to FACT-B total score deterioration | |
| Anastrozole 1 mg | 11.1 | 11.1 |
| Fulvestrant 500 mg | 13.8 | 13.8 |
Olaparib AUC0-τ, in the presence and absence of co-administered anastrozole, and associated AUC0-τ treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 24
| Intervention | mcg*h/mL (Geometric Mean) |
|---|---|
| Cohort 2 - Olaparib (Treatment Period 1) | 55.49 |
| Cohort 2 - Olaparib + Anastrozole (Treatment Period 3) | 44.33 |
Olaparib Cmax ss in the presence and absence of co-administered anastrozole, and associated Cmax ss treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 24
| Intervention | mcg/mL (Geometric Mean) |
|---|---|
| Cohort 2 - Olaparib (Treatment Period 1) | 9.490 |
| Cohort 2 - Olaparib + Anastrozole (Treatment Period 3) | 8.256 |
Olaparib AUC0-τ, in the presence and absence of co-administered letrozole, and associated AUC0-τ treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 43
| Intervention | mcg*h/mL (Geometric Mean) |
|---|---|
| Cohort 3 - Olaparib (Treatment Period 1) | 61.77 |
| Cohort 3 - Olaparib + Letrozole (Treatment Period 3) | 67.82 |
Olaparib Cmax ss in the presence and absence of co-administered letrozole, and associated Cmax ss treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 43
| Intervention | mcg/mL (Geometric Mean) |
|---|---|
| Cohort 3 - Olaparib (Treatment Period 1) | 10.05 |
| Cohort 3 - Olaparib + Letrozole (Treatment Period 3) | 10.48 |
Anastrozole Area under plasma concentration-time curve over the dosing interval at steady state (AUC0-τ), in the presence and absence of co-administered olaparib, and associated AUC0-τ treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 19 and Day 24
| Intervention | mcg*h/mL (Geometric Mean) |
|---|---|
| Cohort 2 - Anastrozole Alone (Treatment Period 2) | 696.8 |
| Cohort 2 - Olaparib + Anastrozole (Treatment Period 3) | 582.5 |
Anastrozole maximum plasma concentration at steady state (Cmax ss) in the presence and absence of co-administered olaparib, and associated Cmax ss treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 19 and Day 24
| Intervention | micrograms per millilitre (mcg/mL) (Geometric Mean) |
|---|---|
| Cohort 2 - Anastrozole Alone (Treatment Period 2) | 40.98 |
| Cohort 2 - Olaparib + Anastrozole (Treatment Period 3) | 35.83 |
Letrozole AUC0-τ, in the presence and absence of co-administered olaparib, and associated AUC0-τ treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 38 and Day 43
| Intervention | mcg*h/mL (Geometric Mean) |
|---|---|
| Cohort 3 - Letrozole Alone (Treatment Period 2) | 2292 |
| Cohort 3 - Olaparib + Letrozole (Treatment Period 3) | 2167 |
Letrozole Cmax ss in the presence and absence of co-administered olaparib, and associated Cmax ss treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 38 and Day 43
| Intervention | mcg/mL (Geometric Mean) |
|---|---|
| Cohort 3 - Letrozole Alone (Treatment Period 2) | 118.9 |
| Cohort 3 - Olaparib + Letrozole (Treatment Period 3) | 111.8 |
Olaparib AUC0-τ, in the presence and absence of co-administered tamoxifen, and associated AUC0-τ treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 31
| Intervention | mcg*h/mL (Geometric Mean) |
|---|---|
| Cohort 1 - Olaparib (Treatment Period 1) | 62.12 |
| Cohort 1 - Olaparib + Tamoxifen (Treatment Period 3) | 42.27 |
Olaparib Cmax ss in the presence and absence of co-administered tamoxifen, and associated Cmax ss treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 31
| Intervention | mcg/mL (Geometric Mean) |
|---|---|
| Cohort 1 - Olaparib (Treatment Period 1) | 9.456 |
| Cohort 1 - Olaparib + Tamoxifen (Treatment Period 3) | 7.216 |
Tamoxifen, N-DMT and endoxifen AUC0-τ, in the presence and absence of co-administered olaparib, and associated AUC0-τ treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 1, 2, 4, 5, 6, 8, 12 and 24 hours post-dose on Day 26 and Day 31
| Intervention | microgram x hour/millilitre (mcg*h/mL) (Geometric Mean) | ||
|---|---|---|---|
| PK analysis of tamoxifen | PK analysis of N-DMT | PK analysis of endoxifen | |
| Cohort 1 - Olaparib + Tamoxifen (Treatment Period 3) | 2751 | 2955 | 115.8 |
| Cohort 1 - Tamoxifen Alone (Treatment Period 2) | 2233 | 3189 | 119.3 |
Tamoxifen, N-desmethyl tamoxifen (N-DMT) and endoxifen Cmax ss in the presence and absence of co-administered olaparib, and associated Cmax ss treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 1, 2, 4, 5, 6, 8, 12 and 24 hours post-dose on Day 26 and Day 31
| Intervention | mcg/mL (Geometric Mean) | ||
|---|---|---|---|
| PK analysis of tamoxifen | PK analysis of N-DMT | PK analysis of endoxifen | |
| Cohort 1 - Olaparib + Tamoxifen (Treatment Period 3) | 154.2 | 149.1 | 5.727 |
| Cohort 1 - Tamoxifen Alone (Treatment Period 2) | 130.3 | 162.9 | 5.923 |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable, Does not qualify for CR, PR, Progression or Symptomatic Deterioration. Clinical Benefit = CR + PR + Stable >= 24 weeks (NCT00075764)
Timeframe: Every 4 weeks while on treatment. Then every 3 months until progression, then six months for two years then annually until four years or until death, which ever occurs first.
| Intervention | percentage of participants (Number) |
|---|---|
| Arm I Anastrozole | 70 |
| Arm II Anastrozole and Fulvestrant | 73 |
From date of randomization to date of death due to any cause. Patients last known to be alive are censored at last date of contact. (NCT00075764)
Timeframe: Every 4 weeks while on treatment. Then every 3 months until progression, then six months for two years then annually until four years or until death, which ever occurs first.
| Intervention | months (Median) |
|---|---|
| Arm I Anastrozole | 41.3 |
| Arm II Anastrozole and Fulvestrant | 47.7 |
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target measurable lesions over the smallest sum observed (over baseline if no decrease during therapy) using the same techniques as baseline. Unequivocal progression of non-measurable disease in the opinion of the treating physician. Appearance of any new lesion/site. Death due to disease without prior documentation of progression and without symptomatic deterioration. From date of randomization to time of first documentation of progression, symptomatic deterioration or death due to any cause. Patients last known to be alive and progression free are considered at last date of contact. (NCT00075764)
Timeframe: Every 4 weeks while on treatment. Then every 3 months until progression, then six months for two years then annually until four years or until death, which ever occurs first.
| Intervention | months (Median) |
|---|---|
| Arm I Anastrozole | 13.5 |
| Arm II Anastrozole and Fulvestrant | 15.0 |
Adverse Events (AEs) are reported by CTCAE version 3.0 terminology. For each patient, worst grade of each event type is reported. Grade3 (Severe), Grade4 (Life-threatening), Grade 5 (Fatal) (NCT00075764)
Timeframe: Patients were assessed for adverse events after each cycle (1 cycle = 28 days) while on treatment.
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT, SGPT (serum glutamic pyruvic transaminase) | AST, SGOT | Albumin, serum-low (hypoalbuminemia) | Alkaline phosphatase | Anorexia | Bilirubin (hyperbilirubinemia) | CNS cerebrovascular ischemia | Calcium, serum-high (hypercalcemia) | Cataract | Confusion | Constipation | Dehydration | Diarrhea | Dizziness | Dyspnea (shortness of breath) | Edema: limb | Fatigue (asthenia, lethargy, malaise) | Febrile neutropenia | Fracture | Glucose, serum-high (hyperglycemia) | Hemoglobin | Hemolysis | Hot flashes/flushes | Hypertension | Inf w/normal ANC or Gr 1-2 neutrophils - Blood | Inf w/normal ANC or Gr 1-2 neutrophils - UTI | Infection with unknown ANC - Urinary tract NOS | Insomnia | Joint-effusion | Leukocytes (total WBC) | Lymphopenia | Memory impairment | Mood alteration - agitation | Mood alteration - anxiety | Mood alteration - depression | Mucositis/stomatitis (functional/symp) - Pharynx | Muscle weakness, not d/t neuropathy - body/general | Nausea | Neurology-Other (Specify) | Neuropathy: sensory | Neutrophils/granulocytes (ANC/AGC) | Pain - Abdomen NOS | Pain - Back | Pain - Bone | Pain - Breast | Pain - Buttock | Pain - Chest wall | Pain - Chest/thorax NOS | Pain - Extremity-limb | Pain - Head/headache | Pain - Joint | Pain - Muscle | Pain - Neck | Pain - Pelvis | Pain-Other (Specify) | Platelets | Rash/desquamation | Sodium, serum-low (hyponatremia) | Speech impairment (e.g., dysphasia or aphasia) | Sudden death | Syncope (fainting) | Thrombosis/embolism (vascular access-related) | Thrombosis/thrombus/embolism | Tinnitus | Tumor flare | Urticaria (hives, welts, wheals) | Vomiting | Weight gain | |
| Arm I Anastrozole | 1 | 3 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 2 | 1 | 1 | 1 | 7 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 1 | 0 | 1 | 1 | 3 | 1 | 1 | 0 | 1 | 5 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 5 | 3 | 0 | 0 | 2 | 2 | 1 | 0 | 1 | 0 | 0 | 3 | 6 | 0 | 0 | 0 | 3 | 0 |
| Arm II Anastrozole and Fulvestrant | 1 | 1 | 1 | 0 | 1 | 0 | 2 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 9 | 0 | 2 | 2 | 3 | 1 | 7 | 1 | 0 | 1 | 2 | 1 | 2 | 1 | 3 | 0 | 1 | 0 | 3 | 0 | 0 | 1 | 0 | 0 | 2 | 2 | 7 | 1 | 0 | 0 | 1 | 1 | 3 | 0 | 7 | 0 | 1 | 3 | 1 | 2 | 1 | 1 | 0 | 1 | 1 | 1 | 7 | 1 | 2 | 1 | 2 | 1 |
"BCsS events has been evaluated in patients treated with Fulvestrant for 3 years and Anastrozole for 5 years as compared to BCsS in patients treated with anastrozole for 5 years.~BCsS event is defined as the death from breast cancer." (NCT00543127)
Timeframe: Up to 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Fulvestrant + Anastrozole | 17 |
| Anastrozole | 18 |
"Disease-free survival (DFS) has been evaluated in patients treated with Fulvestrant for 3 years and Anastrozole for 5 years as compared to DFS in patients treated with anastrozole for 5 years.~DFS event is defined as the evidence of local and/or distant recurrence, new primary breast tumour, or death from any cause." (NCT00543127)
Timeframe: Up to 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Fulvestrant + Anastrozole | 49 |
| Anastrozole | 62 |
"OS event has been evaluated in patients treated with Fulvestrant for 3 years and Anastrozole for 5 years as compared to DFS in patients treated with anastrozole for 5 years.~OS event is defined as the death from any cause." (NCT00543127)
Timeframe: Up to 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Fulvestrant + Anastrozole | 28 |
| Anastrozole | 34 |
"TR event has been evaluated in patients treated with Fulvestrant for 3 years and Anastrozole for 5 years as compared to DFS in patients treated with anastrozole for 5 years.~TR event is defined as the evidence of breast cancer recurrence (local and/or distant recurrence of breast cancer, does not include second primary malignancies or deaths from any cause)." (NCT00543127)
Timeframe: Up to 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Fulvestrant + Anastrozole | 36 |
| Anastrozole | 46 |
For each sample, the Ki67 labelling index is calculated as the percentage of cells stained positive for Ki67. Range 0-100. The greater the change from baseline (randomization) in Ki67 labelling index, the greater the blockage of Ki67 expression and the greater the potential anti-tumour activity. Percentage change from baseline=[(SRG - BL)/BL]x100 (NCT00259090)
Timeframe: Surgery (SRG) was to be performed between days 15 and 22 after baseline (BL)
| Intervention | Percentage change from baseline (Mean) |
|---|---|
| Fulvestrant | -62 |
| Fulvestrant + Anastrozole | -68 |
| Anastrozole | -75 |
For each sample, the ER H-score is calculated from the percentage of cells staining very weak (+/-); weak (+); moderate (++); or strong (+++) as follows: H-score = [(0.5 x percent +/-) + (1 x percent +) + (2 x percent ++) + (3 x percent +++)]. Range 0-300. The greater the change from baseline (randomization) in ER H-score, the greater the blockage of ER expression and the greater the potential anti-tumour activity. Percentage change from baseline=[(SRG - BL)/BL]x100 (NCT00259090)
Timeframe: Surgery (SRG) was to be performed between days 15 and 22 after baseline (BL)
| Intervention | Percentage change from baseline (Mean) |
|---|---|
| Fulvestrant | -37 |
| Fulvestrant + Anastrozole | -38 |
| Anastrozole | -7 |
For each sample, the PgR H-score is calculated from the percentage of cells staining very weak (+/-); weak (+); moderate (++); or strong (+++) as follows: H-score = [(0.5 x percent+/-) + (1 x percent+) + (2 x percent++) + (3 x percent+++)]. Range 0-300. The greater the change from baseline (randomization in PgR H-score, the greater the blockage of PgR expression and the greater the potential anti-tumour activity. Percentage change from baseline=[(SRG - BL)/BL]x100 (NCT00259090)
Timeframe: Surgery (SRG) was to be performed between days 15 and 22 after baseline (BL)
| Intervention | Percentage change from baseline (Mean) |
|---|---|
| Fulvestrant | -31 |
| Fulvestrant + Anastrozole | -38 |
| Anastrozole | -38 |
In part 1 ovarian function recurrence is defined as one estradiol value >20 pg/ml or two consecutive values >10 pg/ml. In part 2 ovarian function recurrence is defined as a >75% increase in estradiol levels over prior if prior value was 15-30 pg/ml, or one estradiol value >30 pg/ml, or three consecutive values >20 pg/ml. (NCT00555477)
Timeframe: 12 months
| Intervention | participants (Number) |
|---|---|
| Anastrozole Part 1 | 8 |
| Anastrozole Part 2 | 13 |
Mean percentage of cells expressing estrogen receptor (ER-beta) (NCT00612560)
Timeframe: Biopsy/Week 1 and Surgical Resection/Week 2
| Intervention | percentage of cells (Mean) | |
|---|---|---|
| Biopsy | Surgical resection | |
| Arm A - Flaxseed & Active Anastrazole | 67.1 | 45.7 |
| Arm B - Flaxseed | 63.3 | 56.7 |
| Arm C - Anastrozole | 45.0 | 46.7 |
| Arm D - Placebo | 62.0 | 70 |
Mean serum level IGF-1(pg/ml) (NCT00612560)
Timeframe: Biopsy/Week 1 and Surgical Resection/Week 2
| Intervention | pg/ml (Mean) | |
|---|---|---|
| Biopsy | Surgical resection | |
| Arm A - Flaxseed & Active Anastrazole | 887.7 | 938.1 |
| Arm B - Flaxseed | 1044.2 | 980.5 |
| Arm C - Anastrozole | 959.1 | 819.8 |
| Arm D - Placebo | 1008.3 | 880.1 |
Mean percentage of cells expressing human epidermal growth factor receptor 2 (Her2) (NCT00612560)
Timeframe: Biopsy/Week 1 and Surgical Resection/Week 2
| Intervention | percentage of cells (Mean) |
|---|---|
| Surgical resection | |
| Arm C - Anastrozole | 17.5 |
Mean percentage of cells expressing human epidermal growth factor receptor 2 (Her2) (NCT00612560)
Timeframe: Biopsy/Week 1 and Surgical Resection/Week 2
| Intervention | percentage of cells (Mean) | |
|---|---|---|
| Biopsy | Surgical resection | |
| Arm A - Flaxseed & Active Anastrazole | 15 | 0 |
| Arm B - Flaxseed | 40 | 17.5 |
| Arm D - Placebo | 55 | 30 |
Mean percentage of cells expressing PR (NCT00612560)
Timeframe: Biopsy/Week 1 and Surgical Resection/Week 2
| Intervention | percentage of cells (Mean) | |
|---|---|---|
| Biopsy | Surgical resection | |
| Arm A - Flaxseed & Active Anastrazole | 4 | 4.5 |
| Arm B - Flaxseed | 3.5 | 2.4 |
| Arm C - Anastrozole | 2 | 1 |
| Arm D - Placebo | 4.7 | 3.5 |
"Objective response rate is defined as the rate of participants with partial or complete responses according to RECIST V1.0.~Complete response is defined as the disappearance of all target lesions and partial response is defined as at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD (RECIST V1.0.)." (NCT00871858)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A (ANA) | 58.9 |
| Arm B (FULV) | 53.8 |
"Objective response rate is defined as the rate of participants with partial or complete responses according to RECIST V1.0.~Complete response is defined as the disappearance of all target lesions and partial response is defined as at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD (RECIST V1.0.)." (NCT00871858)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A (ANA) | 26.1 |
| Arm B (FULV) | 27.8 |
"Objective response rate is defined as the rate of participants with partial or complete responses according to RECIST V1.0.~Complete response is defined as the disappearance of all target lesions and partial response is defined as at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD (RECIST V1.0.)." (NCT00871858)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A (ANA) | 35.1 |
| Arm B (FULV) | 52.4 |
"Relapse-Free survival (RFS) is measured from the date of randomization to the date of the following events, whichever occurs first according to the DATECAN recommendations for breast cancer:~Invasive ipsilateral breast tumor recurrence/ progression ;~Local invasive recurrence/progression ;~Regional invasive recurrence/progression (N+: regional progression) ;~Appearance/Occurrence of Metastatic recurrence;~Death whatever the cause.~Participants who did not experience events were censored at the date of last follow-up. RFS was estimated using the Kaplan-Meier method. No comparison test was performed between the two arms as this study is non-comparative." (NCT00871858)
Timeframe: 5 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Arm A (ANA) | 82.8 |
| Arm B (FULV) | 74.7 |
breast-conserving surgery concerns patients who did not undergo mastectomy. (NCT00871858)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A (ANA) | 60.7 |
| Arm B (FULV) | 50.0 |
The strength of AR signaling was measured by the percentage of downstream AR-regulated genes that were expressed. (NCT02955394)
Timeframe: 16 Weeks
| Intervention | percentage of genes expressed (Median) |
|---|---|
| Fulvestrant Without Enzalutamide | 85 |
| Fulvestrant With Enzalutamide | 80 |
Disease-free survival is defined as the time in months from the start of fulvestrant until documented disease progression or death. Complete and partial response for the single drug arm and combination of enzalutamide/fulvestrant arm separately. (NCT02955394)
Timeframe: 15 months
| Intervention | months (Median) |
|---|---|
| Fulvestrant Without Enzalutamide | 3.6 |
| Fulvestrant With Enzalutamide | 3.7 |
"The preoperative endocrine prognostic index (PEPI) is a validated measure of pathologic response to endocrine therapy. It is a model that combines estrogen receptor (ER) level, pathologic tumor site, nodal status, and Ki67 score at the time of surgery to predict subsequent risk of cancer recurrence.~PEPI scoring is typically discretized into three risk groups: 0 (low risk of recurrence and best outcome), 1-3 (intermediate risk), and >= 4 (high risk). This study was concerned only with the distinction between zero and non-zero PEPI scores. Zero is the minimum score, and there is no maximum score. Lower scores are better." (NCT02955394)
Timeframe: 16 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Fulvestrant Without Enzalutamide | 2 |
| Fulvestrant With Enzalutamide | 8 |
Percentage of patients alive. (NCT00053898)
Timeframe: 10 years
| Intervention | percentage of participants event-free (Number) |
|---|---|
| Group 1: Tamoxifen + Anastrozole Placebo | 92.1 |
| Group 2: Anastrozole + Tamoxifen Placebo | 92.5 |
Percentage of patients free from a disease-free survival event where events include any recurrence, second primary cancer, and death from any cause. Lobular carcinoma in situ (LCIS), basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the colon, melanoma in situ, and cervical carcinoma in situ will not be included as recurrences or second primary cancer. (NCT00053898)
Timeframe: 10 years
| Intervention | percentage of participants event-free (Number) |
|---|---|
| Group 1: Tamoxifen + Anastrozole Placebo | 77.9 |
| Group 2: Anastrozole + Tamoxifen Placebo | 82.7 |
Percentage of patients free from breast cancer event at 10 years where events include local, regional, or distant recurrence or contralateral breast cancer, invasive or DCIS. (NCT00053898)
Timeframe: 10 years
| Intervention | percentage of participants event-free (Number) |
|---|---|
| Group 1: Tamoxifen + Anastrozole Placebo | 89.1 |
| Group 2: Anastrozole + Tamoxifen Placebo | 93.1 |
Percentage of patients free from a breast cancer recurrence in the contralateral breast (invasive and DCIS), occurring as a first cancer event. (NCT00053898)
Timeframe: 10 years
| Intervention | percentage of participants event-free (Number) |
|---|---|
| Group 1: Tamoxifen + Anastrozole Placebo | 94.7 |
| Group 2: Anastrozole + Tamoxifen Placebo | 97.0 |
Percentage of patients free from an invasive breast cancer event where events include invasive local, regional, or distant recurrence, or contralateral breast cancer, occurring as a first cancer event. Note that this endpoint includes only invasive breast cancers and the primary endpoint includes both invasive and DCIS breast cancers. (NCT00053898)
Timeframe: 10 years
| Intervention | percentage of participants event-free (Number) |
|---|---|
| Group 1: Tamoxifen + Anastrozole Placebo | 93.3 |
| Group 2: Anastrozole + Tamoxifen Placebo | 96.4 |
Percentage of patients free from a breast cancer recurrence in the ipsilateral breast (invasive and DCIS), occurring as a first cancer event. (NCT00053898)
Timeframe: 10 years
| Intervention | percentage of participants event-free (Number) |
|---|---|
| Group 1: Tamoxifen + Anastrozole Placebo | 94.6 |
| Group 2: Anastrozole + Tamoxifen Placebo | 96.4 |
Percentage of patients free from any non-breast second primary cancer other than squamous or basal cell carcinoma of the skin, carcinoma in situ of the colon, melanoma in situ, or carcinoma in situ of the cervix, occurring as a first cancer event. (NCT00053898)
Timeframe: 10 years
| Intervention | percentage of participants event-free (Number) |
|---|---|
| Group 1: Tamoxifen + Anastrozole Placebo | 91.5 |
| Group 2: Anastrozole + Tamoxifen Placebo | 91.9 |
Percentage of patients free from fractures of the hip, spine, and wrist. (NCT00053898)
Timeframe: 10 years
| Intervention | percentage of participants event-free (Number) |
|---|---|
| Group 1: Tamoxifen + Anastrozole Placebo | 96.0 |
| Group 2: Anastrozole + Tamoxifen Placebo | 95.3 |
The primary outcome of the QOL substudy was the Medical Outcomes Study-Short Form 12 (SF-12) physical health component scale score. The SF-12 physical score was calculated to have a range of 0-100 and was normalized to have a mean of 50 and a standard deviation of 10 in the general population. Higher scores indicate better health. (NCT00053898)
Timeframe: 5 years
| Intervention | units on a scale (Mean) |
|---|---|
| Group 1: Tamoxifen + Anastrozole Placebo | 46.20 |
| Group 2: Anastrozole + Tamoxifen Placebo | 45.38 |
The mean quality-adjusted survival time (in months) in each treatment group, estimated by the Quality-Adjusted Time without Symptoms and Toxicity (Q-TWIST) method. (NCT00053898)
Timeframe: 10 years
| Intervention | months (Mean) |
|---|---|
| Group 1: Tamoxifen + Anastrozole Placebo | 104.4 |
| Group 2: Anastrozole + Tamoxifen Placebo | 102.9 |
adherence measured with pill counts for the vitamin D at predesignated study timepoints: baseline (after run-in), 3 months and 6 months (NCT01509079)
Timeframe: average for all study ppts for: screening to baseline; baseline to 3 months; 3 month to 6 months
| Intervention | % of adherence for each treatment arm (Number) |
|---|---|
| Vitamin D3 4000 IU | 95 |
| Vitamin D3 600 IU | 95 |
(NCT01509079)
Timeframe: baseline to 6 months
| Intervention | pounds (Mean) |
|---|---|
| Vitamin D3 4000 IU | 1.8 |
| Vitamin D3 600 IU | 1.0 |
The MS subscale is a self-reported measure on a scale of 0 to 4, with lower score indicating less arthralgia/myalgia (NCT01509079)
Timeframe: baseline to 6 months
| Intervention | units on a scale (Mean) |
|---|---|
| Vitamin D3 4000 IU | -0.2 |
| Vitamin D3 600 IU | -0.5 |
PROMIS measures physical functioning on the short form and higher scores reflect better physical functioning with 10 questions on daily activities of life on a Likert scale ranging from 5 (no problem performing activity) to 1 (cannot do activity). Range on this measure is from 50 (best)-10 (worst). (NCT01509079)
Timeframe: baseline to 6 months
| Intervention | units on a scale (Mean) |
|---|---|
| Vitamin D3 4000 IU | 0.6 |
| Vitamin D3 600 IU | 1.7 |
GLM Mean and standard deviation of Whole Body Bone Mineral Density (grams/cm2) of Trial Participants by Treatment Arm after controlling for bisphosphonate use (NCT01509079)
Timeframe: From Baseline and 6 months of D3 supplementation
| Intervention | gm/cm2 (Geometric Least Squares Mean) |
|---|---|
| Vitamin D3 4000 IU | 1.1 |
| Vitamin D3 600 IU | 1.12 |
Difference in steady state concentrations in plasma from baseline to 6 months (NCT01509079)
Timeframe: baseline to 6 months
| Intervention | mg/L (Mean) | |
|---|---|---|
| anastrozole | letrozole | |
| Vitamin D3 4000 IU | -1.31 | 2.16 |
| Vitamin D3 600 IU | 2.4 | -0.83 |
(NCT01509079)
Timeframe: baseline and 6 months
| Intervention | pg/ml (Geometric Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Vitamin D3 4000 IU | 2.83 | 2.94 |
| Vitamin D3 600 IU | 2.77 | 3.0 |
The EuroQol-5D (version 3L) is a brief self-administered, validated instrument consisting of 2 parts. The second part consists of the EQ-5D general health status as measured by a visual analog scale (EQ-5D VAS). EQ-5D VAS measures the participant's self-rated health status on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state). (NCT01942135)
Timeframe: From Cycle 1 to 14, as of 05 December 2014.
| Intervention | Units on a scale (Mean) |
|---|---|
| Palbociclib + Fulvestrant | -1.8 |
| Placebo + Fulvestrant | -2.6 |
The EuroQol-5D (version 3L) is a brief self-administered, validated instrument consisting of 2 parts. The first part consists of 5 descriptors of current health state (mobility, self care, usual activities, pain/discomfort, and anxiety/ depression); a participant is asked to rate each state on a three level scale (1=no problem, 2=some problem, and 3=extreme problem) with higher levels indicating greater severity/ impairment Published weights are available that allow for the creation of a single summary score called the EQ-5D index, which basically ranges from 0 to 1 with low scores representing a higher level of dysfunction and 1 as perfect health. The second part consists of the EQ-5D general health status as measured by a visual analog scale (EQ-5D VAS). EQ-5D VAS measures the participant's self-rated health status on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state). (NCT01942135)
Timeframe: From Cycle 1 to 14, as of 05 December 2014.
| Intervention | Units on a scale (Mean) |
|---|---|
| Palbociclib + Fulvestrant | 0.006 |
| Placebo + Fulvestrant | -0.031 |
CBR is defined as the overall complete response (CR), partial response (PR) , or stable disease (SD) ≥24 weeks according to the RECIST version 1.1. Clinical Benefit Response Rate (CBRR) is defined as the proportion of participants with CR, PR, or SD ≥24 weeks relative to all randomized participants and randomized participants with measurable disease at baseline. Participants who do not have on-study radiographic tumor re-evaluation, who received antitumor treatment other than the study medication prior to reaching a CR or PR, a best response of SD ≥24 weeks, or who died, progressed, or dropped out for any reason prior to reaching a CR or PR and a best response of SD ≥24 weeks was counted as non-responders in the assessment of CBR. Per RECIST v1.1 for target lesions and assessed by MRI: CR, disappearance of all target lesions; PR, ≥30% decrease in the sum of the longest diameter of target lesions; OR = CR + PR. (NCT01942135)
Timeframe: From randomization until end of treatment (assessed up to 12 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Palbociclib + Fulvestrant | 34.0 |
| Placebo + Fulvestrant | 19.0 |
DR is defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of disease progression or to death due to any cause, whichever occurs first. If tumor progression data included more than 1 date, the first date was used. DR was calculated as [the date response ended (ie, date of PD or death) - first CR or PR date + 1)]/30.4. Kaplan-Meier estimate of median of the DR is provided below. No inferential statistical analysis were done for DR. The DR was only calculated for the participants with a CR or PR. (NCT01942135)
Timeframe: From randomization until end of treatment (assessed up to 12 months)
| Intervention | Months (Median) |
|---|---|
| Palbociclib + Fulvestrant | 9.3 |
| Placebo + Fulvestrant | 5.7 |
OR is defined as the overall complete response (CR) or partial response (PR) according to the RECIST version 1.1 Objective Response Rate (ORR) is defined as the proportion of participants with CR or PR relative to all randomized participants and randomized participants with measurable disease at baseline. Participants who do not have on-study radiographic tumor re-evaluation, who received anti-tumor treatment other than the study medication prior to reaching a CR or PR, or who died, progressed, or dropped out for any reason prior to reaching a CR or PR were counted as non-responders in the assessment of ORR. Per response evaluation criteria in solid tumors criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), ≥30% decrease in the sum of the longest diameter of target lesions (longest for non-nodal and short axis for nodal target lesions); Overall Response (OR) = CR + PR. (NCT01942135)
Timeframe: From randomization until end of treatment (assessed up to 12 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Palbociclib + Fulvestrant | 10.4 |
| Placebo + Fulvestrant | 6.3 |
OS is defined as the time from date of randomization to date of death due to any cause. In the absence of confirmation of death, survival time was censored to last date the participant was known to be alive. For participants lacking survival data beyond the date of their last follow-up, the OS time was censored on the last date they were known to be alive. Participants lacking survival data beyond randomization were to have their OS times be censored at randomization. The length of OS was calculated as OS time (months) = [death date (censor date) - randomization date + 1]/30.4. No inferential statistical analysis were done because of the immaturity of the OS data. (NCT01942135)
Timeframe: From randomization until death (up to approximately 36 months)
| Intervention | deaths (Number) |
|---|---|
| Palbociclib + Fulvestrant | 19 |
| Placebo + Fulvestrant | 9 |
PFS is the time from the date of randomization to the date of the first documentation of objective progression of disease (PD)or death due to any cause in absence of documented PD. Participants lacking an evaluation of tumor response after randomization had their PFS time censored on the date of randomization with the duration of a day. Participants with documentation of PD or death after a long interval (2 or more incomplete or non-evaluable assessments) since the last tumor assessment were censored at the time of last objective assessment that did not show PD. The length of PFS was calculated as PFS time (months) =[progression/death date(censor date) - randomization date + 1]/30.4. Progression is defined using Response Evaluation Criteria in Solid Tumors(RECIST v1.1) a 20% increase in the sum of diameters of target lesions and the sum must also demonstrate an absolute increase of at least 5mm or unequivocal progression of existing non-target lesions or the appearance of new lesions. (NCT01942135)
Timeframe: From randomization date to date of first documentation of progression or death (assessed up to 12 months)
| Intervention | Months (Median) |
|---|---|
| Palbociclib + Fulvestrant | 9.2 |
| Placebo + Fulvestrant | 3.8 |
The EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual functioning, sexual enjoyment, future perspective) and four symptom scales (systemic side effects, breast symptoms, arm symptoms, upset by hair loss). QLQ-BR23 questionnaire employs 4-point scales with responses from 'not at all' to 'very much'. All scores are converted to a 0 to 100 scale. For symptom-oriented scales, a higher score represent more severe symptoms. (NCT01942135)
Timeframe: From Cycle 1 to 14, as of 05 December 2014.
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Systemic therapy side effects | Breast symptoms | Arm symptoms | Upset by hair loss | |
| Palbociclib + Fulvestrant | 3.8 | -2.2 | -2.2 | 2.9 |
| Placebo + Fulvestrant | 3.4 | -1.3 | -2.0 | -6.0 |
"The EORTC-QLQ-C30 is a 30-item questionnaire composed of five multi-item functional subscales (physical, role, emotional, cognitive , and social functioning), three multi-item symptom scales (fatigue, nausea/vomiting, and pain), a global quality of life (QOL) subscale, and six single item symptom scales assessing other cancer-related symptoms (dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and the financial impact of cancer). The questionnaire employs 28 4-point Likert scales with responses from not at all to very much and two 7-point Likert scales for global health and overall QOL. Responses to all items are then converted to a 0 to 100 scale. For functional and global QOL scales, higher scores represent a better level of functioning/QOL. For symptom-oriented scales, a higher score represents more severe symptoms. A 10-point or higher change in scores from baseline is considered clinically significant." (NCT01942135)
Timeframe: From Cycle 1 to 14, as of 05 December 2014.
| Intervention | Units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Fatigue | Nausea and vomiting | Pain | Dyspnoea | Insomnia | Appetite loss | Constipation | Diarrhoea | Financial difficulties | |
| Palbociclib + Fulvestrant | 1.8 | 1.7 | -3.3 | 2.8 | -2.4 | 1.1 | 3.5 | 1.9 | -3.7 |
| Placebo + Fulvestrant | 3.3 | 4.2 | 2.0 | 3.3 | -0.4 | 1.7 | 2.8 | 2.4 | -4.0 |
The EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual functioning, sexual enjoyment, future perspective) and four symptom scales (systemic side effects, breast symptoms, arm symptoms, upset by hair loss). QLQ-BR23 questionnaire employs 4-point scales with responses from 'not at all' to 'very much'. All scores are converted to a 0 to 100 scale. For functional scales, higher scores represent a better level of functioning. (NCT01942135)
Timeframe: From Cycle 1 to 14, as of 05 December 2014.
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Body image | Sexual functioning | Sexual enjoyment | Future perspective | |
| Palbociclib + Fulvestrant | 1.9 | -1.1 | -5.2 | 8.1 |
| Placebo + Fulvestrant | -0.3 | -0.4 | -6.6 | 4.5 |
"The EORTC-QLQ-C30 is a 30-item questionnaire composed of five multi-item functional subscales (physical, role, emotional, cognitive , and social functioning), three multi-item symptom scales (fatigue, nausea/vomiting, and pain), a global quality of life (QOL) subscale, and six single item symptom scales assessing other cancer-related symptoms (dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and the financial impact of cancer). The questionnaire employs 28 4-point Likert scales with responses from not at all to very much and two 7-point Likert scales for global health and overall QOL. Responses to all items are then converted to a 0 to 100 scale. For functional and global QOL scales, higher scores represent a better level of functioning/QOL. For symptom-oriented scales, a higher score represents more severe symptoms. A 10-point or higher change in scores from baseline is considered clinically significant." (NCT01942135)
Timeframe: From Cycle 1 to 14, as of 05 December 2014.
| Intervention | Units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Global health status / QoL | Physical functioning | Role functioning | Emotional functioning | Cognitive functioning | Social functioning | |
| Palbociclib + Fulvestrant | -0.9 | -0.7 | -1.8 | 2.7 | -1.7 | -0.5 |
| Placebo + Fulvestrant | -4.0 | -1.7 | -3.7 | -1.9 | -2.9 | -0.6 |
"Ctrough for Fulvestrant (if applicable). The method of dispersion applied here is percent coefficient of variation (%CV)." (NCT01942135)
Timeframe: Cycles 2/Day 1 and Cycle 3/Day 1
| Intervention | ng/mL (Geometric Mean) | |
|---|---|---|
| Cycle 2/Day 1 (N= 35, 19) | Cycle 3/Day 1 (N= 29, 14) | |
| Palbociclib + Fulvestrant | 11.75 | 9.90 |
| Placebo + Fulvestrant | 9.31 | 7.60 |
"Cmin for goserelin (if applicable). The method of dispersion applied here is percent coefficient of variation (%CV)." (NCT01942135)
Timeframe: Cycles 2/ Day 1 and Cycle 3/ Day 1
| Intervention | pg/mL (Geometric Mean) | |
|---|---|---|
| Cycle 2/Day 1 (N= 9, 5) | Cycle 3/Day 1 (N= 7, 3) | |
| Palbociclib + Fulvestrant | 295.1 | 344.8 |
| Placebo + Fulvestrant | 302.5 | 288.5 |
"Ctrough for palbociclib (if applicable). The method of dispersion applied here is percent coefficient of variation (%CV)." (NCT01942135)
Timeframe: Cycle 1/Day 15 and Cycle 2/Day 15
| Intervention | ng/mL (Geometric Mean) | |
|---|---|---|
| Cycle 1/Day 15 (N= 165) | Cycle 2/Day 15 (N= 160) | |
| Palbociclib + Fulvestrant | 70.70 | 75.29 |
An AE is any untoward medical occurrence in a clinical investigation patient administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. An SAE is any untoward medical occurrence at any dose that results in death; is life-threatening; requires hospitalization; results in persistent or significant disability or in congenital anomaly/birth defect. Severity will be graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.0. (NCT01942135)
Timeframe: From the signing of the informed consent until 28 days after the last dose of study medication up to 14 months
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| With AEs | With SAEs | With Grade 3 or 4 AEs | With Grade 5 AEs | Discontinued palbociclib/placebo due to AEs | |
| Palbociclib + Fulvestrant | 97.7 | 9.6 | 70.1 | 0.9 | 3.8 |
| Placebo + Fulvestrant | 89.0 | 14.0 | 18.0 | 1.2 | 4.1 |
One-, Two- or Three-year Survival Probability is defined as the probability of survival 1 year, 2 or 3 years after the date of randomization based on the Kaplan-Meier estimate. Survival time was censored to last date the participant is known to be alive. (NCT01942135)
Timeframe: From randomization until death (assessed up to 36 months)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Survival Probability at Month 12 | Survival Probability at Month 24 | Survival Probability at Month 36 | |
| Palbociclib + Fulvestrant | 89.3 | NA | NA |
| Placebo + Fulvestrant | 89.3 | NA | NA |
A time to event analysis was pre-specified for pain. An analysis of TTD in pain defined as time between baseline and first occurrence of increase of ≥10 points in pain. Deterioration will be defined increase in score of 10 points or greater from baseline. The Kaplan-Meier estimates of quartiles (time to deterioration) with 95% CI is mentioned below. (NCT01942135)
Timeframe: Baseline, Day 1 of Cycles 2 to 4, Day 1 of every alternate cycle after that until the end of treatment
| Intervention | Months (Median) | |
|---|---|---|
| 25% quartile | 50% quartile | |
| Palbociclib + Fulvestrant | 1.9 | 8.0 |
| Placebo + Fulvestrant | 1.0 | 2.8 |
Time from the date of randomization to the date of death (by any cause) (NCT01151215)
Timeframe: Following progression, patients were contacted at 12 weekly intervals until data cut-off at 31 August 2012 to determine survival status
| Intervention | Months (Median) |
|---|---|
| AZD8931 40mg + Anastrozole 1mg | 6.9 |
| AZD8931 20mg + Anastrozole 1mg | 8.3 |
| Placebo + Anastrozole 1mg | 7.9 |
Time from the date of randomization until the date of objective disease progression (as per RECIST 1.1) or the date of death (by any cause in the absence of progression). Disease progression is defined using RECIST 1.1 as >=20% increase in the sum of longest diameters of target lesions and an absolute increase of >=5mm, taking as reference the smallest sum of longest diameters of target lesions since study start, or unequivocal progression in non-target lesions, or appearance of any new lesions. (NCT01151215)
Timeframe: Tumour assessment by RECIST 1.1 every 12 weeks until data cut-off at 31 August 2012
| Intervention | Months (Median) |
|---|---|
| AZD8931 40mg + Anastrozole 1mg | 13.8 |
| AZD8931 20mg + Anastrozole 1mg | 10.9 |
| Placebo + Anastrozole 1mg | 14.0 |
The primary aim is to assess the anti-tumor effect in terms of pathologic CR rates of neo-adjuvant chemotherapy in patients with T2-T4c, any N, M0 breast cancer (by clinical staging) who are endocrine therapy resistant (that is, their Ki-67 level is >10 after 2-4 week of neo-adjuvant endocrine therapy alone). The pCR rate (percentage) for neo-adjuvant chemotherapy is defined as 100 times the number of eligible patients with no histologic evidence of invasive tumor cells in the surgical breast specimen and the axillary or sentinel lymph nodes divided by the total number of eligible patients who received neo-adjuvant chemotherapy. (NCT00265759)
Timeframe: Up to 18 weeks
| Intervention | percentage of patients (Number) |
|---|---|
| Cohort B Arm II: Week 2 Ki67 > 10% | 5.7 |
The clinical response rate (percentage) of a given treatment is defined as 100 times the number of eligible patients randomized to that treatment whose disease meets the WHO criteria for complete or partial response prior to surgery divided by the total number of eligible patients randomized to that treatment. For each treatment arm, a 95% binomial confidence interval will be constructed for the true clinical response rate. Complete Response (CR): The disappearance of all known disease based on a comparison between the measurements at baseline and the Week 16 visit. Partial Response (PR): A 50% or greater decrease in the product of the bi-dimensional measurements of the lesion (total tumor size) based on a comparison between the measurements at baseline and the Week 16 visit. In addition there can be no appearance of new lesions or progression of any lesion. (NCT00265759)
Timeframe: Up to 18 weeks
| Intervention | percentage of patients (Number) |
|---|---|
| Cohort A Arm I: Exemestane | 62.9 |
| Cohort A Arm II: Letrozole | 74.8 |
| Cohort A Arm III: Anastrozole | 69.1 |
The rate (percentage) of improved surgical outcome for patients considered marginal for breast conservation surgery prior to therapy for Cohort A is reported below for each treatment arm. Breast conservation surgery (not mastectomy) as the most extensive surgery performed for a patient is considered an improvement in surgical outcome. (NCT00265759)
Timeframe: At time of surgery up to 18 weeks
| Intervention | percentage of improved surgical outcome (Number) |
|---|---|
| Cohort A Arm I: Exemestane | 85.2 |
| Cohort A Arm II: Letrozole | 77.4 |
| Cohort A Arm III: Anastrozole | 86.4 |
Rate (percentage) of Improved surgical outcome for patients designated as candidates for mastectomy prior to therapy (Cohort A). Breast conservation surgery (not mastectomy) as the most extensive surgery performed for a patient is considered an improvement in surgical outcome. (NCT00265759)
Timeframe: At time of surgery up to 18 weeks
| Intervention | percentage of patients (Number) |
|---|---|
| Cohort A Arm I: Exemestane | 48.1 |
| Cohort A Arm II: Letrozole | 42.1 |
| Cohort A Arm III: Anastrozole | 60.0 |
For those patients who undergo a sentinel lymph node dissection or an axillary lymph node dissection (at least 6 nodes examined with Hematoxylin & Eosin Staining), the LNI rate (percentage) is defined as 100 times the proportion of eligible patients randomized to that treatment with at least one positive node. For each neo-adjuvant endocrine treatment, a 95% binomial confidence interval will be constructed for its true LNI rate. (NCT00265759)
Timeframe: At time of surgery up to 18 weeks
| Intervention | percentage of patients (Number) |
|---|---|
| Cohort A Arm I: Exemestane | 41.1 |
| Cohort A Arm II: Letrozole | 48.2 |
| Cohort A Arm III: Anastrozole | 44.1 |
The pathologic complete response is defined as no histologic evidence of invasive tumor cells in the surgical breast specimen and axillary or sentinel lymph nodes. The pathologic complete response rate (percentage) of a given treatment is defined as 100 times the number of eligible patients randomized to that treatment whose surgical specimen is such that there is no histologic evidence of invasive tumor cells in the surgical breast specimen and axillary or sentinel lymph nodes divided by the total number of eligible patients randomized to that treatment. For each neo-adjuvant endocrine treatment pair, a 95% binomial confidence interval will be constructed for the true difference in the pCR between these 2 treatments. (NCT00265759)
Timeframe: At time of surgery up to 18 weeks
| Intervention | percentage of patients (Number) |
|---|---|
| Cohort A Arm I: Exemestane | 1.7 |
| Cohort A Arm II: Letrozole | 0.0 |
| Cohort A Arm III: Anastrozole | 0.0 |
Incidence of the most common grade 3+ toxicities reported to be probably, possibly, or definitely related to treatment as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (Cohort A) At each treatment evaluation, the type, severity, and attribution of each adverse event reported will be assessed using the NCI-CTCAE definitions. For each treatment, the percentage of patients who developed a severe (grade 3+) toxicity considered possibly, probably or definitively related to treatment will be determined. (NCT00265759)
Timeframe: Up to 30 days after drug therapy
| Intervention | percentage of patients (Number) | ||
|---|---|---|---|
| Fatigue | Hot flashes/flushes | Joint pain | |
| Cohort A Arm I: Exemestane | 2 | 2 | 2 |
| Cohort A Arm II: Letrozole | 2 | 4 | 3 |
| Cohort A Arm III: Anastrozole | 3 | 2 | 2 |
"The overall clinical benefit rate of goserelin followed by anastrozole was evaluated, as determined as the sum of the Complete Response (CR) rate + Partial Response (PR) rate + Stable Disease (SD) rate.~CR = Complete disappearance of all clinically- or pathologically-detectable malignant disease for at least 4 weeks.~PR = ≥ 50% decrease in tumor size for at least 4 weeks, without any new lesion or any ≥ 25% increase in size of any lesion.~SD = No significant change in measurable or evaluable disease for at least 4 weeks.~All measurements by ruler or calipers." (NCT00186121)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Anastrozole + Goserelin | 71.9 |
"ORR was determined as the sum of the Complete Response (CR) rate + Partial Response (PR) rates.~CR = Complete disappearance of all clinically- or pathologically-detectable malignant disease for at least 4 weeks.~PR = ≥ 50% decrease in tumor size for at least 4 weeks, without any new lesion or any ≥ 25% increase in size of any lesion.~All measurements by ruler or calipers." (NCT00186121)
Timeframe: 3 months
| Intervention | percentage of participants (Number) |
|---|---|
| Anastrozole + Goserelin | 37.5 |
Overall survival (OS) was assessed as the median observed in the participants receiving goserelin followed by anastrozole. (NCT00186121)
Timeframe: up to 63 months
| Intervention | months (Median) |
|---|---|
| Anastrozole + Goserelin | NA |
The toxicity of the treatment regimen of goserelin followed by anastrozole is estimated by the rate of Serious Adverse Events (SAEs) that occurred during the course of the study. (NCT00186121)
Timeframe: 6 months
| Intervention | Serious Adverse Events (SAEs) (Number) |
|---|---|
| Anastrozole + Goserelin | 0 |
"Time-to-progression (TTP) was assessed as the median observed in the participant group.~Progression of disease was considered, per protocol, to be ≤ 25% increase in the area of any malignant lesion greater than 2 square cm, or ≤ 25% increase in the sum of the products of the longest perpendicular diameters of individual lesions in a given organ, when compared to baseline values or after therapeutic response." (NCT00186121)
Timeframe: up to 63 months
| Intervention | months (Median) |
|---|---|
| Anastrozole + Goserelin | 8.3 |
Plasma estradiol determinations were performed at baseline, 1 month, 3 months, and 6 months using the Coat-A-Count Estradiol competitive binding assay system, which has a calibrated range for estradiol of 20 to 3,600 pg/mL with an analytical sensitivity of 10 pg/mL. (NCT00186121)
Timeframe: 6 months
| Intervention | pg/mL estradiol (Mean) | |||
|---|---|---|---|---|
| Mean at Baseline | Mean at 1 month treatment | Mean at 3 months treatment | Mean at 6 months treatment | |
| Anastrozole + Goserelin | 74.7 | 20.8 | 18.7 | 14.8 |
"The numbers of participants with metastatic breast cancer experiencing Complete Response (CR); Partial Response (PR); or Stable Disease (SD) after treatment with goserelin followed by anastrozole are reported.~CR = Complete disappearance of all clinically- or pathologically-detectable malignant disease for at least 4 weeks.~PR = ≥ 50% decrease in tumor size for at least 4 weeks, without any new lesion or any ≥ 25% increase in size of any lesion.~SD = No significant change in measurable or evaluable disease for at least 4 weeks.~All measurements by ruler or calipers." (NCT00186121)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Stable Disease (SD) | |
| Anastrozole + Goserelin | 1 | 11 | 11 |
We examined whether differences in lipoprotein lipase expression would be evident across study treatment groups. RNA was isolated from whole adipose tissue gene expression, and complementary DNA (cDNA) was synthesized from 1.5 ug of RNA per sample. Gene expression was measured by polymerase chain reaction (PCR) using predesigned TaqMan® Gene Expression Assays. Standard curves were included on each plate, so Ct values were converted to copy numbers of the target gene. Expression values were normalized to the geometric mean of the housekeeping genes phosphoglycerate kinase and 18s. (NCT01686828)
Timeframe: 4 weeks
| Intervention | gene copy number per ng RNA (Mean) |
|---|---|
| Acyline + Placebo Gel + Placebo Pills | 7493 |
| Acyline + Testosterone Gel (1.25g/d) + Placebo Pills | 8224 |
| Acyline + Testosterone Gel (5g/d) + Placebo Pills | 7885 |
| Acyline + Testosterone Gel (5g/d) + Letrozole | 8320 |
Whole body insulin sensitivity as quantified by Matsuda Index at the end of the treatment period, calculated by the following equation: 10,000/square root of(FPG*FI)*(FPG+PG30*2+PG60*2+PG90*2+PG120)/8*(FPI+PI30*2+PI60*2+PI90*2+PI)/8). FPG=fasting plasma glucose level; FPI=fasting plasma insulin level; PG30,60,90, and 120=plasma glucose levels sampled at 30,60,90, and 120 minutes after oral glucose load; PI30,60,90, and 120=plasma insulin levels sampled at 30,60,90, and 120 minutes after the oral glucose load (NCT01686828)
Timeframe: 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Acyline & Placebo Gel & Placebo Pill | 5.0 |
| Acyline & Testosterone Gel 1.25g/d & Placebo Pill | 9.4 |
| Acyline & Testosterone Gel 5g/d & Placebo Pill | 7.2 |
| Acyline & Testosterone Gel & Letrozole | 7.3 |
Fat mass and lean mass were measured by dual energy X-ray absorptiometry (DEXA) at baseline and at the end of the 4 week treatment period (NCT01686828)
Timeframe: 4 weeks
| Intervention | kg (Mean) | |
|---|---|---|
| Change in fat mass | Change in lean mass | |
| Acyline & Placebo Gel & Placebo Pill | 1.1 | -1.2 |
| Acyline & Testosterone Gel & Letrozole | 0.5 | -0.3 |
| Acyline & Testosterone Gel 1.25g/d & Placebo Pill | 0.7 | -1.4 |
| Acyline & Testosterone Gel 5g/d & Placebo Pill | -0.4 | 0.0 |
The Percentage of Patients Who Experience an Objective Benefit From Treatment (CR+PR). The response categories were assigned using RECIST criteria. Complete Response (CR) = Disappearance of all target lesions ; Partial Response (PR) = >=30% decrease in the sum of the longest diameter of target lesions. (NCT00405938)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Bevacizumab/Anastrozole | 18 |
| Bevacizumab/Fulvestrant | 11 |
Progression Free Survival (PFS) is defined as the interval, in months, from the date of first treatment to the date of disease progression or death, whichever occurred first. (NCT00405938)
Timeframe: 18 months
| Intervention | months (Median) |
|---|---|
| Bevacizumab/Anastrozole | 21 |
| Bevacizumab/Fulvestrant | 9 |
Trough Plasma concentrations (Cmin) of Anastrozole - only Anastrozole arm was evaluated for Trough Plasma concentrations. (NCT00605267)
Timeframe: Assessed at week 12
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Anastrozole 1 mg | 29.7 |
"The BORR were defined as the percentage of patients with confirmed CR or PR in the ITT population during 24 weeks pre-operative treatment period (based on the data from calliper measurement).~CR (or PR) criteria are met at 2 or more time in points every 4 weeks. Per RECIST Criteria (V1.0) and assessed by Calliper: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >= 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR." (NCT00605267)
Timeframe: 24 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Anastrozole 1 mg | 70.4 |
| Tamoxifen 20 mg | 50.5 |
"The BORR were defined as the percentage of patients with confirmed CR or PR in the ITT population during 24 weeks pre-operative treatment period(based on the data from magnetic resonance imaging (MRI) or computed tomography (CT) measurement).~CR (or PR) criteria are met at either 12 weeks or 24 weeks. Per RECIST Criteria (V1.0) and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >= 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR." (NCT00605267)
Timeframe: 24 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Anastrozole 1 mg | 64.3 |
| Tamoxifen 20 mg | 37.4 |
"The BORR were defined as the percentage of patients with confirmed CR or PR in the ITT population during 24 weeks pre-operative treatment period (based on the data from ultra sound (US) measurement).~CR (or PR) criteria are met at 2 or more time in points every 4 weeks. Per RECIST Criteria (V1.0) and assessed by US: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >= 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR." (NCT00605267)
Timeframe: 24 weeks
| Intervention | Participants (Number) |
|---|---|
| Anastrozole 1 mg | 58.2 |
| Tamoxifen 20 mg | 42.4 |
Change from baseline in Bone Mineral Density value (percentage), in all subjects who used DXA(Dual-energy X-ray absorptiometry) method throughout the study, at 24 weeks measured at cervical thighbone. (NCT00605267)
Timeframe: Assessed at baseline and after 24 weeks of treatment
| Intervention | PercentageBMD=Patient'sBMD/standard BMD) (Mean) |
|---|---|
| Anastrozole 1 mg | -2.5 |
| Tamoxifen 20 mg | -0.5 |
Change from baseline in Bone Mineral Density value (percentage), in all subjects who used DXA(Dual-energy X-ray absorptiometry) method throughout the study, at 24 weeks measured at lumbar spine. (NCT00605267)
Timeframe: Assessed at baseline and after 24 weeks of treatment
| Intervention | PercentageBMD=Patient's BMD/standard BMD (Mean) |
|---|---|
| Anastrozole 1 mg | -5.8 |
| Tamoxifen 20 mg | -2.9 |
Change from baseline in serum Bone-Alkaline Phosphatase (BAP) at 24 weeks measured by CLEIA method (NCT00605267)
Timeframe: Assessed at baseline and after 24 weeks of treatment
| Intervention | ug/L (Mean) |
|---|---|
| Anastrozole 1 mg | 3.96 |
| Tamoxifen 20 mg | -0.75 |
Change from baseline in serum Bone-Alkaline Phosphatase (BAP) at 24 weeks measured by EIA method (NCT00605267)
Timeframe: Assessed at baseline and after 24 weeks of treatment
| Intervention | U/L (Mean) |
|---|---|
| Anastrozole 1 mg | 7.1941 |
| Tamoxifen 20 mg | 0.7333 |
Change from baseline in serum crosslinked N-Telopeptide of type I collagen (NTX) at 24 weeks (NCT00605267)
Timeframe: Assessed at baseline and after 24 weeks of treatment
| Intervention | nmolBCE(Bone Collagen Equivalent) /L (Mean) |
|---|---|
| Anastrozole 1 mg | 9.17 |
| Tamoxifen 20 mg | 2.59 |
"Change from baseline in Endocrine Symptom Subscale (ES)) in the ITT population at 24 weeks. ES score = the sum of the responses to all the questions on ES, low scores reflect poor quality of life and high scores reflects better quality of life.~Score range: 0-72" (NCT00605267)
Timeframe: Assessed at baseline and after 24 weeks of treatment
| Intervention | ES score (Mean) |
|---|---|
| Anastrozole 1 mg | -8.85 |
| Tamoxifen 20 mg | -6.27 |
"Change from baseline in Functional Assessment of Cancer Therapy-Breast (FACT-B)in the ITT population at 24 weeks. Trial Outcome Index (TOI) = the sum of the Physical Well-Being (PWB), Functional Well-Being (FWB), and Breast Cancer Scale (BCS) subscales of FACT-B.~FACT-B includes 36 questions; 7 in PWB (Physical Well-Being); 7 inSWB (Social / Family Well-Being); 6 in EWB (Emotional Well-Being); 7 in FWB (Functional Well-Being); 9 in BCS (Breast Cancer Subscale).~Total score of subscores or TOI is calculated from each score of question. Higher score means better and lower score means worthier.~Score range; 0-28 in PWB; 0-28 in SWB; 0-24 in EWB; 0-28 in FWB; 0-36 in BCS; 0-92 in TOI." (NCT00605267)
Timeframe: Assessed at baseline and after 24 weeks of treatment
| Intervention | Trial Outcome Index (TOI) (Prorated) (Mean) |
|---|---|
| Anastrozole 1 mg | -4.42 |
| Tamoxifen 20 mg | -2.65 |
Number of patients in the ITT population defined as histopathological responders over the total number of patients x 100. An histopathological responder = a patient classified as Grade 1b, 2 or 3 for the histopathological response (Grade 0 = no response, 1a = mild response, 1b = moderate response, 2 = marked response or 3 = complete response) (NCT00605267)
Timeframe: Assessed at baseline and after 24 weeks of treatment
| Intervention | Percentage of Participants (Number) |
|---|---|
| Anastrozole 1 mg | 41.8 |
| Tamoxifen 20 mg | 27.3 |
Ratio of serum Oestradiol (E2) concentration (pg/mL) in the ITT population from baseline at 24 weeks. (NCT00605267)
Timeframe: Assessed at baseline and after 24 weeks of treatment
| Intervention | Ratio (Mean) |
|---|---|
| Anastrozole 1 mg | 0.041 |
| Tamoxifen 20 mg | 0.082 |
Ratio of serum Oestrone (E1) concentration (pg/mL) in the ITT population from baseline at 24 weeks. (NCT00605267)
Timeframe: Assessed at baseline and after 24 weeks of treatment
| Intervention | Ratio (Mean) |
|---|---|
| Anastrozole 1 mg | 0.028 |
| Tamoxifen 20 mg | 0.341 |
HER2 status in the ITT population is categorized as Positive or Negative (NCT00605267)
Timeframe: Assessed at baseline and after 24 weeks of treatment
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Baseline Positive & 24 weeks Negative | Baseline Positive & 24 weeks Positive | Baseline Negative & 24 weeks Negative | Baseline Negative & 24 weeks Positive | |
| Anastrozole 1 mg | 0 | 0 | 92 | 2 |
| Tamoxifen 20 mg | 0 | 0 | 88 | 2 |
ER status in the ITT population is categorized as Positive or Negative (NCT00605267)
Timeframe: Assessed at baseline and after 24 weeks of treatment
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Baseline Positive & 24 weeks Negative | Baseline Positive & 24 weeks Positive | Baseline Negative & 24 weeks Negative | Baseline Negative & 24 weeks Positive | |
| Anastrozole 1 mg | 2 | 92 | 0 | 0 |
| Tamoxifen 20 mg | 1 | 89 | 0 | 0 |
PgR status in the ITT population is categorized as Positive or Negative. (NCT00605267)
Timeframe: Assessed at baseline and after 24 weeks of treatment
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Baseline Positive & 24 weeks Negative | Baseline Positive & 24 weeks Positive | Baseline Negative & 24 weeks Negative | Baseline Negative & 24 weeks Positive | |
| Anastrozole 1 mg | 60 | 29 | 4 | 1 |
| Tamoxifen 20 mg | 19 | 59 | 9 | 3 |
intestinal calcium absorption (NCT00766532)
Timeframe: baseline and 6 weeks later
| Intervention | percent calcium absorption (Mean) |
|---|---|
| Aromatase Inhibitor Therapy | 16 |
Clinical benefit = complete response (CR), partial response (PR), or stable disease (SD) lasting for at least 6 months, assessed per Response Evaluation Criteria of Solid Tumor (RECIST).CR=disappearance of all target and non-target lesions. PR= disappearance of or at least 30% decrease in the sum of the longest diameters of target lesions, with non-progressive disease in non-target lesions. SD= sum of the longest diameters of target lesions decrease <30% or increase <20%, with non-progressive disease in non-target lesions. 141 eligible, treated patients were included. (NCT00057941)
Timeframe: assessed every 3 cycles while on treatment, assessed every 3 months when follow up <2 years, every 6 months between 2-3 years,no specific requirements after 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Anastrozole and ZD1839 | 44 |
| Fulvestrant and ZD1839 | 41 |
Assessment of fatigue using the Piper Fatigue Scale at weeks 0 and 8. The Piper Fatigue Scale is the average of 22 numeric items, with higher scores indicating greater fatigue [range of scores: 0-10]. Change is calculated as the fatigue score at 8 weeks minus fatigue score at 0 weeks. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time. (NCT02186015)
Timeframe: 0, 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Cholecalciferol | -0.5 |
"Assessment of quality of life using the functional assessment of cancer therapy-breast symptoms at weeks 0 and 8. Scores range from 0-40 with higher scores indicating better quality of life.~Change was calculated as week 8 score minus week 0 score. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time." (NCT02186015)
Timeframe: 0, 8 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Cholecalciferol | 0 |
Assessment of quality of life using the functional assessment of cancer therapy- endocrine symptoms at weeks 0 and 8. Scores range from 0-76 with higher scores indicating better quality of life. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time. (NCT02186015)
Timeframe: 0, 8 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Cholecalciferol | 9 |
Assessment of mood using the Patient Health Questionnaire 8 (PHQ-8) at weeks 0 and 8. The PHQ-8 ranges from 0-24 with higher scores indicating more distress. Change was assessed as PHQ-8 score at 8 weeks minus 0 weeks. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time. (NCT02186015)
Timeframe: 0, 8 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Cholecalciferol | -1 |
Assessment of muscle function using a hand dynamometer at weeks 0 and 8. Change in dominant handgrip strength in kilograms was calculated as 8 weeks minus 0 weeks. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time. (NCT02186015)
Timeframe: 0, 8 weeks
| Intervention | kilograms (Median) |
|---|---|
| Cholecalciferol | -0.2 |
Change in laboratory serum value of 25(OH)D at 8 weeks post-supplementation for participants who received weekly supplementation of 50,000 IUs of vitamin D3. Change is expressed as laboratory serum value of 25(OH)D at 8 weeks minus baseline. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time. (NCT02186015)
Timeframe: 0, 8 weeks
| Intervention | ng/ml (Median) |
|---|---|
| Cholecalciferol | 32 |
Assessment of sleep using the Pittsburgh Sleep Quality Index (PSQI) at weeks 0 and 8. Scores range from 0-21 with higher scores indicating poorer sleep quality. Change was calculated as week 8 minus week 0 PSQI. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time. (NCT02186015)
Timeframe: 0, 8 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Cholecalciferol | -1 |
Assessment of pain using the Beck Pain Scale at weeks 0 and 8. This is a Likert scale item where a score of 0 corresponds to no pain and a score of 10 corresponds to worst pain. Change is calculated as the worst pain rating at 8 weeks minus the worst pain rating at 0 weeks.Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time. (NCT02186015)
Timeframe: 0, 8 weeks
| Intervention | score on a scale (Median) |
|---|---|
| Cholecalciferol | 0 |
(NCT00073073)
Timeframe: 1 year
| Intervention | mg/dl (Mean) |
|---|---|
| Exemestane | 181.6 |
(NCT00073073)
Timeframe: 2 years
| Intervention | percent change from baseline (Mean) |
|---|---|
| Exemestane | -4.1 |
(NCT00073073)
Timeframe: 1 year
| Intervention | percent change from baseline (Mean) |
|---|---|
| Exemestane | -1.4 |
(NCT00073073)
Timeframe: 1 year
| Intervention | percent change from baseline (Mean) |
|---|---|
| Exemestane | -1.32 |
(NCT00073073)
Timeframe: 1 year
| Intervention | percent change from baseline (Mean) |
|---|---|
| Exemestane | -2.4 |
17 women with early breast cancer receiving adjuvant Aromatase Inhibitor (AI) therapy were treated with a single 5 mg IV dose of zoledronic acid. Urine and serum NTx and serum CTx were measured at baseline and month 12. (NCT00712985)
Timeframe: One year
| Intervention | participants (Number) |
|---|---|
| Zoledronic Acid 5 mg IV | 13 |
253 reviews available for anastrozole and Breast Neoplasms
| Article | Year |
|---|---|
An overview on Estrogen receptors signaling and its ligands in breast cancer.
Topics: Breast Neoplasms; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Hum | 2022 |
An overview on Estrogen receptors signaling and its ligands in breast cancer.
Topics: Breast Neoplasms; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Hum | 2022 |
An overview on Estrogen receptors signaling and its ligands in breast cancer.
Topics: Breast Neoplasms; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Hum | 2022 |
Health-related quality of life of women with breast cancer being treated with hormone therapy: A scoping review.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Hormones; Humans; Quality of Life; Tamo | 2023 |
Health-related quality of life of women with breast cancer being treated with hormone therapy: A scoping review.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Hormones; Humans; Quality of Life; Tamo | 2023 |
Health-related quality of life of women with breast cancer being treated with hormone therapy: A scoping review.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Hormones; Humans; Quality of Life; Tamo | 2023 |
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Topics: Aminopyridines; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combine | 2019 |
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Topics: Aminopyridines; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combine | 2019 |
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Topics: Aminopyridines; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combine | 2019 |
Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2020 |
Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2020 |
Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2020 |
Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; | 2020 |
Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; | 2020 |
Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; | 2020 |
[Endocrine adjuvant treatment specific features for young breast cancer women].
Topics: Adult; Amenorrhea; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2019 |
[Endocrine adjuvant treatment specific features for young breast cancer women].
Topics: Adult; Amenorrhea; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2019 |
[Endocrine adjuvant treatment specific features for young breast cancer women].
Topics: Adult; Amenorrhea; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2019 |
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
Topics: Aminopyridines; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Ant | 2021 |
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
Topics: Aminopyridines; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Ant | 2021 |
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
Topics: Aminopyridines; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Ant | 2021 |
Preventing Breast Cancer Through Identification and Pharmacologic Management of High-Risk Patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Curriculum; Decision Making, Shared; | 2021 |
Preventing Breast Cancer Through Identification and Pharmacologic Management of High-Risk Patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Curriculum; Decision Making, Shared; | 2021 |
Preventing Breast Cancer Through Identification and Pharmacologic Management of High-Risk Patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Curriculum; Decision Making, Shared; | 2021 |
A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Randomized | 2017 |
A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Randomized | 2017 |
A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Randomized | 2017 |
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2017 |
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2017 |
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2017 |
Use of anastrozole in the chemoprevention and treatment of breast cancer: A literature review.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemopreventio | 2017 |
Use of anastrozole in the chemoprevention and treatment of breast cancer: A literature review.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemopreventio | 2017 |
Use of anastrozole in the chemoprevention and treatment of breast cancer: A literature review.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemopreventio | 2017 |
Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Estradi | 2017 |
Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Estradi | 2017 |
Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Estradi | 2017 |
In case of anastrozole-related hallucinations, can switching to letrozole be a treatment option? A case report and literature review.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Halluc | 2019 |
In case of anastrozole-related hallucinations, can switching to letrozole be a treatment option? A case report and literature review.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Halluc | 2019 |
In case of anastrozole-related hallucinations, can switching to letrozole be a treatment option? A case report and literature review.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Halluc | 2019 |
Personalized prevention in high risk individuals: Managing hormones and beyond.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemopreventi | 2018 |
Personalized prevention in high risk individuals: Managing hormones and beyond.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemopreventi | 2018 |
Personalized prevention in high risk individuals: Managing hormones and beyond.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemopreventi | 2018 |
Endocrine Therapy for Ductal Carcinoma In Situ (DCIS) of the Breast with Breast Conserving Surgery (BCS) and Radiotherapy (RT): a Meta-Analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrat | 2020 |
Endocrine Therapy for Ductal Carcinoma In Situ (DCIS) of the Breast with Breast Conserving Surgery (BCS) and Radiotherapy (RT): a Meta-Analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrat | 2020 |
Endocrine Therapy for Ductal Carcinoma In Situ (DCIS) of the Breast with Breast Conserving Surgery (BCS) and Radiotherapy (RT): a Meta-Analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrat | 2020 |
Primary antiphospholipid syndrome during aromatase inhibitors therapy: A case report and review of the literature.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antiphospholipid Syndrome; Aromatase Inhibitors; Breas | 2019 |
Primary antiphospholipid syndrome during aromatase inhibitors therapy: A case report and review of the literature.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antiphospholipid Syndrome; Aromatase Inhibitors; Breas | 2019 |
Primary antiphospholipid syndrome during aromatase inhibitors therapy: A case report and review of the literature.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antiphospholipid Syndrome; Aromatase Inhibitors; Breas | 2019 |
A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Complementary T | 2019 |
A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Complementary T | 2019 |
A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Complementary T | 2019 |
A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; | 2013 |
A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; | 2013 |
A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; | 2013 |
Pharmacogenomics of endocrine therapy in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2013 |
Pharmacogenomics of endocrine therapy in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2013 |
Pharmacogenomics of endocrine therapy in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2013 |
Targeting receptor tyrosine kinases in HER2-negative breast cancer.
Topics: Anastrozole; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clinical Trials, Phase II as To | 2013 |
Targeting receptor tyrosine kinases in HER2-negative breast cancer.
Topics: Anastrozole; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clinical Trials, Phase II as To | 2013 |
Targeting receptor tyrosine kinases in HER2-negative breast cancer.
Topics: Anastrozole; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clinical Trials, Phase II as To | 2013 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: a case of localised urticarial vasculitis following anastrozole therapy and a review of the literature.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Lobular; Chemothera | 2014 |
Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: a case of localised urticarial vasculitis following anastrozole therapy and a review of the literature.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Lobular; Chemothera | 2014 |
Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: a case of localised urticarial vasculitis following anastrozole therapy and a review of the literature.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Lobular; Chemothera | 2014 |
Current concepts in breast cancer chemoprevention.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2014 |
Current concepts in breast cancer chemoprevention.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2014 |
Current concepts in breast cancer chemoprevention.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2014 |
Fulvestrant 250 mg versus anastrozole 1 mg in the treatment of advanced breast cancer: a meta-analysis of randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2014 |
Fulvestrant 250 mg versus anastrozole 1 mg in the treatment of advanced breast cancer: a meta-analysis of randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2014 |
Fulvestrant 250 mg versus anastrozole 1 mg in the treatment of advanced breast cancer: a meta-analysis of randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2014 |
[A case of local recurrence developing thirty-nine years after mastectomy for breast cancer].
Topics: Adenocarcinoma; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy, Needle; Breast Neoplasms | 2014 |
[A case of local recurrence developing thirty-nine years after mastectomy for breast cancer].
Topics: Adenocarcinoma; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy, Needle; Breast Neoplasms | 2014 |
[A case of local recurrence developing thirty-nine years after mastectomy for breast cancer].
Topics: Adenocarcinoma; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy, Needle; Breast Neoplasms | 2014 |
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Topics: Ado-Trastuzumab Emtansine; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Ho | 2014 |
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Topics: Ado-Trastuzumab Emtansine; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Ho | 2014 |
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Topics: Ado-Trastuzumab Emtansine; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Ho | 2014 |
Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phas | 2014 |
Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phas | 2014 |
Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phas | 2014 |
Aromatase inhibitors in breast cancer prevention.
Topics: Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female | 2014 |
Aromatase inhibitors in breast cancer prevention.
Topics: Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female | 2014 |
Aromatase inhibitors in breast cancer prevention.
Topics: Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female | 2014 |
Is there a role for estrogen activity assays? Recombinant cell bioassay for estrogen: Development and applications.
Topics: Anastrozole; Aromatase Inhibitors; Biological Assay; Breast Neoplasms; Child; Estradiol; Female; Hum | 2015 |
Is there a role for estrogen activity assays? Recombinant cell bioassay for estrogen: Development and applications.
Topics: Anastrozole; Aromatase Inhibitors; Biological Assay; Breast Neoplasms; Child; Estradiol; Female; Hum | 2015 |
Is there a role for estrogen activity assays? Recombinant cell bioassay for estrogen: Development and applications.
Topics: Anastrozole; Aromatase Inhibitors; Biological Assay; Breast Neoplasms; Child; Estradiol; Female; Hum | 2015 |
The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Breast Neoplasms; Cytochrome P-450 CYP3A; F | 2014 |
The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Breast Neoplasms; Cytochrome P-450 CYP3A; F | 2014 |
The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Breast Neoplasms; Cytochrome P-450 CYP3A; F | 2014 |
Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistanc | 2014 |
Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistanc | 2014 |
Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistanc | 2014 |
A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Ant | 2015 |
A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Ant | 2015 |
A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Ant | 2015 |
Targeting HER2 for the treatment of breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo | 2015 |
Targeting HER2 for the treatment of breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo | 2015 |
Targeting HER2 for the treatment of breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo | 2015 |
Testosterone and breast cancer prevention.
Topics: Anastrozole; Androgens; Aromatase; Aromatase Inhibitors; Breast; Breast Neoplasms; Drug Implants; Es | 2015 |
Testosterone and breast cancer prevention.
Topics: Anastrozole; Androgens; Aromatase; Aromatase Inhibitors; Breast; Breast Neoplasms; Drug Implants; Es | 2015 |
Testosterone and breast cancer prevention.
Topics: Anastrozole; Androgens; Aromatase; Aromatase Inhibitors; Breast; Breast Neoplasms; Drug Implants; Es | 2015 |
Ductal Carcinoma In Situ: Treatment Update and Current Trends.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrat | 2015 |
Ductal Carcinoma In Situ: Treatment Update and Current Trends.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrat | 2015 |
Ductal Carcinoma In Situ: Treatment Update and Current Trends.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrat | 2015 |
[Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neoplasms; Female; | 2016 |
[Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neoplasms; Female; | 2016 |
[Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neoplasms; Female; | 2016 |
Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhib | 2016 |
Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhib | 2016 |
Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhib | 2016 |
Unravelling exemestane: From biology to clinical prospects.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Apoptosis; Aromatase Inhibitors; Autophagy; Biot | 2016 |
Unravelling exemestane: From biology to clinical prospects.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Apoptosis; Aromatase Inhibitors; Autophagy; Biot | 2016 |
Unravelling exemestane: From biology to clinical prospects.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Apoptosis; Aromatase Inhibitors; Autophagy; Biot | 2016 |
Endocrine therapy for hormone treatment-naïve advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy P | 2016 |
Endocrine therapy for hormone treatment-naïve advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy P | 2016 |
Endocrine therapy for hormone treatment-naïve advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy P | 2016 |
Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Ant | 2016 |
Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Ant | 2016 |
Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Ant | 2016 |
Fulvestrant for hormone-sensitive metastatic breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Estradiol; Fe | 2017 |
Fulvestrant for hormone-sensitive metastatic breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Estradiol; Fe | 2017 |
Fulvestrant for hormone-sensitive metastatic breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Estradiol; Fe | 2017 |
Extended Adjuvant Endocrine Therapy in Breast Cancer: Evidence and Update - A Review.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2017 |
Extended Adjuvant Endocrine Therapy in Breast Cancer: Evidence and Update - A Review.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2017 |
Extended Adjuvant Endocrine Therapy in Breast Cancer: Evidence and Update - A Review.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2017 |
ADJUVANT (HORMONAL) THERAPY AS A CAUSE OF BONE LOSS IN PATIENTS WITH BREAST CANCER (REVIEW OF LITERATURE).
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Chemotherapy, Adj | 2017 |
ADJUVANT (HORMONAL) THERAPY AS A CAUSE OF BONE LOSS IN PATIENTS WITH BREAST CANCER (REVIEW OF LITERATURE).
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Chemotherapy, Adj | 2017 |
ADJUVANT (HORMONAL) THERAPY AS A CAUSE OF BONE LOSS IN PATIENTS WITH BREAST CANCER (REVIEW OF LITERATURE).
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Chemotherapy, Adj | 2017 |
Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2008 |
Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2008 |
Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2008 |
[Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2008 |
[Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2008 |
[Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2008 |
Review of the ATAC study: tamoxifen versus anastrozole in early-stage breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Early Diagnosis; Humans; Nitriles; Tamoxifen; | 2008 |
Review of the ATAC study: tamoxifen versus anastrozole in early-stage breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Early Diagnosis; Humans; Nitriles; Tamoxifen; | 2008 |
Review of the ATAC study: tamoxifen versus anastrozole in early-stage breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Early Diagnosis; Humans; Nitriles; Tamoxifen; | 2008 |
Aromatase inhibitors and breast cancer.
Topics: Anastrozole; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aromatase Inhibitor | 2009 |
Aromatase inhibitors and breast cancer.
Topics: Anastrozole; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aromatase Inhibitor | 2009 |
Aromatase inhibitors and breast cancer.
Topics: Anastrozole; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aromatase Inhibitor | 2009 |
[Adjuvant breast cancer treatment with hormono-radiotherapy].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Huma | 2009 |
[Adjuvant breast cancer treatment with hormono-radiotherapy].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Huma | 2009 |
[Adjuvant breast cancer treatment with hormono-radiotherapy].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Huma | 2009 |
Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer.
Topics: Anastrozole; Androstadienes; Animals; Breast Neoplasms; Disease Management; Early Detection of Cance | 2009 |
Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer.
Topics: Anastrozole; Androstadienes; Animals; Breast Neoplasms; Disease Management; Early Detection of Cance | 2009 |
Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer.
Topics: Anastrozole; Androstadienes; Animals; Breast Neoplasms; Disease Management; Early Detection of Cance | 2009 |
Breast cancer chemoprevention - a vision not yet realized.
Topics: Anastrozole; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Neopla | 2009 |
Breast cancer chemoprevention - a vision not yet realized.
Topics: Anastrozole; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Neopla | 2009 |
Breast cancer chemoprevention - a vision not yet realized.
Topics: Anastrozole; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Neopla | 2009 |
Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibito | 2009 |
Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibito | 2009 |
Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibito | 2009 |
Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormona | 2010 |
Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormona | 2010 |
Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormona | 2010 |
A case of ectopic breast cancer with a literature review.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carc | 2011 |
A case of ectopic breast cancer with a literature review.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carc | 2011 |
A case of ectopic breast cancer with a literature review.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carc | 2011 |
Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2009 |
Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2009 |
Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2009 |
[A negative first-line work-up of Raynaud's phenomenon: And what if it were cancer?].
Topics: Adenocarcinoma, Mucinous; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Ne | 2010 |
[A negative first-line work-up of Raynaud's phenomenon: And what if it were cancer?].
Topics: Adenocarcinoma, Mucinous; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Ne | 2010 |
[A negative first-line work-up of Raynaud's phenomenon: And what if it were cancer?].
Topics: Adenocarcinoma, Mucinous; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Ne | 2010 |
[Management of metastatic HER2-positive breast cancer: present and future].
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormo | 2010 |
[Management of metastatic HER2-positive breast cancer: present and future].
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormo | 2010 |
[Management of metastatic HER2-positive breast cancer: present and future].
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormo | 2010 |
Adjuvant endocrine therapy for early breast cancer: the story so far.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Neopl | 2010 |
Adjuvant endocrine therapy for early breast cancer: the story so far.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Neopl | 2010 |
Adjuvant endocrine therapy for early breast cancer: the story so far.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Neopl | 2010 |
Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; | 2010 |
Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; | 2010 |
Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; | 2010 |
Anastrozole.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Antagonists; F | 2010 |
Anastrozole.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Antagonists; F | 2010 |
Anastrozole.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Antagonists; F | 2010 |
Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.
Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2011 |
The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.
Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2011 |
The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.
Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2011 |
When to start an aromatase inhibitor: now or later?
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Drug Adm | 2011 |
When to start an aromatase inhibitor: now or later?
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Drug Adm | 2011 |
When to start an aromatase inhibitor: now or later?
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Drug Adm | 2011 |
Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole--of clinical importance?
Topics: Anastrozole; Animals; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; C | 2011 |
Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole--of clinical importance?
Topics: Anastrozole; Animals; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; C | 2011 |
Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole--of clinical importance?
Topics: Anastrozole; Animals; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; C | 2011 |
Overview of adjuvant trials of aromatase inhibitors in early breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; B | 2011 |
Overview of adjuvant trials of aromatase inhibitors in early breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; B | 2011 |
Overview of adjuvant trials of aromatase inhibitors in early breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; B | 2011 |
Preventive therapy for breast cancer: a consensus statement.
Topics: Anastrozole; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antin | 2011 |
Preventive therapy for breast cancer: a consensus statement.
Topics: Anastrozole; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antin | 2011 |
Preventive therapy for breast cancer: a consensus statement.
Topics: Anastrozole; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antin | 2011 |
[Neoadjuvant endocrine therapy for postmenopausal estrogen receptor-positive patients with breast cancer].
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozol | 2011 |
[Neoadjuvant endocrine therapy for postmenopausal estrogen receptor-positive patients with breast cancer].
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozol | 2011 |
[Neoadjuvant endocrine therapy for postmenopausal estrogen receptor-positive patients with breast cancer].
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozol | 2011 |
[Aromatase inhibitors and arthralgia].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Brea | 2011 |
[Aromatase inhibitors and arthralgia].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Brea | 2011 |
[Aromatase inhibitors and arthralgia].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Brea | 2011 |
Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2011 |
Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2011 |
Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2011 |
Update on adjuvant hormonal treatment of early breast cancer.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2011 |
Update on adjuvant hormonal treatment of early breast cancer.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2011 |
Update on adjuvant hormonal treatment of early breast cancer.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2011 |
Management of patients with metastatic breast cancer.
Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disea | 2011 |
Management of patients with metastatic breast cancer.
Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disea | 2011 |
Management of patients with metastatic breast cancer.
Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disea | 2011 |
Initialization of adjuvant hormonal treatment for breast cancer.
Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemo | 2011 |
Initialization of adjuvant hormonal treatment for breast cancer.
Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemo | 2011 |
Initialization of adjuvant hormonal treatment for breast cancer.
Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemo | 2011 |
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.
Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brea | 2011 |
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.
Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brea | 2011 |
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.
Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brea | 2011 |
Reviewing the cost-effectiveness of endocrine early breast cancer therapies: influence of differences in modeling methods on outcomes.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Female; Human | 2012 |
Reviewing the cost-effectiveness of endocrine early breast cancer therapies: influence of differences in modeling methods on outcomes.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Female; Human | 2012 |
Reviewing the cost-effectiveness of endocrine early breast cancer therapies: influence of differences in modeling methods on outcomes.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Female; Human | 2012 |
Soy products in the management of breast cancer.
Topics: Anastrozole; Animals; Aryl Hydrocarbon Hydroxylases; Asian People; Breast Neoplasms; Cytochrome P-45 | 2012 |
Soy products in the management of breast cancer.
Topics: Anastrozole; Animals; Aryl Hydrocarbon Hydroxylases; Asian People; Breast Neoplasms; Cytochrome P-45 | 2012 |
Soy products in the management of breast cancer.
Topics: Anastrozole; Animals; Aryl Hydrocarbon Hydroxylases; Asian People; Breast Neoplasms; Cytochrome P-45 | 2012 |
Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer.
Topics: Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast | 2013 |
Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer.
Topics: Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast | 2013 |
Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer.
Topics: Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast | 2013 |
Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer.
Topics: Adjuvants, Pharmaceutic; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Tr | 2001 |
Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer.
Topics: Adjuvants, Pharmaceutic; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Tr | 2001 |
Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer.
Topics: Adjuvants, Pharmaceutic; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Tr | 2001 |
Letrozole for the management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Tol | 2002 |
Letrozole for the management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Tol | 2002 |
Letrozole for the management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Tol | 2002 |
Evolving uses of hormonal agents for breast cancer therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrat | 2002 |
Evolving uses of hormonal agents for breast cancer therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrat | 2002 |
Evolving uses of hormonal agents for breast cancer therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrat | 2002 |
Recent advances in aromatase inhibitor therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2002 |
Recent advances in aromatase inhibitor therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2002 |
Recent advances in aromatase inhibitor therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2002 |
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2002 |
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2002 |
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2002 |
Anastrozole in the management of breast cancer.
Topics: Anastrozole; Animals; Breast Neoplasms; Disease Management; Drug Evaluation; Female; Humans; Nitrile | 2002 |
Anastrozole in the management of breast cancer.
Topics: Anastrozole; Animals; Breast Neoplasms; Disease Management; Drug Evaluation; Female; Humans; Nitrile | 2002 |
Anastrozole in the management of breast cancer.
Topics: Anastrozole; Animals; Breast Neoplasms; Disease Management; Drug Evaluation; Female; Humans; Nitrile | 2002 |
New generation aromatase inhibitors--from the advanced to the adjuvant setting.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2002 |
New generation aromatase inhibitors--from the advanced to the adjuvant setting.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2002 |
New generation aromatase inhibitors--from the advanced to the adjuvant setting.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2002 |
The evolving role of aromatase inhibitors in breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Human | 2002 |
The evolving role of aromatase inhibitors in breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Human | 2002 |
The evolving role of aromatase inhibitors in breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Human | 2002 |
An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme I | 2002 |
An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme I | 2002 |
An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme I | 2002 |
Anastrozole: in early breast cancer.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2002 |
Anastrozole: in early breast cancer.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2002 |
Anastrozole: in early breast cancer.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2002 |
Breast cancer chemoprevention--an update.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 2002 |
Breast cancer chemoprevention--an update.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 2002 |
Breast cancer chemoprevention--an update.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 2002 |
Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Approval; Female; Humans; Nitri | 2002 |
Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Approval; Female; Humans; Nitri | 2002 |
Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Approval; Female; Humans; Nitri | 2002 |
Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cytochro | 2003 |
Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cytochro | 2003 |
Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cytochro | 2003 |
Adjuvant endocrine therapy in postmenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2003 |
Adjuvant endocrine therapy in postmenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2003 |
Adjuvant endocrine therapy in postmenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2003 |
Current and future status of adjuvant therapy for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Che | 2003 |
Current and future status of adjuvant therapy for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Che | 2003 |
Current and future status of adjuvant therapy for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Che | 2003 |
Is tamoxifen the Rosetta stone for breast cancer?
Topics: Acetyltransferases; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, | 2003 |
Is tamoxifen the Rosetta stone for breast cancer?
Topics: Acetyltransferases; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, | 2003 |
Is tamoxifen the Rosetta stone for breast cancer?
Topics: Acetyltransferases; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, | 2003 |
Aromatase inhibitors as adjuvant therapy in breast cancer.
Topics: Aminoglutethimide; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemo | 2003 |
Aromatase inhibitors as adjuvant therapy in breast cancer.
Topics: Aminoglutethimide; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemo | 2003 |
Aromatase inhibitors as adjuvant therapy in breast cancer.
Topics: Aminoglutethimide; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemo | 2003 |
[Present and future of adjuvant hormone therapy in breast cancer: clinical evidence and clinical trials].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Tri | 2003 |
[Present and future of adjuvant hormone therapy in breast cancer: clinical evidence and clinical trials].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Tri | 2003 |
[Present and future of adjuvant hormone therapy in breast cancer: clinical evidence and clinical trials].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Tri | 2003 |
Current status of endocrine therapy for breast cancer.
Topics: Algorithms; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Chemoth | 2003 |
Current status of endocrine therapy for breast cancer.
Topics: Algorithms; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Chemoth | 2003 |
Current status of endocrine therapy for breast cancer.
Topics: Algorithms; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Chemoth | 2003 |
Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.
Topics: Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 2003 |
Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.
Topics: Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 2003 |
Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.
Topics: Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 2003 |
Hormonal therapy in postmenopausal women with breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progre | 2003 |
Hormonal therapy in postmenopausal women with breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progre | 2003 |
Hormonal therapy in postmenopausal women with breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progre | 2003 |
Is low-dose tamoxifen useful for the treatment and prevention of breast cancer?
Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemo | 2003 |
Is low-dose tamoxifen useful for the treatment and prevention of breast cancer?
Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemo | 2003 |
Is low-dose tamoxifen useful for the treatment and prevention of breast cancer?
Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemo | 2003 |
The current status of aromatase inhibitors in the management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breas | 2003 |
The current status of aromatase inhibitors in the management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breas | 2003 |
The current status of aromatase inhibitors in the management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breas | 2003 |
Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 2003 |
Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 2003 |
Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 2003 |
A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast | 2003 |
A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast | 2003 |
A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast | 2003 |
Aromatase inhibitors in prevention--data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study).
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neop | 2003 |
Aromatase inhibitors in prevention--data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study).
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neop | 2003 |
Aromatase inhibitors in prevention--data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study).
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neop | 2003 |
Safety issues surrounding the use of aromatase inhibitors in breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; | 2003 |
Safety issues surrounding the use of aromatase inhibitors in breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; | 2003 |
Safety issues surrounding the use of aromatase inhibitors in breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; | 2003 |
Should aromatase inhibitors replace tamoxifen?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2003 |
Should aromatase inhibitors replace tamoxifen?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2003 |
Should aromatase inhibitors replace tamoxifen?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2003 |
[Perspectives for the hormonal therapy of breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Enzyme Inhibitors; E | 2003 |
[Perspectives for the hormonal therapy of breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Enzyme Inhibitors; E | 2003 |
[Perspectives for the hormonal therapy of breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Enzyme Inhibitors; E | 2003 |
The role of aromatase inhibitors in the treatment of metastatic breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2003 |
The role of aromatase inhibitors in the treatment of metastatic breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2003 |
The role of aromatase inhibitors in the treatment of metastatic breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2003 |
Pharmacokinetics of third-generation aromatase inhibitors.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug | 2003 |
Pharmacokinetics of third-generation aromatase inhibitors.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug | 2003 |
Pharmacokinetics of third-generation aromatase inhibitors.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug | 2003 |
Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Adminis | 2003 |
Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Adminis | 2003 |
Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Adminis | 2003 |
Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Eviden | 2003 |
Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Eviden | 2003 |
Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Eviden | 2003 |
Fulvestrant in postmenopausal women with advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Drug Appro | 2003 |
Fulvestrant in postmenopausal women with advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Drug Appro | 2003 |
Fulvestrant in postmenopausal women with advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Drug Appro | 2003 |
Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast | 2003 |
Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast | 2003 |
Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast | 2003 |
[Adjuvant endocrine treatment of breast cancer beyond St. Gallen 2003].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Huma | 2003 |
[Adjuvant endocrine treatment of breast cancer beyond St. Gallen 2003].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Huma | 2003 |
[Adjuvant endocrine treatment of breast cancer beyond St. Gallen 2003].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Huma | 2003 |
Role of anastrozole in adjuvant therapy for postmenopausal patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2003 |
Role of anastrozole in adjuvant therapy for postmenopausal patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2003 |
Role of anastrozole in adjuvant therapy for postmenopausal patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2003 |
Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators.
Topics: Anastrozole; Animals; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen | 2003 |
Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators.
Topics: Anastrozole; Animals; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen | 2003 |
Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators.
Topics: Anastrozole; Animals; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen | 2003 |
Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibit | 2003 |
Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibit | 2003 |
Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibit | 2003 |
New findings about endocrine therapy for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Randomized | 2003 |
New findings about endocrine therapy for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Randomized | 2003 |
New findings about endocrine therapy for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Randomized | 2003 |
The best use of adjuvant endocrine treatments.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoth | 2003 |
The best use of adjuvant endocrine treatments.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoth | 2003 |
The best use of adjuvant endocrine treatments.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoth | 2003 |
Challenges in the endocrine management of breast cancer.
Topics: Adult; Aged; Anastrozole; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response | 2003 |
Challenges in the endocrine management of breast cancer.
Topics: Adult; Aged; Anastrozole; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response | 2003 |
Challenges in the endocrine management of breast cancer.
Topics: Adult; Aged; Anastrozole; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response | 2003 |
Aromatase inhibitors in breast cancer therapy.
Topics: Anastrozole; Androstadienes; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Enzy | 2003 |
Aromatase inhibitors in breast cancer therapy.
Topics: Anastrozole; Androstadienes; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Enzy | 2003 |
Aromatase inhibitors in breast cancer therapy.
Topics: Anastrozole; Androstadienes; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Enzy | 2003 |
Focus on anastrozole and breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
Focus on anastrozole and breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
Focus on anastrozole and breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; | 2003 |
A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; | 2003 |
A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; | 2003 |
[Neoadjuvant endocrine therapy for breast cancer: an overview].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as T | 2004 |
[Neoadjuvant endocrine therapy for breast cancer: an overview].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as T | 2004 |
[Neoadjuvant endocrine therapy for breast cancer: an overview].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as T | 2004 |
Anastrozole (Arimidex).
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Interacti | 2004 |
Anastrozole (Arimidex).
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Interacti | 2004 |
Anastrozole (Arimidex).
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Interacti | 2004 |
[Controversies in endocrine therapy for breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
[Controversies in endocrine therapy for breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
[Controversies in endocrine therapy for breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; | 2004 |
Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; | 2004 |
Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; | 2004 |
Aromatase inhibitors for breast cancer in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2004 |
Aromatase inhibitors for breast cancer in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2004 |
Aromatase inhibitors for breast cancer in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2004 |
Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2004 |
Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2004 |
Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2004 |
Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breas | 2004 |
Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breas | 2004 |
Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breas | 2004 |
[Aromatase inhibitors in the adjuvant therapy of breast carcinomas].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy P | 2004 |
[Aromatase inhibitors in the adjuvant therapy of breast carcinomas].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy P | 2004 |
[Aromatase inhibitors in the adjuvant therapy of breast carcinomas].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy P | 2004 |
Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Breast Neoplasms; Estradiol; Estrogen Antag | 2004 |
Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Breast Neoplasms; Estradiol; Estrogen Antag | 2004 |
Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Breast Neoplasms; Estradiol; Estrogen Antag | 2004 |
Current developments in hormonal therapy of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
Current developments in hormonal therapy of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
Current developments in hormonal therapy of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2004 |
Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2004 |
Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2004 |
The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial: an update.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-B | 2004 |
The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial: an update.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-B | 2004 |
The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial: an update.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-B | 2004 |
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
Role of aromatase inhibitors in the treatment of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
Role of aromatase inhibitors in the treatment of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
Role of aromatase inhibitors in the treatment of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2004 |
Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2004 |
Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2004 |
Breast cancer (metastatic).
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2003 |
Breast cancer (metastatic).
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2003 |
Breast cancer (metastatic).
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2003 |
[Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
[Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
[Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life.
Topics: Algorithms; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; De | 2004 |
Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life.
Topics: Algorithms; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; De | 2004 |
Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life.
Topics: Algorithms; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; De | 2004 |
Aromatase inhibitors and breast cancer: time for a change?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2004 |
Aromatase inhibitors and breast cancer: time for a change?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2004 |
Aromatase inhibitors and breast cancer: time for a change?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2004 |
Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy P | 2005 |
Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy P | 2005 |
Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy P | 2005 |
Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhib | 2005 |
Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhib | 2005 |
Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhib | 2005 |
Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; B | 2005 |
Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; B | 2005 |
Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; B | 2005 |
Aromatase inhibitors in advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; | 2004 |
Aromatase inhibitors in advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; | 2004 |
Aromatase inhibitors in advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; | 2004 |
Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2005 |
Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2005 |
Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2005 |
Aromatase inhibition: translation into a successful therapeutic approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasm | 2005 |
Aromatase inhibition: translation into a successful therapeutic approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasm | 2005 |
Aromatase inhibition: translation into a successful therapeutic approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasm | 2005 |
Aromatase inhibitors in the treatment of early and advanced breast cancer.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Biopsy, Needle; Breast Neoplasms; Chemotherapy, Adju | 2005 |
Aromatase inhibitors in the treatment of early and advanced breast cancer.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Biopsy, Needle; Breast Neoplasms; Chemotherapy, Adju | 2005 |
Aromatase inhibitors in the treatment of early and advanced breast cancer.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Biopsy, Needle; Breast Neoplasms; Chemotherapy, Adju | 2005 |
Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; | 2005 |
Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; | 2005 |
Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; | 2005 |
Aromatase inhibitors for the treatment and prevention of breast cancer.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Respo | 2005 |
Aromatase inhibitors for the treatment and prevention of breast cancer.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Respo | 2005 |
Aromatase inhibitors for the treatment and prevention of breast cancer.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Respo | 2005 |
[Aromatase inhibitors in adjuvant setting in breast cancer].
Topics: Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Ne | 2004 |
[Aromatase inhibitors in adjuvant setting in breast cancer].
Topics: Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Ne | 2004 |
[Aromatase inhibitors in adjuvant setting in breast cancer].
Topics: Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Ne | 2004 |
A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2005 |
A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2005 |
A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2005 |
Aromatase inhibitors for therapy of advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical | 2005 |
Aromatase inhibitors for therapy of advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical | 2005 |
Aromatase inhibitors for therapy of advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical | 2005 |
The aromatase inhibitors in early breast cancer: who, when, and why?
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Drug Evaluation; Drug Therapy, Combination; Fem | 2005 |
The aromatase inhibitors in early breast cancer: who, when, and why?
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Drug Evaluation; Drug Therapy, Combination; Fem | 2005 |
The aromatase inhibitors in early breast cancer: who, when, and why?
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Drug Evaluation; Drug Therapy, Combination; Fem | 2005 |
Anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2005 |
Anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2005 |
Anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2005 |
Adjuvant endocrine therapy in postmenopausal women with early breast cancer: where are we now?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2005 |
Adjuvant endocrine therapy in postmenopausal women with early breast cancer: where are we now?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2005 |
Adjuvant endocrine therapy in postmenopausal women with early breast cancer: where are we now?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2005 |
Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2005 |
Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2005 |
Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2005 |
New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.
Topics: Aged; Anastrozole; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibi | 2005 |
New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.
Topics: Aged; Anastrozole; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibi | 2005 |
New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.
Topics: Aged; Anastrozole; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibi | 2005 |
Breast adenocarcinoma metastatic to epidural cervical spine meningioma: case report and review of the literature.
Topics: Adenocarcinoma; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carrier Proteins; Ce | 2005 |
Breast adenocarcinoma metastatic to epidural cervical spine meningioma: case report and review of the literature.
Topics: Adenocarcinoma; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carrier Proteins; Ce | 2005 |
Breast adenocarcinoma metastatic to epidural cervical spine meningioma: case report and review of the literature.
Topics: Adenocarcinoma; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carrier Proteins; Ce | 2005 |
Breast cancer (metastatic).
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormo | 2005 |
Breast cancer (metastatic).
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormo | 2005 |
Breast cancer (metastatic).
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormo | 2005 |
Recent advances in the use of aromatase inhibitors for women with postmenopausal breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical | 2005 |
Recent advances in the use of aromatase inhibitors for women with postmenopausal breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical | 2005 |
Recent advances in the use of aromatase inhibitors for women with postmenopausal breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical | 2005 |
Adjuvant endocrine therapy in postmenopausal breast cancer patients.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Nitrile | 2005 |
Adjuvant endocrine therapy in postmenopausal breast cancer patients.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Nitrile | 2005 |
Adjuvant endocrine therapy in postmenopausal breast cancer patients.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Nitrile | 2005 |
The biology of steroid hormones and endocrine treatment of breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 2005 |
The biology of steroid hormones and endocrine treatment of breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 2005 |
The biology of steroid hormones and endocrine treatment of breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 2005 |
New developments in the treatment of postmenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2005 |
New developments in the treatment of postmenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2005 |
New developments in the treatment of postmenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2005 |
Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
Life following aromatase inhibitors--where now for endocrine sequencing?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2005 |
Life following aromatase inhibitors--where now for endocrine sequencing?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2005 |
Life following aromatase inhibitors--where now for endocrine sequencing?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2005 |
Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
Defining the roles of aromatase inhibitors in the adjuvant treatment of early-stage breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; B | 2005 |
Defining the roles of aromatase inhibitors in the adjuvant treatment of early-stage breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; B | 2005 |
Defining the roles of aromatase inhibitors in the adjuvant treatment of early-stage breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; B | 2005 |
Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinica | 2005 |
Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinica | 2005 |
Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinica | 2005 |
Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2006 |
Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2006 |
Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2006 |
Adjuvant endocrine therapy for postmenopausal women with early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Huma | 2006 |
Adjuvant endocrine therapy for postmenopausal women with early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Huma | 2006 |
Adjuvant endocrine therapy for postmenopausal women with early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Huma | 2006 |
Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: Case report and review of the literature.
Topics: Acute Disease; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors | 2006 |
Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: Case report and review of the literature.
Topics: Acute Disease; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors | 2006 |
Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: Case report and review of the literature.
Topics: Acute Disease; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors | 2006 |
Pre-menopausal breast cancer and aromatase inhibitors: Treating a new generation of women.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2006 |
Pre-menopausal breast cancer and aromatase inhibitors: Treating a new generation of women.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2006 |
Pre-menopausal breast cancer and aromatase inhibitors: Treating a new generation of women.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2006 |
Anastrozole for breast cancer: recent advances and ongoing challenges.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2006 |
Anastrozole for breast cancer: recent advances and ongoing challenges.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2006 |
Anastrozole for breast cancer: recent advances and ongoing challenges.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2006 |
The adjuvant endocrine treatment revolution: focus on anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2006 |
The adjuvant endocrine treatment revolution: focus on anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2006 |
The adjuvant endocrine treatment revolution: focus on anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2006 |
Time to response: comparison of fulvestrant and oral endocrine agents.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineopla | 2006 |
Time to response: comparison of fulvestrant and oral endocrine agents.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineopla | 2006 |
Time to response: comparison of fulvestrant and oral endocrine agents.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineopla | 2006 |
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
Topics: Adult; Aged; Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aroma | 2006 |
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
Topics: Adult; Aged; Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aroma | 2006 |
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
Topics: Adult; Aged; Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aroma | 2006 |
Bone safety of aromatase inhibitors versus tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; | 2006 |
Bone safety of aromatase inhibitors versus tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; | 2006 |
Bone safety of aromatase inhibitors versus tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; | 2006 |
Update on the use of aromatase inhibitors in breast cancer.
Topics: Anastrozole; Androstadienes; Animals; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Hum | 2006 |
Update on the use of aromatase inhibitors in breast cancer.
Topics: Anastrozole; Androstadienes; Animals; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Hum | 2006 |
Update on the use of aromatase inhibitors in breast cancer.
Topics: Anastrozole; Androstadienes; Animals; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Hum | 2006 |
Refining the postmenopausal breast cancer treatment paradigm: the FACE trial.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; | 2006 |
Refining the postmenopausal breast cancer treatment paradigm: the FACE trial.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; | 2006 |
Refining the postmenopausal breast cancer treatment paradigm: the FACE trial.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; | 2006 |
Aromatase inhibitors and bone health in women with breast cancer.
Topics: Absorptiometry, Photon; Algorithms; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Ar | 2006 |
Aromatase inhibitors and bone health in women with breast cancer.
Topics: Absorptiometry, Photon; Algorithms; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Ar | 2006 |
Aromatase inhibitors and bone health in women with breast cancer.
Topics: Absorptiometry, Photon; Algorithms; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Ar | 2006 |
Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Disease-Free Su | 2006 |
Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Disease-Free Su | 2006 |
Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Disease-Free Su | 2006 |
Adjuvant therapy for patients who have node-positive breast cancer.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatas | 2006 |
Adjuvant therapy for patients who have node-positive breast cancer.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatas | 2006 |
Adjuvant therapy for patients who have node-positive breast cancer.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatas | 2006 |
Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular | 2007 |
Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular | 2007 |
Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular | 2007 |
Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2007 |
Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2007 |
Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2007 |
Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Female; | 2006 |
Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Female; | 2006 |
Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Female; | 2006 |
Optimizing endocrine therapy for premenopausal and postmenopausal women with breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2007 |
Optimizing endocrine therapy for premenopausal and postmenopausal women with breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2007 |
Optimizing endocrine therapy for premenopausal and postmenopausal women with breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2007 |
[Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
[Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
[Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
[Advancement in endocrine therapy for breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2007 |
[Advancement in endocrine therapy for breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2007 |
[Advancement in endocrine therapy for breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2007 |
Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2007 |
Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2007 |
Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2007 |
Aromatase inhibitors and musculoskeletal pain in patients with breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical | 2007 |
Aromatase inhibitors and musculoskeletal pain in patients with breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical | 2007 |
Aromatase inhibitors and musculoskeletal pain in patients with breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical | 2007 |
[Antiestrogen treatment in postmenopausal patients with metastatic breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic | 2007 |
[Antiestrogen treatment in postmenopausal patients with metastatic breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic | 2007 |
[Antiestrogen treatment in postmenopausal patients with metastatic breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic | 2007 |
Reducing the risk of late recurrence in hormone-responsive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Human | 2007 |
Reducing the risk of late recurrence in hormone-responsive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Human | 2007 |
Reducing the risk of late recurrence in hormone-responsive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Human | 2007 |
The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemot | 2007 |
The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemot | 2007 |
The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemot | 2007 |
Safety of aromatase inhibitors in the adjuvant setting.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2007 |
Safety of aromatase inhibitors in the adjuvant setting.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2007 |
Safety of aromatase inhibitors in the adjuvant setting.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2007 |
Remission of porphyria cutanea tarda after anastrozole treatment of breast cancer.
Topics: Adenocarcinoma; Adult; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Contraceptive | 2007 |
Remission of porphyria cutanea tarda after anastrozole treatment of breast cancer.
Topics: Adenocarcinoma; Adult; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Contraceptive | 2007 |
Remission of porphyria cutanea tarda after anastrozole treatment of breast cancer.
Topics: Adenocarcinoma; Adult; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Contraceptive | 2007 |
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2007 |
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2007 |
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2007 |
Effects of hormonal therapy on cognitive functioning in breast cancer patients: a review of the literature.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2007 |
Effects of hormonal therapy on cognitive functioning in breast cancer patients: a review of the literature.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2007 |
Effects of hormonal therapy on cognitive functioning in breast cancer patients: a review of the literature.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2007 |
Anastrozole for malignant and benign conditions: present applications and future therapeutic integrations.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clini | 2007 |
Anastrozole for malignant and benign conditions: present applications and future therapeutic integrations.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clini | 2007 |
Anastrozole for malignant and benign conditions: present applications and future therapeutic integrations.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clini | 2007 |
Effectively nursing patients receiving aromatase inhibitor therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2008 |
Effectively nursing patients receiving aromatase inhibitor therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2008 |
Effectively nursing patients receiving aromatase inhibitor therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2008 |
Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2008 |
Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2008 |
Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2008 |
The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2008 |
The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2008 |
The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2008 |
Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2008 |
Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2008 |
Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2008 |
Aromatase inhibitors in early breast-cancer treatment: The story so far.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2008 |
Aromatase inhibitors in early breast-cancer treatment: The story so far.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2008 |
Aromatase inhibitors in early breast-cancer treatment: The story so far.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2008 |
The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2008 |
The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2008 |
The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2008 |
Neoadjuvant endocrine therapy for breast cancer: past, present and future.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2008 |
Neoadjuvant endocrine therapy for breast cancer: past, present and future.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2008 |
Neoadjuvant endocrine therapy for breast cancer: past, present and future.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2008 |
Targeting breast cancer with hormonal treatment options.
Topics: Aftercare; Ambulatory Care; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase | 2008 |
Targeting breast cancer with hormonal treatment options.
Topics: Aftercare; Ambulatory Care; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase | 2008 |
Targeting breast cancer with hormonal treatment options.
Topics: Aftercare; Ambulatory Care; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase | 2008 |
The emerging role of aromatase inhibitors in the adjuvant management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
The emerging role of aromatase inhibitors in the adjuvant management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
The emerging role of aromatase inhibitors in the adjuvant management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoa | 2008 |
Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoa | 2008 |
Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoa | 2008 |
ARIMIDEX: a new oral, once-a-day aromatase inhibitor.
Topics: Administration, Oral; Aldosterone; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Drug Adminis | 1995 |
ARIMIDEX: a new oral, once-a-day aromatase inhibitor.
Topics: Administration, Oral; Aldosterone; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Drug Adminis | 1995 |
ARIMIDEX: a new oral, once-a-day aromatase inhibitor.
Topics: Administration, Oral; Aldosterone; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Drug Adminis | 1995 |
New aromatase inhibitors for breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozol | 1997 |
New aromatase inhibitors for breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozol | 1997 |
New aromatase inhibitors for breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozol | 1997 |
ARIMIDEX: a potent and selective aromatase inhibitor for the treatment of advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 1997 |
ARIMIDEX: a potent and selective aromatase inhibitor for the treatment of advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 1997 |
ARIMIDEX: a potent and selective aromatase inhibitor for the treatment of advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 1997 |
Use of aromatase inhibitors in postmenopausal women with advanced breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormo | 1997 |
Use of aromatase inhibitors in postmenopausal women with advanced breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormo | 1997 |
Use of aromatase inhibitors in postmenopausal women with advanced breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormo | 1997 |
Anastrozole: a new selective nonsteroidal aromatase inhibitor.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug | 1997 |
Anastrozole: a new selective nonsteroidal aromatase inhibitor.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug | 1997 |
Anastrozole: a new selective nonsteroidal aromatase inhibitor.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug | 1997 |
The relevance of preclinical models to the treatment of postmenopausal breast cancer.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase I | 1997 |
The relevance of preclinical models to the treatment of postmenopausal breast cancer.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase I | 1997 |
The relevance of preclinical models to the treatment of postmenopausal breast cancer.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase I | 1997 |
Anastrozole--a new generation in aromatase inhibition: clinical pharmacology.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibit | 1997 |
Anastrozole--a new generation in aromatase inhibition: clinical pharmacology.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibit | 1997 |
Anastrozole--a new generation in aromatase inhibition: clinical pharmacology.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibit | 1997 |
Clinical overview of anastrozole--a new selective oral aromatase inhibitor.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 1997 |
Clinical overview of anastrozole--a new selective oral aromatase inhibitor.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 1997 |
Clinical overview of anastrozole--a new selective oral aromatase inhibitor.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 1997 |
Anastrozole: a selective aromatase inhibitor for the treatment of breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibit | 1998 |
Anastrozole: a selective aromatase inhibitor for the treatment of breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibit | 1998 |
Anastrozole: a selective aromatase inhibitor for the treatment of breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibit | 1998 |
Anastrozole: a new addition to the armamentarium against advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 1998 |
Anastrozole: a new addition to the armamentarium against advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 1998 |
Anastrozole: a new addition to the armamentarium against advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 1998 |
Emerging role of aromatase inhibitors in the treatment of breast cancer.
Topics: Aged; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 1998 |
Emerging role of aromatase inhibitors in the treatment of breast cancer.
Topics: Aged; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 1998 |
Emerging role of aromatase inhibitors in the treatment of breast cancer.
Topics: Aged; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 1998 |
Anastrozole (Arimidex), a new aromatase inhibitor for advanced breast cancer: mechanism of action and role in management.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 1998 |
Anastrozole (Arimidex), a new aromatase inhibitor for advanced breast cancer: mechanism of action and role in management.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 1998 |
Anastrozole (Arimidex), a new aromatase inhibitor for advanced breast cancer: mechanism of action and role in management.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 1998 |
Theoretical considerations for the ideal aromatase inhibitor.
Topics: Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neopla | 1998 |
Theoretical considerations for the ideal aromatase inhibitor.
Topics: Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neopla | 1998 |
Theoretical considerations for the ideal aromatase inhibitor.
Topics: Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neopla | 1998 |
Pharmacological and clinical profile of anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 1998 |
Pharmacological and clinical profile of anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 1998 |
Pharmacological and clinical profile of anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 1998 |
Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Neoplasm Staging; Ni | 1998 |
Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Neoplasm Staging; Ni | 1998 |
Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Neoplasm Staging; Ni | 1998 |
The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Belgium; Breast Neoplasms; | 1999 |
The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Belgium; Breast Neoplasms; | 1999 |
The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Belgium; Breast Neoplasms; | 1999 |
New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Antineoplast | 1999 |
New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Antineoplast | 1999 |
New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Antineoplast | 1999 |
[Aromatase inhibitors].
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Antineoplast | 1999 |
[Aromatase inhibitors].
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Antineoplast | 1999 |
[Aromatase inhibitors].
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Antineoplast | 1999 |
Lessons from the use of aromatase inhibitors in the neoadjuvant setting.
Topics: Aged; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as | 1999 |
Lessons from the use of aromatase inhibitors in the neoadjuvant setting.
Topics: Aged; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as | 1999 |
Lessons from the use of aromatase inhibitors in the neoadjuvant setting.
Topics: Aged; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as | 1999 |
Aromatase inhibitors: a dose-response effect?
Topics: Aminoglutethimide; Anastrozole; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplas | 1999 |
Aromatase inhibitors: a dose-response effect?
Topics: Aminoglutethimide; Anastrozole; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplas | 1999 |
Aromatase inhibitors: a dose-response effect?
Topics: Aminoglutethimide; Anastrozole; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplas | 1999 |
Use of aromatase inhibitors in breast carcinoma.
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormo | 1999 |
Use of aromatase inhibitors in breast carcinoma.
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormo | 1999 |
Use of aromatase inhibitors in breast carcinoma.
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormo | 1999 |
Steroidal aromatase inhibitors in elderly patients.
Topics: Aged; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Bre | 2000 |
Steroidal aromatase inhibitors in elderly patients.
Topics: Aged; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Bre | 2000 |
Steroidal aromatase inhibitors in elderly patients.
Topics: Aged; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Bre | 2000 |
[Chemo/endocrine therapy for breast cancer patients].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Gonad | 2000 |
[Chemo/endocrine therapy for breast cancer patients].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Gonad | 2000 |
[Chemo/endocrine therapy for breast cancer patients].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Gonad | 2000 |
[Aromatase inhibitors for treatment of advanced breast cancers].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2000 |
[Aromatase inhibitors for treatment of advanced breast cancers].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2000 |
[Aromatase inhibitors for treatment of advanced breast cancers].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2000 |
New aromatase inhibitors in the treatment of advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhib | 2000 |
New aromatase inhibitors in the treatment of advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhib | 2000 |
New aromatase inhibitors in the treatment of advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhib | 2000 |
Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhib | 2000 |
Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhib | 2000 |
Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhib | 2000 |
[Aromatase inhibitors: a review of clinical trials].
Topics: Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 2000 |
[Aromatase inhibitors: a review of clinical trials].
Topics: Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 2000 |
[Aromatase inhibitors: a review of clinical trials].
Topics: Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 2000 |
[Development of a novel aromatase inhibitor, anastrozole (Arimidex)--its basic and clinical studies].
Topics: Anastrozole; Animals; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase I as Topic; Dog | 2001 |
[Development of a novel aromatase inhibitor, anastrozole (Arimidex)--its basic and clinical studies].
Topics: Anastrozole; Animals; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase I as Topic; Dog | 2001 |
[Development of a novel aromatase inhibitor, anastrozole (Arimidex)--its basic and clinical studies].
Topics: Anastrozole; Animals; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase I as Topic; Dog | 2001 |
[Developments of hormonal agents for breast cancer].
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2001 |
[Developments of hormonal agents for breast cancer].
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2001 |
[Developments of hormonal agents for breast cancer].
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2001 |
Nonsteroidal and steroidal aromatase inhibitors in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2001 |
Nonsteroidal and steroidal aromatase inhibitors in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2001 |
Nonsteroidal and steroidal aromatase inhibitors in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2001 |
Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer.
Topics: Anastrozole; Androstadienes; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibit | 2001 |
Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer.
Topics: Anastrozole; Androstadienes; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibit | 2001 |
Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer.
Topics: Anastrozole; Androstadienes; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibit | 2001 |
New combinations with Herceptin in metastatic breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormo | 2001 |
New combinations with Herceptin in metastatic breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormo | 2001 |
New combinations with Herceptin in metastatic breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormo | 2001 |
Role of anti-aromatase agents in postmenopausal advanced breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast N | 2001 |
Role of anti-aromatase agents in postmenopausal advanced breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast N | 2001 |
Role of anti-aromatase agents in postmenopausal advanced breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast N | 2001 |
Third-generation aromatase inhibitors in the treatment of advanced breast cancer.
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined C | 2001 |
Third-generation aromatase inhibitors in the treatment of advanced breast cancer.
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined C | 2001 |
Third-generation aromatase inhibitors in the treatment of advanced breast cancer.
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined C | 2001 |
Aromatase and aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2001 |
Aromatase and aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2001 |
Aromatase and aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2001 |
A summary of second-line randomized studies of aromatase inhibitors.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Drug Toleran | 2001 |
A summary of second-line randomized studies of aromatase inhibitors.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Drug Toleran | 2001 |
A summary of second-line randomized studies of aromatase inhibitors.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Drug Toleran | 2001 |
A vision for the future?
Topics: Anastrozole; Breast Neoplasms; Estradiol; Female; Fulvestrant; Goserelin; Humans; Menopause; Nitrile | 2001 |
A vision for the future?
Topics: Anastrozole; Breast Neoplasms; Estradiol; Female; Fulvestrant; Goserelin; Humans; Menopause; Nitrile | 2001 |
A vision for the future?
Topics: Anastrozole; Breast Neoplasms; Estradiol; Female; Fulvestrant; Goserelin; Humans; Menopause; Nitrile | 2001 |
Anastrozole (Arimidex)--an aromatase inhibitor for the adjuvant setting?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 2001 |
Anastrozole (Arimidex)--an aromatase inhibitor for the adjuvant setting?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 2001 |
Anastrozole (Arimidex)--an aromatase inhibitor for the adjuvant setting?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 2001 |
Are differences in the available aromatase inhibitors and inactivators significant?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical | 2001 |
Are differences in the available aromatase inhibitors and inactivators significant?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical | 2001 |
Are differences in the available aromatase inhibitors and inactivators significant?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical | 2001 |
Preliminary data from ongoing adjuvant aromatase inhibitor trials.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; B | 2001 |
Preliminary data from ongoing adjuvant aromatase inhibitor trials.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; B | 2001 |
Preliminary data from ongoing adjuvant aromatase inhibitor trials.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; B | 2001 |
Aromatase inhibitors continue their ATAC on tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 2002 |
Aromatase inhibitors continue their ATAC on tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 2002 |
Aromatase inhibitors continue their ATAC on tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 2002 |
Antiaromatase agents: evolving role in adjuvant therapy.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinica | 2002 |
Antiaromatase agents: evolving role in adjuvant therapy.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinica | 2002 |
Antiaromatase agents: evolving role in adjuvant therapy.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinica | 2002 |
[The role of aromatase inhibitors in the treatment of breast neoplasms. An evaluation of clinical efficacy and the tolerability profile].
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, | 2002 |
[The role of aromatase inhibitors in the treatment of breast neoplasms. An evaluation of clinical efficacy and the tolerability profile].
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, | 2002 |
[The role of aromatase inhibitors in the treatment of breast neoplasms. An evaluation of clinical efficacy and the tolerability profile].
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, | 2002 |
[Antiestrogen therapy in the treatment of breast neoplasms].
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Br | 2002 |
[Antiestrogen therapy in the treatment of breast neoplasms].
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Br | 2002 |
[Antiestrogen therapy in the treatment of breast neoplasms].
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Br | 2002 |
266 trials available for anastrozole and Breast Neoplasms
| Article | Year |
|---|---|
Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Anastrozole; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Female; H | 2022 |
Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Anastrozole; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Female; H | 2022 |
Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Anastrozole; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Female; H | 2022 |
A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; F | 2022 |
A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; F | 2022 |
A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; F | 2022 |
Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy.
Topics: Anastrozole; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Progno | 2022 |
Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy.
Topics: Anastrozole; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Progno | 2022 |
Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy.
Topics: Anastrozole; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Progno | 2022 |
Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; End | 2022 |
Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; End | 2022 |
Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; End | 2022 |
Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical
Topics: Anastrozole; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Letrozole; Mastectomy; Neoadjuvant The | 2023 |
Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical
Topics: Anastrozole; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Letrozole; Mastectomy; Neoadjuvant The | 2023 |
Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical
Topics: Anastrozole; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Letrozole; Mastectomy; Neoadjuvant The | 2023 |
Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.
Topics: Adjuvants, Immunologic; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast N | 2023 |
Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.
Topics: Adjuvants, Immunologic; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast N | 2023 |
Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.
Topics: Adjuvants, Immunologic; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast N | 2023 |
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-con
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival | 2023 |
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-con
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival | 2023 |
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-con
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival | 2023 |
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
Topics: Anastrozole; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Rece | 2023 |
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
Topics: Anastrozole; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Rece | 2023 |
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
Topics: Anastrozole; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Rece | 2023 |
Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Neoad | 2023 |
Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Neoad | 2023 |
Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Neoad | 2023 |
Racial and Ethnic Disparities in Outcomes After Breast-Conserving Therapy and Endocrine Therapy for DCIS: A Post-Hoc Analysis of the NSABP B-35 Randomized Clinical Trial.
Topics: Anastrozole; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Ethnicity; Female; Humans; T | 2023 |
Racial and Ethnic Disparities in Outcomes After Breast-Conserving Therapy and Endocrine Therapy for DCIS: A Post-Hoc Analysis of the NSABP B-35 Randomized Clinical Trial.
Topics: Anastrozole; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Ethnicity; Female; Humans; T | 2023 |
Racial and Ethnic Disparities in Outcomes After Breast-Conserving Therapy and Endocrine Therapy for DCIS: A Post-Hoc Analysis of the NSABP B-35 Randomized Clinical Trial.
Topics: Anastrozole; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Ethnicity; Female; Humans; T | 2023 |
The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer.
Topics: Anastrozole; Body Mass Index; Breast Neoplasms; Female; Humans; Obesity; Overweight; Prognosis | 2023 |
The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer.
Topics: Anastrozole; Body Mass Index; Breast Neoplasms; Female; Humans; Obesity; Overweight; Prognosis | 2023 |
The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer.
Topics: Anastrozole; Body Mass Index; Breast Neoplasms; Female; Humans; Obesity; Overweight; Prognosis | 2023 |
Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, D | 2020 |
Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, D | 2020 |
Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, D | 2020 |
Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response.
Topics: Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Female; Fulvestrant; Humans; Neoadjuvant The | 2020 |
Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response.
Topics: Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Female; Fulvestrant; Humans; Neoadjuvant The | 2020 |
Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response.
Topics: Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Female; Fulvestrant; Humans; Neoadjuvant The | 2020 |
Changes in serum estradiol levels with Estring in postmenopausal women with breast cancer treated with aromatase inhibitors.
Topics: Administration, Intravaginal; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrog | 2021 |
Changes in serum estradiol levels with Estring in postmenopausal women with breast cancer treated with aromatase inhibitors.
Topics: Administration, Intravaginal; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrog | 2021 |
Changes in serum estradiol levels with Estring in postmenopausal women with breast cancer treated with aromatase inhibitors.
Topics: Administration, Intravaginal; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrog | 2021 |
Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial.
Topics: Acrylamides; Adolescent; Adult; Aged; Aged, 80 and over; Aminoquinolines; Anastrozole; Androstadiene | 2020 |
Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial.
Topics: Acrylamides; Adolescent; Adult; Aged; Aged, 80 and over; Aminoquinolines; Anastrozole; Androstadiene | 2020 |
Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial.
Topics: Acrylamides; Adolescent; Adult; Aged; Aged, 80 and over; Aminoquinolines; Anastrozole; Androstadiene | 2020 |
Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2020 |
Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2020 |
Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2020 |
PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial.
Topics: Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adj | 2021 |
PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial.
Topics: Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adj | 2021 |
PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial.
Topics: Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adj | 2021 |
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
Topics: Aminopyridines; Anastrozole; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Diarrhea; Doubl | 2021 |
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
Topics: Aminopyridines; Anastrozole; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Diarrhea; Doubl | 2021 |
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
Topics: Aminopyridines; Anastrozole; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Diarrhea; Doubl | 2021 |
Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast Cancer.
Topics: Anastrozole; Androstadienes; Antigens, CD; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Br | 2021 |
Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast Cancer.
Topics: Anastrozole; Androstadienes; Antigens, CD; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Br | 2021 |
Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast Cancer.
Topics: Anastrozole; Androstadienes; Antigens, CD; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Br | 2021 |
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
Topics: Administration, Oral; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Brea | 2021 |
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
Topics: Administration, Oral; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Brea | 2021 |
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
Topics: Administration, Oral; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Brea | 2021 |
Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Ne | 2017 |
Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Ne | 2017 |
Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Ne | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2017 |
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2017 |
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2017 |
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2017 |
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2017 |
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2017 |
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2017 |
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2017 |
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2017 |
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2017 |
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2017 |
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2017 |
Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, | 2018 |
Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, | 2018 |
Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, | 2018 |
Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, | 2018 |
Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, | 2018 |
Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, | 2018 |
Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, | 2018 |
Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, | 2018 |
Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, | 2018 |
Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, | 2018 |
Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, | 2018 |
Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, | 2018 |
Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Breast Neopl | 2018 |
Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Breast Neopl | 2018 |
Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Breast Neopl | 2018 |
Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms | 2018 |
Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms | 2018 |
Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms | 2018 |
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Pharmacological; Biomarkers, Tumor; | 2018 |
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Pharmacological; Biomarkers, Tumor; | 2018 |
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Pharmacological; Biomarkers, Tumor; | 2018 |
Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON).
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast; Breast Neoplas | 2018 |
Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON).
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast; Breast Neoplas | 2018 |
Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON).
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast; Breast Neoplas | 2018 |
Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC).
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 2018 |
Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC).
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 2018 |
Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC).
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 2018 |
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2018 |
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2018 |
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2018 |
Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2018 |
Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2018 |
Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2018 |
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2018 |
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2018 |
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2018 |
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label,
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2018 |
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label,
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2018 |
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label,
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2018 |
Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609).
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; DNA, Neoplasm; Female; Fulvest | 2018 |
Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609).
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; DNA, Neoplasm; Female; Fulvest | 2018 |
Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609).
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; DNA, Neoplasm; Female; Fulvest | 2018 |
Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relations | 2018 |
Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relations | 2018 |
Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relations | 2018 |
Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Cross-Over S | 2018 |
Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Cross-Over S | 2018 |
Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Cross-Over S | 2018 |
Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free S | 2019 |
Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free S | 2019 |
Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free S | 2019 |
Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial.
Topics: Absorptiometry, Photon; Adult; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density | 2019 |
Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial.
Topics: Absorptiometry, Photon; Adult; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density | 2019 |
Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial.
Topics: Absorptiometry, Photon; Adult; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density | 2019 |
Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Breast Neoplasms; Female; Fractures, Bon | 2019 |
Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Breast Neoplasms; Female; Fractures, Bon | 2019 |
Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Breast Neoplasms; Female; Fractures, Bon | 2019 |
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromata | 2019 |
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromata | 2019 |
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromata | 2019 |
Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia.
Topics: Anastrozole; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Breast Neoplasms; Female; Frac | 2019 |
Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia.
Topics: Anastrozole; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Breast Neoplasms; Female; Frac | 2019 |
Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia.
Topics: Anastrozole; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Breast Neoplasms; Female; Frac | 2019 |
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast | 2019 |
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast | 2019 |
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast | 2019 |
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian Tamoxifen Anastrozole trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; | 2013 |
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian Tamoxifen Anastrozole trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; | 2013 |
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian Tamoxifen Anastrozole trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; | 2013 |
Influence of compliance on bone mineral density changes in postmenopausal women with early breast cancer on Anastrozole.
Topics: Absorptiometry, Photon; Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Che | 2013 |
Influence of compliance on bone mineral density changes in postmenopausal women with early breast cancer on Anastrozole.
Topics: Absorptiometry, Photon; Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Che | 2013 |
Influence of compliance on bone mineral density changes in postmenopausal women with early breast cancer on Anastrozole.
Topics: Absorptiometry, Photon; Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Che | 2013 |
Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neo | 2013 |
Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neo | 2013 |
Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neo | 2013 |
A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tu | 2013 |
A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tu | 2013 |
A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tu | 2013 |
Predictors of recovery of ovarian function during aromatase inhibitor therapy.
Topics: Adult; Amenorrhea; Anastrozole; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; | 2013 |
Predictors of recovery of ovarian function during aromatase inhibitor therapy.
Topics: Adult; Amenorrhea; Anastrozole; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; | 2013 |
Predictors of recovery of ovarian function during aromatase inhibitor therapy.
Topics: Adult; Amenorrhea; Anastrozole; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; | 2013 |
A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromat | 2013 |
A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromat | 2013 |
A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromat | 2013 |
Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Anxiety; Aromatase Inhibitors; Breast Neoplasms; | 2014 |
Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Anxiety; Aromatase Inhibitors; Breast Neoplasms; | 2014 |
Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Anxiety; Aromatase Inhibitors; Breast Neoplasms; | 2014 |
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.
Topics: Adolescent; Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Ind | 2013 |
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.
Topics: Adolescent; Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Ind | 2013 |
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.
Topics: Adolescent; Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Ind | 2013 |
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease | 2013 |
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease | 2013 |
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease | 2013 |
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease | 2013 |
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease | 2013 |
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease | 2013 |
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease | 2013 |
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease | 2013 |
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease | 2013 |
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease | 2013 |
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease | 2013 |
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease | 2013 |
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Fol | 2013 |
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Fol | 2013 |
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Fol | 2013 |
Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estr | 2013 |
Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estr | 2013 |
Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estr | 2013 |
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2014 |
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2014 |
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2014 |
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2014 |
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2014 |
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2014 |
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2014 |
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2014 |
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2014 |
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2014 |
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2014 |
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2014 |
COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Breast Neoplasms; Chemotherapy, Adju | 2014 |
COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Breast Neoplasms; Chemotherapy, Adju | 2014 |
COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Breast Neoplasms; Chemotherapy, Adju | 2014 |
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromat | 2014 |
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromat | 2014 |
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromat | 2014 |
A pilot study comparing the effect of flaxseed, aromatase inhibitor, and the combination on breast tumor biomarkers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Biomarkers, Tumor; Bo | 2014 |
A pilot study comparing the effect of flaxseed, aromatase inhibitor, and the combination on breast tumor biomarkers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Biomarkers, Tumor; Bo | 2014 |
A pilot study comparing the effect of flaxseed, aromatase inhibitor, and the combination on breast tumor biomarkers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Biomarkers, Tumor; Bo | 2014 |
The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2014 |
The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2014 |
The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2014 |
Pilot randomised study of early intervention based on tumour markers in the follow-up of patients with primary breast cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neo | 2014 |
Pilot randomised study of early intervention based on tumour markers in the follow-up of patients with primary breast cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neo | 2014 |
Pilot randomised study of early intervention based on tumour markers in the follow-up of patients with primary breast cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neo | 2014 |
Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast | 2014 |
Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast | 2014 |
Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast | 2014 |
A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer.
Topics: Aged; Anastrozole; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Fatty Liver; | 2014 |
A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer.
Topics: Aged; Anastrozole; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Fatty Liver; | 2014 |
A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer.
Topics: Aged; Anastrozole; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Fatty Liver; | 2014 |
Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2014 |
Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2014 |
Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2014 |
Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor-related arthralgia: a randomized trial.
Topics: Aged; Anastrozole; Androstadienes; Anxiety; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Depr | 2014 |
Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor-related arthralgia: a randomized trial.
Topics: Aged; Anastrozole; Androstadienes; Anxiety; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Depr | 2014 |
Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor-related arthralgia: a randomized trial.
Topics: Aged; Anastrozole; Androstadienes; Anxiety; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Depr | 2014 |
Effect of calcitonin on anastrozole-induced bone pain during aromatase inhibitor therapy for breast cancer.
Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Anastrozole; Antineoplastic Agents, Hormonal; Ar | 2014 |
Effect of calcitonin on anastrozole-induced bone pain during aromatase inhibitor therapy for breast cancer.
Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Anastrozole; Antineoplastic Agents, Hormonal; Ar | 2014 |
Effect of calcitonin on anastrozole-induced bone pain during aromatase inhibitor therapy for breast cancer.
Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Anastrozole; Antineoplastic Agents, Hormonal; Ar | 2014 |
Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Aromatase Inhibitors; Breast Neoplasms | 2015 |
Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Aromatase Inhibitors; Breast Neoplasms | 2015 |
Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Aromatase Inhibitors; Breast Neoplasms | 2015 |
Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bre | 2014 |
Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bre | 2014 |
Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bre | 2014 |
Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bre | 2015 |
Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bre | 2015 |
Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bre | 2015 |
Does patient education work in breast cancer? Final results from the global CARIATIDE study.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2015 |
Does patient education work in breast cancer? Final results from the global CARIATIDE study.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2015 |
Does patient education work in breast cancer? Final results from the global CARIATIDE study.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2015 |
Electroretinographic and optical coherence tomography findings in breast cancer patients using aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Electroretinography; Evoked Pot | 2016 |
Electroretinographic and optical coherence tomography findings in breast cancer patients using aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Electroretinography; Evoked Pot | 2016 |
Electroretinographic and optical coherence tomography findings in breast cancer patients using aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Electroretinography; Evoked Pot | 2016 |
Evaluating the feasibility of performing window of opportunity trials in breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neo | 2015 |
Evaluating the feasibility of performing window of opportunity trials in breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neo | 2015 |
Evaluating the feasibility of performing window of opportunity trials in breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neo | 2015 |
Joint symptoms and health-related quality of life in postmenopausal women with breast cancer who completed 5 years of anastrozole.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; B | 2016 |
Joint symptoms and health-related quality of life in postmenopausal women with breast cancer who completed 5 years of anastrozole.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; B | 2016 |
Joint symptoms and health-related quality of life in postmenopausal women with breast cancer who completed 5 years of anastrozole.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; B | 2016 |
A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2015 |
A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2015 |
A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2015 |
Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; | 2015 |
Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; | 2015 |
Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; | 2015 |
[BREAST-CONSERVING SURGERY AFTER NEOADJUVANT THERAPY FOR BREAST CANCER].
Topics: Adult; Aged; Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, | 2015 |
[BREAST-CONSERVING SURGERY AFTER NEOADJUVANT THERAPY FOR BREAST CANCER].
Topics: Adult; Aged; Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, | 2015 |
[BREAST-CONSERVING SURGERY AFTER NEOADJUVANT THERAPY FOR BREAST CANCER].
Topics: Adult; Aged; Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; D | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; D | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; D | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; D | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; D | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; D | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; D | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; D | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; D | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; D | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; D | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; D | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; D | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; D | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; D | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; D | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; D | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; D | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; D | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; D | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; D | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; D | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; D | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; D | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; D | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; D | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; D | 2015 |
Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2016 |
Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2016 |
Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2016 |
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2016 |
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2016 |
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2016 |
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2016 |
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2016 |
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2016 |
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2016 |
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2016 |
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2016 |
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2016 |
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2016 |
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2016 |
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Topics: Administration, Oral; Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2016 |
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Topics: Administration, Oral; Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2016 |
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Topics: Administration, Oral; Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2016 |
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Topics: Administration, Oral; Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2016 |
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Topics: Administration, Oral; Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2016 |
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Topics: Administration, Oral; Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2016 |
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Topics: Administration, Oral; Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2016 |
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Topics: Administration, Oral; Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2016 |
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Topics: Administration, Oral; Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2016 |
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Topics: Administration, Oral; Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2016 |
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Topics: Administration, Oral; Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2016 |
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Topics: Administration, Oral; Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2016 |
Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duc | 2016 |
Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duc | 2016 |
Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duc | 2016 |
A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast | 2016 |
A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast | 2016 |
A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast | 2016 |
A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 2016 |
A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 2016 |
A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 2016 |
Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226.
Topics: Anastrozole; Breast Neoplasms; Drug Interactions; Estradiol; Female; Fulvestrant; Humans; Nitriles; | 2016 |
Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226.
Topics: Anastrozole; Breast Neoplasms; Drug Interactions; Estradiol; Female; Fulvestrant; Humans; Nitriles; | 2016 |
Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226.
Topics: Anastrozole; Breast Neoplasms; Drug Interactions; Estradiol; Female; Fulvestrant; Humans; Nitriles; | 2016 |
Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Bone De | 2016 |
Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Bone De | 2016 |
Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Bone De | 2016 |
Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tu | 2016 |
Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tu | 2016 |
Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tu | 2016 |
Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cardio | 2016 |
Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cardio | 2016 |
Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cardio | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2016 |
Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 2016 |
Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 2016 |
Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 2016 |
Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast | 2016 |
Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast | 2016 |
Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast | 2016 |
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromata | 2017 |
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromata | 2017 |
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromata | 2017 |
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast; Breast Neoplasms; Diseas | 2016 |
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast; Breast Neoplasms; Diseas | 2016 |
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast; Breast Neoplasms; Diseas | 2016 |
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast; Breast Neoplasms; Diseas | 2016 |
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast; Breast Neoplasms; Diseas | 2016 |
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast; Breast Neoplasms; Diseas | 2016 |
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast; Breast Neoplasms; Diseas | 2016 |
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast; Breast Neoplasms; Diseas | 2016 |
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast; Breast Neoplasms; Diseas | 2016 |
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast; Breast Neoplasms; Diseas | 2016 |
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast; Breast Neoplasms; Diseas | 2016 |
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast; Breast Neoplasms; Diseas | 2016 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Breast Neoplasms; Chemotherapy, Adju | 2017 |
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Breast Neoplasms; Chemotherapy, Adju | 2017 |
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Breast Neoplasms; Chemotherapy, Adju | 2017 |
Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Endo | 2008 |
Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Endo | 2008 |
Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Endo | 2008 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2008 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2008 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2008 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2008 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2008 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2008 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2008 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2008 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2008 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2008 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2008 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2008 |
Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II).
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Attention; Breast Neoplasms; Cognition; Double-Blind M | 2008 |
Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II).
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Attention; Breast Neoplasms; Cognition; Double-Blind M | 2008 |
Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II).
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Attention; Breast Neoplasms; Cognition; Double-Blind M | 2008 |
Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS).
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Australia; | 2008 |
Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS).
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Australia; | 2008 |
Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS).
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Australia; | 2008 |
Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Chromatography, High | 2008 |
Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Chromatography, High | 2008 |
Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Chromatography, High | 2008 |
Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density | 2008 |
Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density | 2008 |
Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density | 2008 |
Incidence of joint symptoms and bone fractures in Japanese postmenopausal breast cancer patients treated with adjuvant anastrozole.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Asian People; Bone Density; Breast Neoplasms; Chemotherapy, | 2009 |
Incidence of joint symptoms and bone fractures in Japanese postmenopausal breast cancer patients treated with adjuvant anastrozole.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Asian People; Bone Density; Breast Neoplasms; Chemotherapy, | 2009 |
Incidence of joint symptoms and bone fractures in Japanese postmenopausal breast cancer patients treated with adjuvant anastrozole.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Asian People; Bone Density; Breast Neoplasms; Chemotherapy, | 2009 |
Comparing the cost of adjuvant anastrozole with the benefits of managing less patients with relapsed breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chem | 2009 |
Comparing the cost of adjuvant anastrozole with the benefits of managing less patients with relapsed breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chem | 2009 |
Comparing the cost of adjuvant anastrozole with the benefits of managing less patients with relapsed breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chem | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation | 2009 |
A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Brain Neoplasms; | 2009 |
A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Brain Neoplasms; | 2009 |
A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Brain Neoplasms; | 2009 |
21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biopsy, Needle; Breast Neoplasms; Disease-Free Surviva | 2009 |
21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biopsy, Needle; Breast Neoplasms; Disease-Free Surviva | 2009 |
21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biopsy, Needle; Breast Neoplasms; Disease-Free Surviva | 2009 |
Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Estradiol; Fem | 2009 |
Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Estradiol; Fem | 2009 |
Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Estradiol; Fem | 2009 |
A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Biomarkers; Breast Neopl | 2010 |
A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Biomarkers; Breast Neopl | 2010 |
A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Biomarkers; Breast Neopl | 2010 |
Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2009 |
Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2009 |
Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2009 |
[Safety and compliance with UFT (tegafur and uracil) alone and in combination with hormone therapy in patients with breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combine | 2009 |
[Safety and compliance with UFT (tegafur and uracil) alone and in combination with hormone therapy in patients with breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combine | 2009 |
[Safety and compliance with UFT (tegafur and uracil) alone and in combination with hormone therapy in patients with breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combine | 2009 |
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal; | 2009 |
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal; | 2009 |
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal; | 2009 |
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal; | 2009 |
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal; | 2009 |
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal; | 2009 |
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal; | 2009 |
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal; | 2009 |
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal; | 2009 |
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal; | 2009 |
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal; | 2009 |
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal; | 2009 |
Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast; Breast Neoplasms; Cytochrom | 2009 |
Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast; Breast Neoplasms; Cytochrom | 2009 |
Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast; Breast Neoplasms; Cytochrom | 2009 |
A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Bone and Bones; Bone Resorption; | 2010 |
A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Bone and Bones; Bone Resorption; | 2010 |
A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Bone and Bones; Bone Resorption; | 2010 |
Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 2010 |
Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 2010 |
Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 2010 |
Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neop | 2010 |
Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neop | 2010 |
Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neop | 2010 |
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplas | 2010 |
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplas | 2010 |
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplas | 2010 |
Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast | 2010 |
Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast | 2010 |
Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast | 2010 |
Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Computer Simulation; Cost-Benefit Analysis; Fe | 2010 |
Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Computer Simulation; Cost-Benefit Analysis; Fe | 2010 |
Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Computer Simulation; Cost-Benefit Analysis; Fe | 2010 |
Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2010 |
Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2010 |
Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2010 |
Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.
Topics: Administration, Oral; Aged; Anastrozole; Aromatase Inhibitors; Arthralgia; Bone Density; Bone Densit | 2010 |
Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.
Topics: Administration, Oral; Aged; Anastrozole; Aromatase Inhibitors; Arthralgia; Bone Density; Bone Densit | 2010 |
Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.
Topics: Administration, Oral; Aged; Anastrozole; Aromatase Inhibitors; Arthralgia; Bone Density; Bone Densit | 2010 |
Adding zoledronic acid to endocrine therapy in the adjuvant treatment of hormone-sensitive breast cancer in premenopausal women: a new care standard or a provocative idea?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Di | 2010 |
Adding zoledronic acid to endocrine therapy in the adjuvant treatment of hormone-sensitive breast cancer in premenopausal women: a new care standard or a provocative idea?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Di | 2010 |
Adding zoledronic acid to endocrine therapy in the adjuvant treatment of hormone-sensitive breast cancer in premenopausal women: a new care standard or a provocative idea?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Di | 2010 |
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Br | 2010 |
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Br | 2010 |
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Br | 2010 |
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Br | 2010 |
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Br | 2010 |
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Br | 2010 |
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Br | 2010 |
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Br | 2010 |
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Br | 2010 |
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Br | 2010 |
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Br | 2010 |
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Br | 2010 |
Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Fem | 2010 |
Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Fem | 2010 |
Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Fem | 2010 |
The ATAC adjuvant breast-cancer trial: six-year results of the endometrial subprotocol.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Endom | 2010 |
The ATAC adjuvant breast-cancer trial: six-year results of the endometrial subprotocol.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Endom | 2010 |
The ATAC adjuvant breast-cancer trial: six-year results of the endometrial subprotocol.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Endom | 2010 |
Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; | 2011 |
Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; | 2011 |
Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; | 2011 |
Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-B | 2011 |
Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-B | 2011 |
Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-B | 2011 |
Short-term anastrozole therapy reduces Ki-67 and progesterone receptor expression in invasive breast cancer: a prospective, placebo-controlled, double-blind trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 2011 |
Short-term anastrozole therapy reduces Ki-67 and progesterone receptor expression in invasive breast cancer: a prospective, placebo-controlled, double-blind trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 2011 |
Short-term anastrozole therapy reduces Ki-67 and progesterone receptor expression in invasive breast cancer: a prospective, placebo-controlled, double-blind trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 2011 |
Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Resorption; Breast Neoplasms; Femal | 2011 |
Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Resorption; Breast Neoplasms; Femal | 2011 |
Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Resorption; Breast Neoplasms; Femal | 2011 |
Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; China; Disease Progress | 2011 |
Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; China; Disease Progress | 2011 |
Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; China; Disease Progress | 2011 |
Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benz | 2011 |
Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benz | 2011 |
Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benz | 2011 |
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Topics: Administration, Oral; Anastrozole; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studi | 2010 |
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Topics: Administration, Oral; Anastrozole; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studi | 2010 |
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Topics: Administration, Oral; Anastrozole; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studi | 2010 |
Genome-wide case-control study of musculoskeletal adverse events and functional genomics in women receiving aromatase inhibitors: going beyond associations.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Case-Con | 2010 |
Genome-wide case-control study of musculoskeletal adverse events and functional genomics in women receiving aromatase inhibitors: going beyond associations.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Case-Con | 2010 |
Genome-wide case-control study of musculoskeletal adverse events and functional genomics in women receiving aromatase inhibitors: going beyond associations.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Case-Con | 2010 |
The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemot | 2011 |
The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemot | 2011 |
The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemot | 2011 |
Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1-4 years: N-SAS BC 03.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; N | 2011 |
Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1-4 years: N-SAS BC 03.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; N | 2011 |
Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1-4 years: N-SAS BC 03.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; N | 2011 |
Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Bone and Bones; Bone De | 2010 |
Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Bone and Bones; Bone De | 2010 |
Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Bone and Bones; Bone De | 2010 |
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Effects of toremifene and anastrozole on serum lipids and bone metabolism in postmenopausal females with estrogen receptor-positive breast cancer: the results of a 2-year multicenter open randomized study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Bone and Bones; Breast | 2011 |
Effects of toremifene and anastrozole on serum lipids and bone metabolism in postmenopausal females with estrogen receptor-positive breast cancer: the results of a 2-year multicenter open randomized study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Bone and Bones; Breast | 2011 |
Effects of toremifene and anastrozole on serum lipids and bone metabolism in postmenopausal females with estrogen receptor-positive breast cancer: the results of a 2-year multicenter open randomized study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Bone and Bones; Breast | 2011 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Density Conservatio | 2011 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Density Conservatio | 2011 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Density Conservatio | 2011 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Density Conservatio | 2011 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Density Conservatio | 2011 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Density Conservatio | 2011 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Density Conservatio | 2011 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Density Conservatio | 2011 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Density Conservatio | 2011 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Density Conservatio | 2011 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Density Conservatio | 2011 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Density Conservatio | 2011 |
Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy.
Topics: Aged; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Bre | 2011 |
Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy.
Topics: Aged; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Bre | 2011 |
Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy.
Topics: Aged; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Bre | 2011 |
Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz | 2011 |
Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz | 2011 |
Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz | 2011 |
Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density | 2011 |
Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density | 2011 |
Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density | 2011 |
Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inh | 2012 |
Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inh | 2012 |
Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inh | 2012 |
Differentially expressed genes in window trials are influenced by the wound-healing process: lessons learned from a pilot study with anastrozole.
Topics: Aged; Aged, 80 and over; Anastrozole; Antigens, CD34; Aromatase Inhibitors; Biomarkers, Tumor; Breas | 2012 |
Differentially expressed genes in window trials are influenced by the wound-healing process: lessons learned from a pilot study with anastrozole.
Topics: Aged; Aged, 80 and over; Anastrozole; Antigens, CD34; Aromatase Inhibitors; Biomarkers, Tumor; Breas | 2012 |
Differentially expressed genes in window trials are influenced by the wound-healing process: lessons learned from a pilot study with anastrozole.
Topics: Aged; Aged, 80 and over; Anastrozole; Antigens, CD34; Aromatase Inhibitors; Biomarkers, Tumor; Breas | 2012 |
A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2011 |
A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2011 |
A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2011 |
Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial.
Topics: Adult; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chem | 2011 |
Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial.
Topics: Adult; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chem | 2011 |
Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial.
Topics: Adult; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chem | 2011 |
Outcomes of Japanese breast cancer patients treated with pre-operative and post-operative anastrozole or tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Asian People; Breast N | 2012 |
Outcomes of Japanese breast cancer patients treated with pre-operative and post-operative anastrozole or tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Asian People; Breast N | 2012 |
Outcomes of Japanese breast cancer patients treated with pre-operative and post-operative anastrozole or tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Asian People; Breast N | 2012 |
Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Data Mini | 2012 |
Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Data Mini | 2012 |
Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Data Mini | 2012 |
Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole.
Topics: Adult; Aged; Anastrozole; Anticarcinogenic Agents; Aromatase Inhibitors; Arthralgia; Biomarkers; Bre | 2012 |
Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole.
Topics: Adult; Aged; Anastrozole; Anticarcinogenic Agents; Aromatase Inhibitors; Arthralgia; Biomarkers; Bre | 2012 |
Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole.
Topics: Adult; Aged; Anastrozole; Anticarcinogenic Agents; Aromatase Inhibitors; Arthralgia; Biomarkers; Bre | 2012 |
Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2012 |
Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2012 |
Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2012 |
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neo | 2012 |
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neo | 2012 |
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neo | 2012 |
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neo | 2012 |
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neo | 2012 |
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neo | 2012 |
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neo | 2012 |
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neo | 2012 |
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neo | 2012 |
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neo | 2012 |
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neo | 2012 |
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neo | 2012 |
Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromata | 2012 |
Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromata | 2012 |
Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromata | 2012 |
Aromatase inhibitors and calcium absorption in early stage breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Calcium; | 2012 |
Aromatase inhibitors and calcium absorption in early stage breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Calcium; | 2012 |
Aromatase inhibitors and calcium absorption in early stage breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Calcium; | 2012 |
FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast | 2012 |
FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast | 2012 |
FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast | 2012 |
A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast | 2012 |
A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast | 2012 |
A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast | 2012 |
Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2012 |
Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2012 |
Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2012 |
A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neo | 2012 |
A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neo | 2012 |
A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neo | 2012 |
Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Anti-Inflammatory Agents; Aromatase Inhibitors; Arthralgia; Br | 2012 |
Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Anti-Inflammatory Agents; Aromatase Inhibitors; Arthralgia; Br | 2012 |
Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Anti-Inflammatory Agents; Aromatase Inhibitors; Arthralgia; Br | 2012 |
Lipid profiles within the SABRE trial of anastrozole with and without risedronate.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 2012 |
Lipid profiles within the SABRE trial of anastrozole with and without risedronate.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 2012 |
Lipid profiles within the SABRE trial of anastrozole with and without risedronate.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 2012 |
Combination anastrozole and fulvestrant in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromata | 2012 |
Combination anastrozole and fulvestrant in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromata | 2012 |
Combination anastrozole and fulvestrant in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromata | 2012 |
Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Follow-Up Studies | 2012 |
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Follow-Up Studies | 2012 |
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Follow-Up Studies | 2012 |
Phase II study of neoadjuvant anastrozole and concurrent radiotherapy for postmenopausal breast cancer patients.
Topics: Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Chemoradiotherapy; Female; Humans; Middle Ag | 2014 |
Phase II study of neoadjuvant anastrozole and concurrent radiotherapy for postmenopausal breast cancer patients.
Topics: Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Chemoradiotherapy; Female; Humans; Middle Ag | 2014 |
Phase II study of neoadjuvant anastrozole and concurrent radiotherapy for postmenopausal breast cancer patients.
Topics: Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Chemoradiotherapy; Female; Humans; Middle Ag | 2014 |
Use of a urine anastrozole assay to determine treatment discontinuation among women with hormone-sensitive breast cancer: a pilot study.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Medication Adh | 2012 |
Use of a urine anastrozole assay to determine treatment discontinuation among women with hormone-sensitive breast cancer: a pilot study.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Medication Adh | 2012 |
Use of a urine anastrozole assay to determine treatment discontinuation among women with hormone-sensitive breast cancer: a pilot study.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Medication Adh | 2012 |
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Fe | 2013 |
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Fe | 2013 |
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Fe | 2013 |
The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cance
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Early Detection of Cancer; Fem | 2013 |
The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cance
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Early Detection of Cancer; Fem | 2013 |
The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cance
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Early Detection of Cancer; Fem | 2013 |
The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cance
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Early Detection of Cancer; Fem | 2013 |
The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cance
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Early Detection of Cancer; Fem | 2013 |
The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cance
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Early Detection of Cancer; Fem | 2013 |
The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cance
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Early Detection of Cancer; Fem | 2013 |
The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cance
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Early Detection of Cancer; Fem | 2013 |
The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cance
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Early Detection of Cancer; Fem | 2013 |
The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cance
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Early Detection of Cancer; Fem | 2013 |
The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cance
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Early Detection of Cancer; Fem | 2013 |
The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cance
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Early Detection of Cancer; Fem | 2013 |
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2002 |
Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer.
Topics: Aged; Anastrozole; Antigens, Nuclear; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blin | 2002 |
Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer.
Topics: Aged; Anastrozole; Antigens, Nuclear; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blin | 2002 |
Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer.
Topics: Aged; Anastrozole; Antigens, Nuclear; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blin | 2002 |
The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal patients: factors influencing the success of patient recruitment.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2002 |
The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal patients: factors influencing the success of patient recruitment.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2002 |
The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal patients: factors influencing the success of patient recruitment.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2002 |
Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Dose-Response R | 2002 |
Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Dose-Response R | 2002 |
Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Dose-Response R | 2002 |
Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
Topics: Aged; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors | 2002 |
Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
Topics: Aged; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors | 2002 |
Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
Topics: Aged; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors | 2002 |
Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.
Topics: Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 2003 |
Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.
Topics: Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 2003 |
Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.
Topics: Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 2003 |
Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Estradiol; Fema | 2003 |
Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Estradiol; Fema | 2003 |
Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Estradiol; Fema | 2003 |
Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Neoplasms; Breast Neo | 2003 |
Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Neoplasms; Breast Neo | 2003 |
Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Neoplasms; Breast Neo | 2003 |
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aroma | 2003 |
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aroma | 2003 |
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aroma | 2003 |
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2003 |
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2003 |
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2003 |
Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Double-Blind | 2003 |
Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Double-Blind | 2003 |
Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Double-Blind | 2003 |
Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women?
Topics: Adult; Aged; Anastrozole; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Aromatase | 2003 |
Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women?
Topics: Adult; Aged; Anastrozole; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Aromatase | 2003 |
Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women?
Topics: Adult; Aged; Anastrozole; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Aromatase | 2003 |
Anastrozole and quinapril can be safely coadministered to elderly women with breast cancer and hypertension: a pharmacokinetic study.
Topics: Age Factors; Aged; Aged, 80 and over; Anastrozole; Antihypertensive Agents; Antineoplastic Agents, H | 2003 |
Anastrozole and quinapril can be safely coadministered to elderly women with breast cancer and hypertension: a pharmacokinetic study.
Topics: Age Factors; Aged; Aged, 80 and over; Anastrozole; Antihypertensive Agents; Antineoplastic Agents, H | 2003 |
Anastrozole and quinapril can be safely coadministered to elderly women with breast cancer and hypertension: a pharmacokinetic study.
Topics: Age Factors; Aged; Aged, 80 and over; Anastrozole; Antihypertensive Agents; Antineoplastic Agents, H | 2003 |
An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Enzy | 2003 |
An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Enzy | 2003 |
An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Enzy | 2003 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update ana
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2003 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update ana
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2003 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update ana
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2003 |
Advanced breast cancer updates on anastrozole versus tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Drug Administra | 2003 |
Advanced breast cancer updates on anastrozole versus tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Drug Administra | 2003 |
Advanced breast cancer updates on anastrozole versus tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Drug Administra | 2003 |
'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2003 |
'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2003 |
'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2003 |
The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combine | 2003 |
The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combine | 2003 |
The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combine | 2003 |
Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study.
Topics: Affect; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Anxiet | 2004 |
Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study.
Topics: Affect; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Anxiet | 2004 |
Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study.
Topics: Affect; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Anxiet | 2004 |
Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2004 |
Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2004 |
Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2004 |
Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cros | 2004 |
Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cros | 2004 |
Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cros | 2004 |
Breast surgery in the 'Arimidex, Tamoxifen Alone or in Combination' (ATAC) trial: American women are more likely than women from the United Kingdom to undergo mastectomy.
Topics: Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2004 |
Breast surgery in the 'Arimidex, Tamoxifen Alone or in Combination' (ATAC) trial: American women are more likely than women from the United Kingdom to undergo mastectomy.
Topics: Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2004 |
Breast surgery in the 'Arimidex, Tamoxifen Alone or in Combination' (ATAC) trial: American women are more likely than women from the United Kingdom to undergo mastectomy.
Topics: Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2004 |
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
Giving patients a choice improves quality of life: a multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozole.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; | 2004 |
Giving patients a choice improves quality of life: a multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozole.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; | 2004 |
Giving patients a choice improves quality of life: a multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozole.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; | 2004 |
Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
Topics: Anastrozole; Aromatase Inhibitors; Belgium; Body Mass Index; Breast Neoplasms; Data Interpretation, | 2004 |
Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
Topics: Anastrozole; Aromatase Inhibitors; Belgium; Body Mass Index; Breast Neoplasms; Data Interpretation, | 2004 |
Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
Topics: Anastrozole; Aromatase Inhibitors; Belgium; Body Mass Index; Breast Neoplasms; Data Interpretation, | 2004 |
The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Pro | 2005 |
The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Pro | 2005 |
The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Pro | 2005 |
Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Proliferation; Double-Bli | 2004 |
Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Proliferation; Double-Bli | 2004 |
Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Proliferation; Double-Bli | 2004 |
Molecular markers in the endometrium at baseline of postmenopausal patients with early breast cancer in the ATAC (Arimidex, tamoxifen, alone, or in combination) trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2004 |
Molecular markers in the endometrium at baseline of postmenopausal patients with early breast cancer in the ATAC (Arimidex, tamoxifen, alone, or in combination) trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2004 |
Molecular markers in the endometrium at baseline of postmenopausal patients with early breast cancer in the ATAC (Arimidex, tamoxifen, alone, or in combination) trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2004 |
Biomarker investigations from the ATAC trial: the role of TA01.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adj | 2004 |
Biomarker investigations from the ATAC trial: the role of TA01.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adj | 2004 |
Biomarker investigations from the ATAC trial: the role of TA01.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adj | 2004 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell | 2005 |
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2005 |
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2005 |
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2005 |
Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2005 |
Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2005 |
Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2005 |
[Survival of breast cancer patients treated with inhibitors of the aromatase vs tamoxifen].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 2004 |
[Survival of breast cancer patients treated with inhibitors of the aromatase vs tamoxifen].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 2004 |
[Survival of breast cancer patients treated with inhibitors of the aromatase vs tamoxifen].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 2004 |
Zoledronic acid prevents cancer treatment-induced bone loss.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Resorption; Breast N | 2005 |
Zoledronic acid prevents cancer treatment-induced bone loss.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Resorption; Breast N | 2005 |
Zoledronic acid prevents cancer treatment-induced bone loss.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Resorption; Breast N | 2005 |
Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Ant | 2005 |
Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Ant | 2005 |
Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Ant | 2005 |
Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind M | 2005 |
Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind M | 2005 |
Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind M | 2005 |
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free S | 2005 |
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free S | 2005 |
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free S | 2005 |
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blin | 2005 |
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blin | 2005 |
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blin | 2005 |
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blin | 2005 |
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blin | 2005 |
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blin | 2005 |
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blin | 2005 |
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blin | 2005 |
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blin | 2005 |
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blin | 2005 |
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blin | 2005 |
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blin | 2005 |
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; | 2005 |
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; | 2005 |
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; | 2005 |
Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers; Bone Resorption; Breast Neoplasms; D | 2005 |
Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers; Bone Resorption; Breast Neoplasms; D | 2005 |
Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers; Bone Resorption; Breast Neoplasms; D | 2005 |
Do biomarker changes during neoadjuvant endocrine therapy reflect breast tumor receptor status?
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Dose-Respon | 2005 |
Do biomarker changes during neoadjuvant endocrine therapy reflect breast tumor receptor status?
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Dose-Respon | 2005 |
Do biomarker changes during neoadjuvant endocrine therapy reflect breast tumor receptor status?
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Dose-Respon | 2005 |
The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2006 |
The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2006 |
The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2006 |
Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2005 |
Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2005 |
Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2005 |
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apopto | 2006 |
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apopto | 2006 |
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apopto | 2006 |
Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2006 |
Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2006 |
Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2006 |
Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dilatation and Curettage; Endo | 2006 |
Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dilatation and Curettage; Endo | 2006 |
Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dilatation and Curettage; Endo | 2006 |
Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
Topics: Aged; Anastrozole; Breast Neoplasms; Confidence Intervals; Cross-Sectional Studies; Dose-Response Re | 2006 |
Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
Topics: Aged; Anastrozole; Breast Neoplasms; Confidence Intervals; Cross-Sectional Studies; Dose-Response Re | 2006 |
Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
Topics: Aged; Anastrozole; Breast Neoplasms; Confidence Intervals; Cross-Sectional Studies; Dose-Response Re | 2006 |
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2006 |
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2006 |
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2006 |
Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2006 |
Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2006 |
Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2006 |
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free | 2006 |
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free | 2006 |
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free | 2006 |
Estrogen receptors evolution in neoadjuvant aromatase inhibitor (AI) therapy for breast cancer in elderly women: stability of hormonal receptor expression during treatment.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2006 |
Estrogen receptors evolution in neoadjuvant aromatase inhibitor (AI) therapy for breast cancer in elderly women: stability of hormonal receptor expression during treatment.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2006 |
Estrogen receptors evolution in neoadjuvant aromatase inhibitor (AI) therapy for breast cancer in elderly women: stability of hormonal receptor expression during treatment.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2006 |
Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2006 |
Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2006 |
Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2006 |
Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2006 |
Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2006 |
Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2006 |
Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2006 |
Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2006 |
Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2006 |
Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2006 |
Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2006 |
Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2006 |
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
Topics: Adult; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Dip | 2007 |
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
Topics: Adult; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Dip | 2007 |
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
Topics: Adult; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Dip | 2007 |
Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cryopreservation; Estradiol; | 2007 |
Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cryopreservation; Estradiol; | 2007 |
Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cryopreservation; Estradiol; | 2007 |
Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Hum | 2007 |
Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Hum | 2007 |
Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Hum | 2007 |
The FACE trial: letrozole or anastrozole as initial adjuvant therapy?
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozo | 2007 |
The FACE trial: letrozole or anastrozole as initial adjuvant therapy?
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozo | 2007 |
The FACE trial: letrozole or anastrozole as initial adjuvant therapy?
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozo | 2007 |
Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy.
Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Ther | 2007 |
Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy.
Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Ther | 2007 |
Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy.
Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Ther | 2007 |
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Chemotherapy, | 2007 |
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Chemotherapy, | 2007 |
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Chemotherapy, | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Molecular response to aromatase inhibitor treatment in primary breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Combined Modal | 2007 |
Molecular response to aromatase inhibitor treatment in primary breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Combined Modal | 2007 |
Molecular response to aromatase inhibitor treatment in primary breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Combined Modal | 2007 |
Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2007 |
Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2007 |
Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2007 |
Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Co | 2007 |
Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Co | 2007 |
Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Co | 2007 |
Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-B | 2007 |
Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-B | 2007 |
Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-B | 2007 |
A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; | 2007 |
A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; | 2007 |
A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; | 2007 |
Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers | 2007 |
Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers | 2007 |
Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers | 2007 |
A decade of letrozole: FACE.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2007 |
A decade of letrozole: FACE.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2007 |
A decade of letrozole: FACE.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2007 |
[Phase II clinical trial of neoadjuvant hormone therapy in comparison with chemotherapy of patients with breast cancer].
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
[Phase II clinical trial of neoadjuvant hormone therapy in comparison with chemotherapy of patients with breast cancer].
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
[Phase II clinical trial of neoadjuvant hormone therapy in comparison with chemotherapy of patients with breast cancer].
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplasti | 2007 |
Switching to anastrozole after tamoxifen improves survival in postmenopausal women with breast cancer.
Topics: Aged; Anastrozole; Breast Neoplasms; Female; Humans; Nitriles; Postmenopause; Prospective Studies; S | 2008 |
Switching to anastrozole after tamoxifen improves survival in postmenopausal women with breast cancer.
Topics: Aged; Anastrozole; Breast Neoplasms; Female; Humans; Nitriles; Postmenopause; Prospective Studies; S | 2008 |
Switching to anastrozole after tamoxifen improves survival in postmenopausal women with breast cancer.
Topics: Aged; Anastrozole; Breast Neoplasms; Female; Humans; Nitriles; Postmenopause; Prospective Studies; S | 2008 |
The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2007 |
The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2007 |
The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2007 |
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase | 2007 |
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase | 2007 |
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase | 2007 |
Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blin | 2008 |
Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blin | 2008 |
Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blin | 2008 |
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Alkylating; Aromatase Inhibitors; Breast Neoplasms; Disease-Free | 2008 |
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Alkylating; Aromatase Inhibitors; Breast Neoplasms; Disease-Free | 2008 |
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Alkylating; Aromatase Inhibitors; Breast Neoplasms; Disease-Free | 2008 |
ERBB2 status and outcome of endocrine treatment.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; ErbB Receptors | 2008 |
ERBB2 status and outcome of endocrine treatment.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; ErbB Receptors | 2008 |
ERBB2 status and outcome of endocrine treatment.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; ErbB Receptors | 2008 |
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2008 |
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2008 |
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2008 |
Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Breast Neoplasms; Case-Co | 2008 |
Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Breast Neoplasms; Case-Co | 2008 |
Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Breast Neoplasms; Case-Co | 2008 |
Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, | 2008 |
Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, | 2008 |
Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, | 2008 |
A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 2009 |
A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 2009 |
A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 2009 |
The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blin | 2008 |
The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blin | 2008 |
The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blin | 2008 |
ARIMIDEX: a new oral, once-a-day aromatase inhibitor.
Topics: Administration, Oral; Aldosterone; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Drug Adminis | 1995 |
ARIMIDEX: a new oral, once-a-day aromatase inhibitor.
Topics: Administration, Oral; Aldosterone; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Drug Adminis | 1995 |
ARIMIDEX: a new oral, once-a-day aromatase inhibitor.
Topics: Administration, Oral; Aldosterone; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Drug Adminis | 1995 |
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; | 1996 |
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; | 1996 |
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; | 1996 |
A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 1996 |
A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 1996 |
A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 1996 |
Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Stu | 1996 |
Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Stu | 1996 |
Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Stu | 1996 |
A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 1997 |
A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 1997 |
A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 1997 |
A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aroma | 1997 |
A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aroma | 1997 |
A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aroma | 1997 |
Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Double-Bl | 1998 |
Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Double-Bl | 1998 |
Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Double-Bl | 1998 |
The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Estrogens; Fema | 1999 |
The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Estrogens; Fema | 1999 |
The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Estrogens; Fema | 1999 |
Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy.
Topics: Anastrozole; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhi | 1999 |
Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy.
Topics: Anastrozole; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhi | 1999 |
Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy.
Topics: Anastrozole; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhi | 1999 |
A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex) with intramuscular formestane in postmenopausal women with advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Antineoplastic A | 1999 |
A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex) with intramuscular formestane in postmenopausal women with advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Antineoplastic A | 1999 |
A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex) with intramuscular formestane in postmenopausal women with advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Antineoplastic A | 1999 |
Critique of survival update analysis from two phase III anastrozole clinical trials.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Survival R | 1999 |
Critique of survival update analysis from two phase III anastrozole clinical trials.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Survival R | 1999 |
Critique of survival update analysis from two phase III anastrozole clinical trials.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Survival R | 1999 |
Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Dose-Response | 1999 |
Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Dose-Response | 1999 |
Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Dose-Response | 1999 |
The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relationship, Dr | 2000 |
The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relationship, Dr | 2000 |
The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relationship, Dr | 2000 |
Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Female; Humans; | 2000 |
Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Female; Humans; | 2000 |
Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Female; Humans; | 2000 |
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2000 |
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2000 |
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2000 |
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2000 |
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2000 |
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2000 |
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2000 |
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2000 |
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2000 |
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2000 |
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2000 |
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2000 |
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2000 |
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2000 |
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2000 |
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2000 |
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2000 |
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2000 |
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2000 |
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2000 |
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2000 |
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2000 |
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2000 |
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise | 2000 |
Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; | 2001 |
Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; | 2001 |
Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; | 2001 |
[Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme I | 2001 |
[Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme I | 2001 |
[Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme I | 2001 |
Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combine | 2001 |
Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combine | 2001 |
Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combine | 2001 |
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Doub | 2001 |
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Doub | 2001 |
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Doub | 2001 |
Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.
Topics: Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhi | 2002 |
Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.
Topics: Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhi | 2002 |
Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.
Topics: Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhi | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 2002 |
566 other studies available for anastrozole and Breast Neoplasms
| Article | Year |
|---|---|
Synthesis of 6- or 4-functionalized indoles via a reductive cyclization approach and evaluation as aromatase inhibitors.
Topics: Aromatase; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Gene Expression Regulation, Neoplastic | 2008 |
Synthesis of 6- or 4-functionalized indoles via a reductive cyclization approach and evaluation as aromatase inhibitors.
Topics: Aromatase; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Gene Expression Regulation, Neoplastic | 2008 |
Synthesis of 6- or 4-functionalized indoles via a reductive cyclization approach and evaluation as aromatase inhibitors.
Topics: Aromatase; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Gene Expression Regulation, Neoplastic | 2008 |
Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19).
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Binding Sites; Breast Neoplasms; Computer Si | 2010 |
Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19).
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Binding Sites; Breast Neoplasms; Computer Si | 2010 |
Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19).
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Binding Sites; Breast Neoplasms; Computer Si | 2010 |
Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health.
Topics: Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Discovery; Endometriosi | 2015 |
Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health.
Topics: Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Discovery; Endometriosi | 2015 |
Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health.
Topics: Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Discovery; Endometriosi | 2015 |
[A Case of Advanced Late Recurrence of Hormone Receptor Positive Breast Cancer Successfully Treated with Abemaciclib and Anastrozole].
Topics: Aged; Aminopyridines; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Benzimidaz | 2021 |
[A Case of Advanced Late Recurrence of Hormone Receptor Positive Breast Cancer Successfully Treated with Abemaciclib and Anastrozole].
Topics: Aged; Aminopyridines; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Benzimidaz | 2021 |
[A Case of Advanced Late Recurrence of Hormone Receptor Positive Breast Cancer Successfully Treated with Abemaciclib and Anastrozole].
Topics: Aged; Aminopyridines; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Benzimidaz | 2021 |
Anastrozole Regulates Fatty Acid Synthase in Breast Cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cell Line, Tum | 2022 |
Anastrozole Regulates Fatty Acid Synthase in Breast Cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cell Line, Tum | 2022 |
Anastrozole Regulates Fatty Acid Synthase in Breast Cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cell Line, Tum | 2022 |
Cutaneous metastasis of occult breast cancer: a case report.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Breast Neoplasms; Female; Humans; Progno | 2021 |
Cutaneous metastasis of occult breast cancer: a case report.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Breast Neoplasms; Female; Humans; Progno | 2021 |
Cutaneous metastasis of occult breast cancer: a case report.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Breast Neoplasms; Female; Humans; Progno | 2021 |
Ovarian tissue cryopreservation in a patient with breast cancer during pregnancy: a case report.
Topics: Adult; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplast | 2021 |
Ovarian tissue cryopreservation in a patient with breast cancer during pregnancy: a case report.
Topics: Adult; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplast | 2021 |
Ovarian tissue cryopreservation in a patient with breast cancer during pregnancy: a case report.
Topics: Adult; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplast | 2021 |
Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients.
Topics: Anastrozole; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogens; Estrone; Femal | 2022 |
Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients.
Topics: Anastrozole; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogens; Estrone; Femal | 2022 |
Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients.
Topics: Anastrozole; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogens; Estrone; Femal | 2022 |
Design and synthesis of marine sesterterpene analogues as novel estrogen receptor α degraders for breast cancer treatment.
Topics: Anastrozole; Antineoplastic Agents; Apoptosis; Biological Products; Breast Neoplasms; Cell Prolifera | 2022 |
Design and synthesis of marine sesterterpene analogues as novel estrogen receptor α degraders for breast cancer treatment.
Topics: Anastrozole; Antineoplastic Agents; Apoptosis; Biological Products; Breast Neoplasms; Cell Prolifera | 2022 |
Design and synthesis of marine sesterterpene analogues as novel estrogen receptor α degraders for breast cancer treatment.
Topics: Anastrozole; Antineoplastic Agents; Apoptosis; Biological Products; Breast Neoplasms; Cell Prolifera | 2022 |
[A Case of Late Recurrence of Breast Cancer with Chest Wall Recurrence 43 Years after Surgery].
Topics: Adult; Aged, 80 and over; Anastrozole; Breast Neoplasms; Female; Humans; Mastectomy; Neoplasm Recurr | 2021 |
[A Case of Late Recurrence of Breast Cancer with Chest Wall Recurrence 43 Years after Surgery].
Topics: Adult; Aged, 80 and over; Anastrozole; Breast Neoplasms; Female; Humans; Mastectomy; Neoplasm Recurr | 2021 |
[A Case of Late Recurrence of Breast Cancer with Chest Wall Recurrence 43 Years after Surgery].
Topics: Adult; Aged, 80 and over; Anastrozole; Breast Neoplasms; Female; Humans; Mastectomy; Neoplasm Recurr | 2021 |
Health-related quality of life among elderly breast cancer patients treated with adjuvant endocrine therapy: a U.S Medicare population-based study.
Topics: Aged; Anastrozole; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Sectional Studies; Female; Humans | 2022 |
Health-related quality of life among elderly breast cancer patients treated with adjuvant endocrine therapy: a U.S Medicare population-based study.
Topics: Aged; Anastrozole; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Sectional Studies; Female; Humans | 2022 |
Health-related quality of life among elderly breast cancer patients treated with adjuvant endocrine therapy: a U.S Medicare population-based study.
Topics: Aged; Anastrozole; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Sectional Studies; Female; Humans | 2022 |
Approaches for Enhanced Extrapolation of Long-Term Survival Outcomes Using Electronic Health Records of Patients With Cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Cohort Studies; Databases, Factual; Elec | 2022 |
Approaches for Enhanced Extrapolation of Long-Term Survival Outcomes Using Electronic Health Records of Patients With Cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Cohort Studies; Databases, Factual; Elec | 2022 |
Approaches for Enhanced Extrapolation of Long-Term Survival Outcomes Using Electronic Health Records of Patients With Cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Cohort Studies; Databases, Factual; Elec | 2022 |
Simultaneous Method Development and Validation of Anastrozole Along with Piperine: Degradation Studies and Degradants Characterization Using LC-QTOF-ESI-MS Along with In-silico ADMET Predictions.
Topics: Alkaloids; Anastrozole; Benzodioxoles; Breast Neoplasms; Drug Stability; Female; Humans; Piperidines | 2022 |
Simultaneous Method Development and Validation of Anastrozole Along with Piperine: Degradation Studies and Degradants Characterization Using LC-QTOF-ESI-MS Along with In-silico ADMET Predictions.
Topics: Alkaloids; Anastrozole; Benzodioxoles; Breast Neoplasms; Drug Stability; Female; Humans; Piperidines | 2022 |
Simultaneous Method Development and Validation of Anastrozole Along with Piperine: Degradation Studies and Degradants Characterization Using LC-QTOF-ESI-MS Along with In-silico ADMET Predictions.
Topics: Alkaloids; Anastrozole; Benzodioxoles; Breast Neoplasms; Drug Stability; Female; Humans; Piperidines | 2022 |
Anastrozole-related dermatitis with mainly unilateral distribution.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dermatitis; Female; Humans; Nitriles | 2022 |
Anastrozole-related dermatitis with mainly unilateral distribution.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dermatitis; Female; Humans; Nitriles | 2022 |
Anastrozole-related dermatitis with mainly unilateral distribution.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dermatitis; Female; Humans; Nitriles | 2022 |
Combination Vistusertib and Anastrozole Shows Benefit in Endometrial Cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Benzamides; Breast Neoplasms; Endometrial Neoplasms; F | 2022 |
Combination Vistusertib and Anastrozole Shows Benefit in Endometrial Cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Benzamides; Breast Neoplasms; Endometrial Neoplasms; F | 2022 |
Combination Vistusertib and Anastrozole Shows Benefit in Endometrial Cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Benzamides; Breast Neoplasms; Endometrial Neoplasms; F | 2022 |
Topics: Anastrozole; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Carica; Catec | 2022 |
Topics: Anastrozole; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Carica; Catec | 2022 |
Topics: Anastrozole; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Carica; Catec | 2022 |
Anastrozole and related glucuronic acid conjugate are electrophilic species.
Topics: Anastrozole; Animals; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Female; Glucuronic A | 2022 |
Anastrozole and related glucuronic acid conjugate are electrophilic species.
Topics: Anastrozole; Animals; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Female; Glucuronic A | 2022 |
Anastrozole and related glucuronic acid conjugate are electrophilic species.
Topics: Anastrozole; Animals; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Female; Glucuronic A | 2022 |
Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; F | 2022 |
Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; F | 2022 |
Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; F | 2022 |
Trajectories of neuropsychological symptom burden in postmenopausal women prescribed anastrozole for early-stage breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cohort Studies | 2022 |
Trajectories of neuropsychological symptom burden in postmenopausal women prescribed anastrozole for early-stage breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cohort Studies | 2022 |
Trajectories of neuropsychological symptom burden in postmenopausal women prescribed anastrozole for early-stage breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cohort Studies | 2022 |
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
Topics: Adenosine Triphosphatases; Anastrozole; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cardiac | 2022 |
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
Topics: Adenosine Triphosphatases; Anastrozole; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cardiac | 2022 |
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
Topics: Adenosine Triphosphatases; Anastrozole; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cardiac | 2022 |
Ribosome biogenesis-based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; En | 2023 |
Ribosome biogenesis-based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; En | 2023 |
Ribosome biogenesis-based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; En | 2023 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
Cost-Effectiveness Analysis of Ultra-Hypofractionated Whole Breast Radiation Therapy Alone Versus Hormone Therapy Alone or Combined Treatment for Low-Risk ER-Positive Early Stage Breast Cancer in Women Aged 65 Years and Older.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Breast; Breast Neoplasms; Cost-Benefit Analysis; Cost-Effec | 2023 |
Cost-Effectiveness Analysis of Ultra-Hypofractionated Whole Breast Radiation Therapy Alone Versus Hormone Therapy Alone or Combined Treatment for Low-Risk ER-Positive Early Stage Breast Cancer in Women Aged 65 Years and Older.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Breast; Breast Neoplasms; Cost-Benefit Analysis; Cost-Effec | 2023 |
Cost-Effectiveness Analysis of Ultra-Hypofractionated Whole Breast Radiation Therapy Alone Versus Hormone Therapy Alone or Combined Treatment for Low-Risk ER-Positive Early Stage Breast Cancer in Women Aged 65 Years and Older.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Breast; Breast Neoplasms; Cost-Benefit Analysis; Cost-Effec | 2023 |
[A real-world study of the effects of endocrine therapy on liver function in breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Bilirubin; Breast Neoplasms; Fema | 2023 |
[A real-world study of the effects of endocrine therapy on liver function in breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Bilirubin; Breast Neoplasms; Fema | 2023 |
[A real-world study of the effects of endocrine therapy on liver function in breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Bilirubin; Breast Neoplasms; Fema | 2023 |
Variations in Incidence of Trigger Finger and Response to Corticosteroid Injection after Aromatase Inhibitor Therapy for Breast Cancer.
Topics: Adrenal Cortex Hormones; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Incide | 2023 |
Variations in Incidence of Trigger Finger and Response to Corticosteroid Injection after Aromatase Inhibitor Therapy for Breast Cancer.
Topics: Adrenal Cortex Hormones; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Incide | 2023 |
Variations in Incidence of Trigger Finger and Response to Corticosteroid Injection after Aromatase Inhibitor Therapy for Breast Cancer.
Topics: Adrenal Cortex Hormones; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Incide | 2023 |
An experience of the intervention effect of individualized on the rehabilitation exercise on bone and joint pain symptoms caused by anastrozole.
Topics: Anastrozole; Arthralgia; Bone and Bones; Breast Neoplasms; Exercise Therapy; Female; Humans | 2023 |
An experience of the intervention effect of individualized on the rehabilitation exercise on bone and joint pain symptoms caused by anastrozole.
Topics: Anastrozole; Arthralgia; Bone and Bones; Breast Neoplasms; Exercise Therapy; Female; Humans | 2023 |
An experience of the intervention effect of individualized on the rehabilitation exercise on bone and joint pain symptoms caused by anastrozole.
Topics: Anastrozole; Arthralgia; Bone and Bones; Breast Neoplasms; Exercise Therapy; Female; Humans | 2023 |
Adherence to Adjuvant Endocrine Therapy and Survival Among Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Medicare; Nitr | 2023 |
Adherence to Adjuvant Endocrine Therapy and Survival Among Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Medicare; Nitr | 2023 |
Adherence to Adjuvant Endocrine Therapy and Survival Among Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Medicare; Nitr | 2023 |
Optic Neuritis as a Consequence of Long-Term Medical Treatment Using Anastrozole: A Case Report.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Optic Neuritis; Vision Di | 2023 |
Optic Neuritis as a Consequence of Long-Term Medical Treatment Using Anastrozole: A Case Report.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Optic Neuritis; Vision Di | 2023 |
Optic Neuritis as a Consequence of Long-Term Medical Treatment Using Anastrozole: A Case Report.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Optic Neuritis; Vision Di | 2023 |
Virtual Screening for Identification of Dual Inhibitors against CDK4/6 and Aromatase Enzyme.
Topics: Anastrozole; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cyclin-Dependent Kinase 4; Enzyme In | 2023 |
Virtual Screening for Identification of Dual Inhibitors against CDK4/6 and Aromatase Enzyme.
Topics: Anastrozole; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cyclin-Dependent Kinase 4; Enzyme In | 2023 |
Virtual Screening for Identification of Dual Inhibitors against CDK4/6 and Aromatase Enzyme.
Topics: Anastrozole; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cyclin-Dependent Kinase 4; Enzyme In | 2023 |
[De-escalation in aromatase inhibitors prescription for menopausal women with positive hormonal receptors breast cancer].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2023 |
[De-escalation in aromatase inhibitors prescription for menopausal women with positive hormonal receptors breast cancer].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2023 |
[De-escalation in aromatase inhibitors prescription for menopausal women with positive hormonal receptors breast cancer].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2023 |
Overexpression of BQ323636.1 contributes to anastrozole resistance in AR+ve/ER+ve breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estrogens; Female; Humans; Signal Transduction | 2023 |
Overexpression of BQ323636.1 contributes to anastrozole resistance in AR+ve/ER+ve breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estrogens; Female; Humans; Signal Transduction | 2023 |
Overexpression of BQ323636.1 contributes to anastrozole resistance in AR+ve/ER+ve breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estrogens; Female; Humans; Signal Transduction | 2023 |
Effects of
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cytochrome P-450 CYP2C9; Cytochrome | 2023 |
Effects of
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cytochrome P-450 CYP2C9; Cytochrome | 2023 |
Effects of
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cytochrome P-450 CYP2C9; Cytochrome | 2023 |
Breast Tumor Cells Evade the Cytotoxic Action of Anastrozole, Aspirin, and Clopidogrel Cocktail.
Topics: Anastrozole; Animals; Antineoplastic Agents; Aspirin; Breast Neoplasms; Clopidogrel; Female; Humans; | 2023 |
Breast Tumor Cells Evade the Cytotoxic Action of Anastrozole, Aspirin, and Clopidogrel Cocktail.
Topics: Anastrozole; Animals; Antineoplastic Agents; Aspirin; Breast Neoplasms; Clopidogrel; Female; Humans; | 2023 |
Breast Tumor Cells Evade the Cytotoxic Action of Anastrozole, Aspirin, and Clopidogrel Cocktail.
Topics: Anastrozole; Animals; Antineoplastic Agents; Aspirin; Breast Neoplasms; Clopidogrel; Female; Humans; | 2023 |
Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial.
Topics: Anastrozole; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Patient Reported | 2023 |
Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial.
Topics: Anastrozole; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Patient Reported | 2023 |
Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial.
Topics: Anastrozole; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Patient Reported | 2023 |
Segmental Erythema Multiforme: An Unusual Drug Reaction to Anastrozole.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Drug Eruptions; Erythema Multiforme; Female; Hu | 2023 |
Segmental Erythema Multiforme: An Unusual Drug Reaction to Anastrozole.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Drug Eruptions; Erythema Multiforme; Female; Hu | 2023 |
Segmental Erythema Multiforme: An Unusual Drug Reaction to Anastrozole.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Drug Eruptions; Erythema Multiforme; Female; Hu | 2023 |
Anastrozole: Repurposed drug could prevent thousands of breast cancer cases.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 2023 |
Anastrozole: Repurposed drug could prevent thousands of breast cancer cases.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 2023 |
Anastrozole: Repurposed drug could prevent thousands of breast cancer cases.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 2023 |
Impact of chemotherapy on symptoms and symptom clusters in postmenopausal women with breast cancer prior to aromatase inhibitor therapy.
Topics: Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase | 2019 |
Impact of chemotherapy on symptoms and symptom clusters in postmenopausal women with breast cancer prior to aromatase inhibitor therapy.
Topics: Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase | 2019 |
Impact of chemotherapy on symptoms and symptom clusters in postmenopausal women with breast cancer prior to aromatase inhibitor therapy.
Topics: Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase | 2019 |
Breast Cancer Chemoprevention: A Practical Guide for the Primary Care Provider.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Decision Makin | 2020 |
Breast Cancer Chemoprevention: A Practical Guide for the Primary Care Provider.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Decision Makin | 2020 |
Breast Cancer Chemoprevention: A Practical Guide for the Primary Care Provider.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Decision Makin | 2020 |
Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC study.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Disease Pro | 2020 |
Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC study.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Disease Pro | 2020 |
Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC study.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Disease Pro | 2020 |
Carryover effects of aromatase inhibitors in prevention.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Humans; Receptors, Estrogen; Tamoxifen | 2020 |
Carryover effects of aromatase inhibitors in prevention.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Humans; Receptors, Estrogen; Tamoxifen | 2020 |
Carryover effects of aromatase inhibitors in prevention.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Humans; Receptors, Estrogen; Tamoxifen | 2020 |
First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Female; Follo | 2020 |
First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Female; Follo | 2020 |
First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Female; Follo | 2020 |
Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study.
Topics: Adult; Aged; Anastrozole; Breast Neoplasms; Cohort Studies; Drug Implants; Female; Humans; Incidence | 2019 |
Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study.
Topics: Adult; Aged; Anastrozole; Breast Neoplasms; Cohort Studies; Drug Implants; Female; Humans; Incidence | 2019 |
Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study.
Topics: Adult; Aged; Anastrozole; Breast Neoplasms; Cohort Studies; Drug Implants; Female; Humans; Incidence | 2019 |
Anastrozole-induced pulmonary cryptococcosis in a patient with early breast cancer: A case report.
Topics: Anastrozole; Breast Neoplasms; Cryptococcosis; Female; Humans; Lung Diseases, Fungal; Middle Aged | 2020 |
Anastrozole-induced pulmonary cryptococcosis in a patient with early breast cancer: A case report.
Topics: Anastrozole; Breast Neoplasms; Cryptococcosis; Female; Humans; Lung Diseases, Fungal; Middle Aged | 2020 |
Anastrozole-induced pulmonary cryptococcosis in a patient with early breast cancer: A case report.
Topics: Anastrozole; Breast Neoplasms; Cryptococcosis; Female; Humans; Lung Diseases, Fungal; Middle Aged | 2020 |
A new immunotherapy schedule in addition to first-line hormone therapy for metastatic breast cancer patients in a state of clinical benefit during hormone therapy.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neo | 2020 |
A new immunotherapy schedule in addition to first-line hormone therapy for metastatic breast cancer patients in a state of clinical benefit during hormone therapy.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neo | 2020 |
A new immunotherapy schedule in addition to first-line hormone therapy for metastatic breast cancer patients in a state of clinical benefit during hormone therapy.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neo | 2020 |
Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case | 2020 |
Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case | 2020 |
Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case | 2020 |
Medication Use to Reduce Risk of Breast Cancer.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Medicat | 2020 |
Medication Use to Reduce Risk of Breast Cancer.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Medicat | 2020 |
Medication Use to Reduce Risk of Breast Cancer.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Medicat | 2020 |
Combined Anastrozole and Antiplatelet Therapy Treatment Differentially Promotes Breast Cancer Cell Survival.
Topics: Anastrozole; Annexin A5; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Humans; MCF-7 | 2020 |
Combined Anastrozole and Antiplatelet Therapy Treatment Differentially Promotes Breast Cancer Cell Survival.
Topics: Anastrozole; Annexin A5; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Humans; MCF-7 | 2020 |
Combined Anastrozole and Antiplatelet Therapy Treatment Differentially Promotes Breast Cancer Cell Survival.
Topics: Anastrozole; Annexin A5; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Humans; MCF-7 | 2020 |
Leptin Signaling Contributes to Aromatase Inhibitor Resistant Breast Cancer Cell Growth and Activation of Macrophages.
Topics: Anastrozole; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Movement; Cell Proliferation; D | 2020 |
Leptin Signaling Contributes to Aromatase Inhibitor Resistant Breast Cancer Cell Growth and Activation of Macrophages.
Topics: Anastrozole; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Movement; Cell Proliferation; D | 2020 |
Leptin Signaling Contributes to Aromatase Inhibitor Resistant Breast Cancer Cell Growth and Activation of Macrophages.
Topics: Anastrozole; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Movement; Cell Proliferation; D | 2020 |
[Adjuvant radiotherapy in low-risk breast cancer: long-term results of the ABCSG-8A trial].
Topics: Anastrozole; Breast Neoplasms; Humans; Radiotherapy, Adjuvant; Tamoxifen | 2020 |
[Adjuvant radiotherapy in low-risk breast cancer: long-term results of the ABCSG-8A trial].
Topics: Anastrozole; Breast Neoplasms; Humans; Radiotherapy, Adjuvant; Tamoxifen | 2020 |
[Adjuvant radiotherapy in low-risk breast cancer: long-term results of the ABCSG-8A trial].
Topics: Anastrozole; Breast Neoplasms; Humans; Radiotherapy, Adjuvant; Tamoxifen | 2020 |
The effects of adjuvant hormonotherapy on tear functions in patients with breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; F | 2020 |
The effects of adjuvant hormonotherapy on tear functions in patients with breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; F | 2020 |
The effects of adjuvant hormonotherapy on tear functions in patients with breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; F | 2020 |
A case of delayed-onset scarring alopecia in a 75-year-old woman.
Topics: Aged; Alopecia; Anastrozole; Aromatase Inhibitors; Biopsy; Bone Density Conservation Agents; Breast | 2020 |
A case of delayed-onset scarring alopecia in a 75-year-old woman.
Topics: Aged; Alopecia; Anastrozole; Aromatase Inhibitors; Biopsy; Bone Density Conservation Agents; Breast | 2020 |
A case of delayed-onset scarring alopecia in a 75-year-old woman.
Topics: Aged; Alopecia; Anastrozole; Aromatase Inhibitors; Biopsy; Bone Density Conservation Agents; Breast | 2020 |
Representation of CYP3A4, CYP3A5 and UGT1A4 Polymorphisms within Croatian Breast Cancer Patients' Population.
Topics: Aged; Alleles; Anastrozole; Breast Neoplasms; Croatia; Cytochrome P-450 CYP3A; Female; Genetics, Pop | 2020 |
Representation of CYP3A4, CYP3A5 and UGT1A4 Polymorphisms within Croatian Breast Cancer Patients' Population.
Topics: Aged; Alleles; Anastrozole; Breast Neoplasms; Croatia; Cytochrome P-450 CYP3A; Female; Genetics, Pop | 2020 |
Representation of CYP3A4, CYP3A5 and UGT1A4 Polymorphisms within Croatian Breast Cancer Patients' Population.
Topics: Aged; Alleles; Anastrozole; Breast Neoplasms; Croatia; Cytochrome P-450 CYP3A; Female; Genetics, Pop | 2020 |
Structural Recognition and Binding Pattern Analysis of Human Topoisomerase II Alpha with Steroidal Drugs: In Silico Study to Switchover the Cancer Treatment.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Computer | 2020 |
Structural Recognition and Binding Pattern Analysis of Human Topoisomerase II Alpha with Steroidal Drugs: In Silico Study to Switchover the Cancer Treatment.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Computer | 2020 |
Structural Recognition and Binding Pattern Analysis of Human Topoisomerase II Alpha with Steroidal Drugs: In Silico Study to Switchover the Cancer Treatment.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Computer | 2020 |
Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neopl | 2020 |
Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neopl | 2020 |
Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neopl | 2020 |
Highlights of the San Antonio Breast Cancer Symposium 2019 Part 2: the challenges of tumor heterogeneity.
Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2020 |
Highlights of the San Antonio Breast Cancer Symposium 2019 Part 2: the challenges of tumor heterogeneity.
Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2020 |
Highlights of the San Antonio Breast Cancer Symposium 2019 Part 2: the challenges of tumor heterogeneity.
Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2020 |
[A prospective study of bone loss in early stage postmenopausal breast cancer treated with aromatase inhibitors].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Humans; Letrozole | 2020 |
[A prospective study of bone loss in early stage postmenopausal breast cancer treated with aromatase inhibitors].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Humans; Letrozole | 2020 |
[A prospective study of bone loss in early stage postmenopausal breast cancer treated with aromatase inhibitors].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Humans; Letrozole | 2020 |
The impact of the introduction of generic aromatase inhibitors on adherence to hormonal therapy over the full course of 5-year treatment for breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Drugs, Generic; Female | 2020 |
The impact of the introduction of generic aromatase inhibitors on adherence to hormonal therapy over the full course of 5-year treatment for breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Drugs, Generic; Female | 2020 |
The impact of the introduction of generic aromatase inhibitors on adherence to hormonal therapy over the full course of 5-year treatment for breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Drugs, Generic; Female | 2020 |
The Effect of Theracurmin on Cognitive Function in an Older Patient with Chemobrain.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cognition; Cognition Disorders | 2020 |
The Effect of Theracurmin on Cognitive Function in an Older Patient with Chemobrain.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cognition; Cognition Disorders | 2020 |
The Effect of Theracurmin on Cognitive Function in an Older Patient with Chemobrain.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cognition; Cognition Disorders | 2020 |
[Promising long-term results on the use of anastrozole for prevention of breast cancer in postmenopausal high-risk patients].
Topics: Anastrozole; Breast Neoplasms; Humans; Nitriles; Postmenopause; Tamoxifen | 2020 |
[Promising long-term results on the use of anastrozole for prevention of breast cancer in postmenopausal high-risk patients].
Topics: Anastrozole; Breast Neoplasms; Humans; Nitriles; Postmenopause; Tamoxifen | 2020 |
[Promising long-term results on the use of anastrozole for prevention of breast cancer in postmenopausal high-risk patients].
Topics: Anastrozole; Breast Neoplasms; Humans; Nitriles; Postmenopause; Tamoxifen | 2020 |
Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase; Aromatase Inhibitors; Arthralgia; Biomarkers | 2020 |
Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase; Aromatase Inhibitors; Arthralgia; Biomarkers | 2020 |
Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase; Aromatase Inhibitors; Arthralgia; Biomarkers | 2020 |
Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer.
Topics: Adult; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrone; Female; Genetic Pred | 2021 |
Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer.
Topics: Adult; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrone; Female; Genetic Pred | 2021 |
Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer.
Topics: Adult; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrone; Female; Genetic Pred | 2021 |
Breast Cancer Risk-Reducing Medications.
Topics: Adult; Age Factors; Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Brea | 2020 |
Breast Cancer Risk-Reducing Medications.
Topics: Adult; Age Factors; Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Brea | 2020 |
Breast Cancer Risk-Reducing Medications.
Topics: Adult; Age Factors; Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Brea | 2020 |
Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Drug Costs; D | 2020 |
Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Drug Costs; D | 2020 |
Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Drug Costs; D | 2020 |
Exemestane induced cholestatic liver injury - A case report.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemical and Drug Induced | 2021 |
Exemestane induced cholestatic liver injury - A case report.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemical and Drug Induced | 2021 |
Exemestane induced cholestatic liver injury - A case report.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemical and Drug Induced | 2021 |
Molecular Drivers of Onco
Topics: Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurr | 2021 |
Molecular Drivers of Onco
Topics: Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurr | 2021 |
Molecular Drivers of Onco
Topics: Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurr | 2021 |
Urinary Incontinence and Overactive Bladder Symptoms in Women with Breast Cancer Being Treated with Oral Hormone Therapy.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2020 |
Urinary Incontinence and Overactive Bladder Symptoms in Women with Breast Cancer Being Treated with Oral Hormone Therapy.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2020 |
Urinary Incontinence and Overactive Bladder Symptoms in Women with Breast Cancer Being Treated with Oral Hormone Therapy.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2020 |
Switching of Hormone Therapies in Breast Cancer Women.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Sectional Studies; Dise | 2021 |
Switching of Hormone Therapies in Breast Cancer Women.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Sectional Studies; Dise | 2021 |
Switching of Hormone Therapies in Breast Cancer Women.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Sectional Studies; Dise | 2021 |
[Local Recurrence of Breast Cancer Eight Years after Mastectomy-A Case Report].
Topics: Aged; Anastrozole; Breast Neoplasms; Female; Humans; Letrozole; Mastectomy; Neoplasm Recurrence, Loc | 2020 |
[Local Recurrence of Breast Cancer Eight Years after Mastectomy-A Case Report].
Topics: Aged; Anastrozole; Breast Neoplasms; Female; Humans; Letrozole; Mastectomy; Neoplasm Recurrence, Loc | 2020 |
[Local Recurrence of Breast Cancer Eight Years after Mastectomy-A Case Report].
Topics: Aged; Anastrozole; Breast Neoplasms; Female; Humans; Letrozole; Mastectomy; Neoplasm Recurrence, Loc | 2020 |
Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial.
Topics: Absorptiometry, Photon; Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Cas | 2021 |
Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial.
Topics: Absorptiometry, Photon; Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Cas | 2021 |
Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial.
Topics: Absorptiometry, Photon; Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Cas | 2021 |
Vitamin D Compounds PRI-2191 and PRI-2205 Enhance Anastrozole Activity in Human Breast Cancer Models.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Calcitriol; | 2021 |
Vitamin D Compounds PRI-2191 and PRI-2205 Enhance Anastrozole Activity in Human Breast Cancer Models.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Calcitriol; | 2021 |
Vitamin D Compounds PRI-2191 and PRI-2205 Enhance Anastrozole Activity in Human Breast Cancer Models.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Calcitriol; | 2021 |
Dual treatment of acromegaly and hormone-receptor-positive breast cancer with tamoxifen: a case report.
Topics: Acromegaly; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Ch | 2021 |
Dual treatment of acromegaly and hormone-receptor-positive breast cancer with tamoxifen: a case report.
Topics: Acromegaly; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Ch | 2021 |
Dual treatment of acromegaly and hormone-receptor-positive breast cancer with tamoxifen: a case report.
Topics: Acromegaly; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Ch | 2021 |
Antiplatelet Therapy Combined with Anastrozole Induces Features of Partial EMT in Breast Cancer Cells and Fails to Mitigate Breast-Cancer Induced Hypercoagulation.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aspirin; Blood Coagulation; Breast Neoplasms; C | 2021 |
Antiplatelet Therapy Combined with Anastrozole Induces Features of Partial EMT in Breast Cancer Cells and Fails to Mitigate Breast-Cancer Induced Hypercoagulation.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aspirin; Blood Coagulation; Breast Neoplasms; C | 2021 |
Antiplatelet Therapy Combined with Anastrozole Induces Features of Partial EMT in Breast Cancer Cells and Fails to Mitigate Breast-Cancer Induced Hypercoagulation.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aspirin; Blood Coagulation; Breast Neoplasms; C | 2021 |
The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Genetic Testing; Human | 2021 |
The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Genetic Testing; Human | 2021 |
The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Genetic Testing; Human | 2021 |
Differential biological effects of aromatase inhibitors: Apoptosis, autophagy, senescence and modulation of the hormonal status in breast cancer cells.
Topics: Anastrozole; Androstadienes; Apoptosis; Aromatase Inhibitors; Autophagy; Biomarkers; Breast Neoplasm | 2021 |
Differential biological effects of aromatase inhibitors: Apoptosis, autophagy, senescence and modulation of the hormonal status in breast cancer cells.
Topics: Anastrozole; Androstadienes; Apoptosis; Aromatase Inhibitors; Autophagy; Biomarkers; Breast Neoplasm | 2021 |
Differential biological effects of aromatase inhibitors: Apoptosis, autophagy, senescence and modulation of the hormonal status in breast cancer cells.
Topics: Anastrozole; Androstadienes; Apoptosis; Aromatase Inhibitors; Autophagy; Biomarkers; Breast Neoplasm | 2021 |
RE: Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 2022 |
RE: Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 2022 |
RE: Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 2022 |
Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole?
Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Biomarkers; Body Mass Index; Breast Neop | 2017 |
Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole?
Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Biomarkers; Body Mass Index; Breast Neop | 2017 |
Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole?
Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Biomarkers; Body Mass Index; Breast Neop | 2017 |
A novel long-acting biodegradable depot formulation of anastrozole for breast cancer therapy.
Topics: Absorbable Implants; Anastrozole; Animals; Breast Neoplasms; Drug Implants; Female; Humans; Lactic A | 2017 |
A novel long-acting biodegradable depot formulation of anastrozole for breast cancer therapy.
Topics: Absorbable Implants; Anastrozole; Animals; Breast Neoplasms; Drug Implants; Female; Humans; Lactic A | 2017 |
A novel long-acting biodegradable depot formulation of anastrozole for breast cancer therapy.
Topics: Absorbable Implants; Anastrozole; Animals; Breast Neoplasms; Drug Implants; Female; Humans; Lactic A | 2017 |
Two cases of endometrial cancer arising from adenomyosis during aromatase inhibitors therapy after mastectomy.
Topics: Adenocarcinoma; Adenomyosis; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neopla | 2017 |
Two cases of endometrial cancer arising from adenomyosis during aromatase inhibitors therapy after mastectomy.
Topics: Adenocarcinoma; Adenomyosis; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neopla | 2017 |
Two cases of endometrial cancer arising from adenomyosis during aromatase inhibitors therapy after mastectomy.
Topics: Adenocarcinoma; Adenomyosis; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neopla | 2017 |
Avoidance of Negative Results in Adjuvant Endocrine Therapy Trials for Estrogen Receptor-Positive Breast Cancer.
Topics: Anastrozole; Breast Neoplasms; Humans; Letrozole; Negative Results; Postmenopause; Receptors, Estrog | 2017 |
Avoidance of Negative Results in Adjuvant Endocrine Therapy Trials for Estrogen Receptor-Positive Breast Cancer.
Topics: Anastrozole; Breast Neoplasms; Humans; Letrozole; Negative Results; Postmenopause; Receptors, Estrog | 2017 |
Avoidance of Negative Results in Adjuvant Endocrine Therapy Trials for Estrogen Receptor-Positive Breast Cancer.
Topics: Anastrozole; Breast Neoplasms; Humans; Letrozole; Negative Results; Postmenopause; Receptors, Estrog | 2017 |
Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Breast | 2017 |
Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Breast | 2017 |
Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Breast | 2017 |
Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; China; Cost-Benefit Analysis; Drug C | 2017 |
Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; China; Cost-Benefit Analysis; Drug C | 2017 |
Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; China; Cost-Benefit Analysis; Drug C | 2017 |
Anastrozole-induced Autoimmune Hepatitis: A Rare Complication of Breast Cancer Therapy.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Biopsy; Breast Neoplasms; Female; Hepatitis, Autoimmune; Hu | 2017 |
Anastrozole-induced Autoimmune Hepatitis: A Rare Complication of Breast Cancer Therapy.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Biopsy; Breast Neoplasms; Female; Hepatitis, Autoimmune; Hu | 2017 |
Anastrozole-induced Autoimmune Hepatitis: A Rare Complication of Breast Cancer Therapy.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Biopsy; Breast Neoplasms; Female; Hepatitis, Autoimmune; Hu | 2017 |
Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival | 2018 |
Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival | 2018 |
Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival | 2018 |
Isolated Retinal Metastasis From Breast Cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined | 2017 |
Isolated Retinal Metastasis From Breast Cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined | 2017 |
Isolated Retinal Metastasis From Breast Cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined | 2017 |
Risk of ovarian function recovery should be considered when switching from treatment with adjuvant tamoxifen to aromatase inhibitor therapy in women with chemotherapy-induced amenorrhea.
Topics: Amenorrhea; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Huma | 2018 |
Risk of ovarian function recovery should be considered when switching from treatment with adjuvant tamoxifen to aromatase inhibitor therapy in women with chemotherapy-induced amenorrhea.
Topics: Amenorrhea; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Huma | 2018 |
Risk of ovarian function recovery should be considered when switching from treatment with adjuvant tamoxifen to aromatase inhibitor therapy in women with chemotherapy-induced amenorrhea.
Topics: Amenorrhea; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Huma | 2018 |
Comparison of Changes in the Lipid Profiles of Eastern Chinese Postmenopausal Women With Early-Stage Breast Cancer Treated With Different Aromatase Inhibitors: A Retrospective Study.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Asian People; Breast Neoplasms; China; Fema | 2018 |
Comparison of Changes in the Lipid Profiles of Eastern Chinese Postmenopausal Women With Early-Stage Breast Cancer Treated With Different Aromatase Inhibitors: A Retrospective Study.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Asian People; Breast Neoplasms; China; Fema | 2018 |
Comparison of Changes in the Lipid Profiles of Eastern Chinese Postmenopausal Women With Early-Stage Breast Cancer Treated With Different Aromatase Inhibitors: A Retrospective Study.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Asian People; Breast Neoplasms; China; Fema | 2018 |
Preparation of anastrozole loaded PEG-PLA nanoparticles: evaluation of apoptotic response of breast cancer cell lines.
Topics: Anastrozole; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Survival; Drug Delivery Systems | 2018 |
Preparation of anastrozole loaded PEG-PLA nanoparticles: evaluation of apoptotic response of breast cancer cell lines.
Topics: Anastrozole; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Survival; Drug Delivery Systems | 2018 |
Preparation of anastrozole loaded PEG-PLA nanoparticles: evaluation of apoptotic response of breast cancer cell lines.
Topics: Anastrozole; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Survival; Drug Delivery Systems | 2018 |
Hidden estrogen production from ovarian remnants leading to progression of disease in metastatic breast cancer.
Topics: Adult; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estrogens; Female; Humans; Liver Neoplas | 2018 |
Hidden estrogen production from ovarian remnants leading to progression of disease in metastatic breast cancer.
Topics: Adult; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estrogens; Female; Humans; Liver Neoplas | 2018 |
Hidden estrogen production from ovarian remnants leading to progression of disease in metastatic breast cancer.
Topics: Adult; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estrogens; Female; Humans; Liver Neoplas | 2018 |
The Impact of Perioperative Hormonal Therapy for Breast Cancer on Transverse Rectus Abdominis Myocutaneous Flap Abdominal Complications.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; | 2018 |
The Impact of Perioperative Hormonal Therapy for Breast Cancer on Transverse Rectus Abdominis Myocutaneous Flap Abdominal Complications.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; | 2018 |
The Impact of Perioperative Hormonal Therapy for Breast Cancer on Transverse Rectus Abdominis Myocutaneous Flap Abdominal Complications.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; | 2018 |
[A Case of Breast Cancer with Local Recurrence in the Reconstructed Breast Tissue].
Topics: Adult; Anastrozole; Breast Neoplasms; Female; Gonadotropin-Releasing Hormone; Hormone Replacement Th | 2017 |
[A Case of Breast Cancer with Local Recurrence in the Reconstructed Breast Tissue].
Topics: Adult; Anastrozole; Breast Neoplasms; Female; Gonadotropin-Releasing Hormone; Hormone Replacement Th | 2017 |
[A Case of Breast Cancer with Local Recurrence in the Reconstructed Breast Tissue].
Topics: Adult; Anastrozole; Breast Neoplasms; Female; Gonadotropin-Releasing Hormone; Hormone Replacement Th | 2017 |
[A Case of Stage IV Breast Cancer with Extensive Metastasis Successfully Treated with S-1 plus Anastrozole Therapy].
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Drug Co | 2017 |
[A Case of Stage IV Breast Cancer with Extensive Metastasis Successfully Treated with S-1 plus Anastrozole Therapy].
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Drug Co | 2017 |
[A Case of Stage IV Breast Cancer with Extensive Metastasis Successfully Treated with S-1 plus Anastrozole Therapy].
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Drug Co | 2017 |
Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Breast Neoplasms; Combined Modality The | 2018 |
Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Breast Neoplasms; Combined Modality The | 2018 |
Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Breast Neoplasms; Combined Modality The | 2018 |
Adjuvant aromatase inhibition: more options for patients.
Topics: Anastrozole; Androstadienes; Aromatase; Breast Neoplasms; Humans; Letrozole; Tamoxifen | 2018 |
Adjuvant aromatase inhibition: more options for patients.
Topics: Anastrozole; Androstadienes; Aromatase; Breast Neoplasms; Humans; Letrozole; Tamoxifen | 2018 |
Adjuvant aromatase inhibition: more options for patients.
Topics: Anastrozole; Androstadienes; Aromatase; Breast Neoplasms; Humans; Letrozole; Tamoxifen | 2018 |
Correlation of Serum Estradiol and Duration of Anastrazole Therapy with Treatment Related Adverse Effects Among Postmenopausal Breast Cancer Women: A Cross-sectional Study.
Topics: Aged; Anastrozole; Breast Neoplasms; Cross-Sectional Studies; Estradiol; Female; Hot Flashes; Humans | 2017 |
Correlation of Serum Estradiol and Duration of Anastrazole Therapy with Treatment Related Adverse Effects Among Postmenopausal Breast Cancer Women: A Cross-sectional Study.
Topics: Aged; Anastrozole; Breast Neoplasms; Cross-Sectional Studies; Estradiol; Female; Hot Flashes; Humans | 2017 |
Correlation of Serum Estradiol and Duration of Anastrazole Therapy with Treatment Related Adverse Effects Among Postmenopausal Breast Cancer Women: A Cross-sectional Study.
Topics: Aged; Anastrozole; Breast Neoplasms; Cross-Sectional Studies; Estradiol; Female; Hot Flashes; Humans | 2017 |
Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Case-Co | 2017 |
Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Case-Co | 2017 |
Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Case-Co | 2017 |
RE: "Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer," by Ding H., et al.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Estradiol; Fu | 2018 |
RE: "Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer," by Ding H., et al.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Estradiol; Fu | 2018 |
RE: "Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer," by Ding H., et al.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Estradiol; Fu | 2018 |
A Case of Psoriasis Complicated by Breast Cancer after Systemic Treatments Including Biologics.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biological Products; Breast Neoplasms; Female; H | 2018 |
A Case of Psoriasis Complicated by Breast Cancer after Systemic Treatments Including Biologics.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biological Products; Breast Neoplasms; Female; H | 2018 |
A Case of Psoriasis Complicated by Breast Cancer after Systemic Treatments Including Biologics.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biological Products; Breast Neoplasms; Female; H | 2018 |
Trajectories of Cognitive Function and Associated Phenotypic and Genotypic Factors in Breast Cancer.
Topics: Adult; Age Factors; Aged; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuva | 2018 |
Trajectories of Cognitive Function and Associated Phenotypic and Genotypic Factors in Breast Cancer.
Topics: Adult; Age Factors; Aged; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuva | 2018 |
Trajectories of Cognitive Function and Associated Phenotypic and Genotypic Factors in Breast Cancer.
Topics: Adult; Age Factors; Aged; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuva | 2018 |
Fulvestrant in management of hormone receptor-positive metastatic breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Dose-Respo | 2018 |
Fulvestrant in management of hormone receptor-positive metastatic breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Dose-Respo | 2018 |
Fulvestrant in management of hormone receptor-positive metastatic breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Dose-Respo | 2018 |
Association of Uveitis and Macular Edema With Anastrozole Therapy.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Lobular; Female; Fluorescein A | 2018 |
Association of Uveitis and Macular Edema With Anastrozole Therapy.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Lobular; Female; Fluorescein A | 2018 |
Association of Uveitis and Macular Edema With Anastrozole Therapy.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Lobular; Female; Fluorescein A | 2018 |
Radiation-induced morphea-a rare but severe late effect of adjuvant breast irradiation : Case report and review of the literature.
Topics: Aged; Aminopyridines; Anastrozole; Benzimidazoles; Biopsy; Breast; Breast Neoplasms; Combined Modali | 2018 |
Radiation-induced morphea-a rare but severe late effect of adjuvant breast irradiation : Case report and review of the literature.
Topics: Aged; Aminopyridines; Anastrozole; Benzimidazoles; Biopsy; Breast; Breast Neoplasms; Combined Modali | 2018 |
Radiation-induced morphea-a rare but severe late effect of adjuvant breast irradiation : Case report and review of the literature.
Topics: Aged; Aminopyridines; Anastrozole; Benzimidazoles; Biopsy; Breast; Breast Neoplasms; Combined Modali | 2018 |
[Evaluation of Patient Adherence to Anastrozole Therapy for Breast Cancer].
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Pro | 2018 |
[Evaluation of Patient Adherence to Anastrozole Therapy for Breast Cancer].
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Pro | 2018 |
[Evaluation of Patient Adherence to Anastrozole Therapy for Breast Cancer].
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Pro | 2018 |
Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case | 2018 |
Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case | 2018 |
Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case | 2018 |
Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.
Topics: Age of Onset; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adj | 2018 |
Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.
Topics: Age of Onset; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adj | 2018 |
Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.
Topics: Age of Onset; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adj | 2018 |
Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2019 |
Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2019 |
Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2019 |
[Follicle-Stimulating Hormone and Estradiol Levels in Japanese Women Treated with Toremifene and Anastrozole for Two Years - A Retrospective Analysis of Data from a Prospective Randomized Trial].
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Female; Follicle Stimulating Hormone | 2018 |
[Follicle-Stimulating Hormone and Estradiol Levels in Japanese Women Treated with Toremifene and Anastrozole for Two Years - A Retrospective Analysis of Data from a Prospective Randomized Trial].
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Female; Follicle Stimulating Hormone | 2018 |
[Follicle-Stimulating Hormone and Estradiol Levels in Japanese Women Treated with Toremifene and Anastrozole for Two Years - A Retrospective Analysis of Data from a Prospective Randomized Trial].
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Female; Follicle Stimulating Hormone | 2018 |
Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2.
Topics: Alkaline Phosphatase; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chromosomes, Human, Pair | 2019 |
Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2.
Topics: Alkaline Phosphatase; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chromosomes, Human, Pair | 2019 |
Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2.
Topics: Alkaline Phosphatase; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chromosomes, Human, Pair | 2019 |
Association of Crystalline Retinopathy With Anastrozole.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; | 2019 |
Association of Crystalline Retinopathy With Anastrozole.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; | 2019 |
Association of Crystalline Retinopathy With Anastrozole.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; | 2019 |
Breast cancer cell-induced platelet activation is compounded by tamoxifen and anastrozole in vitro.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Blood Platelets; Breast Neoplasms; Cell Communi | 2019 |
Breast cancer cell-induced platelet activation is compounded by tamoxifen and anastrozole in vitro.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Blood Platelets; Breast Neoplasms; Cell Communi | 2019 |
Breast cancer cell-induced platelet activation is compounded by tamoxifen and anastrozole in vitro.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Blood Platelets; Breast Neoplasms; Cell Communi | 2019 |
Patterns of endocrine therapy in a national cohort of early stage HER2-positive breast cancer patients.
Topics: Adult; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immun | 2019 |
Patterns of endocrine therapy in a national cohort of early stage HER2-positive breast cancer patients.
Topics: Adult; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immun | 2019 |
Patterns of endocrine therapy in a national cohort of early stage HER2-positive breast cancer patients.
Topics: Adult; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immun | 2019 |
Fulvestrant plus anastrozole for metastatic breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; | 2019 |
Fulvestrant plus anastrozole for metastatic breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; | 2019 |
Fulvestrant plus anastrozole for metastatic breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; | 2019 |
Fulvestrant enables better outcomes.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Fulvestrant; Humans | 2019 |
Fulvestrant enables better outcomes.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Fulvestrant; Humans | 2019 |
Fulvestrant enables better outcomes.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Fulvestrant; Humans | 2019 |
Mammary adipose stromal cells derived from obese women reduce sensitivity to the aromatase inhibitor anastrazole in an organotypic breast model.
Topics: Adipocytes; Anastrozole; Aromatase Inhibitors; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Prol | 2019 |
Mammary adipose stromal cells derived from obese women reduce sensitivity to the aromatase inhibitor anastrazole in an organotypic breast model.
Topics: Adipocytes; Anastrozole; Aromatase Inhibitors; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Prol | 2019 |
Mammary adipose stromal cells derived from obese women reduce sensitivity to the aromatase inhibitor anastrazole in an organotypic breast model.
Topics: Adipocytes; Anastrozole; Aromatase Inhibitors; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Prol | 2019 |
Radiation Therapy Without Hormone Therapy for Women Age 70 or Above with Low-Risk Early Breast Cancer: A Microsimulation.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2019 |
Radiation Therapy Without Hormone Therapy for Women Age 70 or Above with Low-Risk Early Breast Cancer: A Microsimulation.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2019 |
Radiation Therapy Without Hormone Therapy for Women Age 70 or Above with Low-Risk Early Breast Cancer: A Microsimulation.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2019 |
Long-Term Survival and Complete Response to
Topics: Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast; Breast Neoplasms; Disease-Free Surviva | 2019 |
Long-Term Survival and Complete Response to
Topics: Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast; Breast Neoplasms; Disease-Free Surviva | 2019 |
Long-Term Survival and Complete Response to
Topics: Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast; Breast Neoplasms; Disease-Free Surviva | 2019 |
[A case of crescentic glomerulonephritis developed under oral anastrozole treatment].
Topics: Administration, Oral; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Breast Neoplasms; | 2013 |
[A case of crescentic glomerulonephritis developed under oral anastrozole treatment].
Topics: Administration, Oral; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Breast Neoplasms; | 2013 |
[A case of crescentic glomerulonephritis developed under oral anastrozole treatment].
Topics: Administration, Oral; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Breast Neoplasms; | 2013 |
Anastrozole-associated joint pain and other symptoms in patients with breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Breast Neoplasms; Cohort Studies; Fe | 2013 |
Anastrozole-associated joint pain and other symptoms in patients with breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Breast Neoplasms; Cohort Studies; Fe | 2013 |
Anastrozole-associated joint pain and other symptoms in patients with breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Breast Neoplasms; Cohort Studies; Fe | 2013 |
Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2013 |
Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2013 |
Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2013 |
Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Biopsy; Breast; Breast Neoplasms; Cluster Analysis; Drug Re | 2013 |
Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Biopsy; Breast; Breast Neoplasms; Cluster Analysis; Drug Re | 2013 |
Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Biopsy; Breast; Breast Neoplasms; Cluster Analysis; Drug Re | 2013 |
[Three patients with local recurrence of ER-positive breast cancer for whom anastrozole was clinically effective].
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Breast Neoplasms; Fem | 2013 |
[Three patients with local recurrence of ER-positive breast cancer for whom anastrozole was clinically effective].
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Breast Neoplasms; Fem | 2013 |
[Three patients with local recurrence of ER-positive breast cancer for whom anastrozole was clinically effective].
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Breast Neoplasms; Fem | 2013 |
Effect of selumetinib on the growth of anastrozole-resistant tumors.
Topics: Anastrozole; Androstenedione; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chem | 2013 |
Effect of selumetinib on the growth of anastrozole-resistant tumors.
Topics: Anastrozole; Androstenedione; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chem | 2013 |
Effect of selumetinib on the growth of anastrozole-resistant tumors.
Topics: Anastrozole; Androstenedione; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chem | 2013 |
Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tum | 2013 |
Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tum | 2013 |
Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tum | 2013 |
[Therapy concept: herceptin in combination with arimidex].
Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brea | 2002 |
[Therapy concept: herceptin in combination with arimidex].
Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brea | 2002 |
[Therapy concept: herceptin in combination with arimidex].
Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brea | 2002 |
Effect of aromatase inhibitors on bone mineral density in a Japanese breast cancer population.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Asian People; Bone Densi | 2013 |
Effect of aromatase inhibitors on bone mineral density in a Japanese breast cancer population.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Asian People; Bone Densi | 2013 |
Effect of aromatase inhibitors on bone mineral density in a Japanese breast cancer population.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Asian People; Bone Densi | 2013 |
Posterior reversible encephalopathy syndrome: more than meets the eye.
Topics: Anastrozole; Biopsy, Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Co | 2013 |
Posterior reversible encephalopathy syndrome: more than meets the eye.
Topics: Anastrozole; Biopsy, Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Co | 2013 |
Posterior reversible encephalopathy syndrome: more than meets the eye.
Topics: Anastrozole; Biopsy, Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Co | 2013 |
Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Bone Neop | 2013 |
Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Bone Neop | 2013 |
Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Bone Neop | 2013 |
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
Topics: Anastrozole; Breast Neoplasms; Female; Gene Expression Profiling; Humans; Neoplasm Recurrence, Local | 2013 |
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
Topics: Anastrozole; Breast Neoplasms; Female; Gene Expression Profiling; Humans; Neoplasm Recurrence, Local | 2013 |
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
Topics: Anastrozole; Breast Neoplasms; Female; Gene Expression Profiling; Humans; Neoplasm Recurrence, Local | 2013 |
Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study.
Topics: Anastrozole; Biomarkers, Tumor; Breast Neoplasms; DNA-Binding Proteins; Female; Gene Expression Regu | 2013 |
Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study.
Topics: Anastrozole; Biomarkers, Tumor; Breast Neoplasms; DNA-Binding Proteins; Female; Gene Expression Regu | 2013 |
Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study.
Topics: Anastrozole; Biomarkers, Tumor; Breast Neoplasms; DNA-Binding Proteins; Female; Gene Expression Regu | 2013 |
Combination endocrine treatments unproven in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Estradio | 2013 |
Combination endocrine treatments unproven in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Estradio | 2013 |
Combination endocrine treatments unproven in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Estradio | 2013 |
Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Estra | 2013 |
Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Estra | 2013 |
Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Estra | 2013 |
Tardive dyskinesia associated with anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Female; Humans; Middle Ag | 2013 |
Tardive dyskinesia associated with anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Female; Humans; Middle Ag | 2013 |
Tardive dyskinesia associated with anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Female; Humans; Middle Ag | 2013 |
Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estrogen Replacement Therapy; Fema | 2013 |
Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estrogen Replacement Therapy; Fema | 2013 |
Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estrogen Replacement Therapy; Fema | 2013 |
Psychometric analysis of the Patient Assessment of Own Functioning Inventory in women with breast cancer.
Topics: Activities of Daily Living; Adult; Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chi-Sq | 2013 |
Psychometric analysis of the Patient Assessment of Own Functioning Inventory in women with breast cancer.
Topics: Activities of Daily Living; Adult; Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chi-Sq | 2013 |
Psychometric analysis of the Patient Assessment of Own Functioning Inventory in women with breast cancer.
Topics: Activities of Daily Living; Adult; Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chi-Sq | 2013 |
A polymorphism at the 3'-UTR region of the aromatase gene is associated with the efficacy of the aromatase inhibitor, anastrozole, in metastatic breast carcinoma.
Topics: 17-Hydroxysteroid Dehydrogenases; 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Alleles; | 2013 |
A polymorphism at the 3'-UTR region of the aromatase gene is associated with the efficacy of the aromatase inhibitor, anastrozole, in metastatic breast carcinoma.
Topics: 17-Hydroxysteroid Dehydrogenases; 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Alleles; | 2013 |
A polymorphism at the 3'-UTR region of the aromatase gene is associated with the efficacy of the aromatase inhibitor, anastrozole, in metastatic breast carcinoma.
Topics: 17-Hydroxysteroid Dehydrogenases; 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Alleles; | 2013 |
Concordant effects of aromatase inhibitors on gene expression in ER+ Rat and human mammary cancers and modulation of the proteins coded by these genes.
Topics: Anastrozole; Animals; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Female; Gene Expres | 2013 |
Concordant effects of aromatase inhibitors on gene expression in ER+ Rat and human mammary cancers and modulation of the proteins coded by these genes.
Topics: Anastrozole; Animals; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Female; Gene Expres | 2013 |
Concordant effects of aromatase inhibitors on gene expression in ER+ Rat and human mammary cancers and modulation of the proteins coded by these genes.
Topics: Anastrozole; Animals; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Female; Gene Expres | 2013 |
Rapid response of breast cancer to neoadjuvant intramammary testosterone-anastrozole therapy: neoadjuvant hormone therapy in breast cancer.
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2014 |
Rapid response of breast cancer to neoadjuvant intramammary testosterone-anastrozole therapy: neoadjuvant hormone therapy in breast cancer.
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2014 |
Rapid response of breast cancer to neoadjuvant intramammary testosterone-anastrozole therapy: neoadjuvant hormone therapy in breast cancer.
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2014 |
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2013 |
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2013 |
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2013 |
Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
Topics: 3-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Member C3; Anastrozole; Antineoplastic | 2013 |
Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
Topics: 3-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Member C3; Anastrozole; Antineoplastic | 2013 |
Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
Topics: 3-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Member C3; Anastrozole; Antineoplastic | 2013 |
The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit | 2014 |
The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit | 2014 |
The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit | 2014 |
Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole.
Topics: Anastrozole; Aromatase Inhibitors; Body Mass Index; Bone and Bones; Breast Neoplasms; Collagen Type | 2014 |
Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole.
Topics: Anastrozole; Aromatase Inhibitors; Body Mass Index; Bone and Bones; Breast Neoplasms; Collagen Type | 2014 |
Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole.
Topics: Anastrozole; Aromatase Inhibitors; Body Mass Index; Bone and Bones; Breast Neoplasms; Collagen Type | 2014 |
Computational studies on the anastrozole and letrozole, effective chemotherapy drugs against breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Carbon-13 Magnetic Resonance Spectroscopy; Com | 2014 |
Computational studies on the anastrozole and letrozole, effective chemotherapy drugs against breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Carbon-13 Magnetic Resonance Spectroscopy; Com | 2014 |
Computational studies on the anastrozole and letrozole, effective chemotherapy drugs against breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Carbon-13 Magnetic Resonance Spectroscopy; Com | 2014 |
Breast cancer chemoprevention: little progress in practice?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duc | 2014 |
Breast cancer chemoprevention: little progress in practice?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duc | 2014 |
Breast cancer chemoprevention: little progress in practice?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duc | 2014 |
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; | 2014 |
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; | 2014 |
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; | 2014 |
Women commencing anastrozole, letrozole or tamoxifen for early breast cancer: the impact of comorbidity and demographics on initial choice.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 2014 |
Women commencing anastrozole, letrozole or tamoxifen for early breast cancer: the impact of comorbidity and demographics on initial choice.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 2014 |
Women commencing anastrozole, letrozole or tamoxifen for early breast cancer: the impact of comorbidity and demographics on initial choice.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 2014 |
Tumour grade on core biopsy and evidence of axillary involvement on ultrasound predicts response in elderly co-morbid patients treated with primary hormone therapy for oestrogen receptor positive breast carcinoma.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Axilla; Biopsy, Large-Core Ne | 2015 |
Tumour grade on core biopsy and evidence of axillary involvement on ultrasound predicts response in elderly co-morbid patients treated with primary hormone therapy for oestrogen receptor positive breast carcinoma.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Axilla; Biopsy, Large-Core Ne | 2015 |
Tumour grade on core biopsy and evidence of axillary involvement on ultrasound predicts response in elderly co-morbid patients treated with primary hormone therapy for oestrogen receptor positive breast carcinoma.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Axilla; Biopsy, Large-Core Ne | 2015 |
Efficacy and safety of Trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients.
Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2013 |
Efficacy and safety of Trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients.
Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2013 |
Efficacy and safety of Trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients.
Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2013 |
Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels.
Topics: Aged; Aged, 80 and over; Anastrozole; Androgens; Aromatase Inhibitors; Body Mass Index; Breast Neopl | 2014 |
Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels.
Topics: Aged; Aged, 80 and over; Anastrozole; Androgens; Aromatase Inhibitors; Body Mass Index; Breast Neopl | 2014 |
Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels.
Topics: Aged; Aged, 80 and over; Anastrozole; Androgens; Aromatase Inhibitors; Body Mass Index; Breast Neopl | 2014 |
New trials highlight breast cancer therapy and prevention.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Nitriles; Postmenopause; Random | 2014 |
New trials highlight breast cancer therapy and prevention.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Nitriles; Postmenopause; Random | 2014 |
New trials highlight breast cancer therapy and prevention.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Nitriles; Postmenopause; Random | 2014 |
Anastrozole may aid breast cancer prevention.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 2014 |
Anastrozole may aid breast cancer prevention.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 2014 |
Anastrozole may aid breast cancer prevention.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 2014 |
Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.
Topics: Aged; Anastrozole; Androgens; Aromatase; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Es | 2014 |
Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.
Topics: Aged; Anastrozole; Androgens; Aromatase; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Es | 2014 |
Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.
Topics: Aged; Anastrozole; Androgens; Aromatase; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Es | 2014 |
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2014 |
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2014 |
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2014 |
Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Biomarkers, Tumor | 2014 |
Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Biomarkers, Tumor | 2014 |
Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Biomarkers, Tumor | 2014 |
Prevention: targeted therapy-anastrozole prevents breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 2014 |
Prevention: targeted therapy-anastrozole prevents breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 2014 |
Prevention: targeted therapy-anastrozole prevents breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 2014 |
Graphene oxide based magnetic nanocomposites for efficient treatment of breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Survival; Drug Carriers; Female | 2014 |
Graphene oxide based magnetic nanocomposites for efficient treatment of breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Survival; Drug Carriers; Female | 2014 |
Graphene oxide based magnetic nanocomposites for efficient treatment of breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Survival; Drug Carriers; Female | 2014 |
The bone substudy of MA.27: does bone make a difference?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Br | 2014 |
The bone substudy of MA.27: does bone make a difference?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Br | 2014 |
The bone substudy of MA.27: does bone make a difference?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Br | 2014 |
[A case of postmenopausal breast cancer becoming HER2 positive after neoadjuvant hormone therapy].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Breast Neoplasms; Female; Humans; Mammog | 2014 |
[A case of postmenopausal breast cancer becoming HER2 positive after neoadjuvant hormone therapy].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Breast Neoplasms; Female; Humans; Mammog | 2014 |
[A case of postmenopausal breast cancer becoming HER2 positive after neoadjuvant hormone therapy].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Breast Neoplasms; Female; Humans; Mammog | 2014 |
Effect of anastrozole on hormone levels in postmenopausal women with early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Remodeling; Breast Neoplasms; | 2015 |
Effect of anastrozole on hormone levels in postmenopausal women with early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Remodeling; Breast Neoplasms; | 2015 |
Effect of anastrozole on hormone levels in postmenopausal women with early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Remodeling; Breast Neoplasms; | 2015 |
A hard pill to swallow: a qualitative study of women's experiences of adjuvant endocrine therapy for breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Attitude to Health; Breast | 2014 |
A hard pill to swallow: a qualitative study of women's experiences of adjuvant endocrine therapy for breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Attitude to Health; Breast | 2014 |
A hard pill to swallow: a qualitative study of women's experiences of adjuvant endocrine therapy for breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Attitude to Health; Breast | 2014 |
Another pill for breast cancer prevention.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmeno | 2014 |
Another pill for breast cancer prevention.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmeno | 2014 |
Another pill for breast cancer prevention.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmeno | 2014 |
Drug cuts breast cancer risk by more than half.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Health Promotion; Huma | 2014 |
Drug cuts breast cancer risk by more than half.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Health Promotion; Huma | 2014 |
Drug cuts breast cancer risk by more than half.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Health Promotion; Huma | 2014 |
Silk fibroin rods for sustained delivery of breast cancer therapeutics.
Topics: Anastrozole; Animals; Antineoplastic Agents; Biodegradation, Environmental; Breast Neoplasms; Drug D | 2014 |
Silk fibroin rods for sustained delivery of breast cancer therapeutics.
Topics: Anastrozole; Animals; Antineoplastic Agents; Biodegradation, Environmental; Breast Neoplasms; Drug D | 2014 |
Silk fibroin rods for sustained delivery of breast cancer therapeutics.
Topics: Anastrozole; Animals; Antineoplastic Agents; Biodegradation, Environmental; Breast Neoplasms; Drug D | 2014 |
[Pulmonary metastasis from breast cancer 38 years after mastectomy; report of a case].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Combined Modality Therapy; Fem | 2014 |
[Pulmonary metastasis from breast cancer 38 years after mastectomy; report of a case].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Combined Modality Therapy; Fem | 2014 |
[Pulmonary metastasis from breast cancer 38 years after mastectomy; report of a case].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Combined Modality Therapy; Fem | 2014 |
AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.
Topics: Anastrozole; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Est | 2014 |
AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.
Topics: Anastrozole; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Est | 2014 |
AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.
Topics: Anastrozole; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Est | 2014 |
Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromat | 2014 |
Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromat | 2014 |
Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromat | 2014 |
Longitudinal trends in utilization of endocrine therapies for breast cancer: an international comparison.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Australia; Breast Neoplasms; Developed | 2015 |
Longitudinal trends in utilization of endocrine therapies for breast cancer: an international comparison.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Australia; Breast Neoplasms; Developed | 2015 |
Longitudinal trends in utilization of endocrine therapies for breast cancer: an international comparison.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Australia; Breast Neoplasms; Developed | 2015 |
Primary Hormonal Therapy for Elderly Breast Cancer Patients: Single Institution Experience.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neopla | 2015 |
Primary Hormonal Therapy for Elderly Breast Cancer Patients: Single Institution Experience.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neopla | 2015 |
Primary Hormonal Therapy for Elderly Breast Cancer Patients: Single Institution Experience.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neopla | 2015 |
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in Kazakhstan.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis | 2015 |
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in Kazakhstan.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis | 2015 |
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in Kazakhstan.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis | 2015 |
No pain, no gain: a fallacy so far.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2015 |
No pain, no gain: a fallacy so far.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2015 |
No pain, no gain: a fallacy so far.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2015 |
An unusual cause of jaundice in a patient with breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Breast Neoplasms; Chemical and Drug Induced Li | 2014 |
An unusual cause of jaundice in a patient with breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Breast Neoplasms; Chemical and Drug Induced Li | 2014 |
An unusual cause of jaundice in a patient with breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Breast Neoplasms; Chemical and Drug Induced Li | 2014 |
Case records of the Massachusetts General Hospital. Case 1-2015. A 66-year-old woman with metastatic breast cancer after endocrine therapy.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Duc | 2015 |
Case records of the Massachusetts General Hospital. Case 1-2015. A 66-year-old woman with metastatic breast cancer after endocrine therapy.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Duc | 2015 |
Case records of the Massachusetts General Hospital. Case 1-2015. A 66-year-old woman with metastatic breast cancer after endocrine therapy.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Duc | 2015 |
[A case of hyoid bone metastasis from breast cancer].
Topics: Aged; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols | 2014 |
[A case of hyoid bone metastasis from breast cancer].
Topics: Aged; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols | 2014 |
[A case of hyoid bone metastasis from breast cancer].
Topics: Aged; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols | 2014 |
Antiproliferative effects of anastrozole on MCF-7 human breast cancer cells in vitro are significantly enhanced by combined treatment with testosterone undecanoate.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apopto | 2015 |
Antiproliferative effects of anastrozole on MCF-7 human breast cancer cells in vitro are significantly enhanced by combined treatment with testosterone undecanoate.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apopto | 2015 |
Antiproliferative effects of anastrozole on MCF-7 human breast cancer cells in vitro are significantly enhanced by combined treatment with testosterone undecanoate.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apopto | 2015 |
Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
PEGylated liposomes of anastrozole for long-term treatment of breast cancer: in vitro and in vivo evaluation.
Topics: Anastrozole; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2016 |
PEGylated liposomes of anastrozole for long-term treatment of breast cancer: in vitro and in vivo evaluation.
Topics: Anastrozole; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2016 |
PEGylated liposomes of anastrozole for long-term treatment of breast cancer: in vitro and in vivo evaluation.
Topics: Anastrozole; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2016 |
Breast cancer risk reduction therapy: the low-hanging fruit.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast; Breast Neoplasms; Carcinoma in Situ; Fema | 2015 |
Breast cancer risk reduction therapy: the low-hanging fruit.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast; Breast Neoplasms; Carcinoma in Situ; Fema | 2015 |
Breast cancer risk reduction therapy: the low-hanging fruit.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast; Breast Neoplasms; Carcinoma in Situ; Fema | 2015 |
Solitary uterine metastasis of invasive lobular carcinoma after adjuvant endocrine therapy: a case report.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Lobula | 2015 |
Solitary uterine metastasis of invasive lobular carcinoma after adjuvant endocrine therapy: a case report.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Lobula | 2015 |
Solitary uterine metastasis of invasive lobular carcinoma after adjuvant endocrine therapy: a case report.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Lobula | 2015 |
Patterns of change in cognitive function with anastrozole therapy.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Patterns of change in cognitive function with anastrozole therapy.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Patterns of change in cognitive function with anastrozole therapy.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Lymph Nodes; Neoplas | 2015 |
Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Lymph Nodes; Neoplas | 2015 |
Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Lymph Nodes; Neoplas | 2015 |
The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; B | 2015 |
The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; B | 2015 |
The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; B | 2015 |
Adjuvant treatments of breast cancer increase the risk of depressive disorders: A population-based study.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; C | 2015 |
Adjuvant treatments of breast cancer increase the risk of depressive disorders: A population-based study.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; C | 2015 |
Adjuvant treatments of breast cancer increase the risk of depressive disorders: A population-based study.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; C | 2015 |
Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Survival | 2015 |
Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Survival | 2015 |
Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Survival | 2015 |
Multiple gene aberrations and breast cancer: lessons from super-responders.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosph | 2015 |
Multiple gene aberrations and breast cancer: lessons from super-responders.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosph | 2015 |
Multiple gene aberrations and breast cancer: lessons from super-responders.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosph | 2015 |
Marketed Drugs Can Inhibit Cytochrome P450 27A1, a Potential New Target for Breast Cancer Adjuvant Therapy.
Topics: Adjuvants, Pharmaceutic; Anastrozole; Anilides; Animals; Antifungal Agents; Antineoplastic Agents; B | 2015 |
Marketed Drugs Can Inhibit Cytochrome P450 27A1, a Potential New Target for Breast Cancer Adjuvant Therapy.
Topics: Adjuvants, Pharmaceutic; Anastrozole; Anilides; Animals; Antifungal Agents; Antineoplastic Agents; B | 2015 |
Marketed Drugs Can Inhibit Cytochrome P450 27A1, a Potential New Target for Breast Cancer Adjuvant Therapy.
Topics: Adjuvants, Pharmaceutic; Anastrozole; Anilides; Animals; Antifungal Agents; Antineoplastic Agents; B | 2015 |
Healthcare professionals' preferences for surgery or primary endocrine therapy to treat older women with operable breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Attitude of Health Personnel; | 2015 |
Healthcare professionals' preferences for surgery or primary endocrine therapy to treat older women with operable breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Attitude of Health Personnel; | 2015 |
Healthcare professionals' preferences for surgery or primary endocrine therapy to treat older women with operable breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Attitude of Health Personnel; | 2015 |
Picking the optimal endocrine adjuvant treatment for pre-menopausal women.
Topics: Age Factors; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemothe | 2015 |
Picking the optimal endocrine adjuvant treatment for pre-menopausal women.
Topics: Age Factors; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemothe | 2015 |
Picking the optimal endocrine adjuvant treatment for pre-menopausal women.
Topics: Age Factors; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemothe | 2015 |
Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2015 |
Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2015 |
Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2015 |
Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2015 |
Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2015 |
Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2015 |
Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duct | 2016 |
Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duct | 2016 |
Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duct | 2016 |
Nanomedicine of anastrozole for breast cancer: Physicochemical evaluation, in vitro cytotoxicity on BT-549 and MCF-7 cell lines and preclinical study on rat model.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Surv | 2015 |
Nanomedicine of anastrozole for breast cancer: Physicochemical evaluation, in vitro cytotoxicity on BT-549 and MCF-7 cell lines and preclinical study on rat model.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Surv | 2015 |
Nanomedicine of anastrozole for breast cancer: Physicochemical evaluation, in vitro cytotoxicity on BT-549 and MCF-7 cell lines and preclinical study on rat model.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Surv | 2015 |
Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Brea | 2015 |
Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Brea | 2015 |
Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Brea | 2015 |
Hypervitaminosis B12 As an Additional Prognostic Indicator in Elderly Adults with a Neoplastic Disease: Report of a Case and Review of the Literature.
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Geriatric | 2015 |
Hypervitaminosis B12 As an Additional Prognostic Indicator in Elderly Adults with a Neoplastic Disease: Report of a Case and Review of the Literature.
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Geriatric | 2015 |
Hypervitaminosis B12 As an Additional Prognostic Indicator in Elderly Adults with a Neoplastic Disease: Report of a Case and Review of the Literature.
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Geriatric | 2015 |
The Effects of Adjuvant Endocrine Treatment on Serum Leptin, Serum Adiponectin and Body Composition in Patients with Breast Cancer: The Izmir Oncology Group (IZOG) Study.
Topics: Adiponectin; Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Composi | 2016 |
The Effects of Adjuvant Endocrine Treatment on Serum Leptin, Serum Adiponectin and Body Composition in Patients with Breast Cancer: The Izmir Oncology Group (IZOG) Study.
Topics: Adiponectin; Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Composi | 2016 |
The Effects of Adjuvant Endocrine Treatment on Serum Leptin, Serum Adiponectin and Body Composition in Patients with Breast Cancer: The Izmir Oncology Group (IZOG) Study.
Topics: Adiponectin; Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Composi | 2016 |
Adjuvant Ovarian Suppression, High-dose Chemotherapy and Immunotherapy for Premenopausal Patients with High-risk Breast Cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Adjuvant Ovarian Suppression, High-dose Chemotherapy and Immunotherapy for Premenopausal Patients with High-risk Breast Cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Adjuvant Ovarian Suppression, High-dose Chemotherapy and Immunotherapy for Premenopausal Patients with High-risk Breast Cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
[Efficacies of aromatase inhibitors in the treatment of hormone dependent metastatic breast cancer in postmenopausal women: a report of 148 cases].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; | 2015 |
[Efficacies of aromatase inhibitors in the treatment of hormone dependent metastatic breast cancer in postmenopausal women: a report of 148 cases].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; | 2015 |
[Efficacies of aromatase inhibitors in the treatment of hormone dependent metastatic breast cancer in postmenopausal women: a report of 148 cases].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; | 2015 |
Ginkgo biloba extract EGb 761-mediated inhibition of aromatase for the treatment of hormone-dependent breast cancer.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase; | 2016 |
Ginkgo biloba extract EGb 761-mediated inhibition of aromatase for the treatment of hormone-dependent breast cancer.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase; | 2016 |
Ginkgo biloba extract EGb 761-mediated inhibition of aromatase for the treatment of hormone-dependent breast cancer.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase; | 2016 |
miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors.
Topics: Anastrozole; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumo | 2016 |
miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors.
Topics: Anastrozole; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumo | 2016 |
miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors.
Topics: Anastrozole; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumo | 2016 |
[A Case of Locally Advanced Breast Cancer Treated with Modified Radical Mastectomy with Immediate Reconstruction Using a Tissue Expander after Endocrine Therapy].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biopsy, Large-Core Needle; Breast Implants; Breast Neo | 2015 |
[A Case of Locally Advanced Breast Cancer Treated with Modified Radical Mastectomy with Immediate Reconstruction Using a Tissue Expander after Endocrine Therapy].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biopsy, Large-Core Needle; Breast Implants; Breast Neo | 2015 |
[A Case of Locally Advanced Breast Cancer Treated with Modified Radical Mastectomy with Immediate Reconstruction Using a Tissue Expander after Endocrine Therapy].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biopsy, Large-Core Needle; Breast Implants; Breast Neo | 2015 |
A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2016 |
A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2016 |
A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2016 |
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; | 2016 |
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; | 2016 |
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; | 2016 |
Long-Term Disease-Free Survival in a Young Patient With Hormone Receptor-Positive Breast Cancer and Oligometastatic Disease in the Brain.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carc | 2016 |
Long-Term Disease-Free Survival in a Young Patient With Hormone Receptor-Positive Breast Cancer and Oligometastatic Disease in the Brain.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carc | 2016 |
Long-Term Disease-Free Survival in a Young Patient With Hormone Receptor-Positive Breast Cancer and Oligometastatic Disease in the Brain.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carc | 2016 |
The association between pre-treatment occupational skill level and mood and symptom burden in early-stage, postmenopausal breast cancer survivors during the first year of anastrozole therapy.
Topics: Affect; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cognition; Employment; Femal | 2016 |
The association between pre-treatment occupational skill level and mood and symptom burden in early-stage, postmenopausal breast cancer survivors during the first year of anastrozole therapy.
Topics: Affect; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cognition; Employment; Femal | 2016 |
The association between pre-treatment occupational skill level and mood and symptom burden in early-stage, postmenopausal breast cancer survivors during the first year of anastrozole therapy.
Topics: Affect; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cognition; Employment; Femal | 2016 |
Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Gene Expression Profiling; H | 2016 |
Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Gene Expression Profiling; H | 2016 |
Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Gene Expression Profiling; H | 2016 |
Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; DNA Mutational Analysis; Drug Administration Sc | 2017 |
Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; DNA Mutational Analysis; Drug Administration Sc | 2017 |
Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; DNA Mutational Analysis; Drug Administration Sc | 2017 |
Hypercalcemic crisis associated with anastrozole use in a patient with breast cancer and primary hyperparathyroidism.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Carcinoma In Situ; Breast Neoplasms; Calcium; F | 2016 |
Hypercalcemic crisis associated with anastrozole use in a patient with breast cancer and primary hyperparathyroidism.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Carcinoma In Situ; Breast Neoplasms; Calcium; F | 2016 |
Hypercalcemic crisis associated with anastrozole use in a patient with breast cancer and primary hyperparathyroidism.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Carcinoma In Situ; Breast Neoplasms; Calcium; F | 2016 |
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Follo | 2016 |
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Follo | 2016 |
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Follo | 2016 |
Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biolog | 2016 |
Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biolog | 2016 |
Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biolog | 2016 |
Anastrozole-induced subacute cutaneous lupus erythematosus.
Topics: Aged; Anastrozole; Antibodies, Antinuclear; Arm; Aromatase Inhibitors; Breast Neoplasms; Female; Hum | 2016 |
Anastrozole-induced subacute cutaneous lupus erythematosus.
Topics: Aged; Anastrozole; Antibodies, Antinuclear; Arm; Aromatase Inhibitors; Breast Neoplasms; Female; Hum | 2016 |
Anastrozole-induced subacute cutaneous lupus erythematosus.
Topics: Aged; Anastrozole; Antibodies, Antinuclear; Arm; Aromatase Inhibitors; Breast Neoplasms; Female; Hum | 2016 |
Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Atrophy; Breast Neoplasms; Female; Huma | 2016 |
Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Atrophy; Breast Neoplasms; Female; Huma | 2016 |
Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Atrophy; Breast Neoplasms; Female; Huma | 2016 |
Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.
Topics: Anastrozole; Aromatase; Aromatase Inhibitors; Arthralgia; ATP Binding Cassette Transporter, Subfamil | 2017 |
Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.
Topics: Anastrozole; Aromatase; Aromatase Inhibitors; Arthralgia; ATP Binding Cassette Transporter, Subfamil | 2017 |
Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.
Topics: Anastrozole; Aromatase; Aromatase Inhibitors; Arthralgia; ATP Binding Cassette Transporter, Subfamil | 2017 |
Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Ci | 2017 |
Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Ci | 2017 |
Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Ci | 2017 |
Mechanism of Bushen Jianpi decoction in preventing and treating osteoporosis caused by aromatase inhibitors in breast cancer treatment.
Topics: Alendronate; Alkaline Phosphatase; Anastrozole; Animals; Aromatase Inhibitors; Bone Density; Bone De | 2017 |
Mechanism of Bushen Jianpi decoction in preventing and treating osteoporosis caused by aromatase inhibitors in breast cancer treatment.
Topics: Alendronate; Alkaline Phosphatase; Anastrozole; Animals; Aromatase Inhibitors; Bone Density; Bone De | 2017 |
Mechanism of Bushen Jianpi decoction in preventing and treating osteoporosis caused by aromatase inhibitors in breast cancer treatment.
Topics: Alendronate; Alkaline Phosphatase; Anastrozole; Animals; Aromatase Inhibitors; Bone Density; Bone De | 2017 |
Abemaciclib Shows Promise for Early Breast Cancer.
Topics: Aminopyridines; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic | 2017 |
Abemaciclib Shows Promise for Early Breast Cancer.
Topics: Aminopyridines; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic | 2017 |
Abemaciclib Shows Promise for Early Breast Cancer.
Topics: Aminopyridines; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic | 2017 |
Obviating the Need for Serial Biopsies Through Random Assignment.
Topics: Anastrozole; Biopsy; Breast Neoplasms; Humans; Indazoles; Phosphatidylinositol 3-Kinases; Receptors, | 2017 |
Obviating the Need for Serial Biopsies Through Random Assignment.
Topics: Anastrozole; Biopsy; Breast Neoplasms; Humans; Indazoles; Phosphatidylinositol 3-Kinases; Receptors, | 2017 |
Obviating the Need for Serial Biopsies Through Random Assignment.
Topics: Anastrozole; Biopsy; Breast Neoplasms; Humans; Indazoles; Phosphatidylinositol 3-Kinases; Receptors, | 2017 |
Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cognit | 2017 |
Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cognit | 2017 |
Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cognit | 2017 |
Letrozole not superior to anastrozole for early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 2017 |
Letrozole not superior to anastrozole for early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 2017 |
Letrozole not superior to anastrozole for early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 2017 |
Estrone and Estradiol Levels in Breast Cancer Patients Using Anastrozole Are Not Related to Body Mass Index.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasm | 2017 |
Estrone and Estradiol Levels in Breast Cancer Patients Using Anastrozole Are Not Related to Body Mass Index.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasm | 2017 |
Estrone and Estradiol Levels in Breast Cancer Patients Using Anastrozole Are Not Related to Body Mass Index.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasm | 2017 |
High Initiation of Adjuvant Hormonal Therapy Among Uninsured Stages I-III Breast Cancer Patients Treated in a Safety-Net Healthcare System.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Ethnicity; F | 2017 |
High Initiation of Adjuvant Hormonal Therapy Among Uninsured Stages I-III Breast Cancer Patients Treated in a Safety-Net Healthcare System.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Ethnicity; F | 2017 |
High Initiation of Adjuvant Hormonal Therapy Among Uninsured Stages I-III Breast Cancer Patients Treated in a Safety-Net Healthcare System.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Ethnicity; F | 2017 |
Anastrozole-associated sclerosing glomerulonephritis in a patient with breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Atrophy; Breast Neoplasms; Fatal Outcome; Female | 2007 |
Anastrozole-associated sclerosing glomerulonephritis in a patient with breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Atrophy; Breast Neoplasms; Fatal Outcome; Female | 2007 |
Anastrozole-associated sclerosing glomerulonephritis in a patient with breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Atrophy; Breast Neoplasms; Fatal Outcome; Female | 2007 |
Is long-term adjuvant treatment of breast cancer with anastrozole indicated?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2008 |
Is long-term adjuvant treatment of breast cancer with anastrozole indicated?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2008 |
Is long-term adjuvant treatment of breast cancer with anastrozole indicated?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2008 |
[Intensification of a diffuse chronic pain syndrome by the introduction of an aromatase inhibitor].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinom | 2008 |
[Intensification of a diffuse chronic pain syndrome by the introduction of an aromatase inhibitor].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinom | 2008 |
[Intensification of a diffuse chronic pain syndrome by the introduction of an aromatase inhibitor].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinom | 2008 |
Cutaneous vasculitis in breast cancer treated with chemotherapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; ErbB Receptors; Female; Humans; Midd | 2008 |
Cutaneous vasculitis in breast cancer treated with chemotherapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; ErbB Receptors; Female; Humans; Midd | 2008 |
Cutaneous vasculitis in breast cancer treated with chemotherapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; ErbB Receptors; Female; Humans; Midd | 2008 |
[Extended adjuvant hormone therapy (in breast cancer): Why? To whom? What? How long?].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Administr | 2008 |
[Extended adjuvant hormone therapy (in breast cancer): Why? To whom? What? How long?].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Administr | 2008 |
[Extended adjuvant hormone therapy (in breast cancer): Why? To whom? What? How long?].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Administr | 2008 |
Characterization of the weak estrogen receptor alpha agonistic activity of exemestane.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Resist | 2009 |
Characterization of the weak estrogen receptor alpha agonistic activity of exemestane.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Resist | 2009 |
Characterization of the weak estrogen receptor alpha agonistic activity of exemestane.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Resist | 2009 |
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2008 |
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2008 |
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2008 |
Vitreo-retinal traction and anastrozole use.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female | 2009 |
Vitreo-retinal traction and anastrozole use.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female | 2009 |
Vitreo-retinal traction and anastrozole use.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female | 2009 |
Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic | 2008 |
Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic | 2008 |
Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic | 2008 |
Clinical trial presentations, agency guidelines, and oncology practice: findings from the arimidex, tamoxifen, alone or in combination trial.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 2008 |
Clinical trial presentations, agency guidelines, and oncology practice: findings from the arimidex, tamoxifen, alone or in combination trial.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 2008 |
Clinical trial presentations, agency guidelines, and oncology practice: findings from the arimidex, tamoxifen, alone or in combination trial.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 2008 |
IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; | 2008 |
IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; | 2008 |
IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; | 2008 |
Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conse | 2008 |
Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conse | 2008 |
Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conse | 2008 |
Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Asian People; Breast Neoplasms; | 2008 |
Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Asian People; Breast Neoplasms; | 2008 |
Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Asian People; Breast Neoplasms; | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Primary uterine rhabdomyosarcoma in a patient with a history of breast cancer and gastrointestinal stromal tumor.
Topics: Aged; Anastrozole; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Gastrointestinal Str | 2008 |
Primary uterine rhabdomyosarcoma in a patient with a history of breast cancer and gastrointestinal stromal tumor.
Topics: Aged; Anastrozole; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Gastrointestinal Str | 2008 |
Primary uterine rhabdomyosarcoma in a patient with a history of breast cancer and gastrointestinal stromal tumor.
Topics: Aged; Anastrozole; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Gastrointestinal Str | 2008 |
[A case of recurrent breast cancer with multiple lung metastases responding to anastrozole monotherapy].
Topics: Anastrozole; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Lung Neoplasms; Middle Aged; Neopl | 2008 |
[A case of recurrent breast cancer with multiple lung metastases responding to anastrozole monotherapy].
Topics: Anastrozole; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Lung Neoplasms; Middle Aged; Neopl | 2008 |
[A case of recurrent breast cancer with multiple lung metastases responding to anastrozole monotherapy].
Topics: Anastrozole; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Lung Neoplasms; Middle Aged; Neopl | 2008 |
Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Biomarkers, Tumor; Breast Neo | 2008 |
Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Biomarkers, Tumor; Breast Neo | 2008 |
Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Biomarkers, Tumor; Breast Neo | 2008 |
A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Genital Diseases, Female; Hu | 2009 |
A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Genital Diseases, Female; Hu | 2009 |
A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Genital Diseases, Female; Hu | 2009 |
Anastrozole: brain draining or sparing?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Attention; Breast Neoplasms; Cognition; Humans; Memory | 2008 |
Anastrozole: brain draining or sparing?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Attention; Breast Neoplasms; Cognition; Humans; Memory | 2008 |
Anastrozole: brain draining or sparing?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Attention; Breast Neoplasms; Cognition; Humans; Memory | 2008 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Diso | 2009 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Diso | 2009 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Diso | 2009 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Diso | 2009 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Diso | 2009 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Diso | 2009 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Diso | 2009 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Diso | 2009 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Diso | 2009 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Diso | 2009 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Diso | 2009 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Diso | 2009 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Diso | 2009 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Diso | 2009 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Diso | 2009 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Diso | 2009 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Diso | 2009 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Diso | 2009 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Diso | 2009 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Diso | 2009 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Diso | 2009 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Diso | 2009 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Diso | 2009 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Diso | 2009 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Diso | 2009 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Diso | 2009 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Diso | 2009 |
A paraneoplastic manifestation of metastatic breast cancer responding to endocrine therapy: a case report.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Creatine Kinase; Female; Humans; Immunoglobulin | 2008 |
A paraneoplastic manifestation of metastatic breast cancer responding to endocrine therapy: a case report.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Creatine Kinase; Female; Humans; Immunoglobulin | 2008 |
A paraneoplastic manifestation of metastatic breast cancer responding to endocrine therapy: a case report.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Creatine Kinase; Female; Humans; Immunoglobulin | 2008 |
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Huma | 2009 |
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Huma | 2009 |
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Huma | 2009 |
Mean platelet volume increase after tamoxifen, but not after anastrazole in adjuvant therapy of breast cancer.
Topics: Adult; Aged; Anastrozole; Blood Platelets; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; | 2010 |
Mean platelet volume increase after tamoxifen, but not after anastrazole in adjuvant therapy of breast cancer.
Topics: Adult; Aged; Anastrozole; Blood Platelets; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; | 2010 |
Mean platelet volume increase after tamoxifen, but not after anastrazole in adjuvant therapy of breast cancer.
Topics: Adult; Aged; Anastrozole; Blood Platelets; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; | 2010 |
Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2009 |
Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2009 |
Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2009 |
[A case of metastatic breast cancer resistant to anastrozole treatment responding to high-dose toremifene].
Topics: Anastrozole; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lymph Node Excision; Lymph | 2009 |
[A case of metastatic breast cancer resistant to anastrozole treatment responding to high-dose toremifene].
Topics: Anastrozole; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lymph Node Excision; Lymph | 2009 |
[A case of metastatic breast cancer resistant to anastrozole treatment responding to high-dose toremifene].
Topics: Anastrozole; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lymph Node Excision; Lymph | 2009 |
Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzodio | 2009 |
Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzodio | 2009 |
Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzodio | 2009 |
[Nineteen years postoperatively, anastrozole, UFT and cyclophosphamide combination therapy remained effective against recurrent hormone responsive breast cancer with intraabdominal lymphnode, pleural, skin and bone metastases in old age following sixteen-
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2009 |
[Nineteen years postoperatively, anastrozole, UFT and cyclophosphamide combination therapy remained effective against recurrent hormone responsive breast cancer with intraabdominal lymphnode, pleural, skin and bone metastases in old age following sixteen-
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2009 |
[Nineteen years postoperatively, anastrozole, UFT and cyclophosphamide combination therapy remained effective against recurrent hormone responsive breast cancer with intraabdominal lymphnode, pleural, skin and bone metastases in old age following sixteen-
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation Agents | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation Agents | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation Agents | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Di | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Di | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Di | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Therapy, Combination; Female; G | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Therapy, Combination; Female; G | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Therapy, Combination; Female; G | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Confidence Intervals; Diphosphonates | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Confidence Intervals; Diphosphonates | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Confidence Intervals; Diphosphonates | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation Agents | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation Agents | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation Agents | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Diphosphonates; Disease-Free Surviva | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Diphosphonates; Disease-Free Surviva | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Diphosphonates; Disease-Free Surviva | 2009 |
Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapy.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neo | 2009 |
Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapy.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neo | 2009 |
Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapy.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neo | 2009 |
Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Arthralgia; Bone Density; Breast | 2010 |
Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Arthralgia; Bone Density; Breast | 2010 |
Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Arthralgia; Bone Density; Breast | 2010 |
Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
Topics: Anastrozole; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Estradiol; Estrogen Antagoni | 2009 |
Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
Topics: Anastrozole; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Estradiol; Estrogen Antagoni | 2009 |
Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
Topics: Anastrozole; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Estradiol; Estrogen Antagoni | 2009 |
Hemicentral retinal artery occlusion in a breast cancer patient using anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitrile | 2009 |
Hemicentral retinal artery occlusion in a breast cancer patient using anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitrile | 2009 |
Hemicentral retinal artery occlusion in a breast cancer patient using anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitrile | 2009 |
Metastasis of lobular breast carcinoma to the uterus in a patient under anastrozole therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Lobular; Diagnosis, Diffe | 2009 |
Metastasis of lobular breast carcinoma to the uterus in a patient under anastrozole therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Lobular; Diagnosis, Diffe | 2009 |
Metastasis of lobular breast carcinoma to the uterus in a patient under anastrozole therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Lobular; Diagnosis, Diffe | 2009 |
Concurrent administration of chemo-endocrine therapy for postmenopausal breast cancer patients.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; | 2010 |
Concurrent administration of chemo-endocrine therapy for postmenopausal breast cancer patients.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; | 2010 |
Concurrent administration of chemo-endocrine therapy for postmenopausal breast cancer patients.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; | 2010 |
How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormo | 2009 |
How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormo | 2009 |
How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormo | 2009 |
NCCN Guideline update: Breast Cancer Version 1.2004.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrat | 2004 |
NCCN Guideline update: Breast Cancer Version 1.2004.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrat | 2004 |
NCCN Guideline update: Breast Cancer Version 1.2004.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrat | 2004 |
Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: of relevance to clinical understanding?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breas | 2010 |
Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: of relevance to clinical understanding?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breas | 2010 |
Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: of relevance to clinical understanding?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breas | 2010 |
Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2010 |
Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2010 |
Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2010 |
Impact of aromatase inhibitors on bone health in breast cancer patients.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone and Bones; | 2010 |
Impact of aromatase inhibitors on bone health in breast cancer patients.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone and Bones; | 2010 |
Impact of aromatase inhibitors on bone health in breast cancer patients.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone and Bones; | 2010 |
Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breas | 2010 |
Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breas | 2010 |
Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breas | 2010 |
A remarkable case of cutaneous metastatic breast carcinoma.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2009 |
A remarkable case of cutaneous metastatic breast carcinoma.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2009 |
A remarkable case of cutaneous metastatic breast carcinoma.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2009 |
Drug-induced pruritic micropapular eruption: anastrozole, a commonly used aromatase inhibitor.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Combined | 2009 |
Drug-induced pruritic micropapular eruption: anastrozole, a commonly used aromatase inhibitor.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Combined | 2009 |
Drug-induced pruritic micropapular eruption: anastrozole, a commonly used aromatase inhibitor.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Combined | 2009 |
Serum estradiol should be monitored not only during the peri-menopausal period but also the post-menopausal period at the time of aromatase inhibitor administration.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2009 |
Serum estradiol should be monitored not only during the peri-menopausal period but also the post-menopausal period at the time of aromatase inhibitor administration.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2009 |
Serum estradiol should be monitored not only during the peri-menopausal period but also the post-menopausal period at the time of aromatase inhibitor administration.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2009 |
ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast N | 2010 |
ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast N | 2010 |
ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast N | 2010 |
Retrospective analysis of concurrent vs. sequential administration of radiotherapy and hormone therapy using aromatase inhibitor for hormone receptor-positive postmenopausal breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2009 |
Retrospective analysis of concurrent vs. sequential administration of radiotherapy and hormone therapy using aromatase inhibitor for hormone receptor-positive postmenopausal breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2009 |
Retrospective analysis of concurrent vs. sequential administration of radiotherapy and hormone therapy using aromatase inhibitor for hormone receptor-positive postmenopausal breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2009 |
[A case of inflammatory breast cancer responding to anastrozole].
Topics: Adenocarcinoma, Scirrhous; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Fem | 2009 |
[A case of inflammatory breast cancer responding to anastrozole].
Topics: Adenocarcinoma, Scirrhous; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Fem | 2009 |
[A case of inflammatory breast cancer responding to anastrozole].
Topics: Adenocarcinoma, Scirrhous; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Fem | 2009 |
[A successful case of advanced breast cancer of the elderly treated with the only breast-hormone therapy as PST].
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aortic Aneurysm, Thoracic; Aortic D | 2009 |
[A successful case of advanced breast cancer of the elderly treated with the only breast-hormone therapy as PST].
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aortic Aneurysm, Thoracic; Aortic D | 2009 |
[A successful case of advanced breast cancer of the elderly treated with the only breast-hormone therapy as PST].
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aortic Aneurysm, Thoracic; Aortic D | 2009 |
Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women.
Topics: Aged; Anastrozole; Breast Neoplasms; Estradiol; Estrogens; Female; Gene Expression Profiling; Humans | 2010 |
Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women.
Topics: Aged; Anastrozole; Breast Neoplasms; Estradiol; Estrogens; Female; Gene Expression Profiling; Humans | 2010 |
Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women.
Topics: Aged; Anastrozole; Breast Neoplasms; Estradiol; Estrogens; Female; Gene Expression Profiling; Humans | 2010 |
Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors.
Topics: Anastrozole; Anesthetics, Combined; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Early Detection | 2010 |
Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors.
Topics: Anastrozole; Anesthetics, Combined; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Early Detection | 2010 |
Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors.
Topics: Anastrozole; Anesthetics, Combined; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Early Detection | 2010 |
Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial.
Topics: Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; | 2010 |
Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial.
Topics: Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; | 2010 |
Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial.
Topics: Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; | 2010 |
Endocrine therapy is associated with low performance on some estrogen-sensitive cognitive tasks in postmenopausal women with breast cancer.
Topics: Aged; Anastrozole; Breast Neoplasms; Case-Control Studies; Cognition Disorders; Estrogen Antagonists | 2010 |
Endocrine therapy is associated with low performance on some estrogen-sensitive cognitive tasks in postmenopausal women with breast cancer.
Topics: Aged; Anastrozole; Breast Neoplasms; Case-Control Studies; Cognition Disorders; Estrogen Antagonists | 2010 |
Endocrine therapy is associated with low performance on some estrogen-sensitive cognitive tasks in postmenopausal women with breast cancer.
Topics: Aged; Anastrozole; Breast Neoplasms; Case-Control Studies; Cognition Disorders; Estrogen Antagonists | 2010 |
Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Cohort Studies; Dose-Response Relatio | 2010 |
Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Cohort Studies; Dose-Response Relatio | 2010 |
Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Cohort Studies; Dose-Response Relatio | 2010 |
[Goserelin plus anastrozole in the treatment of premenopausal patients with metastatic breast cancer].
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Gosere | 2010 |
[Goserelin plus anastrozole in the treatment of premenopausal patients with metastatic breast cancer].
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Gosere | 2010 |
[Goserelin plus anastrozole in the treatment of premenopausal patients with metastatic breast cancer].
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Gosere | 2010 |
Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Female; G | 2010 |
Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Female; G | 2010 |
Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Female; G | 2010 |
Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2011 |
Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2011 |
Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2011 |
Obesity and hormone therapy in breast cancer: an unfinished puzzle.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antag | 2010 |
Obesity and hormone therapy in breast cancer: an unfinished puzzle.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antag | 2010 |
Obesity and hormone therapy in breast cancer: an unfinished puzzle.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antag | 2010 |
Rheumatoid arthritis and aromatase inhibitors.
Topics: Adenocarcinoma; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthritis, Rheumatoid; Brea | 2011 |
Rheumatoid arthritis and aromatase inhibitors.
Topics: Adenocarcinoma; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthritis, Rheumatoid; Brea | 2011 |
Rheumatoid arthritis and aromatase inhibitors.
Topics: Adenocarcinoma; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthritis, Rheumatoid; Brea | 2011 |
Influence of concurrent anastrozole on acute and late side effects of whole breast radiotherapy.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2011 |
Influence of concurrent anastrozole on acute and late side effects of whole breast radiotherapy.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2011 |
Influence of concurrent anastrozole on acute and late side effects of whole breast radiotherapy.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2011 |
Results of the Zometa cost-utility model for the german healthcare system based on the results of the ABCSG-12 study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breas | 2010 |
Results of the Zometa cost-utility model for the german healthcare system based on the results of the ABCSG-12 study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breas | 2010 |
Results of the Zometa cost-utility model for the german healthcare system based on the results of the ABCSG-12 study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breas | 2010 |
A rare case of breast cancer metastasis.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Brea | 2010 |
A rare case of breast cancer metastasis.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Brea | 2010 |
A rare case of breast cancer metastasis.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Brea | 2010 |
The differences in outcome between ATAC and BIG 1-98 suggest efficacy differences between these two nonsteroidal AIs.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; | 2010 |
The differences in outcome between ATAC and BIG 1-98 suggest efficacy differences between these two nonsteroidal AIs.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; | 2010 |
The differences in outcome between ATAC and BIG 1-98 suggest efficacy differences between these two nonsteroidal AIs.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; | 2010 |
[Clinical significance and pathological evaluation of neoadjuvant chemotherapy in breast cancer].
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antin | 2010 |
[Clinical significance and pathological evaluation of neoadjuvant chemotherapy in breast cancer].
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antin | 2010 |
[Clinical significance and pathological evaluation of neoadjuvant chemotherapy in breast cancer].
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antin | 2010 |
Evaluation of the psychometric properties of the BCPT Symptom Checklist with a sample of breast cancer patients before and after adjuvant therapy.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Checklist; Chemotherapy, Adjuv | 2011 |
Evaluation of the psychometric properties of the BCPT Symptom Checklist with a sample of breast cancer patients before and after adjuvant therapy.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Checklist; Chemotherapy, Adjuv | 2011 |
Evaluation of the psychometric properties of the BCPT Symptom Checklist with a sample of breast cancer patients before and after adjuvant therapy.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Checklist; Chemotherapy, Adjuv | 2011 |
Cognitive changes associated with endocrine therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy P | 2010 |
Cognitive changes associated with endocrine therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy P | 2010 |
Cognitive changes associated with endocrine therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy P | 2010 |
Rectal metastasis from lobular carcinoma of the breast: a case report.
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Lobula | 2010 |
Rectal metastasis from lobular carcinoma of the breast: a case report.
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Lobula | 2010 |
Rectal metastasis from lobular carcinoma of the breast: a case report.
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Lobula | 2010 |
[An elderly advanced breast cancer with a good response to anastrozole].
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neopla | 2010 |
[An elderly advanced breast cancer with a good response to anastrozole].
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neopla | 2010 |
[An elderly advanced breast cancer with a good response to anastrozole].
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neopla | 2010 |
Managing bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important.
Topics: Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Me | 2010 |
Managing bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important.
Topics: Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Me | 2010 |
Managing bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important.
Topics: Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Me | 2010 |
Development and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of tamoxifen, anastrozole, and letrozole in human plasma and its application to a clinical study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Chromatography, Liquid; Female; Human | 2010 |
Development and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of tamoxifen, anastrozole, and letrozole in human plasma and its application to a clinical study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Chromatography, Liquid; Female; Human | 2010 |
Development and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of tamoxifen, anastrozole, and letrozole in human plasma and its application to a clinical study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Chromatography, Liquid; Female; Human | 2010 |
Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Cost-Benefit | 2010 |
Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Cost-Benefit | 2010 |
Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Cost-Benefit | 2010 |
Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Blotting | 2011 |
Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Blotting | 2011 |
Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Blotting | 2011 |
Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibi | 2010 |
Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibi | 2010 |
Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibi | 2010 |
Cortical and trabecular bone at the radius and tibia in postmenopausal breast cancer patients: a Peripheral Quantitative Computed Tomography (pQCT) study.
Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Female; | 2011 |
Cortical and trabecular bone at the radius and tibia in postmenopausal breast cancer patients: a Peripheral Quantitative Computed Tomography (pQCT) study.
Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Female; | 2011 |
Cortical and trabecular bone at the radius and tibia in postmenopausal breast cancer patients: a Peripheral Quantitative Computed Tomography (pQCT) study.
Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Female; | 2011 |
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; B | 2010 |
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; B | 2010 |
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; B | 2010 |
What is the value of the 21 gene recurrence score in HER2-negative patients?
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumo | 2010 |
What is the value of the 21 gene recurrence score in HER2-negative patients?
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumo | 2010 |
What is the value of the 21 gene recurrence score in HER2-negative patients?
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumo | 2010 |
Combining luteinising hormone releasing hormone agonists and aromatase inhibitors in breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; | 2010 |
Combining luteinising hormone releasing hormone agonists and aromatase inhibitors in breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; | 2010 |
Combining luteinising hormone releasing hormone agonists and aromatase inhibitors in breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; | 2010 |
Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors.
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bre | 2010 |
Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors.
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bre | 2010 |
Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors.
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bre | 2010 |
10 years of ATAC: one question answered, many others unresolved.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studi | 2010 |
10 years of ATAC: one question answered, many others unresolved.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studi | 2010 |
10 years of ATAC: one question answered, many others unresolved.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studi | 2010 |
[Advanced breast cancer in a patient achieving long-term SD after letrozole administration for liver metastasis developing during anastrozole therapy].
Topics: Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcino | 2010 |
[Advanced breast cancer in a patient achieving long-term SD after letrozole administration for liver metastasis developing during anastrozole therapy].
Topics: Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcino | 2010 |
[Advanced breast cancer in a patient achieving long-term SD after letrozole administration for liver metastasis developing during anastrozole therapy].
Topics: Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcino | 2010 |
Does anastrozole affect bone resorption similarly in early and late postmenopausal women?
Topics: Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Resorption; Brea | 2011 |
Does anastrozole affect bone resorption similarly in early and late postmenopausal women?
Topics: Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Resorption; Brea | 2011 |
Does anastrozole affect bone resorption similarly in early and late postmenopausal women?
Topics: Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Resorption; Brea | 2011 |
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chromatography, Liquid; Cytochrome P | 2010 |
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chromatography, Liquid; Cytochrome P | 2010 |
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chromatography, Liquid; Cytochrome P | 2010 |
[A case of stage IV breast cancer with bone metastases that responded well for long-term to hormonal therapy].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, B | 2010 |
[A case of stage IV breast cancer with bone metastases that responded well for long-term to hormonal therapy].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, B | 2010 |
[A case of stage IV breast cancer with bone metastases that responded well for long-term to hormonal therapy].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, B | 2010 |
Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Body Mass Index; Breast Neoplas | 2011 |
Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Body Mass Index; Breast Neoplas | 2011 |
Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Body Mass Index; Breast Neoplas | 2011 |
Risk of Ipsilateral breast tumor recurrence in patients treated with Tamoxifen or Anastrozole following breast-conserving surgery with or without radiotherapy.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Combi | 2011 |
Risk of Ipsilateral breast tumor recurrence in patients treated with Tamoxifen or Anastrozole following breast-conserving surgery with or without radiotherapy.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Combi | 2011 |
Risk of Ipsilateral breast tumor recurrence in patients treated with Tamoxifen or Anastrozole following breast-conserving surgery with or without radiotherapy.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Combi | 2011 |
Anastrozole can cause severe hypercalcaemia mimicking primary hyperparathyroidism.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Calcium; Female; Humans; Hyper | 2014 |
Anastrozole can cause severe hypercalcaemia mimicking primary hyperparathyroidism.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Calcium; Female; Humans; Hyper | 2014 |
Anastrozole can cause severe hypercalcaemia mimicking primary hyperparathyroidism.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Calcium; Female; Humans; Hyper | 2014 |
Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor-treated ER-positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Cel | 2011 |
Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor-treated ER-positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Cel | 2011 |
Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor-treated ER-positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Cel | 2011 |
A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; | 2011 |
A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; | 2011 |
A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; | 2011 |
10-year analysis of the ATAC trial: wrong conclusion?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Postmenopa | 2011 |
10-year analysis of the ATAC trial: wrong conclusion?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Postmenopa | 2011 |
10-year analysis of the ATAC trial: wrong conclusion?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Postmenopa | 2011 |
Premenopausal hormone-responsive breast cancer with extensive axillary nodes involvement: total estrogen blockade and chemotherapy.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; C | 2011 |
Premenopausal hormone-responsive breast cancer with extensive axillary nodes involvement: total estrogen blockade and chemotherapy.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; C | 2011 |
Premenopausal hormone-responsive breast cancer with extensive axillary nodes involvement: total estrogen blockade and chemotherapy.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; C | 2011 |
Sustained release optimized formulation of anastrozole-loaded chitosan microspheres: in vitro and in vivo evaluation.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Area Under Curve; Breast Neoplasms; Chitosan; Chromato | 2011 |
Sustained release optimized formulation of anastrozole-loaded chitosan microspheres: in vitro and in vivo evaluation.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Area Under Curve; Breast Neoplasms; Chitosan; Chromato | 2011 |
Sustained release optimized formulation of anastrozole-loaded chitosan microspheres: in vitro and in vivo evaluation.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Area Under Curve; Breast Neoplasms; Chitosan; Chromato | 2011 |
Association between breast cancer subtypes and response to neoadjuvant anastrozole.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; | 2011 |
Association between breast cancer subtypes and response to neoadjuvant anastrozole.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; | 2011 |
Association between breast cancer subtypes and response to neoadjuvant anastrozole.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; | 2011 |
Anastrozole-related acute hepatitis with autoimmune features: a case report.
Topics: Acute Disease; Aged; Anastrozole; Antibodies, Antinuclear; Antineoplastic Agents, Hormonal; Aromatas | 2011 |
Anastrozole-related acute hepatitis with autoimmune features: a case report.
Topics: Acute Disease; Aged; Anastrozole; Antibodies, Antinuclear; Antineoplastic Agents, Hormonal; Aromatas | 2011 |
Anastrozole-related acute hepatitis with autoimmune features: a case report.
Topics: Acute Disease; Aged; Anastrozole; Antibodies, Antinuclear; Antineoplastic Agents, Hormonal; Aromatas | 2011 |
Predictive algorithms for adjuvant therapy: TransATAC.
Topics: Algorithms; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bioma | 2011 |
Predictive algorithms for adjuvant therapy: TransATAC.
Topics: Algorithms; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bioma | 2011 |
Predictive algorithms for adjuvant therapy: TransATAC.
Topics: Algorithms; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bioma | 2011 |
An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatase Inhibitors; Breast | 2011 |
An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatase Inhibitors; Breast | 2011 |
An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatase Inhibitors; Breast | 2011 |
Ovarian hyperstimulation syndrome in a patient treated with tamoxifen for breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Substitution; Fema | 2011 |
Ovarian hyperstimulation syndrome in a patient treated with tamoxifen for breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Substitution; Fema | 2011 |
Ovarian hyperstimulation syndrome in a patient treated with tamoxifen for breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Substitution; Fema | 2011 |
Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer.
Topics: Anastrozole; Androgens; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Gas Chromatograph | 2011 |
Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer.
Topics: Anastrozole; Androgens; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Gas Chromatograph | 2011 |
Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer.
Topics: Anastrozole; Androgens; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Gas Chromatograph | 2011 |
Does trauma or an intercurrent surgical intervention lead to a short-term increase in breast cancer recurrence rates?
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Neopl | 2012 |
Does trauma or an intercurrent surgical intervention lead to a short-term increase in breast cancer recurrence rates?
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Neopl | 2012 |
Does trauma or an intercurrent surgical intervention lead to a short-term increase in breast cancer recurrence rates?
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Neopl | 2012 |
Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcin | 2011 |
Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcin | 2011 |
Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcin | 2011 |
Is primary endocrine therapy effective in treating the elderly, unfit patient with breast cancer?
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neopla | 2011 |
Is primary endocrine therapy effective in treating the elderly, unfit patient with breast cancer?
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neopla | 2011 |
Is primary endocrine therapy effective in treating the elderly, unfit patient with breast cancer?
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neopla | 2011 |
Embracing the complexity of comorbidity.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Nitri | 2011 |
Embracing the complexity of comorbidity.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Nitri | 2011 |
Embracing the complexity of comorbidity.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Nitri | 2011 |
Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combine | 2011 |
Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combine | 2011 |
Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combine | 2011 |
The breast cancer chemoprevention debate.
Topics: Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemop | 2011 |
The breast cancer chemoprevention debate.
Topics: Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemop | 2011 |
The breast cancer chemoprevention debate.
Topics: Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemop | 2011 |
Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neopla | 2012 |
Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neopla | 2012 |
Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neopla | 2012 |
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2011 |
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2011 |
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2011 |
A case of aromatase inhibitor (anastrozole)-induced side-effects successfully treated with Kampo medicines.
Topics: Aconitine; Aconitum; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; | 2011 |
A case of aromatase inhibitor (anastrozole)-induced side-effects successfully treated with Kampo medicines.
Topics: Aconitine; Aconitum; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; | 2011 |
A case of aromatase inhibitor (anastrozole)-induced side-effects successfully treated with Kampo medicines.
Topics: Aconitine; Aconitum; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; | 2011 |
Effect of simvastatin on the pharmacokinetics of anastrozole.
Topics: Aged; Anastrozole; Anticholesteremic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 2012 |
Effect of simvastatin on the pharmacokinetics of anastrozole.
Topics: Aged; Anastrozole; Anticholesteremic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 2012 |
Effect of simvastatin on the pharmacokinetics of anastrozole.
Topics: Aged; Anastrozole; Anticholesteremic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 2012 |
[Effects of anastrozole on lipid metabolism in Chinese postmenopausal women with breast cancer].
Topics: Age Factors; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibi | 2011 |
[Effects of anastrozole on lipid metabolism in Chinese postmenopausal women with breast cancer].
Topics: Age Factors; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibi | 2011 |
[Effects of anastrozole on lipid metabolism in Chinese postmenopausal women with breast cancer].
Topics: Age Factors; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibi | 2011 |
Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer.
Topics: Aged; Anastrozole; Aromatase; Aromatase Inhibitors; Biomarkers, Tumor; Biopsy, Fine-Needle; Breast N | 2012 |
Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer.
Topics: Aged; Anastrozole; Aromatase; Aromatase Inhibitors; Biomarkers, Tumor; Biopsy, Fine-Needle; Breast N | 2012 |
Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer.
Topics: Aged; Anastrozole; Aromatase; Aromatase Inhibitors; Biomarkers, Tumor; Biopsy, Fine-Needle; Breast N | 2012 |
Grover disease (transient acantholytic dermatosis) induced by anastrozole.
Topics: Acantholysis; Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Ichthyosis; | 2011 |
Grover disease (transient acantholytic dermatosis) induced by anastrozole.
Topics: Acantholysis; Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Ichthyosis; | 2011 |
Grover disease (transient acantholytic dermatosis) induced by anastrozole.
Topics: Acantholysis; Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Ichthyosis; | 2011 |
Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Computer Simulation; Cost-Benefit An | 2011 |
Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Computer Simulation; Cost-Benefit An | 2011 |
Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Computer Simulation; Cost-Benefit An | 2011 |
Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone De | 2012 |
Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone De | 2012 |
Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone De | 2012 |
Aromatase inhibitors in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; | 2012 |
Aromatase inhibitors in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; | 2012 |
Aromatase inhibitors in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; | 2012 |
Deep time: the long and the short of adjuvant endocrine therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Deep time: the long and the short of adjuvant endocrine therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Deep time: the long and the short of adjuvant endocrine therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Female; Humans; Inc | 2012 |
Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Female; Humans; Inc | 2012 |
Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Female; Humans; Inc | 2012 |
Genesis and outcome of a breast cancer trial to develop the aromatase inhibitor anastrozole.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Nitrile | 2012 |
Genesis and outcome of a breast cancer trial to develop the aromatase inhibitor anastrozole.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Nitrile | 2012 |
Genesis and outcome of a breast cancer trial to develop the aromatase inhibitor anastrozole.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Nitrile | 2012 |
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2012 |
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2012 |
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2012 |
[A case of recurrent breast cancer with brain metastases successfully treated with vinorelbine and anastrozole after multiple chemo-endocrine therapies].
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Fema | 2012 |
[A case of recurrent breast cancer with brain metastases successfully treated with vinorelbine and anastrozole after multiple chemo-endocrine therapies].
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Fema | 2012 |
[A case of recurrent breast cancer with brain metastases successfully treated with vinorelbine and anastrozole after multiple chemo-endocrine therapies].
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Fema | 2012 |
Polyendocrine treatment in estrogen receptor-positive breast cancer: a "FACT" yet to be proven.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fu | 2012 |
Polyendocrine treatment in estrogen receptor-positive breast cancer: a "FACT" yet to be proven.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fu | 2012 |
Polyendocrine treatment in estrogen receptor-positive breast cancer: a "FACT" yet to be proven.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fu | 2012 |
Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial.
Topics: Absorptiometry, Photon; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Densit | 2012 |
Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial.
Topics: Absorptiometry, Photon; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Densit | 2012 |
Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial.
Topics: Absorptiometry, Photon; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Densit | 2012 |
Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Double | 2012 |
Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Double | 2012 |
Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Double | 2012 |
Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estrogens | 2012 |
Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estrogens | 2012 |
Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estrogens | 2012 |
Impact of Aromatase protein variants and drug interactions in breast cancer: a molecular docking approach.
Topics: Anastrozole; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Catalytic Domain; Drug Interactions; | 2012 |
Impact of Aromatase protein variants and drug interactions in breast cancer: a molecular docking approach.
Topics: Anastrozole; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Catalytic Domain; Drug Interactions; | 2012 |
Impact of Aromatase protein variants and drug interactions in breast cancer: a molecular docking approach.
Topics: Anastrozole; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Catalytic Domain; Drug Interactions; | 2012 |
Whole-genome analysis informs breast cancer response to aromatase inhibition.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasm | 2012 |
Whole-genome analysis informs breast cancer response to aromatase inhibition.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasm | 2012 |
Whole-genome analysis informs breast cancer response to aromatase inhibition.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasm | 2012 |
Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; | 2012 |
Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; | 2012 |
Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; | 2012 |
Inflammatory osteoarthritis which was precipitated by Arimidex and resolved with tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Female; Humans; | 2010 |
Inflammatory osteoarthritis which was precipitated by Arimidex and resolved with tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Female; Humans; | 2010 |
Inflammatory osteoarthritis which was precipitated by Arimidex and resolved with tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Female; Humans; | 2010 |
Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Ma | 2012 |
Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Ma | 2012 |
Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Ma | 2012 |
Aromatase inhibition in obese women: how much is enough?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasm | 2012 |
Aromatase inhibition in obese women: how much is enough?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasm | 2012 |
Aromatase inhibition in obese women: how much is enough?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasm | 2012 |
Breast cancer: Anastrozole and fulvestrant--combination to unlock efficacy.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fu | 2012 |
Breast cancer: Anastrozole and fulvestrant--combination to unlock efficacy.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fu | 2012 |
Breast cancer: Anastrozole and fulvestrant--combination to unlock efficacy.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fu | 2012 |
Lichen sclerosus in a breast cancer survivor on an aromatase inhibitor: a case report.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clobetasol; Dr | 2013 |
Lichen sclerosus in a breast cancer survivor on an aromatase inhibitor: a case report.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clobetasol; Dr | 2013 |
Lichen sclerosus in a breast cancer survivor on an aromatase inhibitor: a case report.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clobetasol; Dr | 2013 |
Dry eye syndrome in aromatase inhibitor users.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inh | 2013 |
Dry eye syndrome in aromatase inhibitor users.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inh | 2013 |
Dry eye syndrome in aromatase inhibitor users.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inh | 2013 |
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2013 |
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2013 |
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2013 |
Adherence evaluation of endocrine treatment in breast cancer: methodological aspects.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Data | 2012 |
Adherence evaluation of endocrine treatment in breast cancer: methodological aspects.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Data | 2012 |
Adherence evaluation of endocrine treatment in breast cancer: methodological aspects.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Data | 2012 |
Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Disease-Free Survival; F | 2012 |
Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Disease-Free Survival; F | 2012 |
Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Disease-Free Survival; F | 2012 |
Aromatase inhibitors associated with knee subchondral bone expansion without cartilage loss.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Female; Humans; Letrozole | 2013 |
Aromatase inhibitors associated with knee subchondral bone expansion without cartilage loss.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Female; Humans; Letrozole | 2013 |
Aromatase inhibitors associated with knee subchondral bone expansion without cartilage loss.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Female; Humans; Letrozole | 2013 |
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Budgets; Cost-Benefit Analysis; Drug Costs; Er | 2013 |
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Budgets; Cost-Benefit Analysis; Drug Costs; Er | 2013 |
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Budgets; Cost-Benefit Analysis; Drug Costs; Er | 2013 |
[Quality of life analysis of postmenopausal, early breast cancer patients treated with anastrozole (RADAR-II)].
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2012 |
[Quality of life analysis of postmenopausal, early breast cancer patients treated with anastrozole (RADAR-II)].
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2012 |
[Quality of life analysis of postmenopausal, early breast cancer patients treated with anastrozole (RADAR-II)].
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2012 |
[A successful case of a super-elderly breast cancer patient treated with hormone therapy].
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy, Large-Core Needle; Breast N | 2012 |
[A successful case of a super-elderly breast cancer patient treated with hormone therapy].
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy, Large-Core Needle; Breast N | 2012 |
[A successful case of a super-elderly breast cancer patient treated with hormone therapy].
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy, Large-Core Needle; Breast N | 2012 |
A multicenter prospective study to evaluate bone fracture related to adjuvant anastrozole in Japanese postmenopausal women with breast cancer: two-year interim analysis of Saitama Breast Cancer Clinical Study Group (SBCCSG-06).
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; | 2014 |
A multicenter prospective study to evaluate bone fracture related to adjuvant anastrozole in Japanese postmenopausal women with breast cancer: two-year interim analysis of Saitama Breast Cancer Clinical Study Group (SBCCSG-06).
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; | 2014 |
A multicenter prospective study to evaluate bone fracture related to adjuvant anastrozole in Japanese postmenopausal women with breast cancer: two-year interim analysis of Saitama Breast Cancer Clinical Study Group (SBCCSG-06).
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; | 2014 |
What is the optimal endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2013 |
What is the optimal endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2013 |
What is the optimal endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2013 |
Acupuncture for the treatment of hot flashes in patients with breast cancer receiving antiestrogen therapy: a pilot study in Korean women.
Topics: Acupuncture Therapy; Analysis of Variance; Anastrozole; Breast Neoplasms; Estrogen Antagonists; Fema | 2013 |
Acupuncture for the treatment of hot flashes in patients with breast cancer receiving antiestrogen therapy: a pilot study in Korean women.
Topics: Acupuncture Therapy; Analysis of Variance; Anastrozole; Breast Neoplasms; Estrogen Antagonists; Fema | 2013 |
Acupuncture for the treatment of hot flashes in patients with breast cancer receiving antiestrogen therapy: a pilot study in Korean women.
Topics: Acupuncture Therapy; Analysis of Variance; Anastrozole; Breast Neoplasms; Estrogen Antagonists; Fema | 2013 |
Promising results for Arimidex and Femara.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; | 2001 |
Promising results for Arimidex and Femara.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; | 2001 |
Promising results for Arimidex and Femara.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; | 2001 |
Stick with tried-and-true breast cancer treatment.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Tamoxifen; | 2002 |
Stick with tried-and-true breast cancer treatment.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Tamoxifen; | 2002 |
Stick with tried-and-true breast cancer treatment.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Tamoxifen; | 2002 |
New alternative to tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Huma | 2002 |
New alternative to tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Huma | 2002 |
New alternative to tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Huma | 2002 |
Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androgens; Biological Availability; Biomarkers; Biopsy, | 2002 |
Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androgens; Biological Availability; Biomarkers; Biopsy, | 2002 |
Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androgens; Biological Availability; Biomarkers; Biopsy, | 2002 |
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer: methodologic issues.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Randomized | 2002 |
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer: methodologic issues.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Randomized | 2002 |
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer: methodologic issues.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Randomized | 2002 |
[Advanced breast cancer with lung and pleural metastases responsive to anastrozole--a case report].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duc | 2002 |
[Advanced breast cancer with lung and pleural metastases responsive to anastrozole--a case report].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duc | 2002 |
[Advanced breast cancer with lung and pleural metastases responsive to anastrozole--a case report].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duc | 2002 |
[Campaign against breast cancer. Are aromatase inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2002 |
[Campaign against breast cancer. Are aromatase inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2002 |
[Campaign against breast cancer. Are aromatase inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2002 |
Anastrozole versus progestins/tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Forecasting; Humans; Multice | 2002 |
Anastrozole versus progestins/tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Forecasting; Humans; Multice | 2002 |
Anastrozole versus progestins/tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Forecasting; Humans; Multice | 2002 |
Selective oestrogen receptor downregulator.
Topics: Anastrozole; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Down-Regulation; Estra | 2002 |
Selective oestrogen receptor downregulator.
Topics: Anastrozole; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Down-Regulation; Estra | 2002 |
Selective oestrogen receptor downregulator.
Topics: Anastrozole; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Down-Regulation; Estra | 2002 |
From the Food and Drug Administration.
Topics: Adenine; Anastrozole; Antineoplastic Agents, Hormonal; Antiviral Agents; Breast Neoplasms; Chemother | 2002 |
From the Food and Drug Administration.
Topics: Adenine; Anastrozole; Antineoplastic Agents, Hormonal; Antiviral Agents; Breast Neoplasms; Chemother | 2002 |
From the Food and Drug Administration.
Topics: Adenine; Anastrozole; Antineoplastic Agents, Hormonal; Antiviral Agents; Breast Neoplasms; Chemother | 2002 |
Invasive lobular carcinoma of the breast presenting successively with colonic and gastric metastases.
Topics: Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Colonic | 2002 |
Invasive lobular carcinoma of the breast presenting successively with colonic and gastric metastases.
Topics: Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Colonic | 2002 |
Invasive lobular carcinoma of the breast presenting successively with colonic and gastric metastases.
Topics: Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Colonic | 2002 |
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast carcinoma.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Disease Pr | 2002 |
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast carcinoma.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Disease Pr | 2002 |
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast carcinoma.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Disease Pr | 2002 |
Current role of endocrine therapy in the management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical | 2002 |
Current role of endocrine therapy in the management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical | 2002 |
Current role of endocrine therapy in the management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical | 2002 |
Has tamoxifen had its day?
Topics: Anastrozole; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Nitri | 2002 |
Has tamoxifen had its day?
Topics: Anastrozole; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Nitri | 2002 |
Has tamoxifen had its day?
Topics: Anastrozole; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Nitri | 2002 |
A new day dawns: women without oestrogen or is a balance best?
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; | 2002 |
A new day dawns: women without oestrogen or is a balance best?
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; | 2002 |
A new day dawns: women without oestrogen or is a balance best?
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; | 2002 |
Questions about anastrozole for early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Disease Pr | 2002 |
Questions about anastrozole for early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Disease Pr | 2002 |
Questions about anastrozole for early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Disease Pr | 2002 |
Questions about anastrozole for early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Disease Pr | 2002 |
Questions about anastrozole for early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Disease Pr | 2002 |
Questions about anastrozole for early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Disease Pr | 2002 |
Advances in breast oncology: the 2002 ASCO meeting.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase Inhibitor | 2002 |
Advances in breast oncology: the 2002 ASCO meeting.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase Inhibitor | 2002 |
Advances in breast oncology: the 2002 ASCO meeting.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase Inhibitor | 2002 |
New treatment option for postmenopausal women with early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug App | 2002 |
New treatment option for postmenopausal women with early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug App | 2002 |
New treatment option for postmenopausal women with early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug App | 2002 |
[A case of recurrent breast cancer with carcinomatous pleurisy successfully treated with combined chemoendocrine-therapy of CTF (CPA, THP and 5-FU) and anastrozole following instillation therapy 12 years after radical mastectomy].
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carci | 2002 |
[A case of recurrent breast cancer with carcinomatous pleurisy successfully treated with combined chemoendocrine-therapy of CTF (CPA, THP and 5-FU) and anastrozole following instillation therapy 12 years after radical mastectomy].
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carci | 2002 |
[A case of recurrent breast cancer with carcinomatous pleurisy successfully treated with combined chemoendocrine-therapy of CTF (CPA, THP and 5-FU) and anastrozole following instillation therapy 12 years after radical mastectomy].
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carci | 2002 |
[Summit meeting of breast cancer experts--many new ideas and practical progress. When the breast becomes malignant].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 2003 |
[Summit meeting of breast cancer experts--many new ideas and practical progress. When the breast becomes malignant].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 2003 |
[Summit meeting of breast cancer experts--many new ideas and practical progress. When the breast becomes malignant].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 2003 |
Update on ATAC.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 2003 |
Update on ATAC.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 2003 |
Update on ATAC.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 2003 |
Anastrozole (Arimidex) vs. tamoxifen for treatment of early breast cancer.
Topics: Anastrozole; Asthenia; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; E | 2003 |
Anastrozole (Arimidex) vs. tamoxifen for treatment of early breast cancer.
Topics: Anastrozole; Asthenia; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; E | 2003 |
Anastrozole (Arimidex) vs. tamoxifen for treatment of early breast cancer.
Topics: Anastrozole; Asthenia; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; E | 2003 |
Anastrozole-induced remission of diaphragmatic paralysis from metastatic breast cancer treated with multiple prior therapies.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined | 2003 |
Anastrozole-induced remission of diaphragmatic paralysis from metastatic breast cancer treated with multiple prior therapies.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined | 2003 |
Anastrozole-induced remission of diaphragmatic paralysis from metastatic breast cancer treated with multiple prior therapies.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined | 2003 |
Anastrozole as a preventive agent in breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrat | 2003 |
Anastrozole as a preventive agent in breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrat | 2003 |
Anastrozole as a preventive agent in breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrat | 2003 |
Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Canada; Cost-B | 2003 |
Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Canada; Cost-B | 2003 |
Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Canada; Cost-B | 2003 |
ATAC trial: reporting interim results is not helpful.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 2003 |
ATAC trial: reporting interim results is not helpful.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 2003 |
ATAC trial: reporting interim results is not helpful.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 2003 |
Breast cancer prevention.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Utilization; Female; Humans; Ni | 2003 |
Breast cancer prevention.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Utilization; Female; Humans; Ni | 2003 |
Breast cancer prevention.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Utilization; Female; Humans; Ni | 2003 |
[Hormone therapy, chemotherapy and immunotherapy in breast carcinoma. The best strategy for your patient].
Topics: Adult; Age Factors; Aged; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; An | 2003 |
[Hormone therapy, chemotherapy and immunotherapy in breast carcinoma. The best strategy for your patient].
Topics: Adult; Age Factors; Aged; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; An | 2003 |
[Hormone therapy, chemotherapy and immunotherapy in breast carcinoma. The best strategy for your patient].
Topics: Adult; Age Factors; Aged; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; An | 2003 |
Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Ca | 2003 |
Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Ca | 2003 |
Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Ca | 2003 |
Examining quality of life issues in relation to endocrine therapy for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Decision Makin | 2003 |
Examining quality of life issues in relation to endocrine therapy for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Decision Makin | 2003 |
Examining quality of life issues in relation to endocrine therapy for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Decision Makin | 2003 |
Anastrozole for ductal carcinoma in situ.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Attitude to Health; Breast Neoplasms; Carcinoma in Sit | 2003 |
Anastrozole for ductal carcinoma in situ.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Attitude to Health; Breast Neoplasms; Carcinoma in Sit | 2003 |
Anastrozole for ductal carcinoma in situ.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Attitude to Health; Breast Neoplasms; Carcinoma in Sit | 2003 |
Doctors test drug to prevent cancer in high risk women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, | 2003 |
Doctors test drug to prevent cancer in high risk women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, | 2003 |
Doctors test drug to prevent cancer in high risk women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, | 2003 |
Future directions in the endocrine therapy of breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Endocrine | 2003 |
Future directions in the endocrine therapy of breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Endocrine | 2003 |
Future directions in the endocrine therapy of breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Endocrine | 2003 |
Adjuvant aromatase inhibitors: are we there yet?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2003 |
Adjuvant aromatase inhibitors: are we there yet?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2003 |
Adjuvant aromatase inhibitors: are we there yet?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2003 |
ATAC trial did not report interim results.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 2003 |
ATAC trial did not report interim results.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 2003 |
ATAC trial did not report interim results.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 2003 |
The effects of hormone therapy on cognition in breast cancer.
Topics: Affect; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combin | 2003 |
The effects of hormone therapy on cognition in breast cancer.
Topics: Affect; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combin | 2003 |
The effects of hormone therapy on cognition in breast cancer.
Topics: Affect; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combin | 2003 |
Hormonal therapy: introduction.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Controlled C | 2003 |
Hormonal therapy: introduction.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Controlled C | 2003 |
Hormonal therapy: introduction.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Controlled C | 2003 |
Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Cost-Benef | 2003 |
Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Cost-Benef | 2003 |
Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Cost-Benef | 2003 |
Spreading the word, but not too thinly.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Editorial Policies; Estradiol; Femal | 2004 |
Spreading the word, but not too thinly.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Editorial Policies; Estradiol; Femal | 2004 |
Spreading the word, but not too thinly.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Editorial Policies; Estradiol; Femal | 2004 |
Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemoth | 2004 |
Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemoth | 2004 |
Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemoth | 2004 |
Prevention strategies with aromatase inhibitors.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 2004 |
Prevention strategies with aromatase inhibitors.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 2004 |
Prevention strategies with aromatase inhibitors.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 2004 |
Feasibility of sentinel node biopsy for breast cancer after neoadjuvant endocrine therapy: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Anthracyclines; Antineoplastic Agents, Hormonal; Antine | 2004 |
Feasibility of sentinel node biopsy for breast cancer after neoadjuvant endocrine therapy: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Anthracyclines; Antineoplastic Agents, Hormonal; Antine | 2004 |
Feasibility of sentinel node biopsy for breast cancer after neoadjuvant endocrine therapy: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Anthracyclines; Antineoplastic Agents, Hormonal; Antine | 2004 |
[New prevention strategies against breast cancer and cervical carcinoma. What can you advice to your patients].
Topics: Adolescent; Adult; Age Factors; Anastrozole; Anticarcinogenic Agents; Breast Neoplasms; Celecoxib; C | 2003 |
[New prevention strategies against breast cancer and cervical carcinoma. What can you advice to your patients].
Topics: Adolescent; Adult; Age Factors; Anastrozole; Anticarcinogenic Agents; Breast Neoplasms; Celecoxib; C | 2003 |
[New prevention strategies against breast cancer and cervical carcinoma. What can you advice to your patients].
Topics: Adolescent; Adult; Age Factors; Anastrozole; Anticarcinogenic Agents; Breast Neoplasms; Celecoxib; C | 2003 |
[Interview with Prof. Dr. Wolfgang Eiermann. Which women need a medicamentous breast cancer prophylaxis?].
Topics: Age Factors; Anastrozole; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme In | 2003 |
[Interview with Prof. Dr. Wolfgang Eiermann. Which women need a medicamentous breast cancer prophylaxis?].
Topics: Age Factors; Anastrozole; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme In | 2003 |
[Interview with Prof. Dr. Wolfgang Eiermann. Which women need a medicamentous breast cancer prophylaxis?].
Topics: Age Factors; Anastrozole; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme In | 2003 |
[The uterine sarcoma, a new risk identified for tamoxifen].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinos | 2004 |
[The uterine sarcoma, a new risk identified for tamoxifen].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinos | 2004 |
[The uterine sarcoma, a new risk identified for tamoxifen].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinos | 2004 |
Adjuvant use of anastrozole in breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Huma | 2004 |
Adjuvant use of anastrozole in breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Huma | 2004 |
Adjuvant use of anastrozole in breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Huma | 2004 |
Comment on "Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results" by J.-M. Nabholtz et al.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Letrozole; Ni | 2004 |
Comment on "Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results" by J.-M. Nabholtz et al.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Letrozole; Ni | 2004 |
Comment on "Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results" by J.-M. Nabholtz et al.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Letrozole; Ni | 2004 |
Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy.
Topics: Adult; Aged; Anastrozole; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Goserelin; Human | 2004 |
Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy.
Topics: Adult; Aged; Anastrozole; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Goserelin; Human | 2004 |
Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy.
Topics: Adult; Aged; Anastrozole; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Goserelin; Human | 2004 |
An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the Aromatase inhibitors letrozole and anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; | 2004 |
An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the Aromatase inhibitors letrozole and anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; | 2004 |
An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the Aromatase inhibitors letrozole and anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; | 2004 |
[Ulcus terebrans. Therapy options and their limits].
Topics: Aged; Anastrozole; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Ductal, Breast; Combined Moda | 2004 |
[Ulcus terebrans. Therapy options and their limits].
Topics: Aged; Anastrozole; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Ductal, Breast; Combined Moda | 2004 |
[Ulcus terebrans. Therapy options and their limits].
Topics: Aged; Anastrozole; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Ductal, Breast; Combined Moda | 2004 |
Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Combin | 2004 |
Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Combin | 2004 |
Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Combin | 2004 |
[Therapeutic effects of Anastrozole in patients with advanced and recurrent breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chol | 2004 |
[Therapeutic effects of Anastrozole in patients with advanced and recurrent breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chol | 2004 |
[Therapeutic effects of Anastrozole in patients with advanced and recurrent breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chol | 2004 |
[Combination therapy with Anastrozole and 5'-DFUR as a treatment for metastatic breast cancer].
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 2004 |
[Combination therapy with Anastrozole and 5'-DFUR as a treatment for metastatic breast cancer].
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 2004 |
[Combination therapy with Anastrozole and 5'-DFUR as a treatment for metastatic breast cancer].
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 2004 |
Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2004 |
Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2004 |
Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2004 |
Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Budgets; Cost- | 2004 |
Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Budgets; Cost- | 2004 |
Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Budgets; Cost- | 2004 |
[Anastrozole-resistant breast cancer responsive to exemestane--a case report].
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast | 2004 |
[Anastrozole-resistant breast cancer responsive to exemestane--a case report].
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast | 2004 |
[Anastrozole-resistant breast cancer responsive to exemestane--a case report].
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast | 2004 |
The responsiveness of a tumour to any kind of therapy is reflected by the objective response rate.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Triazoles | 2004 |
The responsiveness of a tumour to any kind of therapy is reflected by the objective response rate.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Triazoles | 2004 |
The responsiveness of a tumour to any kind of therapy is reflected by the objective response rate.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Triazoles | 2004 |
Arimidex inhibition on proliferation of human breast solid tumors measured by ATP bioluminescence.
Topics: Adenosine Triphosphatases; Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormo | 2004 |
Arimidex inhibition on proliferation of human breast solid tumors measured by ATP bioluminescence.
Topics: Adenosine Triphosphatases; Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormo | 2004 |
Arimidex inhibition on proliferation of human breast solid tumors measured by ATP bioluminescence.
Topics: Adenosine Triphosphatases; Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormo | 2004 |
Oestrogen-selective modulation of FSH and LH secretion by pituitary gland.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogens; Female; Follicle Stimulat | 2005 |
Oestrogen-selective modulation of FSH and LH secretion by pituitary gland.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogens; Female; Follicle Stimulat | 2005 |
Oestrogen-selective modulation of FSH and LH secretion by pituitary gland.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogens; Female; Follicle Stimulat | 2005 |
Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bon | 2004 |
Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bon | 2004 |
Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bon | 2004 |
How rapidly do oncologists respond to clinical trial data?
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical | 2005 |
How rapidly do oncologists respond to clinical trial data?
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical | 2005 |
How rapidly do oncologists respond to clinical trial data?
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical | 2005 |
Anastrozole data show continued delay in relapse, but no clear survival advantage.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2005 |
Anastrozole data show continued delay in relapse, but no clear survival advantage.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2005 |
Anastrozole data show continued delay in relapse, but no clear survival advantage.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2005 |
Expression of estrogen receptors-alpha and -beta in primary breast neoplasms and tumors exposed to neoadjuvant hormonal therapy.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2004 |
Expression of estrogen receptors-alpha and -beta in primary breast neoplasms and tumors exposed to neoadjuvant hormonal therapy.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2004 |
Expression of estrogen receptors-alpha and -beta in primary breast neoplasms and tumors exposed to neoadjuvant hormonal therapy.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2004 |
[Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report].
Topics: Adenocarcinoma, Scirrhous; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2005 |
[Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report].
Topics: Adenocarcinoma, Scirrhous; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2005 |
[Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report].
Topics: Adenocarcinoma, Scirrhous; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2005 |
[Breast carcinoma: new, much promising trends. The cancer anxiety of women -- will be taken better care soon?].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Austria; Breast Neoplasms; Clini | 2005 |
[Breast carcinoma: new, much promising trends. The cancer anxiety of women -- will be taken better care soon?].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Austria; Breast Neoplasms; Clini | 2005 |
[Breast carcinoma: new, much promising trends. The cancer anxiety of women -- will be taken better care soon?].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Austria; Breast Neoplasms; Clini | 2005 |
[New strategies against breast carcinoma. To outwit the resistance tendency of tumor cells].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2005 |
[New strategies against breast carcinoma. To outwit the resistance tendency of tumor cells].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2005 |
[New strategies against breast carcinoma. To outwit the resistance tendency of tumor cells].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2005 |
Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cell Division; | 2005 |
Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cell Division; | 2005 |
Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cell Division; | 2005 |
Remission of macroglobulinemia during anastrozole treatment for breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinom | 2005 |
Remission of macroglobulinemia during anastrozole treatment for breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinom | 2005 |
Remission of macroglobulinemia during anastrozole treatment for breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinom | 2005 |
[Three cases of advanced breast cancer successfully treated with a weekly dose of paclitaxel].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone N | 2005 |
[Three cases of advanced breast cancer successfully treated with a weekly dose of paclitaxel].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone N | 2005 |
[Three cases of advanced breast cancer successfully treated with a weekly dose of paclitaxel].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone N | 2005 |
Current and future perspectives on fulvestrant.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Dose-Respo | 2005 |
Current and future perspectives on fulvestrant.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Dose-Respo | 2005 |
Current and future perspectives on fulvestrant.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Dose-Respo | 2005 |
Alternative to tamoxifen effective for preventing breast cancer recurrence.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 2005 |
Alternative to tamoxifen effective for preventing breast cancer recurrence.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 2005 |
Alternative to tamoxifen effective for preventing breast cancer recurrence.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 2005 |
Regression of choroidal metastases from breast carcinoma using aromatase inhibitors.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Choroid | 2005 |
Regression of choroidal metastases from breast carcinoma using aromatase inhibitors.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Choroid | 2005 |
Regression of choroidal metastases from breast carcinoma using aromatase inhibitors.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Choroid | 2005 |
Selected highlights from the 27th San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2004.
Topics: Anastrozole; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2005 |
Selected highlights from the 27th San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2004.
Topics: Anastrozole; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2005 |
Selected highlights from the 27th San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2004.
Topics: Anastrozole; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2005 |
Aromatase inhibitors: cellular and molecular effects.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Pro | 2005 |
Aromatase inhibitors: cellular and molecular effects.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Pro | 2005 |
Aromatase inhibitors: cellular and molecular effects.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Pro | 2005 |
Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neopla | 2005 |
Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neopla | 2005 |
Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neopla | 2005 |
Case records of the Massachusetts General Hospital. Case 24-2005. A 58-year-old woman with early-stage estrogen-receptor-positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemother | 2005 |
Case records of the Massachusetts General Hospital. Case 24-2005. A 58-year-old woman with early-stage estrogen-receptor-positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemother | 2005 |
Case records of the Massachusetts General Hospital. Case 24-2005. A 58-year-old woman with early-stage estrogen-receptor-positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemother | 2005 |
Promising switch to anastrozole for breast-cancer treatment.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Nitriles; Triazoles | 2005 |
Promising switch to anastrozole for breast-cancer treatment.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Nitriles; Triazoles | 2005 |
Promising switch to anastrozole for breast-cancer treatment.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Nitriles; Triazoles | 2005 |
[Neoadjuvant endocrine therapy with anastrozole significantly downstaged an elderly breast cancer woman with locally-advanced breast cancer which became operable].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Duc | 2005 |
[Neoadjuvant endocrine therapy with anastrozole significantly downstaged an elderly breast cancer woman with locally-advanced breast cancer which became operable].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Duc | 2005 |
[Neoadjuvant endocrine therapy with anastrozole significantly downstaged an elderly breast cancer woman with locally-advanced breast cancer which became operable].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Duc | 2005 |
[Aromatase inhibitors in the treatment of breast cancer: current status and some problems].
Topics: Adult; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozol | 2005 |
[Aromatase inhibitors in the treatment of breast cancer: current status and some problems].
Topics: Adult; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozol | 2005 |
[Aromatase inhibitors in the treatment of breast cancer: current status and some problems].
Topics: Adult; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozol | 2005 |
A step too far?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Approval; | 2005 |
A step too far?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Approval; | 2005 |
A step too far?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Approval; | 2005 |
Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cel | 2005 |
Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cel | 2005 |
Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cel | 2005 |
Case 24-2005: a woman with estrogen-receptor-positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Diseases, Metabolic; Breast Neoplasms; Chemothera | 2005 |
Case 24-2005: a woman with estrogen-receptor-positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Diseases, Metabolic; Breast Neoplasms; Chemothera | 2005 |
Case 24-2005: a woman with estrogen-receptor-positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Diseases, Metabolic; Breast Neoplasms; Chemothera | 2005 |
Lobular carcinoma of the breast metastatic to the uterus in a patient under adjuvant anastrozole therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duc | 2006 |
Lobular carcinoma of the breast metastatic to the uterus in a patient under adjuvant anastrozole therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duc | 2006 |
Lobular carcinoma of the breast metastatic to the uterus in a patient under adjuvant anastrozole therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duc | 2006 |
Anal localization as first manifestation of metastatic ductal breast carcinoma.
Topics: Aged; Anastrozole; Anus Neoplasms; Biopsy, Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Chem | 2005 |
Anal localization as first manifestation of metastatic ductal breast carcinoma.
Topics: Aged; Anastrozole; Anus Neoplasms; Biopsy, Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Chem | 2005 |
Anal localization as first manifestation of metastatic ductal breast carcinoma.
Topics: Aged; Anastrozole; Anus Neoplasms; Biopsy, Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Chem | 2005 |
Treatment guidelines for adjuvant breast cancer are moving toward double standards: one for the rich and one for the poor.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Decision Mak | 2005 |
Treatment guidelines for adjuvant breast cancer are moving toward double standards: one for the rich and one for the poor.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Decision Mak | 2005 |
Treatment guidelines for adjuvant breast cancer are moving toward double standards: one for the rich and one for the poor.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Decision Mak | 2005 |
Influence of adjuvant anastrozole on bone mineral density in Japanese postmenopausal breast cancer patients: is there a racial difference?
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Asian People; Biomarkers; Bone Density; Breast N | 2006 |
Influence of adjuvant anastrozole on bone mineral density in Japanese postmenopausal breast cancer patients: is there a racial difference?
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Asian People; Biomarkers; Bone Density; Breast N | 2006 |
Influence of adjuvant anastrozole on bone mineral density in Japanese postmenopausal breast cancer patients: is there a racial difference?
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Asian People; Biomarkers; Bone Density; Breast N | 2006 |
Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Improvement in dermatomyositis rash associated with the use of antiestrogen medication.
Topics: Adult; Anastrozole; Biopsy; Breast Neoplasms; Dermatomyositis; Diagnosis, Differential; Estrogen Ant | 2006 |
Improvement in dermatomyositis rash associated with the use of antiestrogen medication.
Topics: Adult; Anastrozole; Biopsy; Breast Neoplasms; Dermatomyositis; Diagnosis, Differential; Estrogen Ant | 2006 |
Improvement in dermatomyositis rash associated with the use of antiestrogen medication.
Topics: Adult; Anastrozole; Biopsy; Breast Neoplasms; Dermatomyositis; Diagnosis, Differential; Estrogen Ant | 2006 |
Anastrozole called breast cancer "lifesaver". Recipients showed a 40 percent decrease in relapse risk when switched to anastrazole after tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, | 2005 |
Anastrozole called breast cancer "lifesaver". Recipients showed a 40 percent decrease in relapse risk when switched to anastrazole after tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, | 2005 |
Anastrozole called breast cancer "lifesaver". Recipients showed a 40 percent decrease in relapse risk when switched to anastrazole after tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, | 2005 |
Latest studies hint at survival advantage with aromatase inhibitors in early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Europe; Female | 2006 |
Latest studies hint at survival advantage with aromatase inhibitors in early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Europe; Female | 2006 |
Latest studies hint at survival advantage with aromatase inhibitors in early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Europe; Female | 2006 |
Photodynamic therapy for solitary retinal metastasis from breast carcinoma.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Combined Modality Therapy | 2006 |
Photodynamic therapy for solitary retinal metastasis from breast carcinoma.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Combined Modality Therapy | 2006 |
Photodynamic therapy for solitary retinal metastasis from breast carcinoma.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Combined Modality Therapy | 2006 |
[Advance and current status of exemestane and androstadienes in the treatment of breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2005 |
[Advance and current status of exemestane and androstadienes in the treatment of breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2005 |
[Advance and current status of exemestane and androstadienes in the treatment of breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2005 |
Changing the gold standard in adjuvant therapy for breast cancer:from tamoxifen to aromatase inhibition.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2005 |
Changing the gold standard in adjuvant therapy for breast cancer:from tamoxifen to aromatase inhibition.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2005 |
Changing the gold standard in adjuvant therapy for breast cancer:from tamoxifen to aromatase inhibition.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2005 |
Does survival increase in metastatic breast cancer with recently available anticancer drugs?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Ne | 2006 |
Does survival increase in metastatic breast cancer with recently available anticancer drugs?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Ne | 2006 |
Does survival increase in metastatic breast cancer with recently available anticancer drugs?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Ne | 2006 |
Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.
Topics: Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe | 2006 |
Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.
Topics: Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe | 2006 |
Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.
Topics: Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe | 2006 |
[Advances in the treatment of breast carcinoma. New therapy schedules with astonishing success quotas].
Topics: Age Factors; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic | 2006 |
[Advances in the treatment of breast carcinoma. New therapy schedules with astonishing success quotas].
Topics: Age Factors; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic | 2006 |
[Advances in the treatment of breast carcinoma. New therapy schedules with astonishing success quotas].
Topics: Age Factors; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic | 2006 |
Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2006 |
Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2006 |
Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2006 |
Identification of the aromatase inhibitors anastrozole and exemestane in human urine using liquid chromatography/tandem mass spectrometry.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
Identification of the aromatase inhibitors anastrozole and exemestane in human urine using liquid chromatography/tandem mass spectrometry.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
Identification of the aromatase inhibitors anastrozole and exemestane in human urine using liquid chromatography/tandem mass spectrometry.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.
Topics: Adult; Amenorrhea; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 2006 |
Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.
Topics: Adult; Amenorrhea; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 2006 |
Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.
Topics: Adult; Amenorrhea; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 2006 |
Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
Primary hormone treatment in postmenopausal women with breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2006 |
Primary hormone treatment in postmenopausal women with breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2006 |
Primary hormone treatment in postmenopausal women with breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2006 |
Estrogen receptors: role in breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta | 2006 |
Estrogen receptors: role in breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta | 2006 |
Estrogen receptors: role in breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta | 2006 |
Management of choroidal metastases from breast carcinomas using aromatase inhibitors.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemot | 2006 |
Management of choroidal metastases from breast carcinomas using aromatase inhibitors.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemot | 2006 |
Management of choroidal metastases from breast carcinomas using aromatase inhibitors.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemot | 2006 |
Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2006 |
Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2006 |
Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2006 |
Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe | 2007 |
Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe | 2007 |
Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe | 2007 |
Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Mod | 2006 |
Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Mod | 2006 |
Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Mod | 2006 |
Joint symptoms: a practical problem of anastrozole.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Fema | 2006 |
Joint symptoms: a practical problem of anastrozole.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Fema | 2006 |
Joint symptoms: a practical problem of anastrozole.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Fema | 2006 |
Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoth | 2006 |
Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoth | 2006 |
Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoth | 2006 |
Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost | 2006 |
Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost | 2006 |
Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost | 2006 |
Anastrozole-induced hepatotoxicity.
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neopla | 2006 |
Anastrozole-induced hepatotoxicity.
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neopla | 2006 |
Anastrozole-induced hepatotoxicity.
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neopla | 2006 |
Aromatase inhibitors and bipolar mood disorder: a case report.
Topics: Aggression; Anastrozole; Aromatase Inhibitors; Bipolar Disorder; Breast Neoplasms; Carcinoma, Lobula | 2006 |
Aromatase inhibitors and bipolar mood disorder: a case report.
Topics: Aggression; Anastrozole; Aromatase Inhibitors; Bipolar Disorder; Breast Neoplasms; Carcinoma, Lobula | 2006 |
Aromatase inhibitors and bipolar mood disorder: a case report.
Topics: Aggression; Anastrozole; Aromatase Inhibitors; Bipolar Disorder; Breast Neoplasms; Carcinoma, Lobula | 2006 |
Henoch-Schönlein purpura (HSP) during treatment with anastrozole.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neop | 2007 |
Henoch-Schönlein purpura (HSP) during treatment with anastrozole.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neop | 2007 |
Henoch-Schönlein purpura (HSP) during treatment with anastrozole.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neop | 2007 |
Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2007 |
Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2007 |
Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2007 |
Clinically occult cutaneous metastases.
Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormon | 2006 |
Clinically occult cutaneous metastases.
Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormon | 2006 |
Clinically occult cutaneous metastases.
Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormon | 2006 |
Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Ind | 2006 |
Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Ind | 2006 |
Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Ind | 2006 |
Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe | 2007 |
Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe | 2007 |
Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe | 2007 |
[Two patients having recurrent breast cancer with brain metastases well controlled with a gamma knife radio-surgery].
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Fema | 2006 |
[Two patients having recurrent breast cancer with brain metastases well controlled with a gamma knife radio-surgery].
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Fema | 2006 |
[Two patients having recurrent breast cancer with brain metastases well controlled with a gamma knife radio-surgery].
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Fema | 2006 |
[Locally advanced breast cancer with a good response to sequential endocrine monotherapy--a case report].
Topics: Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; C | 2007 |
[Locally advanced breast cancer with a good response to sequential endocrine monotherapy--a case report].
Topics: Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; C | 2007 |
[Locally advanced breast cancer with a good response to sequential endocrine monotherapy--a case report].
Topics: Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; C | 2007 |
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
Topics: Adult; Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; | 2007 |
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
Topics: Adult; Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; | 2007 |
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
Topics: Adult; Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; | 2007 |
Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit | 2007 |
Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit | 2007 |
Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit | 2007 |
Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors.
Topics: Adult; Aged; Amenorrhea; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; | 2007 |
Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors.
Topics: Adult; Aged; Amenorrhea; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; | 2007 |
Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors.
Topics: Adult; Aged; Amenorrhea; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; | 2007 |
t(8;16) AML developed subsequent to breast cancer therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone M | 2006 |
t(8;16) AML developed subsequent to breast cancer therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone M | 2006 |
t(8;16) AML developed subsequent to breast cancer therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone M | 2006 |
Unusual macular degeneration following breast cancer.
Topics: Adenocarcinoma; Anastrozole; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Choroid Neoplas | 2007 |
Unusual macular degeneration following breast cancer.
Topics: Adenocarcinoma; Anastrozole; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Choroid Neoplas | 2007 |
Unusual macular degeneration following breast cancer.
Topics: Adenocarcinoma; Anastrozole; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Choroid Neoplas | 2007 |
[A case of advanced breast cancer with multiple liver metastases resistant to chemotherapy responding to high-dose toremifene].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Dose-Response Relationshi | 2007 |
[A case of advanced breast cancer with multiple liver metastases resistant to chemotherapy responding to high-dose toremifene].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Dose-Response Relationshi | 2007 |
[A case of advanced breast cancer with multiple liver metastases resistant to chemotherapy responding to high-dose toremifene].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Dose-Response Relationshi | 2007 |
A case of porphyria cutanea tarda resulting in digital amputation and improved by anastrazole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Fingers; Hand Dermatoses; Hu | 2007 |
A case of porphyria cutanea tarda resulting in digital amputation and improved by anastrazole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Fingers; Hand Dermatoses; Hu | 2007 |
A case of porphyria cutanea tarda resulting in digital amputation and improved by anastrazole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Fingers; Hand Dermatoses; Hu | 2007 |
[Clinical study of aromatase inhibitors in advanced breast cancer].
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bre | 2007 |
[Clinical study of aromatase inhibitors in advanced breast cancer].
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bre | 2007 |
[Clinical study of aromatase inhibitors in advanced breast cancer].
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bre | 2007 |
Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; C | 2007 |
Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; C | 2007 |
Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; C | 2007 |
Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromat | 2007 |
Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromat | 2007 |
Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromat | 2007 |
Parotid gland metastasis of a breast cancer.
Topics: Anastrozole; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Al | 2007 |
Parotid gland metastasis of a breast cancer.
Topics: Anastrozole; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Al | 2007 |
Parotid gland metastasis of a breast cancer.
Topics: Anastrozole; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Al | 2007 |
Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuv | 2007 |
Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuv | 2007 |
Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuv | 2007 |
Optimal use of aromatase inhibitors: to lead or to follow?
Topics: Aged; Alleles; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-F | 2007 |
Optimal use of aromatase inhibitors: to lead or to follow?
Topics: Aged; Alleles; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-F | 2007 |
Optimal use of aromatase inhibitors: to lead or to follow?
Topics: Aged; Alleles; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-F | 2007 |
Bone density in breast cancer: when to intervene?
Topics: Absorptiometry, Photon; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromata | 2007 |
Bone density in breast cancer: when to intervene?
Topics: Absorptiometry, Photon; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromata | 2007 |
Bone density in breast cancer: when to intervene?
Topics: Absorptiometry, Photon; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromata | 2007 |
Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit | 2008 |
Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit | 2008 |
Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit | 2008 |
Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336).
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Apoptosis; Aromatase Inhibitors; Blotting, We | 2007 |
Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336).
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Apoptosis; Aromatase Inhibitors; Blotting, We | 2007 |
Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336).
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Apoptosis; Aromatase Inhibitors; Blotting, We | 2007 |
Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neop | 2007 |
Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neop | 2007 |
Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neop | 2007 |
Aromatase inhibitor-associated arthralgias: Pathogenesis, frequency and management.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Ch | 2007 |
Aromatase inhibitor-associated arthralgias: Pathogenesis, frequency and management.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Ch | 2007 |
Aromatase inhibitor-associated arthralgias: Pathogenesis, frequency and management.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Ch | 2007 |
Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome.
Topics: Aged; Anastrozole; Antibodies, Antinuclear; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; A | 2007 |
Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome.
Topics: Aged; Anastrozole; Antibodies, Antinuclear; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; A | 2007 |
Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome.
Topics: Aged; Anastrozole; Antibodies, Antinuclear; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; A | 2007 |
Responses to concurrent radiotherapy and hormone-therapy and outcome for large breast cancers in post-menopausal women.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Combined Mo | 2007 |
Responses to concurrent radiotherapy and hormone-therapy and outcome for large breast cancers in post-menopausal women.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Combined Mo | 2007 |
Responses to concurrent radiotherapy and hormone-therapy and outcome for large breast cancers in post-menopausal women.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Combined Mo | 2007 |
Resolution of endometrial hyperplasia with adjuvant anastrozole treatment in postmenopausal breast cancer: a case report.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Endometrial Hyperplasia | 2007 |
Resolution of endometrial hyperplasia with adjuvant anastrozole treatment in postmenopausal breast cancer: a case report.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Endometrial Hyperplasia | 2007 |
Resolution of endometrial hyperplasia with adjuvant anastrozole treatment in postmenopausal breast cancer: a case report.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Endometrial Hyperplasia | 2007 |
Efficacy of anastrozole on local recurrence in patients with favorable early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Combined Modality Therapy; Female; H | 2007 |
Efficacy of anastrozole on local recurrence in patients with favorable early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Combined Modality Therapy; Female; H | 2007 |
Efficacy of anastrozole on local recurrence in patients with favorable early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Combined Modality Therapy; Female; H | 2007 |
[Solitary oesophageal metastasis of breast cancer after 17 years latency].
Topics: Adenocarcinoma; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Breast Neoplasms; Chemotherapy | 2007 |
[Solitary oesophageal metastasis of breast cancer after 17 years latency].
Topics: Adenocarcinoma; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Breast Neoplasms; Chemotherapy | 2007 |
[Solitary oesophageal metastasis of breast cancer after 17 years latency].
Topics: Adenocarcinoma; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Breast Neoplasms; Chemotherapy | 2007 |
Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2008 |
Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2008 |
Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2008 |
Extended adjuvant therapy for breast cancer--how much is enough?
Topics: Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Austria; Brea | 2007 |
Extended adjuvant therapy for breast cancer--how much is enough?
Topics: Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Austria; Brea | 2007 |
Extended adjuvant therapy for breast cancer--how much is enough?
Topics: Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Austria; Brea | 2007 |
Long-term outcomes of aromatase inhibition for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Administr | 2008 |
Long-term outcomes of aromatase inhibition for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Administr | 2008 |
Long-term outcomes of aromatase inhibition for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Administr | 2008 |
Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Prescriptions; Fem | 2008 |
Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Prescriptions; Fem | 2008 |
Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Prescriptions; Fem | 2008 |
Erythema multiforme after radiotherapy with aromatase inhibitor administration in breast-conservation treatment for breast cancer.
Topics: Administration, Oral; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy | 2008 |
Erythema multiforme after radiotherapy with aromatase inhibitor administration in breast-conservation treatment for breast cancer.
Topics: Administration, Oral; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy | 2008 |
Erythema multiforme after radiotherapy with aromatase inhibitor administration in breast-conservation treatment for breast cancer.
Topics: Administration, Oral; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy | 2008 |
[Efficacy of sequential treatment with anastrozole following exemestane compared with exemestane following anastrozole in patients with metastatic breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; | 2008 |
[Efficacy of sequential treatment with anastrozole following exemestane compared with exemestane following anastrozole in patients with metastatic breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; | 2008 |
[Efficacy of sequential treatment with anastrozole following exemestane compared with exemestane following anastrozole in patients with metastatic breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; | 2008 |
Anticancer therapy in patients with porphyrias: evidence today.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Docetaxel; Epoetin Alfa; | 2008 |
Anticancer therapy in patients with porphyrias: evidence today.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Docetaxel; Epoetin Alfa; | 2008 |
Anticancer therapy in patients with porphyrias: evidence today.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Docetaxel; Epoetin Alfa; | 2008 |
Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2008 |
Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2008 |
Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2008 |
Inappropriate ATAC on tamoxifen.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2008 |
Inappropriate ATAC on tamoxifen.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2008 |
Inappropriate ATAC on tamoxifen.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2008 |
Inappropriate ATAC on tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2008 |
Inappropriate ATAC on tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2008 |
Inappropriate ATAC on tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2008 |
[A case of elderly breast cancer achieving partial response by letrozole with stable disease to anastrozole as neoadjuvant endocrine therapy].
Topics: Aged, 80 and over; Anastrozole; Breast Neoplasms; Endocrine System; Female; Humans; Letrozole; Neoad | 2008 |
[A case of elderly breast cancer achieving partial response by letrozole with stable disease to anastrozole as neoadjuvant endocrine therapy].
Topics: Aged, 80 and over; Anastrozole; Breast Neoplasms; Endocrine System; Female; Humans; Letrozole; Neoad | 2008 |
[A case of elderly breast cancer achieving partial response by letrozole with stable disease to anastrozole as neoadjuvant endocrine therapy].
Topics: Aged, 80 and over; Anastrozole; Breast Neoplasms; Endocrine System; Female; Humans; Letrozole; Neoad | 2008 |
Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Aromatase Inhibitor | 2008 |
Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Aromatase Inhibitor | 2008 |
Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Aromatase Inhibitor | 2008 |
Retinal hemorrhages in anastrozole users.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Fluorescein Angiography; Humans; Middle | 2008 |
Retinal hemorrhages in anastrozole users.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Fluorescein Angiography; Humans; Middle | 2008 |
Retinal hemorrhages in anastrozole users.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Fluorescein Angiography; Humans; Middle | 2008 |
Arimidex: a potent and selective fourth-generation aromatase inhibitor.
Topics: Administration, Oral; Anastrozole; Animals; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials | 1994 |
Arimidex: a potent and selective fourth-generation aromatase inhibitor.
Topics: Administration, Oral; Anastrozole; Animals; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials | 1994 |
Arimidex: a potent and selective fourth-generation aromatase inhibitor.
Topics: Administration, Oral; Anastrozole; Animals; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials | 1994 |
Anastrozole for metastatic breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Neoplasm Met | 1996 |
Anastrozole for metastatic breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Neoplasm Met | 1996 |
Anastrozole for metastatic breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Neoplasm Met | 1996 |
New aromatase inhibitors: more selectivity, less toxicity, unfortunately, the same activity.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 1996 |
New aromatase inhibitors: more selectivity, less toxicity, unfortunately, the same activity.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 1996 |
New aromatase inhibitors: more selectivity, less toxicity, unfortunately, the same activity.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 1996 |
Aromatase inhibitors in metastatic breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Fem | 1996 |
Aromatase inhibitors in metastatic breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Fem | 1996 |
Aromatase inhibitors in metastatic breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Fem | 1996 |
Role of new selective aromatase inhibitor in therapy for metastatic breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibit | 1997 |
Role of new selective aromatase inhibitor in therapy for metastatic breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibit | 1997 |
Role of new selective aromatase inhibitor in therapy for metastatic breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibit | 1997 |
Aromatase inhibitors come of age.
Topics: Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibito | 1997 |
Aromatase inhibitors come of age.
Topics: Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibito | 1997 |
Aromatase inhibitors come of age.
Topics: Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibito | 1997 |
A novel in vitro and in vivo breast cancer model for testing inhibitors of estrogen biosynthesis and its action using mammary tumor cells with an activated int-5/aromatase gene.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Aminoglutethimide; Analysis of Variance; Anastrozole; Androstenedi | 1997 |
A novel in vitro and in vivo breast cancer model for testing inhibitors of estrogen biosynthesis and its action using mammary tumor cells with an activated int-5/aromatase gene.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Aminoglutethimide; Analysis of Variance; Anastrozole; Androstenedi | 1997 |
A novel in vitro and in vivo breast cancer model for testing inhibitors of estrogen biosynthesis and its action using mammary tumor cells with an activated int-5/aromatase gene.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Aminoglutethimide; Analysis of Variance; Anastrozole; Androstenedi | 1997 |
Predictors of response to second-line endocrine therapy for breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Bre | 1997 |
Predictors of response to second-line endocrine therapy for breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Bre | 1997 |
Predictors of response to second-line endocrine therapy for breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Bre | 1997 |
[Two new therapeutic principles in the management of breast cancer and colorectal cancer: selective oral aromatase inhibition and thymidilate synthase inhibition].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Colorectal Neo | 1997 |
[Two new therapeutic principles in the management of breast cancer and colorectal cancer: selective oral aromatase inhibition and thymidilate synthase inhibition].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Colorectal Neo | 1997 |
[Two new therapeutic principles in the management of breast cancer and colorectal cancer: selective oral aromatase inhibition and thymidilate synthase inhibition].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Colorectal Neo | 1997 |
Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 1998 |
Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 1998 |
Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 1998 |
Aromatase inhibitors and their future role in post-menopausal women with early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme I | 1998 |
Aromatase inhibitors and their future role in post-menopausal women with early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme I | 1998 |
Aromatase inhibitors and their future role in post-menopausal women with early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme I | 1998 |
The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity.
Topics: Anastrozole; Androstenedione; Aromatase; Aromatase Inhibitors; Base Sequence; Breast Neoplasms; Cell | 1998 |
The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity.
Topics: Anastrozole; Androstenedione; Aromatase; Aromatase Inhibitors; Base Sequence; Breast Neoplasms; Cell | 1998 |
The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity.
Topics: Anastrozole; Androstenedione; Aromatase; Aromatase Inhibitors; Base Sequence; Breast Neoplasms; Cell | 1998 |
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chem | 1999 |
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chem | 1999 |
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chem | 1999 |
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chem | 1999 |
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chem | 1999 |
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chem | 1999 |
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chem | 1999 |
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chem | 1999 |
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chem | 1999 |
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chem | 1999 |
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chem | 1999 |
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chem | 1999 |
Safety and tolerability of endocrine therapies used in the treatment of advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Tolerance; Female; Humans; Mege | 1999 |
Safety and tolerability of endocrine therapies used in the treatment of advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Tolerance; Female; Humans; Mege | 1999 |
Safety and tolerability of endocrine therapies used in the treatment of advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Tolerance; Female; Humans; Mege | 1999 |
Future directions in endocrine treatment of advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 1999 |
Future directions in endocrine treatment of advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 1999 |
Future directions in endocrine treatment of advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 1999 |
A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chromatography, High Pressure Liquid | 2000 |
A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chromatography, High Pressure Liquid | 2000 |
A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chromatography, High Pressure Liquid | 2000 |
Effects of the aromatase inhibitor anastrozole on serum oestrogens in Japanese and Caucasian women.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Asian People; Breast Neopl | 2000 |
Effects of the aromatase inhibitor anastrozole on serum oestrogens in Japanese and Caucasian women.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Asian People; Breast Neopl | 2000 |
Effects of the aromatase inhibitor anastrozole on serum oestrogens in Japanese and Caucasian women.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Asian People; Breast Neopl | 2000 |
[Aromatase inhibitors in the treatment of breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhib | 2000 |
[Aromatase inhibitors in the treatment of breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhib | 2000 |
[Aromatase inhibitors in the treatment of breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhib | 2000 |
Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Canada; Costs and Cost A | 2000 |
Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Canada; Costs and Cost A | 2000 |
Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Canada; Costs and Cost A | 2000 |
An overview of the use of non-steroidal aromatase inhibitors in the treatment of breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2000 |
An overview of the use of non-steroidal aromatase inhibitors in the treatment of breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2000 |
An overview of the use of non-steroidal aromatase inhibitors in the treatment of breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2000 |
Gonadotropins stimulate growth of MCF-7 human breast cancer cells by promoting intracellular conversion of adrenal androgens to estrogens.
Topics: Anastrozole; Androgens; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Chorionic | 2000 |
Gonadotropins stimulate growth of MCF-7 human breast cancer cells by promoting intracellular conversion of adrenal androgens to estrogens.
Topics: Anastrozole; Androgens; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Chorionic | 2000 |
Gonadotropins stimulate growth of MCF-7 human breast cancer cells by promoting intracellular conversion of adrenal androgens to estrogens.
Topics: Anastrozole; Androgens; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Chorionic | 2000 |
Endocrine options for breast cancer treatment: looking beyond tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Goserelin; Humans; Nitriles; | 2000 |
Endocrine options for breast cancer treatment: looking beyond tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Goserelin; Humans; Nitriles; | 2000 |
Endocrine options for breast cancer treatment: looking beyond tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Goserelin; Humans; Nitriles; | 2000 |
Clarification of anastrozole/megestrol acetate trial program design.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; | 2000 |
Clarification of anastrozole/megestrol acetate trial program design.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; | 2000 |
Clarification of anastrozole/megestrol acetate trial program design.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; | 2000 |
Clinical trials in cancer: what makes for a successful study?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2000 |
Clinical trials in cancer: what makes for a successful study?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2000 |
Clinical trials in cancer: what makes for a successful study?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2000 |
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.
Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antine | 2001 |
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.
Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antine | 2001 |
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.
Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antine | 2001 |
The Twenty-third Annual San Antonio Breast Cancer Symposium.
Topics: Anastrozole; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Combined Moda | 2001 |
The Twenty-third Annual San Antonio Breast Cancer Symposium.
Topics: Anastrozole; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Combined Moda | 2001 |
The Twenty-third Annual San Antonio Breast Cancer Symposium.
Topics: Anastrozole; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Combined Moda | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitrile | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitrile | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitrile | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitrile | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitrile | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitrile | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitrile | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitrile | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitrile | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitrile | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitrile | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitrile | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitrile | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitrile | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitrile | 2001 |
Aromatase inhibitors and arthralgia.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Breast Neoplasms; Enzyme Inhibitors; Femal | 2001 |
Aromatase inhibitors and arthralgia.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Breast Neoplasms; Enzyme Inhibitors; Femal | 2001 |
Aromatase inhibitors and arthralgia.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Breast Neoplasms; Enzyme Inhibitors; Femal | 2001 |
Aromatase inhibitors and inactivators in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme I | 2001 |
Aromatase inhibitors and inactivators in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme I | 2001 |
Aromatase inhibitors and inactivators in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme I | 2001 |
HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Female; Gene Amplific | 2001 |
HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Female; Gene Amplific | 2001 |
HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Female; Gene Amplific | 2001 |
[Clinical study of anastrozole in the treatment of postmenopausal women with advanced breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Fema | 1999 |
[Clinical study of anastrozole in the treatment of postmenopausal women with advanced breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Fema | 1999 |
[Clinical study of anastrozole in the treatment of postmenopausal women with advanced breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Fema | 1999 |
Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable?
Topics: Adult; Aged; Anastrozole; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neopl | 2001 |
Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable?
Topics: Adult; Aged; Anastrozole; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neopl | 2001 |
Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable?
Topics: Adult; Aged; Anastrozole; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neopl | 2001 |
World's largest breast cancer treatment trial supports anastrozole use.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind | 2002 |
World's largest breast cancer treatment trial supports anastrozole use.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind | 2002 |
World's largest breast cancer treatment trial supports anastrozole use.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind | 2002 |
Local endocrine effects of aromatase inhibitors within the breast.
Topics: Anastrozole; Androstadienes; Aromatase; Aromatase Inhibitors; Breast; Breast Neoplasms; Cells, Cultu | 2001 |
Local endocrine effects of aromatase inhibitors within the breast.
Topics: Anastrozole; Androstadienes; Aromatase; Aromatase Inhibitors; Breast; Breast Neoplasms; Cells, Cultu | 2001 |
Local endocrine effects of aromatase inhibitors within the breast.
Topics: Anastrozole; Androstadienes; Aromatase; Aromatase Inhibitors; Breast; Breast Neoplasms; Cells, Cultu | 2001 |
Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Estr | 2001 |
Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Estr | 2001 |
Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Estr | 2001 |
[Aromatase inhibitors of the 3rd generation. What can the "pill against breast cancer" really do?].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical | 2002 |
[Aromatase inhibitors of the 3rd generation. What can the "pill against breast cancer" really do?].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical | 2002 |
[Aromatase inhibitors of the 3rd generation. What can the "pill against breast cancer" really do?].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical | 2002 |
Hormones 'R' us.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 2002 |
Hormones 'R' us.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 2002 |
Hormones 'R' us.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trial | 2002 |
Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 2002 |
Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 2002 |
Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 2002 |
New breast cancer drugs expand treatment options.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nit | 2002 |
New breast cancer drugs expand treatment options.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nit | 2002 |
New breast cancer drugs expand treatment options.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nit | 2002 |
Comparison of in vitro exemestane activity versus other antiaromatase agents.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Choriocarcin | 2000 |
Comparison of in vitro exemestane activity versus other antiaromatase agents.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Choriocarcin | 2000 |
Comparison of in vitro exemestane activity versus other antiaromatase agents.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Choriocarcin | 2000 |
Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Enzyme Inhibit | 2002 |
Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Enzyme Inhibit | 2002 |
Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Enzyme Inhibit | 2002 |
A better medication for treating breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibit | 2002 |
A better medication for treating breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibit | 2002 |
A better medication for treating breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibit | 2002 |
The oncology nurse's role in educating patients on endocrine therapy for metastatic breast cancer--focus on fulvestrant.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Recep | 2002 |
The oncology nurse's role in educating patients on endocrine therapy for metastatic breast cancer--focus on fulvestrant.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Recep | 2002 |
The oncology nurse's role in educating patients on endocrine therapy for metastatic breast cancer--focus on fulvestrant.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Recep | 2002 |
Endocrine effects of nonsteroidal aromatase inhibitors and their clinical impact.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Stu | 2002 |
Endocrine effects of nonsteroidal aromatase inhibitors and their clinical impact.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Stu | 2002 |
Endocrine effects of nonsteroidal aromatase inhibitors and their clinical impact.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Stu | 2002 |
Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer.
Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhi | 2002 |
Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer.
Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhi | 2002 |
Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer.
Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhi | 2002 |
Estrogen as therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Pha | 2002 |
Estrogen as therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Pha | 2002 |
Estrogen as therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Pha | 2002 |